<SEC-DOCUMENT>0001459839-19-000011.txt : 20190314
<SEC-HEADER>0001459839-19-000011.hdr.sgml : 20190314
<ACCEPTANCE-DATETIME>20190314163326
ACCESSION NUMBER:		0001459839-19-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190314
DATE AS OF CHANGE:		20190314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SI-BONE, Inc.
		CENTRAL INDEX KEY:			0001459839
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262216351
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38701
		FILM NUMBER:		19681511

	BUSINESS ADDRESS:	
		STREET 1:		471 EL CAMINO REAL, SUITE 101
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050
		BUSINESS PHONE:		4082070700

	MAIL ADDRESS:	
		STREET 1:		471 EL CAMINO REAL, SUITE 101
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SI-Bone Inc.
		DATE OF NAME CHANGE:	20090326
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sibn1231201810-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s81758FCAD75E50FF925CE316ECDEE37A"></a></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:2px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM&#160;10&#8209;K</font></div><div style="line-height:120%;text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Mark&#160;One)</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:center;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">For the fiscal&#160;year ended December&#160;31, 2018</font></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File Number&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001&#8209;38701</font></div><div style="line-height:120%;padding-top:2px;text-align:center;font-size:22pt;"><font style="font-family:inherit;font-size:22pt;font-weight:bold;">SI-BONE,&#160;Inc.</font></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Exact name of Registrant as specified in its Charter)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26-2216351</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or other jurisdiction <br>of incorporation or organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. Employer <br>Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">471 El Camino Real, Suite 101, Santa Clara, California 95050</font></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Address of principal executive offices including zip code)</font></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (408)&#160;207&#8209;0700</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act: Common Stock, Par Value $0.0001 Per Share; Common stock traded on the Nasdaq Stock Market</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#32;None</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;YES&#160;</font><font style="font-family:inherit;font-size:10pt;">&#9744;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;NO&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;&#160;YES&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#9744;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;NO&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;NO&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;YES&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;NO&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K (&#167;229.405) is not contained herein, and will not be contained, to the best of Registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10&#8209;K or any amendment to this Form&#160;10&#8209;K.&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b&#8209;2 of the Exchange Act:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.96296296296296%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:52%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:2%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="font-family:inherit;font-size:10pt;">&#9744;</font><font style="font-family:Wingdings;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b&#8209;2 of the Exchange Act). &#160;&#160;YES&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#9744;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;NO&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The registrant&#8217;s common stock was not publicly traded as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter.&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The number of shares of Registrant&#8217;s Common Stock outstanding as of </font><font style="font-family:inherit;font-size:8pt;">March&#160;13, 2019</font><font style="font-family:inherit;font-size:8pt;">&#32;was </font><font style="font-family:inherit;font-size:8pt;">24,458,938</font><font style="font-family:inherit;font-size:8pt;">.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:5px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:5px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:8pt;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, which will be filed with the Securities and Exchange Commission within 120&#160;days after the end of the Registrant&#8217;s fiscal&#160;year ended December&#160;31, 2018, are incorporated by reference into Part&#160;III of this Report</font><font style="font-family:inherit;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sFA08BC0779EF5AD1AE741E4F3BD5EAF0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:86%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s59df2017562f4397a9841502c9e30fde"><font style="font-family:inherit;font-size:10pt;">Item 1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s59df2017562f4397a9841502c9e30fde"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s59df2017562f4397a9841502c9e30fde">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE88869CFC4450D698B7232E95A77C24"><font style="font-family:inherit;font-size:10pt;">Item 1A</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE88869CFC4450D698B7232E95A77C24"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCE88869CFC4450D698B7232E95A77C24">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8e33343b458241559baa7973c7c1ac43"><font style="font-family:inherit;font-size:10pt;">Item 1B</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8e33343b458241559baa7973c7c1ac43"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8e33343b458241559baa7973c7c1ac43">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8f00698f390942059bb79efe8f840d74"><font style="font-family:inherit;font-size:10pt;">Item 2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8f00698f390942059bb79efe8f840d74"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8f00698f390942059bb79efe8f840d74">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD5DE7FD4A9015BB08963CF091FD78085"><font style="font-family:inherit;font-size:10pt;">Item 3</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD5DE7FD4A9015BB08963CF091FD78085"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD5DE7FD4A9015BB08963CF091FD78085">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE25A0355B669596E9941E452DC84E9EC"><font style="font-family:inherit;font-size:10pt;">Item 4</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE25A0355B669596E9941E452DC84E9EC"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE25A0355B669596E9941E452DC84E9EC">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5a2194d095cd4ae29663bd703a37bd6e"><font style="font-family:inherit;font-size:10pt;">Item 5</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5a2194d095cd4ae29663bd703a37bd6e"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5a2194d095cd4ae29663bd703a37bd6e">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sb05e62c307754abf887d6bf4950fc3fe"><font style="font-family:inherit;font-size:10pt;">Item 6</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sb05e62c307754abf887d6bf4950fc3fe"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sb05e62c307754abf887d6bf4950fc3fe">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3A78FEBFF89B5C2DBCE28A5463264103"><font style="font-family:inherit;font-size:10pt;">Item 7</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3A78FEBFF89B5C2DBCE28A5463264103"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3A78FEBFF89B5C2DBCE28A5463264103">73</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB43532636F1B56E7AD45CFF6C220AC6A"><font style="font-family:inherit;font-size:10pt;">Item 7A</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:24px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB43532636F1B56E7AD45CFF6C220AC6A"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB43532636F1B56E7AD45CFF6C220AC6A">87</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD2F11DD08AB95BE3BCB28ACDAB88D81C"><font style="font-family:inherit;font-size:10pt;">Item 8</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD2F11DD08AB95BE3BCB28ACDAB88D81C"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD2F11DD08AB95BE3BCB28ACDAB88D81C">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62169cdda76d4ae28f7da3c665a3a7b5"><font style="font-family:inherit;font-size:10pt;">Item 9</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62169cdda76d4ae28f7da3c665a3a7b5"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62169cdda76d4ae28f7da3c665a3a7b5">123</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8155CC2D3A35C78A2E418CE3F16A184"><font style="font-family:inherit;font-size:10pt;">Item 9A</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8155CC2D3A35C78A2E418CE3F16A184"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8155CC2D3A35C78A2E418CE3F16A184">123</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2DE78F308FF4501B8F0543DADC101CCA"><font style="font-family:inherit;font-size:10pt;">Item 9B</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2DE78F308FF4501B8F0543DADC101CCA"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2DE78F308FF4501B8F0543DADC101CCA">123</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4c838fa4e09841d18be681975474828b"><font style="font-family:inherit;font-size:10pt;">Item 10</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4c838fa4e09841d18be681975474828b"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4c838fa4e09841d18be681975474828b">124</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6ae6408bd01a43c4bba73f52061966b7"><font style="font-family:inherit;font-size:10pt;">Item 11</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6ae6408bd01a43c4bba73f52061966b7"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6ae6408bd01a43c4bba73f52061966b7">124</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s53e7b04380d748a0ad7f650c4f5a03b4"><font style="font-family:inherit;font-size:10pt;">Item 12</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s53e7b04380d748a0ad7f650c4f5a03b4"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s53e7b04380d748a0ad7f650c4f5a03b4">124</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sbf7b88d1b0134c9b93537ffb3da473f8"><font style="font-family:inherit;font-size:10pt;">Item 13</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sbf7b88d1b0134c9b93537ffb3da473f8"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sbf7b88d1b0134c9b93537ffb3da473f8">124</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sfca1bf5af6ef4350b18a02603c47c501"><font style="font-family:inherit;font-size:10pt;">Item 14</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sfca1bf5af6ef4350b18a02603c47c501"><font style="font-family:inherit;font-size:10pt;">Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sfca1bf5af6ef4350b18a02603c47c501">124</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s697B248C4BA7540C8C5C8B6FE81CE776"><font style="font-family:inherit;font-size:10pt;">Item 15</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s697B248C4BA7540C8C5C8B6FE81CE776"><font style="font-family:inherit;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s697B248C4BA7540C8C5C8B6FE81CE776">125</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s98866d48326b42e198ea1d2379c9bf0f"><font style="font-family:inherit;font-size:10pt;">Item 16</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s98866d48326b42e198ea1d2379c9bf0f"><font style="font-family:inherit;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s98866d48326b42e198ea1d2379c9bf0f">128</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE83EBC0BBFB5480876E1ED952E25BB8"><font style="font-family:inherit;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE83EBC0BBFB5480876E1ED952E25BB8">129</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this Annual Report on Form 10-K, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;SI-BONE,&#8221; and &#8220;the Company&#8221; refer to SI-BONE, Inc. The SI-BONE logo and other trade names, trademarks or service marks of SI-BONE are the property of SI-BONE, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s007842382c2a468ab4956ecb59f53aed"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:130%;padding-bottom:8px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Annual Report on Form&#160;10&#8209;K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectation that, for the foreseeable future, a significant portion of our revenues will be derived from sales of the iFuse Implant System, or iFuse;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to expand our sales and marketing capabilities to increase demand for iFuse, expand geographically, and obtain favorable coverage and reimbursement determinations from third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates of our market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments or disputes concerning our intellectual property or other proprietary rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition in the markets we serve;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectations of the reliability and performance of iFuse;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectations of the benefits to patients, providers, and payors of iFuse;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reliance on a limited number of suppliers, including sole source suppliers, which may impact the availability of replacement instruments and materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the factors we believe drive demand for iFuse and our ability to sustain or increase such demand;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to develop additional revenue opportunities, including new devices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope of protection we establish and maintain for intellectual property rights covering iFuse and any other device we may develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates regarding our costs and risks associated with our international operations and international expansion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to retain and recruit key personnel and expand our sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectations regarding acquisitions and strategic operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to fund our working capital requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our compliance with, and the cost of, federal, state, and foreign regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the factors that may impact our financial results; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">anticipated trends and challenges in our business and the markets in which we operate.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts, and projections about our business and the industry in which we operate, and management&#8217;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors&#8221; and elsewhere in this report. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s4B49173B56A15BA5B1C9C147CF5726EA"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s59df2017562f4397a9841502c9e30fde"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Business.</font></div><div><a name="sdb7921abd6244db083d677b0cb86b8bb"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a medical device company that has pioneered a proprietary minimally invasive surgical implant system, which we call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Since we introduced iFuse in 2009, more than 37,000 procedures have been performed by over 1,800 surgeons, in the United States and 33 other countries. Published clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the sacroiliac joint. We believe iFuse is currently used in the majority of minimally invasive surgical fusions of the sacroiliac joint in the United States. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The two sacroiliac joints are the largest joints in the body and connect the sacrum, near the base of the spine, to the iliac bones, the two major bones of the pelvis. The iFuse system includes a series of patented triangular implants, the instruments we have developed to enable the procedure, as well as the diagnostic and surgical techniques we have developed to enable physicians to perform the procedure. We introduced our second generation implant, the iFuse-3D, in 2017. We market our products with a direct sales force and a number of distributors in the United States, and with a combination of a direct sales force and distributors in other countries. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our growth rate has recently increased, which we attribute in part to more widespread insurance coverage for sacroiliac fusion procedures, with many recent positive payor coverage policies exclusive to our iFuse system, as well as our efforts to educate the market regarding sacroiliac dysfunction. Since January 1, 2018, because of the strength of published clinical evidence on iFuse, 31 U.S. payors have published reimbursement policies exclusively covering the patented triangular design of our iFuse implants and excluding coverage of other products that are intended to fuse the sacroiliac joint. We believe that the full impact of each exclusive coverage decision grows over time as we continue to educate surgeons about the coverage and the medical criteria they need to follow, and train them on the diagnosis and how to perform the iFuse procedure. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018 and 2017, we generated revenue of </font><font style="font-family:inherit;font-size:10pt;">$55.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$48.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, a growth rate of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">, and incurred net losses of </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Our gross margins were </font><font style="font-family:inherit;font-size:10pt;">91%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">89%</font><font style="font-family:inherit;font-size:10pt;">&#32;for 2018 and 2017, respectively. The number of iFuse procedures performed in 2018 and 2017 was </font><font style="font-family:inherit;font-size:10pt;">6,659</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">5,739</font><font style="font-family:inherit;font-size:10pt;">&#32;respectively. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our implants have a triangular cross section, which resists twisting of the implant within the bone in which it is implanted, helping stabilize the joint even before fixation of the bone onto the implant, or bony ingrowth, which results in fusion. Products from our competitors use screws to treat the sacroiliac joint, which do not resist twisting within the bone as well as our patented triangular implants. A study we performed showed that our iFuse implants have more than six times the rotation resistance of a screw designed for sacroiliac joint fusion. We hold issued patents on implants with cross-sections of many non-round shapes, including the triangular shape we use for iFuse. We also hold issued patents for the method of placing those implants across the sacroiliac joint, as well as other parts of the spine and pelvis. Each titanium iFuse implant is at least three times the strength of a typical eight-millimeter surgical screw and the larger porous surface area of our implants allows for bony ingrowth. Three of our implants are typically used in each procedure. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The safety, clinical effectiveness, durability of pain relief and reduction in disability, cost effectiveness, and reduction in opioid users that result from iFuse are supported by a large number of studies that have resulted in more than 60 published papers. Several of these papers publish results from three prospective multicenter studies (INSITE, SIFI, and iMIA), two of which were randomized controlled clinical trials. Additionally, there have been several studies showing longer-term follow-up of up to six years. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.03703703703704%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INSITE is a randomized controlled study conducted in the United States. Positive 24-month follow-up results were published in August 2016 in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Journal of Spine Surgery </font><font style="font-family:inherit;font-size:10pt;">showing statistically significant and clinically important reduction in pain and disability after sacroiliac joint fusion but very little response to maximal non-surgical treatment. In April 2015, INSITE was awarded the &#8220;Best Overall Paper&#8221; out of approximately 450 submitted clinical study papers at the International Society for Advancement of Spine Surgery, or ISASS, conference </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iMIA is a randomized controlled study conducted in Europe. Positive 24-month results were published in March 2019 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Bone and Joint Surgery</font><font style="font-family:inherit;font-size:10pt;">.  Like INSITE, results from iMIA show statistically significant and clinically profound reduction in pain and disability after SI joint fusion but little improvement after non-surgical treatment. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIFI is a single-arm study conducted in the United States. Positive 24-month follow-up results were published in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Journal of Spine Surgery </font><font style="font-family:inherit;font-size:10pt;">in April 2016, showing substantial and sustained reduction in pain and disability. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LOIS is a prospective follow-on study, enrolling subjects at a subset of INSITE and SIFI sites treated with iFuse. Study outcomes at four years were published in July 2018 in Medical Devices: Evidence and Research.  Among 103 enrolled subjects, mean sacroiliac joint pain at three years decreased from 82 preoperatively to 28 (a 54-point improvement from baseline, p&lt;.0001).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A study in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Neurosurgery</font><font style="font-family:inherit;font-size:10pt;">&#160;published in April 2017 showed similar improvements in pain and disability in patients followed for up to six years. The study also showed a substantial reduction in the number of subjects using opioids in patients treated with iFuse at their last follow-up visit. At the last follow-up visit, 84% of patients who received non-surgical management were using opioids, while only 7% of patients treated with iFuse were using opioids. </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The INSITE clinical trial included 148 subjects treated at 19 centers in the United States, with subjects randomized in a two-to-one ratio to either immediate sacroiliac joint fusion with iFuse or non-surgical management. The study design allowed subjects in the non-surgical management group to cross over and have surgery after six months. By 24 months after the start of the clinical trial, 89% of the non-surgical management group subjects still participating in the trial had elected to cross over to have the iFuse procedure, primarily because they derived little clinical benefit from non-surgical treatments. The study&#8217;s results can be summarized as follows: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.85185185185186%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reduction in Pain</font><font style="font-family:inherit;font-size:10pt;">. There was a statistically significant and clinically important pain reduction in subjects treated with iFuse as compared to very small responses in those treated with non-surgical management. Subjects surgically treated with iFuse had mean 52- 54- and 55-point reductions in sacroiliac joint pain at 6, 12 and 24 months, respectively, as measured by the VAS. By contrast, subjects in the non-surgical management group had only a mean 12-point reduction (p&lt;0.0001) at six months. 12 points is below the commonly accepted 20-point threshold for clinically important improvement. In addition, the non-surgical management group subjects who elected after six months to cross over to have the iFuse procedure had pain reduction similar to that seen in subjects originally assigned to sacroiliac joint fusion with iFuse. At 24 months, the proportion of subjects with a reduction in VAS sacroiliac joint pain of 20 or more points due to the assigned treatment only was 83% in the iFuse group and 10% in the non-surgical management group. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reduction in Disability</font><font style="font-family:inherit;font-size:10pt;">. There was a statistically significant and clinically important reduction in disability in subjects treated with iFuse as compared to very little response in those treated with non-surgical management. Subjects surgically treated with iFuse had a mean 27-point reduction in disability at six months, on the 0&#8211;100 Oswestry Disability Index, or ODI, while subjects in the non-surgical management group had only a mean five-point reduction (p&lt;0.0001). Five points is less than the commonly accepted 15-point threshold to denote a clinically important response. At 24 months, the iFuse group had a mean 28-point reduction in ODI. At six months, the proportion of subjects with ODI improvements of at least 15 points was 72.5% with iFuse treatment and only 13.0% in those undergoing non-surgical management (p&lt;0.0001 for difference in response rate). In addition, the subjects who elected after six months to cross over to have the iFuse procedure had similar reduction in disability as the subjects originally assigned to sacroiliac joint fusion with iFuse. At 24 months, the proportion of subjects with an ODI improvement of at least 15 points with the assigned treatment only was 68.2% and 7.5% in the iFuse and non-surgical management groups, respectively (p&lt;0.0001 for difference in response rate). These are very large differences.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients from certain sites participating in the INSITE study will be followed for up to five years as part of LOIS, a separate long-term study. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgical revision rate is an important measurement of a treatment&#8217;s effectiveness for patients. Studies on lumbar, or lower back, fusion, a different type of spine procedure from iFuse, have shown revision rates as approximately 12%. A study published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Medical Devices: Evidence and Research</font><font style="font-family:inherit;font-size:10pt;">&#32;in November 2015 showed that the cumulative four-year revision rate with iFuse was 3.5%. A single surgeon retrospective study published in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Journal of Spine Surgery </font><font style="font-family:inherit;font-size:10pt;">in January 2017 showed that the cumulative four-year revision rate for screw-based treatment of the sacroiliac joint was five times higher than the cumulative four-year revision rate for iFuse. </font></div><div><a name="sf2e626e07c6b4def8368222e4e48e4b0"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Opportunity </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that over 30 million American adults have chronic lower back pain</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">For patients whose chronic lower back pain stems from the sacroiliac joint,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">our experience in both clinical trials and commercial settings indicates that iFuse could be beneficial for at least 30% of patients who are properly diagnosed and screened for surgery by trained healthcare providers. Approximately 282,000 patients in the United States were estimated to have received multiple non-surgical steroid injections for sacroiliac joint pain in 2018. Based on our market experience and internal estimates, and the assumption that the average person suffering from sacroiliac joint dysfunction has been in pain for five years, we estimate that the potential market for iFuse in the United States could be 279,000 patients annually, for a potential annual market in the United States of approximately $2.7 billion. While we have made significant inroads at penetrating this market, U.S. patients received only 5,094 iFuse procedures in 2018. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients with sacroiliac joint dysfunction may experience debilitating pain. We believe that the sacroiliac joint is the last major joint to be addressed by the orthopedic implant industry. Studies have shown that the disability that results from disease of the sacroiliac joint is comparable to the disability associated with a number of other serious orthopedic conditions, such as knee and hip arthritis and degenerative disc disease, each of which has surgical solutions where an implant is used and a multi-billion dollar market exists. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Frequently, sacroiliac joint patients are aging and/or may have experienced one or more of the following events that have contributed to disruption or degeneration of the sacroiliac joint: falls, previous lumbar surgery, automobile accidents, and/or pregnancies. We believe that Americans spend approximately $85.9 billion per year on spine problems and that approximately 65% of people who suffer from sacroiliac pain are women. In the United States, iFuse is intended for sacroiliac joint fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months. In all other countries where iFuse is available commercially, the system is indicated for sacroiliac joint fusion. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Diagnosis </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is often difficult to identify the source of lower back pain. As a result, some surgical procedures performed on the spine have a sub-optimal success rate. For example, published studies of lumbar fusion have shown success rates of only approximately 60%. Unsuccessful spine surgery may result in failed back surgery syndrome, which has been shown to result in high healthcare costs with poor overall relief of pain. Published studies have shown that the sacroiliac joint is a cause of the pain in 32% to 43% of patients who have previously had lumbar fusion surgery and are experiencing recurrent low back pain. We believe low success rates of lumbar fusion are likely related, in many cases, to failure to diagnose the sacroiliac joint as the correct cause of pain. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since we launched iFuse, we have made considerable investments in teaching healthcare professionals to accurately diagnose sacroiliac joint disorders. We provide instruction and training on how to perform the provocative maneuvers in a physician&#8217;s office that can help establish the sacroiliac joint as the source of pain. If provocative tests are positive, surgeons confirm the diagnosis by injecting a small amount of local anesthetic into the joint under fluoroscopic guidance. The sacroiliac joint is confirmed as a pain source if the local anesthetic produces immediate and significant pain reduction. In addition to the differentiated characteristics of our iFuse procedure and triangular iFuse implants, we believe that more accurate diagnosis is part of the reason for the high success and patient satisfaction rates of the iFuse procedure. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Surgical Treatment of Sacroiliac Joint Disease </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients with sacroiliac joint dysfunction or sacroiliac joint arthritis frequently experience significant pain simply from sitting, standing, or rolling over in bed. These activities result in small movements of the sacroiliac joints and pressure transferred across the joints. The pain can be exacerbated with activity&#8212;when a patient walks or runs, for example, the shock from each step is transmitted up the leg, through the iliac bones of the pelvis to the sacroiliac joint. The initial goal in fusion of the sacroiliac joint is to immediately stabilize the joint which very quickly decreases the pain. Following initial stabilization of the sacroiliac joint, the goal is to permanently fuse the joint. We believe our proprietary triangular implants stabilize the joint better and more quickly than competing technologies such as screws. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgical fusion of the sacroiliac joint with an open surgical technique was first reported in 1908, with further reports in the 1920s. The open procedure uses plates and screws, requires a 6- to 12-inch incision and is extremely invasive. The iFuse procedure involves a 1- to 2-inch incision and is much less invasive. For these reasons, we believe that open surgery for elective sacroiliac joint fusion has become less common in the United States since we introduced iFuse. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to its invasiveness, pain, long recovery time, and infrequent use, the open sacroiliac joint fusion procedure was rarely taught in medical school or residency programs. Prior to our launch of iFuse, most spine surgeons were unfamiliar with the sacroiliac joint and had never performed a sacroiliac joint fusion. As a result, when patients presented with lower back pain, spine surgeons often did not include evaluation of the sacroiliac joint in their diagnostic work-up. Surgeons who did recognize the condition typically told their patients they had nothing to offer surgically. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Surgical Treatment of Sacroiliac Joint Disease </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although a number of non-surgical treatments exist for sacroiliac joint pain, they did not provide the level of pain or disability relief seen with the iFuse procedure for the patients participating in the INSITE study. Non-surgical treatments include: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.77777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical therapy, including opiates and non-steroidal anti-inflammatory medications. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physical therapy, which can involve exercises as well as massage. </font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intra-articular injections of steroid medications, which are typically performed by physicians who specialize in pain treatment or anesthesia. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Radiofrequency ablation, or the cauterizing, of the lateral branches of the sacral nerve roots. </font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Solution&#8212;The iFuse Implant System </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our iFuse system, which includes our implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based fusion procedures. As shown in the graphic below, our iFuse implants are triangular, and three implants are typically used in each procedure. Our implants are made of titanium and have a porous surface. Each iFuse implant is at least three times the strength of a typical eight-millimeter surgical screw and the large porous surface area allows fixation of the bone to the implants. We introduced the original iFuse implants in 2009, and our second generation iFuse-3D implants in 2017. </font></div><div style="line-height:120%;text-align:center;"><img src="doc193009209v1sibonef_image1.jpg" alt="doc193009209v1sibonef_image1.jpg" style="height:161px;width:474px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The iFuse procedure is typically performed under general anesthesia. The surgeon uses a custom instrument set we provide to prepare a triangular channel for each implant through the ilium, across the sacroiliac joint, and into the sacrum. An iFuse implant is then pressed into the triangular channel, which is slightly smaller than the implant, creating what is known as an interference fit. The triangular cross section of our iFuse implants, as shown below, prevents them from rotating. Our triangular iFuse implants cross the sacroiliac joint and provide immediate joint stability, which is why we believe pain diminishes soon after the iFuse procedure. Over time, bone grows onto the implants and across the joint, permanently stabilizing or fusing the joint. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By contrast, open fusion of the sacroiliac joint, as well as the minimally invasive solutions offered by other companies, typically use screws and/or plates for fixation. When placed across the sacroiliac joint, standard orthopedic screws, which lack features to encourage biologic fixation, have an exhibited propensity to rotate and loosen over time. Because of the triangular shape, porous surface, strength, and other differentiating factors of our iFuse implants, we believe that our published clinical data do not apply to other minimally invasive solutions. Little published evidence of safety, clinical effectiveness, durability, or economic utility currently exists for sacroiliac fusion devices other than iFuse. We are unaware of any data to show that our competitors&#8217; sacroiliac joint screws, with features allowing biologic fixation, have a lower rate of loosening than standard orthopedic screws. In addition, placement of plates for open fusion procedures typically requires larger incisions and more invasive dissection, which results in longer recovery times and increased morbidity. We believe that the differences between iFuse and other products, as well as the substantial published </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical evidence showing the safety and effectiveness of iFuse, are the reason why a growing number of payors have recommended that iFuse be reimbursed for sacroiliac surgery to the exclusion of other technologies that are designed for the procedure. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our implants cross the sacroiliac joint and provide immediate stability, which is why we believe pain diminishes soon after the iFuse procedure. Typically, surgeons recommend protected weight-bearing for three weeks. However, post-operative instructions are patient-specific and some patients are allowed to perform weight-bearing activities sooner. Follow-up studies have shown that bony bridging across the sacroiliac joint is present in the majority of cases five years after the iFuse procedure. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three implants are used in most iFuse procedures. Each implant bridges across the joint from the iliac bone to the sacrum. Placing each implant requires four basic steps: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.66666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pin</font><font style="font-family:inherit;font-size:10pt;">. The surgeon inserts a guide pin through the iliac bone, across the sacroiliac joint and into the sacrum. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Drill</font><font style="font-family:inherit;font-size:10pt;">. Surgeons drill over the guide pin, through the iliac bone, across the sacroiliac joint and just into the sacrum. This step is optional if using the sharp-tip broach. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Broach</font><font style="font-family:inherit;font-size:10pt;">. The surgeon impacts a triangular broach over the pin which prepares a triangular channel that is slightly smaller than the iFuse implant. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Implant</font><font style="font-family:inherit;font-size:10pt;">. The surgeon impacts the implant into the triangular channel thereby spanning the sacroiliac joint and docking the implant in the sacrum. The channel is slightly smaller than the implant, which produces an interference fit. </font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iFuse is a cannulated system, which means that the drill, broach and implants have hollow channels which fit over the pin for guidance purposes. As is typical across the orthopedic implant industry, a member of our team is normally present in the operating suite during surgery to provide technical assistance for the use of iFuse. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently offer three custom instrument sets for surgical placement of iFuse implants in the body. The standard set comprises largely stainless steel materials; the XL (Extra Long) set is the same as the standard set but most instruments are elongated by three inches for treatment of larger patients; and the radiolucent set comprises instruments made with more radiolucent materials, such as PEEK and aluminum to improve visualization under fluoroscopy during an iFuse procedure. We also have instrument sets which have been cleared for use with Medtronic&#8217;s surgical navigation system and with the Mazor surgical robot. </font></div><div><a name="s4ef7a3acd5e74425aa0fbe0e6ae449e7"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Published Studies </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iFuse is the only minimally invasive product for sacroiliac joint fusion commercially available in the United States that, to our knowledge, is supported by substantial high-quality published evidence of safety, clinical effectiveness, durability, and economic utility. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These benefits are supported by more than 65 published papers (48 of which we financially supported), including two prospective, randomized controlled multi-center clinical trials referred to as &#8220;INSITE&#8221; and &#8220;iMIA&#8221; respectively, and a prospective multi-center clinical study referred to as &#8220;SIFI.&#8221; INSITE 24-month follow-up results were published in August 2016 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Journal of Spine Surgery</font><font style="font-family:inherit;font-size:10pt;">. Six-month and one-year summaries were also published in reputable journals.  Twenty-four month results from iMIA were published in the March 2019 issue of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Bone and Joint Surgery</font><font style="font-family:inherit;font-size:10pt;">, a general orthopedics journal.  A prospective, follow-on study called &#8220;LOIS&#8221; tracks certain study participants from INSITE and SIFI for up to five years after their initial surgery.  A four-year summary from LOIS was published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Medical Devices Evidence &amp; Research </font><font style="font-family:inherit;font-size:10pt;">in July 2018.  Published results from each of these studies demonstrate clinically important and statistically significant improvement in sacroiliac joint pain, disability due to lower back pain, quality of life, and patient satisfaction. Moreover, the level of published evidence supporting the safety and effectiveness of sacroiliac joint fusion using iFuse is high. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, the iFuse Implant System is FDA-cleared with the following indication statement: The iFuse Implant System</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months. Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iFuse-3D, which was FDA-cleared in 2017, has a very similar indication statement but does not have the statement regarding improvement in pain, function, and quality of life. In the United States, our marketing strategies must adhere to the above statements. In all other countries, the indication statement for the iFuse Implant System (including iFuse-3D) more broadly indicates that the device is indicated for sacroiliac joint fusion. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">INSITE Study Design </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INSITE is a prospective multicenter randomized controlled trial conducted in the US. This section describes INSITE in more detail. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INSITE enrollment took place between January 2013 and May 2014 at 19 sites in the United States. Adults between 21 and 70 years old were eligible to participate if they had a confirmed diagnosis of sacroiliac dysfunction due to degenerative sacroiliitis and/or sacroiliac joint disruption. Diagnosis was based on the subject&#8217;s history, provocative tests performed in the surgeon&#8217;s office, and at least a 50% decrease in sacroiliac joint pain 30 to 60 minutes after local anesthetic was injected into the joint under image guidance. Eligibility required a sacroiliac VAS pain score of at least 50, where zero represents no pain and 100 represents the worst pain imaginable, as well as a baseline ODI score of at least 30, which has a scale of 0-100, where zero represents no disability and scores greater than 60 represent very severe disability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exclusion criteria included inability to diagnose pain related to the sacroiliac joint, sacroiliac joint pain due to inflammatory conditions, severe back pain deemed to be due primarily to other causes, history of recent major trauma to the pelvis, metabolic bone disease, or any condition that made treatment with the study devices infeasible or interfered with the ability to participate in physical therapy. Subjects involved in litigation, on disability leave, or receiving workers&#8217; compensation related to their back or sacroiliac joint pain were also excluded.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subjects were randomly assigned to sacroiliac joint fusion or non-surgical management in a two to one ratio. After six months of follow-up, subjects could elect to receive sacroiliac joint fusion surgery using iFuse. All of the subjects who were randomized to non-surgical management completed at least six months of follow-up before electing to cross over to surgery. There was no early crossover. Baseline assessments included medical history and physical examination. Subjects were scheduled for follow-up at 1, 3, 6, 12, 18, and 24 months after enrollment. At each follow-up, the subjects evaluated their pain and disability by completing questionnaires to assess pain and disability. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subjects assigned to non-surgical management began immediately with treatment consisting of one or more of the following: 1) management of pain with medication, including narcotics; 2) physical therapy; 3) steroid injections in the sacroiliac joint; and 4) radiofrequency ablation of local nerves. Physical therapy followed American Physical Therapy Association, or APTA, guidelines. Not all non-surgical management interventions were provided to all non-surgical management subjects. Non-surgical management interventions were provided serially, typically in order of increasing invasiveness, according to individual needs. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A high-resolution pelvic CT scan was performed at the 24-month follow-up for those subjects randomized to and treated with iFuse. The primary purpose of the CT scan is to judge the adherence of bone onto the implants on both the sacral and iliac sides of the sacroiliac joint and to determine whether there is bone bridging across the joint. Other radiographic endpoints were assessed as well. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The study required that subjects receive only the assigned treatment to month six. After six months, the study allowed subjects assigned to non-surgical treatment to cross over to surgery. Crossover was allowed because the anticipated success rate for non- surgical management was low, and many subjects would not have participated without the ability to cross over to surgical care within the study. One-hundred percent of subjects who crossed over to surgical treatment in the study did so shortly after their six-month visit was complete in compliance with the design of the study. Nearly 90% of non-surgical management subjects still participating at month six crossed over to surgical care. All subjects who crossed over had sacroiliac joint fusion using iFuse and were subsequently evaluated with follow-up visits. No early crossover occurred. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the study, 442 subjects at 19 centers were screened for participation, of which 148 were enrolled and treated. Mean subject age was 51 years and 18 (12%) were 65 years of age or older. Most subjects (94.6%) were Caucasian and approximately two-thirds were female. Follow-up was excellent with 96% of non-surgical subjects having 6-month follow-up and 87% of sacroiliac joint fusion patients having 24-month follow-up. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary endpoint was a composite success or failure endpoint. Success was defined as reduction from baseline VAS sacroiliac joint pain by at least 20 points, absence of device-related serious adverse events, absence of neurological worsening related to the sacral spine, and absence of surgical re-intervention (removal, revision, reoperation, or supplemental fixation) for sacroiliac joint pain. Secondary endpoints included improvement from baseline in VAS, ODI, as well as treatment satisfaction and other criteria. Other important measures included quality of life assessments. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enrolled subjects were highly debilitated by sacroiliac joint pain as indicated by high baseline VAS scores (mean 82.3) and ODI scores (mean 56.8). Nineteen percent were not working due to chronic pain. The duration of pain prior to enrollment averaged 6.4 years (range 0.5 to 40.7 years), and 87.2% had had pain for more than one year and 73.6% had pain for more than two years. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trial subjects had previously undergone sacroiliac-specific physical therapy (72.3% of subjects), sacroiliac steroid injections (85.8%) and radiofrequency ablation of the sacroiliac joint (16.2%). Approximately two-thirds were taking opioid pain medications at baseline and all reported that multiple activities commonly caused or worsened their sacroiliac joint pain.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All subjects assigned to sacroiliac joint fusion underwent the procedure. Of the subjects assigned to surgery, 76 had the iFuse procedure on one sacroiliac joint, while 26 underwent the procedure on both sacroiliac joints. Mean procedure time was 45 minutes (range 14 to 140 minutes). Mean estimated blood loss was 33 ml (range 0.5 to 250 ml). Three implants were used in 91.2% of cases and most implants were seven millimeters in diameter. The hospital length of stay ranged from zero to seven days, and 97.1% were discharged in two days or less. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Of the 46 subjects assigned to non-surgical management: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.92592592592592%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All but one received physical therapy during the six months after treatment assignment;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73.9% underwent at least one steroid injection;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.7% underwent radiofrequency ablation of the sacroiliac joint; and</font></div><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87.0% underwent at least two types of non-surgical management treatments in addition to pain medications.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above data suggests that the intensity of non-surgical management interventions was high and representative of that provided in standard clinical practice.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INSITE clinical outcomes can be summarized as follows. </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.25925925925927%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:3%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reduction in Pain</font><font style="font-family:inherit;font-size:10pt;">. There was a statistically significant and clinically important reduction in pain among subjects treated with iFuse as compared to non-surgical management. As shown in the graph below, subjects surgically treated with iFuse had a mean 52-point VAS reduction in sacroiliac joint pain at six months. The reduction in pain was sustained with a mean 54- and 55-point reduction in sacroiliac joint pain observed at 12 and 24 months, respectively. By contrast, subjects in the non-surgical management group had only a mean 12-point reduction (p&lt;0.0001) at six months. In addition, the non-surgical management group subjects who elected after six months to cross over to have the iFuse procedure had pain reduction similar to that seen in subjects originally assigned to sacroiliac joint fusion with iFuse. At 24 months, the proportion of subjects with a reduction in VAS sacroiliac joint pain of 20 or more points was 83% in the iFuse group and 10% in the non-surgical management group. </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="doc193009209v1sibonef_image2.jpg" alt="doc193009209v1sibonef_image2.jpg" style="height:425px;width:581px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subjects who elected not to cross over to surgery had reduced pain at six months, but their pain worsened somewhat over time. In contrast, the non-surgical management group subjects who elected to cross over to have the iFuse procedure had pain reduction similar to that seen in subjects originally assigned to sacroiliac joint fusion with iFuse. These clinically important differences show the effectiveness of sacroiliac joint fusion with iFuse. </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.25925925925927%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:3%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reduction in Disability</font><font style="font-family:inherit;font-size:10pt;">. There was a statistically significant reduction in disability with iFuse as compared to non-surgical management. As shown in the graph below, subjects surgically treated with iFuse had a mean 27-point ODI reduction in disability at six months, while subjects in the non-surgical management group had only a mean 4.6-point decrease (p&lt;0.0001). At 12 and 24 months, the iFuse group had a mean 29- and 28-point reduction in disability, respectively. At six months, the proportion of subjects with ODI improvements of at least 15 points was 72.5% and 13.0% in the iFuse and non-surgical management groups, respectively. At 24 months, the proportion of subjects with an improvement of at least 15 points due to the assigned treatment was 68.2% and 7.5% in the iFuse and non-surgical management groups, respectively (p&lt;0.0001).</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As shown in the figure below, the subjects who elected after six months to cross over to have the iFuse procedure had similar reduction in disability as the subjects originally assigned to sacroiliac joint fusion with iFuse. These clinically important differences show the effectiveness of sacroiliac joint fusion with iFuse. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="doc193009209v1sibonef_image3.jpg" alt="doc193009209v1sibonef_image3.jpg" style="height:416px;width:581px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patient Satisfaction </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient satisfaction was assessed by asking subjects whether they were very satisfied, somewhat satisfied, somewhat dissatisfied or very dissatisfied with the treatment received. At six months, 79.0% of subjects who had received the iFuse procedure were very satisfied, compared with 27.3% of subjects in the non-surgical management group. At six months, 81.0% of surgery subjects said they would definitely have the procedure again. At 24 months, satisfaction rates were high, with 73.3% reporting being very satisfied with surgical treatment of the sacroiliac joint, and 71.1% indicated they would have the procedure again. These results are consistent with the satisfaction results from other iFuse studies, covering approximately 500 subjects. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adverse Events </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first six months, the mean number of adverse events per subject was slightly but not statistically significantly higher in the surgery group (1.3 events) as compared to the non-surgical management group (1.1 events, p=0.3063). The most common adverse event related to our implant was leg pain resulting from misplacement of the implant, resulting in impingement of the implant on a lumbar spine nerve root. The most common adverse event for our implant procedure has been minor wound infections. None of these adverse events required surgical treatment. The following table shows the number and percentages of subjects who had adverse events related to the iFuse device and the iFuse procedure. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.14814814814815%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:66%;"></td><td style="width:3%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-Surgical <br>Management <br>(n=46)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sacroiliac <br>Joint Fusion <br>(n=102)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">N (%*)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">N (%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Related to iFuse implant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitely related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 (2.0%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Probably related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 (1.0%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 (2.9%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Related to non-surgical management or iFuse procedure**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definitely related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 (6.5%)</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 (5.9%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Probably related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1 (2.2%)</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 (9.8%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 (8.7%)</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16 (15.7%)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percent reported as number of events divided by number assigned to treatment.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td colspan="10" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Events from first 180 days shown.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In summary, we believe the INSITE study, a prospective, randomized controlled multi-center clinical trial, provides substantial evidence of clinically important and statistically significant efficacy supporting the superiority of sacroiliac joint fusion using iFuse as compared to non-surgical management. Further, the fact that subjects who crossed over responded, as well as those who were originally assigned to the iFuse group, adds significantly to the trial&#8217;s validity and importance. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">iMIA European Clinical Trial </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">iMIA is a second prospective, randomized clinical trial of sacroiliac joint fusion using iFuse compared to non-surgical management with a design very similar to that of INSITE. iMIA enrolled and included treatment of 103 subjects at nine sites in four European countries. The trial&#8217;s six-month results were published in European Spine Journal in May 2016 and 12-month results were published in August 2017 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pain Physician</font><font style="font-family:inherit;font-size:10pt;">. Twenty-four month results were published in March 2019 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Bone and Joint Surgery</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In iMIA, 103 adults with chronic sacroiliac joint pain at nine sites in four European countries were randomly assigned in a one-to-one ratio to either immediate sacroiliac joint fusion with iFuse or conservative management. Conservative management was performed according to the European guidelines for the diagnosis and management of pelvic girdle pain and consisted of optimization of medical therapy, individualized physical therapy and adequate information and reassurance as part of a multifactorial treatment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At 24 months, low back pain in the surgically treated group improved by 45 points and ODI improved by 26 points (p&lt;.0001 from baseline). Adverse events occurred at a low rate and the frequency of adverse events did not differ meaningfully between groups. One case of postoperative nerve impingement occurred in the surgical group, which was resolved by repositioning the implant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The figure below shows low back pain scores at baseline and throughout follow-up, as well as several other endpoints. The results show clinically profound, rapid and sustained reduction in pain following treatment with iFuse, in contrast with conservative management. The results also show parallel improvements in disability and quality of life.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;"><img src="feb2019sibonevasimia1yr.jpg" alt="feb2019sibonevasimia1yr.jpg" style="height:471px;width:720px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The figure below shows mean ODI scores at baseline and throughout follow-up. The results show clinically profound, rapid and sustained reduction in disability following treatment with iFuse, in contrast with conservative management. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="feb2019siboneodiimia1yr.jpg" alt="feb2019siboneodiimia1yr.jpg" style="height:471px;width:720px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">SIFI Clinical Trial </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sacroiliac Joint Fusion with iFuse Implant System, or SIFI, is a prospective, multicenter single-arm clinical trial. Eligibility criteria and endpoints were identical to INSITE. A manuscript summarizing 24-month results was published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Journal of Spine Surgery </font><font style="font-family:inherit;font-size:10pt;">in April 2016. Each of the 172 enrolled subjects received the iFuse procedure at one of 26 participating sites between August 2012 and December 2013. Mean subject age was 51 years and 96.5% of subjects were Caucasian and approximately 70% were female. Follow-up rates at month 6, 12, and 24 were 97%, 91%, and 87%, respectively. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baseline sacroiliac pain and disability scores were high. The mean baseline VAS score was 79.8, while the mean baseline ODI score was 55.2. The mean duration of pain prior to enrollment was five years (range 0.4 to 41 years), and 84.3% had had pain for more than one year and 64.5% had had pain for more than two years. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Seventy-six percent were taking opioid pain medications at baseline and all reported that multiple activities commonly caused their sacroiliac joint pain. Many subjects (44.2%) had a history of prior lumbar fusion, and concomitant spine disease was common. Sacroiliac joint pain persisted despite prior treatments with physical therapy (64.5% of subjects), sacroiliac joint steroid injections (94.2%), and prior radiofrequency ablation of the joint (15.7%). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hospital length of stay ranged from zero to seven days, and 95.3% were discharged in two days or less. Prolonged hospital stays were related to subject comorbidities, not procedure-related adverse events.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The figure on the left below shows mean VAS pain scores at baseline and throughout follow-up. The figure on the right shows mean ODI scores at baseline and throughout follow-up. The results for both VAS pain and ODI scores each show clinically important and sustained reduction in disability across the subject population and follow-up period, consistent with the results observed in the surgical group in INSITE. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="item1image2.jpg" alt="item1image2.jpg" style="height:403px;width:720px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Satisfaction rates were high, with 78.1% reporting being very satisfied with sacroiliac joint treatment by month 24 and 93.8% being very or somewhat satisfied. 74.7% indicated they would definitely have the procedure again; 88.4% indicated they would probably or definitely have the procedure again. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most common adverse events were wound infection, irritation or drainage, sacroiliac joint pain related to implant malposition, and recurrent sacroiliac joint pain related to inadequate device placement. One subject had a deep wound infection that required surgical debridement. Four adverse events (2.4% of all subjects) were rated by the investigator to be definitely device-related and three (1.8%) were probably device-related. Pain related to implant impingement on sacral nerve roots occurred in three cases (including one non-study-related side), all of which resolved with immediate repositioning of implants. In four cases, sacroiliac joint or hip pain was attributed to the presence of an implant or bone growth around the implant. Twenty-six events were rated as probably or definitely related to the placement procedure.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">LOIS Clinical Trial </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LOIS is a prospective follow-on study, enrolling subjects at a subset of INSITE and SIFI sites who underwent sacroiliac joint fusion. Enrolled subjects will be followed out to five years following surgery. Study outcomes at four years were published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Medical Devices: Evidence and Research</font><font style="font-family:inherit;font-size:10pt;">&#32;in August 2018. Among 103 enrolled subjects, mean sacroiliac joint pain at four years decreased from 82 preoperatively to 27 (a 54-point improvement from baseline, p&lt;.0001), as shown in the graph below. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="item1image3.jpg" alt="item1image3.jpg" style="height:409px;width:720px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subjects in the LOIS study experienced similar improvements in disability and quality of life. As shown in the graph above on the right, average disability prior to treatment as measured on the ODI scale was 56 and fell to an average of 30 by 48 months following treatment, a 26 point improvement compared to the commonly accepted 15-point threshold for meaningful change in this measure.  Quality of life scores also improved markedly in this study. Average quality of life as measured by the EuroQol-5D prior to treatment was 0.45 and had improved to 0.75 by 48 months following treatment with iFuse.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Additional Published Clinical Studies </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have demonstrated the long-term durability of pain relief resulting from treatment with iFuse in several other published studies. A study published in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Open Orthopedics Journal </font><font style="font-family:inherit;font-size:10pt;">in 2014, which we financially supported, showed that significant clinical pain relief observed at 12 months was maintained for five years. Similar results with four and one-half year follow-up were published in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Journal of Spine </font><font style="font-family:inherit;font-size:10pt;">in 2014. A retrospective multicenter analysis of three-year outcomes after sacroiliac joint fusion with iFuse showed similar responses. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Among eleven clinical studies including more than 500 patients in which satisfaction with the iFuse procedure was measured, an average of 92% of participants were satisfied or very satisfied with the results of the surgery. We financially supported nine of these 11 studies. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, several studies, some of which we did not sponsor, have been published on the safety and effectiveness of sacroiliac joint fusion using iFuse. These are prospective or retrospective, single site or multi-site, and U.S.- or Europe-based. These clinical studies demonstrate the iFuse procedure to be safe and effective. These studies demonstrate pain reduction and/or ODI improvement that is statistically significant and clinically important. The type and rate of reported adverse events were similar to those reported in INSITE, iMIA, and SIFI. These additional studies are consistent with the results of INSITE, iMIA, and SIFI. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A study published in April 2017 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Neurosurgery </font><font style="font-family:inherit;font-size:10pt;">shows the impact of non-coverage of sacroiliac joint fusion by the healthcare system. In this study, a Spanish neurosurgeon reports the clinical experience of 423 patients seen in his clinic for sacroiliac joint pain. While many patients&#8217; pain resolved without intervention, 152 of the patients (36%) had continued sacroiliac joint pain. Of these patients, 74 did not have access to the procedure due to their insurers&#8217; denial of coverage and instead were only able to pursue continued non-surgical treatment. Of the remaining 78 patients, 51 underwent radiofrequency ablation of lateral branches of sacral nerve roots and 27 underwent sacroiliac joint fusion with iFuse. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The group treated non-surgically had poor outcomes, including increased pain, disability, and opioid use, as well as worsened work status. By contrast, patients who were able to undergo the iFuse procedure had very large improvements in pain and disability, improved work status, and a decreased incidence of opioid use. The differences in all outcomes (pain, disability, work status, and opioid use) were both statistically significant and clinically profound. The graph below shows the pain scores of the three treatment cohorts followed in this study. </font></div><div style="line-height:120%;text-align:center;"><img src="doc193009209v1sibone_image10.jpg" alt="doc193009209v1sibone_image10.jpg" style="height:438px;width:606px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The graph below shows the changes in the percentage of subjects using opioids among the iFuse and conservative care groups in the study. Forty-nine percent of subjects who were not able to access treatment with iFuse were using opioids at the beginning of the study, whereas 80% of them were using opioids at the time of their final follow-up. In contrast, 63% of the subjects who were able to obtain treatment with iFuse were using opioids prior to treatment, whereas only 7% were using opioids at their final follow-up visit. </font></div><div style="line-height:120%;text-align:center;"><img src="doc193009209v1sibone_image11.jpg" alt="doc193009209v1sibone_image11.jpg" style="height:304px;width:410px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are several important aspects to this study: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.37037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It can be considered a &#8220;pseudorandomized trial&#8221; in that insurance denials (which dictated which treatment the patient could receive) was not clearly related to any important predictor of clinical outcomes. This enhances the comparability of groups. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is the longest reported cohort of non-surgical treatment of sacroiliac joint pain published to date.</font></div><div style="padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-surgical treatment was clearly associated with poor outcomes, consistent with our experience in the US, in which patients receive repeated, and sometimes expensive, non-surgical treatments but do not derive significant benefit.</font></div><div style="padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recently finished enrollment in SALLY, a prospective single-arm multicenter trial of iFuse-3D for the treatment of sacroiliac joint dysfunction. The enrolled patient population was very similar to that of INSITE, SIFI and iMIA. Early results from SALLY show preoperative and six-month pain scores that are nearly identical to those of the three earlier prospective trials of iFuse. In addition, SALLY showed improvements in physical function tests and a larger reduction in opioid usage. A manuscript describing early SALLY results was submitted for publication in a peer-reviewed journal in February 2019.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to clinical evidence, a number of economic publications we financially supported, including those in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ClinicoEconomics and Outcomes Research, </font><font style="font-family:inherit;font-size:10pt;">demonstrate that the iFuse procedure provides a cost savings to the healthcare system when compared to non-surgical management over time. One of these studies used data from INSITE to calculate the incremental cost-effectiveness of the iFuse procedure and found it to be similar to that of hip and knee arthroplasty, commonly known as total joint replacement. The two latter procedures are generally accepted as being safe, effective, and highly cost-effective. The incremental cost effectiveness ratio, or ICER, of a procedure or therapy is a common way of quantifying its cost-effectiveness and represents the incremental cost to the healthcare system of providing one additional quality adjusted life-year, obtained by dividing the average cost of the therapy by the average increase in quality-adjusted life years that it achieves. Therapies with ICERs below $50,000 are considered cost-effective and generally gain acceptance. For example, studies have shown that the ICER of total joint replacement surgery for knees is approximately $12,000 and that for hip replacements is approximately $10,000. One study showed the ICER of the iFuse procedure to be $13,000, nearly as cost-effective as knee and hip surgeries, which are both common and well-accepted procedures. The ICER of iFuse derived from data from the INSITE trial is significantly better than the published ICERs of other common spine surgeries derived from one of the few other randomized controlled clinical trials of spine surgeries. Published analyses of the data from this trial showed the ICER of discectomy to be approximately $21,000, the ICER of standard decompressive laminectomy to be approximately $64,000, and the ICER of posterior decompressive laminectomy to be approximately $59,000. Each of these is a commonly performed spine surgery. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A second study detailed a health economics model examining the cost impact of failing to consider the sacroiliac joint in the diagnosis of patients with low back pain in patients seeking surgery. Taking into account both the prevalence of sacroiliac joint dysfunction and the costs of diagnostic workup and surgical treatment, if a surgeon evaluating a patient with chronic low back pain fails to consider the sacroiliac joint, on average $3,100 more healthcare expenditures will ensue. The study concluded that taking the sacroiliac joint into account can save healthcare systems substantial amounts due primarily to reduction in misdiagnosis and its attendant costs. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A third study used data from our two prospective trials conducted in the United States to examine the impact of sacroiliac joint fusion on worker productivity. Results suggest that sacroiliac joint fusion can increase the productivity of affected workers by an average of $6,900 compared to continued non-surgical care. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A fourth health economic study conducted by Optum, a division of UnitedHealth Group, and published in October 2018 examined healthcare costs for low back pain before and after sacroiliac joint fusion in patients in a commercial insurance database. Analysis showed reductions in median low back pain-related healthcare costs after sacroiliac joint fusion compared to before. A break-even analysis for health plan reimbursements for patients undergoing minimally invasive sacroiliac joint fusion on an outpatient basis showed similar cumulative claims for patients not undergoing the procedure within approximately 2.5 years. Following the procedure, per patient costs related to sacroiliac joint pain decrease to approximately $250 per quarter among the group who underwent sacroiliac joint fusion. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Second-Generation Implant </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our second-generation iFuse implant, iFuse-3D, shown on the left below, was cleared for marketing by the U.S. Food and Drug Administration in March 2017 and the European Union in May 2017. This patented titanium implant combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design. This design also allows the surgeon to fill the implant with ground-up bone before implanting it, which some surgeons believe accelerates bone through-growth. iFuse-3D implants have shown positive bony ingrowth in cell culture and animal studies, whether or not ground-up bone is used, as shown in two peer reviewed studies published in June 2017 in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Journal of Spine Surgery</font><font style="font-family:inherit;font-size:10pt;">. The image on the right below shows the cross section cut from an iFuse-3D implant removed from an animal as part of the study and reveals robust growth of bone into and through the implant.  We have completed enrollment of SALLY, described above, a clinical trial to evaluate the performance of iFuse-3D.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;"><img src="item1image1.jpg" alt="item1image1.jpg" style="height:268px;width:720px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s9403ab43117c45c281b99208168c0ee7"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Coverage and Reimbursement </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage and reimbursement for iFuse products and related procedures vary by setting of care, payor type, and region. In the United States, healthcare providers that purchase iFuse products look to various third-party payors, such as Medicare, Medicaid, private commercial insurance companies, health maintenance organizations, accountable care organization, or ACOs, and other healthcare-related organizations, to cover and pay for all or part of the costs of these procedures. These providers bill patients for any applicable deductibles or co-payments. Sales volumes and prices of company products will continue to depend in large part on the availability of coverage and reimbursement from such third-party payors. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Medicare program is commonly used as a model for how private payors and other governmental payors develop their coverage and reimbursement policies for healthcare items and services, including iFuse procedures. Unless a national coverage policy exists for a particular technology, each of the Medicare Administrative Contractors is permitted to make its own determination of whether that item or service is covered by Medicare. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare&#8217;s reimbursement rates for the iFuse procedure vary due to geographic location, the nature of facility in which the procedure is performed (i.e., hospital inpatient department, hospital outpatient department, or ambulatory surgical center) and other factors. Medicare reviews and updates its payment rates and methodologies for these settings of care annually, and rates can change from year to year. In addition, Congress can alter reimbursement rates at any time by mandating changes to Medicare&#8217;s payment methodologies. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similarly, private payor coverage policies and reimbursement rates tend to vary across payors and settings of care. Payors continually review the clinical evidence for new technologies and can change their coverage policies without notice or deny payment if the product was not used in accordance with the payor&#8217;s coverage policy. Payors also review and challenge the prices charged for products and procedures. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, the American Medical Association, or AMA, generally creates specific billing codes for surgical procedures under a coding system known as Current Procedure Terminology, or CPT, which surgeons must use to bill and receive reimbursement for our iFuse procedure. Once the CPT code is established, the Centers for Medicare &amp; Medicaid Services, or CMS, establishes payment levels and coverage rules under Medicare while private payors establish rates and coverage rules independently. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to our launch of iFuse, Medicare and most private insurance companies reimbursed surgeons for sacroiliac joint fusions using either an established Category I CPT code or an unlisted code. A Category I CPT code is typically assigned to procedures that are consistent with contemporary medical practice and are widely performed. Procedures with a longstanding Category I CPT code are usually reimbursed. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">However, effective July 1, 2013, the AMA&#8217;s CPT Editorial Panel created a new Category III CPT code for fusion of the sacroiliac joint using a minimally invasive or percutaneous approach. Category III CPT codes are used for new and emerging technologies and are reimbursed sporadically. This new code functionally redefined coding for sacroiliac joint fusions because it meant that minimally invasive or percutaneous fusion procedures should not be billed using the general Category I CPT code for sacroiliac fusion surgery. This coding change was accompanied by the establishment of a Medicare hospital outpatient prospective payment rate for the new code. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the creation of the new Category III CPT code, a number of papers demonstrating the clinical success of the iFuse procedure were published. As a result of these studies, along with the support of several professional medical specialty societies and leading academic surgeons, the AMA CPT Editorial Panel established a new Category I CPT code specifically for sacroiliac joint fusion surgery using a minimally invasive or percutaneous approach. This new Category I CPT code became effective on January 1, 2015. However, the new code did not immediately lead to positive coverage decisions by payors. In many cases, the payors wanted additional published evidence before deciding to cover the procedure. As a result, positive reimbursement decisions covering the procedure have occurred over the last few years, and some payors are still in the process of making decisions based on the most recent evidence. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, our INSITE prospective, randomized controlled multi-center clinical trial was published. In June 2015, the largest spine society in the world, the North American Spine Society, or NASS, published a positive coverage recommendation, based on the clinical evidence, advocating to insurance companies and Medicare Administrative Contractors that sacroiliac joint fusion using a minimally invasive surgical approach should be routinely reimbursed. In March 2015, the International Society for Advancement of Spine Surgery, or ISASS, also published a similar, updated positive advocacy document intended to encourage insurance companies in the United States to reimburse for the procedure. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage decisions for this code are made independently by each private insurance company and each of the Medicare Administrative Contractors that help manage Medicare. The process of obtaining coverage is laborious. As of June 30, 2016, because of the iFuse clinical evidence, all Medicare Administrative Contractors were covering the procedure. At the time, very few private payors were covering. As of December 31, 2017, U.S. payors covering 162 million lives regularly reimbursed for the iFuse procedure. However, by December 31, 2018, U.S. payors covering 256.5 million lives regularly reimbursed for the iFuse procedures, a 58% increase over December 31, 2017.  Of the 65 largest private payors that we track, 45 had positive coverage policies for the procedure, were consistently covering the procedure, or had announced coming future coverage. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payors, whether governmental or commercial, are also developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for medical device products and services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly process that requires us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement. Third-party payors regularly update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes annual updates to payments to physicians, hospitals, and ambulatory surgical centers for procedures during which our products are used. An example of payment updates is the Medicare program&#8217;s updates to hospital and physician payments, which are done on an annual basis using a prescribed statutory formula. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specialty benefit managers and companies which perform healthcare technology assessments have significant influence on coverage decisions. In May 2016, the ECRI Institute Health Technology Assessment Information Service published a positive review of the iFuse Implant System, citing our clinical evidence. In January 2018, the Blue Cross Blue Shield Association, the licensor to all 36 Blue Cross and Blue Shield insurers across the United States, wrote a favorable review of the clinical evidence conferring a positive coverage recommendation for minimally invasive sacroiliac fusion, but only when performed with iFuse. In February 2018, Milliman Care Guidelines, a Hearst Company publication, also recommended coverage and in May 2018, AIM Specialty Health, owned by Anthem, established coverage for only iFuse and none of our competitors. In October 2018, eviCore recommended our iFuse system exclusively for sacroiliac joint fusion or stabilization. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Private Payors</font><font style="font-family:inherit;font-size:10pt;">. Private payors also decide whether to cover and how much to pay on an individual basis. We target and track 65 of the largest private payors that cover 256.5 million lives in the United States as of December 31, 2018. Of the targeted and tracked payors, 45 were covering regularly, or had announced coverage for, the iFuse procedure, while the remaining private payors were reevaluating their coverage policies. Of the private payors who are covering regularly, 26 have issued positive coverage policies exclusive to iFuse for sacroiliac joint fusion because of the clinical evidence. Twenty of these exclusive coverage policies have published since January 1, 2018. The private payors covering iFuse exclusively are: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SelectHealth</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Health Care Service Corporation [IL]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Health Care Service Corporation [NM]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Health Care Service Corporation [OK]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Health Care Service Corporation [TX]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Health Care Service Corporation [MT]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-NJ- Horizon Blue Cross Blue Shield of New Jersey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-SC-Blue Cross Blue Shield of South Carolina</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-WY-BlueCross BlueShield of Wyoming</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-MS-Blue Cross Blue Shield of Mississippi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-KC-Blue Cross and Blue Shield of Kansas City</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-FL-BlueCross BlueShield of Florida (Florida Blue)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital Health Blue Cross (Florida)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-MN-Blue Cross Blue Shield of Minnesota</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-LA-BlueCross BlueShield of Louisiana</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-ID-Blue Cross of Idaho</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-TN-BlueCross BlueShield of Tennessee</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-PA-Capital Blue Cross (Central Pennsylvania)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-KS-BlueCross BlueShield of Kansas</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-PA-Independence Blue Cross (Philadelphia, Southeastern Pennsylvania)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-MA-Blue Cross Blue Shield of Massachusetts</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Regence Blue Cross/Cambia Solutions</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-NY-HealthNow NY: BlueShield of Northeastern New York/BCBS - BCBS of Western NY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-NC-Blue Cross Blue Shield of North Carolina</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neighborhood Health</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-AZ-BlueCross BlueShield of Arizona</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The private payors covering iFuse and other sacroiliac joint fusion products are: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.25925925925927%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Priority Health</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kaiser California</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kaiser Northwest</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Health New England</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Geisinger Health Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-MI-Blue Cross Blue Shield of Michigan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Harvard Pilgrim</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-NE-Blue Cross Blue Shield of Nebraska</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kern Health Systems</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Network Health</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-VT-BlueCross BlueShield of Vermont</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-Blue Cross of Northeastern Pennsylvania (Highmark)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Utah Public Employee Health Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BCBS-ND-Blue Cross Blue Shield of North Dakota</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emblem Health</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United Healthcare</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical Mutual of Ohio</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HealthPartners</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott &amp; White</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, U.S. payors covering 256.5 million lives reimburse for iFuse, 121.7 million of which are covered by private payors. The chart below shows the overall coverage as of December 31, 2018: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:30px;"><img src="waterfallchartasof12312018je.jpg" alt="waterfallchartasof12312018je.jpg" style="height:553px;width:720px;"></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note that because many individuals are covered by more than one health insurance plan or may switch plans during the year, the total number of covered lives reported by the payors represented above may be larger than the number of individuals who have access to the iFuse procedure through their health insurance provider at any given time. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of large and small private payors, including Aetna, Cigna, Humana, and Anthem, that are not yet reimbursing for the procedure. Some of these non-covering payors are reevaluating coverage given the latest data, but there can be no assurance they will reach positive coverage decisions. In most cases, the payors who are not covering are reevaluating coverage. Many payors will only review their coverage policies for a procedure on a scheduled basis, which can be every few months or as infrequently as once per year. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to payor coverage, surgeons have been reluctant to get trained on a procedure for which they could not reliably be reimbursed. While we believe the increased coverage described above will have a positive effect on the number of iFuse procedures and our associated revenue in the future, the effect likely will happen with a lag time: after a positive coverage decision is made, a number of months may pass before it impacts the number of procedures and associated revenue, since the surgeons have to be made aware of the coverage decision, schedule re-examinations of patients who were candidates for surgery and subsequently schedule surgeries for the patients who are still candidates. We believe it takes between 6 and 24 months for surgeons to fully incorporate iFuse into their practices after payors initiate coverage. Further, the administrative burden on surgical practices can be substantial for patients where reimbursement coverage is new, and some surgeons do not believe that the current average surgeon reimbursement is yet adequate to compensate them. However, as reimbursement coverage has improved, surgeon interest in learning to diagnose the sacroiliac joint and perform iFuse procedures has been increasing. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Coverage Outside the United States </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside the United States, reimbursement levels vary significantly by country, and by region within some countries. Reimbursement is obtained from a variety of sources, including government-sponsored and private health insurance plans, and combinations of both. Some countries will require us to gather additional clinical data before recognizing and granting broader coverage and reimbursement for our products. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, the UK&#8217;s National Institute for Health and Care Excellence, or NICE, published guidance on minimally invasive sacroiliac joint fusion, recommending that the procedure be available to properly diagnosed patients in the UK National Health System. NICE develops guidance and quality standards in health and social care and is a worldwide leader in technology evaluations. The recommendation states that the safety and efficacy of minimally invasive sacroiliac joint fusion surgery is adequate provided that standard arrangements are in place. Use with standard arrangements is the most positive recommendation that NICE can make for an interventional procedure such as MIS SI joint fusion. In October 2018, NICE published medical technology guidance specific to the iFuse Implant System, recommending that it be used in the National Health System because of the evidence demonstrating that treatment with iFuse improves pain, quality of life, and disability in properly selected patients. Additionally, in August 2018, the public hospital system in France announced it would initiate coverage for iFuse exclusively beginning September 6, 2018. Some countries will require us to gather additional clinical data before recognizing and granting broader coverage and reimbursement for our products. It is our intent to complete the requisite clinical studies and obtain coverage and reimbursement approval beyond what we have today in countries where it makes economic sense to do so. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9585cc52b8e343c5a32699eca6d08340"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Affairs and Education </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have created a medical affairs team that focuses both internally and externally. Internally, specialized medical knowledge, and practical experience with iFuse are used to help train our sales, marketing, quality, reimbursement, clinical, regulatory, engineering, and product development teams. This same specialized medical knowledge and practical experience allow us to create and execute a wide variety of programs to train the relevant external medical community, to assist them in identifying and diagnosing patients with sacroiliac joint dysfunction and in performing the iFuse procedure. The medical affairs team is led by a board-certified fellowship trained orthopedic spine surgeon. As of December 31, 2018, our U.S. faculty consisted of 82 surgeons, 22 pain management physicians, 15 nurse practitioners/physician&#8217;s assistants, and 90 physical therapists. These third-party consultants educate surgeons, physician&#8217;s assistants, nurses, physical therapists, and other healthcare professionals regarding sacroiliac joint diagnosis and the iFuse procedure.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our surgeon training programs are for orthopedic spine surgeons, neurosurgeons, general orthopedic surgeons, and orthopedic trauma surgeons. Since its introduction, over 1,800 surgeons have treated patients with iFuse. We also have a large number of educational programs for the broader medical community including primary care physicians and other healthcare practitioners that may manage a sacroiliac joint patient non-surgically, such as physical therapists, pain management physicians, and chiropractors. As of December 31, 2018, our medical affairs team and physical therapist consultants have educated over 4,600 physical therapists on sacroiliac joint dysfunction, its diagnosis and iFuse as a potential treatment. We also work to educate case managers, facilities where the iFuse procedure is performed such as hospitals, as well as payors and health plans. For example, as of December 31, 2018, we have trained over 1,200 case managers across the United States. Case managers help patients navigate the healthcare system so that they receive the appropriate treatment. In addition to the continuing education program for case managers, we have created continuing education programs for physical therapists and chiropractors. As of December 31, 2018, our physical therapy continuing education programs were approved in 47 states. These programs include instruction on the diagnosis and non-surgical treatment of sacroiliac joint dysfunction due to degenerative sacroiliitis and sacroiliac joint disruptions. Our medical affairs programs focus on working with leading spine surgeons to educate other surgeons on the differential diagnosis of sacroiliac joint disorders and the use of iFuse. We also work closely with medical societies to raise the awareness of and the appropriate diagnosis of sacroiliac joint dysfunction and the associated treatment options. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s73b4a908afe54ee7b7fb8a95a409f375"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales and Marketing </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We market and sell iFuse primarily through a direct sales force and a small number of third-party distributors. Our target customer base includes approximately 7,500 surgeons who perform spine and/or pelvic surgery, including orthopedic spine surgeons, neurosurgeons, general orthopedic surgeons, and orthopedic trauma surgeons. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our direct sales organization in the United States was comprised of seven sales regions as of December 31, 2018. Each region is comprised of a number of territory sales managers who act as the primary customer contact. Our territory sales managers have extensive training and experience selling medical devices for spine problems and pain management, generally focusing on emerging technologies and markets. For large and/or high volume territories, we also employ territory associate representatives who cover cases.  As of December 31, 2018, our territory sales managers were led by seven regional sales managers who reported to our Vice President of U.S. Sales. The Vice President of U.S. Sales reports to our Chief Commercial Officer. As of December 31, 2018, our U.S. sales force consisted of 45 sales representatives directly employed by us, and 30 third-party distributors. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to general sales and marketing training, we provide our sales organization with comprehensive, hands-on cadaveric and dry-lab training sessions focusing on the clinical benefits of our products and how to use them. We believe our robust training and professional development programs have been an important component of our success to date and will help support our anticipated future growth. We expect to continue to increase the size of our sales organization in order to increase sales and market penetration and to provide the significant, ongoing level of customer support required by our sales and marketing strategy. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, we had 27 employees working in our European operations, and have established operations in Italy (2010), Germany (2014), and the United Kingdom (2015). As of December 31, 2018, our international sales force consisted of 14 sales representatives directly employed by us and 23 exclusive third-party distributors, which together had sales in 33 countries through December 31, 2018. We anticipate continuing to build our operations in the major European countries while establishing distributor arrangements in smaller ones. We intend to follow a similar model in Europe to the one established in the United States, working with internationally recognized healthcare professional experts as we expand our training and reimbursement activities. As of December 31, 2018, beyond Europe and the United States, surgeons had performed the first iFuse procedures in Australia, Cayman Islands, Hong Kong, Israel, Japan, Kuwait, New Zealand, Saudia Arabia, Taiwan and Turkey. </font></div><div><a name="s3fa08dd3fdd9489c9c8f0902de24aea5"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our initial launch of the iFuse system, we have introduced a number of new instrument enhancements, product enhancements and procedure enhancements. An example is the iFuse-3D implant, which we developed over several years and launched in 2017. The most notable instrument enhancement was the release of the revamped instruments set which included a number of radiolucent instruments. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, we introduced an instrument set which is cleared for use with Medtronic&#8217;s surgical navigation system, allowing the surgeon to visualize the positioning of certain instruments intra-operatively. In March 2018, we introduced surgical pins cleared for use with the Mazor surgical robot, allowing the surgeon to robotically place the guide pin according to a computer-generated surgical plan. We expect to continue developing enhancements to iFuse to meet our customers&#8217; changing needs and improve the surgery&#8217;s effectiveness. For example, we know that some surgeons use iFuse to treat SI joint dysfunction in patients in whom the surgeon is also implanting other devices to treat other spine conditions. We are developing products and techniques to help surgeons improve the treatment of these patients, and we will seek any additional regulatory clearances which may be required. We also design and manufacture, Class I instruments for our surgeon customers based on special request under our &#8220;Non-Standard Product&#8221; program. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="se8c66057d1cf49f884ca4b6798b1fd4f"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe we were the first company to develop, manufacture, and market a minimally invasive implant cleared by the FDA expressly for sacroiliac joint fusion other than a modified screw. Over the past several years, other companies have subsequently recognized the opportunity and have entered the minimally invasive sacroiliac joint fusion market. However, all of these products are either screw-based or allograft products. We expect more competitors to enter into the market and an increased number of new product introductions by existing competitors. Many of our competitors are large, publicly traded companies that can dedicate far greater resources to the minimally invasive sacroiliac joint market than we can. These companies often have wide product offerings for spine and orthopedic surgery, which allow them to bundle products in order to win large hospital group contracts and can increase the barrier to entry for us. For example, some of our competitors offer sacroiliac joint fusion products which integrate with their surgical navigation and robotics platforms, enabling navigation of their procedures or performance of aspects of these procedures by surgical robots. Many of these companies also have much larger sales forces than ours, which allow them to reach more surgeons. We also expect there to be a continued push for non-surgical alternatives. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, we believe that our primary competitors currently are Globus Medical, Inc., Medtronic plc, XTant Medical Holdings, Inc., and RTI Surgical, Inc. Our primary competitors in Europe are Globus Medical, SIGNUS Medizintechnik GmbH, and XTant Medical Holdings.&#160;However, they sell screw-based products, which we believe to be weaker and less able to resist rotation than our triangular iFuse implants. We also compete against non-hardware products, such as allograft bone implants. These allograft products comprise human cells or tissues and are regulated by the FDA differently from implantable medical devices made of metallic or other non-tissue based materials, unless they include specific claims about their intended use which exceed a homologous use, or use consistent with the original function of the donor tissue. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on our commercial experience and market research, we believe iFuse is currently used in the majority of minimally invasive surgical fusions of the sacroiliac joint in the United States. iFuse is the only minimally invasive product for sacroiliac joint fusion commercially available in the United States that, to our knowledge, is supported by published clinical evidence including randomized controlled studies that demonstrate the safety, clinical effectiveness, durability, and economic utility. These benefits are supported by more than 65 published papers. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the primary competitive factors on which companies compete in our industry: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product and clinical procedure effectiveness;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ease of surgical technique and use of associated instruments;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">safety;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">published clinical outcomes and evidence;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales force knowledge;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product support and service, and customer service;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">comprehensive training, including disease, anatomy, diagnosis and treatment;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product innovation and the speed of innovation;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intellectual property;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accountability and responsiveness to customers&#8217; demands; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pricing and reimbursement;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">scientific (biomechanics) data; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">attracting and retaining key personnel.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="scb56a583f0ec4a699b4b5f317706b326"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We protect our intellectual property through our pending patent applications and issued patents. As of December 31, 2018, we had been issued 35 patents in the United States, five patents in Japan, three in Europe and one in China. Also, as of December 31, 2018, we have 14 pending patent applications in the United States and five pending patent applications outside of United States. We have focused the majority of our foreign patent efforts in China, Europe, and Japan. Generally, our current U.S. patents are expected to expire between August 2024 and September 2035, and our Japanese patents are expected to expire between August 2025 and October 2031. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have 12 registered trademarks in the United States and have filed for two more. In other countries, we have focused on registering three primary trademarks: &#8220;iFuse Implant System,&#8221; &#8220;SI-BONE,&#8221; and the SI-BONE logo. As of December 31, 2018, we have sought protection for at least two of these trademarks in 60 countries including the 28 European member countries of the Madrid Protocol. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely upon trade secrets, know-how and continuing technological innovation, and may rely upon licensing opportunities in the future, to develop and maintain our competitive position. We may seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their employment. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. There can be no assurance that patents will be issued from any of our pending applications or that, if patents are issued, they will be of sufficient scope or strength to provide meaningful protection for our technology. Notwithstanding the scope of the patent protection available to us, a competitor could develop treatment methods or devices that are not covered by our patents but that compete with our proprietary technology and products. Furthermore, numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing products. Because patent applications can take many years to issue, there may be applications unknown to us, which applications may later result in issued patents that our existing or future products or proprietary technologies may be alleged and/or found to infringe. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or know-how and brands, to defend against claims of infringement of the rights of others or to determine the scope and validity of the proprietary rights of others. Litigation could be costly and could divert our attention from other functions and responsibilities. Adverse determinations in litigation could reduce the barriers to entry that we have established for iFuse, or subject us to significant liabilities to third parties, require us to seek licenses from third parties or prevent us from manufacturing, selling or using iFuse, any of which could severely harm our business. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="s88fe0b7f2c814c1fbbac6b4552f28c44"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulation </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Domestic Regulation of Our Products and Business </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in the United States and other countries. Most notably, all of our products sold in the United States are subject to the FDCA as implemented and enforced by the FDA. The FDA governs the following activities that we perform or that are performed on our behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.96296296296296%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product design, development, and manufacture;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product safety, testing, labeling, and storage;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">record keeping procedures;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product marketing, sales, distribution and export; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-marketing surveillance, complaint handling, medical device reporting, reporting of deaths, serious injuries or device malfunctions, and repair or recall of products.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are numerous FDA regulatory requirements governing the clearance or approval and marketing of our products. These include: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">investigational device exemptions to conduct premarket clinical trials, which include extensive monitoring, recordkeeping, and reporting requirements;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clearance of product modifications that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approval of product modifications that affect the safety or effectiveness of one of our approved devices;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-approval restrictions or conditions, including post-approval study commitments;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA&#8217;s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations; </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulations pertaining to voluntary recalls; and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">notices of corrections or removals.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have registered our facility with the FDA as a medical device manufacturer. The FDA has broad post-market and regulatory enforcement powers. We and our third-party manufacturers are subject to announced and unannounced inspections by the FDA to determine our compliance with the QSR and other regulations and these inspections may include the manufacturing facilities of our suppliers. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Premarket Clearance and Approval Requirements </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless an exemption applies, each medical device we wish to commercially distribute in the United States will require either premarket notification, or 510(k), clearance or approval of a PMA from the FDA. The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either Class I or II, which typically requires the manufacturer to submit to the FDA a premarket notification requesting permission to commercially distribute the device. This process is generally known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III, requiring a PMA. If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the &#8220;de novo&#8221; process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. All of our currently marketed products are Class II devices, subject to 510(k) clearance. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, PMA approval. The determination as to whether or not a modification could significantly affect the device&#8217;s safety or effectiveness is initially left to the manufacturer using available FDA guidance. Many minor modifications today are accomplished by a &#8220;letter to file&#8221; in which the manufacture documents the rationale for the change and why a new 510(k) is not required. However, the FDA may review such letters to file to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trials </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) clearance. Such trials for implanted devices such as iFuse generally require an investigational device exemption application, or IDE, approved in advance by the FDA for a specified number of subjects and study sites, unless the product is deemed a nonsignificant risk device eligible for more abbreviated IDE requirements. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements. Clinical trials must be conducted under the oversight of an institutional review board, or IRB, for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. To conduct a clinical trial, we also are required to obtain the subjects&#8217; informed consent in form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. We, the FDA, or the institutional review board, or IRB, could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and effectiveness of the device or may otherwise not be sufficient to obtain FDA clearance or approval to market the product in the United States. Similarly, in Europe the clinical study must be approved by a local ethics committee and in some cases, including studies with high- risk devices, by the ministry of health in the applicable country. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pervasive and Continuing Regulation </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After a device is placed on the market, numerous regulatory requirements continue to apply. These include: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.5925925925926%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the manufacturing process;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clearance of product modifications that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approval of product modifications that affect the safety or effectiveness of one of our approved devices;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-approval restrictions or conditions, including post-approval study commitments;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA&#8217;s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations; </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulations pertaining to voluntary recalls; and </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">notices of corrections or removals.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of some of our subcontractors. Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other regulatory authorities, which may result in sanctions including, but not limited to: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.22222222222223%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">untitled letters, warning letters, fines, injunctions, consent decrees, and civil penalties;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated expenditures to address or defend such actions</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">customer notifications for repair, replacement, refunds;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recall, detention or seizure of our products;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions or partial suspension or total shutdown of production;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusing or delaying our requests for 510(k) clearance or PMA approval of new products or modified products;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawing 510(k) clearances or PMA approvals that have already been granted;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to grant export approval for our products; or</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">criminal prosecution.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA inspected our facilities in May 2014. As a result, we received a Form 483 with three observations that have been since been corrected following a corrective and preventative action plan. We responded to the Agency in writing and the matter was closed as of October 2014. To date, the FDA has not taken any further actions with respect to the May 2014 inspection or its findings. The FDA inspected our facilities again in December 2016. As a result, no findings were noted. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Promotional Materials&#8212;&#8220;Off-Label&#8221; Promotion </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. If the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine, or criminal penalties. It is also possible that other federal, state, or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of the products would be impaired. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under the federal Lanham Act and similar state laws, competitors, and others can initiate litigation relating to advertising claims. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International Regulation of Our Products </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research, development and clinical programs, as well as our manufacturing and marketing operations, are subject to extensive regulation in other countries. For example, in the EEA our devices are required to comply with the Essential Requirements concerning medical devices. Compliance with these requirements entitles us to affix the CE mark to our medical devices, without which they cannot be commercialized in the EEA. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To demonstrate compliance with the Essential Requirements, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization designated by the competent authorities of a EEA country to conduct conformity assessments. The Notified Body typically audits and examines products&#8217; Technical File and the quality system for the manufacture, design and final inspection of our devices before issuing a CE Certificate of Conformity demonstrating compliance with the relevant Essential Requirements. Following the issuance of this CE Certificate of Conformity, we can draw up an EC Declaration of Conformity and affix the CE mark to the products covered by this CE Certificate of Conformity and the EC Declaration of Conformity. We have successfully completed several Notified Body audits since our original certification in November 2010. Following these audits, our Notified Body issued International Standards Organization Certificates and CE Certificates of Conformity allowing us to draw up an EC Declaration of Conformity and affix the CE mark to certain of our devices. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the product has been CE marked and placed on the market in the EEA, we must comply with a number of regulatory requirements relating to: </font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.11111111111111%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">registration of medical devices in individual EEA countries;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pricing and reimbursement of medical devices;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishment of post-marketing surveillance and adverse event reporting procedures;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Field Safety Corrective Actions, including product recalls and withdrawals; and</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interactions with physicians.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to comply with these requirements may result in enforcement measures being taken against us by the competent authorities of the EEA countries. These can include fines, administrative penalties, compulsory product withdraws, injunctions, and criminal prosecution. Such enforcement measures would have an adverse effect on our capacity to market our products in the EEA and, consequently, on our business and financial position. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, the advertising and promotion of our products in the EEA is subject to the provisions of the Medical Devices Directive, Directive 2006/114/EC concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other national legislation in the EEA countries governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Status </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2008, we received 510(k) clearance to market our first generation iFuse implant from the FDA. Since 2008, we have received additional FDA 510(k) clearances for new instruments, additional implant sizes and labeling changes. In the United States, the iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruptions and degenerative sacroiliitis. This includes conditions where symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months. Clinical Studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life. In the future, we plan to pursue additional 510(k) clearances for new products and changes to the current indication for iFuse. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2010, we obtained a CE Certificate of Conformity and affixed a CE mark to our iFuse Implant System to allow commercialization of iFuse in the EEA. In the EEA and Switzerland, iFuse is intended for sacroiliac joint fusion. Since 2010, we have added additional instruments, implant sizes and labeling updates and iFuse-3D, our second generation iFuse implant, to our product offerings in Europe. We plan to continue to work with our Notified Body to incorporate new products and labeling updates in our Technical Files for CE marking in European. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since July 2013, we have obtained approval for iFuse in regions beyond the United States and the EEA, including Australia, Canada, Hong Kong, Israel, Malaysia, New Zealand, Saudi Arabia, Singapore and Taiwan. We are currently collecting information to determine our regulatory strategy in Japan. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Healthcare Fraud and Abuse </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state governmental agencies and equivalent foreign authorities subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. These laws constrain the sales, marketing and other promotional activities of medical device manufacturers by limiting the kinds of financial arrangements we may have with hospitals, physicians and other potential purchases of our products. Federal healthcare fraud and abuse laws apply to our business when a customer submits a claim for an item or service that is reimbursed under Medicare, Medicaid, or other federally funded healthcare programs. Descriptions of some of the laws and regulations that may affect our ability to operate follows. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, items or services for which payment may be made, in whole or in part, under federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of, or a specific intent to violate, the law. The Anti-Kickback Statute is subject to evolving interpretations and has been applied by government enforcement officials to a number of common business arrangements in the medical device industry. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; however, those exceptions and safe harbors are drawn narrowly, and there is no exception or safe harbor for many common business activities. Failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute, but the legality of the arrangement will be evaluated on a case-by-case basis based on the totality of the facts and circumstances. A number of states also have anti-kickback laws that establish similar prohibitions that may apply to items or services reimbursed by government programs, as well as by any third-party payors, including commercial payors. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The civil False Claims Act prohibits, among other things, knowingly presenting or causing the presentation of a false or fraudulent claim for payment of federal funds, or knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. A claim including items or services resulting from a violation of the Anti- Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Actions under the False Claims Act may be brought by the government or as a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam </font><font style="font-family:inherit;font-size:10pt;">action by a private individual in the name of the government. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Qui tam </font><font style="font-family:inherit;font-size:10pt;">actions are filed under seal and impose a mandatory duty on the U.S. Department of Justice to investigate such allegations. Most private citizen actions are declined by the Department of Justice or dismissed by federal courts. However, the investigation costs for a company can be significant and material even if the allegations are without merit. There are also criminal penalties, including imprisonment and criminal fines, for making or presenting a false or fictitious or fraudulent claim to the federal government. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $11,181 to $22,363 per claim (adjusted annually for inflation). Because of the potential for large monetary exposure, healthcare companies often resolve allegations without admissions of liability for significant and sometimes material amounts to avoid the uncertainty of treble damages and per claim penalties that may awarded in litigation proceedings. Moreover, to avoid the risk of exclusion from federal healthcare programs as a result of a False Claims Act settlement, companies may enter into corporate integrity agreements with the government, which may impose substantial costs on companies to ensure compliance. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, HIPAA created federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The federal Physician Payment Sunshine Act, implemented by CMS as the Open Payments program, requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments or other &#8220;transfers of value&#8221; made to physicians and teaching hospitals, and requires applicable manufacturers to report annually to CMS ownership and investment interests held by physicians and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain states also mandate implementation of corporate compliance programs, impose restrictions on device manufacturer marketing practices, and/or require tracking and reporting of gifts, compensation, and other remuneration to healthcare professionals and entities. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FCPA and similar anti-bribery laws in other countries, such as the UKBA, generally prohibit companies and their intermediaries from making improper payments to government officials and/or other persons for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Violations of these federal and state fraud and abuse laws can subject us to administrative, civil, and criminal penalties, including imprisonment, substantial fines, penalties, damages, and exclusion from participation in federal healthcare programs, including Medicare and Medicaid. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Data Privacy and Security Laws </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to various federal, state and foreign laws that protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information by healthcare providers, such as HIPAA, as amended by HITECH, in the United States. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA requires the notification of patients, and other compliance actions, in the event of a breach of unsecured PHI. If notification to patients of a breach is required, such notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, we could be required to report the improper use or disclosure to the U.S. Department of Health and Human Services, or HHS, which would post the violation on its website, and to the media. Failure to comply with the HIPAA privacy and security standards can result in civil monetary penalties up to $55,910 per violation, not to exceed $1.68 million per calendar year for non-compliance of an identical provision, and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the European Union, we may be subject to laws relating to our collection, control, processing and other use of personal data (i.e. data relating to an identifiable living individual). We process personal data in relation to our operations. We process data of our employees, consultants and certain individuals who may be affiliated with our customers, including physician users of our products. The personal data may include sensitive personal data including health information. The data privacy regime in the EU includes the EU General Data Protection Regulation, or the GDPR, effective on May 25, 2018 and the E-Privacy Directive 2002/58/EC and national laws implementing each of them. Each EU Member State may adopt additional legislation implementing these regulations into its own national data privacy regime and therefore the laws may differ by jurisdiction, sometimes significantly. We need to ensure compliance with the rules in each jurisdiction where we are established or are otherwise subject to local privacy laws. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new EU-wide GDPR became applicable on May 25, 2018, replacing the data protection laws previously issued by each EU member state based on the Directive 95/46/EC. Unlike the Directive (which needed to be transposed at national level), the GDPR text is directly applicable in each EU Member State, resulting in a more uniform application of data privacy laws across the EU. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. It requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of information, increases requirements pertaining to pseudonymized (i.e., key-coded) data, introduces mandatory data breach notification requirements and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. Fines for non-compliance with the GDPR will be significant&#8212;the greater of EUR 20 million or 4% of global turnover. The GDPR provides that EU member states may introduce further conditions, including limitations, to the processing of genetic, biometric, or health data, which could limit our ability to collect, use and share personal data, or could cause our compliance costs to increase, ultimately having an adverse impact on our business. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the supervision of local data protection authorities in those jurisdictions where we are established or otherwise subject to applicable law. We depend on a number of third parties in relation to our provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions, and that they have sufficient technical and organizational security measures in place. Where we transfer personal data outside the EEA, we do so in compliance with the relevant data export requirements. We take our data protection obligations seriously, as any improper disclosure, particularly with regard to our customers&#8217; sensitive personal data, could negatively impact our business and/or our reputation. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="seea6aaccd48a41bdb468cbe1f8c3ebb1"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing and Supply </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use third-party manufacturers to produce our instruments and implants. The majority of our instruments have secondary manufacturing suppliers and we continually work with additional manufacturers to establish secondary suppliers. Our iFuse implants are currently provided by a single source, Orchid Bio-Coat, a division of Orchid Orthopedic Solutions LLC. In April 2016, we entered into a Quality and Manufacturing Agreement with Orchid MPS Holdings, LLC, or Orchid, which agreement was amended in March 2017, pursuant to which Orchid manufactures certain of our implants in accordance with our specifications. We purchase product under the agreement pursuant to purchase orders we are required to deliver against a blanket purchase order we provide based on our product forecast. However, while we are required to purchase the amounts forecast in the blanket purchase order, we are not required to purchase product in excess of a specified amount of inventory based on our original forecast. During the first year of the agreement, the prices we pay for products are fixed under the agreement; provided that on an annual basis thereafter we will meet with Orchid to review changes in direct costs beyond certain thresholds and may negotiate changes to prices based on such changes in costs. In addition, the prices we pay for product may be increased with our consent to the extent such products are ordered with delivery timelines shorter than agreed upon order timelines. The initial term of the agreement is three years; provided, however, the agreement may be terminated immediately by (a)(i) either party as the result of the other party&#8217;s bankruptcy or insolvency, (ii) in the case of Orchid, our failure to make payments for products purchased under the agreement if such failure continues for a specified period after notice from Orchid, or (iii) either party as the result of a material breach of the agreement and such breaching party fails to cure such breach within a specified period after notice from the non-breaching party, (b) us in the event Orchid fails to remedy any deficiencies we may identify pursuant to our right to inspect Orchid&#8217;s facilities under the agreement, and (c) either party with prior written notice as provided under the agreement. To mitigate supply risk, we carry a minimum of two months of reserve stock based on current sales estimates and typically place implant orders with Orchid prior to estimated demand. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also added a second source supplier for machine parts. On February 1, 2017, we entered into a non-exclusive Manufacturing, Quality and Supply Agreement with rms Company, or RMS, pursuant to which RMS manufactures certain of our implants in accordance with our specifications, including both purchased and sterilized iFuse-3D implants, as well as uncoated machined implants which are subsequently coated to become our finished first generation iFuse implants. We amended this agreement on July 7, 2017 to provide for our purchase of product pursuant to purchase orders we must deliver against a blanket purchase order we provide based on our product forecast. While we are required to purchase the amounts forecast in the blanket purchase order, we are not required to purchase product in excess of a specified amount of inventory based on our original forecast. During the initial three-year term of the agreement, the prices we pay for products are fixed under the agreement provided that if order volumes deviate from forecasted amounts beyond certain thresholds we or RMS may request to negotiate further price changes. After the initial term, the agreement automatically renews for successive one-year periods; provided, however, the agreement may be terminated early by either party in the event of a material breach of the agreement by the other party or by the insolvency of the other party. We may terminate the agreement at any time in the event (i) RMS fails to ship conforming product and such failure results in delays as specified in the agreement, (ii) RMS changes its manufacturing site without our prior approval, (iii) of a change of control of RMS, or (iv) RMS breaches a non-solicit covenant with respect to our employees or consultants. With respect to our first generation iFuse implant, the parts manufactured by RMS need to be coated by Orchid to finish the goods. RMS is currently our only supplier of iFuse-3D implants. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aside from quality agreements, we do not currently have manufacturing agreements with any of our other manufacturers and orders are controlled through purchase orders. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our manufacturing operations, and those of our suppliers, comply with regulations mandated by the FDA, as well as Medical Devices Directive regulations in the EEA. Manufacturing facilities that produce medical devices or component parts intended for distribution world-wide are subject to regulation and periodic planned and unannounced inspection by the FDA and other domestic and international regulatory agencies. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, products we sell are required to be manufactured in compliance with the FDA&#8217;s QSR, which covers the methods used in, and the facilities used for, the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage, and shipping. In international markets, we are required to obtain and maintain various quality assurance and quality management certifications. We have obtained the following international certifications: Quality Management System ISO13485, Full Quality Assurance Certification for the design and manufacture of iFuse, and a Design Examination certificate for iFuse. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to demonstrate continuing compliance with applicable regulatory requirements to maintain these certifications and will continue to be periodically inspected by international regulatory authorities for certification purposes. Further, we and certain of our suppliers are required to comply with all applicable regulations and current good manufacturing practices. As set forth above, these FDA and international regulations cover, among other things, the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage, and shipping of our products. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections. If we or our manufacturers fail to adhere to current good manufacturing practice requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory approvals, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="saa17a631c98a4e819518bc59595afc18"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Liability and Insurance </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacture and sale of our products subjects us to the risk of financial exposure to product liability claims. Our products are used in situations in which there is a risk of serious injury or death. We carry insurance policies which we believe to be customary for similar companies in our industry. We cannot assure you that these policies will be sufficient to cover all or substantially all losses that we experience. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We endeavor to maintain executive and organization liability insurance in a form and with aggregate coverage limits that we believe are adequate for our business purposes, but our coverage limits may prove not to be adequate in some circumstances. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s925747c5569841bbbb5cada04e32eab7"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, we had 183 employees, including sales and marketing, product development, general administrative and accounting, both domestically and internationally. As of December 31, 2018, we had a direct field sales organization of 83 in the United States and 19 in Europe. In the United States, we sell primarily through our direct field organization, and we have 30 third-party distributors. None of our employees is subject to a collective bargaining agreement, and we consider our relationship with our employees to be good. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s68b7c20a08d4425d95801724fe9ca038"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Company History </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE was founded in 2008 by the main inventor of iFuse and member of our board of directors, orthopedist Mark A. Reiley, M.D., our President, Chief Executive Officer, and Chairman, Jeffrey W. Dunn, and orthopedic surgeon Leonard Rudolf, M.D. Dr. Reiley previously invented balloon kyphoplasty and founded Kyphon Inc., which was sold to Medtronic plc in 2007. He also invented the INBONE total ankle replacement system, which was sold to Wright Medical Technology, Inc. in 2008. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4512dea9f84746c8afc5aa778c9792a1"></a></div><div style="line-height:130%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Information </font></div><div style="line-height:130%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We were incorporated in March 2008 in Delaware. Our principal executive offices are located at 471 El Camino Real, Suite 101, Santa Clara, California 95050 and our telephone number is (408)&#160;207-0700.&#160;Our website address is&#160;www.si-bone.com.&#160;The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only.</font></div><div style="line-height:130%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Annual Report on Form 10-K, Quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website. The information contained on or that can be accessed through our website is not incorporated by reference into this report, and you should not consider information on our website to be part of this report. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="sCE88869CFC4450D698B7232E95A77C24"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing in our common stock involves a high degree of risk. Investors should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and our stockholders may lose all or part of their investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Our Industry</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred significant operating losses since inception, we expect to continue to incur operating losses in the future, and we may not be able to achieve or sustain future profitability.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception in 2008. For </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had net losses of </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$157.2 million</font><font style="font-family:inherit;font-size:10pt;">. To date, we have financed our operations primarily through the proceeds of our initial public offering of our common stock, or IPO, private placements of equity securities, certain debt-related financing arrangements, and from sales of our products. We have devoted substantially all of our resources to research and development of our products, sales and marketing activities, investments in training and educating surgeons and other healthcare providers, and clinical and regulatory matters for our products. There can be no assurances that we will be able to generate sufficient revenue from our existing products or from any of our product candidates in development, and to transition to profitability and generate consistent positive cash flows. We expect that our operating expenses will continue to increase as we continue to build our commercial infrastructure, develop, enhance, and commercialize our existing and new products and incur additional operational and reporting costs associated with being a public company. As a result, we expect to continue to incur operating losses for the foreseeable future and may never achieve profitability. Furthermore, even if we do achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis. If we do not achieve profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our expected future capital requirements may depend on many factors including expanding our surgeon base, the expansion of our sales force, and the timing and extent of spending on the development of our technology to increase our product offerings. We may need additional funding to fund our operations but additional funds may not be available to us on acceptable terms on a timely basis, if at all. We may seek funds through borrowings or through additional rounds of financing, including private or public equity or debt offerings. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments, and engage in certain merger, consolidation or asset sale transactions. Any future debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Furthermore, we cannot be certain that additional funding will be available on acceptable terms, if</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at all. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to curtail planned activities to reduce costs, which will likely harm our ability to execute on our business plan and continue operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If hospitals, surgeons, and other healthcare providers are unable to obtain coverage and reimbursement from third-party payors for procedures performed using our products, adoption of our products may be delayed, and it is unlikely that they will gain further acceptance.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maintaining and growing sales of our products depends on the availability of adequate coverage and reimbursement from third-party payors, including government programs such as Medicare and Medicaid, private insurance plans, and managed care programs. Hospitals, surgeons, and other healthcare providers that purchase or use medical devices generally rely on third-party payors to pay for all or part of the costs and fees associated with the procedures performed with these devices.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adequate coverage and reimbursement for procedures performed with our products is central to the acceptance of our current and future products. We may be unable to sell our products on a profitable basis if third-party payors deny coverage, continue to deny coverage or reduce their current levels of payment, or if our costs of production increase faster than increases in reimbursement levels. For example, our sales decreased significantly after minimally invasive sacroiliac joint fusion was assigned to a Category III Current Procedure Terminology, or CPT, code effective July&#160;1, 2013. After implementation of this Category III CPT Code, surgeons were no longer able to consistently obtain reimbursement for procedures performed using our products. However, effective January&#160;1, 2015, minimally invasive sacroiliac joint fusion was assigned to a Category I CPT Code.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many private payors refer to coverage decisions and payment amounts determined by the Centers for Medicare and Medicaid Services, or CMS, which administers the Medicare program, as guidelines for setting their coverage and reimbursement policies. By </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, all Medicare Administrative Contractors were regularly reimbursing for minimally invasive sacroiliac joint fusion. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private payors that do not follow the Medicare guidelines may adopt different coverage and reimbursement policies for procedures performed with our products. Private commercial payors have been slower to adopt positive coverage policies for minimally invasive sacroiliac joint fusion, and many private payors still have policies that treat the procedure as experimental or investigational and do not regularly reimburse for the procedure. Future action by CMS or third-party payors may further reduce the availability of payments to physicians, outpatient surgery centers, and/or hospitals for procedures using our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The healthcare industry in the United States has experienced a trend toward cost containment as government and private insurers seek to control healthcare costs. Payors are imposing lower payment rates and negotiating reduced contract rates with service providers and being increasingly selective about the technologies and procedures they chose to cover. For example, several Blue Cross Blue Shield payors have recently adopted policies that treat 3D-printed orthopedic implants that come in standard sizes, rather than customized to the patient&#8217;s anatomy, such as our iFuse-3D implant, as experimental and investigational and therefore not eligible for reimbursement. There can be no guarantee that we will be able to provide the scientific and clinical data necessary to overcome these policies. Such policies may contribute to a decrease in sales of our iFuse-3D implants. Payors may adopt policies in the future restricting access to medical technologies like ours and/or the procedures performed using such technologies. Therefore, we cannot be certain that the procedures performed with each of our products will be reimbursed. There can be no guarantee that, should we introduce additional products in the future, payors will cover those products or the procedures in which they are used.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market acceptance of our products in foreign markets may depend, in part, upon the availability of coverage and reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment systems in international markets vary significantly by country and include both government-sponsored healthcare and private insurance. We may not obtain additional international coverage and reimbursement approvals in a timely manner, if at all. Our failure to receive such approvals would negatively impact market acceptance of our products in the international markets in which those approvals are sought.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the reimbursement provided by third-party payors to hospitals, surgeons, and other healthcare providers for procedures performed using our products is insufficient, adoption and use of our products and the prices paid for our implants may decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When an iFuse procedure is performed, both the surgeon and the healthcare facility, either a hospital or ambulatory surgical center, submit claims for reimbursement to the healthcare payor. Generally, the facility obtains a lump sum payment, or facility fee, for minimally invasive sacroiliac joint fusions. Our products are purchased by the facility, along with other supplies used in the procedure. The facility must also pay for its own fixed costs of operation, including certain operating room personnel involved in the procedure. If these costs exceed the facility fee reimbursement, the facility&#8217;s managers may discourage or restrict surgeons from performing the procedure in the facility or using certain technologies, such as our iFuse implants, to perform the procedure.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The national average Medicare payment per procedure to hospital outpatient departments increased from $10,538 to $14,704 effective January&#160;1, 2017. Effective January&#160;1, 2019, the national average Medicare payment to hospital outpatient departments is $15,402. Effective January&#160;1, 2019, the Medicare payment to an ambulatory surgical center for a sacroiliac joint fusion is $12,481. We believe that payments to facilities are generally adequate for these facilities to offer the iFuse procedure. However, there can be no guarantee that these facility fee payments will not decline in the future. The number of iFuse procedures performed and the prices paid for our implants may in the future decline if payments to facilities for minimally invasive sacroiliac joint fusions decline.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgeons are reimbursed separately for their professional time and effort to perform a surgical procedure. Prior to reassignment of minimally invasive sacroiliac joint fusion to a Category III CPT Code, the national average Medicare physician fee schedule payment to surgeons for CPT codes commonly used to submit claims for reimbursement for the iFuse procedure was approximately $1,000 and the procedure was commonly covered by both government and private commercial payors in the United States. In 2015, the national average physician payment for the new Category I CPT Code for minimally invasive sacroiliac fusion was $574, and we believe that this payment caused adoption of the procedure to slow. Effective January&#160;1, 2016, the national average Medicare payment for the Category I CPT code increased to $718, and the national average payment effective January&#160;1, 2019, is $720. Many private payors set their payment amounts with reference to the Medicare payment, often approximately 10% to 33% higher than the Medicare payment for a procedure. For some governmental programs, such as Medicaid, coverage and reimbursement differ from state to state, and some state Medicaid programs may not pay an adequate amount for the procedures performed with our products, if any payment is made at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that some surgeons view the current Medicare reimbursement amount as insufficient for the procedure, given the work effort involved with the procedure, including the time to diagnose the patient and obtain prior authorization from the patient&#8217;s health insurer if necessary. Many private payors require extensive documentation of a multi-step diagnosis before authorizing minimally invasive sacroiliac joint fusion for a patient. We believe that some private payors apply their own coverage policies and criteria inconsistently, and surgeons may not be able to consistently have minimally invasive sacroiliac fusions approved and covered. The perception by physicians that the reimbursement for minimally invasive sacroiliac joint fusion is insufficient to compensate them for the work required, including diagnosis, documentation, obtaining payor approval for the procedure, and burden on their office staff, may negatively affect the number of procedures performed and may therefore impede the growth of our revenues or cause them to decline.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">{{</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If healthcare payors reverse decisions to cover minimally invasive sacroiliac joint fusion exclusively when performed with iFuse and choose to reimburse for procedures performed with competitive products, our market share could decline, adversely affecting our revenues.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, 48 of the largest 65 U.S. private payors that we track and target have issued positive coverage policies covering the patented triangular design of our iFuse implants and excluding coverage of other products that are intended to fuse the sacroiliac joint because of the clinical evidence supporting the use of iFuse and the lack of clinical evidence supporting the use of other products. Additionally, the public hospital system in France initiated coverage for iFuse exclusively beginning September&#160;6, 2018. We believe that payors have adopted these exclusive coverage decisions due to the strength of our clinical evidence and in part due to recommendations of specialty benefit managers and healthcare technology assessment organizations. In 2018, AIM Specialty Health, Blue Cross Blue Shield Association Evidence Street, and eviCore Healthcare published positive coverage recommendations to their constituents and payor customers, recommending that iFuse be covered exclusively. Clinical trials of the type and size necessary to offer evidence of the safety and efficacy of competing products could be performed and could show that other products for sacroiliac joint fusion are as effective as, or more effective than, iFuse. Payors could also abandon their decisions to cover iFuse exclusively for other reasons.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to convince physicians that iFuse is an attractive alternative to our competitors&#8217; products and that our procedure is an attractive alternative to existing surgical and non-surgical treatments of the sacroiliac joint.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgeons play the primary role in determining the course of treatment in consultation with their patients and, ultimately, the product that will be used to treat a patient. In order for us to sell our iFuse solution successfully, we must convince surgeons through education and training that treatment with iFuse is beneficial, safe, and cost-effective for patients as compared to our competitors&#8217; products. If we are not successful in convincing surgeons of the merits of iFuse, they may not use our product, and we will be unable to increase our sales and achieve or grow profitability.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, most spine surgeons did not include sacroiliac joint pain in their diagnostic work-up because they did not have an adequate surgical procedure to perform for patients diagnosed with the condition. As a result, some patients with lower back pain resulting from sacroiliac joint dysfunction are misdiagnosed. We believe that educating surgeons and other healthcare professionals about the clinical merits and patient benefits of iFuse is an important element of our growth. If we fail to effectively educate surgeons and other medical professionals, they may not include a sacroiliac joint evaluation as part of their diagnosis and, as a result, those patients may continue to receive unnecessary or only non-surgical treatment.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgeons may also hesitate to change their medical treatment practices for other reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of experience with minimally invasive procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perceived liability risks generally associated with the use of new products and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs associated with the purchase of new products; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">time commitment that may be required for training.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we believe surgeons will not widely use iFuse unless they determine, based on experience, clinical data, and published peer-reviewed publications, that surgical intervention provides benefits or is an attractive alternative to non-surgical treatments of sacroiliac joint dysfunction. In addition, we believe support of our products relies heavily on long-term data showing the benefits of using our products. If we are unable to provide that data, surgeons may not use our products. In such circumstances, we may not achieve expected sales and may be unable to achieve profitability.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Surgeons and payors may not find our clinical evidence to be compelling, which could limit our sales and revenue, and on-going and future research may prove our products to be less safe and effective than initially anticipated.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The products we currently market in the United States have either received premarket clearance under Section&#160;510(k) of the U.S. Federal Food, Drug, and Cosmetic Act, or FDCA, or are exempt from premarket review. Those marketed in the European Union, or EU, have been the subject of a CE Certificate of Conformity. The 510(k) clearance process of the U.S. Food and Drug Administration, or FDA, requires us to document that our product is &#8220;substantially equivalent&#8221; to another 510(k)-cleared products. The 510(k) process is shorter and typically requires the submission of less supporting documentation than other FDA approval processes, such as a premarket approval, or PMA, and does not usually require pre-clinical or clinical studies. Additionally, to date, we have not been required to complete clinical studies in connection with the sale of our products outside the United States. As a result, while there are a number of published studies relating to iFuse and minimally invasive sacroiliac joint surgery that support the safety and effectiveness of our products and the benefits they offer, our clinical studies may lack the size and scope of randomized controlled clinical trials required to support approval of a PMA. For these reasons, surgeons may be slow to adopt our products, third-party payors may be slow to provide coverage, and we may be subject to greater regulatory and product liability risks. Further, future patient studies or clinical experience may indicate that treatment with our products does not improve patient outcomes. Such results would slow the adoption of our products by surgeons, significantly reduce our ability to achieve expected sales, and could prevent us from achieving profitability. Moreover, if future results and experience indicate that our products cause unexpected or serious complications or other unforeseen negative effects, we could be subject to mandatory product recalls, suspension, or withdrawal of FDA clearance, and suspension, variation, or withdrawal of our CE Certificates of Conformity, significant legal liability or harm to our business reputation, which could have a material adverse effect on our results or operations and financial condition. Similar risks apply to product approvals and registrations in other countries outside the United States and the EU as well.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pricing pressure from our competitors, changes in third-party coverage and reimbursement, healthcare provider consolidation, payor consolidation and the proliferation of &#8220;physician-owned distributorships&#8221; may impact our ability to sell our product at prices necessary to support our current business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If competitive forces drive down the prices we are able to charge for our product, our profit margins will shrink, which will adversely affect our ability to invest in and grow our business. The sacroiliac joint fusion market has attracted numerous new companies and technologies. As a result of this increased competition, we believe there will be continuing increased pricing pressure, resulting in lower gross margins, with respect to our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even to the extent our product and procedures using our product are currently covered and reimbursed by third-party private and public payors, adverse changes in coverage and reimbursement policies that affect our products, discounts, and number of implants used may also drive our prices down and harm our ability to market and sell our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are unable to predict what changes will be made to the reimbursement methodologies used by third-party payors. We cannot be certain that under current and future payment systems, in which healthcare providers may be reimbursed a set amount based on the type of procedure performed, such as those utilized by Medicare and in many privately managed care systems, the cost of our products will be justified and incorporated into the overall cost of the procedure. In addition, to the extent there is a shift from inpatient setting to outpatient settings, we may experience pricing pressure and a reduction in the number of iFuse procedures performed.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidation in the healthcare industry, including both third-party payors and healthcare providers, could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, results of operations, or financial condition. Because healthcare costs have risen significantly over the past several years, numerous initiatives and reforms initiated by legislators, regulators, and third-party payors to curb these costs have resulted in a consolidation trend in the healthcare industry to aggregate purchasing power. As the healthcare industry consolidates, competition to provide products and services to industry participants has become and will continue to become more intense. This in turn has resulted and will likely continue to result in greater pricing pressures and the exclusion of certain suppliers from important market segments as group purchasing organizations, independent delivery networks, and large single accounts continue to use their market power to consolidate purchasing decisions for hospitals. We expect that market demand, government regulation, third-party coverage, and reimbursement policies and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may reduce competition, exert further downward pressure on the prices of our products, and adversely impact our business, results of operations, or financial condition. As we continue to expand into international markets, we will face similar risks relating to adverse changes in coverage and reimbursement procedures and policies in those markets.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physician-owned distributorships, or PODs, are medical device distributors that are owned, directly or indirectly, by physicians. These physicians profit from selling or arranging the sale of medical devices for use in procedures they perform on their own patients at hospitals that purchase the devices from the POD. We currently do not engage with PODs. The proliferation of PODs could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales and operating results may be negatively affected and we may not grow.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our currently marketed products are, and any future products we commercialize will likely be, subject to intense competition. Our field is subject to rapid change and highly sensitive to the introduction of new products or other market activities of industry participants. Our ability to compete successfully will depend on our ability to develop proprietary products that reach the market in a timely manner, receive adequate coverage and reimbursement from third-party payors, and are safer, less invasive, and more effective than alternatives available for similar purposes as demonstrated in peer-reviewed clinical publications. Because of the size of the potential market, we anticipate that other companies will dedicate significant resources to developing competing products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of competitors that we are aware of marketing sacroiliac joint fusion products in the United States has grown from zero to 22 since 2008. Many of our current and potential competitors are major medical device companies that have substantially greater financial, technical, and marketing resources than we do, and they may succeed in developing products that would render our products obsolete or noncompetitive. In addition, many of these competitors have significantly longer operating history and more established reputations than we do. Some of these companies sell a broad suite of products that can be used together in the operating room in order to facilitate surgery, such as surgical imaging, navigation and robotic systems, or a large number of implants intended to treat different conditions affecting the spine and pelvis.  The ability of these competitors to sell these products together or as part of larger purchasing arrangements may put as at a disadvantage.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, we believe that our primary competitors currently are Globus Medical, Inc., Medtronic plc, XTant Medical Holdings and RTI Surgical, Inc. Our primary competitors in Europe are Globus Medical, SIGNUS Medizintechnik GmbH, and XTant Medical Holdings. At any time, these or other industry participants may develop alternative treatments, products or procedures for the treatment of the sacroiliac joint that compete directly or indirectly with our products. They may also develop and patent processes or products earlier than we can or obtain domestic and international regulatory clearances or approvals and CE Certificates of Conformity for competing products in the European Economic Area, or EEA, more rapidly than we can, which could impair our ability to develop and commercialize similar processes or products. If alternative treatments are, or are perceived to be, superior to our products, sales of our products and our results of operations could be negatively affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of our larger competitors are either publicly traded or divisions or subsidiaries of publicly traded companies. These competitors may enjoy several competitive advantages over us, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater financial, human, and other resources for product research and development, sales and marketing, and legal matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significantly greater name recognition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">established relationships with surgeons, hospitals, and other healthcare providers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">large and established sales and marketing and distribution networks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater experience in obtaining and maintaining domestic and international regulatory clearances or approvals, or CE Certificates of Conformity for products and product enhancements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">more expansive portfolios of intellectual property rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">greater ability to cross-sell their products or to incentivize hospitals or surgeons to use their products.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New participants have increasingly entered the medical device industry. Many of these new competitors specialize in a specific product or focus on a particular market segment, making it more difficult for us to increase our overall market position. The frequent introduction by competitors of products that are or claim to be superior to our products or that are alternatives to our existing or planned products may make it difficult to differentiate the benefits of our products over competing products. In addition, the entry of multiple new products and competitors may lead some of our competitors to employ pricing strategies that could adversely affect the pricing of our products and pricing in the market generally.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result, without the timely introduction of new products and enhancements, our products may become obsolete over time. If we are unable to develop innovative new products, maintain competitive pricing, and offer products that surgeons and other physicians perceive to be as reliable as those of our competitors, our sales or margins could decrease, thereby harming our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently manufacture and sell products used in a single procedure, which could negatively affect our operations and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not sell any product other than iFuse and related tools and instruments. Therefore, we are solely dependent on widespread market adoption of iFuse and we will continue to be dependent on the success of this single product for the foreseeable future. There can be no assurance that iFuse will gain a substantial degree of market acceptance among surgeons, patients or healthcare providers. Our failure to successfully increase sales of iFuse or any other event impeding our ability to sell iFuse, would result in a material adverse effect on our results of operations, financial condition and continuing operations.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to maintain and expand our network of direct sales representatives and third-party distributors, we may not be able to generate anticipated sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our U.S. sales force consisted of 45 sales representatives directly employed by us and 30 third-party distributors. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, our international sales force consisted of 14 sales representatives and 23 exclusive third-party distributors, which together have had sales in 33 countries through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Our operating results are directly dependent upon the sales and marketing efforts of both our direct sales force and of our third-party distributors.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As we launch new products and increase our marketing efforts with respect to existing products, we will need to expand the reach of our marketing and sales networks. Our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled direct sales representatives and third-party distributors with significant technical knowledge in various areas, such as spine health and treatment. New hires require training and take time to achieve full productivity. If we fail to train new hires adequately, or if we experience high turnover in our sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. Our intention is for our direct sales representatives and third-party distributors to develop long-lasting relationships with the surgeons they serve. If our direct sales representatives or third-party distributors fail to adequately promote, market and sell our products or decide to leave or cease to do business with us, our sales could significantly decrease.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face significant challenges and risks in managing our geographically dispersed distribution network and retaining the individuals who make up that network. Some of our international third-party distributors account for a significant portion of our international sales volume, and if any such third-party distributor were to cease to distribute our products, our sales could be adversely affected. In such a situation, we may need to seek alternative third-party distributors or increase our reliance on our direct sales representatives, which may not prevent our sales from being adversely affected. If a direct sales representative or third-party distributor were to depart and be retained by one of our competitors, we may be unable to prevent them from helping competitors solicit business from our existing customers, which could further adversely affect our sales. Because of the intense competition for their services, we may be unable to recruit or retain additional qualified third-party distributors or to hire additional direct sales representatives to work with us. Furthermore, we may not be able to enter into agreements with them on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified direct sales representatives or third-party distributors would prevent us from expanding our business and generating sales.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, distribution arrangements are complex and time consuming to negotiate and document, especially outside the United States. We may not be able to negotiate distribution arrangements on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of our products, delay their potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our products or bring them to market and generate revenue.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to expand our sales and marketing capabilities domestically and internationally, we may not be able to effectively commercialize our products, which would adversely affect our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a limited operating history and may face difficulties encountered by early stage companies in new and rapidly evolving markets.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were formed in 2008. Accordingly, we have a limited operating history upon which to base an evaluation of our business and prospects. In assessing our prospects, investors must consider the risks and difficulties frequently encountered by early stage companies in new and rapidly evolving markets, particularly companies engaged in the development and sales of medical devices. These risks include our inability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increase coverage by third-party, private, and government payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish and increase awareness of our brand and strengthen customer loyalty;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain domestic and international regulatory clearances or approvals, and CE Certificates of Conformity;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conformity to commercialize new products and enhance our existing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manage rapidly changing and expanding operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">grow our direct sales force and increase the number of our third-party distributors to expand sales of our products in the United States and in targeted international markets;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">implement and successfully execute our business and marketing strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">respond effectively to competitive pressures and developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to develop and enhance our products and product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expand our presence and commence operations in international markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">perform clinical research and trials on our existing products and current and future product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">attract and retain qualified personnel.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We can also be negatively affected by general economic conditions. Because of our limited operating history, we may not have insight into trends that could emerge and negatively affect our business. As a result of these or other risks, our business strategy might not be successful.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our sales volumes and our operating results may fluctuate over the course of the year.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have experienced and continue to experience meaningful variability in our sales and gross profit from quarter to quarter, as well as within each quarter. Our sales and results of operations will be affected by numerous factors, including, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payor coverage and reimbursement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of products sold in the quarter and our ability to drive increased sales of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to establish and maintain an effective and dedicated sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pricing pressure applicable to our products, including adverse third-party coverage and reimbursement outcomes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">results of clinical research and trials on our existing products and products in development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the mix of our products sold because profit margins differ amongst our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability of our suppliers to timely provide us with an adequate supply of materials and components;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the evolving product offerings of our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the demand for, and pricing of, our products and the products of our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">factors that may affect the sale of our products, including seasonality and budgets of our customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">domestic and international regulatory clearances or approvals, or CE Certificates of Conformity, and legislative changes affecting the products we may offer or those of our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interruption in the manufacturing or distribution of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing technological, industry and market developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to expand the geographic reach of our sales and marketing efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of maintaining adequate insurance coverage, including product liability insurance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability and cost of components and materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of selling days in the quarter;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fluctuation in foreign currency exchange rates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment and other special charges.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the products we may seek to develop and introduce in the future will require FDA clearance or approval before commercialization in the United States, and commercialization of such products outside of the United States would likely require additional regulatory approvals, or Certificates of Conformity and import licenses. As a result, it will be difficult for us to forecast demand for these products with any degree of certainty. In addition, we will be increasing our operating expenses as we expand our commercial capabilities. Accordingly, we may experience significant, unanticipated losses. If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. Quarterly comparisons of our financial results may not always be meaningful and should not be relied upon as an indication of our future performance.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our business strategy proves to be flawed, or if we do not successfully implement our business strategy, our business and results of operations will be adversely affected</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business strategy was based on assumptions about the market that might prove wrong. We believe that various demographics and industry-specific trends will help drive growth in the market and our business, but these demographics and trends have been and will continue to be uncertain. Actual demand for our products could differ materially from projected demand if our assumptions regarding these factors prove to be incorrect or do not materialize, or if alternative treatments to those offered by our products gain widespread acceptance.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To implement our business strategy we need to, among other things, develop and introduce new products, find new applications for and improve our existing products, obtain new domestic and international regulatory clearances or approvals and CE Certificates of Conformity and domestic and international regulatory clearance or approval for new products and applications, and educate surgeons and payors about the clinical benefits and cost effectiveness of our products. We may not be able to successfully implement our business strategy. Also, our strategy of focusing exclusively on the sacroiliac joint market may limit our ability to grow. In addition, in order to increase our sales, we will need to commercialize additional products and expand our direct and third-party distributor sales forces in existing and new regions, all of which could result in our becoming subject to additional or different foreign and domestic regulatory requirements, with which we may not be able to comply. Moreover, we may decide to alter or discontinue aspects of our business strategy and may adopt different strategies due to business or competitive factors not currently foreseen, such as new medical technologies that would make our products obsolete. Any failure to implement our business strategy may adversely affect our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are dependent upon the continued services of key members of our senior management and a limited number of key advisors and personnel. In particular, we are highly dependent on the skills and leadership of our President, Chief Executive Officer, and Chairman, Jeffrey W. Dunn. The loss of members of our senior management team, key advisors or personnel, or our inability to attract or retain other qualified personnel or advisors, could have a material adverse effect on our business, results of operations, and financial condition. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees. In addition, several of the members of our executive management team are not subject to non-competition agreements that restrict their ability to compete with us. Accordingly, the adverse effect resulting from the loss of certain executives could be compounded by our inability to prevent them from competing with us.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although currently subject to lock-up agreements and other restrictions on trading, a portion of the equity of our management team will not contain other contractual transfer restrictions and may become tradable in April 2019 after the expiration of the lock-up agreements entered into with the underwriters in our IPO. This liquidity may represent material wealth to such individuals and impact retention and focus of existing key members of management.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products may have undesirable side effects which may require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unforeseen adverse events related to our products could arise either during clinical development or, if cleared, approved, or subject to CE Certificate of Conformity, after the product has been marketed. In clinical research, the most common adverse event related to our implant was leg pain resulting from misplacement. The most common adverse event for our implant procedure has been minor wound infections. Additional adverse effects from iFuse or any of our other products could arise either during clinical development or, if approved, cleared, or subject to CE Certificate of Conformity, after the product has been marketed.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we or others later identify adverse events caused by our products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of the product may decrease significantly and we may not achieve the anticipated market share;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities or our Notified Body may require changes to the labeling of our product. This may include the addition of labeling statements, specific warnings, and contraindications and issuing field alerts to physicians and patients;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to change instructions regarding the way the product is implanted or conduct additional clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to limitations on how we may promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to take our approved product off the market (temporarily or permanently) or to conduct other field safety corrective actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to modify our product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to litigation fines or product liability claims; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Various factors outside our direct control may adversely affect manufacturing, sterilization, and distribution of our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacture, sterilization, and distribution of our products is challenging. Changes that our suppliers may make outside the purview of our direct control can have an impact on our processes, quality of our products, and the successful delivery of products to our customers. Mistakes and mishandling are not uncommon and can affect supply and delivery. Some of these risks include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to complete sterilization on time or in compliance with the required regulatory standards;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">transportation and import and export risk;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in analytical results or failure of analytical techniques that we will depend on for quality control and release of products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">natural disasters, labor disputes, financial distress, raw material availability, issues with facilities and equipment, or other forms of disruption to business operations affecting our manufacturers or suppliers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">latent defects that may become apparent after products have been released and that may result in a recall of such products.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these risks were to materialize, our ability to provide our products to customers on a timely basis would be adversely impacted.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on a limited number of third-party suppliers, some of them single-source and some of them in single locations, for most of our products and components, and the loss of any of these suppliers, or their inability to provide us with an adequate supply of materials in a timely and cost-effective manner, could materially adversely affect our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on third-party suppliers to supply substantially all of our products. For us to be successful, our suppliers must be able to provide us with products and components in substantial quantities, in compliance with regulatory requirements, in accordance with agreed upon specifications, at acceptable prices, and on a timely basis. We do not have long-term supply contracts for some of our suppliers, and in some cases, even where we do have agreements in place, we purchase important parts of the iFuse Implant System from a single supplier. Therefore, we cannot assure investors that we will be able to obtain sufficient quantities of product in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our anticipated growth could strain the ability of our suppliers to deliver an increasingly large supply of products, materials, and components. Suppliers often experience difficulties in scaling up production, including financial issues, or problems with production yields and quality control and assurance. For example, from time to time, we have experienced certain delays and may experience delays from our suppliers in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally use a small number of suppliers for our instruments and rely on one supplier, Orchid Bio-Coat, a division of Orchid Orthopedic Solutions LLC, for our iFuse implants and one supplier, rms Company, for our second-generation iFuse-3D implants. Our dependence on such a limited number of suppliers exposes us to risks, including, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party contract manufacturers or suppliers may fail to comply with regulatory requirements or make errors in manufacturing that could negatively affect the safety or effectiveness of our products or cause delays in shipments of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party contract manufacturers or suppliers may fail to maintain good manufacturing practices, leading to quality control problems or regulatory findings that could cause disruptions in their manufacturing processes and lead to delays in shipments of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our third-party manufacturers and suppliers may not be able to respond to unanticipated changes in customer orders, and if orders do not match forecasts, we or our suppliers may have excess or inadequate inventory of materials and components;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our third-party manufacturers and suppliers may be subject to price fluctuations due to a lack of long-term supply arrangements for key components;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our third-party manufacturers and suppliers may lose access to critical services and components, resulting in an interruption in the manufacture, assembly and shipment of our systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may experience delays in delivery by our third-party manufacturers and suppliers due to changes in demand from us or their other customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fluctuations in demand for products that our third-party manufacturers and suppliers manufacture for others may affect their ability or willingness to deliver components to us in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our third-party manufacturers and suppliers may wish to discontinue supplying components or services to us for risk management reasons;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to find new or alternative components or reconfigure our system and manufacturing processes in a timely manner if the necessary components become unavailable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our third-party manufacturers and suppliers may encounter financial hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any one or more of these risks materialize, it could significantly increase our costs and impact our ability to meet demand for our products. If we are unable to satisfy commercial demand for our system in a timely manner, our ability to generate revenue would be impaired, market acceptance of our products could be adversely affected, and customers may instead purchase or use our competitors&#8217; products. Additionally, we could be forced to seek alternative sources of supply.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, most of our supply and manufacturing agreements do not have minimum manufacturing or purchase obligations. As such, with many of our suppliers, we have no obligation to buy any given quantity of products, and the suppliers have no obligation to sell us or to manufacture for us any given quantity of components or products. As a result, our ability to purchase adequate quantities of components or our products may be limited and we may not be able to convince suppliers to make components and products available to us in some instances. Our suppliers may also encounter problems that limit their ability to supply components or manufacture products for us, including financial difficulties, damage to their manufacturing equipment or facilities, product discontinuations or adverse findings in quality audits. As a result, there is a risk that certain components could be discontinued and no longer available to us. We may be required to make significant &#8220;last time&#8221; purchases of component inventory that is being discontinued by the supplier to ensure supply continuity. If we fail to obtain sufficient quantities of high quality components to meet demand for our products in a timely manner or on terms acceptable to us, we would have to seek alternative sources of supply. Securing a replacement third-party manufacturer or supplier could be difficult. The introduction of new or alternative manufacturers or suppliers also may require design changes to our iFuse system that are subject to domestic and international regulatory clearances or approvals and the review of our Notified Body.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the nature of our internal quality control requirements, regulatory requirements, and the custom and proprietary nature of the parts, we may not be able to quickly engage additional or replacement suppliers for many of our critical components. We may also be required to assess any potential new manufacturer&#8217;s compliance with all applicable regulations and guidelines, which could further impede our ability to manufacture our products in a timely manner. As a result, we could incur increased production costs, experience delays in deliveries of our products, suffer damage to our reputation, and experience an adverse effect on our business and financial results. Failure of any of our third-party suppliers to meet our product demand level would limit our ability to meet our sales commitments to our customers and could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA our Notified Body the competent authorities in the countries of the EEA, or other foreign regulatory authorities, and the failure of our suppliers to comply with strictly enforced regulatory requirements could expose us to delays in obtaining clearances or approvals, regulatory action including warning letters, product recalls, termination of distribution, product seizures, civil, administrative, or criminal penalties and the suspension, variation, or withdrawal of our CE Certificates of Conformity. We could incur delays while we locate and engage qualified alternative suppliers, and we may be unable to engage alternative suppliers on favorable terms or at all. Any such disruption or increased expenses could harm our commercialization efforts and adversely affect our ability to generate sales.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, each of our third-party suppliers operates at a facility in a single location and substantially all of our inventory of component supplies and finished goods is held at these locations. We, and our suppliers, take precautions to safeguard facilities, including acquiring insurance, employing back-up generators, adopting health and safety protocols, and utilizing off-site storage of computer data. However, vandalism, terrorism, or a natural or other disaster, such as an earthquake, fire, or flood, could damage or destroy equipment or our inventory of component supplies or finished products, cause substantial delays in our operations, result in the loss of key information, and cause us to incur additional expenses. Our insurance may not cover our losses in any particular case. In addition, regardless of the level of insurance coverage, damage to our or our suppliers&#8217; facilities could harm our business, financial condition, and operating results.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">As our sales grow, we may encounter problems or delays in the assembly of our products or fail to meet certain regulatory requirements which could result in an adverse effect on our business and financial results.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To become profitable, we must assemble our products in adequate quantities in compliance with regulatory requirements and at an acceptable cost. Increasing our capacity to assemble and test our products will require us to improve internal efficiencies. We may encounter a number of difficulties in increasing our assembly and testing capacity, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">managing production yields;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintaining quality control and assurance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">providing component and service availability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintaining adequate control policies and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">hiring and retaining qualified personnel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">complying with state, federal, and foreign regulations.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to satisfy commercial demand for our iFuse solution due to our inability to assemble and test, our ability to generate revenue would be impaired, market acceptance of our products could be adversely affected and customers may instead purchase or use our competitors&#8217; products.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not enhance our product offerings through our research and development efforts, we may be unable to compete effectively.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to increase our market share in the sacroiliac joint fusion market, we must enhance and broaden our product offerings in response to changing customer demands and competitive pressures and technologies. We might not be able to successfully develop, obtain domestic and international regulatory clearances or approvals, or CE Certificates of Conformity for, or market new products, and our future products might not be accepted by the surgeons or the third-party payors who reimburse for many of the procedures performed with our products. The success of any new product offering or enhancement to an existing product will depend on numerous factors, including our ability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">properly identify and anticipate surgeon and patient needs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">develop and introduce new products or product enhancements in a timely manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrate the safety and effectiveness of new products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain the necessary domestic and international regulatory clearances or approvals and CE Certificates of Conformity for new products or product enhancements.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we do not develop and obtain domestic and international regulatory clearances or approvals and CE Certificates of Conformity for new products or product enhancements in time to meet market demand, or if there is insufficient demand for these products or enhancements, our results of operations will suffer. Our research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material, or other innovation. In addition, even if we are able to successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not produce sales in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are required to maintain adequate levels of inventory, the failure of which could consume our resources and reduce our cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the need to maintain adequate levels of inventory, we are subject to the risk of inventory obsolescence. Many of our products come in sets, which feature components in a variety of sizes so that the implant or device may be customized to the patient&#8217;s needs. In order to market our products effectively, we often maintain and provide surgeons and hospitals with back-up products and products of different sizes. For each surgery, fewer than all of the components of the set are used, and therefore certain portions of the set may become obsolete before they can be used. In the event that a substantial portion of our inventory becomes obsolete, it could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The size and future growth in the market for iFuse has not been established with precision and may be smaller than we estimate, possibly materially. In addition, our estimates of cost savings to the economy and healthcare system as a result of the iFuse procedure are based on our internal estimates and market research and could also be smaller than we estimate, possibly materially. If our estimates and projections overestimate the size of this market or cost savings, our sales growth may be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not aware of an independent third-party study that reliably reports the potential market size for iFuse or cost savings as a result of the iFuse procedure. Therefore, our estimates of the size and future growth in the market for our iFuse products, including cost savings to the economy overall, including patients and employers, and to the healthcare system and the number of people currently suffering from lower back pain who may benefit from and be amenable to our iFuse procedure, is based on a number of internal and third-party studies, surveys, reports, and estimates. While we believe these factors have historically provided and may continue to provide us with effective tools in estimating the total market for our iFuse products and procedures and health cost savings, these estimates may not be correct and the conditions supporting our estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. For example, the surveys we have conducted are based on a small number of respondents and are not statistically significant and may have other limitations. The actual incidence of lower back pain, and the actual demand for our products or competitive products, could differ materially from our projections if our assumptions and estimates are incorrect. As a result, our estimates of the size and future growth in the market for our iFuse products may prove to be incorrect. In addition, actual health cost savings to the healthcare system as a result of the iFuse procedure may materially differ from those we expect. If the actual number of people with lower back pain who would benefit from our iFuse products and the size and future growth in the market for iFuse products and related costs savings to the healthcare system is smaller than we have estimated, it may impair our projected sales growth and have an adverse impact on our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our results of operations could suffer if we are unable to manage our planned international expansion effectively.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expansion into international markets is an element of our business strategy and involves risk. The sale and shipment of our products across international borders, as well as the purchase of components and products from international sources, subject us to extensive U.S. and foreign governmental trade, import, and export and customs regulations and laws. Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly affect us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, and the United Kingdom Bribery Act, or UKBA, anti-boycott laws, anti-money laundering laws, and regulations relating to economic sanctions imposed by the United States, including the Office of Foreign Asset Control of the U.S. Treasury. Any failure to comply with applicable legal and regulatory obligations in the United States or abroad could adversely affect us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments and restrictions on certain business activities. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our distribution and sales activities.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, some of the countries in which we sell or plan to sell our products are, to some degree, subject to various risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exposure to different legal and regulatory standards;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of stringent protection of intellectual property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obstacles to obtaining domestic and foreign export, import, and other governmental approvals, permits, and licenses and compliance with foreign laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potentially adverse tax consequences and the complexities of foreign value-added tax systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse changes in tariffs and trade restrictions;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations on the repatriation of earnings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulties in staffing and managing foreign operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">transportation delays and difficulties of managing international distribution channels;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">longer collection periods and difficulties in collecting receivables from foreign entities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased financing costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">currency risks; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">political, social, and economic instability and increased security concerns.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These risks may limit or disrupt our expansion, restrict the movement of funds or result in the deprivation of contractual rights or the taking of property by nationalization or expropriation without fair compensation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal of a successful international expansion depends, in part, on our ability to develop and implement policies and strategies that are effective in anticipating and managing these and other risks in the countries in which we plan to do business. Failure to manage these and other risks may have a material adverse effect on our operations in any particular country and on our business as a whole.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">In the future our products may become obsolete, which would negatively affect operations and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical device industry is characterized by rapid and significant change. There can be no assurance that other companies will not succeed in developing or marketing devices, and products that are more effective than our iFuse system or that would render the iFuse system obsolete or noncompetitive. Additionally, new surgical procedures, medications and other therapies could be developed that replace or reduce the importance of our product. Accordingly, our success will depend in part on our ability to respond quickly to medical and changes through the development and introduction of new products. Product development involves a high degree of risk and there can be no assurance that our new product development efforts will result in any commercially successful products.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we experience significant disruptions in our information technology systems, our business, results of operations, and financial condition could be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The efficient operation of our business depends on our information technology systems. We rely on our information technology systems to effectively manage:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales and marketing, accounting, and financial functions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inventory management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">engineering and product development tasks; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our research and development data.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our information technology systems are vulnerable to damage or interruption from:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">earthquakes, fires, floods, and other natural disasters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">terrorist attacks and attacks by computer viruses or hackers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">power losses; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">computer systems, or Internet, telecommunications, or data network failures.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The failure of our information technology systems to perform as we anticipate or our failure to effectively implement new systems could disrupt our entire operation and could result in decreased sales, increased overhead costs, excess inventory and product shortages, and legal liability issues, all of which could have a material adverse effect on our reputation, business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we accept payments for many of our sales through credit card transactions, which are handled through a third-party payment processor. As a result, we are subject to a number of risks related to credit card payments. As a result of these transactions, we pay interchange and other fees, which may increase over time and could require us to either increase the prices we charge for our products or experience an increase in our costs and expenses. In addition, as part of the payment processing process, we transmit our customers&#8217; credit card information to our third-party payment processor. We may in the future become subject to lawsuits or other proceedings for purportedly fraudulent transactions arising out of the actual or alleged theft of our customers&#8217; credit card information if the security of our third-party credit card payment processor is breached. We and our third-party credit card payment processor are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers, which could change or be reinterpreted to make it difficult or impossible for us to comply. If we or our third-party credit card payment processor fail to comply with these rules or requirements, we may be subject to fines and higher transaction fees and lose our ability to accept credit card payments from our customers, and there may be an adverse impact on our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may seek to grow our business through acquisitions of or investments in new or complementary businesses, products or technologies, and the failure to manage acquisitions or investments, or the failure to integrate them with our existing business, could have a material adverse effect on us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we expect to consider opportunities to acquire or make investments in other technologies, products, and businesses that may enhance our capabilities, complement our current products, or expand the breadth of our markets or customer base. Potential and completed acquisitions and strategic investments involve numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">problems assimilating the purchased technologies, products, or business operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issues maintaining uniform standards, procedures, controls, and policies;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated costs and liabilities associated with acquisitions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of management&#8217;s attention from our core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse effects on existing business relationships with suppliers and customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">risks associated with entering new markets in which we have limited or no experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential loss of key employees of acquired businesses; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased legal and accounting compliance costs.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no current commitments with respect to any acquisition or investment. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired business, product, or technology into our business or retain any key personnel, suppliers, or distributors. Our ability to successfully grow through acquisitions depends upon our ability to identify, negotiate, complete, and integrate suitable target businesses and to obtain any necessary financing. These efforts could be expensive and time consuming, and may disrupt our ongoing business and prevent management from focusing on our operations. If we are unable to successfully integrate any acquired businesses, products, or technologies effectively, our business, results of operations, and financial condition will be materially adversely affected.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships with third-parties that may not result in the development of commercially viable products or the generation of significant future revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships, or other arrangements to develop products and to pursue new markets. We have not entered into any collaboration arrangements to date. Proposing, negotiating, and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenue and could be terminated prior to developing any products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any future collaborators, they may act in their self- interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any future collaborators devote to our or their future products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence, commercialization, royalty, or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Legal and Regulatory Environment</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We, our suppliers, and our third-party manufacturers are subject to extensive governmental regulation both in the United States and abroad, and failure to comply with applicable requirements could cause our business to suffer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical device industry is regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">design, development, and manufacturing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">testing, labeling, content, and language of instructions for use and storage;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product safety;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">marketing, sales, and distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">premarket clearance and approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conformity assessment procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">record keeping procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advertising and promotion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with good manufacturing practices requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recalls and field safety corrective actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">post-market approval studies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product import and export.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, difficulties achieving new product clearances, higher than anticipated costs or lower than anticipated sales.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before we can market or sell a new regulated product or make a significant modification to an existing product in the United States, with very limited exception, we must obtain either clearance under Section&#160;510(k) of the FDCA for Class&#160;II devices or approval of a premarket approval, or PMA, application from the FDA for a Class&#160;III device. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, with respect to intended use, technology, and safety and effectiveness, in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing, and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices. Products that are approved through a PMA application generally need FDA approval before they can be modified. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k). Both the 510(k) and PMA processes can be expensive and lengthy and require the payment of significant fees, unless exempt. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but may last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is submitted to the FDA until an approval is obtained. The process of obtaining domestic and international regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, our currently commercialized products have either received premarket clearance under Section&#160;510(k) of the FDCA or are exempt from premarket review. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline. In addition, the FDA may determine that future products will require the more costly, lengthy, and uncertain PMA process. Although we do not currently market any devices under PMA, the FDA may demand that we obtain a PMA prior to marketing certain of our future products. In addition, if the FDA disagrees with our determination that a product we currently market is subject to an exemption from premarket review, the FDA may require us to submit a 510(k) or PMA in order to continue marketing the product. Further, even with respect to those future products where a PMA is not required, we cannot assure investors that we will be able to obtain the 510(k) clearances with respect to those products.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to demonstrate to the FDA&#8217;s satisfaction that our products are safe and effective for their intended users;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the manufacturing process or facilities we use may not meet applicable requirements.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay clearance or approval of our products under development or impact our ability to modify our currently approved or cleared products on a timely basis.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any delay in, or failure to receive or maintain, clearance or approval for our products under development could prevent us from generating revenue from these products or achieving profitability.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, even after we have obtained the proper regulatory clearance or approval to market a product, the FDA has the power to require us to conduct postmarketing studies. These studies can be very expensive and time consuming to conduct. Failure to comply with those studies in a timely manner could result in the revocation of the 510(k) clearance for a product that is subject to such a 522 Order and the recall or withdrawal of the product, which could prevent us from generating sales from that product in the United States.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the EEA, our medical devices must comply with the Essential Requirements set forth in Annex I to the EU Medical Devices Directive (Council Directive 93/42/EEC), or Essential Requirements. Compliance with these requirements is a prerequisite to be able to affix the CE mark to our medical devices, without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low risk medical devices (Class I), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements, a conformity assessment procedure requires the intervention of a third-party organization designated by the competent authorities of a EEA country to conduct conformity assessments, known as a Notified Body. The Notified Body would typically audit and examine the medical device&#8217;s Technical File, the quality system for the manufacture, design and conduct a final inspection of our medical devices before issuing a CE Certificate of Conformity demonstrating compliance with the Essential Requirements or the QSR of the Medical Devices Directive.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, as part of the conformity assessment process, medical device manufacturers must carry out a clinical evaluation of their medical devices to verify that they comply with the relevant Essential Requirements covering safety and performance. A clinical evaluation includes an assessment of whether a medical device&#8217;s performance is in accordance with its intended use and that the known and foreseeable risks linked to the use of the device under normal conditions are minimized and acceptable when weighed against the benefits of its intended purpose. The clinical evaluation conducted by the manufacturer must also address any clinical claims, the adequacy of the device labeling and information (particularly claims, contraindications, precautions/ warnings) and the suitability of related Instructions for Use. This assessment must be based on clinical data, which can be obtained from (i)&#160;clinical studies conducted on the devices being assessed; (ii)&#160;scientific literature from similar devices whose equivalence with the assessed device can be demonstrated; or (iii)&#160;both clinical studies and scientific literature. With respect to implantable devices, or devices classified as Class&#160;III in the EU, the manufacturer must conduct clinical studies to obtain the required clinical data, unless the relying on existing clinical data from similar devices can be justified. As part of the conformity assessment procedure, depending on the type of devices, the Notified Body will review the manufacturer&#8217;s clinical evaluation for the medical device. The conduct of clinical studies to obtain clinical data that might be required as part of the described clinical evaluation process can be expensive and time consuming.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could dissuade some surgeons from using our products and adversely affect our reputation and the perceived safety and effectiveness of our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">civil penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">termination of distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recalls or seizures of products;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in the introduction of products into the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">total or partial suspension of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">facility closures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal of the FDA or our Notified Body or other regulator to grant future clearances or approvals or to issue CE Certificates of Conformity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawals or suspensions of current clearances or approvals and CE Certificates of Conformity, resulting in prohibitions on sales of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the most serious cases, criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adverse action by an applicable regulatory agency, our Notified Body or the FDA could result in inability to produce our products in a cost-effective and timely manner, or at all, decreased sales, higher prices, lower margins, additional unplanned costs or actions, damage to our reputation, and could have material adverse effect on our reputation, business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We and our sales representatives must comply with U.S. federal and state fraud and abuse laws, including those relating to physician kickbacks and false claims for reimbursement, as well as equivalent foreign laws.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare providers, distributors, physicians, and third-party payors play a primary role in the distribution, recommendation, ordering, and purchasing of any implant or other medical device for which we have or obtain marketing clearance or approval. Through our arrangements with customers and third-party payors, we are exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, or third-party distributors may engage in fraudulent or other illegal activity. Misconduct by these parties could include, among other infractions or violations, intentional, reckless and/or negligent conduct or unauthorized activity that violates FDA regulations, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, laws that require the true, complete, and accurate reporting of financial information or data, other commercial or regulatory laws or requirements, and equivalent foreign rules. We have a compliance program, Code of Conduct, and associated policies and procedures, but it is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations, and government authorities may conclude that our business practices do not comply with applicable fraud and abuse or other healthcare laws and regulations or guidance despite our good faith efforts to comply.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are numerous U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback and false claims laws. Our relationships and our distributors&#8217; relationships with surgeons, other healthcare professionals, and hospitals are subject to scrutiny under these laws.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare fraud and abuse laws and related regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. The laws that may affect our ability to operate include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, items or services for which payment may be made, in whole or in part, under federal healthcare programs, such as the Medicare and Medicaid programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment of government funds; knowingly making, using, or causing to be made or used, a false record or statement to get a false claim paid or to avoid, decrease, or conceal an obligation to pay money to the federal government. A claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. There are also criminal penalties for making or presenting a false or fictitious or fraudulent claim to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, which imposes criminal and civil liability for, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program including private third-party payors, or knowingly and willfully falsifying, concealing, or covering up a material fact or making a materially false, fictitious, or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments or other &#8220;transfers of value&#8221; made to physicians and teaching hospitals, and requires applicable manufacturers to report annually to CMS ownership and investment interests held by physicians and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state beneficiary inducement laws, and state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we or our employees are found to have violated any of the above laws we may be subjected to administrative, civil and criminal penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and significant fines, monetary penalties and damages, and damage to our reputation. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into consulting agreements and royalty agreements with surgeons, including some who are customers. We also engage in co-marketing arrangements with certain surgeons who use our products. In addition, a small number of our current customer surgeons own less than 1.0% of our stock, which they either purchased in an arm&#8217;s length transaction on terms identical to those offered to others or received from us as fair market value consideration for consulting services performed. While all of these transactions were structured with the intention of complying with all applicable laws, including the federal Anti-Kickback Statute, state anti-kickback laws and other applicable laws, to the extent applicable, it is possible that regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to significant penalties. We would be materially and adversely affected if regulatory agencies interpret our financial relationships with surgeons who order our products to be in violation of applicable laws and we were unable to comply with such laws, which could subject us to, among other things, monetary penalties for non-compliance, the cost of which could be substantial.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In certain cases, federal and state authorities pursue actions for false claims on the basis that manufacturers and distributors are promoting unapproved, or &#8220;off-label&#8221; uses of their products. Pursuant to FDA regulations, we can only market our products for cleared or approved uses. Although surgeons are permitted to use medical devices for indications other than those cleared or approved by the FDA, we are prohibited from promoting products for &#8220;off-label&#8221; uses. We market our products and provide promotional materials and training programs to surgeons regarding the use of our products. If it is determined that our marketing, promotional materials or training programs constitute promotion of unapproved uses, we could be subject to significant fines in addition to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, criminal penalty, and damage to our reputation. Federal and state authorities also pursue actions for false claims based upon improper billing and coding advice or recommendations, as well as decisions related to the medical necessity of procedures, including the site-of-service where procedures are performed. Actions under the federal False Claims Act may also be brought by whistleblowers under its </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;">&#32;provisions.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To enforce compliance with the federal laws, the U.S. Department of Justice has increased its scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations can be time- and resource-consuming and can divert management&#8217;s attention from the business. Additionally, if a healthcare company settles an investigation with the Department of Justice or other law enforcement agencies, it may need to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our financial condition and divert resources and the attention of our management from operating our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The scope and enforcement of these laws is uncertain and subject to rapid change. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that we may run afoul of one or more of the requirements or that federal or state regulatory authorities might challenge our current or future activities under these laws. Additionally, we cannot predict the impact of any changes in these laws, whether or not retroactive.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to adequately protect personal information in compliance with evolving legal requirements could harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of our business, we collect and store sensitive data, including legally protected personally identifiable information. We collect this kind of information during the course of clinical trials and for post-marketing safety vigilance, helping enable surgeons and their patients to pursue claims for reimbursement for procedures using iFuse and servicing potential warranty claims.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of state, federal, and international laws protecting the privacy and security of health information and personal data. These data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny of companies&#8217; data practices and escalating levels of enforcement and sanctions. As part of the American Recovery and Reinvestment Act 2009, or ARRA, Congress amended the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA. HIPAA imposes certain requirements regarding the privacy, security, use, and disclosure of an individual&#8217;s protected health information, or PHI, by certain health care providers, health care clearinghouses, and health insurance plans, collectively referred to as &#8220;covered entities,&#8221; and their &#8220;business associates,&#8221; or subcontractors who provide services to covered entities that involve the creation, use, maintenance, or disclosure of PHI. ARRA included significant increases in the penalties for improper use or disclosure of an individual&#8217;s PHI under HIPAA and extended enforcement authority to state attorneys general. The amendments also created notification requirements applicable to covered entities and business associates in certain cases when PHI in their control has been inappropriately accessed or disclosed. In the case of a breach of unsecured PHI, covered entities may be required to provide notification to individuals affected by the breach, federal regulators, and, in some cases, local and national media. In addition to HIPAA, most states have laws requiring notification of affected individuals and state regulators in the event of a breach of &#8220;personal information,&#8221; which is a broader class of information than the PHI protected by HIPAA. Certain states also have data privacy requirements applicable to individually identifiable health information. Privacy laws in different states may contain different requirements, and such laws may not be pre-empted by HIPAA, which could complicate our efforts to comply.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many foreign countries and governmental bodies, including the EU, Australia, and other relevant jurisdictions, have laws and regulations concerning the collection and use of personal or sensitive data obtained from their residents or by businesses operating within their jurisdiction. For example, the European Commission recently adopted the General Data Protection Regulation, or the GDPR, effective on May&#160;25, 2018, that superseded current EU data protection legislation, imposed more stringent EU data protection requirements and provides for greater penalties for noncompliance. The GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use &#8220;personal data,&#8221; or any information relating to an identified or identifiable natural person, in connection with the offering goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data breach notification requirements, and substantial new obligations on services providers. Non-compliance with the GDPR can trigger steep fines of up to &#8364;20&#160;million or 4% of total worldwide annual revenues, whichever is higher. Given the breadth and depth of changes in data protection obligations, achieving and maintaining GDPR compliance will require considerable time and resources.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are at risk of enforcement actions taken by certain EU data protection authorities until such point in time that we may be able to ensure that all transfers of personal data to us from the European Economic Area are conducted in compliance with all applicable regulatory obligations, the guidance of data protection authorities and evolving best practices. We may find it necessary to establish systems to maintain personal data originating from the EU in the European Economic Area, which may involve substantial expense and may cause us to need to divert resources from other aspects of our business, all of which may adversely affect our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our failure to comply with applicable laws and regulations, or to protect such data, could result in enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by end-customers, and other affected individuals, and the imposition of integrity obligations and agency oversight, damage to our reputation, and loss of goodwill, any of which could harm on our operations, financial performance, and business. Evolving and changing definitions of personal data and personal information, within the European Union, the United States, and elsewhere, may limit or inhibit our ability to operate or expand our business, including limiting strategic partnerships that may involve the sharing of data. Moreover, if the relevant laws and regulations change, or are interpreted and applied in a manner that is inconsistent with our data practices or the operation of our products, or if we expand into new regions and are required to comply with new requirements, we may need to expend resources in order to change our business operations, data practices, or the manner in which our products operate. Even the perception of privacy concerns, whether or not valid, may harm our reputation and inhibit adoption of our products.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to risks associated with our non-U.S. operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FCPA prohibits companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business. Other anti-corruption or anti-bribery laws, such as the UKBA, prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business in foreign countries. The FCPA also imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of slush funds from which such improper payments can be made. Because of the predominance of government-sponsored healthcare systems around the world, many of our customer relationships outside of the United States are with governmental entities and are therefore subject to such anti-bribery laws. Our internal control policies and procedures may not always protect us from reckless or criminal acts committed by our employees or agents. Violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, and result in a material adverse effect on our business, results of operations, and financial condition. We also could suffer severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures, including further changes or enhancements to our procedures, policies, and controls, as well as potential personnel changes and disciplinary actions.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, we are subject to anti-boycott laws, anti-money laundering laws, and the export controls and economic embargo rules and regulations of the United States, including, but not limited to, the Export Administration Regulations and trade sanctions against embargoed countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as the laws and regulations administered by the Department of Commerce. These regulations limit our ability to market, sell, distribute, or otherwise transfer our products or technology to prohibited countries or persons. A determination that we have failed to comply, whether knowingly or inadvertently, may result in substantial penalties, including fines and enforcement actions and civil and/or criminal sanctions, the disgorgement of profits, and the imposition of a court-appointed monitor, as well as the denial of export privileges, and may have an adverse effect on our reputation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our products are approved by regulatory authorities or CE marked, if we, our contractors, or our suppliers fail to comply with ongoing FDA or other foreign regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any product for which we obtain regulatory clearance or approval, or a CE Certificate of Conformity, and the manufacturing processes, reporting requirements, post-approval clinical data, and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA, our Notified Body and other domestic and foreign regulatory bodies. In particular, we and our suppliers are required to comply with FDA&#8217;s Quality System Regulations, or QSR, and International Standards Organization, regulations for the manufacture of our products and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage, and shipping of any product for which we obtain regulatory clearance or approval, or a CE Certificate of Conformity.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The failure by us or one of our suppliers to comply with applicable statutes and regulations, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">untitled letters, warning letters, fines, injunctions, consent, and civil penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated expenditures to address or defend such actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">customer notifications for repair, replacement, refunds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recall, detention, or seizure of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions or partial suspension or total shutdown of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusing or delaying our requests for 510(k) clearance or premarket approval and conformity assessments of new products or modified products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations on the intended uses for which the product may be marketed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operating restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawing 510(k) clearances or PMA approvals that have already been granted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of CE Certificates of Conformity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to grant export approval for our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">criminal prosecution.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace, or refund the cost of any medical device we manufacture or distribute, fines, suspension, variation, or withdrawal of regulatory approvals or CE Certificates of Conformity, product seizures, injunctions, or the imposition of civil, administrative, or criminal penalties which would adversely affect our business, operating results, and prospects.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false or fraudulent claims for payment of government funds.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these actions were to occur it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA inspected our facilities in May 2014. As a result, we received a Notice of Inspectional Observations, or Form 483, with three observations that have since been addressed with a corrective and preventative action, or CAPA, plan. We responded to the Agency in writing and the matter was closed as of October 2014 through the issuance of an Establishment Inspection Report. To date, the FDA has not taken any further action with respect to the May 2014 inspection or its findings. The FDA inspected our facilities again in December 2016 and no findings were noted.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, manufacturers, and third-party distributors may engage in misconduct or other improper activities, relating to regulatory standards and requirements. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to the risk that our employees, independent contractors, consultants, manufacturers, and third-party distributors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have a compliance program, code of conduct and associated policies and procedures, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, disgorgement of profits, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to enforcement action, including fines, penalties or injunctions, if we are determined to be engaging in the off-label promotion of our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition of the promotion of off-label use. Physicians may use our products off-label, as the FDA does not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. In the United States, the full indication for the iFuse Implant System is: &#8220;The iFuse Implant System is intended for sacroiliac joint fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than six months. Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life.&#8221; Moreover, iFuse is one of the few devices regulated through the class II pathway that has claims for clinical improvements. iFuse-3D, which was FDA-cleared in 2017, has a very similar indication statement but does not have the statement regarding improvement in pain, function and quality of life. In the United States, our marketing strategies must adhere to the above statements. In all other countries, the indication statement for the iFuse Implant System (including iFuse-3D) more broadly indicates that the device is indicated for sacroiliac joint fusion. The above-described potential limitation in indication statements in the U.S. does not apply in other geographies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that the specific surgical procedures for which our products are marketed fall within the scope of the surgical applications that have been cleared by the FDA. However, if the FDA determines that our promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials, require us to stop promoting our products for those specific procedures until we obtain FDA clearance or approval for them, or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fines, and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false or fraudulent claims for payment of government fund. In that event, our reputation could be damaged and adoption of the products would be impaired. Although our policy is to refrain from statements that could be considered off-label promotion of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. In addition, the off-label use of our products may increase the risk of injury to patients, and, in turn, the risk of product liability claims. Product liability claims are expensive to defend and could divert our management&#8217;s attention, result in substantial damage awards against us and harm our reputation.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are required to report certain malfunctions, deaths, and serious injuries associated with our products, which can result in voluntary corrective actions or agency enforcement actions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, under the FDA&#8217;s medical device reporting, regulations, we are required to report to the FDA any information that our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. If we fail to report these events to the FDA within the required timeframes, or at all, FDA could take enforcement action against us. Any such adverse event involving our products or repeated product malfunctions may result in a voluntary or involuntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and timely manner, and have an adverse effect on our reputation, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the EEA, we must comply with the EU Medical Device Vigilance System. Under this system, incidents must be reported to the relevant authorities of the Member States of the EEA, and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any adverse event involving our products, whether in the United States or abroad could result in future voluntary corrective actions, such as recalls, including corrections, or customer notifications, or agency action, such as inspection or enforcement actions. If malfunctions do occur, we may be unable to correct the malfunctions adequately or prevent further malfunctions, in which case we may need to cease manufacture and distribution of the affected products, initiate voluntary recalls, and redesign the products. Regulatory authorities may also take actions against us, such as ordering recalls, imposing fines, or seizing the affected products. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, including foreign governmental authorities, or the discovery of serious safety issues or malfunctions with our products, can result in voluntary corrective actions or agency enforcement actions, which could have a significant adverse impact on us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is an unreasonable risk of substantial public harm. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. A government-mandated or voluntary recall by us or one of our third-party distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our reputation, results of operations, and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Modifications to our products may require new 510(k) clearances or premarket approvals and new conformity assessment by our Notified Body, or may require us to cease marketing or recall the modified products until clearances, approvals, or CE Certificates of Conformity are obtained.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires a new 510(k) clearance or, possibly, a PMA. The FDA requires every manufacturer make and document this determination in the first instance. A manufacturer may determine that a modification could not significantly affect safety or effectiveness and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. FDA may review any manufacturer&#8217;s decision and may not agree with our decisions regarding whether new clearances or approvals are necessary. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our products in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our products as modified until clearance or approvals can be obtained, which could require us to redesign our products and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have modified some of our 510(k) cleared products, and have determined based on our review of the applicable FDA guidance that in certain instances new 510(k) clearances or PMAs are not required. If the FDA disagrees with our determination and requires us to submit new 510(k) clearances or PMAs for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant enforcement action, regulatory fines, or penalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket approval application. Where we determine that modifications to our products require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. FDA&#8217;s ongoing review of the 510(k) program may make it more difficult for us to make modifications to our previously cleared products, either by imposing more strict requirements on when a new 510(k) for a modification to a previously cleared product must be submitted, or applying more onerous review criteria to such submissions.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the EEA, we must inform the Notified Body that carried out the conformity assessment of the medical devices we market or sell in the EEA of any planned substantial changes to our quality system or changes to our devices which could affect compliance with the essential requirements or the devices&#8217; intended use. The Notified Body will then assess the changes and verify whether they affect the products&#8217; conformity. There can be no assurances that the assessment will be favorable and that the Notified Body will attest our compliance with the essential requirements, which will prevent us from selling our products in the EEA.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obtaining regulatory clearances or approvals and CE Certificates of Conformity can be a time-consuming process, and delays in obtaining required future regulatory clearances or approvals, and CE Certificates of Conformity would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There is no guarantee that the FDA will grant 510(k) clearance or premarket approval of our future products or that our Notified Body will issue the required CE Certificate of Conformity, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are in the process of developing our regulatory strategies for obtaining clearance or approval for future products. Some of them may require 510(k) clearance by the FDA or a new CE Certificate of Conformity. Other future products may require premarket approval. In addition, some of our new products may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these products or our Notified Body may not issue CE Certificate of Conformity for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or premarket approval of new products, new intended uses, or modifications to existing products. Failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may fail to obtain or maintain foreign regulatory approvals to market our products in other countries.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently market our products internationally and intend to expand our international marketing. International jurisdictions require separate regulatory approvals and compliance with numerous and varying regulatory requirements. For example, we intend to continue to seek domestic and international regulatory clearance to market our primary products Asia, Latin America, and the Middle East and other key markets. The approval procedures vary among countries and may involve requirements for substantial additional testing, and the time required to obtain approval may differ from country to country and from that required to obtain FDA clearance or approval or to obtain CE Certificates of Conformity.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clearance or approval by the FDA or obtaining a CE Certificate of Conformity does not ensure approval or certification by regulatory authorities in other countries or jurisdictions, and approval or certification by one foreign regulatory authority does not ensure approval or certification by regulatory authorities in other foreign countries or by the FDA, and the CE marking of our products in the EEA. The foreign regulatory approval or certification process may include all of the risks associated with obtaining FDA clearance or approval, or a CE Certificate of Conformity for a medical device in the EEA in addition to other risks. In addition, the time required to obtain foreign approval may differ from that required to obtain FDA clearance or approval, or a CE Certificate of Conformity in the EEA and we may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals or certifications and may not receive necessary approvals to commercialize our products in any market. If we fail to receive necessary approvals or certifications to commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, results of operations, and financial condition could be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials necessary to support a 510(k) or PMA application or a conformity assessment procedure will be expensive and may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new products and will adversely affect our business, operating results and prospects.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initiating and completing clinical trials necessary to support a PMA application for our future products and additional safety and effectiveness data beyond that typically required for a 510(k) clearance for iFuse, as well as other possible future product candidates, and to support a conformity assessment procedure would be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the inclusion and exclusion criteria for participation in the clinical trial and patient compliance. Development of sufficient and appropriate clinical protocols to demonstrate safety and effectiveness are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA or our Notified Body may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA or our Notified Body may not consider our data adequate to demonstrate safety and effectiveness. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our facility and our clinical investigational sites operate under procedures that govern the conduct and management of FDA-regulated clinical studies under 21 CFR Parts 50 and 812, and Good Clinical Practices. The FDA may conduct Bioresearch Monitoring inspections of us and/or our clinical sites to assess compliance with 21 CFR Parts 50 and 812, our procedures, and the clinical protocol. If the FDA were to find that we or our clinical investigators are not operating in compliance with applicable regulations, we could be subject to the above FDA enforcement action, as well as refusal to accept all or part of our data in support of our 510(k) or PMA, or we may need to conduct additional studies.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA, foreign authorities, or our Notified Body will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenue. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate&#8217;s profile.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. legislative or FDA or foreign regulatory reforms may make it more difficult and costly for us to obtain regulatory clearances or approvals, or CE Certificates of Conformity for our product candidates and to manufacture, market, and distribute our products after approval is obtained.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, Congress introduces legislation that could significantly change the statutory provisions governing the regulatory approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance, or interpretations changed, and what the impact of such changes, if any, may be.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the 21st Century Cures Act was enacted, with a number of provisions impacting medical device regulation. The FDA has implemented, and continues to implement, these reforms, which could impose additional regulatory requirements upon us and delay our ability to obtain new 510(k) clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market, and distribute existing products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, the policies of the Trump Administration and their impact on the regulation of our products in the United States remain uncertain. The outcome of the 2016 election and the forthcoming 2018 mid-term elections could result in significant legislative and regulatory reforms impacting the FDA&#8217;s regulation of our products. Any change in the laws or regulations that govern the clearance and approval processes relating to our current and future products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Another example can be found in the EEA. On September&#160;26, 2012, the European Commission adopted a package of legislative proposals designed to replace the existing regulatory framework for medical devices in the EEA. These proposals are intended to strengthen the medical devices rules in the EEA. On April&#160;5, 2017, the final text of the Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) were adopted by the Parliament and the Council. These regulations, which will substantially impact medical devices manufacturers, will be applicable from May 2020 for the MDR and May 2022 for the IVDR. Examples of the changes which will be introduced by these regulations include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional scrutiny during the conformity assessment procedure for high risk medical devices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strengthening of the clinical data requirements related to medical devices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">strengthening of the designation and monitoring processes governing notified bodies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the obligation for manufacturers and authorized representative to have a person responsible for regulatory compliance continuously at their disposal;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorized representatives would be held legally responsible and liable for defective products placed on the EU market;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased traceability of medical devices following the introduction of a Unique Device Identification, or UDI, system;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new rules governing the reprocessing of medical devices; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased transparency with the establishment of EUDAMED III as information from several databases concerning economic operators, CE Certificates of Conformity, conformity assessment, clinical investigations, the UDI system, adverse event reporting and market surveillance would be available to the public.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sales of our products depend in part on the availability of coverage and reimbursement from third-party payors such as government health administration authorities, private health insurers, health maintenance organizations, and other healthcare-related organizations. Recent political, economic, and regulatory influences are subjecting the healthcare industry to fundamental changes that can impact coverage and reimbursement from third-party payors. For example, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2011, among other things, reduced and/or limited Medicare reimbursement to certain providers. Legislative changes to the Patient Protection and Affordable Care Act remain possible in the 115th United States Congress and under the Trump Administration. We expect that the Patient Protection and Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our existing products. Other federal laws further reduce Medicare&#8217;s payments to providers by two percent through 2024. These reductions reduce reimbursement for our products, which could potentially negatively impact our revenue, and may reduce providers&#8217; revenues or profits, which could affect their ability to purchase new technologies. Both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation and regulations designed to contain or reduce the cost of healthcare. Such legislation and regulations may result in decreased reimbursement for medical devices, which may further exacerbate industry-wide pressure to reduce the prices charged for medical devices. This could harm our ability to market our products and generate sales.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our financial performance may be adversely affected by medical device tax provisions in the healthcare reform laws.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2011, imposes, among other things, an annual excise tax on any entity that manufactures or imports medical devices offered for sale in the United States. Under these provisions, the Congressional Research Service predicts that the total cost to the medical device industry may be up to $20.0&#160;billion over the next decade. A two-year moratorium currently applies to this tax through December 2019. After that time, the tax may be repealed or modified, or the moratorium may be lifted, in which case sales of our iFuse would be subject to this excise tax.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business exposes us to potential product liability claims that are inherent in the testing, design, manufacture, and sale of medical devices for sacroiliac joint surgery procedures. Sacroiliac joint surgery involves significant risk of serious complications, including bleeding, nerve injury, paralysis, and even death. In addition, if longer-term patient results and experience indicates that our products or any component of a product cause tissue damage, motor impairment, or other adverse effects, we could be subject to significant liability. Surgeons may misuse or ineffectively use our products, which may result in unsatisfactory patient outcomes or patient  injury. We could become the subject of product liability lawsuits alleging that component failures, manufacturing flaws, design defects, or inadequate disclosure of product-related risks or product-related information resulted in an unsafe condition or injury to patients. Product liability lawsuits and claims, safety alerts, or product recalls, regardless of their ultimate outcome, could have a material adverse effect on our business and reputation, our ability to attract and retain customers and our results of operations or financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we maintain third-party product liability insurance coverage, it is possible that claims against us may exceed the coverage limits of our insurance policies or cause us to record a self-insured loss. Even if any product liability loss is covered by an insurance policy, these policies typically have substantial retentions or deductibles that we are responsible for. Product liability claims in excess of applicable insurance coverage could have a material adverse effect on our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, any product liability claim brought against us, with or without merit, could result in an increase of our product liability insurance rates. Insurance coverage varies in cost and can be difficult to obtain, and we cannot guarantee that we will be able to obtain insurance coverage in the future on terms acceptable to us or at all.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to environmental laws and regulations that can impose significant costs and expose us to potential financial liabilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacture of certain of our products, including our implants and products, and the handling of materials used in the product testing process, including in our cadaveric laboratory, involve the use of biological, hazardous and/or radioactive materials and wastes. Our business and facilities and those of our suppliers are subject to foreign, federal, state, and local laws and regulations relating to the protection of human health and the environment, including those governing the use, manufacture, storage, handling, and disposal of, and exposure to, such materials and wastes. In addition, under some environmental laws and regulations, we could be held responsible for costs relating to any contamination at our past or present facilities and at third-party waste disposal sites even if such contamination was not caused by us. A failure to comply with current or future environmental laws and regulations could result in severe fines or penalties. Any such expenses or liability could have a significant negative impact on our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The comprehensive tax reform bill adopted in 2017 could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, President Trump signed into law new legislation that significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses arising after 2017 to 80% of current year taxable income and elimination of carrybacks of such net operating losses, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modification or repeal of many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely primarily on patent, copyright, trademark and trade secret laws, as well as confidentiality and non- disclosure agreements and other methods, to protect our proprietary technologies and know-how. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we owned 35 issued U.S. patents and had 14 pending U.S. patent applications, and we owned nine issued foreign patents and had five pending foreign patent applications. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have 12 registered trademarks in the United States and have filed for two more. We have sought protection for at least two of these trademarks in 60 countries including the 28 European member countries of the Madrid Protocol.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have applied for patent protection relating to certain existing and proposed products and processes. While we generally apply for patents in those countries where we intend to make, have made, use, or sell patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. Furthermore, we cannot assure investors that any of our patent applications will be approved. The rights granted to us under our patents, including prospective rights sought in our pending patent applications, may not be meaningful or provide us with any commercial advantage. In addition, those rights could be opposed, contested, or circumvented by our competitors or be declared invalid or unenforceable in judicial or administrative proceedings. The failure of our patents to adequately protect our technology might make it easier for our competitors to offer the same or similar products or technologies. Competitors may be able to design around our patents or develop products that provide outcomes that are comparable to ours without infringing on our intellectual property rights. Due to differences between foreign and U.S. patent laws, our patented intellectual property rights may not receive the same degree of protection in foreign countries as they would in the United States. Even if patents are granted outside the United States, effective enforcement in those countries may not be available. Since most of our issued patents are for the United States only, we lack a corresponding scope of patent protection in other countries. In countries where we do not have significant patent protection, we may not be able to stop a competitor from marketing products in such countries that are the same as or similar to our products.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on our trademarks, trade names and brand names to distinguish our products from the products of our competitors and have registered or applied to register many of these trademarks. We cannot assure investors that our trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. Further, we cannot assure investors that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. We try to protect this information by entering into confidentiality and intellectual property assignment agreements with parties that develop intellectual property for us and/or have access to it, such as our officers, employees, consultants, and advisors. However, in the event of unauthorized use or disclosure or other breaches of such agreements, we may not be provided with meaningful protection for our trade secrets or other proprietary information. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know- how and inventions. If any of our trade secrets, know-how or other technologies not protected by a patent were to be disclosed to or independently developed by a competitor, our business, financial condition, and results of operations could be materially adversely affected.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the future, we may enter into licensing agreements to maintain our competitive position. If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence, commercialization, royalty, or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek damages or to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a competitor infringes upon one of our patents, trademarks, or other intellectual property rights, enforcing those patents, trademarks, and other rights may be difficult and time consuming. Even if successful, litigation to defend our patents and trademarks against challenges or to enforce our intellectual property rights could be expensive and time consuming and could divert management&#8217;s attention from managing our business. Moreover, we may not have sufficient resources to defend our patents or trademarks against challenges or to enforce our intellectual property rights. In addition, if third parties infringe any intellectual property that is not material to the products that we make, have made, use, or sell, it may be impractical for us to enforce this intellectual property against those third parties.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees, or our third-party distributors have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our employees were previously employed at other medical device companies, including our competitors or potential competitors, in some cases until recently. Some of our third-party distributors sell, or in the past have sold, products of our competitors. We may be subject to claims that we, our employees, or our third-party distributors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of these former employers or competitors. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Even if we are successful in defending against these claims, litigation could result in substantial costs, divert the attention of management from our core business and harm our reputation. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There can be no assurance that this type of litigation will not continue, and any future litigation or the threat thereof may adversely affect our ability to hire additional direct sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations, and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The medical device industry is characterized by patent litigation and we could become subject to litigation that could be costly, result in the diversion of management&#8217;s time and efforts, require us to pay damages, and/or prevent us from developing or marketing our existing or future products.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success will depend in part on not infringing the patents or violating the other proprietary rights of third parties. Significant litigation regarding patent rights exists in our industry. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit, or otherwise interfere with our ability to make and sell our products. We have conducted a limited review of patents issued to third parties. The large number of patents, the rapid rate of new patent issuances, the complexities of the technology involved, and the uncertainty of litigation increase the risk of business assets and management&#8217;s attention being diverted to patent litigation. Any litigation or claim against us, even those without merit, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business, and harm our reputation. Further, as the number of participants in the medical device industry grows, the possibility of intellectual property infringement claims against us increases. If we are found to infringe the intellectual property rights of third parties, we could be required to pay substantial damages, including treble, or triple, damages if an infringement is found to be willful, and/or royalties and could be prevented from selling our products unless we obtain a license or are able to redesign our products to avoid infringement. Any such license may not be available on reasonable terms, if at all, and there can be no assurance that we would be able to redesign our products in a way that would not infringe the intellectual property rights of others. If we fail to obtain any required licenses or make any necessary changes to our products or technologies, we may have to withdraw existing products from the market or may be unable to commercialize one or more of our products, all of which could have a material adverse effect on our business, results of operations, and financial condition. If passed into law, patent reform legislation currently pending in the U.S. Congress could significantly change the risks associated with bringing or defending a patent infringement lawsuit. For example, fee shifting legislation could require a non-prevailing party to pay the attorney fees of the prevailing party in some circumstances.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we generally indemnify our customers and third-party distributors with respect to infringement by our products of the proprietary rights of third parties. Third parties may assert infringement claims against our customers or third-party distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or third-party distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers or third-party distributors or may be required to obtain licenses to intellectual property owned by such third parties. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers and third-party distributors may be forced to stop using or selling our products.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our common stock may be volatile, and the value of an investment in our common stock could decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to October 17, 2018, there was no public market for our common stock. Medical device stocks have historically experienced volatility, and the trading price of our common stock may fluctuate substantially. These fluctuations could cause our stockholders to lose all or part of their investment in our common stock. Factors that could cause fluctuations in the trading price of our common stock include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated changes or fluctuations in our results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">results of our clinical trials and that of our competitors&#8217; products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory actions with respect to our products or our competitor&#8217;s products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements of new offerings, products, services or technologies, commercial relationships, acquisitions, or other events by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price and volume fluctuations in the overall stock market from time to time; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant volatility in the market price and trading volume of healthcare companies, in general, and of companies in the medical device industry in particular;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fluctuations in the trading volume of our shares or the size of our public float;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">negative publicity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether our results of operations meet the expectations of securities analysts or investors or those expectations change;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">litigation involving us, our industry, or both;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory developments in the United States, foreign countries, or both;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lock-up releases and sales of large blocks of our common stock;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key employees or scientific personnel; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general economic conditions and trends.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, if the market for healthcare stocks or the stock market, in general, experience a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, results of operations, or financial condition. The trading price of our common stock might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. If our stock price is volatile, we may become the target of securities litigation. Securities litigation could result in substantial costs and divert our management&#8217;s attention and resources from our business. This could have a material adverse effect on our business, results of operations, and financial condition.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sales of substantial amounts of our common stock in the public markets, including when the &#8220;lock-up&#8221; or &#8220;market standoff&#8221; period from our IPO ends, or the perception that sales might occur, could reduce the price of our common stock and may dilute our stockholders' voting power and ownership interest in us.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales could occur, could adversely affect the market price of our common stock, and may make it more difficult for our stockholders to sell our common stock at a time and price that they deem appropriate. All of the shares of common stock sold in our IPO are freely tradable without restrictions or further registration under the Securities Act of 1933, as amended, or the Securities Act, except for any shares held by our &#8220;affiliates&#8221; as defined in Rule 144 under the Securities Act. However, subject to certain exceptions, we, our directors and officers and the holders of substantially all of our capital stock, warrants and stock options prior to the IPO have agreed not to offer, sell or agree to sell, directly or indirectly, any shares of common stock without the permission of Morgan Stanley&#160;&amp; Co. LLC and Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated until April 14, 2019. When the lock-up period expires, our security holders will be able to sell shares in the public market subject to any restrictions under the securities laws. In addition, Morgan Stanley and Merrill Lynch may, in their discretion, release all or some portion of the shares subject to lock-up agreements prior to the expiration of the lock-up period. Sales of a substantial number of such shares upon expiration or early release of the lock-up, or the perception that such sales may occur, could cause our share price to fall, or make it more difficult for our stockholders to sell our common stock at a time and price that they deem appropriate. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of approximately 12 million shares, or approximately 55.4%, of our common stock, have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also registered the offer and sale of all shares of common stock that we may issue under our equity compensation plans.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investments or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Insiders have substantial control over us, which could limit our other stockholders' ability to influence the outcome of key transactions, including a change of control.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our directors, executive officers, and each of our stockholders that own greater than 5% of our outstanding common stock, in the aggregate, beneficially own approximately 52.0% of the outstanding shares of our common stock.  As a result, these stockholders will be able to influence or control matters requiring approval by our stockholders, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may also have interests that differ from our other stockholders' interests and may vote in a manner that is adverse to our other stockholders' interests. This concentration of ownership may have the effect of deterring, delaying, or preventing a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might ultimately affect the market price of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to utilize our federal net operating loss carryforwards to reduce our income taxes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had net operating loss, or NOL, carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$135.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$109.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available to reduce future taxable income, if any, for U.S. federal income tax and state income tax purposes, respectively. If not utilized, our federal and state NOL carryforwards begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2029</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, respectively. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, under Section&#160;382 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We have determined that we have experienced Section&#160;382 ownership changes in 2010 and $1.4&#160;million of our NOL and tax credit carryforwards are subject to limitation. In addition, we are still analyzing the effect that our IPO may have had on our NOLs, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result of our IPO, or if a future ownership change occurs, our ability to use our NOL tax credit carryforwards may be materially limited, which would harm our future operating results by effectively increasing our future tax obligations.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, divert our management&#8217;s attention, and affect our ability to attract and retain qualified board members.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are required to comply with the applicable requirements of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the listing requirements of the Nasdaq Global Market and other applicable securities rules and regulations. Compliance with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time consuming, or costly and increase demand on our systems and resources. Among other things, the Exchange Act requires that we file annual, quarterly, and current reports with respect to our business and results of operations and maintain effective disclosure controls and procedures and internal controls over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal controls over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could harm our business and results of operations. Although we have already hired additional employees to comply with these requirements, we may need to hire even more employees in the future, which will increase our costs and expenses.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, these new rules and regulations have made it more expensive for us to obtain director and officer liability insurance.  In the future, we may be required to accept reduced coverage. These factors could make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to establish and maintain an effective system of internal controls could result in material misstatements of our financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud in which case, our stockholders could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq Global Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. Commencing with the year ending December&#160;31, 2019, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K for that year, as required by Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404. This will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. As a result, we may experience difficulty in producing accurate financial statements in a timely manner.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. In addition, our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. In addition, in connection with the future attestation process by our independent registered public accounting firm, we may encounter problems or delays in completing the implementation of any requested improvements and receiving a favorable attestation. If we cannot favorably assess the effectiveness of our internal control over financial reporting, or if our independent registered public accounting firm is unable to provide an unqualified attestation report on our internal controls, our stockholders could lose confidence in our reporting, and the market price of our stock could decline. In addition, we could be subject to sanctions or investigations by the Nasdaq Global Market, the Securities and Exchange Commission, or SEC, or other regulatory authorities.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an exception from compliance with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements, and registration statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exemption from complying with new or revised financial accounting standards until such time as such standards are applicable to private companies.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If some investors find our common stock less attractive because we will rely on these exemptions, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a) in 2023, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non- affiliates exceeds $700&#160;million as of the prior June 30, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or publish unfavorable research reports about our business, our share price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock depends, to some extent, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us publishes unfavorable commentary about us or changes their opinion of our business prospects, our share price would likely decline. If one or more of these analysts ceases coverage of or fails to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not intend to pay dividends for the foreseeable future and, consequently, our stockholders' ability to achieve a return on investment in our common stock will depend on appreciation in the price of our common stock.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared or paid any dividends on our common stock. We intend to retain any earnings to finance the operation and expansion of our business, and we do not anticipate paying any cash dividends in the future. As a result, our stockholders may only receive a return on an investment in our common stock if the market price of our common stock increases. In addition, our loan and security agreements contain restrictions on our ability to pay dividends.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our credit facility contains covenants that may restrict our business and financing activities.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Borrowings under our credit facility are secured by substantially all of our assets. Our credit facility also restricts our ability to, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">dispose of or sell assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make material changes in our business or management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consolidate or merge with or acquire other entities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incur additional indebtedness;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incur liens on our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pay dividends or make distributions on our capital stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make certain investments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enter into transactions with our affiliates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make any payment in respect of any subordinated indebtedness; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">waive or amend any of our current intellectual property agreements or material contracts.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These restrictions are subject to certain exceptions. In addition, our loan and security agreement requires us to maintain a minimum cash balance and revenue targets. Beginning with the three months ended March 31, 2019, we are required to meet either revenue or earnings targets </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The covenants in our credit facility, as well as any future financing agreements that we may enter into, may restrict our ability to finance our operations, engage in, expand, or otherwise pursue our business activities and strategies. Our ability to comply with these covenants may be affected by events beyond our control, and future breaches of any of these covenants could result in a default under our credit facility agreements. If not waived, future defaults could cause all of the outstanding indebtedness under our credit facility agreement to become immediately due and payable and terminate all commitments to extend further credit.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate our business.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our charter documents and Delaware law could discourage takeover attempts and lead to management entrenchment.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors that are not nominated by the current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors, or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the requirement for the affirmative vote of holders of at least 66&#160;2/3% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquiror to effect such amendments to facilitate an unsolicited takeover attempt; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, as a Delaware corporation, we are subject to Section&#160;203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of, and do not currently intend to opt out of, this provision.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer, or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for our stockholders to realize value in a corporate transaction.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which restricts our stockholders&#8217; ability to bring a lawsuit against us or our directors, officers, or employees in jurisdictions other than Delaware and federal district courts.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees. Some companies that adopted a similar federal district court forum selection provision are currently subject to a suit in the Chancery Court of Delaware by stockholders who assert that the provision is not enforceable. If a court were to find either choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><a name="s8e33343b458241559baa7973c7c1ac43"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1B Unresolved Staff Comments.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8f00698f390942059bb79efe8f840d74"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2. Properties.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our leased headquarters in Santa Clara, California, comprises approximately 21,848 square feet. Our headquarters houses our research, product development, marketing, finance, education, and administration functions. We believe our facilities are adequate and suitable for our current needs but in the future we may need additional space.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">We also lease office spaces in Gallarate, Italy, Mannheim, Germany and Knaresborough, United Kingdom to accommodate mainly our European sales and marketing team.</font></div><div><a name="sD5DE7FD4A9015BB08963CF091FD78085"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Legal Proceedings</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are, and from time to time may be, party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect our future results of operations, cash flow or financial position. We are not presently party to any legal proceedings that in the opinion of management would, individually or taken together, likely have a material adverse effect on our business, operating results, financial condition, or cash flow. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE25A0355B669596E9941E452DC84E9EC"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><a name="s2d2a05de143d45b5b0dccba3eb2603ef"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><a name="s5a2194d095cd4ae29663bd703a37bd6e"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Price of Common Stock</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock has been listed on the Nasdaq Global Market under the symbol &#8220;SIBN&#8221; since October&#160;17, 2018. Prior to that date, there was no public trading market for our common stock. </font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Holders of Record</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;13, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">441</font><font style="font-family:inherit;font-size:10pt;">&#32;holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividend Policy</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future. In addition, our credit facility with Biopharma Credit Investments IV Sub LP, or Pharmakon, restricts our ability to pay dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws, and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions, and capital requirements. Our future ability to pay cash dividends on our capital stock may also be limited by the terms of any future debt or preferred securities or future credit facility.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;None.</font></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Proceeds from our Public Offering of Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;16, 2018, our registration statement on Form S-1 (File No.&#160;333-227445) relating to our IPO of common stock became effective. The IPO closed on October&#160;16, 2018 at which time we issued 8,280,000 shares of our common stock at an initial offering price of $15.00 per share for gross proceeds of $124.2 million. We received net proceeds from the IPO of approximately $113.6 million, after deducting the underwriting discount of $8.7 million and other estimated offering-related expenses paid or payable by us of approximately $1.9 million. None of the expenses associated with the IPO or private placement were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates,&#160;or to our affiliates. Morgan Stanley&#160;&amp; Co. LLC, Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated, Canaccord Genuity Inc. and&#160;JMP Securities LLC acted as underwriters for the offering.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares of our common stock began trading on the Nasdaq Global Market on October&#160;17, 2018. The shares were registered under the Securities Act on registration statement on Form&#160;S-1 (Registration No.&#160;333-227445).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on October&#160;16, 2018.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Repurchases of Shares or of Company Equity Securities</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sb05e62c307754abf887d6bf4950fc3fe"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6. Selected Financial Data.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable to a smaller reporting company.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><a name="s3A78FEBFF89B5C2DBCE28A5463264103"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those set forth in the "Risk Factors" section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied, by these forward-looking statements.</font></div><div><a name="s889489A5B05256068B68EE9949A3F56E"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a medical device company that has pioneered a proprietary minimally invasive surgical implant system, which we call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Since we introduced iFuse in 2009, more than 37,000 procedures have been performed by over 1,800 surgeons, in the United States and 33 other countries. Published clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the sacroiliac joint. We believe iFuse is currently used in the majority of minimally invasive surgical fusions of the sacroiliac joint in the United States. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The two sacroiliac joints are the largest joints in the body and connect the sacrum, near the base of the spine, to the iliac bones, the two major bones of the pelvis. The iFuse system includes a series of patented triangular implants, the instruments we have developed to enable the procedure, as well as the diagnostic and surgical techniques we have developed to enable physicians to perform the procedure. We introduced our second generation implant, the iFuse-3D, in 2017. We market our products with a direct sales force and a number of distributors in the United States, and with a combination of a direct sales force and distributors in other countries. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred net losses since our inception in 2008. We had net losses of </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$157.2 million</font><font style="font-family:inherit;font-size:10pt;">. To date, we have financed our operations primarily through private placements of equity securities, certain debt-related financing arrangements, and sales of our products. We have devoted substantially all of our resources to research and development of our products, reimbursement-related initiatives, sales and marketing activities, and clinical, quality assurance, and regulatory matters for our products.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we completed our IPO by issuing 8.28 million shares of common stock, at an offering price of $15.00 per share, for net proceeds of $113.6 million after deducting underwriting discounts and commissions and offering expenses payable by us.</font></div><div><a name="s0327C73D2AE5548996119F812C383768"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Factors Affecting Results of Operations</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Coverage and Reimbursement</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to our launch of iFuse in 2009, Medicare and most private insurance companies reimbursed surgeons routinely for sacroiliac joint fusions, which were primarily invasive. However, effective July&#160;1, 2013, the AMA&#8217;s Editorial Panel effectively restricted reimbursement for minimally invasive sacroiliac joint fusion because they considered the published clinical evidence at the time to be inadequate.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequently, as a result of the growing number of published clinical studies demonstrating the effectiveness and safety of iFuse, along with the support of several professional medical specialty societies and leading academic surgeons, the AMA Editorial Panel established a new reimbursement code for minimally invasive sacroiliac joint fusion surgery, effective January&#160;1, 2015. However, the new code did not immediately lead to positive coverage decisions by payors&#8212;in many cases, the payors wanted additional published evidence before deciding to cover the procedure. As a result, positive reimbursement decisions covering the procedure have occurred over the last few years, and some payors are still in the process of making decisions based on the most recent evidence.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage decisions for this code are made independently by each private insurance company and each of the seven regional Medicare Administrative Contractors that help manage Medicare. The process of obtaining coverage is laborious. As of June 30, 2016, because of the iFuse clinical evidence, all Medicare Administrative Contractors were covering the procedure. At the time, very few private payors were covering. By December 31, 2017, U.S. payors covering 162 million lives regularly reimbursed for the iFuse procedure, and as of December 31, 2018, U.S. payors covering 256.5 million lives regularly reimbursed for the iFuse procedures, 121.7 million of which are covered by private payors.  Forty-five of the largest 65 private payors that we track had positive coverage policies for the procedure, were consistently covering the procedure, or had announced coming future coverage. Of these 45 private payors, 26&#160;of them have issued positive coverage policies exclusive to iFuse for sacroiliac joint fusion because of the clinical evidence. Twenty of these exclusive coverage policies have published since January&#160;1, 2018, which we believe has contributed to our accelerating sales growth in our fiscal year 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of large and small private payors, including Aetna, Cigna, Humana, and Anthem that are not yet reimbursing for the procedure. Some of these non-covering payors are reevaluating coverage given the latest data, but there can be no assurance they will reach positive coverage decisions.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Sales Force</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We market and sell iFuse primarily through a direct sales force and a small number of third-party distributors. Our target customer base includes approximately 7,500 surgeons who perform spine and/or pelvic surgery, including orthopedic spine surgeons, neurosurgeons, general orthopedic surgeons, and orthopedic trauma surgeons. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our direct sales organization in the United States was comprised of seven sales regions as of December 31, 2018. Each region is comprised of a number of territory sales managers who act as the primary customer contact. Our territory sales managers have extensive training and experience selling medical devices for spine problems and pain management, generally focusing on emerging technologies and markets. For large and/or high volume territories, we also employ territory associate representatives who cover cases.  As of December 31, 2018, our territory sales managers were led by seven regional sales directors who reported to our Vice President of U.S. Sales. The Vice President of U.S. Sales reports to our Chief Commercial Officer. As of December 31, 2018, our U.S. sales force consisted of 45 sales representatives directly employed by us, and 30 third-party distributors. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to general sales and marketing training, we provide our sales organization with comprehensive, hands-on cadaveric and dry-lab training sessions focusing on the clinical benefits of our products and how to use them. We believe our robust training and professional development programs have been an important component of our success to date and will help support our anticipated future growth. We expect to continue to increase the size of our sales organization in order to increase sales and market penetration and to provide the significant, ongoing level of customer support required by our sales and marketing strategy. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, we had 28 employees working in our European operations, and have established operations in Italy (2010), Germany (2014), and the United Kingdom (2015). As of December 31, 2018, our international sales force consisted of 14 sales representatives directly employed by us and 23 exclusive third-party distributors, which together had sales in 33 countries through December 31, 2018. We anticipate continuing to build our operations in the major European countries while establishing distributor arrangements in smaller ones. We intend to follow a similar model in Europe to the one established in the United States, working with internationally recognized healthcare professional experts as we expand our training and reimbursement activities. As of December 31, 2018, beyond Europe and the United States, surgeons had performed the first iFuse procedures in Australia, Cayman Islands, Hong Kong, Israel, Japan, Kuwait, New Zealand, Saudi Arabia, Taiwan and Turkey. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have in the past and expect in the future to enter into different compensation arrangements with our sales professionals, which may include minimum guaranteed commissions. This has impacted our compensation expenses in the past and we expect it will in the future.  </font></div><div><a name="sCA23B12E65D757C4AA4C85B00428CB03"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Components of Results of Operations</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We derive substantially all our revenue from sales of iFuse. Revenue from sales of iFuse fluctuate based on volume of cases (procedures performed), discounts, mix of international and U.S. sales, and the number of implants used for a particular patient. Similar to other orthopedic companies, our revenue can also fluctuate from quarter to quarter due to a variety of factors, including reimbursement, sales force changes, physician activities, and seasonality. Our revenue from international sales may also be significantly impacted by fluctuations in foreign currency exchange rates between the U.S. dollar (our reporting currency) and the local currency.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Goods Sold, Gross Profit, and Gross Margin</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We utilize third-party manufacturers for production of the iFuse implants and instrument sets. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold consists primarily of costs of the components of iFuse implants and instruments, scrap and inventory obsolescence, and distribution-related expenses such as logistics and shipping costs. We anticipate that our cost of goods sold will increase in absolute dollars as case levels increase.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our gross profit has been and will continue to be affected by a variety of factors, including the cost to have our products manufactured, pricing pressure from increasing competition, and the factors described above impacting our revenue. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our gross margins are typically higher on products we sell directly as compared to products we sell through third-party distributors. As a result, changes in the mix of direct versus distributor sales can directly influence our gross margins.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, we began to incur an excise tax on sales of medical devices in the United States. Effective December 2015, the Act was amended to include a provision to suspend the tax on medical devices through 2017. In January 2018, the suspension on the tax on medical devices was further extended through 2019. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses consist of sales and marketing, research and development, and general and administrative expenses. Personnel costs are the most significant component of operating expenses and consist of salaries, sales commissions and other cash and stock-based compensation related expenses. We expect operating expenses to increase in absolute dollars as we continue to invest and grow our business, but we anticipate that it will decrease as a percentage of revenue over time. In September 2017, we implemented cost-saving measures, which reduced our operational expenses though headcount reductions, reduced project spending, and more targeted marketing and surgeon training activities.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sales and Marketing Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing expenses primarily consist of salaries, stock-based compensation expense, and other compensation related costs, for personnel employed in sales, marketing, medical affairs, and professional education departments. In addition, our sales and marketing expenses include commissions and bonuses, generally based on a percentage of sales, to our sales managers and directors, direct sales representatives and third-party distributors. We expect our sales and marketing expenses to increase in absolute dollars with the continued commercialization of our current and future products and continued investment in our global sales organization, including broadening our relationships with third-party distributors, expanding exclusivity commitments among them and increasing the number of our direct sales representatives, especially with increased reimbursement and adoption in the United States. Our sales and marketing expenses may fluctuate from period to period due to the seasonality of our business and as we continue to add direct sales representatives in new territories.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development expenses primarily consist of engineering, product development, clinical and regulatory expenses (including clinical study expenses), and consulting services, outside prototyping services, outside research activities, materials, depreciation, and other costs associated with development of our products. Research and development expenses also include related personnel and consultants&#8217; compensation and stock-based compensation expense. We expense research and development costs as they are incurred. We expect research and development expense to increase in absolute dollars as we develop new products, add research and development personnel, and undergo clinical activities, including more clinical studies to gain additional regulatory clearances and wider surgeon adoption.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses primarily consist of compensation, stock-based compensation expense, and other costs for finance, accounting, legal, compliance, reimbursement, and administrative matters. We expect our general and administrative expenses to increase in absolute dollars to support the growth of our business. We also expect to incur additional general and administrative expenses as a result of operating as a public company, including but not limited to: expenses related to compliance with the rules and regulations of the Securities and Exchange Commission and those of the Nasdaq Global Market on which our securities are traded; additional insurance expenses; investor relations activities; and other administrative and professional services. While we expect the general and administrative expenses to increase in absolute dollars, we anticipate that it will decrease as a percentage of revenue over time.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense is related to borrowings and includes the amortization of debt discounts derived from the issuance of warrants.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net consists primarily of the changes in fair value of our preferred stock warrant liability and net gain (loss) on foreign currency transactions. In connection with our initial public offering, or IPO, our preferred stock warrant liability was reclassed to equity as a result of the preferred stock warrants being converted to common stock warrants.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><a name="s7E2EA5380EEE5543B752DEEE497F1EEE"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our results of operations for the period presented (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:74.62962962962963%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,547</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,639</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,965</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,350</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,149</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our results of operations as a percentage of revenue:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:74.62962962962963%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations Data:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income (expense), net:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our United States and international revenue (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our United States and international revenue as a percentage of our total revenue:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the years ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$&#160;Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands except for percentages)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(279</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,547</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,871</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,676</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue. </font><font style="font-family:inherit;font-size:10pt;">Revenue increased </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  This is primarily due to an increase of </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from growth of domestic revenue from higher sales force productivity and more active surgeons from improved U.S. reimbursement coverage. In addition, revenue increased </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from growth of international revenue from increased case volume in the United Kingdom, increased sales force productivity in Germany, and new business in Australia and Taiwan.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Goods Sold, Gross Profit, and Gross Margin.</font><font style="font-family:inherit;font-size:10pt;">&#32;Total cost of goods sold </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. This is primarily due to a decrease of $0.3 million in depreciation expense for fully depreciated instrument sets, employee related costs of $0.1 million due to lower headcount, and $0.1 million in lower consulting and other professional fees.  These decreases were partially offset by increases in direct product costs from higher case volumes. Gross profit </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$7.7 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;">, to </font><font style="font-family:inherit;font-size:10pt;">$50.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;due to higher revenue and lower cost of goods sold, resulting in an increase in gross margin to </font><font style="font-family:inherit;font-size:10pt;">91%</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">89%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the respective periods.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$&#160;Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands except for percentages)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,851</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,639</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,512</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sales and Marketing Expenses. </font><font style="font-family:inherit;font-size:10pt;">Sales and marketing expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The increase was primarily due to an increase of $1.2&#160;million in salaries and other employee incentive expense and related costs as a result of improved company performance during the period, $0.7 million in additional general operational costs, $0.5 million in travel expense as a result of an increase in field sales personnel, $0.6&#160;million in increased commissions (net of lower minimum guaranteed commissions), and $0.2 million in distributor commissions due to higher revenues.  These increases were partially offset by a decrease of $0.4&#160;million in general marketing expenses.  </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses. </font><font style="font-family:inherit;font-size:10pt;">Research and development expenses </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The decrease was primarily due to a reduction of $0.3&#160;million in salaries and related expenditures from lower headcount and $0.2 million in clinical trial expense as the INSITE and SIFI studies mature. These reductions were partially offset by an increase in prototype materials and supplies for new product development of $0.4 million. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font><font style="font-family:inherit;font-size:10pt;">. General and administrative expenses </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The decrease was primarily due to $1.3 million of offering costs written off in September 2017 from delays in the public offering process and a decrease of $0.5 million from the forgiveness of a loan to the Chief Executive Officer in 2017. These decreases were partially offset by an increase in compensation expense and stock-based compensation of $0.8 million, an increase in insurance costs of $0.3 million and an increase in consulting and professional services of $0.3 million, all in conjunction of becoming a publicly traded company. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest and Other Income (Expense), Net</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$&#160;Change</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands except for percentages)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,149</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(438</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Income.</font><font style="font-family:inherit;font-size:10pt;">&#32;Interest income </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">339%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, due to an increase of investments of excess cash in money market funds and marketable securities.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</font><font style="font-family:inherit;font-size:10pt;">. Interest expense decreased </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">18%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, primarily due to the extinguishment of a credit facility with Silicon Valley Bank, or SVB, and Oxford Finance LLC, or Oxford, in October 2017.  In conjunction with the extinguishment, we entered into a new term loan with Pharmakon, or the New Term Loan, with an increased principal balance from $30.6 million to $40 million.  The extinguishment resulted in $1.5 million in early termination fees and we expensed an additional $0.7 million of unamortized debt discounts during 2017.  The decrease was partially offset by $1.1 million of additional interest expense in 2018 on the increase in borrowings.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense), Net. </font><font style="font-family:inherit;font-size:10pt;">Other income (expense), net, decreased </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">438%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, due to losses from the change in the fair value of outstanding preferred stock warrants, which are accounted for as a liability and revalued at each reporting period. In connection with our initial public offering, or IPO, our preferred stock warrant liability was reclassed to equity as a result of the preferred stock warrants being converted to common stock warrants.</font></div><div><a name="s8CA9AC04A4BA5CF390BF8A9B957417F2"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$25.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and short-term investments of </font><font style="font-family:inherit;font-size:10pt;">$97.1 million</font><font style="font-family:inherit;font-size:10pt;">. Since inception, we have financed our operations through our initial public offering, private placements of preferred stock, debt financing arrangements, and the sale of our products. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;principal amount of outstanding debt, net of debt discounts.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$157.2 million</font><font style="font-family:inherit;font-size:10pt;">. During the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2017, we incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and expect to incur additional losses in the future. We have not achieved positive cash flow from operations to date. The debt covenants associated with our current debt agreement required us to maintain a minimum cash balance of $5.0 million and achieve certain revenue targets, which we were in compliance with as of December 31, 2018. Beginning with the three months ended March 31, 2019, we are required to meet either revenue or earnings targets. If we do not comply with these covenants, the debt will immediately become due. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We continue to face challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to: (a)&#160;decreases in sales of our products and the uncertainty of future revenues from new products; (b)&#160;changes we may make to the business that affect ongoing operating expenses; (c)&#160;changes we may make in our business strategy; (d)&#160;regulatory developments affecting our existing products; (e)&#160;changes we may make in our research and development spending plans; and (f)&#160;other items affecting our forecasted level of expenditures and use of cash resources.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we need to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our sales and marketing efforts, research and development activities, or other operations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we extinguished a term loan and revolving line of credit facility with Silicon Valley Bank and Oxford Finance, LLC and concurrently, entered into the New Term Loan with Pharmakon Advisors for $40.0&#160;million. The New Term Loan includes an interest-only period for 35 months through September 2020 and is then repaid for 25 months of equal principal payments plus interest through December 2022. The New Term Loan carries a fixed interest rate of 11.5% and a closing fee of 1.5% of the funded amount, or $0.6&#160;million. The New Term Loan includes a pre-payment fee of the remaining interest payable for the first 30 months of the agreement if it is prepaid within the first 30 months, a 2% prepayment penalty for months 31-48, and a 1% penalty for months 49-60. The New Term Loan required us to maintain a minimum cash balance of $5.0&#160;million and achieve certain minimum net sales, which we were in compliance with through December 31, 2018. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning with the three months ended March 31, 2019, we are required to meet either minimum net sales or trailing 12-month consolidated EBITDA targets. We need to meet one or the other, but not both.  If we do not meet either the minimum net sales or trailing 12-month consolidated EBITDA targets, the debt will immediately become due. The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:33px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:32%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Minimum Net Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trailing 12-Month Consolidated EBITDA</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thereafter, as applicable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Term Loan is collateralized by all of our assets, including intellectual property.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we were in compliance with all of our debt obligations and covenants.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our contractual obligations as of&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.92592592592592%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due By Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than 1 year</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1-3 years</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4-5 years</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Principal obligations on the debt arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest obligations on the debt arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,464</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we entered into a new seven-year lease for our Santa Clara, California facility. The total commitment is $5.1 million.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the primary sources and uses of cash for each of the periods presented below:  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br>December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$&#160;Change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except for percentages)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,519</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,530</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,011</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">795</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effects of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,712</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,492</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Used in Operating Activities  </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities decreased </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">17%</font><font style="font-family:inherit;font-size:10pt;">, from the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The decrease in the net cash used in operating activities was primarily due to a decrease of </font><font style="font-family:inherit;font-size:10pt;">$5.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in our net loss from higher sales, lower cost of good sold, and modest increases in operating expenses, partially offset by a decrease of&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in non-cash charges and decrease in changes in operating assets and liabilities of $1.4 million. The decrease in non-cash charges were mainly due charges related to write-off of public offering costs of $1.3 million, write-off of debt discount of $0.7 million and forgiveness of notes receivable of $0.4 million recognized during the year ended December 31, 2017. These charges were partially offset by higher stock-based compensation of $0.9 million and change in fair value of redeemable convertible preferred stock warrants of $1.0 million in the year ended December 31, 2018 compared to the year ended December 31, 2017. The decrease in changes in operating assets and liabilities was mainly due to higher inventory and accounts receivable as of December 31, 2018 compared to December 31, 2017. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Used in Investing Activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in investing activities increased </font><font style="font-family:inherit;font-size:10pt;">$97.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Cash used in investing activities for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily consisted of purchase of short-term investments of $96.9 million as a result of the investments of the net proceeds from our IPO, and leasehold improvements related to the new building lease entered into in February 2018 of $0.6&#160;million. Cash used in investing activities for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily consisted of instrument set purchases of $0.5 million. The instrument sets are carried by our sales representatives and used during iFuse procedures.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Provided by Financing Activities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash provided by financing activities increased </font><font style="font-family:inherit;font-size:10pt;">$102.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;to the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Cash provided by financing activities for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of net proceeds from issuance of common stock with our IPO of $113.6 million and  exercises of common stock options of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">. Cash provided by financing activities for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted primarily of proceeds of $40&#160;million from debt financing, proceeds of $5.4&#160;million from the issuance of Series&#160;7 preferred stock from February through March 2017 and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in proceeds from exercises of common stock options, partially offset by $29.1&#160;million in extinguishment of debt financing, $1.1&#160;million in repayment of debt financing, payments of debt issuance costs of $1.5&#160;million, and payments for public offering costs of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div><a name="s87D54C93DF8151F5AA52618D7B19386B"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies, Significant Judgments, and Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. For more detail on our critical accounting policies, see Note 2 to our consolidated financial statements appearing elsewhere in this&#160;report.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We derive our revenue from the sale of our products to medical groups and hospitals through our direct sales force and distributors throughout the United States and Europe.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 605, Revenue Recognition, we recognize revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where our sales representative delivers the product at the point of implantation at hospitals or other medical facilities, we recognize revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, we recognize revenue based on shipping or delivery, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and we have no post-delivery obligations.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure our stock-based awards made to employees based on the estimated fair value of the awards as of the grant date using the Black-Scholes option-pricing model.  We recognize stock-based compensation cost over the requisite service period using the straight-line method and base stock-based compensation cost on the value of the portion of stock-based payment awards ultimately expected to vest.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record equity instruments issued to nonemployees at their fair value on the measurement date and are subject to periodic adjustment as the underling equity instruments vest. We believe that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. We recognize stock-based compensation related to stock options granted to nonemployees as the stock options are earned.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Determining Fair Value of Stock Options</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize compensation costs related to stock-based awards granted to employees and directors, including stock options, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. We generally recognize the grant date fair value of the stock-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Black-Scholes option-pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">-The expected term represents the period that we expect stock-based awards to be outstanding. We determine the expected term for option grants using the simplified method. The simplified method deems the expected term to be the midpoint between the vesting date and the contractual life of the stock-based awards.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">-Since we have been privately held until October 2018 and prior to that time did not have any trading history for our common stock, we estimated the expected volatility prior to our IPO based on the average volatility for comparable publicly traded companies over a period equal to the expected term of the stock option grants. We chose the comparable companies based on their similar size, stage in the life cycle, or area of specialty.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">-The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend</font><font style="font-family:inherit;font-size:10pt;">-We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our board of directors intends all options granted to be exercisable at a price per share not less than the per share fair value of our common stock underlying those options on the date of grant. Prior to our IPO, the estimated fair value of our common stock was determined at each valuation date in accordance with the guidelines outlined in the&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font><font style="font-family:inherit;font-size:10pt;">. Our board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including developments at our company, market conditions, and contemporaneous independent third-party valuations. In valuing our common stock, the fair value of our business, or enterprise value, was determined using both the income approach and market approach. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate based on the capital rates of return for venture-backed early stage companies and is adjusted to reflect the risks inherent in our cash flows. The market approach estimates value based on a comparison of the subject company to comparable public companies in a similar line of business. From the comparable companies, a representative market value multiple is determined and then applied to the subject company&#8217;s financial results to estimate the value of the subject company.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We then allocated the enterprise values derived from the approaches discussed above to each of our classes of stock using a hybrid methodology, which included both the Option Pricing Method, or OPM, and the Probability Weighted Expected Return Method, or PWERM. The allocation of these enterprise values to each part of our capital structure, including our common stock, was done based on the OPM. OPM treats the rights of the holders of preferred and common shares as equivalent to call options on any value of the enterprise above certain breakpoints of value based upon the liquidation preferences of the holders of preferred shares, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. The OPM backsolve method derives the implied enterprise value of a company from a recent transaction involving our own securities issued on an arms-length basis. Under the PWERM the value is estimated based upon analysis of future values for the enterprise under varying scenarios, probabilities are ascribed to these scenarios based on expected future outcomes. PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering scenarios.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the equity value is determined and allocated to the various classes of shares, a discount for lack of marketability, or DLOM, is applied to arrive at the fair value of common stock. A DLOM is applied based on the theory that as an owner of a private company stock, the stockholder has limited opportunities to sell this stock and any such sale would involve significant transaction costs, thereby reducing overall fair market value.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following our IPO, the fair value of our common stock has been determined based on the closing price of our common stock on the Nasdaq Global Market.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Preferred Stock Warrant Liability</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued freestanding warrants to purchase shares of common and preferred stock in connection with our prior debt facilities. We accounted for these warrants as a liability in our consolidated financial statements because the underlying instrument into which the warrants were exercisable contained deemed liquidation provisions that were outside our control.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants were recorded at fair value using the Black-Scholes option pricing model. The warrants were&#160;re-measured&#160;at each financial reporting period with any changes in fair value being recognized as a component of other income (expense), net in the consolidated statements of operations. We adjusted the liability for changes in fair value until the the closing of our initial public offering, at which time certain preferred stock warrants were converted into warrants to purchase common stock and the liability was reclassified to additional&#160;paid-in&#160;capital.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; deficit section of the consolidated balance sheet. We determined that the warrants for shares of common stock issued in connection with our prior debt facilities. We estimate the fair value of our warrants for shares of common stock by using the Black-Scholes option pricing model. Warrants classified as equity are recorded as additional&#160;paid-in-capital on the consolidated balance sheet and no further adjustments to their valuation are made after the issuance of the warrants.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Income Taxes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. We assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had net operating loss carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$135.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$109.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, our federal and state net operating loss carryforwards begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2029</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and valuation allowances have been established, where necessary. We also have research credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available to reduce future taxable income, if any, for both federal and California state income tax purposes, respectively. The federal credits begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2030</font><font style="font-family:inherit;font-size:10pt;">, and the California credits have no expiration date. Realization of these net operating loss and research credit carryforwards could expire unused and be unavailable to reduce future income tax liabilities, which could materially and adversely affect our results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not record a provision or benefit for income taxes during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. We continue to maintain a full valuation allowance against our net deferred tax assets.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the positions sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if we experience a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of our pre-change NOL carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code (California has similar laws). The annual limitation generally is determined by multiplying the value of our stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. We have not utilized any NOL carryovers through December 31, 2018. In addition, our deferred tax assets are subject to full valuation allowance, and thus no benefit for deferred tax assets have been recorded. The Company has determined that it experienced Section 382 ownership changes in 2010 and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of its NOLs are limited. The Company is currently performing an analysis to determine whether any additional NOL carryforwards are limited due to a change in ownership as a result of its recent IPO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the United States enacted a law commonly known as the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) which makes widespread changes to the Internal Revenue Code, including a reduction in the federal corporate tax rate to 21%, effective January 1, 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;The Company is subject to the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. The carrying value of U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of deferred tax assets. Under the new corporate income tax rate of 21%, the U.S. net deferred tax asset position decreased by approximately $15.8 million. Uncertainty regarding the impact of tax reform remains, as a result of factors including future regulatory and rulemaking processes, the prospects of additional corrective or supplemental legislation, potential trade or other litigation, and other factors.</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the SEC staff issued Staff Accounting Bulletin No.&#160;118 (&#8220;SAB 118&#8221;), which provides guidance for the tax effect of the 2017 Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the 2017 Tax Act&#8217;s enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&#8220;ASC 740&#8221;). In accordance with SAB 118, we must reflect the income tax effects of those aspects of the 2017 Tax Act for which the accounting under ASC 740 is complete. To the extent that its accounting for certain income tax effects of the 2017 Tax Act is incomplete, but we are able to determine a reasonable estimate, we must record a provisional estimate in its consolidated financial statements. If we cannot determine a provisional estimate to be included in its consolidated financial statements, we should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the 2017 Tax Act. It is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the 2017 Tax Act. We analyzed the guidance and other necessary information related to the tax effects of the 2017 Tax Act and consider the accounting of our net deferred tax assets complete in accordance with SAB 118. </font></div><div><a name="s300A1585D15F581C8A73FC2B567E27DE"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.</font></div><div><a name="s7588207728A557CD919A3BF6C8DCA90E"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Seasonality</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business is affected by seasonal variations. For instance, we have historically experienced lower sales in the summer months and higher sales in the last quarter of the fiscal year. However, taken as a whole, seasonality does not have a material impact on our financial results.</font></div><div><a name="sE0A7BF1F2DCA5C5BB406EF4C4456CE10"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">JOBS Act Accounting Election</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2012, the JOBS Act was enacted. Section&#160;107(b) of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><a name="sFDDF309B82B9522282511DBC9557674A"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the guidance on the subsequent measurement of inventory, excluding inventory measured using last-in, first out or the retail inventory method. Under the new standard, in scope inventory should be measured at the lower of cost and net realizable value. The new standard will become&#160;effective for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2016, for public companies. For all other entities, the new standard is effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017, with early adoption permitted. We adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17,&#160;Balance Sheet Classification of Deferred Taxes. ASU 2015-17 specifies that deferred tax assets and liabilities shall be classified as non-current, or long-term, in a classified statement of financial position. The new standard is effective for public entities for fiscal years beginning after&#160;December 15, 2016, and interim periods within those fiscal years. For private entities, the new standard is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within fiscal years beginning after December&#160;15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or an annual reporting period. We early adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, which simplified several aspects of accounting for stock-based compensation transactions. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new guidance is effective for public entities for fiscal years beginning after December&#160;15, 2016 and interim periods within those years. Other entities must apply the new guidance in fiscal years beginning after December&#160;15, 2017 and in interim periods within fiscal years beginning after December 15, 2018, with early adoption permitted. We early adopted this standard in the first quarter of 2017 by recording the cumulative impact of applying this guidance to retained earnings, which was not material. We elected to continue to&#160;estimate the number of awards&#160;that are expected to vest.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued&#160;ASU 2016-01.&#160;Recognition and Measurement of Financial Assets and Financial Liabilities, which amends Accounting Standards Codification, or ASC,&#160;Subtopic 825-10,&#160;Financial Instruments - Overall, and includes updates on certain aspects of recognition, measurement, presentation and disclosure of financial instruments and applies to all entities that hold financial assets or owe financial liabilities. The new standard is effective for our annual period beginning after December 15, 2018, with early adoption permitted</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">beginning after December 15, 2017. We have adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09, Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for all entities for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2017. Early adoption is permitted. We adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Effective</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S.&#160;GAAP when it becomes effective. The new standard is effective for fiscal years beginning after December&#160;15, 2017 for public companies, and for fiscal years beginning after December&#160;15, 2018, and interim periods beginning after December&#160;15, 2019, for private companies. Early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. In March&#160;2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April&#160;2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May&#160;2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date as ASU&#160;2014-09. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continue to evaluate the impacts of adoption of the new standard on its accounting policies, processes, and system requirements and have assigned internal resources, in addition to the engagement of third party service providers, to assist in the evaluation.&#160;At this time, as it relates to product sales where our sales representative delivers the product at the point of implantation at hospital or other medical facilities, we expect revenue to continue to be recognized upon completion of the procedure&#160;and authorization by the customer. Additionally, the new standard requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. We expect to continue expensing all sales commissions as incurred. Management will adopt the standard using the modified retrospective method for the fiscal year ending December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued its new lease accounting guidance. Under the new guidance, ASU 2016-02, Leases (Topic 842), lessor accounting is largely unchanged. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Under the new guidance, lessees will be required to recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date. The new guidance is effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018 for public companies and beginning after December&#160;15, 2019 for private companies. Early adoption is permitted for any interim or annual financial statements net yet issued. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing and operating leases) must apply a modified retrospective approach for all leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the impact of this standard on our consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15 &#8220;Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments&#8221;. ASU 2016-15 provides guidance on the following eight specific cash flow classification issues: (1)&#160;debt prepayment or debt extinguishment costs; (2)&#160;settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3)&#160;contingent consideration payments made after a business combination; (4)&#160;proceeds from the settlement of insurance claims; (5)&#160;proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6)&#160;distributions received from equity method investees; (7)&#160;beneficial interests in securitization transactions; and (8)&#160;separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December&#160;15, 2017 for public companies, and fiscal years beginning after December&#160;15, 2018 and interim periods within fiscal years beginning after December 15, 2019 for private companies, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2016-15 on our consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part&#160;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&#160;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in Part&#160;I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the amendments in Part&#160;I of this Update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. We are currently evaluating the impact that the adoption of this standard will have on our consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement&#8212;Reporting Comprehensive Income (Topic 220).&#160;This update provides companies with the option to reclassify stranded tax effects caused by the 2017 Tax Cuts and Jobs Act (the 2017 Tax Act) from accumulated other comprehensive income to retained earnings. This standard is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. Early adoption is permitted. We are currently evaluating the impact that the adoption of this standard will have on our consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU&#160;2018-07,&#160;Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation&#8212;Stock Compensation, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity&#8212;Equity-Based Payments to&#160;Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December&#160;15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">beginning after December&#160;15, 2020. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of ASC 606. We are currently evaluating the impact that the adoption of this standard will have on the consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB43532636F1B56E7AD45CFF6C220AC6A"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable to a smaller reporting company.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><a name="sD2F11DD08AB95BE3BCB28ACDAB88D81C"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8. Financial Statements and Supplementary Data</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.37037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:95%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2d050d88896a4468a71689d05c8a1fb3">89</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAA4BFEC1E5CD509EBD2BFAD008867FE6">90</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s01149F937B3C56E3822702E6E6B63E5B">91</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s77ab369a92ee4d54a69967d3a4475faf">92</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA2D24756782E52548C77217748D120EF">94</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s559C0F790CE4534FA95E23F05E1051FD">96</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s2d050d88896a4468a71689d05c8a1fb3"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Board of Directors and Stockholders of SI-BONE, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of SI-BONE, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2018 and 2017, and the related consolidated statements of operations and comprehensive loss, of changes in redeemable convertible preferred stock and stockholders' equity (deficit) and of cash flows for each of the years then ended including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Jose, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 14, 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company's auditor since 2013.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sAA4BFEC1E5CD509EBD2BFAD008867FE6"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">CURRENT ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25,120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">97,103</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable, net of allowance for doubtful accounts of $263 and $268 at December&#160;31, 2018 and 2017, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,416</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,553</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">136,042</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33,629</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">TOTAL ASSETS </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">138,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">CURRENT LIABILITIES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued liabilities and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Redeemable convertible preferred stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">422</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Long-term borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,963</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">TOTAL LIABILITIES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48,329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46,664</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Commitments and contingencies (Note 6)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Redeemable convertible preferred stock, $0.0001 par value;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Authorized: 0 and 12,104,749 shares at December&#160;30, 2018 and December 31, 2017; issued and outstanding: 0 and 11,871,578 shares at December&#160;30, 2018 and December&#160;31, 2017; (Liquidation preference of $0 and $119,194 at December&#160;30, 2018 and December&#160;31, 2017).</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">118,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Preferred stock, $0.0001 par value; Authorized: 5,000,000 and 0 shares at December&#160;31, 2018 and 2017, respectively; no shares issued and outstanding as of December&#160;31, 2018 and 2017.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock, $0.0001 par value; Authorized: 100,000,000 and 19,333,333 shares at December&#160;31, 2018 and 2017, respectively; issued and outstanding: 24,450,757 and 3,603,140 shares, at December&#160;31, 2018 and 2017, respectively.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">246,927</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,943</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(157,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(139,724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(129,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">138,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s01149F937B3C56E3822702E6E6B63E5B"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share amounts) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.37037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,833</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,112</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,646</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,062</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income (expense), net:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain of marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in foreign currency translation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,416</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares used to compute basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,950,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,467,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><a name="s77ab369a92ee4d54a69967d3a4475faf"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share amounts) </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.289972899729%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:17%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable <br>Convertible <br>Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional <br>Paid-in <br>Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; <br>Notes <br>Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated <br>Other <br>Comprehensive <br>Income (Loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated <br>Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total <br>Stockholders&#8217; Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,330,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,446,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(108,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of unvested stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of redeemable convertible preferred stock, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repayment of stockholders&#8217; notes receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forgiveness of stockholders&#8217; note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vesting of early exercised stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,603,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(139,724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,077</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,136</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,136</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock upon exercise of unvested stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion from preferred stock to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,871,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,548</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,547</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,548</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion from preferred stock warrants to common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.289972899729%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:17%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock from warrants exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock from IPO Proceeds, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,280,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repurchase of unvested early exercised stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,628</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vesting of early exercised stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,450,757</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">246,927</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(157,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,192</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA2D24756782E52548C77217748D120EF"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.25925925925925%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:6px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,453</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,039</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">722</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,013</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in allowance for doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of redeemable convertible preferred stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss on write-off of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">214</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Write-off of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortization of debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">259</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">285</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Write-off of public offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forgiveness of notes receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term investments accretion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Changes in operating assets and liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(759</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(980</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued liabilities and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,260</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,792</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,519</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,530</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchase of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(942</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(478</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchase of short-term investments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(96,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(97,825</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(478</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from initial public offering, net of underwriting discounts and commissions</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,506</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from the exercise of common stock options, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,614</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Repurchase of common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Repayment of stockholders&#8217; notes receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Repayment of debt financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,119</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Extinguishment of debt financing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(29,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from debt financing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payment of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Proceeds from the issuance of redeemable convertible preferred stock, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,427</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of public offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,292</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(94</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,712</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,492</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Cash and cash equivalents at</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,900</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">End of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Supplemental disclosure of non-cash information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Conversion of redeemable convertible preferred stock to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">118,547</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.25925925925925%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:6px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Conversion of preferred stock warrants to common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,248</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vesting of early exercised stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">139</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Purchases of property and equipment included in accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Public offering costs included in accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:26px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:26px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s559C0F790CE4534FA95E23F05E1051FD"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sEA70ABD004C35B379249063896953D46"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. The Company and Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its iFuse Implant System, or iFuse, in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company's board of directors and stockholders approved a 1-for-18 reverse stock split of the Company's common stock and redeemable convertible preferred stock, which was effected on October&#160;4, 2018. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse split. All issued and outstanding share and per share amounts of common stock, redeemable convertible preferred stock, stock options, and warrants included in the accompanying consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;16, 2018, the Company&#8217;s Registration Statement on Form S-1 (File No.&#160;333-227445) relating to the initial public offering (IPO) of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">8,280,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares at an initial public offering price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$113.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Company, net of underwriting discounts and commissions and offering costs. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, and the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">160,657</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional paid-in-capital.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#4e586a;">&#160;</font></div><div><a name="s5D553F674A69558984D89CBB0572428C"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long-lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates. </font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The chief operating decision makers for the Company are the Chief Executive Officer and Chief Financial Officer. The Chief Executive Officer and the Chief Financial Officer review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company derives substantially all of its revenue from sales to customers in the United States. Revenue by geography is based on billing address of the customer. No single country outside the United States accounts for more than 10% of the total revenue during the periods presented. Long-lived assets held outside the United States are immaterial. Following table summarizes the Company's revenue by geography (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.74074074074075%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses resulting from the translation of the Company&#8217;s consolidated balance sheets are recorded as a component of accumulated other comprehensive income. Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company&#8217;s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenue and accounts receivable are spread across a large number of customers, primarily in the United States, and no one customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Risks and Uncertainties</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors, uncertainty of market acceptance of products, and the need to obtain additional financing.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of and for the year ended December 31, 2018, the Company had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$157.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and used </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of cash in operations. The Company has not achieved positive cash flow from operations to date. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$25.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and short-term investments of </font><font style="font-family:inherit;font-size:10pt;">$97.1 million</font><font style="font-family:inherit;font-size:10pt;">. The Company held cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$22.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December 31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s primary cash needs are for the ongoing commercialization of its iFuse products. The Company also has certain debt covenants associated with its current debt agreement. These covenants include a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;minimum cash balance and revenue targets, which if not met would result in the debt becoming immediately due. The revenue target is assessed quarterly based on the rolling twelve months of revenue, and increases by approximately </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;each quarter. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. The Company has met the minimum liquidity and revenue targets as of December 31, 2018; however there can be no assurances that the Company will continue to meet these targets in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based upon the Company's current operating plan, the Company believes that its existing cash, cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements through at least the next 12 months. The Company continues to face challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to: (a)&#160;decreases in sales of our products and the uncertainty of future revenues from new products; (b)&#160;changes that the Company may make to the business that affect ongoing operating expenses; (c)&#160;changes that the Company may make in its business strategy; (d)&#160;regulatory developments affecting the Company's existing products; (e)&#160;changes that the Company may make in its research and development spending plans; and (f)&#160;other items affecting the Company's forecasted level of expenditures and use of cash resources.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate. The carrying amount of the redeemable convertible preferred stock warrants has been marked to fair value such that the carrying amount represents its estimated fair value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s cash equivalents consist of money market funds as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The money market funds are classified as Level&#160;1 of the fair value hierarchy. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy. The Company&#8217;s redeemable convertible preferred stock warrants are classified within Level&#160;3 of the fair value hierarchy. The redeemable convertible preferred stock warrants have been valued using a Black-Scholes valuation model and are subsequently marked to fair value at each reporting period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's marketable securities primarily consist of investments in U.S. treasury securities, corporate bonds, and commercial paper. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. Based upon maturity dates, all marketable securities as available for use in current operations, and therefore we classify these securities as current assets in the accompanying consolidated balance sheets. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in Accumulated other comprehensive income (loss) ("OCI"). We evaluate our investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in Other income (expense), net on the consolidated statements of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;If quoted prices for identical instruments are available in an active market, marketable securities are classified within Level 1 of the fair value hierarchy. If quoted prices for identical instruments in active markets are not available, fair values are estimated using quoted prices of similar instruments and are classified within Level 2 of the fair value hierarchy. To date, all of the Company's marketable securities can be valued using one of these two methodologies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#8217;s operating results or change in financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, inventory consisted entirely of finished goods.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:80%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset&#8217;s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has not experienced impairment losses on its long-lived assets.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public Offering Costs</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specific incremental costs (i.e. consisting of legal, accounting and other fees and costs) directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. In the event a planned IPO does not occur or is significantly delayed, all of the costs will be expensed. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;capitalized offering costs as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;included in other non-current assets on the consolidated balance sheets. Costs incurred and capitalized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;amounting to </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;were transferred to additional paid-in capital upon completion of the IPO on October 16, 2018. Offering costs of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;were also incurred and expensed in the </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, as a result of delays in the IPO process during the period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; deficit section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and other similar instruments related to shares that are contingently redeemable are classified as liabilities on the consolidated balance sheet at their estimated fair value because the shares underlying the warrants may obligate the Company to transfer assets to the holders at a future date under certain circumstances such as a deemed liquidation event. The warrants are exercisable into the Company&#8217;s redeemable convertible preferred stock and are classified as liabilities on the consolidated balance sheet. The warrants, measured at fair value, are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company adjusted the liability for changes in fair value until the the closing of our initial public offering, at which time certain preferred stock warrants were converted into warrants to purchase common stock and the liability was reclassified to additional&#160;paid-in&#160;capital.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 605, Revenue Recognition (&#8220;ASC 605&#8221;), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company&#8217;s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warranty Program</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company implemented a warranty program which provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period following an original procedure where an implant is not required. These one-time credits are accounted for as sales reserves. Sales and warranty reserves from the warranty program were immaterial as of both </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medical Device Excise Tax</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the United States. The medical device excise tax is included in cost of goods sold in the consolidated statements of operations and comprehensive loss for all the periods presented. Effective December 2015, the Act was amended to include a provision to suspend the tax on medical devices through 2017. In January 2018, the suspension on the tax on medical devices was further extended through 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shipping and handling costs are expensed as incurred and are included in cost of goods sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#8217;s product which include (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense (2)&#160;external research and development expenses (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expenditures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of advertising is included in Sales and Marketing expense in the consolidated financial statements and expensed as incurred. Advertising costs totaled </font><font style="font-family:inherit;font-size:10pt;">$0.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions including expected volatility, expected life, risk-free interest rate and expected dividends. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to nonemployees is recognized as the stock options are earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. The guidance also prescribes treatment for derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company calculates basic and diluted net loss per common share attributable to shareholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock and early exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the redeemable convertible preferred stock and early exercised stock options as the holders of redeemable convertible preferred stock and early exercised stock options do not have a contractual obligation to share in losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, redeemable convertible preferred stock and common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss represents all changes in the stockholders&#8217; equity (deficit) except those resulting from distributions to stockholders. The Company&#8217;s unrealized foreign currency translation income (losses) and unrealized gain (losses) of marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the guidance on the subsequent measurement of inventory, excluding inventory measured using last-in, first out or the retail inventory method. Under the new standard, in scope inventory should be measured at the lower of cost and net realizable value. The new standard will become&#160;effective for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2016, for public companies. For all other entities, the new standard is effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017, with early adoption permitted. The Company has adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17,&#160;Balance Sheet Classification of Deferred Taxes. ASU 2015-17 specifies that deferred tax assets and liabilities shall be classified as non-current, or long-term, in a classified statement of financial position. The new standard is effective for public entities for fiscal years beginning after&#160;December 15, 2016, and interim periods within those fiscal years. For private entities, the new standard is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within fiscal years beginning after December&#160;15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or an annual reporting period. The Company has early adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, which simplified several aspects of accounting for stock-based compensation transactions. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new guidance is effective for public entities for fiscal years beginning after December&#160;15, 2016 and interim periods within those years. Other entities must apply the new guidance in fiscal years beginning after December&#160;15, 2017 and in interim periods within fiscal years beginning after December 15, 2018, with early adoption permitted. The Company early adopted this standard in the first quarter of 2017 by recording the cumulative impact of applying this guidance to retained earnings, which was not material. The Company elected to continue to&#160;estimate the number of awards&#160;that are expected to vest.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01. Recognition and Measurement of Financial Assets and Financial Liabilities, which amends Accounting Standards Codification, or ASC, Subtopic 825-10, Financial Instruments - Overall, and includes updates on certain aspects of recognition, measurement, presentation and disclosure of financial instruments and applies to all entities that hold financial assets or owe financial liabilities. The new standard is effective for the Company&#8217;s annual period beginning after December 15, 2018, with early adoption permitted beginning after December 15, 2017. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&#8217;s consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09, Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for all entities for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2017. Early adoption is permitted. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Effective</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S.&#160;GAAP when it becomes effective. The new standard is effective for fiscal years beginning after December&#160;15, 2017 for public companies, and for fiscal years beginning after December&#160;15, 2018, and interim periods beginning after December&#160;15, 2019, for private companies. Early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. In March&#160;2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April&#160;2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May&#160;2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date as ASU&#160;2014-09. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to evaluate the impacts of adoption of the new standard on its accounting policies, processes, and system requirements and has assigned internal resources, in addition to the engagement of third party service providers, to assist in the evaluation.&#160;At this time, as  it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or other medical facilities, the Company expects revenue to continue to be recognized upon completion of the procedure&#160;and authorization by the customer. Additionally, the new standard requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company expects to continue expensing all sales commissions as incurred. Management will adopt the standard using the modified retrospective method for the fiscal year ending December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued its new lease accounting guidance. Under the new guidance, ASU 2016-02, Leases (Topic 842), lessor accounting is largely unchanged. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Under the new guidance, lessees will be required to recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date. The new guidance is effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018 for public companies and beginning after December&#160;15, 2019 for private companies. Early adoption is permitted for any interim or annual financial statements net yet issued. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing and operating leases) must apply a modified retrospective approach for all leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15 &#8220;Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments&#8221;. ASU 2016-15 provides guidance on the following eight specific cash flow classification issues: (1)&#160;debt prepayment or debt extinguishment costs; (2)&#160;settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3)&#160;contingent consideration payments made after a business combination; (4)&#160;proceeds from the settlement of insurance claims; (5)&#160;proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6)&#160;distributions received from equity method investees; (7)&#160;beneficial interests in securitization transactions; and (8)&#160;separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December&#160;15, 2017 for public companies, and fiscal years beginning after December&#160;15, 2018 and interim periods within fiscal years beginning after December 15, 2019 for private companies, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-15 on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part&#160;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&#160;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in Part&#160;I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the amendments in Part&#160;I of this Update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement&#8212;Reporting Comprehensive Income (Topic 220).&#160;This update provides companies with the option to reclassify stranded tax effects caused by the 2017 Tax Cuts and Jobs Act (the 2017 Tax Act) from accumulated other comprehensive income to retained earnings. This standard is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU&#160;2018-07,&#160;Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation&#8212;Stock Compensation, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity&#8212;Equity-Based Payments to&#160;Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December&#160;15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of ASC 606. The Company is currently evaluating the impact that the adoption of this standard will have on the consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div><a name="s1bc7a0d224fb41769e2a33989e147f6c"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Marketable Securities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,708</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All marketable securities of at December 31, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of money market funds which were classified as cash equivalents.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s3F89136262CA52CCAF592B78E33C85FD"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Fair Value Measurement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font><font style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">[1]</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font><font style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">[1]</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">[1]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents on the consolidated balance sheet</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the redeemable convertible preferred stock warrants, the Company&#8217;s Level&#160;3 financial liability, which is measured on a recurring basis (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:93%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value recorded in other (income) expense, net </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">826</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of preferred stock warrants to common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sFDA88AA646CE53B9A3BB9D84A4A29B40"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Balance Sheet Components</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, net</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,518</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,918</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities and Other </font><font style="font-family:inherit;font-size:10pt;">(in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales tax payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for early exercise of unvested stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and warranty reserves</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sDF5052C353C05CC3AF21A13E16858257"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2012, the Company entered into a new </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year non-cancelable operating lease for its existing office building space in San Jose, California which commenced in January 2013. In February 2014, the Company expanded the existing lease space and extended the lease terms through June 2017. In May 2016, the Company entered into another extension of the lease with its lessor for additional 12 months beginning in July 2017. Effective May 2018, the Company entered into an early termination agreement on an operating lease for its San&#160;Jose office. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;early termination fees were incurred and all previously agreed-to rent payments were released, with no further obligations. In February 2018, the Company entered into a new </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">-year non-cancelable operating lease for an office building space in Santa Clara, California which commenced in April 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also entered into non-cancelable operating leases for its office building space in Gallarate, Italy and Mannheim, Germany which both expire in November 2024. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2019 to 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;text-align:left;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;The aggregate future minimum lease payments under all leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands): </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments and Obligations</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain purchase commitments related to inventory used in normal course of business. These commitments totaled </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The amounts paid under these arrangements may be less in the event that the arrangement is renegotiated or canceled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the United States District Court, Northern District of California. The complaint alleges violations of the Telephone Consumer Protection Act (the &#8220;TCPA&#8221;) on behalf of an individual and putative classes of persons alleged to be similarly situated.  The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission.  The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship.  The Company believes that it has meritorious defenses and intends to vigorously defend itself in the action.  It is too early in this matter to reasonably predict the probability of the outcomes or to estimate the range of possible loss, if any.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;">&#32;incurred costs to defend lawsuits or settle claims related to these indemnification agreements. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;liability associated with such indemnifications has been recorded to date.</font></div><div><a name="s1DACEDE2FF4F564595133687BDD6775B"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Borrowings</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$38.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of outstanding debt, net of debt discounts, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Company entered into a Term Loan facility and a revolving line of credit with Silicon Valley Bank, or SVB and Oxford Finance LLC, or Oxford for </font><font style="font-family:inherit;font-size:10pt;">$35.2 million</font><font style="font-family:inherit;font-size:10pt;">. The Term Loan had interest only periods for </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;">&#32;up to October&#160;1, 2017 and was then to be repaid over </font><font style="font-family:inherit;font-size:10pt;">25 months</font><font style="font-family:inherit;font-size:10pt;">&#32;of equal principal payments plus interest. The maturity date of the term loan was December&#160;1, 2019, and it carried an interest rate equal to the greater of </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;">&#32;or the WSJ Prime rate plus </font><font style="font-family:inherit;font-size:10pt;">7.75%</font><font style="font-family:inherit;font-size:10pt;">. The Term Loan borrowings were senior unsecured obligations of the Company, ranking equally and ratably among themselves and with the Company&#8217;s existing and future unsecured and unsubordinated debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the above Term Loan agreement, the Company issued redeemable convertible preferred stock warrants (refer to Note 9 for details).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company extinguished the Term Loan with SVB and Oxford. Concurrently, the Company entered into a New Term Loan with Pharmakon Advisors, or Pharmakon. As a result of the extinguished debt, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$29.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in principal payments to SVB and Oxford. The Company also paid </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in early termination fees and recorded </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of unamortized debt discounts. This loss on extinguishment of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is reflected as interest expense in the consolidated statement of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into the New Term Loan with Pharmakon for </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in October 2017. Debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;were recorded as a direct deduction from the carrying amount of the New Term Loan on the consolidated balance sheet, and are being amortized over the period of the New Term Loan using the effective interest method to interest expense in the consolidated statement of operations. The New Term Loan includes an interest-only period for </font><font style="font-family:inherit;font-size:10pt;">35</font><font style="font-family:inherit;font-size:10pt;">&#32;months through September 2020 and is then repaid in equal quarterly principal payments plus interest through December 2022, and is classified as long-term borrowings on the consolidated balance sheet. The New Term Loan carries a fixed interest rate of </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;and a closing fee of </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the funded amount, or </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">. The New Term Loan includes a pre-payment fee equal to the interest due for the first 30 months of the agreement if it is prepaid within the first 30 months, a </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;prepayment penalty for months 31-48, and a </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;penalty for months 49-60. The New Term Loan required the Company to maintain a minimum cash balance of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and to achieve certain revenue targets through December 31, 2018. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. Under the New Term Loan, the Company also has a second tranche of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available through January 2019, contingent upon the achievement of certain revenue milestones. The Company did not draw upon the second tranche. The New Term Loan is a senior obligation secured with a blanket first lien on the assets of the Company. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total loan balance, net of debt discount, was </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$38.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, with an effective interest rate of </font><font style="font-family:inherit;font-size:10pt;">12.3%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">12.0%</font><font style="font-family:inherit;font-size:10pt;">, respectively, and the Company was in compliance with all debt covenants.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approximate annual future minimum principal payments under the loan agreements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending at, December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount representing debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Term Loan required the Company to maintain a minimum cash balance of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and to achieve certain revenue targets, which we were in compliance with through December 31, 2018. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning with the three months ended March 31, 2019, the Company is required to meet either minimum net sales or trailing 12-month consolidated EBITDA targets. The Company needs to meet one or the other, but not both.  If the Company does not meet either the minimum net sales or trailing 12-month consolidated EBITDA targets, the debt will immediately become due. The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:33px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:32%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Minimum Net Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trailing 12-Month Consolidated EBITDA</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thereafter, as applicable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Term Loan is collateralized by all of the Company's assets, including intellectual property.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company was in compliance with all of its debt obligations and covenants.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Line of Credit</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, the Company entered into an agreement with its existing lender SVB and Oxford. The amount of the revolving line of credit was </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(or </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the amount of certain customer accounts receivable). It carried an interest rate equal to the WSJ Prime rate plus </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">&#32;with a maturity of December&#160;1, 2019. In October 2017, this line of credit was cancelled in conjunction with the SVB and Oxford debt extinguishment discussed above. No draws were made on this facility through its cancellation. </font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s40E75F5863C35C70966CE35F6679717E"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Redeemable Convertible Preferred Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;preferred stock balance outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:51%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Series</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liquidation&#160;Value </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,617</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,047</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,032</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,807</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,086,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,009,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,389,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,319,274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,508</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,666,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,580,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,104,749</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,194</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the conversion of redeemable preferred stock to common stock during the IPO, the holders of preferred stock had various rights and preferences as follows:</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Voting Rights</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock shares were entitled to vote on all matters on which the common stockholders were entitled to vote. The holders of Series&#160;1, Series 2, Series 3 had the right to </font><font style="font-family:inherit;font-size:10pt;">0.352941</font><font style="font-family:inherit;font-size:10pt;">&#32;votes for each share of Series 2 common stock into which such preferred stock would had converted and the holders of Series 4, Series 5, Series 6 and Series 7 had the right to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;vote for each share of Series 2 common stock into which such preferred stock would had converted. As long as there were any shares of Series 4, Series 5, Series 6, and Series 7 shares that were outstanding, the holders of such Series 4, Series 5, Series 6 and Series 7, at each respective series, were entitled to elect </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;member of the Board of Directors each; the holders of Series 2 common stock were entitled to elect </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;members of the Board of Directors; and the holders of the preferred stock and Series 2 common stock, voting together as a single class were entitled to elect the remaining members of the Board of Directors, as determined at each annual meeting of the Board of Directors.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As long as at least </font><font style="font-family:inherit;font-size:10pt;">277,778</font><font style="font-family:inherit;font-size:10pt;">&#32;preferred stock shares remained outstanding, the Company must obtain approval from a majority of the holders of the then outstanding shares of preferred stockholders and a majority of the voting power of all outstanding shares of Series 5 preferred stock in order to (i)&#160;consummate or agree to consummate a Liquidation Event (as defined in the Company&#8217;s certificate of incorporation); (ii) amend, alter, restate or repeal any provision of the Company&#8217;s certificate of incorporation or bylaws so as to adversely alter, affect or change the powers, preferences, rights or privileges of the shares of preferred stock; (iii)&#160;increase or decrease (other than by redemption or conversion) the total number of authorized shares of common stock or preferred stock or designated shares of any series of preferred stock; (iv)&#160;authorize or issue, or obligate itself to issue, any equity security (including any other security convertible into or exercisable for any such equity security) having a preference over, or being on a parity with, any series of preferred stock with respect to dividends, liquidation or redemption, other than the issuance of any authorized but unissued shares of Series&#160;6 preferred stock designated in the Company&#8217;s certificate of incorporation (including any security convertible into or exercisable for such shares of preferred stock); (v) redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any share or shares of preferred stock or common stock; provided, however, that this restriction shall not apply to the repurchase of shares of common stock from employees, officers, directors, consultants or other persons performing services for the Company or any subsidiary pursuant to agreements under which the Company has the option to repurchase such shares upon the occurrence of certain events, such as the termination of employment or service, or pursuant to an agreement providing for a right of first refusal in favor of the Company, in each case, provided that such agreement has been approved by the Company&#8217;s board of directors; or (vi)&#160;pay or declare any dividend on any shares of capital stock of the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of preferred stock were entitled to receive noncumulative dividends, when and if declared by the Board of Directors, out of any assets legally available, prior to and in preference to any declaration or payment of dividends on the common stock of the Company. Dividend rates, on a per annum basis, for Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock are </font><font style="font-family:inherit;font-size:10pt;">$0.050112</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.171360</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.4608</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.504</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.72774</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.317744</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.802656</font><font style="font-family:inherit;font-size:10pt;">, respectively, (adjusted to reflect subsequent stock dividends, stock splits or recapitalization). </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;dividends on preferred stock or common stock have been declared as of December&#160;31, 2018 and 2017.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of any liquidation, dissolution or winding-up of the Company or Liquidating Event, the holders of the preferred stock were entitled to receive prior to and in preference to any distribution to holders of the common stock, an amount equal to their respective original issuance price per share (original issuance price per share for Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock are </font><font style="font-family:inherit;font-size:10pt;">$0.6264</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.142</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.76</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.30</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$9.0954</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$16.4718</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$10.0332</font><font style="font-family:inherit;font-size:10pt;">, respectively), plus any declared but unpaid dividends on such shares. Should the Company&#8217;s legally available assets be insufficient to satisfy the full liquidation preference, the funds will be distributed ratably among the holders of the preferred stock in proportion to the preferential amount each holder is otherwise entitled to receive.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the distribution as above, the remaining proceeds shall be distributed among the holders of Series&#160;4, Series&#160;5, Series&#160;6, Series&#160;7 preferred stock and common stock pro rata based on the number of shares of common stock held by each until the holders of the preferred stock have received the &#8220;participation cap.&#8221; Thereafter, if proceeds remain, the holders of Series&#160;7 preferred stock and common stock of this corporation shall receive all of the remaining proceeds pro rata based on the number of shares of common stock held by each (assuming full conversion of all such Series&#160;7 preferred stock). The Company has a per share &#8220;Participation Cap&#8221; of </font><font style="font-family:inherit;font-size:10pt;">$32.9436</font><font style="font-family:inherit;font-size:10pt;">&#32;for the Series&#160;6 preferred stock, </font><font style="font-family:inherit;font-size:10pt;">$18.1908</font><font style="font-family:inherit;font-size:10pt;">&#32;for the Series&#160;5 preferred stock, and </font><font style="font-family:inherit;font-size:10pt;">$12.60</font><font style="font-family:inherit;font-size:10pt;">&#32;for the Series&#160;4 preferred stock (each as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like with respect to such series of preferred stock).</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conversion</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each share of Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock was convertible at the option of the holder, into the number of shares of Series 2 common stock into which such shares are at the then effective conversion ratio or </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to one ratio. The conversion price per share for Series 1, Series 2, Series 3 and Series 4, Series 5, Series 6, and Series 7 preferred stock shall be the respective issuance price per share, respectively. The initial conversion price was subject to adjustment from time to time. In March 2017, the conversion price per share for the Series 6 preferred stock was amended from </font><font style="font-family:inherit;font-size:10pt;">$15.714</font><font style="font-family:inherit;font-size:10pt;">&#32;per share to </font><font style="font-family:inherit;font-size:10pt;">$15.5574</font><font style="font-family:inherit;font-size:10pt;">&#32;per share which resulted in the conversion ratio increasing from </font><font style="font-family:inherit;font-size:10pt;">1.05</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">1.06</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each share of preferred stock shall be converted into common stock shares upon the earlier of (i)&#160;immediately before the closing of a firm commitment underwritten public offering in which the aggregate gross proceeds of not less than </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a per share public offering of not less than </font><font style="font-family:inherit;font-size:10pt;">$30.0996</font><font style="font-family:inherit;font-size:10pt;">, or (ii)&#160;the Company&#8217;s receipt of a written request for such conversion from the holders of at least the voting majority of all outstanding preferred stock (voting as a single class and on an&#160;as-converted&#160;basis).</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the conversion of redeemable convertible preferred stock to common stock during the IPO, the Company has classified the preferred stock as temporary equity on the consolidated balance sheets as the shares can be redeemed upon the occurrence of certain change in control events that are outside the Company&#8217;s control, including deemed liquidation, sale or transfer of the Company. The Company has not adjusted the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of preferred stock. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB6BCDCA2005B5B87937D551825BC43C5"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">160,657</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional paid-in-capital. In addition, warrants to purchase Series 6 Preferred Stock were converted to warrants to purchase common stock at a conversion ratio of 1:1.06.   </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows(in thousands, except share and per share data): </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.91642924976259%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of <br>Shares <br>Underlying <br>Warrants</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price&#160;per <br>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants to purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total outstanding common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[a]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants will remain outstanding until exercised by the holder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[b]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of issuance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[c]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&#160;&#160;&#160;&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands, except share and per share data): </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of <br>Shares <br>Underlying <br>Warrants</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price&#160;per <br>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants to purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,928</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series&#160;5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/1/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/25/2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[d]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,917</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,283</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,550</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total outstanding common and redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,876</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[a]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants will remain outstanding until exercised by the holder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[b]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of issuance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[c]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value as of December 31, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[d]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">These warrants will be net exercised immediately upon the closing of the Company&#8217;s IPO, or upon&#160;a corporate transaction as defined in the Note and Warrant Purchase Agreement dated July&#160;25, 2012. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[e]</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Convertible preferred stock warrants will remain outstanding until exercised by the holder and will convert to common stock warrants upon an IPO. The warrants will be exercisable for </font><font style="font-family:inherit;font-size:8pt;">10 years</font><font style="font-family:inherit;font-size:8pt;">&#32;from the date of issuance. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with previously issued debt, the Company issued </font><font style="font-family:inherit;font-size:10pt;">101,010</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants to purchase common shares of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$3.96</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in July 2013. Additionally, the Company issued warrants to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">21,928</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$3.42</font><font style="font-family:inherit;font-size:10pt;">&#160;per share in November 2014. The Company determined that its warrants to purchase shares of common stock meet the requirements for equity classification.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with debt issued in July 2012, the Company issued warrants which became exercisable for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">54,917</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series 5 preferred stock of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.10</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with debt issued in 2013 and 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">32,983</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants to purchase Series&#160;5 redeemable convertible preferred stock of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.10</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. Subsequently, the Company issued additional warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">6,310</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series&#160;6 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.47</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the debt agreement with SVB and Oxford, or Term Loan agreement (refer to Note 7), the Company issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">39,339</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series 6 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.47</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in October 2015 and additional </font><font style="font-family:inherit;font-size:10pt;">24,283</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series 6 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.47</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in November 2015.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the Term Loan agreement and its modification (refer to Note 7), the Company issued additional warrants for the purchase of </font><font style="font-family:inherit;font-size:10pt;">9,712</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series 7 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$10.03</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in December 2016.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company issued a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">1,388</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$5.94</font><font style="font-family:inherit;font-size:10pt;">&#32;to a consultant. The Company determined that such warrant meets the requirements for equity classification.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company extinguished its debt with SVB and Oxford. All related debt discounts were written off upon repayment of the loan.</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the fair value of warrants using the Black-Scholes option valuation model. The fair value is estimated using certain assumptions. Refer to Note 11. Stock-Based Incentive Compensation Plans, for further discussions on how the Company determines these input assumptions. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of warrants to purchase preferred stock were recorded at the date of issuance as a discount to debt and amortized to interest expense over the term of the note. The changes in the fair value of the redeemable convertible preferred stock warrants are recorded in other income and expense. Weighted-average assumptions used in computation of the fair value of the redeemable convertible preferred stock warrants are summarized in the table below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.07882241215574%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining contractual term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sF67EFF0A67EF54389F36D6B5E80A5319"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Board of Directors approved an increase of </font><font style="font-family:inherit;font-size:10pt;">555,555</font><font style="font-family:inherit;font-size:10pt;">&#32;Series&#160;2 common stock. As a result, the Company&#8217;s restated certificate of incorporation, as amended, authorizes the Company to issue </font><font style="font-family:inherit;font-size:10pt;">19,333,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">&#32;par value common stock, of which </font><font style="font-family:inherit;font-size:10pt;">6,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;has been designated as Series 1 common stock and </font><font style="font-family:inherit;font-size:10pt;">13,333,333</font><font style="font-family:inherit;font-size:10pt;">&#32;has been designated as Series 2 common stock. The holders of Series 1 common stock shall have no voting rights; the holders of Series 2 common stock shall have the right to one vote for each such share. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company amended and restated its certification of incorporation, which authorizes the Company to issue </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of preferred stock, each having a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">. At December 31, 2018, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;preferred stock issued and outstanding.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;dividends declared to date.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has reserved shares of common stock, on an issued and as-converted basis, for future issuance as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:45%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock <br>Equivalent&#160;Shares</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,450,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 1 common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112,955</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112,955</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2 common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,760,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,787,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,986,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s88571AC622C45025A5B6B9A651DC218C"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Stock-Based Incentive Compensation Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2008, the Company adopted the 2008 Stock Option Plan, as amended, under which the Board of Directors may issue incentive and nonqualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan, which serves as the successor to the 2008 Stock Option Plan, under which the Board of Directors may issue incentive and nonqualified stock options and restricted stock units (RSUs) to employees, directors and consultants. No new options have been granted under the 2008 Stock Option Plan since August 2018. Outstanding options under the 2008 Stock Option Plan continue to be subject to the terms and conditions of that plan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding shares, the price of each share shall be at least </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a nonqualified stock option shall not be less than </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the fair market value on the date of grant. As of  </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a total of </font><font style="font-family:inherit;font-size:10pt;">5,350,080</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock had been reserved for issuance under the 2008 Stock Option Plan. As of&#160;December&#160;31, 2018, a total of </font><font style="font-family:inherit;font-size:10pt;">2,576,538</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock had been reserved for issuance under the 2018 Equity Incentive Plan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted have a term of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">&#32;years, except, options granted to individuals holding more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding shares have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years. Options generally vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period. Certain shares issued under the Plan are exercisable immediately, but subject to a right of repurchase by the Company of any unvested shares. RSUs granted under the 2018 Equity Incentive Plan generally vest over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;years based upon continued services and are settled at vesting in shares of the Company's common stock. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;for all stock plans:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.25925925925927%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:36%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Contractual Remaining Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.88</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options canceled </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,762,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and expected to vest - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,366,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair value of all options granted were </font><font style="font-family:inherit;font-size:10pt;">$3.98</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.80</font><font style="font-family:inherit;font-size:10pt;">&#32;for years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest were calculated as the difference between the exercise price of the options and the close price of the Company&#8217;s common stock on the last trading day of the year, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the lesser of the fair market value of the stock as of the first date or the ending date of each </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;month offering period.  </font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early Exercise of Unvested Stock Options</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early exercises of stock options are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders&#8217; equity (deficit) as the options vest. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had a total of </font><font style="font-family:inherit;font-size:10pt;">74,019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">16,117</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, respectively, subject to repurchase under the Plan and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of associated liabilities for the repurchase.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth stock-based compensation expense recognized for the periods presented (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.70370370370371%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts above do not include </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of stock-based compensation expense related to forgiveness of notes receivable for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;amounts of stock-based compensation expense related to forgiveness of notes receivable were recognized for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Refer to Note 13 for details.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company&#8217;s common stock underlying the stock options has historically been determined by the Company&#8217;s Board of Directors. Because there had been no public market for the Company&#8217;s common stock prior to its IPO, its Board of Directors has determined the fair value of the Company&#8217;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including independent third-party valuations, the Company&#8217;s stage of development, sales of the Company&#8217;s redeemable convertible preferred stock, the Company&#8217;s operating and financial performance, equity market conditions affecting comparable public companies, the lack of liquidity of the Company&#8217;s capital stock, and the general and industry-specific economic outlooks.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the NASDAQ Global Market on the date of grant.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected term represents the period that the share-based awards are expected to be outstanding. The Company used the simplified method to determine the expected term, which is calculated as the average of the time to vesting and the contractual life of the options.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the Company&#8217;s common stock has never been publicly traded, the expected volatility is derived from the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend Yield</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Forfeiture Rate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant date fair value of the stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:61%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.71</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42%-47%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42%-55%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.35%-2.96%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73%-2.31%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Stock Options</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">564,098</font><font style="font-family:inherit;font-size:10pt;">&#32;performance stock options at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$5.94</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">408,544</font><font style="font-family:inherit;font-size:10pt;">&#32;performance options will vest monthly over </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;years and </font><font style="font-family:inherit;font-size:10pt;">155,554</font><font style="font-family:inherit;font-size:10pt;">&#32;performance options will vest monthly over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years. The vesting period will begin on the date of the closing of an IPO, the performance condition, subject to the optionee&#8217;s continuous service. Stock-based compensation expense for performance stock options is based on the probability of achieving certain performance criteria, as defined in the individual option grant agreement. Periodically, the Company estimates the number of performance options ultimately expected to vest and recognizes stock-based compensation expense for those options when it becomes probable that the performance criteria will be met. In October 2018, the Company completed its IPO and recognized </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;expense related to the performance stock options for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company modified the terms of </font><font style="font-family:inherit;font-size:10pt;">394,652</font><font style="font-family:inherit;font-size:10pt;">&#32;unvested stock option awards granted in March 2017, by reducing their exercise price from </font><font style="font-family:inherit;font-size:10pt;">$5.94</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$4.68</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. In addition, the vesting performance conditions for these options were removed and the vesting commencement date changed from the IPO date to September 2017. There were no other changes in any of the other terms of the option awards. Due to these options previously subject to performance conditions that were not deemed probable of occurring, the Company had not recognized any expense related to these grants. The modification resulted in total expense of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that is recognized over the amended vesting period of forty-eight months</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock units activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.77777777777777%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of <br>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted- <br>Average <br>Grant Date Fair  <br>Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Unvested as of  December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Unvested as of  December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was a total unrecognized compensation cost of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">. These costs are expected to be recognized over a period of approximately </font><font style="font-family:inherit;font-size:10pt;">2.29 years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;In October 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "ESPP"). </font><font style="font-family:inherit;font-size:10pt;">515,307</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock are reserved for issuance under the ESPP.  The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compensation expense for the ESPP.  As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation cost for the ESPP was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used to determine the grant date fair value of employee stock options and ESPP purchase rights for the periods presented are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.7037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:75%;"></td><td style="width:24%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.96%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><a name="s92CC38BBA4AC53139688728589F95AAD"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Employee Benefit Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. The Company has made no contributions to the 401(k) plan since its inception.</font></div><div><a name="s2454B18A852F5EBE92453B5F53626E27"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Related Party Transactions</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2013, the Company granted a loan to its then current Chief Financial Officer to assist with the exercise of his stock option grants in the form of a full recourse promissory note with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. The note is collateralized by the common stock issued upon the exercise of the stock options, as well as personal assets of the borrower. Interest under this note will accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">1.09%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum. In November 2016, the loan amount was partially repaid in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(including principal and interest). The remainder of the principal balance of this note, together with all accrued and unpaid interest to date, was fully paid in December 2017.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company granted a loan to its Chief Executive Officer to assist with the exercise of his stock option grants in the form of a full recourse promissory note with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. The note is collateralized by the common stock issued upon the exercise of the stock options, as well as personal assets of the borrower. At the time of issuance, the Company accounted for the note as a full recourse promissory note based on historical pattern of collecting payment on notes in full and no other notes had been forgiven, nor had any recourse notes been substantively converted to nonrecourse. Interest under this note will accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">1.97%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum. The principal balance of this note, together with all accrued and unpaid interest to date, was due in February 2019.  In March 2017, the Company forgave </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of principal and interest due on this promissory note from its Chief Executive Officer. In addition, the Board of Directors approved the forgiveness of the remaining </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal balance of the note in January 2018. At the time of the forgiveness, all of the related stock options were fully vested. As a result, the Company expensed the principal note balance of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to stock-based compensation expense and accrued interest of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to general and administrative expenses in the consolidated statement of operations in the year ended December 31, 2017.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sECE266EB07645E0E94CB44072035C78B"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Net Loss Per Share of Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basic and Diluted Net Loss per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the computation of basic and diluted net loss per share (in thousands, except share and per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used to compute basic and diluted net loss per share*</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,950,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,467,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted*</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*        Calculated based on the 1-for-18 reverse stock split effected October 4, 2018.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested shares for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were excluded from the weighted-average shares used to compute basic and diluted net loss per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:69%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares subject to repurchase</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,117</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated ESPP shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,657</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sBBC07383AB115CB7B787FB2301E7866F"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. Income Taxes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the Company&#8217;s loss before income taxes are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(618</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of income tax expense are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current tax expense:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax expense:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,513</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax at statutory federal rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State tax, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement of deferred taxes as a result of tax reform</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.25925925925925%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,070</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and reserves</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,835</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The following table summarizes changes in the valuation allowance for the year ended December 31, 2018 and 2017 (in thousands): </font></div><div style="line-height:120%;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions during the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$135.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$109.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company&#8217;s federal net operating loss carryforward begins to expire in </font><font style="font-family:inherit;font-size:10pt;">2029</font><font style="font-family:inherit;font-size:10pt;">, and the state net operating loss carryforward begins to expire in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company had credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2030</font><font style="font-family:inherit;font-size:10pt;">, and the state credits have no expiration date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code (California has similar laws). The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company has not utilized any NOL carryovers through December 31, 2018. In addition, the Company&#8217;s deferred tax assets are subject to full valuation allowance, and thus no benefit for deferred tax assets have been recorded. The Company has determined that it experienced Section 382 ownership changes in 2010 and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of its NOLs are limited. The Company is currently performing an analysis to determine whether any additional NOL carryforwards are limited due to a change in ownership as a result of its recent IPO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company&#8217;s uncertain income tax positions for the years ended December 31, 2018 and 2017 consisted of the following (in thousands):</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SI-BONE, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.37037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance as of January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases in balances related to tax positions taken during 2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance as of December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases in balances related to tax positions taken during 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,084</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has accrued </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;at December 31, 2018 and 2017 for payment of interest related to unrecognized tax benefits. None of the Company&#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rate at December 31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently has no federal or state tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company&#8217;s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the United States enacted a law commonly known as the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) which makes widespread changes to the Internal Revenue Code, including a reduction in the federal corporate tax rate to 21%, effective January 1, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. The carrying value of U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of deferred tax assets. Under the new corporate income tax rate of 21%, the U.S. net deferred tax asset position decreased by approximately </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">. Uncertainty regarding the impact of tax reform remains, as a result of factors including future regulatory and rulemaking processes, the prospects of additional corrective or supplemental legislation, potential trade or other litigation, and other factors.</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the SEC staff issued Staff Accounting Bulletin No.&#160;118 (&#8220;SAB 118&#8221;), which provides guidance for the tax effect of the 2017 Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the 2017 Tax Act&#8217;s enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&#8220;ASC 740&#8221;). In accordance with SAB 118, the Company must reflect the income tax effects of those aspects of the 2017 Tax Act for which the accounting under ASC 740 is complete. To the extent that its accounting for certain income tax effects of the 2017 Tax Act is incomplete, but the Company is able to determine a reasonable estimate, the Company must record a provisional estimate in its consolidated financial statements. If the Company cannot determine a provisional estimate to be included in its consolidated financial statements, the Company should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the 2017 Tax Act. It is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the 2017 Tax Act. The Company has analyzed the guidance and other necessary information related to the tax effects of the 2017 Tax Act and considers the accounting of its net deferred tax assets complete in accordance with SAB 118.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s62169cdda76d4ae28f7da3c665a3a7b5"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE8155CC2D3A35C78A2E418CE3F16A184"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9A. Controls and Procedures.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of disclosure controls and procedures.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 201, our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules&#160;13a&#8209;15(e)&#160;and 15d&#8209;15(e)&#160;under the Securities Exchange Act of 1934, as amended). Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of December&#160;31, 2018, our disclosure controls and procedures were effective at the reasonable assurance level. Additionally, our management has concluded that the financial statements included elsewhere in this report present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with GAAP.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exemption from management&#8217;s report on internal control over financial reporting for the fiscal&#160;year ended December&#160;31, 2018.</font></div><div style="line-height:100%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Annual Report on Form&#160;10&#8209;K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by the rules&#160;of the SEC for newly public companies.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in internal control over financial reporting.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting during the&#160;fourth quarter of the year ended December&#160;31, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><a name="s2DE78F308FF4501B8F0543DADC101CCA"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B. Other Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s0C0C6A5B2B5050DD9395DDD8D545ECFD"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4c838fa4e09841d18be681975474828b"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;10. Directors, Executive Officers and Corporate Governance.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2019 Annual Meeting of Stockholders, or the Proxy Statement, which will be filed not later than 120&#160;days after the end of our fiscal&#160;year ended December&#160;31, 2018, under the headings &#8220;Management,&#8221; &#8220;Proposal 1 - Election of Directors,&#8221; &#8220;Board Committees and Meetings,&#8221; and &#8220;Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance,&#8221; and is incorporated herein by reference.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees which is available on our website at www.si-bone.com. The Code of Business Conduct and Ethics is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section&#160;406 of the Sarbanes-Oxley Act of 2002 and Item&#160;406 of Regulation&#160;S-K. In addition, we intend to promptly disclose (1)&#160;the nature of any substantive amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2)&#160;the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver, on our website in the future.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6ae6408bd01a43c4bba73f52061966b7"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;11. Executive Compensation.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item regarding executive compensation will be incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; and &#8220;Compensation of Non-Employee Board Members&#8221; in our Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s53e7b04380d748a0ad7f650c4f5a03b4"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item regarding security ownership of certain beneficial owners and management will be incorporated by reference to the information set forth in the sections titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; in our Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sbf7b88d1b0134c9b93537ffb3da473f8"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item regarding certain relationships and related transactions and director independence will be incorporated by reference to the information set forth in the sections titled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 - Election of Directors&#8221;, respectively, in our Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sfca1bf5af6ef4350b18a02603c47c501"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;14. Principal Accounting Fees and Services.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item regarding principal accountant fees and services will be incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s71661c3b104d4ed5b0f62b118092705f"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></div><hr style="page-break-after:always"><div><a name="s697B248C4BA7540C8C5C8B6FE81CE776"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;15. Exhibits, Financial Statement Schedules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;The following documents are filed as part of this report:</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;Financial Statements</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;padding-left:18px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information in response to this Item&#160;is included in Part&#160;II, Item&#160;8 of this Annual Report on Form&#160;10&#8209;K.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;Financial Statement Schedules</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;padding-left:18px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;3.&#160;Exhibits</font></div><div style="line-height:130%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT&#160;INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:2%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;font-weight:bold;">Incorporation By Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit <br>Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SEC File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Filing Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518303020/d641574dex31.htm"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Amended and Restated Certificate of Incorporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">001-38701</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/19/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex34.htm"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Amended and Restated Bylaws.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex41.htm"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Form&#160;of Common Stock Certificate of the Company.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Reference is made to Exhibits </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518303020/d641574dex31.htm"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">3.1</font></a><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;and </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex34.htm"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">3.2</font></a><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex101.htm"><font style="font-family:inherit;font-size:10pt;">Form of Indemnity Agreement between the Registrant and each of its directors and executive officers.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex102.htm"><font style="font-family:inherit;font-size:10pt;">2008 Stock Plan and forms of agreements thereunder.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.3+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex103.htm"><font style="font-family:inherit;font-size:10pt;">2018 Equity Incentive Plan</font></a><font style="font-family:inherit;font-size:10pt;color:#0000ff;">.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.4+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex104.htm"><font style="font-family:inherit;font-size:10pt;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Equity Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.5+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex105.htm"><font style="font-family:inherit;font-size:10pt;">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.6+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex106.htm"><font style="font-family:inherit;font-size:10pt;">2018 Employee Stock Purchase Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.7#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex105.htm"><font style="font-family:inherit;font-size:10pt;">Quality and Manufacturing Agreement, dated April 18, 2016, between the Registrant and Orchid MPS Holdings, LLC and Addendum No. 1 dated March 1, 2017.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:2%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.8#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex106.htm"><font style="font-family:inherit;font-size:10pt;">Manufacturing, Quality and Supply Agreement, dated January 31, 2017, between the Registrant and rms Company and Addendum No. 1 dated July 7, 2017.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.9+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex107.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter Agreement, dated December 15, 2009, between the Registrant and Jeffrey W. Dunn.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.10+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex108.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter Agreement, dated February 19, 2015, between the Registrant and Michael A. Pisetsky</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.11+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex109.htm"><font style="font-family:inherit;font-size:10pt;">Letter Regarding Change to Employment Terms, dated June 20, 2016, between the Registrant and Michael A. Pisetsky.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.12+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1010.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter Agreement, dated April 27, 2015, between the Registrant and Laura Francis.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.13+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1011.htm"><font style="font-family:inherit;font-size:10pt;">Severance and Change in Control Agreement dated March 15, 2016, between the Registrant and Laura Francis.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.14+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1012.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Letter Agreement, dated March 1, 2017, between the Registrant and Laura Francis.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.15+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1013.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter Agreement, dated February 7, 2012, between the Registrant and W. Carlton Reckling.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.16+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1014.htm"><font style="font-family:inherit;font-size:10pt;">Severance and Change in Control Agreement, dated March 15, 2016, between the Registrant and W. Carlton Reckling.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.17+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1015.htm"><font style="font-family:inherit;font-size:10pt;">Letter Agreement, dated January 18, 2017, between the Registrant and W. Carlton Reckling.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.18+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1016.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter Agreement, dated December 16, 2010, between the Registrant and Scott A. Yerby.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.19+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1017.htm"><font style="font-family:inherit;font-size:10pt;">Severance and Change in Control Agreement dated March 15, 2016, between the Registrant and Scott A. Yerby.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.20+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1018.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter Agreement, dated June 19, 2016, between the Registrant and Anthony J. Recupero.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518293978/d452987dex1021.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Investors&#8217; Rights Agreement, dated June 2, 2016, by and among the Registrant and the parties thereto, as amended on October 4, 2018.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/5/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1020.htm"><font style="font-family:inherit;font-size:10pt;">Loan Agreement, dated October 13, 2017, between the Registrant and Biopharma Credit Investments IV Sub LP, as amended on June 15, 2018.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1021.htm"><font style="font-family:inherit;font-size:10pt;">Office Lease Agreement, dated February 2, 2018, between the Registrant and Bixby SPE Finance 11, LLC, as amended on April 16, 2018.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1022.htm"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Common Stock issued to Westriver Mezzanine Loans, LLC.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1023.htm"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Common Stock issued to Silicon Valley Bank.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:2%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1024.htm"><font style="font-family:inherit;font-size:10pt;">Warrant to Purchase Series 5 Preferred Stock issued to Silicon Valley Bank dated July 17, 2013.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1025.htm"><font style="font-family:inherit;font-size:10pt;">Warrant to Purchase Series 6 Preferred Stock issued to Silicon Valley Bank dated November 26, 2014.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1026.htm"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Series 6 Preferred Stock issued to Silicon Valley Bank.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1027.htm"><font style="font-family:inherit;font-size:10pt;">Form of Warrant to Purchase Series 6 Preferred Stock issued to Oxford Finance, LLC.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1028.htm"><font style="font-family:inherit;font-size:10pt;">Warrant to Purchase Series 7 Preferred Stock issued to Oxford Finance, LLC dated December 22, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1029.htm"><font style="font-family:inherit;font-size:10pt;">Warrant to Purchase Series 7 Preferred Stock issued to Silicon Valley Bank dated December 22, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">10.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1459839/000119312518278797/d452987dex1030.htm"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Unit Grant Notice and Award Agreement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333-227445</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9/20/2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">21.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sibn-ex211_listxofxsubsidi.htm"><font style="font-family:inherit;font-size:10pt;">List of Subsidiaries of Registrant</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">23.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sibn-ex231_pwcxconsent.htm"><font style="font-family:inherit;font-size:10pt;">Consent of PricewaterhouseCoopers, Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">24.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE83EBC0BBFB5480876E1ED952E25BB8"><font style="font-family:inherit;font-size:10pt;">Power of Attorney (contained in the signature page of this report)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">31.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sibn-ex311_12311810xk.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Rules&#160;13a&#8209;14(a)&#160;and 15d&#8209;14(a)&#160;under the Securities Exchange Act of 1934, as amended.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">31.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sibn-ex312_12311810xk.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Rules&#160;13a&#8209;14(a)&#160;and 15d&#8209;14(a)&#160;under the Securities Exchange Act of 1934, as amended.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">32.1**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="sibn-ex321_12311810xk.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFA08BC0779EF5AD1AE741E4F3BD5EAF0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:6%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:2%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;text-indent:-10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furnished herewith. Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">+</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicates a management contract or compensatory plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">#</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.</font></div></td></tr></table><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;We have filed, or incorporated into this Annual Report on Form&#160;10&#8209;K by reference, the exhibits listed on the Exhibit&#160;Index immediately above.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;See Item&#160;15(a)2 above.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:32px;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s98866d48326b42e198ea1d2379c9bf0f"></a></div><div style="line-height:130%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 16. Form 10-K Summary</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></div><hr style="page-break-after:always"><div><a name="sAE83EBC0BBFB5480876E1ED952E25BB8"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in Santa Clara, California, on this 14th day of March,&#160;2019.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:53%;"></td><td style="width:7%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey W. Dunn </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey W. Dunn </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Duly Authorized Officer and Principal Executive Officer</font><font style="font-family:inherit;font-size:8pt;">) </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laura A. Francis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laura A. Francis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laura A. Francis, and Michael A. Pisetsky, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10&#8209;K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</font></div><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:24%;"></td><td style="width:2%;"></td><td style="width:52%;"></td><td style="width:2%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey W. Dunn</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey W. Dunn</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer) and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laura A. Francis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laura A. Francis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David P. Bonita, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David P. Bonita, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Timothy E. Davis, Jr.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Timothy E. Davis, Jr.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/John G. Freund, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John G. Freund, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Gregory K. Hinckley</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gregory K. Hinckley</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Karen A. Licitra</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Karen A. Licitra</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark A. Reiley, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark A. Reiley, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/sTimothy B. Petersen.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Timothy B. Petersen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;/s/ Keith C. Valentine</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;14, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keith C. Valentine</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>sibn-ex211_listxofxsubsidi.htm
<DESCRIPTION>EXHIBIT 21.1 LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s749eda7620a3442c85b5a2238171abf8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 21.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">List of subsidiaries of the Registrant</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:631px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:329px;"></td><td style="width:17px;"></td><td style="width:285px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jurisdiction</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SI-BONE S.R.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SI-BONE Deutschland GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SI-BONE UK LTD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>sibn-ex231_pwcxconsent.htm
<DESCRIPTION>EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s436363dce4b64eebb0fe32e591eef261"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 23.1</font></div><div style="line-height:120%;padding-top:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-227907) of SI-BONE, Inc. of our report dated March 14, 2019&#160;relating to the financial statements, which appears in this Form 10-K.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ PricewaterhouseCoopers LLP </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Jose, California </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 14, 2019 </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sibn-ex311_12311810xk.htm
<DESCRIPTION>EXHIBIT 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5C5BB1BB0D61588095E88D56A7438B77"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Jeffrey W. Dunn, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-K of SI-Bone, Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey W. Dunn</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 14, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey W. Dunn</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sibn-ex312_12311810xk.htm
<DESCRIPTION>EXHIBIT 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s50BA0F6A33A45CE7A1518E34BEB229E3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Laura A. Francis, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-K of SI-Bone, Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laura A. Francis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 14, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laura A. Francis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sibn-ex321_12311810xk.htm
<DESCRIPTION>EXHIBIT 32.1 CERTIFICATION OF CHIEF EXECUTIVE AND CHIEF FINANCIAL OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBEDA254526B8530A945652C5D601CE90"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Jeffrey W. Dunn, President and Chief Executive Officer of SI-Bone, Inc. (the &#8220;Company&#8221;), and Laura A. Francis, Chief Financial Officer of the Company, each hereby certify that, to the best of his or her knowledge: </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. The Company&#8217;s  Annual Report on Form 10-K for the period ended December 31, 2018, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:43%;"></td><td style="width:2%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey W. Dunn </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 14, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey W. Dunn</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Laura A. Francis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 14, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laura A. Francis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of SI-Bone, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>sibn-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:74C1704679835F0CB38D5BB2E0310EE7,x:e7f3b29a39ce4084aeb15bd4bd6b73ff-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sibn="http://si-bone.com/20181231" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="sibn-20181231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Mar13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct16">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-16</xbrli:startDate>
			<xbrli:endDate>2018-10-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct16_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-16</xbrli:startDate>
			<xbrli:endDate>2018-10-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Oct16_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct16_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-16</xbrli:startDate>
			<xbrli:endDate>2018-10-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Oct16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct01-Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sibn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May01-May31_srt_StatementGeographicalAxis_sibn_SanJoseCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sibn:SanJoseCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3Aug31_srt_StatementGeographicalAxis_sibn_SanJoseCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sibn:SanJoseCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28_srt_StatementGeographicalAxis_sibn_SantaClaraCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sibn:SantaClaraCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Oct31_sibn_DebtPrepaymentPenaltyPeriodAxis_sibn_PrepaymentPenalty3148MonthsMember_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtPrepaymentPenaltyPeriodAxis">sibn:PrepaymentPenalty3148MonthsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Aug31_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Oct31_sibn_DebtPrepaymentPenaltyPeriodAxis_sibn_PrepaymentPenalty4960MonthsMember_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtPrepaymentPenaltyPeriodAxis">sibn:PrepaymentPenalty4960MonthsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:PharmakonTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Oct30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Oct_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sibn:SVBAndOxfordTermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodSevenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodSevenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodSixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodSixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="sibn:DebtCovenantPeriodAxis">sibn:PeriodFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb28_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyNineteenthTwentyThirteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Nov09_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-11-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Oct20_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov26_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q3Jul19_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyNineteenthTwentyThirteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-07-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov26_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3Jul01_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyFirstTwentyTwelveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-07-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q3Jul19_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyNineteenthTwentyThirteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-07-19</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Mar01_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec22_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberNinthTwentyFifteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedMarchFirstTwentySeventeenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedOctoberTwentiethTwentyFifteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedDecemberTwentySecondTwentySixteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyFirstTwentyTwelveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyNineteenthTwentyThirteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsIssuedJulyNineteenthTwentyThirteenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sibn:WarrantsLiabilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_NonvotingCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_NonvotingCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_sibn_StockOptionsandESPPPurchaseRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:StockOptionsandESPPPurchaseRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_sibn_IncentiveStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:IncentiveStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_sibn_NonqualifiedStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sibn:NonqualifiedStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Oct31_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2021Q3Sep012017-Sep302021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2021-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_sibn_A2008StockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2008StockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct01-Oct31_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_sibn_A2018EquityIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sibn:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:ForgivenessOfRelatedPartyPromissoryNoteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefFinancialOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar_us-gaap_RelatedPartyTransactionAxis_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sibn:ForgivenessOfRelatedPartyPromissoryNoteMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefFinancialOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-01</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2014-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q1Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefFinancialOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_ShareSubjectToRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:ShareSubjectToRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_RedeemableConvertiblePreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_EmployeeStockPurchasePlanSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:EmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_EmployeeStockPurchasePlanSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:EmployeeStockPurchasePlanSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_RedeemableConvertiblePreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_ShareSubjectToRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sibn:ShareSubjectToRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Oct04-Oct04">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-04</xbrli:startDate>
			<xbrli:endDate>2018-10-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001459839</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="vote">
		<xbrli:measure>sibn:vote</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>sibn:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="director">
		<xbrli:measure>sibn:director</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q4YTD" id="Fact-27439EA162EC5643A0F7E6EF288DB98B">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q4YTD" id="Fact-D45F18070FE65EBC83AC7FBB794E0755">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q4YTD" id="Fact-C3C36EBD3AB457A6BEAB55AAF31C89CE">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q4YTD" id="Fact-DCBAF240E35353979FC1BD77214AC953">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q4YTD" id="Fact-BF29A8D3007651108962B79C63CD89B3">2018-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q4YTD" id="Fact-C3DD64550212510FA1B2FCBEE82B3EE0">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q4YTD" id="Fact-81A0D97444BB51A2A7CB68505FA07CB1">0001459839</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1Mar13" decimals="INF" id="Fact-10DDA02F3EA59DA7C67C4A17A7B76993" unitRef="shares">24458938</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2018Q4YTD" id="Fact-D0E9D6298ED5102ABF7E4A1B2D43DAA5">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q4YTD" id="Fact-1DF0258E933D5DBEACEEA3A91DAB6B91">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2018Q4YTD" id="Fact-9734A242945B5752A2A531E907DA1319">false</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2018Q4YTD" id="Fact-990A4FBD579559C781FAB3C146FC6960">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2018Q2" decimals="INF" id="Fact-B892E20A0F9D00733A0B4A1C3238244E" unitRef="usd">0</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2018Q4YTD" id="Fact-1543F81593A8534A940D01D5F3BA333B">SI-BONE,&#160;INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2018Q4YTD" id="Fact-8EFD1046280A3316FEA64A1B4767CE89">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2018Q4YTD" id="Fact-7C6C4934B27A5BFD9ABB4B0723A26E9F">true</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2018Q4YTD" id="Fact-D203C94FF7E843B7FB8C4A1B1B88CD3D">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q4YTD" id="Fact-F804B99EE3902C4534424A1B01899C3E">No</dei:EntityWellKnownSeasonedIssuer>
	<sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2BD087B49A9A131F8EE94EED6E793AF3" unitRef="usd">122000</sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions>
	<sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9FA5C6ED85A30732C8F24EED6E6F25EA" unitRef="usd">122000</sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions>
	<sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-389ACC0832890C68C0E74EED4015520E" unitRef="usd">139000</sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions>
	<sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B05513435053939BF8354EED4008FA15" unitRef="usd">139000</sibn:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions>
	<sibn:AdjustmentstoAdditionalPaidinCapitalWarrantConverted contextRef="FD2018Q4YTD" decimals="-3" id="Fact-53FCC53EC10E41B96EC44F09D3BA4046" unitRef="usd">1248000</sibn:AdjustmentstoAdditionalPaidinCapitalWarrantConverted>
	<sibn:AdjustmentstoAdditionalPaidinCapitalWarrantConverted contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C67B803800FD7BF4FF4D4F09A3424C21" unitRef="usd">1248000</sibn:AdjustmentstoAdditionalPaidinCapitalWarrantConverted>
	<sibn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted contextRef="D2018Q4Oct16_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-012051E67F3D5E99BA33B1A922268646" unitRef="shares">156550</sibn:ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted>
	<sibn:ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-5BE5AA52852157BD82809E9FDE74B8F5" unitRef="shares">124326</sibn:ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights>
	<sibn:ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-DFFB2B430C885532BFAC3F23FD8A5363" unitRef="shares">160657</sibn:ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights>
	<sibn:CommonStockEquivalentSharesStockOptionsOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-AEC9584DF9F1529ABA077C6D0E26331F" unitRef="shares">3001929</sibn:CommonStockEquivalentSharesStockOptionsOutstanding>
	<sibn:CommonStockSeriesTwoNumberOfDirectorsEntitledToElect contextRef="FD2017Q4YTD" decimals="INF" id="Fact-E36F595F44F3A0AF1B3878C35613B750" unitRef="director">2</sibn:CommonStockSeriesTwoNumberOfDirectorsEntitledToElect>
	<sibn:CommonStockSharesAuthorizedIncreaseDuringPeriod contextRef="D2017Q1Mar_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-D5C0E43B638554ADA7F77489F4B54074" unitRef="shares">555555</sibn:CommonStockSharesAuthorizedIncreaseDuringPeriod>
	<sibn:ConvertiblePreferredStockConversionPrice contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-56CC1379EED7D4EF44BB78B8FE882141" unitRef="usdPerShare">15.5574</sibn:ConvertiblePreferredStockConversionPrice>
	<sibn:ConvertiblePreferredStockConversionPrice contextRef="I2017Q1Feb28_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-394467CB9A133E26C57678B848F74C20" unitRef="usdPerShare">15.714</sibn:ConvertiblePreferredStockConversionPrice>
	<sibn:ConvertiblePreferredStockMinimumPublicOfferingForConversion contextRef="FI2017Q4" decimals="-5" id="Fact-AE52F46F032C12B14BB2788DEF007185" unitRef="usd">50000000</sibn:ConvertiblePreferredStockMinimumPublicOfferingForConversion>
	<sibn:ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion contextRef="FI2017Q4" decimals="INF" id="Fact-E5F1558665DDAF4EE704788EA29CF523" unitRef="usdPerShare">30.0996</sibn:ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodFiveMember" decimals="-3" id="Fact-642D485FD2B0F11D8AEF5DC6527EB17E" unitRef="usd">57500000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodFourMember" decimals="-3" id="Fact-AF42EC24BCB7248F51F15DC6506E3A8D" unitRef="usd">56000000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodOneMember" decimals="-3" id="Fact-7314BB09A76B0A45A4685DC651627140" unitRef="usd">52000000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodSevenMember" decimals="-3" id="Fact-B1B7E3B4BC4BABC49EBE5DC650949D1D" unitRef="usd">60000000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodSixMember" decimals="-3" id="Fact-4002A5209DD1777911075DC6510A2107" unitRef="usd">58500000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodThreeMember" decimals="-3" id="Fact-E6EC9CBF3F2255091DC05DC6505C07BF" unitRef="usd">54500000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodTwoMember" decimals="-3" id="Fact-96701CA955F21CDC1E595DC650CFA386" unitRef="usd">53500000</sibn:DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodFiveMember" decimals="-3" id="Fact-4270F9856EE1052E77B35DC7580D0C09" unitRef="usd">1000000</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodFourMember" decimals="-3" id="Fact-F72D50160CB869A3D8455DC758051357" unitRef="usd">0</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodOneMember" decimals="-3" id="Fact-210A8629BE944EDDD7D45DC7582F11BF" unitRef="usd">-5000000</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodSevenMember" decimals="-3" id="Fact-58988DD277567F320C8B5DC7580015F2" unitRef="usd">3000000</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodSixMember" decimals="-3" id="Fact-24AC503F1DA4D7F0C0405DC75816D8BD" unitRef="usd">2000000</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodThreeMember" decimals="-3" id="Fact-F9708ECAF9D8BEE155CB5DC7583FD521" unitRef="usd">-2000000</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA contextRef="FD2018Q4YTD_sibn_DebtCovenantPeriodAxis_sibn_PeriodTwoMember" decimals="-3" id="Fact-28B29C3C323F2A0D6AEC5DC758219A19" unitRef="usd">-3500000</sibn:DebtCovenantTrailing12MonthConsolidatedEBITDA>
	<sibn:DebtInstrumentClosingFeePercentage contextRef="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-6BC01A38113755F086B9543EE5590A7A" unitRef="number">0.015</sibn:DebtInstrumentClosingFeePercentage>
	<sibn:DebtInstrumentCovenantMinimumCashBalance contextRef="FI2018Q4" decimals="-5" id="Fact-EC5A29573D18DD160B52786A50650A7B" unitRef="usd">5000000</sibn:DebtInstrumentCovenantMinimumCashBalance>
	<sibn:DebtInstrumentCovenantMinimumCashBalance contextRef="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-B919FE87DD225B8C9495D3CD379889F7" unitRef="usd">5000000</sibn:DebtInstrumentCovenantMinimumCashBalance>
	<sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod contextRef="D2016Q3Aug_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" id="Fact-6D95AAED431D575B8D795908C60B36D5">P6M</sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
	<sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod contextRef="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-59EDBCABBF2052F2A14D596D6ABB0508">P35M</sibn:DebtInstrumentPeriodicPaymentInterestOnlyPeriod>
	<sibn:DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod contextRef="D2016Q3Aug_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" id="Fact-E447D8EBDF6E57A6BF03B7FB5DC93EB3">P25M</sibn:DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod>
	<sibn:DebtInstrumentPrepaymentPenaltyPercentage contextRef="I2017Q3Oct31_sibn_DebtPrepaymentPenaltyPeriodAxis_sibn_PrepaymentPenalty3148MonthsMember_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-5EA5DA102B5F573BAA40E4B98A685823" unitRef="number">0.02</sibn:DebtInstrumentPrepaymentPenaltyPercentage>
	<sibn:DebtInstrumentPrepaymentPenaltyPercentage contextRef="I2017Q3Oct31_sibn_DebtPrepaymentPenaltyPeriodAxis_sibn_PrepaymentPenalty4960MonthsMember_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-5BC2D16718C25404A9FD1EDCEEA05B09" unitRef="number">0.01</sibn:DebtInstrumentPrepaymentPenaltyPercentage>
	<sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1182C12BFC69EF17393E53F284BD7194" unitRef="usd">0</sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance>
	<sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F1F46AD1172CC6064E2953F284B92D6E" unitRef="usd">0</sibn:DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance>
	<sibn:DeferredTaxAssetsDepreciationAndAmortization contextRef="FI2017Q4" decimals="-3" id="Fact-A641EB53F57A77C26E4F54173F3D359B" unitRef="usd">179000</sibn:DeferredTaxAssetsDepreciationAndAmortization>
	<sibn:DeferredTaxAssetsDepreciationAndAmortization contextRef="FI2018Q4" decimals="-3" id="Fact-1B82A753AED9830646AE54173F34B078" unitRef="usd">132000</sibn:DeferredTaxAssetsDepreciationAndAmortization>
	<sibn:EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance contextRef="FI2017Q4" decimals="INF" id="Fact-9F8D58C1AAC453E5BF0DD5A53BB2B301" unitRef="shares">18986360</sibn:EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance>
	<sibn:EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance contextRef="FI2017Q4" decimals="INF" id="Fact-05A9706A71915DEDBE764755FE346EE3" unitRef="shares">18787177</sibn:EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance>
	<sibn:EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance contextRef="FI2018Q4" decimals="INF" id="Fact-9ECCC4DC0D2AB9A7B1DE4C5B0224F4A7" unitRef="shares">29760595</sibn:EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance>
	<sibn:IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="-5" id="Fact-3343AE658B7434358EED5433C97FE095" unitRef="usd">-15800000</sibn:IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate>
	<sibn:InitialPublicOfferingCostsIncurredButNotYetPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9CC112D814B7572A835D91645682CCC0" unitRef="usd">0</sibn:InitialPublicOfferingCostsIncurredButNotYetPaid>
	<sibn:InitialPublicOfferingCostsIncurredButNotYetPaid contextRef="FD2018Q4YTD" decimals="-3" id="Fact-67DFA143DFD15CBB905AE029DE479A51" unitRef="usd">7000</sibn:InitialPublicOfferingCostsIncurredButNotYetPaid>
	<sibn:LiabilityForEarlyExerciseOfOptionsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-B615F282FDC65FCAB30176335D9F270E" unitRef="usd">100000</sibn:LiabilityForEarlyExerciseOfOptionsCurrent>
	<sibn:LiabilityForEarlyExerciseOfOptionsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-96F84613CF9A54FA922A9E9EED117E28" unitRef="usd">65000</sibn:LiabilityForEarlyExerciseOfOptionsCurrent>
	<sibn:LiabilityForEarlyExerciseOfOptionsCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-F352B15B10C75660BA3F24F72CF4335A" unitRef="usd">300000</sibn:LiabilityForEarlyExerciseOfOptionsCurrent>
	<sibn:LiabilityForEarlyExerciseOfOptionsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-02A11C2F22E75BAD81273851BAE61A4D" unitRef="usd">331000</sibn:LiabilityForEarlyExerciseOfOptionsCurrent>
	<sibn:LineOfCreditFacilityPercentOfCustomerAccountsReceivable contextRef="I2015Q4Oct30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-5FBEFFBF99075CB1849CB4F8AA8CC5B5" unitRef="number">0.8</sibn:LineOfCreditFacilityPercentOfCustomerAccountsReceivable>
	<sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-EF6D175130789E232A074FEAFF9422C0" unitRef="usd">17000</sibn:MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-DB4D5F9C2454A260B25D4FEBB8BCB79D" unitRef="usd">7000</sibn:MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<sibn:MarketableSecuritiesAmortizedCost contextRef="FI2018Q4" decimals="-3" id="Fact-41DD4091D90BC035D0564FE779D84B84" unitRef="usd">119951000</sibn:MarketableSecuritiesAmortizedCost>
	<sibn:MarketableSecuritiesFairValue contextRef="FI2018Q4" decimals="-3" id="Fact-975B0C2CE321C2AAF4C74FE9B782D089" unitRef="usd">119961000</sibn:MarketableSecuritiesFairValue>
	<sibn:NetExerciseofCommonWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-19B3639CFA673117DFCC5DD6687A9683" unitRef="usd">0</sibn:NetExerciseofCommonWarrants>
	<sibn:NetExerciseofCommonWarrants contextRef="FD2018Q4YTD" decimals="-3" id="Fact-44767022CAB86D9DC0935DD66871F8F6" unitRef="usd">1248000</sibn:NetExerciseofCommonWarrants>
	<sibn:NotesReceivableForgiveness contextRef="FD2017Q4YTD" decimals="-5" id="Fact-7E03373CB28C5F6EA89A3DC75C601BF8" unitRef="usd">400000</sibn:NotesReceivableForgiveness>
	<sibn:NotesReceivableForgiveness contextRef="FD2018Q4YTD" decimals="INF" id="Fact-DA6CC47F52BB9EC1609E4FA660EA2358" unitRef="usd">0</sibn:NotesReceivableForgiveness>
	<sibn:OfferingCostsExpensed contextRef="FD2017Q4QTD" decimals="-5" id="Fact-4E04D6439E2A53EB8EC66AA2A76BE0CE" unitRef="usd">1300000</sibn:OfferingCostsExpensed>
	<sibn:OfferingCostsExpensed contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A460CD5D9B985BBD8D306A0464C680F8" unitRef="usd">1300000</sibn:OfferingCostsExpensed>
	<sibn:OperatingLossCarryforwardsLimited contextRef="FI2018Q4" decimals="-5" id="Fact-9B7A6ED765FF5FDCA98E54292BA210F4" unitRef="usd">1400000</sibn:OperatingLossCarryforwardsLimited>
	<sibn:PreferredStockNumberOfDirectorsEntitledToElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-390B3D8460B2F089B39178BDCC7FBE73" unitRef="director">1</sibn:PreferredStockNumberOfDirectorsEntitledToElect>
	<sibn:PreferredStockNumberOfDirectorsEntitledToElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-DF8252DBB38371410C4678C1378A8327" unitRef="director">1</sibn:PreferredStockNumberOfDirectorsEntitledToElect>
	<sibn:PreferredStockNumberOfDirectorsEntitledToElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-EEFC6DF09B9C25D149A778C148793424" unitRef="director">1</sibn:PreferredStockNumberOfDirectorsEntitledToElect>
	<sibn:PreferredStockNumberOfDirectorsEntitledToElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-B24DC209A0B9C84D06ED78C15F1C83B7" unitRef="director">1</sibn:PreferredStockNumberOfDirectorsEntitledToElect>
	<sibn:PreferredStockWarrantLiability contextRef="FI2017Q4" decimals="-3" id="Fact-0A4811B54DD85A22B3F2CC14967016D0" unitRef="usd">422000</sibn:PreferredStockWarrantLiability>
	<sibn:PreferredStockWarrantLiability contextRef="FI2018Q4" decimals="-3" id="Fact-6CEE26B2A6505569B46718258A96458B" unitRef="usd">0</sibn:PreferredStockWarrantLiability>
	<sibn:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven contextRef="D2017Q1Mar_us-gaap_RelatedPartyTransactionAxis_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="-5" id="Fact-6B997837CD865000A104028B3E5F3C44" unitRef="usd">200000</sibn:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven>
	<sibn:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness contextRef="D2017Q1Mar_us-gaap_RelatedPartyTransactionAxis_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="INF" id="Fact-31C294B4B97D53288C341658D1C970B7" unitRef="number">0.5</sibn:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness>
	<sibn:RevenueTargetQuarterlyIncreasePercentage contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-775E99208E1C913AF87D78717E963AF2" unitRef="number">0.04</sibn:RevenueTargetQuarterlyIncreasePercentage>
	<sibn:RevenueTargetQuarterlyIncreasePercentage contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" decimals="INF" id="Fact-22F871980E58BFCA62B17870C1BBFBC3" unitRef="number">0.02</sibn:RevenueTargetQuarterlyIncreasePercentage>
	<sibn:SalesAndProductWarrantyAccrualCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-75DF5E41AC915DC781BCA22F051B5698" unitRef="usd">149000</sibn:SalesAndProductWarrantyAccrualCurrent>
	<sibn:SalesAndProductWarrantyAccrualCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-819748AD5A8C5D099D0F6201F85C31B5" unitRef="usd">35000</sibn:SalesAndProductWarrantyAccrualCurrent>
	<sibn:SalesCreditReservePeriod contextRef="FD2018Q4YTD" id="Fact-64DD353A9F6253AC91ED28D30BAB7D7D">P1Y</sibn:SalesCreditReservePeriod>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-DBDEE455BBAB55E6ACF05C1335D0C1ED">P5Y</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember" id="Fact-7A6F66D7E64BF2B06C414F94ACBED2A9">P6M</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase contextRef="FI2017Q4" decimals="INF" id="Fact-74125A27888253E997F21985DAC617E7" unitRef="shares">16117</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase contextRef="FI2018Q4" decimals="INF" id="Fact-60F191E40FE45351A3921D14AD8C9F66" unitRef="shares">74019</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_sibn_IncentiveStockOptionMember" decimals="INF" id="Fact-8411AA66558C591F99F1BEB73EEAB329" unitRef="number">1</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_sibn_NonqualifiedStockOptionMember" decimals="INF" id="Fact-7C068EAC778A5ED09FF46A9D91A6127F" unitRef="number">0.85</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" decimals="INF" id="Fact-993B7B712F535E47999C1EE57D275E75" unitRef="number">1.1</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares>
	<sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified contextRef="D2017Q4Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-14EA3008D5D575E9DAF64FB02843BDDF" unitRef="shares">394652</sibn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified>
	<sibn:StandardProductWarrantyTerm contextRef="FD2018Q4YTD" id="Fact-005800EC31B35C3EB6A5EB41535F258C">P1Y</sibn:StandardProductWarrantyTerm>
	<sibn:StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D8871EB141AA908C01BF4EE09CE9ABA7" unitRef="shares">4312</sibn:StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised>
	<sibn:StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-010E5C534352D033CA3B4EE09CD5DDC1" unitRef="shares">106028</sibn:StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised>
	<sibn:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-050F7DDDAE9262BC78BA4F0798C95195" unitRef="shares">121486</sibn:StockIssuedDuringPeriodSharesWarrantsExercised>
	<sibn:StockIssuedDuringPeriodValueUnvestedStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-14226779097BDD489B924EE0B5E6F737" unitRef="usd">0</sibn:StockIssuedDuringPeriodValueUnvestedStockOptionsExercised>
	<sibn:StockIssuedDuringPeriodValueUnvestedStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B371848622E9919BD1A14EE0B5DDDA5D" unitRef="usd">0</sibn:StockIssuedDuringPeriodValueUnvestedStockOptionsExercised>
	<sibn:StockIssuedDuringPeriodValueWarrantsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-658378BC15CD5466F2D94F081CB54275" unitRef="usd">0</sibn:StockIssuedDuringPeriodValueWarrantsExercised>
	<sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1B02174CD6F7420FE3D44EF8B4AB9608" unitRef="shares">15628</sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares>
	<sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5D2478B4A6A15A859C744F0A73FD4740" unitRef="usd">0</sibn:StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue>
	<sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D36AF3AD8D7DFB2DC8A04EEACF13667D" unitRef="usd">437000</sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt>
	<sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-921D7964CB8D81A9D1254EEACF014C1E" unitRef="usd">437000</sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt>
	<sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived contextRef="FD2017Q4YTD" decimals="-3" id="Fact-91A10C7357EDE2F607C54EEA8141DC42" unitRef="usd">84000</sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived>
	<sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-8E124FB4AEF3CDCB55414EEA8136192B" unitRef="usd">84000</sibn:StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived>
	<sibn:TemporaryEquityCommonStockEquivalentSharesIfConvertedShares contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-2EDE0556487A568480385F6CD4E84D84" unitRef="shares">12066654</sibn:TemporaryEquityCommonStockEquivalentSharesIfConvertedShares>
	<sibn:TemporaryEquityConversionOfTemporaryEquityToEquityShares contextRef="FD2018Q4YTD" decimals="INF" id="Fact-DEB42309B8773EFC5DF24EFDE348D5A5" unitRef="shares">11871578</sibn:TemporaryEquityConversionOfTemporaryEquityToEquityShares>
	<sibn:TemporaryEquityConversionOfTemporaryEquityToEquityValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1BC0EA9D0EA84DB300BD4EFF0005AD6A" unitRef="usd">118548000</sibn:TemporaryEquityConversionOfTemporaryEquityToEquityValue>
	<sibn:TemporaryEquityLiquidationParticipationCapPerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-F4999BC723B96D2E34E678B6B4475162" unitRef="usdPerShare">12.60</sibn:TemporaryEquityLiquidationParticipationCapPerShare>
	<sibn:TemporaryEquityLiquidationParticipationCapPerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-F49C5A89F9A0431A7D2578B6A03EFEFA" unitRef="usdPerShare">18.1908</sibn:TemporaryEquityLiquidationParticipationCapPerShare>
	<sibn:TemporaryEquityLiquidationParticipationCapPerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-87EEB065E27EE41A2EF678B5D94D624F" unitRef="usdPerShare">32.9436</sibn:TemporaryEquityLiquidationParticipationCapPerShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-0070B92C57BC88ACA2C678802E4F882D" unitRef="vote">0.352941</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-DB4A479D4393300DA06578816168A9F5" unitRef="vote">0.352941</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-28E71C3AE17B0E9594C9788184E755BD" unitRef="vote">0.352941</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-20C7113B35E5A58284777882252A9399" unitRef="vote">1</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-EE855E0FB15F8BD2BCA678828013D176" unitRef="vote">1</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-1E43ED43DAF037AC2968788280C7596F" unitRef="vote">1</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityRightsToVotesForEachShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-B3ACBB1E60F79359015C78828192B172" unitRef="vote">1</sibn:TemporaryEquityRightsToVotesForEachShare>
	<sibn:TemporaryEquityShareholderApprovalMinimumSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-B713C9C9E7822E592AD4788C452FD63E" unitRef="shares">277778</sibn:TemporaryEquityShareholderApprovalMinimumSharesOutstanding>
	<sibn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD" decimals="INF" id="Fact-129872832CA556F310894EF2EC16EDAF" unitRef="shares">540874</sibn:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<sibn:VestingOfEarlyExercisedStockOptions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B23382005F045BCE82B1D65B40D460AA" unitRef="usd">122000</sibn:VestingOfEarlyExercisedStockOptions>
	<sibn:VestingOfEarlyExercisedStockOptions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-19B4CBEAAD5B5FA280DE22439FFC2688" unitRef="usd">139000</sibn:VestingOfEarlyExercisedStockOptions>
	<sibn:WarrantsConversionRatio contextRef="FD2018Q4YTD_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="4" id="Fact-97DA5ADA2585D9C44F135DC1FB075736" unitRef="number">0.9433</sibn:WarrantsConversionRatio>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="-3" id="Fact-BA73ACE201B95F9496EA3CD26FAD683B" unitRef="usd">45000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="-3" id="Fact-D944EAEDCE3754C5AC8A8CEE8A2FD22F" unitRef="usd">255000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-C12806B2EB9A55DD9209CC6CD8126226" unitRef="usd">244000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="-3" id="Fact-12B327DD12205193971EE1FE75F65662" unitRef="usd">122000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-6EA3A15168B35F56A1C948D0EDAD4F75" unitRef="usd">5000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="-3" id="Fact-BF4B92A8338E5EDA86DEB6DCA6E80415" unitRef="usd">244000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-07B330108BB7520DA2C2A82C837FEAFA" unitRef="usd">47000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="-3" id="Fact-DB740DA1157F537FB2DDBA03DDEA0623" unitRef="usd">49000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="-3" id="Fact-0832583748C35395AD14E159E6E961BE" unitRef="usd">396000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-0B3099520D99F04F2B534C295626992F" unitRef="usd">45000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-F37721ADE3D1C375F57D4C271CD0DBFB" unitRef="usd">122000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-0915B552F0E445F4ECF04C279AAAB804" unitRef="usd">5000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-2DC6E39A7ECC456E2C2E4C290B4B5BEC" unitRef="usd">244000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-220441EA8A551EF155694C275B9DB833" unitRef="usd">49000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="-3" id="Fact-11381281E8F23718D5C04C289A9D15F6" unitRef="usd">396000</sibn:WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion>
	<sibn:WriteOffOfDebtDiscount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BA2F9165A755CF9A50354A544C7FC715" unitRef="usd">650000</sibn:WriteOffOfDebtDiscount>
	<sibn:WriteOffOfDebtDiscount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-18243A49D2E90D629D184A544C7588DE" unitRef="usd">0</sibn:WriteOffOfDebtDiscount>
	<sibn:WriteOffOfInitialPublicOfferingCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5FADDE21FF185C31A84E1D39E126940A" unitRef="usd">1292000</sibn:WriteOffOfInitialPublicOfferingCosts>
	<sibn:WriteOffOfInitialPublicOfferingCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1F5765581DAF5685864F45C5C19DDF0B" unitRef="usd">0</sibn:WriteOffOfInitialPublicOfferingCosts>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BD033F18B1AF5568B04D7952FC75B684" unitRef="usd">1814000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4E0E6180DC3A52308D64AAEB53924D9C" unitRef="usd">2146000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-29383BD0D1365684B494C2CC68DF7688" unitRef="usd">7416000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-210B08E250D75E4DBFE6AD01CD36BD96" unitRef="usd">8486000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1D775E5D270085120EB94A4849E30A40" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-597A380C29C14E9F13CF4A4849E3C8B2" unitRef="usd">209000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3BE695643D315D0FBA5B9F373ABF9358" unitRef="usd">5724000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-106CBCE7275F5937B4EC48543C99798D" unitRef="usd">6860000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-6184FB571E0450FC81DD05940729A793" unitRef="usd">341000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-5FA7636B086E5A18B91FE51E59A4B85F" unitRef="usd">583000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-146DC08C6C145AE1BB677E3094C87EBD" unitRef="usd">3022000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-9BE66EDF30EF52758F629A809C64EF24" unitRef="usd">3364000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-D89A34FFA23950019CDD03F97C805968" unitRef="usd">402000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-86F11E558D535D5084DC7A4054FEEE0F" unitRef="usd">439000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-3" id="Fact-584D1C092B9B5EB4ABC8180F62F02DFF" unitRef="usd">9943000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-3" id="Fact-E0E7DE38D5F75E95A7328B7B9359A49B" unitRef="usd">246927000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4420EA0C0B58D8854E3D4EE1BF8B4B0F" unitRef="usd">1438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CEEC4CED7B0B6B060BFC4EE1BF6DEB90" unitRef="usd">1438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-27BD7D41481BFF6B31DF4EE1BF96D7C7" unitRef="usd">2312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4BF5A35BB25B019794524EE1BF776E35" unitRef="usd">2312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2018Q4YTD" decimals="-5" id="Fact-3B1797F3A6C51E637E094FE112DFAE4C" unitRef="usd">1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="D2018Q4Oct16" decimals="-5" id="Fact-66BB6F69B0645350992CADB1E0E89BB2" unitRef="usd">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdvertisingExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D863345902435F3A950CD9C925F60FD1" unitRef="usd">800000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B0D8B9DF80315B2DBC7890E146B0FDC7" unitRef="usd">700000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q4Oct01-Oct31_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-E41CF0D8F0A822FFF2014FC16ADC7797" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-0B4616C79CAD528D962C89A98649916B" unitRef="usd">1875000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-2151BBC2B15455BDBFEB96638F5C2D52" unitRef="usd">23000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-0983B7DA2B4A543B9F01A3E23357099A" unitRef="usd">1271000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-78A292C681705170AC83881E153AEB58" unitRef="usd">143000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" decimals="-3" id="Fact-77171530D0E75ADCA07CF361F7A4306C" unitRef="usd">438000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="-5" id="Fact-25006FC369BB56F382AD8D102BE4CDD5" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-737C24807AA652FCA92B1A939470DA6D" unitRef="usd">2312000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-3" id="Fact-896F5924CBB959E1BF47CBE940450DF3" unitRef="usd">34000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-5745717A41385EB589EEBEB7EC51ACDE" unitRef="usd">1471000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3C34EFA2765053DDACDDBE037327E704" unitRef="usd">156000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" decimals="-3" id="Fact-AF9E9D94C0F15CAB91869271DB0496BD" unitRef="usd">651000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-08902E780D7F54AA69C54F54DA731738" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-8794DDA709875AA59A89237518969A0A" unitRef="usd">268000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-220ABEA31D955BAA991E61B741115DB9" unitRef="usd">263000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D42224A9F1E354B2BA781067157C0DBA" unitRef="usd">36000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9D3E7E5474D353668DC6236C53E0640A" unitRef="usd">5000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-5" id="Fact-55DC9388499252F2877AFD4B6F99E30B" unitRef="usd">700000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6EAD17D396B75C69BC59D890956B3552" unitRef="usd">285000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2018Q4YTD" decimals="-3" id="Fact-50B11C8840315D339FAD2062A775CF24" unitRef="usd">259000</us-gaap:AmortizationOfDebtDiscountPremium>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_CommonStockWarrantsMember" decimals="INF" id="Fact-B8D1E83BD8B85EC5A092704B06AF3EE0" unitRef="shares">124326</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_EmployeeStockPurchasePlanSharesMember" decimals="INF" id="Fact-A69CDCD99B2AD9D796614C69AA6CB5C1" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_RedeemableConvertiblePreferredStockWarrantsMember" decimals="INF" id="Fact-32DAEF85998F5374B8695777964F1964" unitRef="shares">160657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_ShareSubjectToRepurchaseMember" decimals="INF" id="Fact-8F3C965CE4335F038163EC25A1E5B002" unitRef="shares">16117</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-39CE78B8A1605D53808F1B449D7A578D" unitRef="shares">3001929</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-BE57C3F47F0E52F198D14432F5193525" unitRef="shares">12066654</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-42B287F16151E1A78FFD4C69A54CC5A6" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_CommonStockWarrantsMember" decimals="INF" id="Fact-5E5B894B5E0152558D541A91B31B4B44" unitRef="shares">118122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_EmployeeStockPurchasePlanSharesMember" decimals="INF" id="Fact-644E6EED2B77F9D5E8A14C69A7D33E14" unitRef="shares">89606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_RedeemableConvertiblePreferredStockWarrantsMember" decimals="INF" id="Fact-ED77EFD9642F5480A252D0B07C92923F" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sibn_ShareSubjectToRepurchaseMember" decimals="INF" id="Fact-796927EAD5995C9380D6380A5E2F8FA1" unitRef="shares">74019</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-8424D64166E45378AE24D30DFFC2D405" unitRef="shares">2641198</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-BF8B0255AD5E536A8AA470DC598853E3" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-545AE54E681F24282F5C4F718E90952B" unitRef="shares">53436</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-F841C2F089C450548477A3D085223E5F" unitRef="usd">35834000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-F105C05C628F514DA170077FFAA6E782" unitRef="usd">138521000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2D6A91FBC1BD50899039058F4FF42692" unitRef="usd">33629000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E1BE6B7D2A1E5E139CD6FD908E296D55" unitRef="usd">136042000</us-gaap:AssetsCurrent>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-51179DB4914FACDE88DA4A8E75F4DD89" unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C00E8D63F1EB43D2EB474A8E7600C378" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-8E71B7AF569261C5C7914A8E75EECCB3" unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-8B5ADFBC474F895C4C884A8E75E63373" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-44A8BA89F0BFFA536D754A8E9C6E6E45" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-C7BBEF763986B3D13B404A8E9C743CC0" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-42BD676C19ABEE3842944A8E9C7897BE" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-017B6A3880B01C54FDAA4A8E9C7D076A" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-3" id="Fact-E7049874F267AC1B5BD64A8E3630090C" unitRef="usd">97093000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-4B10360442053E072D1F4A8E361A5440" unitRef="usd">11894000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-0C44D185E4B4527F1CF34A8E363B006B" unitRef="usd">19708000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-D99D90F25F5645BD3C924A8E363507F4" unitRef="usd">65491000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-00099097F7304573643D49AE4F19C963" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4" decimals="-3" id="Fact-0FFC7E44395900EBB6F049AE4F0E2EBC" unitRef="usd">97103000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E42F68E0F482B3BEC5514A9003E3215D" unitRef="usd">11894000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-B74CEEC9052E000F8F9A4A9003DB1A81" unitRef="usd">19720000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-775C4658646A08560E664A9003DF909A" unitRef="usd">65489000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2017Q4YTD" decimals="-3" id="Fact-09BEBC232D0551EA884A4AA5581E7E74" unitRef="usd">97000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0DCCB5ED71D75767B8BF954DF203B434" unitRef="usd">82000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-DC97A9411BD7589DABBED5571E120445" unitRef="usd">27900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-0A5136D83320C18E36FF49DFA89E4645" unitRef="usd">22408000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-34CDDF1F2EDF462FAF8349DFA8A172DC" unitRef="usd">25120000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F2410FD3919C5368A0EE9D022763F9C3" unitRef="usd">-5492000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A102D21301165ECD99C71F42123999CF" unitRef="usd">2712000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-429C1E1BC047A51AE5906DDA1EE2A010" unitRef="usd">22100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-1C3C1E61BB39DB5713B14A9142A0D778" unitRef="usd">22858000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-806EA28E11009D756D344A912436D73F" unitRef="usd">6635000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-AFB1D3FD44C5CD16B3044A9124223FAD" unitRef="usd">15223000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-777365D75AAF41E176904A91243F9302" unitRef="usd">1000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-C120AB37F71A5B1CB72C325267AC4857" unitRef="usdPerShare">10.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-9106238B8045550AAD130F2D3F679C5F" unitRef="usdPerShare">9.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-9E9043833E675E8DA3F54C4336C58BCE" unitRef="usdPerShare">3.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-C657CA33676E5399A617AB2E4F26B3CC" unitRef="usdPerShare">9.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-198A2CE537C152B6816A59DBCA070373" unitRef="usdPerShare">5.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-866F41ABDAF652C0865616619A4781D7" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-439166D85F15547AAEC658BB2C7E3499" unitRef="usdPerShare">3.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-3E9C9B6F82A95F0E928F39729045AA28" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-445822DFF65D5BC1A1A6813F773A1C7E" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-F6DC778E16FAA97E152A4C2950970693" unitRef="usdPerShare">10.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-8342E1DBD4D88AF28A624C2717959461" unitRef="usdPerShare">9.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-9D718DA129002DD3F5E34C2795BB5F7B" unitRef="usdPerShare">5.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-50ED5D0A5C9A813863FF4C290601BB9C" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-4B1B6C96745FF1DCA1964C27564853B3" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-9A1AF764EB8187C5DF4C4C2895164320" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2012Q3Jul01_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-BF2CCBEA9E3750A48C8570D687FAF161" unitRef="usdPerShare">9.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q3Jul19_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-BB8F994D24F65211B880122D9AFF2F85" unitRef="usdPerShare">3.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2013Q3Jul19_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-763554B772075E3B962593FF25B015A9" unitRef="usdPerShare">9.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2014Q4Nov26_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-3C8D2909B1BB517085B0D1B1DF3E1BA9" unitRef="usdPerShare">3.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2014Q4Nov26_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-1C0E438DB7A856CAA6026CE20F6B248F" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q4Nov09_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-9B9D174BE57A5F43B87AC7725BDCDD69" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q4Oct20_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-93ED014FB52E5B868A93B4687136C49E" unitRef="usdPerShare">16.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q4Dec22_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-630746D29BAB518E8E24E311F20B0561" unitRef="usdPerShare">10.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q1Mar01_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-07B8BFAF35675C20AAB5604F3B420FD5" unitRef="usdPerShare">5.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4" decimals="INF" id="Fact-A2B203F5DB3550EB8CF7805C5BF5DFFB" unitRef="shares">280876</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-A704E80336595F31B98889D6165A26FD" unitRef="shares">9712</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-C371F449709252CF8226E7F05F0BF310" unitRef="shares">54917</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-923FD78CAD1E505A9A9EA31570CB2740" unitRef="shares">101010</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-495D7EE9050B550688971346D92D66B6" unitRef="shares">21989</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-34F608CE07EA5EED85A68D7D3443D436" unitRef="shares">1388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-5041D4711A3C5134A5FB71EF19AE0E31" unitRef="shares">24283</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-9F1332623B8557E386C59C48564EF956" unitRef="shares">21928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-8E510E4FEC285C9BA6F44643F1EE5C4B" unitRef="shares">6310</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-B057A74BBBA55B07BD83A5C051696485" unitRef="shares">39339</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-7261B8C3A3005B148348FC353DA57BFB" unitRef="shares">156550</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-023CE0DD71D151FA8D754ABB102F0DC9" unitRef="shares">124326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-141E30C97EE151F7B6D2AEAADCCCB0A8" unitRef="shares">124326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-C55B04A627F15469B16625A4803CAF58" unitRef="shares">156550</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-42633D28D34276283FAF4C294B2A62B5" unitRef="shares">9712</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-F7AA86102D4D68DA51974C2713020AE8" unitRef="shares">32983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-69AED4A89BAF147B525C4C2790DC3A19" unitRef="shares">1388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-4245952C160BCDAA2DCF4C29006DF888" unitRef="shares">25709</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-8C716D598E339D3E419A4C27510EF056" unitRef="shares">6680</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-96AD3C24E5A5D60D278D4C288F6368E3" unitRef="shares">41650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-D064F80638D89DF520E94C2A1A3359D7" unitRef="shares">118122</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-AE0179DB35A75B62AB93DD2E8FD118E3" unitRef="shares">118122</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-28636C2A5AD4594C977CCB470B7B28DE" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2012Q3Jul01_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-33F4109C38305DCDA96760ED14BD825A" unitRef="shares">54917</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q3Jul19_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-9F9B74E144B65B76999FDBB8A8FDD923" unitRef="shares">101010</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2013Q3Jul19_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-D5707661C0DE2689C06B53C44AA0F518" unitRef="shares">32983</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2014Q4Nov26_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-1270FB14E41B5A65A48215BD5FA4C14B" unitRef="shares">21928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2014Q4Nov26_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-9BFEEFAAEE215070B6E939F17552E7FF" unitRef="shares">6310</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q4Nov09_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-4655F73AC17D5AFC87F1420AF5DFD033" unitRef="shares">24283</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q4Oct20_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-ADC7A1094E1C5204BE2C96F0B6850A34" unitRef="shares">39339</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q4Dec22_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-08DE189B43C85A75ADCB51406432C68B" unitRef="shares">9712</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q1Mar01_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-EABBA1979F6C5FD7B6B40B312ACDF609" unitRef="shares">1388</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2018Q4Oct16_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-0FFF76FA35B45D0BBEFB5CB635FFF124" unitRef="shares">160657</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-627527B530A9D6A7419F49CE4BF7F935" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-D7657B7E588FBA1CC37C49CE4C0B83D8" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_PlanNameAxis_sibn_A2008StockOptionPlanMember" decimals="INF" id="Fact-FD6EEF8A7AD85C458FB7EDBBAE66AA9A" unitRef="shares">5350080</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2018Q4_us-gaap_PlanNameAxis_sibn_A2018EquityIncentivePlanMember" decimals="INF" id="Fact-9127B58DFA5D1DF10AD54F824A8B4A2A" unitRef="shares">2576538</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2018Q3Oct31_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember" decimals="0" id="Fact-F02E9B207CDA91723ACB4FC01966E8A2" unitRef="shares">515307</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockDividendsPerShareDeclared contextRef="FD2017Q4YTD" decimals="INF" id="Fact-42F284DDB4FEE8AE1FF678A6B5C71D4A" unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
	<us-gaap:CommonStockDividendsPerShareDeclared contextRef="FD2018Q4YTD" decimals="INF" id="Fact-C765D22B7C73617D356078A669CB8188" unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-A88CE95E81105F6081007B09E231AC51" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-46460CFC70645155A83256EE23204ED8" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-4B245A110FFA5884AED72218AF7C02DE" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2018Q3Oct31" decimals="INF" id="Fact-2CCC863696C4B78A36944C53FD6F44F2" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q1" decimals="INF" id="Fact-8D20B8186715550DA967CA6DDC0D7326" unitRef="shares">19333333</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-DA7E37C5DA0A5B4C9386E5E418363C9D" unitRef="shares">13333333</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_NonvotingCommonStockMember" decimals="INF" id="Fact-166357F8780F5E45A2B91CE6FB25DFF9" unitRef="shares">6000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-951211C40E145631A1D4D310D4348348" unitRef="shares">19333333</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-0A1E9972E07E5D1084807BA580A8076D" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2018Q3Oct31" decimals="INF" id="Fact-A3833A3D8CB8D08AE1664C539442439B" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-5E47595319AE54EBA208AE467EFCDB50" unitRef="shares">3603140</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-D76D507FA7D55B5C933295D9AFFFAA36" unitRef="shares">24450757</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-E1FB256B291054DE86EB18CE4D01B67E" unitRef="shares">3603140</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember" decimals="INF" id="Fact-4416121A6D385FBDAC62417E3D3796D8" unitRef="shares">490185</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_NonvotingCommonStockMember" decimals="INF" id="Fact-088DC34EACD45BC280313E6DAB62A311" unitRef="shares">3112955</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-A87779D02E815FFBBDCB0038C216C1B2" unitRef="shares">24450757</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-DB9A4CD56D5D576BBD78E5CA4FBB2045" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-542214B6022F5BB89F8B0DFDDD8694F0" unitRef="usd">3000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3398A4E0313D57A7BD6A548387C1C0DF" unitRef="usd">-23109000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-972E76B36E885C6DB09E69CE09EBFA06" unitRef="usd">-17416000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6C26124340087174BA105DD34C37C5A6" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BCB4434DDED5B8C6929E5DD34C16D304" unitRef="usd">118547000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="FI2017Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="2" id="Fact-11A79DA359B027A2E54E78BA265373AB" unitRef="shares">1.06</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2017Q1Feb28_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="2" id="Fact-BDFA5854EE571AF4D04578B9AF3C2333" unitRef="shares">1.05</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6914296C15F15F85B31630CD5D78D17A" unitRef="usd">5112000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F126656F3030555D8A9005BD4A0ACB01" unitRef="usd">4833000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6DC95DE0E5042751CADA53EC37B6E73E" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1B3DE882F9F5695D4DCE53EC37A866F8" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B69FB4561F9BCDF6FDE853EC853A959C" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C376597FB6D87DD1516C53EC8537CE4D" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E2F47CFA664E85126A2F53ECA4CD69DE" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-523FE0F762A6D13FA81A53ECA4D1B2DD" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-193B91A068E3FE01FEBE53EC69223F1A" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C8858CB06F5E043A9BAC53EC6916240D" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2015Q3Oct_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-4BC52ED683AB51ECB8D07B69C01A5C4D" unitRef="number">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2016Q3Aug_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-E30AF7B2495C57E98004C9C131025654" unitRef="number">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2018Q4" decimals="-3" id="Fact-75F6F337D42055D0AD90B2CC1477D143" unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="FD2017Q4YTD" decimals="-3" id="Fact-ABDAC9877F9D54C19FF486225239A3B2" unitRef="usd">437000</us-gaap:DebtInstrumentDecreaseForgiveness>
	<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B0EB3B6CDC6D5B27842E93389467491E" unitRef="usd">0</us-gaap:DebtInstrumentDecreaseForgiveness>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q3Aug31_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="INF" id="Fact-42720AA7A6FF5EE0A9F2C6DA0342BF21" unitRef="usd">35200000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-DF19D1B696DD57B086153918FFBD40AA" unitRef="usd">40000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFeeAmount contextRef="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-8C08769759275F07BB0491B94B712CF8" unitRef="usd">600000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="3" id="Fact-180C92A56B8955729AA2E0C9B6FEC6DF" unitRef="number">0.120</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="3" id="Fact-53D51F94ACC85ADB9219547AF53B8C38" unitRef="number">0.123</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q3Aug31_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="INF" id="Fact-B97CD3D11F2C572399A668D2B4024E4A" unitRef="number">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-4B0A679C45395CBFB441C562C3E52357" unitRef="number">0.115</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-B12B83D04D7A5A8E9D68B2FB58CE5690" unitRef="usd">10000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2E0802A66D157A40D99E53EE111ED8BD" unitRef="usd">-9574000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-532BE551BF6550CE4E9653EE11143925" unitRef="usd">3555000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFinanceCostsGross contextRef="I2017Q3Oct31_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-068BFC7F4A8B57E48783FFEAA80B6C06" unitRef="usd">1300000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2018Q4" decimals="-3" id="Fact-8FFBE9CDFCB75F579DE42FC627377358" unitRef="usd">1037000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-412682087DB2A291EA1153EE9A74B35B" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BE2AC94AB2E9DB57267953EE9A79B28E" unitRef="usd">200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-63281DD0D221462D175A53EEB6336BDE" unitRef="usd">-7513000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-164FD723D82D58570BDB53EEB62A0EEC" unitRef="usd">4577000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredOfferingCosts contextRef="FI2017Q4" decimals="INF" id="Fact-A51B47C0D81436C881BA4C8309961BA9" unitRef="usd">0</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredOfferingCosts contextRef="FI2018Q4" decimals="0" id="Fact-7DA7ED991A06AFF7AC1E4C82DBC9FA3F" unitRef="usd">0</us-gaap:DeferredOfferingCosts>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-238108392E1F19B4459653EE31DF5578" unitRef="usd">2061000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A4ABD0DE930091314EEF53EE31E277E7" unitRef="usd">822000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-127D33279A02474FBC9754178F0F83A0" unitRef="usd">35835000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-3" id="Fact-1DC22BD0B417634C518A54178F12788D" unitRef="usd">40412000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2017Q4" decimals="-3" id="Fact-57491FDC24A15F0CA3265414A4EB89D1" unitRef="usd">2070000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2018Q4" decimals="-3" id="Fact-E1F2279F575274BB86485414A4E7B0B4" unitRef="usd">2255000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-7202559126B7AD84E2D05417CD8BA9D5" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-77DCE897616801E130125417CD817C72" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-1728A04CFA4365544A895414732D5FB5" unitRef="usd">32210000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-EE6634F126B7F53E4D9F54147338F6F9" unitRef="usd">35067000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="FI2017Q4" decimals="-3" id="Fact-FF0CB8A32FC5F1885592541769A6CB8D" unitRef="usd">1376000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="FI2018Q4" decimals="-3" id="Fact-DF668A6EF2A0940626A0541769AA74A1" unitRef="usd">2958000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-663186C6175332F3997D78DAE7147CFB" unitRef="usd">43348000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-B08105B69E593A19AFC45417B117D6CF" unitRef="usd">35835000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-4F304ED910D39482AE635417B12100EB" unitRef="usd">40412000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DA28E34C79745DD28F2ABCDCD4DA5CA4" unitRef="usd">1000000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD" decimals="-5" id="Fact-D717EEB19B035E94BCF7A056ED92FF07" unitRef="usd">700000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5B992414A2225AED8B453C70A2F1ED89" unitRef="usd">1013000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D5BB524A927959A380C1C7D8E222681E" unitRef="usd">722000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-F85002B152AD5FABB02701712EBD5C85" unitRef="usdPerShare">-6.65</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-1CEF1AF2F92754C8BFD35F73AA843F12" unitRef="usdPerShare">-2.20</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F91196EA1F84587CAEE460DF1981CB32" unitRef="usd">-346000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6F3277A08A055C16ABB93968779740C7" unitRef="usd">-94000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="3" id="Fact-B0078F7181ED5B33A19653FAF36F2DD3" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q4YTD" decimals="3" id="Fact-80AB205CC5AA711596C753FAF36B3C6D" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-44CB48D0763610515EA853F9490C50D7" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="INF" id="Fact-935892C1B356967DA13553F9490C063B" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="3" id="Fact-08757D9BBBB3DA5BE97153F9E5884F98" unitRef="number">0.326</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="3" id="Fact-CCD9606A9BD935F3A52353F9E599D3AF" unitRef="number">-0.262</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-C4CE0AADC520B77FD37253FB5C7DC59E" unitRef="number">-0.687</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-D9B70FC74EF66D212D0253FB5C922DA3" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="3" id="Fact-81432384B6541A1DDC5153FAD88FE00E" unitRef="number">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2018Q4YTD" decimals="3" id="Fact-98F420DBE6EE763D1DCD53FAD89E7F0D" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="3" id="Fact-837F98601900A93DD57553F960D8EA6B" unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="3" id="Fact-3A84781D6D94E48A28E353F960D36072" unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q4YTD" decimals="3" id="Fact-2B59962A441E8483CFA853FA39B6D2EB" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2018Q4YTD" decimals="3" id="Fact-EB6138AF3E7F3023B55C53FA39B1874C" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2EE9DBF1A4595460B82CD9F134C59378" unitRef="usd">3732000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-86029F35B4105F6FBE3DBE9EC483E119" unitRef="usd">5425000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4" decimals="-5" id="Fact-F5C5C2C0B41059F6BCE426817BC00DD9" unitRef="usd">4500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD" id="Fact-03CE4D86567956C28FECA37FDF1D1DF7">P2Y3M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2018Q4_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-822781BAC3C3975662B34FC3FB43871D" unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F075EEFC25205BF69716E17EAF831A26" unitRef="usd">-166000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6EAA9201BDAE59B9AEBF80BFD2772B87" unitRef="usd">826000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0AD51DE49C305EEA877EA9E31161BDED" unitRef="usd">826000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q4YTD" decimals="-3" id="Fact-85375ECEF63FE9550C154A9FABEECE85" unitRef="usd">1248000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4" decimals="-3" id="Fact-24445B7D4FC05022A04546EA8083B7B4" unitRef="usd">422000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4" decimals="-3" id="Fact-0DBFA3DB379559FDA3C6AB4286F79FC1" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GainLossOnContractTermination contextRef="D2018Q2May01-May31_srt_StatementGeographicalAxis_sibn_SanJoseCaliforniaMember" decimals="INF" id="Fact-05291E433C615A31847988E1F92BD31E" unitRef="usd">0</us-gaap:GainLossOnContractTermination>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F9523A98CDDA5020B1F39644BB0A0A47" unitRef="usd">-214000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F58E6FF6B87E5F54AC61C7F55091249D" unitRef="usd">-52000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember" decimals="-5" id="Fact-A568CA8DEAEE5C9387E263CE85F7FA92" unitRef="usd">-2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7895CB547B1E5005ACC81D1351C0E777" unitRef="usd">13062000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D61BA7569EF85FA785E7942ECD0C219A" unitRef="usd">12639000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GrossProfit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-919DD92A0A4D56A5B48F3E0B872E6226" unitRef="usd">42871000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B46E1A3ED7F2542CA62C7BC8BB98D217" unitRef="usd">50547000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2017Q4YTD" decimals="INF" id="Fact-31701B191B745D18B46FB1E764E93230" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2018Q4YTD" decimals="INF" id="Fact-70468CC017495AC79DAA0595F7B19576" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-34A6F8120D7EF6B65A4653E766BE7426" unitRef="usd">-22717000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2018Q4YTD" decimals="-3" id="Fact-12ACFA4FC755B86FA2D253E766B907F5" unitRef="usd">-16835000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2017Q4YTD" decimals="-3" id="Fact-95DF616E62ECAF55866953E782E6A552" unitRef="usd">-322000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9C11D4E4AC3BCC2650BD53E782EA582F" unitRef="usd">-618000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4AAFFA4F6BFE291E160F53E7A7D54DCE" unitRef="usd">-23039000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E1B670C44B70C19AA0A153E7A7D86EA6" unitRef="usd">-17453000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7958AF173F21F647408B53F003BF6E6C" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0B3A339CD838F25195B453F003C28774" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D608FE34EA6A5B2D8DB1DB1F4986EA6C" unitRef="usd">811000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A5D721D6600B5FA0A9445EDD37FC0898" unitRef="usd">251000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-24DD22BD04C25A8DA7E15F710F28AA10" unitRef="usd">1313000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-41D58A86D9A450AB81E4044441D8F320" unitRef="usd">1023000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3EA989C3A544596788AFC32D62C9FCAD" unitRef="usd">1792000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2AB3720D840B58A6AF9EF113F9672FED" unitRef="usd">1260000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q4YTD" decimals="-3" id="Fact-02264B1DE3035F498739E94E52275ECC" unitRef="usd">980000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q4YTD" decimals="-3" id="Fact-929178C5183959D8B400CCF1DE162C61" unitRef="usd">759000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1B97A0DF20F851A2AD9E7EF1965DD3B8" unitRef="usd">-72000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B693E071517B52068509009DC39B6357" unitRef="usd">752000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F55087E39C1656C695903F7C3A8F003A" unitRef="usd">6204000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionAxis_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="-5" id="Fact-AE7BCFD05F2656358E81A02B18DE1930" unitRef="usd">100000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-26AE4C41FFBE54228DC9BBDF5B780D7E" unitRef="usd">5108000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-66B582D229AB5664BCD3FC33D9C73910" unitRef="usd">4514000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-37C7AA3D4BAE55B2A379E5F25E6F5D7A" unitRef="usd">5500000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1FC061C4D1285C0BA9829CC5737AC567" unitRef="usd">831000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-9D29046FF8E35E019FECEECE90C9D818" unitRef="usd">0</us-gaap:InterestPayableCurrent>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-3" id="Fact-8C135ECFBAB75CD1A9474CB910DEAB5F" unitRef="usd">2553000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-3" id="Fact-335A1DF012F852CA9E6076E7E623BDCF" unitRef="usd">3343000</us-gaap:InventoryNet>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q4YTD" decimals="-3" id="Fact-028BEBB7F54152EDADB1C35038082F89" unitRef="usd">175000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-99FC95AEB98D55679C7826EA43CF88B6" unitRef="usd">769000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-926AB14E869C50F79760F943659C972C" unitRef="usd">22115000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-BF15B342F369574FAF09857C626D9EFF" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-192F980822205550A7E1EC9398E9C2AF" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-A41D2DD3CF3757509D5B3EA1A8D559C6" unitRef="usd">22115000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-62EF30525A7F5B5DEBAA4FD63074B528" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-D686FE3F53C953E3ED384FD6305668A2" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-99E82AF9455B5AC1A9F49C563C4D0735" unitRef="usd">15223000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-1B142C52DD0D0F816E024FD6309CB55E" unitRef="usd">66489000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-5CA3822C11DA36CED8D44FD6307EA905" unitRef="usd">18529000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-29C7B554DAB9F6EBC17B4FD630B03107" unitRef="usd">19720000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-8F693354464C57B8B9C9A3F1E47F42BA" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-417D538EE1EC74DEB8034FD630CE34F4" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-1D9CA4C46F521CBA96104FD630A606BE" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-42E5B66949DFAF4AAD134FD6308831E2" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7AB215A029DA5DD4AE595A318249F461" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-860D02370E89834026AA4FD6306A32CC" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-3AFE1C597E8CE007B9D04FD6306A5C8C" unitRef="usd">18529000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-65C492ED295BFF36928B4FD63088C45C" unitRef="usd">19720000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-26BA8E30125552838F362C1B60F19834" unitRef="usd">15223000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-9BCE8FC35AC38BB4ED5C4FD6307ECDB3" unitRef="usd">66489000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2012Q3Aug31_srt_StatementGeographicalAxis_sibn_SanJoseCaliforniaMember" id="Fact-900D472DD41E5A0EB7A5C20863203CC6">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2018Q1Feb28_srt_StatementGeographicalAxis_sibn_SantaClaraCaliforniaMember" id="Fact-1BA0360B2E535B4084AE9ACE728498CC">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-ED9061DE2C75599D92D22441EC804A64" unitRef="usd">46664000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-522EF83B2C915A8F96E3EEDCC2F8FB1E" unitRef="usd">48329000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-12D045FD1DFA5676B8AAD2C0A3FB8B06" unitRef="usd">35834000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-DADE088EF1D75BFDB943399B39A84362" unitRef="usd">138521000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0228FB73D5DB5C0EB2AEC2F4C4530439" unitRef="usd">7538000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-81AC42221E3A5E2E9EB2B8C3CE38380D" unitRef="usd">9006000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2015Q4Oct30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-2C361B227B1658AAB790EE3399C9451F" unitRef="usd">4000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LitigationReserve contextRef="FI2018Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember" decimals="INF" id="Fact-EFD7823F1B72596CA669D660366B24DC" unitRef="usd">0</us-gaap:LitigationReserve>
	<us-gaap:LitigationSettlementExpense contextRef="FD2018Q4YTD_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember" decimals="INF" id="Fact-BDCD5FEBF0A25B4BBA990908E6080FB6" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="-5" id="Fact-2CBA6EEC5F375F549E280CA4B970A72C" unitRef="usd">38700000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-B8085DE933C851019A6A7B54CCBA9A23" unitRef="usd">38700000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q4" decimals="-3" id="Fact-0547C89C02355E4C8C8BECCD271732FF" unitRef="usd">38963000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q4" decimals="-5" id="Fact-9A07E251455D5204896630A325742AED" unitRef="usd">39000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_sibn_PharmakonTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-B5DB6A3890D2539BAACE4D4397A552A4" unitRef="usd">39000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2018Q4" decimals="-3" id="Fact-1A11464BC185575F870E50A6877F943B" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2018Q4" decimals="-3" id="Fact-EC8637AE172F5EFD994C11A01950DC49" unitRef="usd">17778000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2018Q4" decimals="-3" id="Fact-B8B2D832AE8E5E3C9B61B1D57D4DA319" unitRef="usd">17778000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2018Q4" decimals="-3" id="Fact-ABDB84B85D28538894B8643656C5F942" unitRef="usd">4444000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-11A61143AB5D5E24841A2F261AE3AF07" unitRef="usd">38704000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E9AAC11D0E505A01B793C5CBDB4A4C55" unitRef="usd">38963000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F6ABCC6D719657ABA825B6A3994EDD50" unitRef="usd">12862000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0F83BE0C07525820A0DD5CBE8D95B940" unitRef="usd">115150000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AC2ACDA6994A51FFBBCCA308BF4C8DF0" unitRef="usd">-478000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D34442510AFC50E9B4E397C50900D6A8" unitRef="usd">-97825000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B645112840FB56AD9232B98FA5028F41" unitRef="usd">-17530000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F883EBD7B4B85AEEBCCC700C4C0E8204" unitRef="usd">-14519000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-92BCADAEAB6B4FAC9AC47820E27C44FD" unitRef="usd">-14500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C6EBC58E898253838ED6206913C74302" unitRef="usd">-23039000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-EED8C68E2B7FCD03C4104EEC5EC2D289" unitRef="usd">-23039000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E8CE9AE3E24058148E27B9EEFA899CD1" unitRef="usd">-17453000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-ADCF81E4CE22D8EA27324EEC7DB5AFCE" unitRef="usd">-17453000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2018Q4YTD" decimals="INF" id="Fact-5FAAC38F24BF5BAEA9822965E0587E61" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:NumberOfReportableSegments contextRef="FD2018Q4YTD" decimals="INF" id="Fact-9FC59C3BF6BF593081540AD8CEB02A0C" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2A0EEEBAF9C5586E84E5E1D5ECDBA408" unitRef="usd">60221000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B71AE786564D5A54BE2BDA104E9CE024" unitRef="usd">62512000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4E2DDBF731325B98B3F8C1D9B51996D9" unitRef="usd">-17350000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4CB3A032D8305764B82B1288C4363E12" unitRef="usd">-11965000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-BCEE9358C0E05CEE85B7F77ECB3BBE4F" unitRef="usd">5852000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2018Q4" decimals="-3" id="Fact-E2E00270E233504282C41B9A63520E9A" unitRef="usd">844000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2018Q4" decimals="-3" id="Fact-F583A29316155E97B9C30B48CB1CC367" unitRef="usd">842000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-3" id="Fact-ACCE3CA6D2BE52A38AB0318BF9479C48" unitRef="usd">914000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-4EAB372D8FF25CA89BAACDEC117423B6" unitRef="usd">1033000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2018Q4" decimals="-3" id="Fact-93E2B4DCFC2655238D39F3908F355D6D" unitRef="usd">1184000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-731294BEB0475A74A1B7FB5BB2471F18" unitRef="usd">1035000</us-gaap:OperatingLeasesFutureMinimumPaymentsReceivableCurrent>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D654B90FE1DD54CE9DE6D43D58FD82C4" unitRef="usd">1000000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CC6B3F7C235D5D31B82555013E0B589C" unitRef="usd">1200000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-262302FE19F2A1372F8E5424A6E426FE" unitRef="usd">135500000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-B4AB4A69C4861EFE1DD354250922B454" unitRef="usd">109900000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-120CD11ECC24537AAB2CCE348D4412BA" unitRef="usd">140000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-72906335D18F50DFAAD56A070FE55051" unitRef="usd">98000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E5E77E96107A54B3B54FEA6ECFD39A10" unitRef="usd">309000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0880285CCF8559F1BE08D97ECF04792E" unitRef="usd">325000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-00FA846E89C50CA3BC0B4A2887FB1834" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FB8F3A8DCB7AEF70B1774A2887F73222" unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6382ACF86A2D16377D274EECE0BBB4F9" unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EA2529CBDBDC54B58B5ED625DDA62497" unitRef="usd">-70000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-41FAA52D3E26066D80604EEC4B431725" unitRef="usd">-70000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1E7A1ED02D1C5F05804FC9A6F8BD88D6" unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-00008188722A2435D5D24EEC2B2FC5FC" unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-CE47FB9B0F6B57DF860A623C2E69A242" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-DD1285CF5D3555BF85BE9C425EFC1CB3" unitRef="usd">360000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5220DA00693F5AC88F98A7C3A76216FB" unitRef="usd">340000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-31C282AC417055C8BFED0DF92C494F6A" unitRef="usd">-1149000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DFFAB58019F93DEB80C24A5E0EBE11DF" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2B1203AD03508A0D6A474A5E0EB47016" unitRef="usd">73000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember" decimals="-5" id="Fact-A785791C8E4C575ABA92120ECECC61A6" unitRef="usd">1500000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
	<us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9071F0A347D3503A85046E0740213BA6" unitRef="usd">29081000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
	<us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BE65E18D8855514380E01BDABEBB10CE" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BAEF00E77AFA5FBE9ABFD4050563AFCD" unitRef="usd">1540000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BA981CB6D80D569782146EC0E5D95DF6" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4E480A89D2DE5BEB98430DFC3AE43210" unitRef="usd">1292000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E5C3F963037C58ADAAD138DEE51A56E4" unitRef="usd">1897000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AEE6629C410B6DE8336A4A5CF93E2F2C" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D921008946155E1BCBBF4A5CF94AEEFA" unitRef="usd">96883000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-770668E9F7155888A339AE9587401560" unitRef="usd">478000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F41A775B8EED5A7CAEB76C5CC231EA84" unitRef="usd">942000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-45E24893BA289308660D789267DC9D76" unitRef="usdPerShare">0.050112</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-17D7241994F61BFFE3027895CCBCADBF" unitRef="usdPerShare">0.171360</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-96943A6A2C0356C300DE7895E03A858B" unitRef="usdPerShare">0.4608</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-A62BFF8E9B66092EA79B7895F4AD3CD1" unitRef="usdPerShare">0.504</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-20F52283C0E0E874D37A78961DC66065" unitRef="usdPerShare">0.72774</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-6C6CD0E18016B86A98D2789632684B8C" unitRef="usdPerShare">1.317744</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-19CDA27D134841B5EDF07896456513C5" unitRef="usdPerShare">0.802656</us-gaap:PreferredStockDividendRatePerDollarAmount>
	<us-gaap:PreferredStockDividendsPerShareDeclared contextRef="FD2017Q4YTD" decimals="INF" id="Fact-7DF04BB0C40FD4E746A0789D5B974409" unitRef="usdPerShare">0</us-gaap:PreferredStockDividendsPerShareDeclared>
	<us-gaap:PreferredStockDividendsPerShareDeclared contextRef="FD2018Q4YTD" decimals="INF" id="Fact-9ED535712B00FCF56720789DAF250959" unitRef="usdPerShare">0</us-gaap:PreferredStockDividendsPerShareDeclared>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-421A79A765682EB191D26E76ED96FA91" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2018Q3Oct31" decimals="4" id="Fact-13BC578DDA87E5B8A6B74C56639BDFDD" unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-4FC8E2015D64F82EEC0E6E7710055EB4" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2018Q3Oct31" decimals="INF" id="Fact-C529A55AFA2D8BA16EE04C54DFB842D4" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-ACECC0B44A36594E231A6E7723325136" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-B19A1A938EE028F8B5F06E7740496FEA" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-03BCADA332367FE5F58578F8AC975174" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-F275348FF4301886B47678F8ACA18A77" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-BF2486BB97B85269919A731A35E6137C" unitRef="usd">1252000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-64E810DF7F1D5E978B73F8A7F3EA4144" unitRef="usd">1990000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AD0D61F8C1E6E3B3B1774A5DC35756CE" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7554233BB1AC007965A84A5DC34DE99F" unitRef="usd">115506000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-623E2A2D8B3A5940883D28CD63F76E7B" unitRef="usd">40000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8F8A00DA13975F7E9A3F4D07A90C434C" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-669EA7C0D299547B97E033E59EA1ECC7" unitRef="usd">5427000</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0232904B37D65D36B02B2A7BBC2FE6D8" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-01B487E48C1E5D29A2635211682453F6" unitRef="usd">383000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-02239726BC7E531299CC9CE394FEE5D9" unitRef="usd">1614000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-46B7306A847655AF8089A2AD1D93F337" unitRef="usd">4918000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember" decimals="-3" id="Fact-4E8E2AA4886C5FAC8D433E62B590DEC5" unitRef="usd">310000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-B741F889D8A25D4F87890D761576744E" unitRef="usd">879000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-9B593E2E6A905957B737A5077B795701" unitRef="usd">29000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-58F9400DD5145C1E902D5D1993B5E7A3" unitRef="usd">272000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-AC1236E2B1E257EFA5FC872AC359E8B2" unitRef="usd">3428000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="-3" id="Fact-65A4848E2B1D5F50AE61607ED362C655" unitRef="usd">5518000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember" decimals="-3" id="Fact-6A86F33522345740A0D753A1F94E8379" unitRef="usd">407000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-71431AB24C3E53D19B891F1A3B4EBA3A" unitRef="usd">730000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-CCC871AA0BB05993BB2B832D24FDACAE" unitRef="usd">148000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-AF2EB8CB8E8E50FBBDAFD8A63EB16919" unitRef="usd">448000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-3" id="Fact-9EB3C76C40C75B7F80C6CF49BED9B0F4" unitRef="usd">3785000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-7FAC5316EEC75BCDB5D8CDE3E1D0B4B5" unitRef="usd">1896000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-12E832C887755AAEB10DEB872B5F8F80" unitRef="usd">2154000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember" id="Fact-9E088A4A302D59C5AFD60FF513AAE1BD">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-FC5E182739BD58B3A2009A5E307C7733">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_sibn_ComputerAndOfficeEquipmentMember" id="Fact-D418A0921AFB55F0AEFFDDED4DCB11E4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-BBCC64D78EB85D228E649829CA56A9D3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-BF81795C170A52D2AA118044C785AE76">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PurchaseObligation contextRef="FI2017Q4" decimals="-5" id="Fact-BE1057D5056158C18A1BFFEB3E4D134E" unitRef="usd">100000</us-gaap:PurchaseObligation>
	<us-gaap:PurchaseObligation contextRef="FI2018Q4" decimals="-5" id="Fact-7A81BC1529685688828B3550D7C0CEA3" unitRef="usd">200000</us-gaap:PurchaseObligation>
	<us-gaap:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock contextRef="I2013Q1Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefFinancialOfficerMember" decimals="-5" id="Fact-1C8DB5C5D61D579290C3E2AFADF67137" unitRef="usd">200000</us-gaap:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock>
	<us-gaap:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock contextRef="I2014Q1Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="-5" id="Fact-B0DE5C5C73985ED5BAB8252EC3CE5B5E" unitRef="usd">400000</us-gaap:ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock>
	<us-gaap:RelatedPartyTransactionRate contextRef="D2013Q1Mar31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefFinancialOfficerMember" decimals="INF" id="Fact-5FE74F0543D45C2F824347A1CA16FCF9" unitRef="number">0.0109</us-gaap:RelatedPartyTransactionRate>
	<us-gaap:RelatedPartyTransactionRate contextRef="D2014Q1Feb28_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefExecutiveOfficerMember" decimals="INF" id="Fact-C1171A6FCBAB5CA9A781D9315AB15759" unitRef="number">0.0197</us-gaap:RelatedPartyTransactionRate>
	<us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="D2016Q4Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ChiefFinancialOfficerMember" decimals="-5" id="Fact-8FEB0E44DE2A5966B1CAF496A9401AE4" unitRef="usd">100000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
	<us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7FE01818E614561FB8EDA52A352A3FC2" unitRef="usd">84000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
	<us-gaap:RepaymentOfNotesReceivableFromRelatedParties contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D8565E1E8F815C2FA607684306FFD4CF" unitRef="usd">0</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2017Q3Oct_us-gaap_DebtInstrumentAxis_sibn_SVBAndOxfordTermLoanMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" decimals="-5" id="Fact-F3C2CC53385455548607279F1DA7013F" unitRef="usd">29100000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-529AB96378D15778807CAD53F19D4014" unitRef="usd">1119000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0D411754588B5622B88C3D29E33278E6" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E345B74D1884505D8D2C53EC0012DA7B" unitRef="usd">5513000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8C268D7AB3815BF091CEDC9D9616AD1F" unitRef="usd">5376000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-B0E4DF4D1C715A9584C4734F262401FA" unitRef="usd">-139724000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-F6474FF1192156778D1D4DF9C03A1ACE" unitRef="usd">-157177000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-5" id="Fact-7C295627B55914E1C035781E2F0E2124" unitRef="usd">-157200000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8C00C4C0B6AE5B59A94D76B9034B4617" unitRef="usd">47983000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-5C4E7FF4A1F05A08BD5F44CA277241C3" unitRef="usd">43351000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-3" id="Fact-C50F18DA629C58BB8F81B3584E3BAA16" unitRef="usd">4632000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9C3CD3E076985609AF27C7C0537E0953" unitRef="usd">55380000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-9E2CC04506C05D69B9C8A19DB9AA2130" unitRef="usd">50137000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-3" id="Fact-A42EDB617125562C8826B65C652EB12E" unitRef="usd">5243000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2018Q4Oct16_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-85ABF4E3B5F85A14A4C362E700CC45A9" unitRef="usd">113600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q4Oct16_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-864CFF13ABD4516298C1B59B02AD189E" unitRef="shares">8280000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q4Oct16_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-0F46832D69A95FAB9BFEC14A1EC4B144" unitRef="usdPerShare">15.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SalesAndExciseTaxPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-DCBFE5BA867455028FEC9F07F82D483D" unitRef="usd">466000</us-gaap:SalesAndExciseTaxPayableCurrent>
	<us-gaap:SalesAndExciseTaxPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-F534CD2F24025E01ACF8EA8569791959" unitRef="usd">388000</us-gaap:SalesAndExciseTaxPayableCurrent>
	<us-gaap:SellingAndMarketingExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DA86FEBB00235FA0A6B866FCB26586BA" unitRef="usd">41646000</us-gaap:SellingAndMarketingExpense>
	<us-gaap:SellingAndMarketingExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E828089E25CA527985B6168DA40941E8" unitRef="usd">44497000</us-gaap:SellingAndMarketingExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AC1FC590073B5EB48F5BFF0E843D95B4" unitRef="usd">1438000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1780CB43AD9F55178A6A757FF444FECC" unitRef="usd">2312000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact-457AECC045CB54B08B83B7571303CE49">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact-AD097294BF1654EB8F2E328BFD61DFD3">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-5C25404FDF9D8550B49E4F8980636DD2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-CFB57B24FB695D4216F44F8921F8F845">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-48A9BA9D8F585074966A264BBB2B8389">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-56ABDBD46C4D514ED51B4F6AFB0E5927" unitRef="shares">600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-7FD9CDCDAAF6E18CCE9E4F76DB1C76A9" unitRef="usdPerShare">20.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-577B9B952FF03343228D4F6AE72FA3A3" unitRef="shares">54036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-D4AF96D06C1E81F15A204F76C1836843" unitRef="usdPerShare">11.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-E309E825BB9124AF317D4F2BC217F626" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-9C41FC6A6476079F19904F2BC217F41E" unitRef="shares">53436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-62CB61454A037FE7A4504F76283B166A" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-01098F2EBCB15CB90F3E4F77BE38AE8D" unitRef="usdPerShare">11.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-F03D49884F9DE239A0CF4FBBAC638677" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-8F9DC071CE7B153262C44F6B0E4E99A2" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-38598A068F82C0B8D4454F76F2655F88" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-94864959871D9536FABE4F5FEFED1FC6" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_sibn_StockOptionsandESPPPurchaseRightsMember" decimals="INF" id="Fact-9BDCD987F643E8AFB5A65DBAC08DBF25" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-0450F75ECFB08399041F4F5FEFDE9153" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_sibn_StockOptionsandESPPPurchaseRightsMember" decimals="4" id="Fact-C5363DCE61B2AC55A35B5DBB030B0DC6" unitRef="number">0.4396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-80967CEBE93D525C8928971F32FB36F8" unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A0F9B5E900E95D5E924B6687F0592115" unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-88050B46F98E5CE09139FF627AD13808" unitRef="number">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-46BF70F9328756A7BEAEFAA06B155115" unitRef="number">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_sibn_StockOptionsandESPPPurchaseRightsMember" decimals="4" id="Fact-58830D4171ACD95F91CB5DBB652A7337" unitRef="number">0.0249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-B5298A966FD35185AB437C8F66BE0B7B" unitRef="number">0.0231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-63AFEAEFBCAC5D76BAEA806A7528BE40" unitRef="number">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-DED861D4A8E059598F3094434C9DD14A" unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-E695B7E473BB5CFD964D27FF6E78804B" unitRef="number">0.0235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4" decimals="INF" id="Fact-A86D453ED2CB5AE1AC916955E6FE1F57" unitRef="shares">29654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2018Q4" decimals="INF" id="Fact-81FDC75D95B7778E7B634C5B02243EEE" unitRef="shares">2497082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2018Q4YTD" decimals="INF" id="Fact-FDA6F17226A8564EBCEB7F2FD505032A" unitRef="shares">65694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-C38AE99691345CF7A72D39B6A5E548FD" unitRef="shares">564098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-238049A673AB5848BF7F66DC67A6B1ED" unitRef="shares">408544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="INF" id="Fact-E13BC20937ED59C5A534B1BCFCA91118" unitRef="shares">155554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2018Q4YTD" decimals="INF" id="Fact-97E424A7246452FC857C5A876CC6FA55" unitRef="shares">100080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-7253697E01471DDACEA84F8BD7911FFE" unitRef="usdPerShare">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD" decimals="2" id="Fact-1F5620C9D1EE5A2F79F94F8BD79B4C01" unitRef="usdPerShare">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-975E924D2B4ADBD377CE4F45394A7F1F" unitRef="usd">3585000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-A7E63ADDA84677DACB394F456E3F2A9C" unitRef="usd">43905000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-58C61A61A3235A65AAD5B37ADBEA3B46" unitRef="shares">3001929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-70A628545CA05311A6B39945644B8AF8" unitRef="shares">2641198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-B6187951F9F91019F76D4F3E39F7CE70" unitRef="usdPerShare">4.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-7F232C60BB74B6BA0B394F3EE5E3E37B" unitRef="usdPerShare">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-1037B517D27A573EB6DB373D5A1A6D67" unitRef="usd">41882000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="FI2018Q4" decimals="INF" id="Fact-1673E364CB14588597B8A53FE95EC263" unitRef="shares">1762687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-F5E695CAF7FC57AFA99C6E269970046B" unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-99F2A0E59DF35B13AF6AC47805EB53EF" unitRef="usd">40154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-3957E4DC6C82550397E1907A1CB01A8C" unitRef="shares">2366723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-E263ABEAE0DE5406954A5FBB2CBA2D15" unitRef="usdPerShare">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="D2021Q3Sep012017-Sep302021_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-C635E752F6740E42649B4FB2A3133AB0" unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-383A318E0A7477928BEC4F3EC8B7EC7B" unitRef="usdPerShare">4.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-B8E14656932E4D93692C4F3ED8C3E15F" unitRef="usdPerShare">4.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2017Q1Mar_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-85362E7B70CB527091220EA8527F1A0B" unitRef="usdPerShare">5.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2017Q4Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-6BBF5F99C0E87720CC6B4FB1035ECA6D" unitRef="usdPerShare">4.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-2189BD3EEB5D572E1C4E4F3EB9570DED" unitRef="usdPerShare">8.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-7BE67E60374A5C3BA1254B6E43A6361D">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-73952ADDD5A9AE089CEC4F5FA34393A0">P5Y8M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_sibn_StockOptionsandESPPPurchaseRightsMember" id="Fact-B8832414A4BE2DFE2EE15DBA9501D9D3">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-FB6C3EBC445A10683C9B4F5FA33F6064">P6Y1M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-D84A48C85B0B5F21A4690A2974E93BF6">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD" id="Fact-6B28C0A23146579498EF86B01E940A30">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2018Q4YTD" id="Fact-BC3D45AE26A95233B1639872589C1082">P6Y5M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_sibn_A2018EmployeeStockPurchasePlanMember" decimals="2" id="Fact-81182C83978267FF9F974F91AF3C7B5A" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-47045E9B513A5CF37AE54ECD470D0DA1" unitRef="shares">3446137</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-CAA7FC174D99C77E5F6B4ECF449F646B" unitRef="shares">3603140</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-93C9C145635D68A985194ECFA07964D7" unitRef="shares">24450757</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2018Q4Oct16" decimals="INF" id="Fact-580E5D8EDA9A5107B62B9B4A4E001B7E" unitRef="shares">12066654</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AEDB39600C6D89FCE4D84F04B2285F5B" unitRef="shares">12066654</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B25AC3B87A10F930C8A84EF707920EEF" unitRef="shares">8280000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-22EF70289C9F2E07F38F4EDFBB9EEB2C" unitRef="shares">152691</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD" decimals="INF" id="Fact-B15EC4D3906854B5B4249F2E068EDE13" unitRef="shares">395117</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E73CA7521FC8B479F46B4EDFBB2F17F1" unitRef="shares">289077</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BCEEFF9443C000192F974F0493EACA08" unitRef="usd">118548000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6A789777055968139F084F0493EAEBF9" unitRef="usd">118547000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B678C6B1B57C6E3056994F0493E04814" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD" decimals="-3" id="Fact-978B14425E80F584B8084EF79A512188" unitRef="usd">113603000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E2B67F035054C16D430C4EF79A47DD1F" unitRef="usd">113602000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-42D91AAD1978668BF485539C2D8D8DCB" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3E8284BBA8D6AD25D03A4EDFBBA89ABF" unitRef="usd">383000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4214482312BBCEC8E7E24EDFBB2ACABB" unitRef="usd">383000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8B6CE9CB44233BE4D2FB4EDFBB9E9410" unitRef="usd">1136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-329FE9ADBCC0659601C54EDFBB2F2400" unitRef="usd">1136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-A5F175CE782BE4467A464ECD05D3E43B" unitRef="usd">-108733000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D6ACC29540FF3AB4BCA74ECD05838351" unitRef="usd">472000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CD8416149ABE85361A844ECD05B5C7EF" unitRef="usd">8000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A7B4197F4AAE36CAD03A4ECD05690953" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-112DC5F61240F56C894D4ECD05DD74DE" unitRef="usd">-521000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A6EFFCDAFE8E5485C31A4ECD05973D95" unitRef="usd">-116685000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-79D3E4D230775F9E8E5A545B770687F7" unitRef="usd">-129378000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4FCF019B838975C47D864ECF4FAE055D" unitRef="usd">402000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4368971BC9C1739672C14ECF49CE15A7" unitRef="usd">9943000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-BC26001858A4A8D97F8B4ECF47497C33" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-9E607F207943B2247D424ECF4CDE0F33" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-6965C54CA8F6422B6EBE4ECF526C07AD" unitRef="usd">-139724000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-8401CACEE26B56FCA63008E04BCD9973" unitRef="usd">90192000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-20D312FEC0F3783B1BB44ECFAC4FAB1B" unitRef="usd">439000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-24D42A6BEE02441DF47F4ECFA6CF0AC4" unitRef="usd">246927000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3F4AE3337431D9DDA26A4ECFA3D75F8B" unitRef="usd">3000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-5AE96DECCD3AB6A472B14ECFA9464062" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DA2716BDDD1B7E8B63BE4ECFAF977EE8" unitRef="usd">-157177000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q1Oct04-Oct04" decimals="4" id="Fact-6E440577FC664B06798E4C6E6E19FB21" unitRef="number">0.0556</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q4Oct01-Oct31" decimals="4" id="Fact-DEE2BE52B48353CA93BF73C5B46958BB" unitRef="number">0.0556</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-6362DCC43A058A7DD2CA542716E50AF2" unitRef="usd">1700000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-A7DB2E190D8C5AF9954D542716EFF231" unitRef="usd">1900000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4" decimals="-3" id="Fact-A1F78AEA7BEC589253264ECD6BEECFE8" unitRef="usd">113121000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4" decimals="-3" id="Fact-03E23A14F9A8534DA988EF5228D25499" unitRef="usd">118548000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-93437A1D3F0A5512AAAB35AEAA608FB2" unitRef="usd">154000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-805689BA8D2E590C8B2E4A8BB888167A" unitRef="usd">1489000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-C79530339C3D5516A6C37BE50F5AC3C2" unitRef="usd">2862000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="-3" id="Fact-632447C45E25505E8F79815E84779208" unitRef="usd">15656000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="-3" id="Fact-A2275EE27F3F55768780D58387CBBA85" unitRef="usd">18127000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="-3" id="Fact-6272FD3B764E560A83AE64F878A33A1D" unitRef="usd">54508000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="-3" id="Fact-D3EB5A47DDA95FFEA362D8586D77D330" unitRef="usd">25752000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2018Q4" decimals="-3" id="Fact-8FA917920C025021A3CE8FA0E98152F8" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4" decimals="-3" id="Fact-D9CF57787A18540E94BA955EB9C0C2C5" unitRef="usd">119194000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-C9B07E26130A55FEB14EA387827ED423" unitRef="usd">154000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-2E8AB5EF98E553C696E95E16B199B0FF" unitRef="usd">1520000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-688351FF9FCE521ABF89CEABE940690E" unitRef="usd">2874000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="-3" id="Fact-3EE39C1F53EE559DBEADBFD63D8DDD78" unitRef="usd">15807000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="-3" id="Fact-3E46682D65C250D7BBFE63DD89272B85" unitRef="usd">18275000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="-3" id="Fact-3FCC9A762A7F5E2BAE0CD4C21D3E7321" unitRef="usd">54674000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="-3" id="Fact-8335844243925396B016652CAE52FBAB" unitRef="usd">25890000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2018Q4" decimals="-3" id="Fact-738DE5ED1D6A5757AF9395642DFF5ADE" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-B0CCD097FEB7B2D6368F78B15DA3A2A7" unitRef="usdPerShare">0.6264</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-7346C2A0C7BF9FC9A77478B1FA44C8CC" unitRef="usdPerShare">2.142</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-CCBEB617D96C31D8745578B20D6ADD36" unitRef="usdPerShare">5.76</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-FE1C58B76E66AB10CE3778B224AF14DA" unitRef="usdPerShare">6.30</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-A7DED7A562104FA110C278B23BADC4D5" unitRef="usdPerShare">9.0954</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-C564AF54F915488DB81A78B25997D346" unitRef="usdPerShare">16.4718</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-567CA26CB2D15DE0B4BF78B28D19EDC0" unitRef="usdPerShare">10.0332</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-49E09BE87F9B55BDA41A65B463C62DC9" unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-AE04EA30AAA55F759BC907A9DD2849EC" unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-DE82462620BB55BD951836A7BF780A95" unitRef="shares">12104749</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-3122CC0DC0995EFBA6F93B082BA5C353" unitRef="shares">245096</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-7E4D5E5EE7CA5E708422B0CD4007AFB6" unitRef="shares">709617</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-1DA12F67A3225AAB9A1B43AC5F79D593" unitRef="shares">498958</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-40EFB0A4FC9255F6B1ADDDBF0DDD9583" unitRef="shares">2509047</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-86ED9825E6875758846F135EEEF07C24" unitRef="shares">2086138</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-7B9CBA038D1A5215AB362DC3131201BD" unitRef="shares">3389227</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-C1C214C75F3357BFAE8C89B396968CD1" unitRef="shares">2666666</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-6F3C1C00E0255CA899896944929F3CD7" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-AEA34AF814A65825AB20BECA52831E54" unitRef="shares">11871578</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-36765957CFD75BF0957FDBA55B0625E6" unitRef="shares">245096</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-E90C77F1690452A4A712EBC73EC8DB85" unitRef="shares">709608</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-BD2CAB6FACDA5C1F982C7D676F89994C" unitRef="shares">498938</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-6E976EA7D9C75EAFBCF62579C09529BC" unitRef="shares">2509032</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-ED07DA94F6865514B2498CA2236738C5" unitRef="shares">2009226</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-8732AC0F388B535ABD4E3E2A3CEDB706" unitRef="shares">3319274</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-975F7C9625E9540FB8ACE858F35D9528" unitRef="shares">2580404</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-59565C7E07C45557AC4C3D73FD91792A" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-41E96009C453641D150D4ECD8C94798F" unitRef="shares">11330704</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-02C863D603385D888552251162FA09CF" unitRef="shares">11871578</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-9AE54540CB6D52FB9D492114A10F4805" unitRef="shares">11871578</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-A4DA61FB9F9A588FA04A63E4945FE45F" unitRef="shares">245096</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-A85B9BAC6A485322BF63894E531369DD" unitRef="shares">709608</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-923D8A9F601E517EA29FD91DB9D3A4E0" unitRef="shares">498938</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesDPreferredStockMember" decimals="INF" id="Fact-D8DE131D9FF35DBC8C06DA92FE992B6A" unitRef="shares">2509032</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesEPreferredStockMember" decimals="INF" id="Fact-FCC395C66A765469827F9C22A6F81584" unitRef="shares">2009226</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesFPreferredStockMember" decimals="INF" id="Fact-660F7337956D55F99A05F2134BA65407" unitRef="shares">3319274</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesGPreferredStockMember" decimals="INF" id="Fact-95DF9F057D88547FBA7AA45C2A2A4830" unitRef="shares">2580404</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-431A68CA33895965BC7421EF0ACA8FF1" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" decimals="INF" id="Fact-11C319501B635E1A848A13E627AC09BF" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0B545F20F7256AF8E4204EEEB1D356B1" unitRef="usd">5427000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-A3F478899E4C161EB92B541C1D520BA8" unitRef="usd">950000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-0B032DA6F51374374CE6541C1D582CCC" unitRef="usd">993000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-D1B127CA96C65BF971D9541C1D55D232" unitRef="usd">1084000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4B5314287FFCB609BD33541C9E26CF95" unitRef="usd">43000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C06C4D715566589949EB541CCCDBBA82" unitRef="usd">91000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2017Q4" decimals="INF" id="Fact-E71A2DEC2B619C04FDC2542C786F2C7A" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2018Q4" decimals="INF" id="Fact-538312274FEC9C5C8F44542BD786B20B" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5070ABFBB32D276182D178DAFE29E391" unitRef="usd">-7513000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FC9C48785F65A4469BF97A4DF44BC601" unitRef="usd">4577000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B8D16D4E1D3D582A9C9EE498E3124D10" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A73225F0C6D05C7A82511FD90DBA086D" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E89C2A439F67565A9D390C9D1EA727C3" unitRef="usd">422000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D182681A501A56E68A835D0FBCFDDD72" unitRef="usd">422000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-228FECFF0554551AA77E2A37CF8CDD13" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2713F0D4B856596C97FC42CA6E17A10B" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-18D3CCC427B85AE2882FFAA737C09A6E" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E350040D81B257A3988E4A7109E4A246" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-9A7DB1D56F8D52539AC7ABA56FB90BA8" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" decimals="4" id="Fact-8F624B0AFB2757238A8B253187F23AA8" unitRef="number">0.5906</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="4" id="Fact-3A04355C661B5BD4A607AA55B49DEA2D" unitRef="number">0.0216</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact-683B276CF7115F4497BD12C64B2CC960" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember" decimals="4" id="Fact-A3ED4FB9072F5EE8A837B3BA22E3F682" unitRef="number">0.5389</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="4" id="Fact-2A2D057339C8571E8C8F6430A785C5B1" unitRef="number">0.0262</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="FI2017Q4_us-gaap_ClassOfWarrantOrRightAxis_sibn_WarrantsLiabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemablePreferredStockMember" id="Fact-91098878CC0A57ADB5B0F32D0D8AFDA6">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" id="Fact-748086592FFD58198E918CE1FA0B53C4">P5Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" id="Fact-74300154AD0D55EFBCA57158D114B882">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-773E001A36E6521896064F5AAE2E5F57" unitRef="shares">3467096</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q4YTD" decimals="0" id="Fact-90E1E46873EA5FF9B23163883F087650" unitRef="shares">7950284</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<sibn:DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-D852FFB20F4FDA7E1F065DC4098BB421">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;text-indent:33px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.48148148148148%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Twelve Months Ending&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Minimum Net Sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Trailing 12-Month Consolidated EBITDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 30, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;thereafter, as applicable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sibn:DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock>
	<sibn:MedicalDeviceExciseTaxPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-EA3CDD2D51835C11B1FC87D4BA6BDFC3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Medical Device Excise Tax&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the Patient Protection and Affordable Care Act, effective January&amp;#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the United States. The medical device excise tax is included in cost of goods sold in the consolidated statements of operations and comprehensive loss for all the periods presented. Effective December 2015, the Act was amended to include a provision to suspend the tax on medical devices through 2017. In January 2018, the suspension on the tax on medical devices was further extended through 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</sibn:MedicalDeviceExciseTaxPolicyPolicyTextBlock>
	<sibn:WarrantsClassifiedAsEquityPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-1DA2D8588EBA5B4DA55AD359B42CFA42">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&amp;#160;indexed to the entity&amp;#8217;s own stock and (ii)&amp;#160;classified in the stockholders&amp;#8217; deficit section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</sibn:WarrantsClassifiedAsEquityPolicyTextBlock>
	<sibn:WarrantsClassifiedAsLiabilitiesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-D77959CDE8815427869A122B355D285C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Redeemable Convertible Preferred Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants and other similar instruments related to shares that are contingently redeemable are classified as liabilities on the consolidated balance sheet at their estimated fair value because the shares underlying the warrants may obligate the Company to transfer assets to the holders at a future date under certain circumstances such as a deemed liquidation event. The warrants are exercisable into the Company&amp;#8217;s redeemable convertible preferred stock and are classified as liabilities on the consolidated balance sheet. The warrants, measured at fair value, are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company adjusted the liability for changes in fair value until the the closing of our initial public offering, at which time certain preferred stock warrants were converted into warrants to purchase common stock and the liability was reclassified to additional&amp;#160;paid-in&amp;#160;capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</sibn:WarrantsClassifiedAsLiabilitiesPolicyTextBlock>
	<us-gaap:AdvertisingCostPolicyExpensedAdvertisingCost contextRef="FD2018Q4YTD" id="Fact-3EAA737839535955BE4A928E5CD4EB28">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising Expenditures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The cost of advertising is included in Sales and Marketing expense in the consolidated financial statements and expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdvertisingCostPolicyExpensedAdvertisingCost>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-CA8E056FD5B7538DA1FED912EC6AA8A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-1CFA86E7C4505EAC86100A519BFEC1F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-6C5998C0C15451D384853FE7CE10AA6B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2012, the Company entered into a new &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year non-cancelable operating lease for its existing office building space in San Jose, California which commenced in January 2013. In February 2014, the Company expanded the existing lease space and extended the lease terms through June 2017. In May 2016, the Company entered into another extension of the lease with its lessor for additional 12 months beginning in July 2017. Effective May 2018, the Company entered into an early termination agreement on an operating lease for its San&amp;#160;Jose office. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; early termination fees were incurred and all previously agreed-to rent payments were released, with no further obligations. In February 2018, the Company entered into a new &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;seven&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year non-cancelable operating lease for an office building space in Santa Clara, California which commenced in April 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company also entered into non-cancelable operating leases for its office building space in Gallarate, Italy and Mannheim, Germany which both expire in November 2024. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2019 to 2021.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases totaled approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;text-align:left;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;           The aggregate future minimum lease payments under all leases as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Commitments and Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has certain purchase commitments related to inventory used in normal course of business. These commitments totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The amounts paid under these arrangements may be less in the event that the arrangement is renegotiated or canceled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the United States District Court, Northern District of California. The complaint alleges violations of the Telephone Consumer Protection Act (the &amp;#8220;TCPA&amp;#8221;) on behalf of an individual and putative classes of persons alleged to be similarly situated.  The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission.  The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship.  The Company believes that it has meritorious defenses and intends to vigorously defend itself in the action.  It is too early in this matter to reasonably predict the probability of the outcomes or to estimate the range of possible loss, if any.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Indemnification&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&amp;#8217;s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;not&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; incurred costs to defend lawsuits or settle claims related to these indemnification agreements. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability associated with such indemnifications has been recorded to date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-B7412DB3CB42530EA436010F32CFADB0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss represents all changes in the stockholders&amp;#8217; equity (deficit) except those resulting from distributions to stockholders. The Company&amp;#8217;s unrealized foreign currency translation income (losses) and unrealized gain (losses) of marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q4YTD" id="Fact-F4FE4218E3D95F1484117F9CA56E2786">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company&amp;#8217;s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company&amp;#8217;s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-7BE9A4E3471F5931A08C26E5F1A8EB28">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-C60224A7A1C15113A56168C719481239">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Borrowings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$38.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of outstanding debt, net of debt discounts, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Term Loan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the Company entered into a Term Loan facility and a revolving line of credit with Silicon Valley Bank, or SVB and Oxford Finance LLC, or Oxford for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$35.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Term Loan had interest only periods for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; up to October&amp;#160;1, 2017 and was then to be repaid over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of equal principal payments plus interest. The maturity date of the term loan was December&amp;#160;1, 2019, and it carried an interest rate equal to the greater of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or the WSJ Prime rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Term Loan borrowings were senior unsecured obligations of the Company, ranking equally and ratably among themselves and with the Company&amp;#8217;s existing and future unsecured and unsubordinated debt.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In conjunction with the above Term Loan agreement, the Company issued redeemable convertible preferred stock warrants (refer to Note 9 for details).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2017, the Company extinguished the Term Loan with SVB and Oxford. Concurrently, the Company entered into a New Term Loan with Pharmakon Advisors, or Pharmakon. As a result of the extinguished debt, the Company paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in principal payments to SVB and Oxford. The Company also paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in early termination fees and recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unamortized debt discounts. This loss on extinguishment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is reflected as interest expense in the consolidated statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into the New Term Loan with Pharmakon for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in October 2017. Debt issuance costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were recorded as a direct deduction from the carrying amount of the New Term Loan on the consolidated balance sheet, and are being amortized over the period of the New Term Loan using the effective interest method to interest expense in the consolidated statement of operations. The New Term Loan includes an interest-only period for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months through September 2020 and is then repaid in equal quarterly principal payments plus interest through December 2022, and is classified as long-term borrowings on the consolidated balance sheet. The New Term Loan carries a fixed interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a closing fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the funded amount, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The New Term Loan includes a pre-payment fee equal to the interest due for the first 30 months of the agreement if it is prepaid within the first 30 months, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; prepayment penalty for months 31-48, and a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; penalty for months 49-60. The New Term Loan required the Company to maintain a minimum cash balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and to achieve certain revenue targets through December 31, 2018. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. Under the New Term Loan, the Company also has a second tranche of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available through January 2019, contingent upon the achievement of certain revenue milestones. The Company did not draw upon the second tranche. The New Term Loan is a senior obligation secured with a blanket first lien on the assets of the Company. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the total loan balance, net of debt discount, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$38.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, with an effective interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and the Company was in compliance with all debt covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Approximate annual future minimum principal payments under the loan agreements as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Year Ending at, December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future minimum payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amount representing debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total minimum payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The New Term Loan required the Company to maintain a minimum cash balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and to achieve certain revenue targets, which we were in compliance with through December 31, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning with the three months ended March 31, 2019, the Company is required to meet either minimum net sales or trailing 12-month consolidated EBITDA targets. The Company needs to meet one or the other, but not both.  If the Company does not meet either the minimum net sales or trailing 12-month consolidated EBITDA targets, the debt will immediately become due. The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;text-indent:33px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.48148148148148%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Twelve Months Ending&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Minimum Net Sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Trailing 12-Month Consolidated EBITDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;52,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 30, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;thereafter, as applicable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;or&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The New Term Loan is collateralized by all of the Company's assets, including intellectual property.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company was in compliance with all of its debt obligations and covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Line of Credit&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2015, the Company entered into an agreement with its existing lender SVB and Oxford. The amount of the revolving line of credit was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the amount of certain customer accounts receivable). It carried an interest rate equal to the WSJ Prime rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a maturity of December&amp;#160;1, 2019. In October 2017, this line of credit was cancelled in conjunction with the SVB and Oxford debt extinguishment discussed above. No draws were made on this facility through its cancellation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q4YTD" id="Fact-58339A09D59A51BA87E06CFC18B0B16E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-Based Incentive Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2008, the Company adopted the 2008 Stock Option Plan, as amended, under which the Board of Directors may issue incentive and nonqualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan, which serves as the successor to the 2008 Stock Option Plan, under which the Board of Directors may issue incentive and nonqualified stock options and restricted stock units (RSUs) to employees, directors and consultants. No new options have been granted under the 2008 Stock Option Plan since August 2018. Outstanding options under the 2008 Stock Option Plan continue to be subject to the terms and conditions of that plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding shares, the price of each share shall be at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a nonqualified stock option shall not be less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of the fair market value on the date of grant. As of  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,350,080&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of common stock had been reserved for issuance under the 2008 Stock Option Plan. As of&amp;#160;December&amp;#160;31, 2018, a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,576,538&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock had been reserved for issuance under the 2018 Equity Incentive Plan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted have a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, except, options granted to individuals holding more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding shares have a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. Options generally vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period. Certain shares issued under the Plan are exercisable immediately, but subject to a right of repurchase by the Company of any unvested shares. RSUs granted under the 2018 Equity Incentive Plan generally vest over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years based upon continued services and are settled at vesting in shares of the Company's common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option activity for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for all stock plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.25925925925927%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Contractual Remaining Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,585&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(395,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options canceled &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(65,694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,641,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested and exercisable - December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,762,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested and expected to vest - December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,366,723&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted-average grant date fair value of all options granted were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.98&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.80&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest were calculated as the difference between the exercise price of the options and the close price of the Company&amp;#8217;s common stock on the last trading day of the year, as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the lesser of the fair market value of the stock as of the first date or the ending date of each &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; month offering period.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Early Exercise of Unvested Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Early exercises of stock options are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders&amp;#8217; equity (deficit) as the options vest. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74,019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,117&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, respectively, subject to repurchase under the Plan and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of associated liabilities for the repurchase.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth stock-based compensation expense recognized for the periods presented (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.70370370370371%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;br clear="none"/&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales and marketing&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts above do not include &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of stock-based compensation expense related to forgiveness of notes receivable for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; amounts of stock-based compensation expense related to forgiveness of notes receivable were recognized for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Refer to Note 13 for details.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the shares of the Company&amp;#8217;s common stock underlying the stock options has historically been determined by the Company&amp;#8217;s Board of Directors. Because there had been no public market for the Company&amp;#8217;s common stock prior to its IPO, its Board of Directors has determined the fair value of the Company&amp;#8217;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including independent third-party valuations, the Company&amp;#8217;s stage of development, sales of the Company&amp;#8217;s redeemable convertible preferred stock, the Company&amp;#8217;s operating and financial performance, equity market conditions affecting comparable public companies, the lack of liquidity of the Company&amp;#8217;s capital stock, and the general and industry-specific economic outlooks.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the NASDAQ Global Market on the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected Term&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The expected term represents the period that the share-based awards are expected to be outstanding. The Company used the simplified method to determine the expected term, which is calculated as the average of the time to vesting and the contractual life of the options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected Volatility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As the Company&amp;#8217;s common stock has never been publicly traded, the expected volatility is derived from the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Risk-Free Interest Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Dividend Yield&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Expected Forfeiture Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The grant date fair value of the stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4074074074074%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42%-47%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42%-55%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.35%-2.96%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.73%-2.31%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Performance Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2017, the Company granted &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;564,098&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; performance stock options at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.94&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;408,544&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; performance options will vest monthly over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155,554&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; performance options will vest monthly over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. The vesting period will begin on the date of the closing of an IPO, the performance condition, subject to the optionee&amp;#8217;s continuous service. Stock-based compensation expense for performance stock options is based on the probability of achieving certain performance criteria, as defined in the individual option grant agreement. Periodically, the Company estimates the number of performance options ultimately expected to vest and recognizes stock-based compensation expense for those options when it becomes probable that the performance criteria will be met. In October 2018, the Company completed its IPO and recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; expense related to the performance stock options for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2017, the Company modified the terms of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;394,652&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unvested stock option awards granted in March 2017, by reducing their exercise price from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.94&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.68&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. In addition, the vesting performance conditions for these options were removed and the vesting commencement date changed from the IPO date to September 2017. There were no other changes in any of the other terms of the option awards. Due to these options previously subject to performance conditions that were not deemed probable of occurring, the Company had not recognized any expense related to these grants. The modification resulted in total expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that is recognized over the amended vesting period of forty-eight months&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes restricted stock units activity for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.77777777777777%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of &lt;br clear="none"/&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;Average &lt;br clear="none"/&gt;Grant Date Fair  &lt;br clear="none"/&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;"&gt;Unvested as of  December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;"&gt;Unvested as of  December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;53,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was a total unrecognized compensation cost of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. These costs are expected to be recognized over a period of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.29 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;          In October 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "ESPP"). &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;515,307&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock are reserved for issuance under the ESPP.  The Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; compensation expense for the ESPP.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the unrecognized compensation cost for the ESPP was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The assumptions used to determine the grant date fair value of employee stock options and ESPP purchase rights for the periods presented are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.7037037037037%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.96%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-52FC49E9FFDD55B68A5041B4C1DD1A45">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Share of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company calculates basic and diluted net loss per common share attributable to shareholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock and early exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the redeemable convertible preferred stock and early exercised stock options as the holders of redeemable convertible preferred stock and early exercised stock options do not have a contractual obligation to share in losses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, redeemable convertible preferred stock and common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-A623D44FE80D56D3BCB147C6D63FB1E8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basic and Diluted Net Loss per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;br clear="none"/&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares used to compute basic and diluted net loss per share*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,950,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,467,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;_________________________________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*        Calculated based on the 1-for-18 reverse stock split effected October 4, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested shares for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were excluded from the weighted-average shares used to compute basic and diluted net loss per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,641,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74,019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated ESPP shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,066,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-61E23CE7189E59919BBCB609BE0E0887">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average assumptions used in computation of the fair value of the redeemable convertible preferred stock warrants are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.07882241215574%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Remaining contractual term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-7297F2BB43D5563AAC8079D74D093A3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the fair value of the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;[1]&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;[1]&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.51851851851852%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:1px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[1]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents on the consolidated balance sheet&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth a summary of the changes in the fair value of the redeemable convertible preferred stock warrants, the Company&amp;#8217;s Level&amp;#160;3 financial liability, which is measured on a recurring basis (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:93%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value recorded in other (income) expense, net &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversion of preferred stock warrants to common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q4YTD" id="Fact-4EDE566C24DB5EAC99F4AF36945F64B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth a summary of the changes in the fair value of the redeemable convertible preferred stock warrants, the Company&amp;#8217;s Level&amp;#160;3 financial liability, which is measured on a recurring basis (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:93%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value recorded in other (income) expense, net &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversion of preferred stock warrants to common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-1281870F71515CE3ACC43B631CB9AB7A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Carrying amounts of certain of the Company&amp;#8217;s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&amp;#8217;s long-term debt also approximates fair value based on management&amp;#8217;s estimation that a current interest rate would not differ materially from the stated rate. The carrying amount of the redeemable convertible preferred stock warrants has been marked to fair value such that the carrying amount represents its estimated fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&amp;#160;1 inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&amp;#160;3 inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s cash equivalents consist of money market funds as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The money market funds are classified as Level&amp;#160;1 of the fair value hierarchy. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy. The Company&amp;#8217;s redeemable convertible preferred stock warrants are classified within Level&amp;#160;3 of the fair value hierarchy. The redeemable convertible preferred stock warrants have been valued using a Black-Scholes valuation model and are subsequently marked to fair value at each reporting period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-4466DCD06692559DBE8C81466DB00356">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses resulting from the translation of the Company&amp;#8217;s consolidated balance sheets are recorded as a component of accumulated other comprehensive income. Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-C07B76B0E93D5E2EA1AC155B42E5EF66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset&amp;#8217;s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-CCAE1066D9E77D33B1A64C72E0F3D282">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of the Company&amp;#8217;s loss before income taxes are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of income tax expense are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current tax expense:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax expense:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,555&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax at statutory federal rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State tax, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Measurement of deferred taxes as a result of tax reform&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.25925925925925%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accruals and reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The following table summarizes changes in the valuation allowance for the year ended December 31, 2018 and 2017 (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions during the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deductions during the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2018, the Company had net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$135.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$109.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company&amp;#8217;s federal net operating loss carryforward begins to expire in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2029&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the state net operating loss carryforward begins to expire in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2018, the Company had credit carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the state credits have no expiration date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code (California has similar laws). The annual limitation generally is determined by multiplying the value of the Company&amp;#8217;s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company has not utilized any NOL carryovers through December 31, 2018. In addition, the Company&amp;#8217;s deferred tax assets are subject to full valuation allowance, and thus no benefit for deferred tax assets have been recorded. The Company has determined that it experienced Section 382 ownership changes in 2010 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its NOLs are limited. The Company is currently performing an analysis to determine whether any additional NOL carryforwards are limited due to a change in ownership as a result of its recent IPO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company&amp;#8217;s uncertain income tax positions for the years ended December 31, 2018 and 2017 consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.37037037037037%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Beginning balance as of January&amp;#160;1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases in balances related to tax positions taken during 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Ending balance as of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases in balances related to tax positions taken during 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Ending balance as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has accrued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at December 31, 2018 and 2017 for payment of interest related to unrecognized tax benefits. None of the Company&amp;#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rate at December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company currently has no federal or state tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company&amp;#8217;s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the United States enacted a law commonly known as the Tax Cuts and Jobs Act (&amp;#8220;TCJA&amp;#8221;) which makes widespread changes to the Internal Revenue Code, including a reduction in the federal corporate tax rate to 21%, effective January 1, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to the provisions of the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. The carrying value of U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of deferred tax assets. Under the new corporate income tax rate of 21%, the U.S. net deferred tax asset position decreased by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Uncertainty regarding the impact of tax reform remains, as a result of factors including future regulatory and rulemaking processes, the prospects of additional corrective or supplemental legislation, potential trade or other litigation, and other factors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2017, the SEC staff issued Staff Accounting Bulletin No.&amp;#160;118 (&amp;#8220;SAB 118&amp;#8221;), which provides guidance for the tax effect of the 2017 Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the 2017 Tax Act&amp;#8217;s enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&amp;#8220;ASC 740&amp;#8221;). In accordance with SAB 118, the Company must reflect the income tax effects of those aspects of the 2017 Tax Act for which the accounting under ASC 740 is complete. To the extent that its accounting for certain income tax effects of the 2017 Tax Act is incomplete, but the Company is able to determine a reasonable estimate, the Company must record a provisional estimate in its consolidated financial statements. If the Company cannot determine a provisional estimate to be included in its consolidated financial statements, the Company should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the 2017 Tax Act. It is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the 2017 Tax Act. The Company has analyzed the guidance and other necessary information related to the tax effects of the 2017 Tax Act and considers the accounting of its net deferred tax assets complete in accordance with SAB 118.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-873A438053F151E6A3B2ACAEDFABD5E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. The guidance also prescribes treatment for derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-C4BBF72455C158A9AE40026D902BFD2F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&amp;#160;purchase costs&amp;#160;on a&amp;#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-967288BEF3F0B06324BC4A8256918289">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, marketable securities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.4074074074074%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All marketable securities of at December 31, 2017 of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of money market funds which were classified as cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="FD2018Q4YTD" id="Fact-2683E87550F3595A0C455DF4F0A46A18">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's marketable securities primarily consist of investments in U.S. treasury securities, corporate bonds, and commercial paper. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. Based upon maturity dates, all marketable securities as available for use in current operations, and therefore we classify these securities as current assets in the accompanying consolidated balance sheets. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in Accumulated other comprehensive income (loss) ("OCI"). We evaluate our investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in Other income (expense), net on the consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;            If quoted prices for identical instruments are available in an active market, marketable securities are classified within Level 1 of the fair value hierarchy. If quoted prices for identical instruments in active markets are not available, fair values are estimated using quoted prices of similar instruments and are classified within Level 2 of the fair value hierarchy. To date, all of the Company's marketable securities can be valued using one of these two methodologies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:MarketableSecuritiesTextBlock contextRef="FD2018Q4YTD" id="Fact-97A3A515FF9B68FE79594A8317006ABF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, marketable securities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.4074074074074%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,951&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2018Q4YTD" id="Fact-E4CF2C3DAB2B58C781A766FAC07C338B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;The Company and Nature of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;SI-BONE, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated in the state of Delaware on March&amp;#160;18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its iFuse Implant System, or iFuse, in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Company's board of directors and stockholders approved a 1-for-18 reverse stock split of the Company's common stock and redeemable convertible preferred stock, which was effected on October&amp;#160;4, 2018. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse split. All issued and outstanding share and per share amounts of common stock, redeemable convertible preferred stock, stock options, and warrants included in the accompanying consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Initial Public Offering &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October&amp;#160;16, 2018, the Company&amp;#8217;s Registration Statement on Form S-1 (File No.&amp;#160;333-227445) relating to the initial public offering (IPO) of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,280,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares at an initial public offering price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$113.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Company, net of underwriting discounts and commissions and offering costs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,066,654&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, and the Company's outstanding warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,550&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,657&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in additional paid-in-capital.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-3F6099CCBF0450C0B684F911C35B28DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the guidance on the subsequent measurement of inventory, excluding inventory measured using last-in, first out or the retail inventory method. Under the new standard, in scope inventory should be measured at the lower of cost and net realizable value. The new standard will become&amp;#160;effective for fiscal years, including interim periods within those fiscal years, beginning after December&amp;#160;15, 2016, for public companies. For all other entities, the new standard is effective for fiscal years beginning after December&amp;#160;15, 2016, and interim periods within fiscal years beginning after December&amp;#160;15, 2017, with early adoption permitted. The Company has adopted this standard for the fiscal year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU 2015-17,&amp;#160;Balance Sheet Classification of Deferred Taxes. ASU 2015-17 specifies that deferred tax assets and liabilities shall be classified as non-current, or long-term, in a classified statement of financial position. The new standard is effective for public entities for fiscal years beginning after&amp;#160;December 15, 2016, and interim periods within those fiscal years. For private entities, the new standard is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within fiscal years beginning after December&amp;#160;15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or an annual reporting period. The Company has early adopted this standard for the fiscal year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-09, which simplified several aspects of accounting for stock-based compensation transactions. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new guidance is effective for public entities for fiscal years beginning after December&amp;#160;15, 2016 and interim periods within those years. Other entities must apply the new guidance in fiscal years beginning after December&amp;#160;15, 2017 and in interim periods within fiscal years beginning after December 15, 2018, with early adoption permitted. The Company early adopted this standard in the first quarter of 2017 by recording the cumulative impact of applying this guidance to retained earnings, which was not material. The Company elected to continue to&amp;#160;estimate the number of awards&amp;#160;that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU 2016-01. Recognition and Measurement of Financial Assets and Financial Liabilities, which amends Accounting Standards Codification, or ASC, Subtopic 825-10, Financial Instruments - Overall, and includes updates on certain aspects of recognition, measurement, presentation and disclosure of financial instruments and applies to all entities that hold financial assets or owe financial liabilities. The new standard is effective for the Company&amp;#8217;s annual period beginning after December 15, 2018, with early adoption permitted beginning after December 15, 2017. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation&amp;#8212;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for all entities for fiscal years, including interim periods within those fiscal years, beginning after December&amp;#160;15, 2017. Early adoption is permitted. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Issued Accounting Standards Not Yet Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May&amp;#160;2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S.&amp;#160;GAAP when it becomes effective. The new standard is effective for fiscal years beginning after December&amp;#160;15, 2017 for public companies, and for fiscal years beginning after December&amp;#160;15, 2018, and interim periods beginning after December&amp;#160;15, 2019, for private companies. Early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. In March&amp;#160;2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April&amp;#160;2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May&amp;#160;2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date as ASU&amp;#160;2014-09. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company continues to evaluate the impacts of adoption of the new standard on its accounting policies, processes, and system requirements and has assigned internal resources, in addition to the engagement of third party service providers, to assist in the evaluation.&amp;#160;At this time, as  it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or other medical facilities, the Company expects revenue to continue to be recognized upon completion of the procedure&amp;#160;and authorization by the customer. Additionally, the new standard requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company expects to continue expensing all sales commissions as incurred. Management will adopt the standard using the modified retrospective method for the fiscal year ending December&amp;#160;31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued its new lease accounting guidance. Under the new guidance, ASU 2016-02, Leases (Topic 842), lessor accounting is largely unchanged. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Under the new guidance, lessees will be required to recognize a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date. The new guidance is effective for fiscal years, and for interim periods within those fiscal years, beginning after December&amp;#160;15, 2018 for public companies and beginning after December&amp;#160;15, 2019 for private companies. Early adoption is permitted for any interim or annual financial statements net yet issued. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing and operating leases) must apply a modified retrospective approach for all leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU 2016-15 &amp;#8220;Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments&amp;#8221;. ASU 2016-15 provides guidance on the following eight specific cash flow classification issues: (1)&amp;#160;debt prepayment or debt extinguishment costs; (2)&amp;#160;settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3)&amp;#160;contingent consideration payments made after a business combination; (4)&amp;#160;proceeds from the settlement of insurance claims; (5)&amp;#160;proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6)&amp;#160;distributions received from equity method investees; (7)&amp;#160;beneficial interests in securitization transactions; and (8)&amp;#160;separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December&amp;#160;15, 2017 for public companies, and fiscal years beginning after December&amp;#160;15, 2018 and interim periods within fiscal years beginning after December 15, 2019 for private companies, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-15 on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part&amp;#160;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&amp;#160;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in Part&amp;#160;I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2018. For all other entities, the amendments in Part&amp;#160;I of this Update are effective for fiscal years beginning after December&amp;#160;15, 2019, and interim periods within fiscal years beginning after December&amp;#160;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the FASB issued ASU 2018-02, Income Statement&amp;#8212;Reporting Comprehensive Income (Topic 220).&amp;#160;This update provides companies with the option to reclassify stranded tax effects caused by the 2017 Tax Cuts and Jobs Act (the 2017 Tax Act) from accumulated other comprehensive income to retained earnings. This standard is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU&amp;#160;2018-07,&amp;#160;Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07&amp;#160;expands the scope of Topic 718,&amp;#160;Compensation&amp;#8212;Stock Compensation, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU&amp;#160;2018-07 supersedes Subtopic&amp;#160;505-50,&amp;#160;Equity&amp;#8212;Equity-Based Payments to&amp;#160;Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December&amp;#160;15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December&amp;#160;15, 2019, and interim periods within fiscal years beginning after December&amp;#160;15, 2020. Early adoption is permitted, but no earlier than a company&amp;#8217;s adoption date of ASC 606. The Company is currently evaluating the impact that the adoption of this standard will have on the consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-E289C078E20B5828A9E509417AF7EF63">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the IPO, the Company's outstanding warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,550&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,657&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in additional paid-in-capital. In addition, warrants to purchase Series 6 Preferred Stock were converted to warrants to purchase common stock at a conversion ratio of 1:1.06.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants issued and outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows(in thousands, except share and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.91642924976259%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number&amp;#160;of &lt;br clear="none"/&gt;Shares &lt;br clear="none"/&gt;Underlying &lt;br clear="none"/&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Price&amp;#160;per &lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Warrants to purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/19/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/22/2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total outstanding common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Common stock warrants will remain outstanding until exercised by the holder.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value at the date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants issued and outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands, except share and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.335232668566%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Series&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number&amp;#160;of &lt;br clear="none"/&gt;Shares &lt;br clear="none"/&gt;Underlying &lt;br clear="none"/&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Price&amp;#160;per &lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Warrants to purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/19/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/22/2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series&amp;#160;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/1/2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/25/2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[d]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Series 5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/19/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/22/2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Series 7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total outstanding common and redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;280,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Common stock warrants will remain outstanding until exercised by the holder. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value at the date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value as of December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[d]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;These warrants will be net exercised immediately upon the closing of the Company&amp;#8217;s IPO, or upon&amp;#160;a corporate transaction as defined in the Note and Warrant Purchase Agreement dated July&amp;#160;25, 2012. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Convertible preferred stock warrants will remain outstanding until exercised by the holder and will convert to common stock warrants upon an IPO. The warrants will be exercisable for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; from the date of issuance. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with previously issued debt, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,010&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants to purchase common shares of the Company at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.96&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in July 2013. Additionally, the Company issued warrants to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,928&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.42&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;per share in November 2014. The Company determined that its warrants to purchase shares of common stock meet the requirements for equity classification.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In conjunction with debt issued in July 2012, the Company issued warrants which became exercisable for an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,917&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series 5 preferred stock of the Company at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In conjunction with debt issued in 2013 and 2014, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,983&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants to purchase Series&amp;#160;5 redeemable convertible preferred stock of the Company at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. Subsequently, the Company issued additional warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,310&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series&amp;#160;6 redeemable convertible preferred stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.47&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In conjunction with the debt agreement with SVB and Oxford, or Term Loan agreement (refer to Note 7), the Company issued warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,339&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series 6 redeemable convertible preferred stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.47&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in October 2015 and additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,283&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series 6 redeemable convertible preferred stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.47&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in November 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In conjunction with the Term Loan agreement and its modification (refer to Note 7), the Company issued additional warrants for the purchase of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,712&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series 7 redeemable convertible preferred stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.03&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in December 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2017, the Company issued a warrant to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,388&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.94&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to a consultant. The Company determined that such warrant meets the requirements for equity classification.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2017, the Company extinguished its debt with SVB and Oxford. All related debt discounts were written off upon repayment of the loan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company estimates the fair value of warrants using the Black-Scholes option valuation model. The fair value is estimated using certain assumptions. Refer to Note 11. Stock-Based Incentive Compensation Plans, for further discussions on how the Company determines these input assumptions. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of warrants to purchase preferred stock were recorded at the date of issuance as a discount to debt and amortized to interest expense over the term of the note. The changes in the fair value of the redeemable convertible preferred stock warrants are recorded in other income and expense. Weighted-average assumptions used in computation of the fair value of the redeemable convertible preferred stock warrants are summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.07882241215574%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Remaining contractual term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-77A790C870065957AD1C38E35CB5145C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Employee Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. The Company has made no contributions to the 401(k) plan since its inception.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PreferredStockTextBlock contextRef="FD2018Q4YTD" id="Fact-C3D7DCB2A9FC596F9B56D0C53937AB02">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Redeemable Convertible Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,066,654&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. There was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; preferred stock balance outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Series&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issued and &lt;br clear="none"/&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Carrying&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;text-indent:1px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liquidation&amp;#160;Value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;709,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;709,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,086,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,009,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,389,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,319,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,666,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,580,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,104,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,871,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to the conversion of redeemable preferred stock to common stock during the IPO, the holders of preferred stock had various rights and preferences as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Voting Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The holders of Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock shares were entitled to vote on all matters on which the common stockholders were entitled to vote. The holders of Series&amp;#160;1, Series 2, Series 3 had the right to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.352941&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; votes for each share of Series 2 common stock into which such preferred stock would had converted and the holders of Series 4, Series 5, Series 6 and Series 7 had the right to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; vote for each share of Series 2 common stock into which such preferred stock would had converted. As long as there were any shares of Series 4, Series 5, Series 6, and Series 7 shares that were outstanding, the holders of such Series 4, Series 5, Series 6 and Series 7, at each respective series, were entitled to elect &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; member of the Board of Directors each; the holders of Series 2 common stock were entitled to elect &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; members of the Board of Directors; and the holders of the preferred stock and Series 2 common stock, voting together as a single class were entitled to elect the remaining members of the Board of Directors, as determined at each annual meeting of the Board of Directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As long as at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277,778&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; preferred stock shares remained outstanding, the Company must obtain approval from a majority of the holders of the then outstanding shares of preferred stockholders and a majority of the voting power of all outstanding shares of Series 5 preferred stock in order to (i)&amp;#160;consummate or agree to consummate a Liquidation Event (as defined in the Company&amp;#8217;s certificate of incorporation); (ii) amend, alter, restate or repeal any provision of the Company&amp;#8217;s certificate of incorporation or bylaws so as to adversely alter, affect or change the powers, preferences, rights or privileges of the shares of preferred stock; (iii)&amp;#160;increase or decrease (other than by redemption or conversion) the total number of authorized shares of common stock or preferred stock or designated shares of any series of preferred stock; (iv)&amp;#160;authorize or issue, or obligate itself to issue, any equity security (including any other security convertible into or exercisable for any such equity security) having a preference over, or being on a parity with, any series of preferred stock with respect to dividends, liquidation or redemption, other than the issuance of any authorized but unissued shares of Series&amp;#160;6 preferred stock designated in the Company&amp;#8217;s certificate of incorporation (including any security convertible into or exercisable for such shares of preferred stock); (v) redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any share or shares of preferred stock or common stock; provided, however, that this restriction shall not apply to the repurchase of shares of common stock from employees, officers, directors, consultants or other persons performing services for the Company or any subsidiary pursuant to agreements under which the Company has the option to repurchase such shares upon the occurrence of certain events, such as the termination of employment or service, or pursuant to an agreement providing for a right of first refusal in favor of the Company, in each case, provided that such agreement has been approved by the Company&amp;#8217;s board of directors; or (vi)&amp;#160;pay or declare any dividend on any shares of capital stock of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Dividends&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The holders of preferred stock were entitled to receive noncumulative dividends, when and if declared by the Board of Directors, out of any assets legally available, prior to and in preference to any declaration or payment of dividends on the common stock of the Company. Dividend rates, on a per annum basis, for Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.050112&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.171360&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4608&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.504&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.72774&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.317744&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.802656&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, (adjusted to reflect subsequent stock dividends, stock splits or recapitalization). &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividends on preferred stock or common stock have been declared as of December&amp;#160;31, 2018 and 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the event of any liquidation, dissolution or winding-up of the Company or Liquidating Event, the holders of the preferred stock were entitled to receive prior to and in preference to any distribution to holders of the common stock, an amount equal to their respective original issuance price per share (original issuance price per share for Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6264&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.142&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.76&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.0954&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.4718&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0332&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively), plus any declared but unpaid dividends on such shares. Should the Company&amp;#8217;s legally available assets be insufficient to satisfy the full liquidation preference, the funds will be distributed ratably among the holders of the preferred stock in proportion to the preferential amount each holder is otherwise entitled to receive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon the closing of the distribution as above, the remaining proceeds shall be distributed among the holders of Series&amp;#160;4, Series&amp;#160;5, Series&amp;#160;6, Series&amp;#160;7 preferred stock and common stock pro rata based on the number of shares of common stock held by each until the holders of the preferred stock have received the &amp;#8220;participation cap.&amp;#8221; Thereafter, if proceeds remain, the holders of Series&amp;#160;7 preferred stock and common stock of this corporation shall receive all of the remaining proceeds pro rata based on the number of shares of common stock held by each (assuming full conversion of all such Series&amp;#160;7 preferred stock). The Company has a per share &amp;#8220;Participation Cap&amp;#8221; of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32.9436&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the Series&amp;#160;6 preferred stock, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.1908&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the Series&amp;#160;5 preferred stock, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.60&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the Series&amp;#160;4 preferred stock (each as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like with respect to such series of preferred stock).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Conversion&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Each share of Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock was convertible at the option of the holder, into the number of shares of Series 2 common stock into which such shares are at the then effective conversion ratio or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to one ratio. The conversion price per share for Series 1, Series 2, Series 3 and Series 4, Series 5, Series 6, and Series 7 preferred stock shall be the respective issuance price per share, respectively. The initial conversion price was subject to adjustment from time to time. In March 2017, the conversion price per share for the Series 6 preferred stock was amended from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.714&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.5574&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share which resulted in the conversion ratio increasing from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.05&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.06&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Each share of preferred stock shall be converted into common stock shares upon the earlier of (i)&amp;#160;immediately before the closing of a firm commitment underwritten public offering in which the aggregate gross proceeds of not less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a per share public offering of not less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0996&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or (ii)&amp;#160;the Company&amp;#8217;s receipt of a written request for such conversion from the holders of at least the voting majority of all outstanding preferred stock (voting as a single class and on an&amp;#160;as-converted&amp;#160;basis).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to the conversion of redeemable convertible preferred stock to common stock during the IPO, the Company has classified the preferred stock as temporary equity on the consolidated balance sheets as the shares can be redeemed upon the occurrence of certain change in control events that are outside the Company&amp;#8217;s control, including deemed liquidation, sale or transfer of the Company. The Company has not adjusted the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-DA61E4C96AC65212949821D338221073">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&amp;#160;&amp;#8211;&amp;#160;5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&amp;#160;&amp;#8211;&amp;#160;5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2018Q4YTD" id="Fact-1F78456130EF5E96BEEEB40F9AF80346">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&amp;#160;&amp;#8211;&amp;#160;5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&amp;#160;&amp;#8211;&amp;#160;5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, net&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-E4D1B457D2C15809BA3FE26AE2E5BB14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&amp;#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&amp;#8217;s operating results or change in financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-1B4D5AC5539B5192B0E288DEDEC714C9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2013, the Company granted a loan to its then current Chief Financial Officer to assist with the exercise of his stock option grants in the form of a full recourse promissory note with an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The note is collateralized by the common stock issued upon the exercise of the stock options, as well as personal assets of the borrower. Interest under this note will accrue at the rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.09%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum. In November 2016, the loan amount was partially repaid in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (including principal and interest). The remainder of the principal balance of this note, together with all accrued and unpaid interest to date, was fully paid in December 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2014, the Company granted a loan to its Chief Executive Officer to assist with the exercise of his stock option grants in the form of a full recourse promissory note with an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The note is collateralized by the common stock issued upon the exercise of the stock options, as well as personal assets of the borrower. At the time of issuance, the Company accounted for the note as a full recourse promissory note based on historical pattern of collecting payment on notes in full and no other notes had been forgiven, nor had any recourse notes been substantively converted to nonrecourse. Interest under this note will accrue at the rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.97%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum. The principal balance of this note, together with all accrued and unpaid interest to date, was due in February 2019.  In March 2017, the Company forgave &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of principal and interest due on this promissory note from its Chief Executive Officer. In addition, the Board of Directors approved the forgiveness of the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal balance of the note in January 2018. At the time of the forgiveness, all of the related stock options were fully vested. As a result, the Company expensed the principal note balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to stock-based compensation expense and accrued interest of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to general and administrative expenses in the consolidated statement of operations in the year ended December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2018Q4YTD" id="Fact-883806C9361154C2A03E4A4F0A189547">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&amp;#8217;s product which include (1)&amp;#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense (2)&amp;#160;external research and development expenses (3)&amp;#160;other expenses, which include direct and allocated expenses for facilities and other costs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="FD2018Q4YTD" id="Fact-FDAB5FBA096A5B40B3DA719CD72C4C0B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Following table summarizes the Company's revenue by geography (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.74074074074075%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,137&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;International&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
	<us-gaap:RevenueRecognitionSalesOfGoods contextRef="FD2018Q4YTD" id="Fact-A6DA6311936A5F3E8A4749BB05F5A6E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC Topic 605, Revenue Recognition (&amp;#8220;ASC 605&amp;#8221;), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company&amp;#8217;s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionSalesOfGoods>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-B5C2D1E448D65D97B026782D84EF8A4C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities and Other &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,732&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales tax payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability for early exercise of unvested stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales and warranty reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;149&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-E42D1CA50F04546F89343F71F3219E51">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,641,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74,019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Estimated ESPP shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,066,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2018Q4YTD" id="Fact-2CD6382D53FD34F12BE84C7569AF35C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of income tax expense are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current tax expense:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax expense:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,555&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-DD4CF2A1B452D41C4CD84C78BCB5D69E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.25925925925925%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;179&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accruals and reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2018Q4YTD" id="Fact-9C2C6BBADA735729BF20F125ABE1754C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;br clear="none"/&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average shares used to compute basic and diluted net loss per share*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,950,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,467,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;_________________________________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*        Calculated based on the 1-for-18 reverse stock split effected October 4, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-40046FA6C537674C746C4C761E45CD15">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax at statutory federal rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State tax, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Measurement of deferred taxes as a result of tax reform&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in deferred tax valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q4YTD" id="Fact-F35B746F51A0533CB87065883DAF7244">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the fair value of the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;[1]&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,720&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;[1]&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:21px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.51851851851852%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:33px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:1px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[1]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Included in cash and cash equivalents on the consolidated balance sheet&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-E2B2AAF9799556BDBA55368C9E67E302">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate future minimum lease payments under all leases as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,035&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,184&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="FD2018Q4YTD" id="Fact-4FA98E228344E4AAA92B4C76950646E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of the Company&amp;#8217;s loss before income taxes are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,717&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2018Q4YTD" id="Fact-8A9340BB51525AFCA9F4A576C9616565">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Approximate annual future minimum principal payments under the loan agreements as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:89%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Year Ending at, December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total future minimum payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amount representing debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,037&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total minimum payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-AFFAA76999565C3F9F041E8A2DCE9E6A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth stock-based compensation expense recognized for the periods presented (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.70370370370371%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;br clear="none"/&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;143&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales and marketing&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,471&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-BD8AAE0763D14F598F274C612F39A605">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes restricted stock units activity for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.77777777777777%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of &lt;br clear="none"/&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted- &lt;br clear="none"/&gt;Average &lt;br clear="none"/&gt;Grant Date Fair  &lt;br clear="none"/&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;"&gt;Unvested as of  December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;"&gt;Unvested as of  December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;53,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-71B844E85DF553DF80C1B42496A2C08B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option activity for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for all stock plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.25925925925927%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Contractual Remaining Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,585&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(395,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options canceled &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(65,694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balances at December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,641,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested and exercisable - December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,762,687&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested and expected to vest - December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,366,723&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-A9D8798AE86F591C8E62D64F919C3555">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The grant date fair value of the stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4074074074074%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42%-47%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42%-55%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.35%-2.96%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.73%-2.31%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The assumptions used to determine the grant date fair value of employee stock options and ESPP purchase rights for the periods presented are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.7037037037037%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43.96%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockByClassTextBlock contextRef="FD2018Q4YTD" id="Fact-9E62995C773D52D99795E64D72D850FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has reserved shares of common stock, on an issued and as-converted basis, for future issuance as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.48148148148148%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issued and &lt;br clear="none"/&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issued and &lt;br clear="none"/&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Common Stock &lt;br clear="none"/&gt;Equivalent&amp;#160;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,450,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 1 common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,112,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,112,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 2 common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;490,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;490,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,871,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,066,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,641,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares available for grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,497,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,760,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,787,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,986,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2018Q4YTD" id="Fact-150676B3803E5DF1AA905F074298DA1F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants issued and outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows(in thousands, except share and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.91642924976259%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number&amp;#160;of &lt;br clear="none"/&gt;Shares &lt;br clear="none"/&gt;Underlying &lt;br clear="none"/&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Price&amp;#160;per &lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Warrants to purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/19/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/22/2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total outstanding common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Common stock warrants will remain outstanding until exercised by the holder.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value at the date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants issued and outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands, except share and per share data): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.335232668566%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Series&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Number&amp;#160;of &lt;br clear="none"/&gt;Shares &lt;br clear="none"/&gt;Underlying &lt;br clear="none"/&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Price&amp;#160;per &lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Warrants to purchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/19/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/22/2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,010&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3/1/2027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series&amp;#160;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/1/2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/25/2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[d]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Series 5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/19/2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7/22/2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/26/2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10/20/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,339&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11/9/2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Series 7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12/22/2026&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total outstanding common and redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;280,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="1" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:100%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[a]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Common stock warrants will remain outstanding until exercised by the holder. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[b]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value at the date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[c]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Fair value as of December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[d]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;These warrants will be net exercised immediately upon the closing of the Company&amp;#8217;s IPO, or upon&amp;#160;a corporate transaction as defined in the Note and Warrant Purchase Agreement dated July&amp;#160;25, 2012. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;[e]&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Convertible preferred stock warrants will remain outstanding until exercised by the holder and will convert to common stock warrants upon an IPO. The warrants will be exercisable for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; from the date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2018Q4YTD" id="Fact-3064628313E159B97E674C7827A0C873">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The changes in the Company&amp;#8217;s uncertain income tax positions for the years ended December 31, 2018 and 2017 consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.37037037037037%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Beginning balance as of January&amp;#160;1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases in balances related to tax positions taken during 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Ending balance as of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases in balances related to tax positions taken during 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Ending balance as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-E16457244B4C58F3AEFF831FAE440511">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The chief operating decision makers for the Company are the Chief Executive Officer and Chief Financial Officer. The Chief Executive Officer and the Chief Financial Officer review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2018Q4YTD" id="Fact-E9D67266238A57AD935D5F2927BC38B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions including expected volatility, expected life, risk-free interest rate and expected dividends. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&amp;#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to nonemployees is recognized as the stock options are earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-0727F1670728503C84196ABC0E01D575">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Shipping and Handling Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shipping and handling costs are expensed as incurred and are included in cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q4YTD" id="Fact-A8E2AB6EDD4358AFA75762A8B3DAE78C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;). The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long-lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;JOBS Act Accounting Election&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The chief operating decision makers for the Company are the Chief Executive Officer and Chief Financial Officer. The Chief Executive Officer and the Chief Financial Officer review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company derives substantially all of its revenue from sales to customers in the United States. Revenue by geography is based on billing address of the customer. No single country outside the United States accounts for more than 10% of the total revenue during the periods presented. Long-lived assets held outside the United States are immaterial. Following table summarizes the Company's revenue by geography (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.74074074074075%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,137&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;International&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,632&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses resulting from the translation of the Company&amp;#8217;s consolidated balance sheets are recorded as a component of accumulated other comprehensive income. Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company&amp;#8217;s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company&amp;#8217;s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s revenue and accounts receivable are spread across a large number of customers, primarily in the United States, and no one customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors, uncertainty of market acceptance of products, and the need to obtain additional financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of and for the year ended December 31, 2018, the Company had an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$157.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and used &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of cash in operations. The Company has not achieved positive cash flow from operations to date. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, we had cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and short-term investments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$97.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company held cash and cash equivalents of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December 31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s primary cash needs are for the ongoing commercialization of its iFuse products. The Company also has certain debt covenants associated with its current debt agreement. These covenants include a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; minimum cash balance and revenue targets, which if not met would result in the debt becoming immediately due. The revenue target is assessed quarterly based on the rolling twelve months of revenue, and increases by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; each quarter. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. The Company has met the minimum liquidity and revenue targets as of December 31, 2018; however there can be no assurances that the Company will continue to meet these targets in the future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Based upon the Company's current operating plan, the Company believes that its existing cash, cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements through at least the next 12 months. The Company continues to face challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to: (a)&amp;#160;decreases in sales of our products and the uncertainty of future revenues from new products; (b)&amp;#160;changes that the Company may make to the business that affect ongoing operating expenses; (c)&amp;#160;changes that the Company may make in its business strategy; (d)&amp;#160;regulatory developments affecting the Company's existing products; (e)&amp;#160;changes that the Company may make in its research and development spending plans; and (f)&amp;#160;other items affecting the Company's forecasted level of expenditures and use of cash resources.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Carrying amounts of certain of the Company&amp;#8217;s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&amp;#8217;s long-term debt also approximates fair value based on management&amp;#8217;s estimation that a current interest rate would not differ materially from the stated rate. The carrying amount of the redeemable convertible preferred stock warrants has been marked to fair value such that the carrying amount represents its estimated fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&amp;#160;1 inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&amp;#160;3 inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s cash equivalents consist of money market funds as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The money market funds are classified as Level&amp;#160;1 of the fair value hierarchy. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy. The Company&amp;#8217;s redeemable convertible preferred stock warrants are classified within Level&amp;#160;3 of the fair value hierarchy. The redeemable convertible preferred stock warrants have been valued using a Black-Scholes valuation model and are subsequently marked to fair value at each reporting period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's marketable securities primarily consist of investments in U.S. treasury securities, corporate bonds, and commercial paper. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. Based upon maturity dates, all marketable securities as available for use in current operations, and therefore we classify these securities as current assets in the accompanying consolidated balance sheets. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in Accumulated other comprehensive income (loss) ("OCI"). We evaluate our investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in Other income (expense), net on the consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;            If quoted prices for identical instruments are available in an active market, marketable securities are classified within Level 1 of the fair value hierarchy. If quoted prices for identical instruments in active markets are not available, fair values are estimated using quoted prices of similar instruments and are classified within Level 2 of the fair value hierarchy. To date, all of the Company's marketable securities can be valued using one of these two methodologies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&amp;#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&amp;#8217;s operating results or change in financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&amp;#160;purchase costs&amp;#160;on a&amp;#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inventory consisted entirely of finished goods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&amp;#160;&amp;#8211;&amp;#160;5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&amp;#160;&amp;#8211;&amp;#160;5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset&amp;#8217;s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. Through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has not experienced impairment losses on its long-lived assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Public Offering Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Specific incremental costs (i.e. consisting of legal, accounting and other fees and costs) directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. In the event a planned IPO does not occur or is significantly delayed, all of the costs will be expensed. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; capitalized offering costs as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included in other non-current assets on the consolidated balance sheets. Costs incurred and capitalized during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; amounting to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were transferred to additional paid-in capital upon completion of the IPO on October 16, 2018. Offering costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were also incurred and expensed in the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as a result of delays in the IPO process during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&amp;#160;indexed to the entity&amp;#8217;s own stock and (ii)&amp;#160;classified in the stockholders&amp;#8217; deficit section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Redeemable Convertible Preferred Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants and other similar instruments related to shares that are contingently redeemable are classified as liabilities on the consolidated balance sheet at their estimated fair value because the shares underlying the warrants may obligate the Company to transfer assets to the holders at a future date under certain circumstances such as a deemed liquidation event. The warrants are exercisable into the Company&amp;#8217;s redeemable convertible preferred stock and are classified as liabilities on the consolidated balance sheet. The warrants, measured at fair value, are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company adjusted the liability for changes in fair value until the the closing of our initial public offering, at which time certain preferred stock warrants were converted into warrants to purchase common stock and the liability was reclassified to additional&amp;#160;paid-in&amp;#160;capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with ASC Topic 605, Revenue Recognition (&amp;#8220;ASC 605&amp;#8221;), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company&amp;#8217;s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Warranty Program&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the Company implemented a warranty program which provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period following an original procedure where an implant is not required. These one-time credits are accounted for as sales reserves. Sales and warranty reserves from the warranty program were immaterial as of both &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Medical Device Excise Tax&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the Patient Protection and Affordable Care Act, effective January&amp;#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the United States. The medical device excise tax is included in cost of goods sold in the consolidated statements of operations and comprehensive loss for all the periods presented. Effective December 2015, the Act was amended to include a provision to suspend the tax on medical devices through 2017. In January 2018, the suspension on the tax on medical devices was further extended through 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Shipping and Handling Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shipping and handling costs are expensed as incurred and are included in cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&amp;#8217;s product which include (1)&amp;#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense (2)&amp;#160;external research and development expenses (3)&amp;#160;other expenses, which include direct and allocated expenses for facilities and other costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Advertising Expenditures&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The cost of advertising is included in Sales and Marketing expense in the consolidated financial statements and expensed as incurred. Advertising costs totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions including expected volatility, expected life, risk-free interest rate and expected dividends. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&amp;#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to nonemployees is recognized as the stock options are earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. The guidance also prescribes treatment for derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Share of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company calculates basic and diluted net loss per common share attributable to shareholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock and early exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the redeemable convertible preferred stock and early exercised stock options as the holders of redeemable convertible preferred stock and early exercised stock options do not have a contractual obligation to share in losses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, redeemable convertible preferred stock and common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss represents all changes in the stockholders&amp;#8217; equity (deficit) except those resulting from distributions to stockholders. The Company&amp;#8217;s unrealized foreign currency translation income (losses) and unrealized gain (losses) of marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the guidance on the subsequent measurement of inventory, excluding inventory measured using last-in, first out or the retail inventory method. Under the new standard, in scope inventory should be measured at the lower of cost and net realizable value. The new standard will become&amp;#160;effective for fiscal years, including interim periods within those fiscal years, beginning after December&amp;#160;15, 2016, for public companies. For all other entities, the new standard is effective for fiscal years beginning after December&amp;#160;15, 2016, and interim periods within fiscal years beginning after December&amp;#160;15, 2017, with early adoption permitted. The Company has adopted this standard for the fiscal year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU 2015-17,&amp;#160;Balance Sheet Classification of Deferred Taxes. ASU 2015-17 specifies that deferred tax assets and liabilities shall be classified as non-current, or long-term, in a classified statement of financial position. The new standard is effective for public entities for fiscal years beginning after&amp;#160;December 15, 2016, and interim periods within those fiscal years. For private entities, the new standard is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within fiscal years beginning after December&amp;#160;15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or an annual reporting period. The Company has early adopted this standard for the fiscal year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU 2016-09, which simplified several aspects of accounting for stock-based compensation transactions. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new guidance is effective for public entities for fiscal years beginning after December&amp;#160;15, 2016 and interim periods within those years. Other entities must apply the new guidance in fiscal years beginning after December&amp;#160;15, 2017 and in interim periods within fiscal years beginning after December 15, 2018, with early adoption permitted. The Company early adopted this standard in the first quarter of 2017 by recording the cumulative impact of applying this guidance to retained earnings, which was not material. The Company elected to continue to&amp;#160;estimate the number of awards&amp;#160;that are expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU 2016-01. Recognition and Measurement of Financial Assets and Financial Liabilities, which amends Accounting Standards Codification, or ASC, Subtopic 825-10, Financial Instruments - Overall, and includes updates on certain aspects of recognition, measurement, presentation and disclosure of financial instruments and applies to all entities that hold financial assets or owe financial liabilities. The new standard is effective for the Company&amp;#8217;s annual period beginning after December 15, 2018, with early adoption permitted beginning after December 15, 2017. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation&amp;#8212;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for all entities for fiscal years, including interim periods within those fiscal years, beginning after December&amp;#160;15, 2017. Early adoption is permitted. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recently Issued Accounting Standards Not Yet Effective&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May&amp;#160;2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S.&amp;#160;GAAP when it becomes effective. The new standard is effective for fiscal years beginning after December&amp;#160;15, 2017 for public companies, and for fiscal years beginning after December&amp;#160;15, 2018, and interim periods beginning after December&amp;#160;15, 2019, for private companies. Early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. In March&amp;#160;2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April&amp;#160;2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May&amp;#160;2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date as ASU&amp;#160;2014-09. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company continues to evaluate the impacts of adoption of the new standard on its accounting policies, processes, and system requirements and has assigned internal resources, in addition to the engagement of third party service providers, to assist in the evaluation.&amp;#160;At this time, as  it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or other medical facilities, the Company expects revenue to continue to be recognized upon completion of the procedure&amp;#160;and authorization by the customer. Additionally, the new standard requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company expects to continue expensing all sales commissions as incurred. Management will adopt the standard using the modified retrospective method for the fiscal year ending December&amp;#160;31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued its new lease accounting guidance. Under the new guidance, ASU 2016-02, Leases (Topic 842), lessor accounting is largely unchanged. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Under the new guidance, lessees will be required to recognize a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date. The new guidance is effective for fiscal years, and for interim periods within those fiscal years, beginning after December&amp;#160;15, 2018 for public companies and beginning after December&amp;#160;15, 2019 for private companies. Early adoption is permitted for any interim or annual financial statements net yet issued. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing and operating leases) must apply a modified retrospective approach for all leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2016, the FASB issued ASU 2016-15 &amp;#8220;Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments&amp;#8221;. ASU 2016-15 provides guidance on the following eight specific cash flow classification issues: (1)&amp;#160;debt prepayment or debt extinguishment costs; (2)&amp;#160;settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3)&amp;#160;contingent consideration payments made after a business combination; (4)&amp;#160;proceeds from the settlement of insurance claims; (5)&amp;#160;proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6)&amp;#160;distributions received from equity method investees; (7)&amp;#160;beneficial interests in securitization transactions; and (8)&amp;#160;separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December&amp;#160;15, 2017 for public companies, and fiscal years beginning after December&amp;#160;15, 2018 and interim periods within fiscal years beginning after December 15, 2019 for private companies, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-15 on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part&amp;#160;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&amp;#160;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in Part&amp;#160;I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2018. For all other entities, the amendments in Part&amp;#160;I of this Update are effective for fiscal years beginning after December&amp;#160;15, 2019, and interim periods within fiscal years beginning after December&amp;#160;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the FASB issued ASU 2018-02, Income Statement&amp;#8212;Reporting Comprehensive Income (Topic 220).&amp;#160;This update provides companies with the option to reclassify stranded tax effects caused by the 2017 Tax Cuts and Jobs Act (the 2017 Tax Act) from accumulated other comprehensive income to retained earnings. This standard is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&amp;#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the FASB issued ASU&amp;#160;2018-07,&amp;#160;Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07&amp;#160;expands the scope of Topic 718,&amp;#160;Compensation&amp;#8212;Stock Compensation, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU&amp;#160;2018-07 supersedes Subtopic&amp;#160;505-50,&amp;#160;Equity&amp;#8212;Equity-Based Payments to&amp;#160;Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December&amp;#160;15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December&amp;#160;15, 2019, and interim periods within fiscal years beginning after December&amp;#160;15, 2020. Early adoption is permitted, but no earlier than a company&amp;#8217;s adoption date of ASC 606. The Company is currently evaluating the impact that the adoption of this standard will have on the consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StandardProductWarrantyPolicy contextRef="FD2018Q4YTD" id="Fact-E1C883BB6C3A5C3A8F7ABC350B41D94E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Warranty Program&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the Company implemented a warranty program which provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period following an original procedure where an implant is not required. These one-time credits are accounted for as sales reserves.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-991A2C9C393558228DEFA532681D4938">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2017, the Board of Directors approved an increase of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;555,555&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series&amp;#160;2 common stock. As a result, the Company&amp;#8217;s restated certificate of incorporation, as amended, authorizes the Company to issue &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,333,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; par value common stock, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been designated as Series 1 common stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,333,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been designated as Series 2 common stock. The holders of Series 1 common stock shall have no voting rights; the holders of Series 2 common stock shall have the right to one vote for each such share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Company amended and restated its certification of incorporation, which authorizes the Company to issue &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock, each having a par value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. At December 31, 2018, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; preferred stock issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividends declared to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has reserved shares of common stock, on an issued and as-converted basis, for future issuance as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.48148148148148%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:9px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issued and &lt;br clear="none"/&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issued and &lt;br clear="none"/&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Common Stock &lt;br clear="none"/&gt;Equivalent&amp;#160;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,450,757&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 1 common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,112,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,112,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 2 common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;490,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;490,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,871,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,066,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,436&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,641,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shares available for grant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,497,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,550&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;160,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,760,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,787,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,986,360&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-286940768CEA51A39DC02FF56F655A64">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Public Offering Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Specific incremental costs (i.e. consisting of legal, accounting and other fees and costs) directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. In the event a planned IPO does not occur or is significantly delayed, all of the costs will be expensed.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
	<us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="FD2018Q4YTD" id="Fact-B0FD5648075748C96DB778D543F88368">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes changes in the valuation allowance for the year ended December 31, 2018 and 2017 (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,348&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions during the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deductions during the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,412&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,835&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-6E9F317AF71F5310BA40761F732DCED1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance Sheet Components&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment, net&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,428&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,896&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities and Other &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"&gt;&lt;div style="text-align:center;padding-left:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and related expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,732&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales tax payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;466&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability for early exercise of unvested stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Sales and warranty reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;149&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,724&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:TemporaryEquityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-C928FE5F42A35D0C83EA741CBA038EDD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred stock at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Series&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Issued and &lt;br clear="none"/&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Carrying&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;text-indent:1px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liquidation&amp;#160;Value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;245,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;154&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;709,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;709,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;498,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,509,032&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,086,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,009,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,389,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,319,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series 7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,666,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,580,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,104,749&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,871,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q4YTD" id="Fact-26135CABF45C5AE296B6289A247E101D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long-lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sibn-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://si-bone.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sibn="http://si-bone.com/20181231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sibn-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheetComponents" roleURI="http://si-bone.com/role/BalanceSheetComponents">
        <link:definition>2105100 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails">
        <link:definition>2405403 - Disclosure - Balance Sheet Components - Accrued Liabilities and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsPropertyAndEquipmentNetDetails" roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails">
        <link:definition>2405402 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://si-bone.com/role/BalanceSheetComponentsTables">
        <link:definition>2305301 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://si-bone.com/role/Borrowings">
        <link:definition>2107100 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails">
        <link:definition>2407403 - Disclosure - Borrowings - Annual Future Minimum Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsEbitdaTargetsDetails" roleURI="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails">
        <link:definition>2407404 - Disclosure - Borrowings - EBITDA Targets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails">
        <link:definition>2407402 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://si-bone.com/role/BorrowingsTables">
        <link:definition>2307301 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://si-bone.com/role/CommitmentsAndContingencies">
        <link:definition>2106100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" roleURI="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails">
        <link:definition>2406403 - Disclosure - Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://si-bone.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2306301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://si-bone.com/role/CommonStock">
        <link:definition>2110100 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockNarrativeDetails" roleURI="http://si-bone.com/role/CommonStockNarrativeDetails">
        <link:definition>2410402 - Disclosure - Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesOfStockIssuedAndReservedDetails" roleURI="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails">
        <link:definition>2410403 - Disclosure - Common Stock - Shares of Stock Issued and Reserved (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://si-bone.com/role/CommonStockTables">
        <link:definition>2310301 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyAndNatureOfBusiness" roleURI="http://si-bone.com/role/CompanyAndNatureOfBusiness">
        <link:definition>2101100 - Disclosure - The Company and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyAndNatureOfBusinessDetails" roleURI="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails">
        <link:definition>2401401 - Disclosure - The Company and Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://si-bone.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://si-bone.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://si-bone.com/role/EmployeeBenefitPlan">
        <link:definition>2112100 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://si-bone.com/role/FairValueMeasurement">
        <link:definition>2104100 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2404402 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" roleURI="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails">
        <link:definition>2404403 - Disclosure - Fair Value Measurement - Changes in Redeemable Convertible Preferred Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://si-bone.com/role/FairValueMeasurementTables">
        <link:definition>2304301 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://si-bone.com/role/IncomeTaxes">
        <link:definition>2115100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesInValuationAllowanceDetails" roleURI="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails">
        <link:definition>2415406 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfIncomeTaxExpenseDetails" roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails">
        <link:definition>2415403 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails">
        <link:definition>2415402 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2415408 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" roleURI="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails">
        <link:definition>2415404 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://si-bone.com/role/IncomeTaxesTables">
        <link:definition>2315301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails">
        <link:definition>2415405 - Disclosure - Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUncertainIncomeTaxPositionsDetails" roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails">
        <link:definition>2415407 - Disclosure - Income Taxes - Uncertain Income Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://si-bone.com/role/MarketableSecurities">
        <link:definition>2103100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://si-bone.com/role/MarketableSecuritiesDetails">
        <link:definition>2403402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://si-bone.com/role/MarketableSecuritiesTables">
        <link:definition>2303301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareOfCommonStock" roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStock">
        <link:definition>2114100 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails">
        <link:definition>2414403 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails">
        <link:definition>2414402 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareOfCommonStockTables" roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockTables">
        <link:definition>2314301 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2108100 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockIpoNarrativeDetails" roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails">
        <link:definition>2408402 - Disclosure - Redeemable Convertible Preferred Stock - IPO Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockPreferredStockDetails" roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails">
        <link:definition>2408403 - Disclosure - Redeemable Convertible Preferred Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockTables" roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables">
        <link:definition>2308301 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://si-bone.com/role/RelatedPartyTransactions">
        <link:definition>2113100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2413401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlans" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlans">
        <link:definition>2111100 - Disclosure - Stock-Based Incentive Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails">
        <link:definition>2411407 - Disclosure - Stock-Based Incentive Compensation Plans - Employee Stock Options and ESPP Purchase Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansNarrativeDetails" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails">
        <link:definition>2411402 - Disclosure - Stock-Based Incentive Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails">
        <link:definition>2411406 - Disclosure - Stock-Based Incentive Compensation Plans - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails">
        <link:definition>2411404 - Disclosure - Stock-Based Incentive Compensation Plans - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansStockOptionActivityDetails" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails">
        <link:definition>2411403 - Disclosure - Stock-Based Incentive Compensation Plans - Stock Option Activity  (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansTables" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables">
        <link:definition>2311301 - Disclosure - Stock-Based Incentive Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails">
        <link:definition>2411405 - Disclosure - Stock-Based Incentive Compensation Plans - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails">
        <link:definition>2402409 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesLiquidityDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Public Offering Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRevenuesDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails">
        <link:definition>2402408 - Disclosure - Summary of Significant Accounting Policies - Warranty Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://si-bone.com/role/Warrants">
        <link:definition>2109100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsIpoNarrativeDetails" roleURI="http://si-bone.com/role/WarrantsIpoNarrativeDetails">
        <link:definition>2409402 - Disclosure - Warrants - IPO Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsIssuedAndOutstandingDetails" roleURI="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails">
        <link:definition>2409403 - Disclosure - Warrants - Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://si-bone.com/role/WarrantsTables">
        <link:definition>2309301 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" roleURI="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails">
        <link:definition>2409404 - Disclosure - Warrants - Weighted-Average Assumptions in Computation of Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="sibn_A2008StockOptionPlanMember" name="A2008StockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_A2018EmployeeStockPurchasePlanMember" name="A2018EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_A2018EquityIncentivePlanMember" name="A2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions" name="AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted" name="AdjustmentstoAdditionalPaidinCapitalWarrantConverted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights" name="ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_CommonStockEquivalentSharesStockOptionsOutstanding" name="CommonStockEquivalentSharesStockOptionsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect" name="CommonStockSeriesTwoNumberOfDirectorsEntitledToElect" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod" name="CommonStockSharesAuthorizedIncreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion" name="ConvertiblePreferredStockMinimumPublicOfferingForConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion" name="ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock" name="DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount" name="DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_DebtCovenantPeriodAxis" name="DebtCovenantPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_DebtCovenantPeriodDomain" name="DebtCovenantPeriodDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA" name="DebtCovenantTrailing12MonthConsolidatedEBITDA" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_DebtInstrumentClosingFeePercentage" name="DebtInstrumentClosingFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_DebtInstrumentCovenantMinimumCashBalance" name="DebtInstrumentCovenantMinimumCashBalance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" name="DebtInstrumentPeriodicPaymentInterestOnlyPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod" name="DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_DebtInstrumentPrepaymentPenaltyPercentage" name="DebtInstrumentPrepaymentPenaltyPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sibn_DebtPrepaymentPenaltyPeriodAxis" name="DebtPrepaymentPenaltyPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_DebtPrepaymentPenaltyPeriodDomain" name="DebtPrepaymentPenaltyPeriodDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" name="DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sibn_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_EmployeeStockPurchasePlanSharesMember" name="EmployeeStockPurchasePlanSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance" name="EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance" name="EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sibn_ForgivenessOfRelatedPartyPromissoryNoteMember" name="ForgivenessOfRelatedPartyPromissoryNoteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_IncentiveStockOptionMember" name="IncentiveStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_IncomeTaxesValuationAllowanceRollForward" name="IncomeTaxesValuationAllowanceRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate" name="IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_InitialPublicOfferingCostsIncurredButNotYetPaid" name="InitialPublicOfferingCostsIncurredButNotYetPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_LiabilityForEarlyExerciseOfOptionsCurrent" name="LiabilityForEarlyExerciseOfOptionsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable" name="LineOfCreditFacilityPercentOfCustomerAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" name="MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sibn_MarketableSecuritiesAmortizedCost" name="MarketableSecuritiesAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sibn_MarketableSecuritiesFairValue" name="MarketableSecuritiesFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" name="MedicalDeviceExciseTaxPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_NetExerciseofCommonWarrants" name="NetExerciseofCommonWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_NonqualifiedStockOptionMember" name="NonqualifiedStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_NotesReceivableForgiveness" name="NotesReceivableForgiveness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_OfferingCostsExpensed" name="OfferingCostsExpensed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_OperatingLossCarryforwardsLimited" name="OperatingLossCarryforwardsLimited" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sibn_PeriodFiveMember" name="PeriodFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PeriodFourMember" name="PeriodFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PeriodOneMember" name="PeriodOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PeriodSevenMember" name="PeriodSevenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PeriodSixMember" name="PeriodSixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PeriodThreeMember" name="PeriodThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PeriodTwoMember" name="PeriodTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PharmakonTermLoanMember" name="PharmakonTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_PreferredStockNumberOfDirectorsEntitledToElect" name="PreferredStockNumberOfDirectorsEntitledToElect" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_PreferredStockWarrantLiability" name="PreferredStockWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="sibn_PrepaymentPenalty3148MonthsMember" name="PrepaymentPenalty3148MonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_PrepaymentPenalty4960MonthsMember" name="PrepaymentPenalty4960MonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven" name="ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness" name="ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_RedeemableConvertiblePreferredStockWarrantsMember" name="RedeemableConvertiblePreferredStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_RevenueTargetQuarterlyIncreasePercentage" name="RevenueTargetQuarterlyIncreasePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_SVBAndOxfordTermLoanMember" name="SVBAndOxfordTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_SalesAndProductWarrantyAccrualCurrent" name="SalesAndProductWarrantyAccrualCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sibn_SalesCreditReservePeriod" name="SalesCreditReservePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_SanJoseCaliforniaMember" name="SanJoseCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_SantaClaraCaliforniaMember" name="SantaClaraCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_ShareSubjectToRepurchaseMember" name="ShareSubjectToRepurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_StandardProductWarrantyTerm" name="StandardProductWarrantyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised" name="StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised" name="StockIssuedDuringPeriodValueUnvestedStockOptionsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_StockOptionsandESPPPurchaseRightsMember" name="StockOptionsandESPPPurchaseRightsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" name="StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" name="StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt" name="StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived" name="StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares" name="TemporaryEquityCommonStockEquivalentSharesIfConvertedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares" name="TemporaryEquityConversionOfTemporaryEquityToEquityShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue" name="TemporaryEquityConversionOfTemporaryEquityToEquityValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_TemporaryEquityLiquidationParticipationCapPerShare" name="TemporaryEquityLiquidationParticipationCapPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_TemporaryEquityRightsToVotesForEachShare" name="TemporaryEquityRightsToVotesForEachShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding" name="TemporaryEquityShareholderApprovalMinimumSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_VestingOfEarlyExercisedStockOptions" name="VestingOfEarlyExercisedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="sibn_WarrantsClassifiedAsEquityPolicyTextBlock" name="WarrantsClassifiedAsEquityPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" name="WarrantsClassifiedAsLiabilitiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_WarrantsConversionRatio" name="WarrantsConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" name="WarrantsIssuedDecemberTwentySecondTwentySixteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedJulyFirstTwentyTwelveMember" name="WarrantsIssuedJulyFirstTwentyTwelveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember" name="WarrantsIssuedJulyNineteenthTwentyThirteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" name="WarrantsIssuedMarchFirstTwentySeventeenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" name="WarrantsIssuedNovemberNinthTwentyFifteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" name="WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" name="WarrantsIssuedOctoberTwentiethTwentyFifteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="sibn_WarrantsLiabilityMember" name="WarrantsLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" name="WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="sibn_WriteOffOfDebtDiscount" name="WriteOffOfDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="sibn_WriteOffOfInitialPublicOfferingCosts" name="WriteOffOfInitialPublicOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sibn-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponents" xlink:href="sibn-20181231.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/Borrowings" xlink:href="sibn-20181231.xsd#Borrowings" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:href="sibn-20181231.xsd#BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails" xlink:href="sibn-20181231.xsd#BorrowingsEbitdaTargetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:href="sibn-20181231.xsd#BorrowingsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsTables" xlink:href="sibn-20181231.xsd#BorrowingsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingencies" xlink:href="sibn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesTables" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStock" xlink:href="sibn-20181231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockNarrativeDetails" xlink:href="sibn-20181231.xsd#CommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails" xlink:href="sibn-20181231.xsd#CommonStockSharesOfStockIssuedAndReservedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockTables" xlink:href="sibn-20181231.xsd#CommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CompanyAndNatureOfBusiness" xlink:href="sibn-20181231.xsd#CompanyAndNatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails" xlink:href="sibn-20181231.xsd#CompanyAndNatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedBalanceSheets" xlink:href="sibn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="sibn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/DocumentAndEntityInformation" xlink:href="sibn-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlan" xlink:href="sibn-20181231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurement" xlink:href="sibn-20181231.xsd#FairValueMeasurement" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="sibn-20181231.xsd#FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:href="sibn-20181231.xsd#FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementTables" xlink:href="sibn-20181231.xsd#FairValueMeasurementTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxes" xlink:href="sibn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesChangesInValuationAllowanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTables" xlink:href="sibn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecurities" xlink:href="sibn-20181231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:href="sibn-20181231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesTables" xlink:href="sibn-20181231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStock" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockTables" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStock" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactions" xlink:href="sibn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:href="sibn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlans" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/Warrants" xlink:href="sibn-20181231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIpoNarrativeDetails" xlink:href="sibn-20181231.xsd#WarrantsIpoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails" xlink:href="sibn-20181231.xsd#WarrantsIssuedAndOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsTables" xlink:href="sibn-20181231.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:href="sibn-20181231.xsd#WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_246557bf-247d-ae14-75c6-f807977be209" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_246557bf-247d-ae14-75c6-f807977be209" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LiabilityForEarlyExerciseOfOptionsCurrent" xlink:label="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_86376D6909F4037CC3591D04B678D798" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_86376D6909F4037CC3591D04B678D798" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SalesAndProductWarrantyAccrualCurrent" xlink:label="loc_sibn_SalesAndProductWarrantyAccrualCurrent_80F0C96C394715D7F8B61D13E15BC3C6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_sibn_SalesAndProductWarrantyAccrualCurrent_80F0C96C394715D7F8B61D13E15BC3C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6931594C444A5AE6A6848017644E3361" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0D8FE70E6A8D5920A092DBCEFFC81181" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6931594C444A5AE6A6848017644E3361" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0D8FE70E6A8D5920A092DBCEFFC81181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_569A54EF2E3559B399C5BCACCBA9823A" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6931594C444A5AE6A6848017644E3361" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_569A54EF2E3559B399C5BCACCBA9823A" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/Borrowings" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_88b8f1df-ff6f-5cd6-e45f-5878f70c11d5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_450782c6-2839-854f-cd33-795c87a08ecc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_450782c6-2839-854f-cd33-795c87a08ecc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/BorrowingsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_303e0947-c299-2fc2-37ba-ef22b7b93517" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_303e0947-c299-2fc2-37ba-ef22b7b93517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommonStockNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CommonStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CompanyAndNatureOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PreferredStockWarrantLiability" xlink:label="loc_sibn_PreferredStockWarrantLiability_F9831C65FB4DA268E3A853C451987815" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_sibn_PreferredStockWarrantLiability_F9831C65FB4DA268E3A853C451987815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_812aff88-265a-55f7-439e-e51eedec6492" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_812aff88-265a-55f7-439e-e51eedec6492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_6d9fa272-75a9-735f-4833-24b064c3a10a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_6d9fa272-75a9-735f-4833-24b064c3a10a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2d563f7c-9c66-4ccb-995c-599c680a5434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef1b7738-192b-a4ca-6396-5577f303c271" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef1b7738-192b-a4ca-6396-5577f303c271" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WriteOffOfDebtDiscount" xlink:label="loc_sibn_WriteOffOfDebtDiscount_1375C36365E85CD60DDB1DC37DA44766" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_sibn_WriteOffOfDebtDiscount_1375C36365E85CD60DDB1DC37DA44766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d883e212-a0a2-0f3a-80cd-5a5472a7f783" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d883e212-a0a2-0f3a-80cd-5a5472a7f783" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WriteOffOfInitialPublicOfferingCosts" xlink:label="loc_sibn_WriteOffOfInitialPublicOfferingCosts_BA8EDED229F0378C8EDF1DC60DD5A2D1" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_sibn_WriteOffOfInitialPublicOfferingCosts_BA8EDED229F0378C8EDF1DC60DD5A2D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_ed4807ab-a990-836b-0ec5-7ba4ff35842d" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_ed4807ab-a990-836b-0ec5-7ba4ff35842d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f3832d5-e2fd-470b-5e04-ece38e7ab02d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="14" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee3fb709-d548-2ee3-f8d1-e07a929829cb" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee3fb709-d548-2ee3-f8d1-e07a929829cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_678cc0a1-75a1-b1b0-39a1-094379144ce2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_678cc0a1-75a1-b1b0-39a1-094379144ce2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_71e2708d-dbed-a2d2-c337-422e8e94c78c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_71e2708d-dbed-a2d2-c337-422e8e94c78c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfa1e746-5920-c3b5-33ed-a7dee018f26c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_204acd11-57b2-232a-d32d-d0824032cd6a" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_204acd11-57b2-232a-d32d-d0824032cd6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_60ab1096-bf53-5d61-76bd-431fe857fc03" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_60ab1096-bf53-5d61-76bd-431fe857fc03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6accd1a2-f190-7888-29dd-29802af49bdc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6accd1a2-f190-7888-29dd-29802af49bdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_007d9109-9595-5f2c-7482-78ac7c9eb888" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_007d9109-9595-5f2c-7482-78ac7c9eb888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ea422513-12bd-029b-0166-7c34286633bc" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ea422513-12bd-029b-0166-7c34286633bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_df00e688-c7aa-f044-9cba-c48e7c14e35b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_334a0036-49ae-85df-fa8d-a7de18d975ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_SellingAndMarketingExpense_334a0036-49ae-85df-fa8d-a7de18d975ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c7333cca-378d-a6fc-ae13-b512babfcdeb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_c7333cca-378d-a6fc-ae13-b512babfcdeb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_29b707e4-876d-47bd-8655-71c027f42964" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_29b707e4-876d-47bd-8655-71c027f42964" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:label="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_19B275CFB25865F0FC1853F27D3E6429" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_19B275CFB25865F0FC1853F27D3E6429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_19B275CFB25865F0FC1853F27D3E6429" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5c1aec47-de9f-ce8d-f168-ced9011d51ba" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_19B275CFB25865F0FC1853F27D3E6429" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5c1aec47-de9f-ce8d-f168-ced9011d51ba" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8cc5c29a-fc27-b861-be5d-a8aecede9ea0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8cc5c29a-fc27-b861-be5d-a8aecede9ea0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_CB13F2393AF4A661D592541736A83F28" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_CB13F2393AF4A661D592541736A83F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3e8259e4-f50c-f014-e08e-1363b80d4e32" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3e8259e4-f50c-f014-e08e-1363b80d4e32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/MarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAmortizedCost" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_30865C7EBDF4BCC5AD274FE770E97E92" xlink:type="locator" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49437074224F97401EA34FEAF6E71EC9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_30865C7EBDF4BCC5AD274FE770E97E92" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49437074224F97401EA34FEAF6E71EC9" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C9EE2A0FD961FC236D654FEBB1E78939" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_30865C7EBDF4BCC5AD274FE770E97E92" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C9EE2A0FD961FC236D654FEBB1E78939" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesFairValue" xlink:label="loc_sibn_MarketableSecuritiesFairValue_1F81A1E8B17EB48253D64FE9AFBC284F" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_30865C7EBDF4BCC5AD274FE770E97E92" xlink:to="loc_sibn_MarketableSecuritiesFairValue_1F81A1E8B17EB48253D64FE9AFBC284F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d23fa7e-7f76-6507-b72f-382f81b88e34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e0f935d0-20e2-15fc-55a1-79c116fbc07c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/Warrants" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/WarrantsIpoNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/WarrantsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sibn-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponents" xlink:href="sibn-20181231.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/Borrowings" xlink:href="sibn-20181231.xsd#Borrowings" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:href="sibn-20181231.xsd#BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails" xlink:href="sibn-20181231.xsd#BorrowingsEbitdaTargetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:href="sibn-20181231.xsd#BorrowingsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsTables" xlink:href="sibn-20181231.xsd#BorrowingsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingencies" xlink:href="sibn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesTables" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStock" xlink:href="sibn-20181231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockNarrativeDetails" xlink:href="sibn-20181231.xsd#CommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails" xlink:href="sibn-20181231.xsd#CommonStockSharesOfStockIssuedAndReservedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockTables" xlink:href="sibn-20181231.xsd#CommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CompanyAndNatureOfBusiness" xlink:href="sibn-20181231.xsd#CompanyAndNatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails" xlink:href="sibn-20181231.xsd#CompanyAndNatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedBalanceSheets" xlink:href="sibn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="sibn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/DocumentAndEntityInformation" xlink:href="sibn-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlan" xlink:href="sibn-20181231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurement" xlink:href="sibn-20181231.xsd#FairValueMeasurement" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="sibn-20181231.xsd#FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:href="sibn-20181231.xsd#FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementTables" xlink:href="sibn-20181231.xsd#FairValueMeasurementTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxes" xlink:href="sibn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesChangesInValuationAllowanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTables" xlink:href="sibn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecurities" xlink:href="sibn-20181231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:href="sibn-20181231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesTables" xlink:href="sibn-20181231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStock" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockTables" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStock" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactions" xlink:href="sibn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:href="sibn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlans" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/Warrants" xlink:href="sibn-20181231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIpoNarrativeDetails" xlink:href="sibn-20181231.xsd#WarrantsIpoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails" xlink:href="sibn-20181231.xsd#WarrantsIssuedAndOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsTables" xlink:href="sibn-20181231.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:href="sibn-20181231.xsd#WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D7BD57F15BD5EA950266571F92B43941_6E54C67D88E95831A5B374BA9B31F907" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D7BD57F15BD5EA950266571F92B43941_6E54C67D88E95831A5B374BA9B31F907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ComputerAndOfficeEquipmentMember" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/Borrowings" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:to="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodAxis" xlink:label="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:to="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodDomain" xlink:label="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:to="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E_default" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodDomain" xlink:label="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:to="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodOneMember" xlink:label="loc_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodTwoMember" xlink:label="loc_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodThreeMember" xlink:label="loc_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodFourMember" xlink:label="loc_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodFiveMember" xlink:label="loc_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodSixMember" xlink:label="loc_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodSevenMember" xlink:label="loc_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount" xlink:label="loc_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:to="loc_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA" xlink:label="loc_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:to="loc_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="loc_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="loc_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="loc_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:to="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:to="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SVBAndOxfordTermLoanMember" xlink:label="loc_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:to="loc_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PharmakonTermLoanMember" xlink:label="loc_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:to="loc_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:to="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:to="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:to="loc_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069_default" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PrepaymentPenalty3148MonthsMember" xlink:label="loc_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:to="loc_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PrepaymentPenalty4960MonthsMember" xlink:label="loc_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:to="loc_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentClosingFeePercentage" xlink:label="loc_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable" xlink:label="loc_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/BorrowingsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:to="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:to="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:to="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SanJoseCaliforniaMember" xlink:label="loc_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:to="loc_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SantaClaraCaliforniaMember" xlink:label="loc_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:to="loc_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:to="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:to="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaap_NonvotingCommonStockMember_1BA35C91E6A8549AA1A26E6A3F4120FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:to="loc_us-gaap_NonvotingCommonStockMember_1BA35C91E6A8549AA1A26E6A3F4120FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_A3558C43FAE29B7C4AD16E6A3F42B7C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:to="loc_us-gaap_CommonClassAMember_A3558C43FAE29B7C4AD16E6A3F42B7C3" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod" xlink:label="loc_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_AEAB286CB6CFC06A4BB36E6A3F42A7BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_AEAB286CB6CFC06A4BB36E6A3F42A7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7F0EC44FC62760D6E5396E6A3F43F204" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7F0EC44FC62760D6E5396E6A3F43F204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4D681658FE08682002AF6E6A3F43892D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4D681658FE08682002AF6E6A3F43892D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DA3DBC645C32ED5DDD486E6A3F43115D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DA3DBC645C32ED5DDD486E6A3F43115D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D1B8230B2A003AA7E31F6E8095A99A84" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D1B8230B2A003AA7E31F6E8095A99A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2A32ECFD8422FB501E016E810B6150A6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2A32ECFD8422FB501E016E810B6150A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:to="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_98BBEBC07576056FD8514F2E4D0778F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_98BBEBC07576056FD8514F2E4D0778F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:to="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:to="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:to="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:to="loc_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:to="loc_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_D72D2547F44E8D3997724EFE1A71445B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_D72D2547F44E8D3997724EFE1A71445B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_911819D7B815FD9510D74EFE1A7251EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_911819D7B815FD9510D74EFE1A7251EF" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares" xlink:label="loc_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockEquivalentSharesStockOptionsOutstanding" xlink:label="loc_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C63C55AAC0B1C0C979B34EFE1A72D044" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C63C55AAC0B1C0C979B34EFE1A72D044" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights" xlink:label="loc_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance" xlink:label="loc_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance" xlink:label="loc_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/CommonStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CompanyAndNatureOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_0D854EE662BAB2444E5049CA52140BFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254" xlink:to="loc_sibn_WarrantsLiabilityMember_0D854EE662BAB2444E5049CA52140BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:to="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:to="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_B079439337D6B78E1CE149CA5215400E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_B079439337D6B78E1CE149CA5215400E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_D21F2E5B2106E7B1DFAE49CA52150927" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:to="loc_us-gaap_CommonClassAMember_D21F2E5B2106E7B1DFAE49CA52150927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:to="loc_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" xlink:label="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:to="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:to="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:to="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares" xlink:label="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue" xlink:label="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted" xlink:label="loc_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived" xlink:label="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt" xlink:label="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions" xlink:label="loc_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurement" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:to="loc_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_OperatingLossCarryforwardsLimited" xlink:label="loc_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate" xlink:label="loc_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/MarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:to="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_E5053ECECF6533AF52DE6D433F3FFF77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_E5053ECECF6533AF52DE6D433F3FFF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_85396A5A0F9720BADB1C6D433F3F2879" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_85396A5A0F9720BADB1C6D433F3F2879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_38EA44E3EF070F83F61C6D433F406D73" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_CommercialPaperMember_38EA44E3EF070F83F61C6D433F406D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2F0D746EA3D8B4917FE26D433F40BA35" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2F0D746EA3D8B4917FE26D433F40BA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAmortizedCost" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesFairValue" xlink:label="loc_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareSubjectToRepurchaseMember" xlink:label="loc_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EmployeeStockPurchasePlanSharesMember" xlink:label="loc_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="loc_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockWarrantsMember" xlink:label="loc_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:to="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:to="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_4E2F51502CFAFFA09B307869650F187A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_4E2F51502CFAFFA09B307869650F187A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_267DDB10D98627AF801D7869650F6C16" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_267DDB10D98627AF801D7869650F6C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_E3AED4854D8C6A645F287869650F93E4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_E3AED4854D8C6A645F287869650F93E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityRightsToVotesForEachShare" xlink:label="loc_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PreferredStockNumberOfDirectorsEntitledToElect" xlink:label="loc_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect" xlink:label="loc_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding" xlink:label="loc_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityLiquidationParticipationCapPerShare" xlink:label="loc_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockConversionPrice" xlink:label="loc_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion" xlink:label="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion" xlink:label="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:to="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:to="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ForgivenessOfRelatedPartyPromissoryNoteMember" xlink:label="loc_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:to="loc_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven" xlink:label="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness" xlink:label="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:to="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockOptionsandESPPPurchaseRightsMember" xlink:label="loc_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:to="loc_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:to="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:to="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2008StockOptionPlanMember" xlink:label="loc_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="loc_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2018EquityIncentivePlanMember" xlink:label="loc_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="loc_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="loc_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncentiveStockOptionMember" xlink:label="loc_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NonqualifiedStockOptionMember" xlink:label="loc_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4F49735BE78A7375C29678FFDE597BCE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4F49735BE78A7375C29678FFDE597BCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_09A72ECC8093412D5D8C78FFDE598496" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_09A72ECC8093412D5D8C78FFDE598496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:to="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:to="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:to="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:to="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_94E59053F329CDF4FFEA78FFDE5BE904" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:to="loc_srt_MinimumMember_94E59053F329CDF4FFEA78FFDE5BE904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0D39934BBD82CD7BE49878FFDE5B6D42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:to="loc_srt_MaximumMember_0D39934BBD82CD7BE49878FFDE5B6D42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:to="loc_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LiabilityForEarlyExerciseOfOptionsCurrent" xlink:label="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NotesReceivableForgiveness" xlink:label="loc_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E5E79933F3F5DAC4AE278FFDE5FCE16" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E5E79933F3F5DAC4AE278FFDE5FCE16" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:to="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9D3E28C3B0CCD0670BF78FFDE369C5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9D3E28C3B0CCD0670BF78FFDE369C5B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:to="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CAB3029EB3250DB3E3FE78FFDE347573" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CAB3029EB3250DB3E3FE78FFDE347573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EB8FB209F6A48EA38C2678FFDE36415F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9D3E28C3B0CCD0670BF78FFDE369C5B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EB8FB209F6A48EA38C2678FFDE36415F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D65918F0D84F8A7615A278FFDE2C04CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D65918F0D84F8A7615A278FFDE2C04CC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:to="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308" xlink:to="loc_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D65918F0D84F8A7615A278FFDE2C04CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2BC26AECE65565E841B978FFDE2C04A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2BC26AECE65565E841B978FFDE2C04A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EEFB6C134544C11E555C78FFDE2D8F55" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EEFB6C134544C11E555C78FFDE2D8F55" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:to="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:to="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:to="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:to="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_39D6BAA6442AB22E37F578710EE0A8EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:to="loc_srt_MinimumMember_39D6BAA6442AB22E37F578710EE0A8EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_679A3771E429598FB6127871DC97B13D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:to="loc_srt_MaximumMember_679A3771E429598FB6127871DC97B13D" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_RevenueTargetQuarterlyIncreasePercentage" xlink:label="loc_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:to="loc_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4076FA32E26B94032259372B28E06C7E_6E54C67D88E95831A5B374BA9B31F907" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4076FA32E26B94032259372B28E06C7E_6E54C67D88E95831A5B374BA9B31F907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ComputerAndOfficeEquipmentMember" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_8F21FFF1B5735CC5894DC0FE54C7477A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_8F21FFF1B5735CC5894DC0FE54C7477A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4501FA4907475120B175A1D0B2BEA36C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4501FA4907475120B175A1D0B2BEA36C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_50E7F0D4735C5689A3F40F281E14A957" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_50E7F0D4735C5689A3F40F281E14A957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:to="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6B326CA52BA75A5673D2372B28E1618F_6E54C67D88E95831A5B374BA9B31F907" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:to="loc_srt_RangeMember_6B326CA52BA75A5673D2372B28E1618F_6E54C67D88E95831A5B374BA9B31F907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:to="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:to="loc_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:to="loc_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:to="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:to="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:to="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1E35F20844A191D2063249CA51F3A859" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:to="loc_country_US_1E35F20844A191D2063249CA51F3A859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:to="loc_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:to="loc_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/Warrants" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/WarrantsIpoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:to="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:to="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_7CE402F222CA2AEDE1886E6A3F63736D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_7CE402F222CA2AEDE1886E6A3F63736D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_D4881B750E51B83DEA826E6A3F6360A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:to="loc_us-gaap_CommonClassAMember_D4881B750E51B83DEA826E6A3F6360A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_8D3F0E9C42C3F664E61C6E8958AEC7F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_8D3F0E9C42C3F664E61C6E8958AEC7F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_3AD2B0DA36A8619D64BB6E6A3F638282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8" xlink:to="loc_sibn_WarrantsLiabilityMember_3AD2B0DA36A8619D64BB6E6A3F638282" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" xlink:label="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_DC6A3046F1F2E5070EBC6E6A3F646513" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_DC6A3046F1F2E5070EBC6E6A3F646513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_98F174E60E05968039E06E6A3F64BE68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_98F174E60E05968039E06E6A3F64BE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_914A9B142236D3FDF67A6E6A3F65F080" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_914A9B142236D3FDF67A6E6A3F65F080" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsConversionRatio" xlink:label="loc_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:to="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:to="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:to="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:to="loc_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedJulyFirstTwentyTwelveMember" xlink:label="loc_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember" xlink:label="loc_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:label="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:label="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:label="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:label="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:label="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:label="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://si-bone.com/role/WarrantsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:to="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:to="loc_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sibn-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recorded in other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock warrants to common stock warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DFE97A58CFBB353B4490372B2730E4A9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:to="lab_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_73F33975B904A790458F372B27306720_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_73F33975B904A790458F372B27306720_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1482C0443DB61D3F8ACD372B2730D361_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1482C0443DB61D3F8ACD372B2730D361_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:to="lab_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:to="lab_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:to="lab_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8_label_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="lab_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 5 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998_label_en-US" xlink:label="lab_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:to="lab_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 6 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C_label_en-US" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series F Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 7 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709_label_en-US" xlink:label="lab_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:to="lab_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 7/1/2012</link:label>
    <link:label id="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313_label_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued July First Twenty Twelve [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued July First Twenty Twelve [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedJulyFirstTwentyTwelveMember" xlink:label="loc_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:to="lab_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 7/19/2013</link:label>
    <link:label id="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D_label_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued July Nineteenth Twenty Thirteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued July Nineteenth Twenty Thirteen [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember" xlink:label="loc_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:to="lab_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 11/26/2014</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F_label_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued November Twenty-Sixth Twenty Fourteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued November Twenty-Sixth Twenty Fourteen [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:label="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:to="lab_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 3/1/2017</link:label>
    <link:label id="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1_label_en-US" xlink:label="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued March First Twenty Seventeen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued March First Twenty Seventeen [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:label="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:to="lab_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 10/20/2015</link:label>
    <link:label id="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C_label_en-US" xlink:label="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued October Twentieth Twenty Fifteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued October Twentieth Twenty Fifteen [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:label="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:to="lab_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 11/9/2015</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453_label_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued November Ninth Twenty Fifteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued November Ninth Twenty Fifteen [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:label="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:to="lab_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44_terseLabel_en-US" xlink:label="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued 12/22/2016</link:label>
    <link:label id="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44_label_en-US" xlink:label="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued December Twenty-Second Twenty Sixteen [Member]</link:label>
    <link:label id="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44_documentation_en-US" xlink:label="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued December Twenty-Second Twenty Sixteen [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:label="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:to="lab_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60_terseLabel_en-US" xlink:label="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:label id="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60_label_en-US" xlink:label="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Liability [Member]</link:label>
    <link:label id="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60_documentation_en-US" xlink:label="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Liability [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:to="lab_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Underlying Warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63_terseLabel_en-US" xlink:label="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63_label_en-US" xlink:label="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion</link:label>
    <link:label id="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63_documentation_en-US" xlink:label="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:label="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:to="lab_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercise period from date of issuance</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC_label_en-US" xlink:label="lab_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:to="lab_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="lab_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:to="lab_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Notes Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C_label_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from Stockholder [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:to="lab_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:to="lab_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:to="lab_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684_terseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of redeemable convertible preferred stock, net of issuance costs (shares)</link:label>
    <link:label id="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684_label_en-US" xlink:label="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:to="lab_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83_negatedTerseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion from preferred stock to common stock (shares)</link:label>
    <link:label id="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83_label_en-US" xlink:label="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Conversion Of Temporary Equity To Equity, Shares</link:label>
    <link:label id="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Conversion Of Temporary Equity To Equity, Shares</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares" xlink:label="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:to="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698_negatedTerseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion from preferred stock to common stock</link:label>
    <link:label id="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698_label_en-US" xlink:label="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Conversion Of Temporary Equity To Equity, Value</link:label>
    <link:label id="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Conversion Of Temporary Equity To Equity, Value</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue" xlink:label="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:to="lab_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, ending balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit), beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:to="lab_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit), beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:to="lab_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:type="arc" />
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029_terseLabel_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of unvested stock options (shares)</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029_label_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Unvested Stock Options Exercised</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029_documentation_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Unvested Stock Options Exercised</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:to="lab_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:type="arc" />
    <link:label id="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072_terseLabel_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of unvested stock options</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072_label_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Unvested Stock Options Exercised</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072_documentation_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Unvested Stock Options Exercised</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:to="lab_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion from preferred stock to common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion from preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:type="arc" />
    <link:label id="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C_terseLabel_en-US" xlink:label="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion from preferred stock warrants to common stock warrants</link:label>
    <link:label id="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C_label_en-US" xlink:label="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Converted</link:label>
    <link:label id="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C_documentation_en-US" xlink:label="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Converted</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted" xlink:label="loc_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:to="lab_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:type="arc" />
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F_terseLabel_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from warrants exercise (shares)</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F_label_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F_documentation_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:to="lab_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:type="arc" />
    <link:label id="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA_terseLabel_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from warrants exercise</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA_label_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA_documentation_en-US" xlink:label="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:to="lab_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from IPO Proceeds, net (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from IPO Proceeds, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:type="arc" />
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8_negatedTerseLabel_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of unvested early exercised stock options (shares)</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8_label_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8_documentation_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:to="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:type="arc" />
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E_terseLabel_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of unvested early exercised stock options</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E_label_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value</link:label>
    <link:label id="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E_documentation_en-US" xlink:label="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:to="lab_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:type="arc" />
    <link:label id="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B_terseLabel_en-US" xlink:label="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of stockholders&#8217; notes receivable</link:label>
    <link:label id="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B_label_en-US" xlink:label="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity, Receivable From Officers And Directors For Issuance Of Capital Stock, Payment Received</link:label>
    <link:label id="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B_documentation_en-US" xlink:label="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity, Receivable From Officers And Directors For Issuance Of Capital Stock, Payment Received</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived" xlink:label="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:to="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:type="arc" />
    <link:label id="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6_terseLabel_en-US" xlink:label="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of stockholders&#8217; note receivable</link:label>
    <link:label id="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6_label_en-US" xlink:label="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity, Receivable From Officers And Directors For Issuance Of Capital Stock, Forgiveness Of Debt</link:label>
    <link:label id="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6_documentation_en-US" xlink:label="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity, Receivable From Officers And Directors For Issuance Of Capital Stock, Forgiveness Of Debt</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt" xlink:label="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:to="lab_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:type="arc" />
    <link:label id="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E_terseLabel_en-US" xlink:label="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercised stock options</link:label>
    <link:label id="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E_label_en-US" xlink:label="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Vesting Of Early Exercised Stock Options</link:label>
    <link:label id="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E_documentation_en-US" xlink:label="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Vesting Of Early Exercised Stock Options</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions" xlink:label="loc_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:to="lab_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain of marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:to="lab_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit), ending balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C" xlink:to="lab_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit), ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2" xlink:to="lab_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5_label_en-US" xlink:label="lab_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:to="lab_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from IPO</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon conversion of redeemable convertible preferred stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:type="arc" />
    <link:label id="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732_terseLabel_en-US" xlink:label="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants converted (in shares)</link:label>
    <link:label id="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732_label_en-US" xlink:label="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Or Rights Converted</link:label>
    <link:label id="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732_documentation_en-US" xlink:label="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Warrants or Rights Converted</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" xlink:label="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:to="lab_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase shares of stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to additional paid-in capital related to warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:to="lab_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="lab_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $263 and $268 at December 31, 2018 and 2017, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA_label_en-US" xlink:label="lab_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:to="lab_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:to="lab_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06_label_en-US" xlink:label="lab_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:to="lab_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:to="lab_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:to="lab_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:type="arc" />
    <link:label id="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279_terseLabel_en-US" xlink:label="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279_label_en-US" xlink:label="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279_documentation_en-US" xlink:label="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PreferredStockWarrantLiability" xlink:label="loc_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:to="lab_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441_label_en-US" xlink:label="lab_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:to="lab_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:to="lab_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, $0.0001 par value;</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock; Authorized: 0 and 12,104,749 shares at December 30, 2018 and December 31, 2017; issued and outstanding: 0 and 11,871,578 shares at December 30, 2018 and December 31, 2017; (Liquidation preference of $0 and $119,194 at December 30, 2018 and December 31, 2017).</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="lab_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; Authorized: 5,000,000 and 0 shares at December 31, 2018 and 2017, respectively; no shares issued and outstanding as of December 31, 2018 and 2017.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:to="lab_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; Authorized: 100,000,000 and 19,333,333 shares at December 31, 2018 and 2017, respectively; issued and outstanding: 24,450,757 and 3,603,140 shares, at December 31, 2018 and 2017, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:to="lab_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:to="lab_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F" xlink:to="lab_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:type="arc" />
    <link:label id="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A_terseLabel_en-US" xlink:label="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warranty term (in years)</link:label>
    <link:label id="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A_label_en-US" xlink:label="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty Term</link:label>
    <link:label id="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A_documentation_en-US" xlink:label="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standard Product Warranty Term</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StandardProductWarrantyTerm" xlink:label="loc_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:to="lab_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:type="arc" />
    <link:label id="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B_terseLabel_en-US" xlink:label="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales credit reserve term (in years)</link:label>
    <link:label id="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B_label_en-US" xlink:label="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Credit Reserve Period</link:label>
    <link:label id="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B_documentation_en-US" xlink:label="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Credit Reserve Period</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SalesCreditReservePeriod" xlink:label="loc_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:to="lab_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A97E40EFFF0F993BE3C0571F92B35066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A97E40EFFF0F993BE3C0571F92B35066_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_475AE77301A5AFB9EE4D571F92B43FFF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_475AE77301A5AFB9EE4D571F92B43FFF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D7BD57F15BD5EA950266571F92B43941_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D7BD57F15BD5EA950266571F92B43941_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_214C00BCAA5CBA58AD81571F92B57A6B_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_214C00BCAA5CBA58AD81571F92B57A6B_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_582EFBF285BC7A716446571F92B5B4D4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_582EFBF285BC7A716446571F92B5B4D4_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:to="lab_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:type="arc" />
    <link:label id="lab_sibn_ComputerAndOfficeEquipmentMember_520A8847813F4802C1E7571F92B5BD4C_terseLabel_en-US" xlink:label="lab_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_sibn_ComputerAndOfficeEquipmentMember_520A8847813F4802C1E7571F92B5BD4C_label_en-US" xlink:label="lab_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer And Office Equipment [Member]</link:label>
    <link:label id="lab_sibn_ComputerAndOfficeEquipmentMember_520A8847813F4802C1E7571F92B5BD4C_documentation_en-US" xlink:label="lab_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer And Office Equipment [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ComputerAndOfficeEquipmentMember" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:to="lab_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8F2FF6B09092D71DF28C571F92B5E6E2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8F2FF6B09092D71DF28C571F92B5E6E2_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7BF8C70D3039C5C4DFB2571F92B50022_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7BF8C70D3039C5C4DFB2571F92B50022_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4C36B20B300497AD73DC571F92B51F71_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_4C36B20B300497AD73DC571F92B51F71_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2593801740939E5A9B19571F92B67112_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2593801740939E5A9B19571F92B67112_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_829A8B6516F7F8E0DAFD571F92B60EFC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_829A8B6516F7F8E0DAFD571F92B60EFC_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_EB560EC7EA854464B598571F92B6F8A5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_B69A121130DA8D0638AE571F92B76BDF_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_B69A121130DA8D0638AE571F92B76BDF_label_en-US" xlink:label="lab_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:to="lab_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E9714FB63E34B48B568A5C5DEE2D8EAA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4BC1FE5AF49D5C1CBC2312C07A3BBAE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4BC1FE5AF49D5C1CBC2312C07A3BBAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4BC1FE5AF49D5C1CBC2312C07A3BBAE5" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4BC1FE5AF49D5C1CBC2312C07A3BBAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F7178FA13C2D24AEE2AD5C5DEE2DF5F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Aggregate Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F7178FA13C2D24AEE2AD5C5DEE2DF5F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs capitalized</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:to="lab_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs transferred to additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:type="arc" />
    <link:label id="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB_terseLabel_en-US" xlink:label="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs expensed</link:label>
    <link:label id="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB_label_en-US" xlink:label="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Expensed</link:label>
    <link:label id="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB_documentation_en-US" xlink:label="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offering Costs Expensed</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_OfferingCostsExpensed" xlink:label="loc_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:to="lab_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used In Computation of Fair Value of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A" xlink:to="lab_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="lab_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:to="lab_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:to="lab_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:to="lab_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:to="lab_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:to="lab_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:to="lab_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:type="arc" />
    <link:label id="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E_terseLabel_en-US" xlink:label="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SVB and Oxford Term Loan</link:label>
    <link:label id="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E_label_en-US" xlink:label="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SVB And Oxford Term Loan [Member]</link:label>
    <link:label id="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E_documentation_en-US" xlink:label="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SVB And Oxford Term Loan [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SVBAndOxfordTermLoanMember" xlink:label="loc_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:to="lab_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:type="arc" />
    <link:label id="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944_terseLabel_en-US" xlink:label="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loan</link:label>
    <link:label id="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944_label_en-US" xlink:label="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loan [Member]</link:label>
    <link:label id="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944_documentation_en-US" xlink:label="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loan [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PharmakonTermLoanMember" xlink:label="loc_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:to="lab_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:to="lab_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:to="lab_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:to="lab_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:type="arc" />
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5_terseLabel_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5_label_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5_documentation_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:to="lab_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:type="arc" />
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069_terseLabel_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, Prepayment Penalty, Period [Domain]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069_label_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Prepayment Penalty, Period [Domain]</link:label>
    <link:label id="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069_documentation_en-US" xlink:label="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt, Prepayment Penalty, Period [Axis]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:to="lab_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:type="arc" />
    <link:label id="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648_terseLabel_en-US" xlink:label="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment Penalty, 31-48 Months</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648_label_en-US" xlink:label="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment Penalty, 31-48 Months [Member]</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648_documentation_en-US" xlink:label="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment Penalty, 31-48 Months [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PrepaymentPenalty3148MonthsMember" xlink:label="loc_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:to="lab_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:type="arc" />
    <link:label id="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE_terseLabel_en-US" xlink:label="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment Penalty, 49-60 Months</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE_label_en-US" xlink:label="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment Penalty, 49-60 Months [Member]</link:label>
    <link:label id="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE_documentation_en-US" xlink:label="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment Penalty, 49-60 Months [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PrepaymentPenalty4960MonthsMember" xlink:label="loc_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:to="lab_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:to="lab_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:type="arc" />
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt period payment, interest only period</link:label>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574_label_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest Only Period</link:label>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest Only Period</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:to="lab_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:type="arc" />
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt period payment, principal and interest period</link:label>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487_label_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal And Interest Period</link:label>
    <link:label id="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal And Interest Period</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:to="lab_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt financing</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:type="arc" />
    <link:label id="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt closing fee percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252_label_en-US" xlink:label="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Closing Fee Percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Closing Fee Percentage</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentClosingFeePercentage" xlink:label="loc_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:to="lab_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument fee amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:type="arc" />
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt prepayment penalty percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052_label_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Percentage</link:label>
    <link:label id="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty Percentage</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:to="lab_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:type="arc" />
    <link:label id="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7_terseLabel_en-US" xlink:label="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt covenant minimum cash balance</link:label>
    <link:label id="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7_label_en-US" xlink:label="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash Balance</link:label>
    <link:label id="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7_documentation_en-US" xlink:label="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Cash Balance</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:to="lab_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt borrowing capacity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:type="arc" />
    <link:label id="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758_terseLabel_en-US" xlink:label="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit percent of customer accounts receivable</link:label>
    <link:label id="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758_label_en-US" xlink:label="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility, Percent Of Customer Accounts Receivable</link:label>
    <link:label id="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758_documentation_en-US" xlink:label="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Percent Of Customer Accounts Receivable</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable" xlink:label="loc_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:to="lab_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_38F2AA6F746AB343A1711E68BA8CC653_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_C93050EA6CCC5197874B3535E6205025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C93050EA6CCC5197874B3535E6205025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_C93050EA6CCC5197874B3535E6205025" xlink:to="lab_us-gaap_EquityAbstract_C93050EA6CCC5197874B3535E6205025" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_C7327EA1F64FC136BC5E1E68BAEBE229_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_C7327EA1F64FC136BC5E1E68BAEBE229_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:to="lab_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:type="arc" />
    <link:label id="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E_terseLabel_en-US" xlink:label="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options and ESPP Purchase Rights</link:label>
    <link:label id="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E_label_en-US" xlink:label="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and ESPP Purchase Rights [Member]</link:label>
    <link:label id="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E_documentation_en-US" xlink:label="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options and ESPP Purchase Rights [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockOptionsandESPPPurchaseRightsMember" xlink:label="loc_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:to="lab_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:to="lab_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:to="lab_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:to="lab_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:to="lab_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:type="arc" />
    <link:label id="lab_country_US_1E35F20844A191D2063249CA51F3A859_terseLabel_en-US" xlink:label="lab_country_US_1E35F20844A191D2063249CA51F3A859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_1E35F20844A191D2063249CA51F3A859_label_en-US" xlink:label="lab_country_US_1E35F20844A191D2063249CA51F3A859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1E35F20844A191D2063249CA51F3A859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_1E35F20844A191D2063249CA51F3A859" xlink:to="lab_country_US_1E35F20844A191D2063249CA51F3A859" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794_label_en-US" xlink:label="lab_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:to="lab_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B_label_en-US" xlink:label="lab_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:to="lab_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_51654401C04F11E770A232AB78166543_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_51654401C04F11E770A232AB78166543_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="lab_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43_label_en-US" xlink:label="lab_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:to="lab_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:to="lab_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:to="lab_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:to="lab_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:to="lab_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:to="lab_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59_label_en-US" xlink:label="lab_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:to="lab_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9" xlink:to="lab_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in foreign currency translation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses on long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax at statutory federal rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Measurement of deferred taxes as a result of tax reform (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in deferred tax valuation allowance (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:to="lab_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_D64187DC68DE3B8122D6372B28858481_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_D64187DC68DE3B8122D6372B28858481_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EBC40D9BA4A9934F10EA372B28866DC8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities and Other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_EBC40D9BA4A9934F10EA372B28866DC8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_49A1409D07332047E9A51D07B94CD1BD_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_49A1409D07332047E9A51D07B94CD1BD_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:type="arc" />
    <link:label id="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A_terseLabel_en-US" xlink:label="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Valuation Allowance</link:label>
    <link:label id="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A_label_en-US" xlink:label="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A_documentation_en-US" xlink:label="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes Valuation Allowance [Roll Forward]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncomeTaxesValuationAllowanceRollForward" xlink:label="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:to="lab_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions (Deductions) during the period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A_terseLabel_en-US" xlink:label="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant conversion ratio</link:label>
    <link:label id="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A_label_en-US" xlink:label="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Conversion Ratio</link:label>
    <link:label id="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A_documentation_en-US" xlink:label="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Conversion Ratio</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsConversionRatio" xlink:label="loc_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:to="lab_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:to="lab_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001_label_en-US" xlink:label="lab_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:to="lab_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:to="lab_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes option-pricing model assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:to="lab_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification Agreement</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:type="arc" />
    <link:label id="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141_terseLabel_en-US" xlink:label="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Jose, California</link:label>
    <link:label id="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141_label_en-US" xlink:label="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Jose, California [Member]</link:label>
    <link:label id="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141_documentation_en-US" xlink:label="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Jose, California [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SanJoseCaliforniaMember" xlink:label="loc_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:to="lab_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:type="arc" />
    <link:label id="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC_terseLabel_en-US" xlink:label="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Santa Clara, California</link:label>
    <link:label id="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC_label_en-US" xlink:label="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Santa Clara, California [Member]</link:label>
    <link:label id="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC_documentation_en-US" xlink:label="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Santa Clara, California [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SantaClaraCaliforniaMember" xlink:label="loc_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:to="lab_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cancelable operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early termination fees</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:to="lab_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments related to inventory</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:to="lab_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs to defend lawsuits or settle claims</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:to="lab_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs accrued to defend lawsuits</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063_label_en-US" xlink:label="lab_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:to="lab_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 1 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 2 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 3 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 4 Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9_label_en-US" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="lab_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidation Value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339_terseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock votes per share</link:label>
    <link:label id="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339_label_en-US" xlink:label="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Rights To Votes For Each Share</link:label>
    <link:label id="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Rights To Votes For Each Share</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityRightsToVotesForEachShare" xlink:label="loc_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:to="lab_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:type="arc" />
    <link:label id="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3_terseLabel_en-US" xlink:label="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, number of directors entitled to elect</link:label>
    <link:label id="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3_label_en-US" xlink:label="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number Of Directors Entitled To Elect</link:label>
    <link:label id="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3_documentation_en-US" xlink:label="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number Of Directors Entitled To Elect</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PreferredStockNumberOfDirectorsEntitledToElect" xlink:label="loc_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:to="lab_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:type="arc" />
    <link:label id="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99_terseLabel_en-US" xlink:label="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 2 common stock, number of directors entitled to elect</link:label>
    <link:label id="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99_label_en-US" xlink:label="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Series Two, Number Of Directors Entitled To Elect</link:label>
    <link:label id="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99_documentation_en-US" xlink:label="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Series Two, Number Of Directors Entitled To Elect</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect" xlink:label="loc_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:to="lab_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155_terseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholder approval, minimum shares outstanding (in shares)</link:label>
    <link:label id="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155_label_en-US" xlink:label="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shareholder Approval, Minimum Shares Outstanding</link:label>
    <link:label id="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shareholder Approval, Minimum Shares Outstanding</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding" xlink:label="loc_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:to="lab_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:to="lab_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:to="lab_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidation preference per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC_terseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidation participation cap per share (in dollars per share)</link:label>
    <link:label id="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC_label_en-US" xlink:label="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Participation Cap Per Share</link:label>
    <link:label id="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Participation Cap Per Share</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityLiquidationParticipationCapPerShare" xlink:label="loc_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:to="lab_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:type="arc" />
    <link:label id="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52_terseLabel_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52_label_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:label id="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52_documentation_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockConversionPrice" xlink:label="loc_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:to="lab_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:type="arc" />
    <link:label id="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0_terseLabel_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum public offering for conversion</link:label>
    <link:label id="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0_label_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Minimum Public Offering For Conversion</link:label>
    <link:label id="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0_documentation_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Minimum Public Offering For Conversion</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion" xlink:label="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:to="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:type="arc" />
    <link:label id="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A_terseLabel_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum public offering per share for conversion (in dollars per share)</link:label>
    <link:label id="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A_label_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Minimum Public Offering Per Share For Conversion</link:label>
    <link:label id="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A_documentation_en-US" xlink:label="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Minimum Public Offering Per Share For Conversion</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion" xlink:label="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:to="lab_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_FA0F78C054C9E828CE30372B28E133D5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_FA0F78C054C9E828CE30372B28E133D5_label_en-US" xlink:label="lab_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:to="lab_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_6B326CA52BA75A5673D2372B28E1618F_terseLabel_en-US" xlink:label="lab_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_6B326CA52BA75A5673D2372B28E1618F_label_en-US" xlink:label="lab_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:to="lab_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_2B3772BEB8BC6D32FAE1372B28E264CB_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_2B3772BEB8BC6D32FAE1372B28E264CB_label_en-US" xlink:label="lab_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:to="lab_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_7251ECAD43A0C1305740372B28E2264E_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_7251ECAD43A0C1305740372B28E2264E_label_en-US" xlink:label="lab_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:to="lab_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_BC7EFF32F848A375D4FC372B28E2DFFD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6FD8193CE87FEC22E0C2372B28E2CE41_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6FD8193CE87FEC22E0C2372B28E2CE41_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual life, options outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual life, options vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual life, options vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, options vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Incentive Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in deferred tax valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577" xlink:type="arc" />
    <link:label id="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C_totalLabel_en-US" xlink:label="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax expense</link:label>
    <link:label id="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C_label_en-US" xlink:label="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance</link:label>
    <link:label id="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C_documentation_en-US" xlink:label="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:label="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:to="lab_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:to="lab_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:type="arc" />
    <link:label id="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894_terseLabel_en-US" xlink:label="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly increase in revenue target (percent)</link:label>
    <link:label id="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894_label_en-US" xlink:label="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Target, Quarterly Increase, Percentage</link:label>
    <link:label id="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894_documentation_en-US" xlink:label="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Target, Quarterly Increase, Percentage</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_RevenueTargetQuarterlyIncreasePercentage" xlink:label="loc_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:to="lab_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B" xlink:type="arc" />
    <link:label id="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Axis]</link:label>
    <link:label id="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC_label_en-US" xlink:label="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Axis]</link:label>
    <link:label id="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC_documentation_en-US" xlink:label="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Axis]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodAxis" xlink:label="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:to="lab_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:type="arc" />
    <link:label id="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Domain]</link:label>
    <link:label id="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E_label_en-US" xlink:label="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Domain]</link:label>
    <link:label id="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E_documentation_en-US" xlink:label="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Covenant Period [Axis]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodDomain" xlink:label="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="lab_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB_terseLabel_en-US" xlink:label="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB_label_en-US" xlink:label="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period One [Member]</link:label>
    <link:label id="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB_documentation_en-US" xlink:label="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period One [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodOneMember" xlink:label="loc_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:to="lab_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874_terseLabel_en-US" xlink:label="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874_label_en-US" xlink:label="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Two [Member]</link:label>
    <link:label id="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874_documentation_en-US" xlink:label="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Two [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodTwoMember" xlink:label="loc_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:to="lab_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B_terseLabel_en-US" xlink:label="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Three</link:label>
    <link:label id="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B_label_en-US" xlink:label="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Three [Member]</link:label>
    <link:label id="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B_documentation_en-US" xlink:label="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Three [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodThreeMember" xlink:label="loc_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:to="lab_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4_terseLabel_en-US" xlink:label="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Four</link:label>
    <link:label id="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4_label_en-US" xlink:label="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Four [Member]</link:label>
    <link:label id="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4_documentation_en-US" xlink:label="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Four [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodFourMember" xlink:label="loc_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:to="lab_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4_terseLabel_en-US" xlink:label="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Five</link:label>
    <link:label id="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4_label_en-US" xlink:label="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Five [Member]</link:label>
    <link:label id="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4_documentation_en-US" xlink:label="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Five [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodFiveMember" xlink:label="loc_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:to="lab_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B_terseLabel_en-US" xlink:label="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Six</link:label>
    <link:label id="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B_label_en-US" xlink:label="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Six [Member]</link:label>
    <link:label id="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B_documentation_en-US" xlink:label="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Six [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodSixMember" xlink:label="loc_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:to="lab_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:type="arc" />
    <link:label id="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861_terseLabel_en-US" xlink:label="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Seven</link:label>
    <link:label id="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861_label_en-US" xlink:label="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Seven [Member]</link:label>
    <link:label id="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861_documentation_en-US" xlink:label="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Seven [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodSevenMember" xlink:label="loc_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:to="lab_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:type="arc" />
    <link:label id="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant, Minimum Net Sales</link:label>
    <link:label id="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A_label_en-US" xlink:label="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant, Minimum Net Sales, Trailing Twelve Months, Amount</link:label>
    <link:label id="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A_documentation_en-US" xlink:label="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant, Minimum Net Sales, Trailing Twelve Months, Amount</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount" xlink:label="loc_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:to="lab_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:type="arc" />
    <link:label id="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant, Trailing 12-Month Consolidated EBITDA</link:label>
    <link:label id="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897_label_en-US" xlink:label="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Trailing 12-Month Consolidated EBITDA</link:label>
    <link:label id="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897_documentation_en-US" xlink:label="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Trailing 12-Month Consolidated EBITDA</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA" xlink:label="loc_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:to="lab_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Annual Future Minimum Principal Payments Under Loan Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:type="arc" />
    <link:label id="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70_terseLabel_en-US" xlink:label="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant EBITDA Targets</link:label>
    <link:label id="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70_label_en-US" xlink:label="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant EBITDA and Net Revenue Targets [Table Text Block]</link:label>
    <link:label id="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70_documentation_en-US" xlink:label="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant EBITDA and Net Revenue Targets [Table Text Block]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock" xlink:label="loc_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:to="lab_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013_terseLabel_en-US" xlink:label="lab_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 1 Common Stock</link:label>
    <link:label id="lab_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013_label_en-US" xlink:label="lab_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvoting Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:to="lab_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series 2 Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:to="lab_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="lab_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:type="arc" />
    <link:label id="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92_terseLabel_en-US" xlink:label="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock outstanding, common stock equivalents (in shares)</link:label>
    <link:label id="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92_label_en-US" xlink:label="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Common Stock Equivalent Shares If-Converted, Shares</link:label>
    <link:label id="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92_documentation_en-US" xlink:label="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock equivalent shares related to potential conversion of temporary equity shares.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares" xlink:label="loc_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:to="lab_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:type="arc" />
    <link:label id="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B_terseLabel_en-US" xlink:label="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, common stock equivalents (in shares)</link:label>
    <link:label id="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B_label_en-US" xlink:label="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Equivalent Shares, Stock Options Outstanding</link:label>
    <link:label id="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B_documentation_en-US" xlink:label="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock equivalent shares related to potential exercise of stock options outstanding.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockEquivalentSharesStockOptionsOutstanding" xlink:label="loc_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:to="lab_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:type="arc" />
    <link:label id="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0_verboseLabel_en-US" xlink:label="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase shares of stock, common stock equivalents (in shares)</link:label>
    <link:label id="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0_label_en-US" xlink:label="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Common Stock Equivalent Securities Called by Warrants or Rights</link:label>
    <link:label id="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0_documentation_en-US" xlink:label="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock equivalent shares related to potential conversion of warrants into common stock, preferred stock, or temporary equity.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights" xlink:label="loc_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:to="lab_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:type="arc" />
    <link:label id="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404_terseLabel_en-US" xlink:label="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404_label_en-US" xlink:label="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity And Temporary Equity, Shares Issued And Reserved For Future Issuance</link:label>
    <link:label id="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404_documentation_en-US" xlink:label="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity And Temporary Equity, Shares Issued And Reserved For Future Issuance</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance" xlink:label="loc_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:to="lab_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:type="arc" />
    <link:label id="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8_terseLabel_en-US" xlink:label="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total issued and reserved for issuance, common stock equivalents (in shares)</link:label>
    <link:label id="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8_label_en-US" xlink:label="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity And Temporary Equity, Common Stock Equivalent Shares Issued And Reserved For Future Issuance</link:label>
    <link:label id="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8_documentation_en-US" xlink:label="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity And Temporary Equity, Common Stock Equivalent Shares Issued And Reserved For Future Issuance</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance" xlink:label="loc_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:to="lab_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_ECC5565C5968FC605F09192B3DA5D787_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company and Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_ECC5565C5968FC605F09192B3DA5D787_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:to="lab_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain income tax positions [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Uncertain income tax positions, beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases in balances related to tax positions taken during current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Uncertain income tax positions, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:to="lab_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6_terseLabel_en-US" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6_label_en-US" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:to="lab_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1_terseLabel_en-US" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1_label_en-US" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:type="arc" />
    <link:label id="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD_terseLabel_en-US" xlink:label="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of Related Party Promissory Note</link:label>
    <link:label id="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD_label_en-US" xlink:label="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgiveness Of Related Party Promissory Note [Member]</link:label>
    <link:label id="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD_documentation_en-US" xlink:label="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Forgiveness Of Related Party Promissory Note [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ForgivenessOfRelatedPartyPromissoryNoteMember" xlink:label="loc_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:to="lab_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; notes receivable</link:label>
    <link:label id="lab_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD_label_en-US" xlink:label="lab_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable from Officers and Directors for Issuance of Capital Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:to="lab_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' note interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:to="lab_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of stockholders&#8217; notes receivable</link:label>
    <link:label id="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A_label_en-US" xlink:label="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of Notes Receivable from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:to="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:type="arc" />
    <link:label id="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E_terseLabel_en-US" xlink:label="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes receivable forgiven</link:label>
    <link:label id="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E_label_en-US" xlink:label="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable From Officers And Directors For Issuance Of Capital Stock, Forgiven</link:label>
    <link:label id="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E_documentation_en-US" xlink:label="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable From Officers And Directors For Issuance Of Capital Stock, Forgiven</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven" xlink:label="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:to="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:type="arc" />
    <link:label id="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302_terseLabel_en-US" xlink:label="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes receivable percentage of principal approved for forgiveness</link:label>
    <link:label id="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302_label_en-US" xlink:label="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable From Officers And Directors For Issuance Of Capital Stock, Percentage Of Principal Approved For Forgiveness</link:label>
    <link:label id="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302_documentation_en-US" xlink:label="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable From Officers And Directors For Issuance Of Capital Stock, Percentage Of Principal Approved For Forgiveness</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness" xlink:label="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:to="lab_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:to="lab_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:to="lab_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:to="lab_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:to="lab_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:type="arc" />
    <link:label id="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356_terseLabel_en-US" xlink:label="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356_label_en-US" xlink:label="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Depreciation And Amortization</link:label>
    <link:label id="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356_documentation_en-US" xlink:label="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Depreciation And Amortization</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:to="lab_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:to="lab_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="lab_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:type="arc" />
    <link:label id="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377_terseLabel_en-US" xlink:label="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Stock Option Plan</link:label>
    <link:label id="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377_label_en-US" xlink:label="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2008 Stock Option Plan [Member]</link:label>
    <link:label id="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377_documentation_en-US" xlink:label="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2008 Stock Option Plan [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2008StockOptionPlanMember" xlink:label="loc_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:to="lab_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:type="arc" />
    <link:label id="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487_terseLabel_en-US" xlink:label="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487_label_en-US" xlink:label="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487_documentation_en-US" xlink:label="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A2018 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2018EquityIncentivePlanMember" xlink:label="loc_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:to="lab_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:type="arc" />
    <link:label id="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B_terseLabel_en-US" xlink:label="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B_label_en-US" xlink:label="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B_documentation_en-US" xlink:label="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:to="lab_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:type="arc" />
    <link:label id="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0_terseLabel_en-US" xlink:label="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0_label_en-US" xlink:label="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:label id="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0_documentation_en-US" xlink:label="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Stock Option [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncentiveStockOptionMember" xlink:label="loc_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:to="lab_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:type="arc" />
    <link:label id="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026_terseLabel_en-US" xlink:label="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonqualified Stock Options</link:label>
    <link:label id="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026_label_en-US" xlink:label="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonqualified Stock Option [Member]</link:label>
    <link:label id="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026_documentation_en-US" xlink:label="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonqualified Stock Option [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NonqualifiedStockOptionMember" xlink:label="loc_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:to="lab_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:to="lab_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9_label_en-US" xlink:label="lab_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:to="lab_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631_label_en-US" xlink:label="lab_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:to="lab_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:to="lab_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:to="lab_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:type="arc" />
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of option as percent of fair market value when individual owns more than 10% of shares outstanding (percent)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than Ten Percent Of Outstanding Shares</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than 10% Of Outstanding Shares</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:type="arc" />
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of option as percent of fair market value (percent)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:type="arc" />
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period when individual holds more than 10% of shares outstanding (in years)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than Ten Percent Of Outstanding Shares</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than 10% Of Outstanding Shares</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock as a percent of fair market value (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:type="arc" />
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees stock purchase program offering period interval (in months)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:type="arc" />
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early exercise of stock options, share subject to repurchase (in shares)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:type="arc" />
    <link:label id="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990_terseLabel_en-US" xlink:label="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for early exercise of unvested stock options</link:label>
    <link:label id="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990_label_en-US" xlink:label="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Early Exercise Of Options, Current</link:label>
    <link:label id="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990_documentation_en-US" xlink:label="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Early Exercise Of Options, Current</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LiabilityForEarlyExerciseOfOptionsCurrent" xlink:label="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:to="lab_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:type="arc" />
    <link:label id="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F_terseLabel_en-US" xlink:label="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of notes receivable</link:label>
    <link:label id="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F_label_en-US" xlink:label="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Forgiveness</link:label>
    <link:label id="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F_documentation_en-US" xlink:label="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Receivable, Forgiveness</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NotesReceivableForgiveness" xlink:label="loc_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:to="lab_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Grant price of stock options granted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:type="arc" />
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB_terseLabel_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options with modification of terms (in shares)</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB_label_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Options Modified</link:label>
    <link:label id="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB_documentation_en-US" xlink:label="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Options Modified</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:to="lab_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense to be recognized related to modification of terms</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost, expected period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_622C29DE21EDFF8C04B95B6CAB33F7BD_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geography</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_622C29DE21EDFF8C04B95B6CAB33F7BD_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_67CD6D3709DE82E421495B3BA1C2123F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DB390508241753AD86A2C682BE9604FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DB390508241753AD86A2C682BE9604FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DB390508241753AD86A2C682BE9604FA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DB390508241753AD86A2C682BE9604FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Uncertain Income Tax Positions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:to="lab_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:type="arc" />
    <link:label id="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607_totalLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, Amortized Cost</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Amortized Cost</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total amortized cost for marketable securities included in cash equivalents and investments.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAmortizedCost" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:to="lab_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:type="arc" />
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26_terseLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, Unrealized Gains</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:to="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:type="arc" />
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60_negatedTerseLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, Unrealized Losses</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:to="lab_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:type="arc" />
    <link:label id="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC_terseLabel_en-US" xlink:label="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, Aggregate Fair Value</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC_label_en-US" xlink:label="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Fair Value</link:label>
    <link:label id="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC_documentation_en-US" xlink:label="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total aggregate fair value for marketable securities included in cash equivalents and investments.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesFairValue" xlink:label="loc_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:to="lab_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Recoveries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:to="lab_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on write-off of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:type="arc" />
    <link:label id="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0_terseLabel_en-US" xlink:label="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-off of debt discount</link:label>
    <link:label id="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0_label_en-US" xlink:label="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write-Off Of Debt Discount</link:label>
    <link:label id="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0_documentation_en-US" xlink:label="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Write off of Debt Discount</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WriteOffOfDebtDiscount" xlink:label="loc_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:to="lab_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:type="arc" />
    <link:label id="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A_terseLabel_en-US" xlink:label="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-off of public offering costs</link:label>
    <link:label id="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A_label_en-US" xlink:label="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write Off Of Initial Public Offering Costs</link:label>
    <link:label id="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A_documentation_en-US" xlink:label="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Write off of Initial Public Offering Costs</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WriteOffOfInitialPublicOfferingCosts" xlink:label="loc_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:to="lab_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgiveness of notes receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:to="lab_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments accretion</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of common stock options, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt financing</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of debt financing</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt financing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of redeemable convertible preferred stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments of public offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:to="lab_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash information</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:type="arc" />
    <link:label id="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462_terseLabel_en-US" xlink:label="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock warrants to common stock warrants</link:label>
    <link:label id="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462_label_en-US" xlink:label="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Exercise of Common Warrants</link:label>
    <link:label id="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462_documentation_en-US" xlink:label="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Exercise of Common Warrants</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NetExerciseofCommonWarrants" xlink:label="loc_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:to="lab_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:type="arc" />
    <link:label id="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D_terseLabel_en-US" xlink:label="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercised stock options</link:label>
    <link:label id="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D_label_en-US" xlink:label="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Of Early Exercised Stock Options</link:label>
    <link:label id="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D_documentation_en-US" xlink:label="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting of Early Exercised Stock Options</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_VestingOfEarlyExercisedStockOptions" xlink:label="loc_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:to="lab_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:type="arc" />
    <link:label id="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399_terseLabel_en-US" xlink:label="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399_label_en-US" xlink:label="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Public Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399_documentation_en-US" xlink:label="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Public Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_InitialPublicOfferingCostsIncurredButNotYetPaid" xlink:label="loc_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:to="lab_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock authorized (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, liquidation preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:to="lab_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:to="lab_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:to="lab_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:type="arc" />
    <link:label id="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07_terseLabel_en-US" xlink:label="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to repurchase</link:label>
    <link:label id="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07_label_en-US" xlink:label="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Subject To Repurchase [Member]</link:label>
    <link:label id="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07_documentation_en-US" xlink:label="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Subject To Repurchase [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareSubjectToRepurchaseMember" xlink:label="loc_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:to="lab_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:type="arc" />
    <link:label id="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1_terseLabel_en-US" xlink:label="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated ESPP shares</link:label>
    <link:label id="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1_label_en-US" xlink:label="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Shares [Member]</link:label>
    <link:label id="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1_documentation_en-US" xlink:label="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Shares [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EmployeeStockPurchasePlanSharesMember" xlink:label="loc_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:to="lab_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:type="arc" />
    <link:label id="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303_terseLabel_en-US" xlink:label="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303_label_en-US" xlink:label="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303_documentation_en-US" xlink:label="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="loc_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:to="lab_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:type="arc" />
    <link:label id="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0_terseLabel_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0_label_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0_documentation_en-US" xlink:label="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockWarrantsMember" xlink:label="loc_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:to="lab_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock equivalents excluded from the computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:to="lab_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering Costs</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288_terseLabel_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288_label_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Classified As Equity [Policy Text Block]</link:label>
    <link:label id="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288_documentation_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for warrants classified as equity.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsClassifiedAsEquityPolicyTextBlock" xlink:label="loc_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:to="lab_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:type="arc" />
    <link:label id="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A_terseLabel_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:label id="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A_label_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Classified As Liabilities [Policy Text Block]</link:label>
    <link:label id="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A_documentation_en-US" xlink:label="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for warrants classified as liabilities.</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:label="loc_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:to="lab_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Sales of Goods [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="loc_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:to="lab_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warranty Program</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:type="arc" />
    <link:label id="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC_terseLabel_en-US" xlink:label="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical Device Excise Tax</link:label>
    <link:label id="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC_label_en-US" xlink:label="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Device Excise Tax Policy [Policy Text Block]</link:label>
    <link:label id="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC_documentation_en-US" xlink:label="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Device Excise Tax Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:label="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:to="lab_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expenditures</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost" xlink:label="loc_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:to="lab_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:to="lab_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:to="lab_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:type="arc" />
    <link:label id="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C_terseLabel_en-US" xlink:label="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limited net operating loss carryforwards</link:label>
    <link:label id="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C_label_en-US" xlink:label="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Limited</link:label>
    <link:label id="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C_documentation_en-US" xlink:label="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Limited</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_OperatingLossCarryforwardsLimited" xlink:label="loc_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:to="lab_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:type="arc" />
    <link:label id="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F_negatedTerseLabel_en-US" xlink:label="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in net deferred tax asset position due to change in tax rate</link:label>
    <link:label id="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F_label_en-US" xlink:label="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Net Deferred Tax Asset Position, Change In Enacted Tax Rate</link:label>
    <link:label id="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F_documentation_en-US" xlink:label="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Net Deferred Tax Asset Position, Change In Enacted Tax Rate</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate" xlink:label="loc_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:to="lab_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:type="arc" />
    <link:label id="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5_terseLabel_en-US" xlink:label="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in common stock authorized (in shares)</link:label>
    <link:label id="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5_label_en-US" xlink:label="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized, Increase During Period</link:label>
    <link:label id="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5_documentation_en-US" xlink:label="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized, Increase During Period</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod" xlink:label="loc_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:to="lab_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions Related to Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:type="arc" />
    <link:label id="lab_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F_label_en-US" xlink:label="lab_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F_documentation_en-US" xlink:label="lab_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DocumentAndEntityInformationAbstract" xlink:label="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="lab_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67_terseLabel_en-US" xlink:label="lab_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67_label_en-US" xlink:label="lab_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:to="lab_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B_label_en-US" xlink:label="lab_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:to="lab_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:to="lab_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:to="lab_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:to="lab_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931_label_en-US" xlink:label="lab_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:to="lab_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:to="lab_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:to="lab_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60_label_en-US" xlink:label="lab_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:to="lab_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:to="lab_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:to="lab_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:to="lab_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:to="lab_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:to="lab_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800_label_en-US" xlink:label="lab_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:to="lab_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D_label_en-US" xlink:label="lab_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:to="lab_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:to="lab_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F628E4A15F69CFF95E441CE979343037_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F628E4A15F69CFF95E441CE979343037_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_EC0F09FD5CAEFFB6CF771CE97934CBFB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Fair Value of the Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_EC0F09FD5CAEFFB6CF771CE97934CBFB_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:to="lab_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:type="arc" />
    <link:label id="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9_terseLabel_en-US" xlink:label="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and warranty reserves</link:label>
    <link:label id="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9_label_en-US" xlink:label="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Product Warranty Accrual, Current</link:label>
    <link:label id="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9_documentation_en-US" xlink:label="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Product Warranty Accrual, Current</link:label>
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SalesAndProductWarrantyAccrualCurrent" xlink:label="loc_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:to="lab_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount representing debt discount</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5" xlink:to="lab_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sibn-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponents" xlink:href="sibn-20181231.xsd#BalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:href="sibn-20181231.xsd#BalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/Borrowings" xlink:href="sibn-20181231.xsd#Borrowings" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:href="sibn-20181231.xsd#BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails" xlink:href="sibn-20181231.xsd#BorrowingsEbitdaTargetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:href="sibn-20181231.xsd#BorrowingsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/BorrowingsTables" xlink:href="sibn-20181231.xsd#BorrowingsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingencies" xlink:href="sibn-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommitmentsAndContingenciesTables" xlink:href="sibn-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStock" xlink:href="sibn-20181231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockNarrativeDetails" xlink:href="sibn-20181231.xsd#CommonStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails" xlink:href="sibn-20181231.xsd#CommonStockSharesOfStockIssuedAndReservedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CommonStockTables" xlink:href="sibn-20181231.xsd#CommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CompanyAndNatureOfBusiness" xlink:href="sibn-20181231.xsd#CompanyAndNatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails" xlink:href="sibn-20181231.xsd#CompanyAndNatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedBalanceSheets" xlink:href="sibn-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="sibn-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="sibn-20181231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/DocumentAndEntityInformation" xlink:href="sibn-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/EmployeeBenefitPlan" xlink:href="sibn-20181231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurement" xlink:href="sibn-20181231.xsd#FairValueMeasurement" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="sibn-20181231.xsd#FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:href="sibn-20181231.xsd#FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/FairValueMeasurementTables" xlink:href="sibn-20181231.xsd#FairValueMeasurementTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxes" xlink:href="sibn-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesChangesInValuationAllowanceDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTables" xlink:href="sibn-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:href="sibn-20181231.xsd#IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecurities" xlink:href="sibn-20181231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:href="sibn-20181231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/MarketableSecuritiesTables" xlink:href="sibn-20181231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStock" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/NetLossPerShareOfCommonStockTables" xlink:href="sibn-20181231.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStock" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables" xlink:href="sibn-20181231.xsd#RedeemableConvertiblePreferredStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactions" xlink:href="sibn-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:href="sibn-20181231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlans" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:href="sibn-20181231.xsd#StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:href="sibn-20181231.xsd#SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/Warrants" xlink:href="sibn-20181231.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIpoNarrativeDetails" xlink:href="sibn-20181231.xsd#WarrantsIpoNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails" xlink:href="sibn-20181231.xsd#WarrantsIssuedAndOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsTables" xlink:href="sibn-20181231.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:href="sibn-20181231.xsd#WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DFC1341A82AB66C3FD304BC9B1BA96BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DFC1341A82AB66C3FD304BC9B1BA96BB" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_C62DDDB9754AD9C5D8614BC9B1BA1E8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13AD8B498603C33FAD065A87C6DD1EA7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13AD8B498603C33FAD065A87C6DD1EA7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_06FF76C93F7F5F274D7E5A87C6DE4BCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_us-gaap_InterestPayableCurrent_E5D4CDD577FC8866BEC85A87C6DE55A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_C6B938FA9804D0DED6595A87C6DE9897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_AA1058E18F11228E98655A87C6DE775D" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LiabilityForEarlyExerciseOfOptionsCurrent" xlink:label="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_7A5D45A0D9D189129CA65A87C6DF65F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_7A5D45A0D9D189129CA65A87C6DF65F1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SalesAndProductWarrantyAccrualCurrent" xlink:label="loc_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_sibn_SalesAndProductWarrantyAccrualCurrent_32BBA95BACA48EB4911B5A87C6DF42D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4D080F3773B2A73E89B25A87C6DF7408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_28A0A662B6D76B7FFC9C5A87C6DDE78E" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B8246CE3F28528B67E615A87C6DFF9CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D98DD8E2C0E5B32B108E5255123E1C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3D98DD8E2C0E5B32B108E5255123E1C8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6C1C6B827938566795D595C243D6561B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_C87F812195525C28909545146A1EF8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_ConstructionInProgressMember_094347573B215CC3AC6E194CA72B5C2E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ComputerAndOfficeEquipmentMember" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_5BEA1F9F4991571389A262FB0F98FFAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_96AE88F33C4C5B78A9949C11FA65C327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_97D237D44A6B5720B63AA37C953E370B" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_B17D46EF8C165D9787B6BBA1FC9B85F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D2F59D34DA2257C28DB3800168C64B92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_F8F160068528516DB7B729A951289EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EDE117B96084524CBF386418BFDA0F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_AA17A16E90C05204B306CBDE07F36102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D12004FDA61D5AC99FA06C1E91BF71AF" xlink:to="loc_us-gaap_Depreciation_FD704C09A65C5A87B59C25C2FC51E36B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_444A7E7F636A51C2B11BFAE476F7332C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_444A7E7F636A51C2B11BFAE476F7332C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_75E6E297559F5AD492D0A1CB5FD7BFF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_444A7E7F636A51C2B11BFAE476F7332C" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BACC7A5FC58C56748968D57CDD815DAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_64AEDC0D2B4D2243AF004BC9AF47AFE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_64AEDC0D2B4D2243AF004BC9AF47AFE9" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_19B44B17C8C5E8A567574BC9AF47017C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B00D3E63B1EA29DD053F4BDAC0D53B89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B00D3E63B1EA29DD053F4BDAC0D53B89" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2BA2E2B858093CACADE74BDFE2AEB865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_C4A5F2DDEA961ED5FDF04BDAC0D52137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1A9C442EF84AAD79FAAB4BDAC0D5FFA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8BB619249144D71224864BDAC0D53882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_989B370D2F742929F1BE4BDAC0D5072A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_F53A407C2341A15719F04BDAC0D5AD02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_2969E15D2AF07FC291F64BDAC0D5D7EE" xlink:to="loc_us-gaap_LongTermDebt_47455130D75CDA41E7854BDAC0D587A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsEbitdaTargetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_AEB6996EF4EA0FD6E5956E6A3F7ED949" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_AEB6996EF4EA0FD6E5956E6A3F7ED949" xlink:to="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodAxis" xlink:label="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:to="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantPeriodDomain" xlink:label="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodAxis_24DD264E171D2EDE4D0B6E6A3F7F45AC" xlink:to="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodOneMember" xlink:label="loc_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodOneMember_8991003E8E0E2AF8AF156E6A3F7FB1FB" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodTwoMember" xlink:label="loc_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodTwoMember_0A8D13409452E821C1E36E6A3F809874" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodThreeMember" xlink:label="loc_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodThreeMember_EB19669689B3842788ED6E6A3F80AC3B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodFourMember" xlink:label="loc_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodFourMember_0A505BECA19C7541C9ED6E6A3F800AC4" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodFiveMember" xlink:label="loc_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodFiveMember_8FECFC8F0F96257090CF6E6A3F802EC4" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodSixMember" xlink:label="loc_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodSixMember_442551F28C0AA474573D6E6A3F80655B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PeriodSevenMember" xlink:label="loc_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtCovenantPeriodDomain_2C7586CA18B8799A51186E6A3F7F8C2E" xlink:to="loc_sibn_PeriodSevenMember_D207EF60B4E24234638E6E6A3F816861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0022CF214604AF8ACBE06E6A3F7E4D6E" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount" xlink:label="loc_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:to="loc_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount_7405636E640A830817D16E6A3F813A7A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA" xlink:label="loc_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6EE8BF582119A1894CFC6E6A3F8190B6" xlink:to="loc_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA_504D4C82A888A42A8A8A6E6A3F81B897" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1B3022399B8592A7EC064BDAB8CFB44A" xlink:to="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E16912840D9CA15FCD644BDAB8CF1BFF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="loc_us-gaap_UnsecuredDebtMember_99899144A0F59D1AF0FB4BDAB8CFC031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="loc_us-gaap_SecuredDebtMember_EC36BF2859B8DC87C4FD4BDAB8CFE480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B840BAB53F275F9DD9284BDAB8CF9B13" xlink:to="loc_us-gaap_LineOfCreditMember_F4CBA1003F2068FE8F6A4BDAB8CFA473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_DE921628AEA8B1E99CB94BDAB8CFB35E" xlink:to="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_D4E1594E264F1DCFB32A4BDAB8CFC7DE" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_421F509F594DB5D26DB04BDAB8CFF144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_C422E3A00E03799F13D04BDAB8CF53A3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SVBAndOxfordTermLoanMember" xlink:label="loc_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:to="loc_sibn_SVBAndOxfordTermLoanMember_D662AB3C3DD4A2F374704BDAB8CF7F5E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PharmakonTermLoanMember" xlink:label="loc_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6BD2214FC530DF6BEAE54BDAB8CF3392" xlink:to="loc_sibn_PharmakonTermLoanMember_7DD09CEA6E131DFDA54D4BDAB8CF0944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6A5F38F9B0672C5AD3C84BDAB8CF4231" xlink:to="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_9FB59589A24FCEDFE5D44BDAB8CF7E4C" xlink:to="loc_us-gaap_PrimeRateMember_748D43C0DA25CC27630A4BDAB8CFE4E6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodAxis" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtPrepaymentPenaltyPeriodDomain" xlink:label="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodAxis_23D04335FE4B696357D04BDAB8CF8CE5" xlink:to="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PrepaymentPenalty3148MonthsMember" xlink:label="loc_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:to="loc_sibn_PrepaymentPenalty3148MonthsMember_7A7019296BB89CBA73834BDAB8CFA648" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PrepaymentPenalty4960MonthsMember" xlink:label="loc_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DebtPrepaymentPenaltyPeriodDomain_0C22742A780C94B8857C4BDAB8CF2069" xlink:to="loc_sibn_PrepaymentPenalty4960MonthsMember_669DB480F2FB78C2415F4BDAB8CFB4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6FBC2E52DF79DAA7E0764BDAB8CF869A" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_LongTermDebt_2ECFE3F00CFF00A409A74BDAB8CF8FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_EA33CBAC6C002071A0F44BDAB8CF1F3A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod_45DF4815B761AC4A03724BDAB8CF8574" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod" xlink:label="loc_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod_FA24FE78E42AACD172814BDAB8CFE487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_24416F77B20A0DBB8D874BDAB8CF5695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1CB97F6A94F536E897A54BDAB8CF1BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_EFFBE743FBA25D132EFF4BDAB8CF5657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_DE00E0E08E5B61D7420F4BDAB8CF6D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0D31A7A33632D4AF22414BDAB8CFA5CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F0C7CC952F2CAEBC30EA4BDAB8CF5EE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_0590171152365106FBE64BDAB8CF040F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentClosingFeePercentage" xlink:label="loc_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentClosingFeePercentage_26EFCBB72E31D3C768674BDAB8CFE252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_0610382418B4A26F23844BDAB8CF38A0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentPrepaymentPenaltyPercentage_CD10B981A47DE579E1CF4BDAB8CF3052" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_2675EBC6A36B797603134BDAB8CF20D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_DDAE68E7BAA11CBCFBE74BDAB8CF081A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3A63ECA09BED230E31D24BDAB8CF540F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3E69E9CB365E0DEB4E414BDAB8CFA26B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable" xlink:label="loc_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0B746A22E83C65FA50E14BDAB8CFFDF3" xlink:to="loc_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable_8717FDA7EFF01393ACF74BDAB8CF8758" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_25EAC9FE283BA4B762075DBC661794D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_25EAC9FE283BA4B762075DBC661794D4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_66010D62F924E07917995DBC66172CD2" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock" xlink:label="loc_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_25EAC9FE283BA4B762075DBC661794D4" xlink:to="loc_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock_22EB4FA69A9F4FD985FE5DC409514E70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FAA5539726199DE71F9F4BC9B692A316" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FAA5539726199DE71F9F4BC9B692A316" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_65AC9B2E72C30AC7E2A54BC9B692D1BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0537E2A0802A0D2FF5E153A451410005" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0537E2A0802A0D2FF5E153A451410005" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent_1C0BC7F9F45784184B2853A45141D017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_45044341092217C6C8AB53A451424167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F1EF6497E29F2148E06F53A45142AFE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_D85494BB12860F5A862453A45142968D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_C7B2018B3BF4B92BBDFF53A451425D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_F4FB3DC672F920275E6A53A451425F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_B9405D3DE8DAA55625DA53A45141BD77" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4FAAC5752F576D5CD6953A4514336A9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EF820284FEDB6AF3045DE396145FDA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89EF820284FEDB6AF3045DE396145FDA" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_AAF744C5F17751FFA8E35DE3961519B2" xlink:to="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_87EE35D36AB3423B66E15DE396156A76" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_581DE7A08D556AA183ED5DE39616F274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:to="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_C0F1D7C2A7F9293B28775DE396167B9A" xlink:to="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SanJoseCaliforniaMember" xlink:label="loc_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:to="loc_sibn_SanJoseCaliforniaMember_468CE81B820275DEB1955DE39617E141" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SantaClaraCaliforniaMember" xlink:label="loc_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A5C6A4007EABCAB1BC2C5DE39617A421" xlink:to="loc_sibn_SantaClaraCaliforniaMember_7B75BFB2D6DC0E9912CE5DE39617A0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_DFB9CD3CC3E34C6D4D4F5DE39615918A" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_A0F65645568EA92FD5B95DE3961836AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnContractTermination" xlink:label="loc_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_GainLossOnContractTermination_2F608C47C12BE3C706B85DE3961853B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1A2AE3A73EDE7DE9D7915DE396196FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_PurchaseObligation_662C3A1DA40B60C241BA5DE396193FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_LitigationSettlementExpense_F3D76502908F19168C965DE396193300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2B27ED4FD9230D00C1415DE3961784D9" xlink:to="loc_us-gaap_LitigationReserve_EB248E750ACBC558D0DB5DE396193063" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4BC1FE5AF49D5C1CBC2312C07A3BBAE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4BC1FE5AF49D5C1CBC2312C07A3BBAE5" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_F87C1065892B505193E94CC110A377C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0734C27461AD6FD9969B4BC9B2DCFAC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0734C27461AD6FD9969B4BC9B2DCFAC9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_837EA5D1F0D1D903C5394BC9B2DC9C43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_033B771ADD423F1E00506E6A3F4001A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_033B771ADD423F1E00506E6A3F4001A9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0A8F8095C0A42C1906576E6A3F4165FB" xlink:to="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaap_NonvotingCommonStockMember_1BA35C91E6A8549AA1A26E6A3F4120FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:to="loc_us-gaap_NonvotingCommonStockMember_1BA35C91E6A8549AA1A26E6A3F4120FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_A3558C43FAE29B7C4AD16E6A3F42B7C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1F05CF8A51345B32D0646E6A3F41D336" xlink:to="loc_us-gaap_CommonClassAMember_A3558C43FAE29B7C4AD16E6A3F42B7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A15894276D12999DEA806E6A3F40B7F2" xlink:to="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod" xlink:label="loc_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod_D2734FC8525877456E016E6A3F428BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_AEAB286CB6CFC06A4BB36E6A3F42A7BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_AEAB286CB6CFC06A4BB36E6A3F42A7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7F0EC44FC62760D6E5396E6A3F43F204" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7F0EC44FC62760D6E5396E6A3F43F204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4D681658FE08682002AF6E6A3F43892D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4D681658FE08682002AF6E6A3F43892D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DA3DBC645C32ED5DDD486E6A3F43115D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DA3DBC645C32ED5DDD486E6A3F43115D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D1B8230B2A003AA7E31F6E8095A99A84" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D1B8230B2A003AA7E31F6E8095A99A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2A32ECFD8422FB501E016E810B6150A6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2A32ECFD8422FB501E016E810B6150A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E43FB4A86034197AC676E6A3F42A3CC" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_0E384B30D81F7E36227A6E6A3F43F0A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1EF2C658987C0FD67E084EFE1A6F6039" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1EF2C658987C0FD67E084EFE1A6F6039" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:to="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6C59F803A9EC1911C51A4F2E0A7AE575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_98BBEBC07576056FD8514F2E4D0778F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EEB7ABE3CA757721819D4F2E0A7ABF13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_98BBEBC07576056FD8514F2E4D0778F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:to="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_504BDAA792E74170459C4EFE1A7039F9" xlink:to="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:to="loc_us-gaap_NonvotingCommonStockMember_3A682DBBCB5179435A4B4EFE1A70B013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:to="loc_us-gaap_CommonClassAMember_1F3B016990052BCA542A4EFE1A71F211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_D72D2547F44E8D3997724EFE1A71445B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A04603BBC64E12492F744EFE1A70C844" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_D72D2547F44E8D3997724EFE1A71445B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6CD2A20A91C89323BCAB4EFE1A6F4C95" xlink:to="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A34118DE2117E2B73B8C4EFE1A71F223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_911819D7B815FD9510D74EFE1A7251EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_911819D7B815FD9510D74EFE1A7251EF" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares" xlink:label="loc_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares_12D488066A046030A6C54EFE1A72CB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_26042A69C2F279D4BFDF4F2BC550BCB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8109299845BA63D00D8D4EFE1A727F99" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockEquivalentSharesStockOptionsOutstanding" xlink:label="loc_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_CommonStockEquivalentSharesStockOptionsOutstanding_9BA1E85CC96B050785484EFE1A72338B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E8C1051C5F9589D3DCF74EFE1A72A6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C63C55AAC0B1C0C979B34EFE1A72D044" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C63C55AAC0B1C0C979B34EFE1A72D044" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights" xlink:label="loc_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights_B31EF9ADA774F04823A14EFE1A73FAA0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance" xlink:label="loc_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance_3C3567BF1E084F0B1AD94EFE1A73B404" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance" xlink:label="loc_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4F118B086143CB98D79F4EFE1A71A161" xlink:to="loc_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance_72B6578FD940BF8FB86A4EFE1A738DE8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C93050EA6CCC5197874B3535E6205025" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C93050EA6CCC5197874B3535E6205025" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_07772CB5466056BA94C2D7414BE6889B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CompanyAndNatureOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_670FAF55CEB0561C960EDD967DD9AB86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_670FAF55CEB0561C960EDD967DD9AB86" xlink:to="loc_us-gaap_NatureOfOperations_0475ED316C9156F1965ED1BCDA29221C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/CompanyAndNatureOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0A2598731427FAF2B2349CA5212E9C5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DA910F89FADC0E18080C49CA5213704F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_0D854EE662BAB2444E5049CA52140BFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F7A1D8A275A47EFA545B49CA5214F254" xlink:to="loc_sibn_WarrantsLiabilityMember_0D854EE662BAB2444E5049CA52140BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_88BD0229985C90F736DA49CA5214540C" xlink:to="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_B079439337D6B78E1CE149CA5215400E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_B079439337D6B78E1CE149CA5215400E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_D21F2E5B2106E7B1DFAE49CA52150927" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4A45CD60A911FABAAAFF49CA5215C5AD" xlink:to="loc_us-gaap_CommonClassAMember_D21F2E5B2106E7B1DFAE49CA52150927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_99C34213D8D0B2E8AECC49CA5215A04D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3619F2E271158005D71A49CA5215219E" xlink:to="loc_us-gaap_IPOMember_505C4A47156F7F3D390549CA5216B3F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_260A62F542A1CF97E17849CA5212998D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B0948DF3C8BF1423E78049CA52164027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7BE03D448BAA1B26C32B49CA5217696E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_29B41112F1CD1B5CD54049CA52172DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5FD03DE77B532972988F49CA52177C95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_71456F2448DF0DF076C049CA52172F77" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" xlink:label="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_C362249C556BDDFA4E1949CA5217F732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_62B9B4C4C68695EE39E249CA5217E3C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_73915F6A6F01E724661049CA5216D0FA" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17F0D71C0C68329F5B5449CA5218EA04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:to="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:to="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81749B16CD99B1E1F39378FFE01FA7AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BAB24B32D08A5EBA040578FFE01FA7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6F7E010E987202BA135B78FFE0202C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="loc_us-gaap_InventoryNet_E50872FDC2827E7AAE9478FFE02096DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_EF8DEE8A6E8AB8E6E9FF78FFE0205F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_A103F68B3D8774661C8778FFE01FC214" xlink:to="loc_us-gaap_AssetsCurrent_8EAB4067DD9B29A74F2F78FFE020427A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3DDAADF6DC2F6853063A78FFE021FADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2CC0C763D08AB5E7099678FFE02122DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_085E1F32BB286D8947FD78FFE01E5663" xlink:to="loc_us-gaap_Assets_D4704DE8BA222C4D599E78FFE021DE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86915DE92B8AB6A65C7078FFE01E63C0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:to="loc_us-gaap_AccountsPayableCurrent_DBBE06F1971B67FDF58678FFE022E126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_51E02A3A0EB8E4DEA90778FFE0226E53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B9A25044CFC9817F42D78FFE0214CC9" xlink:to="loc_us-gaap_LiabilitiesCurrent_8D0E7153E0592B2F44E778FFE02282A4" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PreferredStockWarrantLiability" xlink:label="loc_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_sibn_PreferredStockWarrantLiability_47486A94C605186A922478FFE0221279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_F0A9D67CD611EA4F5DB178FFE023728E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2BD0192DCA4158C3E49E78FFE02388A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_Liabilities_944932CBD745CBFEE3E578FFE023E441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_CommitmentsAndContingencies_FD687456C68FEB7115E078FFE0230674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_A7ED32A81C479BEB181678FFE0237D42" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_982D21449AD7881775AE78FFE0244C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="loc_us-gaap_PreferredStockValue_89B2A85DA13503783F4C78FFE024D235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="loc_us-gaap_CommonStockValue_E284AC82484FC1323F4778FFE024A742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="loc_us-gaap_AdditionalPaidInCapital_F55BC139822497B0FA4978FFE0255C45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4A897E34FF79C98E4C9F78FFE0252CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6A5F5B755D843F3F08778FFE0252289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06DBB37D7A6E96BD466978FFE0241E92" xlink:to="loc_us-gaap_StockholdersEquity_255776A6BE0D2BBA2D8278FFE025D14F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DDD536B05BF06C2AC8DC78FFE0219888" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4DC1536A37CE455BA6C878FFE02534E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_B7BE102708A8B32329BF6E6A41FFD958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_36F70F5D2F735FB678906E6A41FFEC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_C36BFE5838DB96FC4B286E6A41FFDD87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_48E3DB5052EF99C9F8ED6E6A42009255" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_48E3DB5052EF99C9F8ED6E6A42009255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6AE1D50CA47A154995AB6E6A4200128A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6AE1D50CA47A154995AB6E6A4200128A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_CAD83FEA3972873E20106E6A4200D2E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31EB9C3FCED4529E517F6E76F03AE0D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ABAE7082006ED9265C696E770FF637B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_PreferredStockSharesIssued_34912966EFDB57A4255B6E77230ECA53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_F9BC5163AE4606E712F66E77401CD9BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_288D228C2A77E80777866E6A4200DAF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3DC30E8CE6295F2357BF6E6A42007D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_CommonStockSharesIssued_38130F2FC98275C9D6766E6A42000386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F2417FAEB16AE5F088C66E6A4201C360" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1EBA94D544AF46732E766E6A41FF3541" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F2417FAEB16AE5F088C66E6A4201C360" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EC2F72A0A9716606E7526D433F9779AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:to="loc_us-gaap_NetIncomeLoss_EC2F72A0A9716606E7526D433F9779AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3585202E42E67A9AD9486D433F9824EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_E5FAAC2EEC04EF96E0846D433F985C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_ShareBasedCompensation_1EF1A11DF11D11EA9EEE6D433F987A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_80334F251E2B5CAC55EF6D433F99522F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F5431EC22E7A0F6268B16D433F99ECB4" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WriteOffOfDebtDiscount" xlink:label="loc_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_sibn_WriteOffOfDebtDiscount_E0CE542B46C2E558231F6D433F9913A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_85F346A0C65437B8569D6D433F9989EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_85F346A0C65437B8569D6D433F9989EA" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WriteOffOfInitialPublicOfferingCosts" xlink:label="loc_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_sibn_WriteOffOfInitialPublicOfferingCosts_1D2DC7B85957D09636AC6D433F9A4A8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_F4C894BF84319464E09C6D433F9AAD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_20BFB1BAB6778D3F594E6D433F98FD34" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3A0819497948B5328D1E6D433F9AD21B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9D3C0C21E2CB9BAA45106D433F9A75C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5F6F871C9B16DDCEB70A6D433F9AABFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A55E6E25594CF3EF90856D433F9B3684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_E0C4EDA8BDA8722233266D433F9B5EB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C0EC84111BEC471347476D433F9AD996" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1C8ABB2F12A78C24F1CD6D433F9B3D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AF3E89BCE2DE46B1FF1B6D433F978125" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57239F56371F3CA342D76D433F9CF7E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9B48DAA7F51F7382D0526D433F9C237D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_B4EE0667B4F3BF029BDD6D433F9C414C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C20F2AD2BA72359B6DD16D433F9CE63B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_D8450EFC6F52671D0ED16D433F9C8B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_562FA25B94B77777B0526D433F9D16DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_D8E46C1DA43DEDFCAD666D433F9DE9E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B70068BE9E784A958CE26D433F9D64EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_6531A2986C761323ACFA6D433F9D23D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_6531A2986C761323ACFA6D433F9D23D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_53D5BD5F529C726655B86D433F9E0949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_D5CC681C308C6169044F6D433F9E592D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_F0083BEC98AD980AF5766D433F9E413D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_857AA68221A078945CB66D433F9EB658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_003992A530BEE93954F16D433F9E7990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_F505B35D76F3830FAF706D433F9F58E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_EBB3B3CC49F95C1943C96D433F9D09AD" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_C3B145571E2E349149106D433F9F5E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7CB8F1164397AD6098AD6D433F9FE7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B3ECEB06BF86C7F55C76D433F9FA82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D7F6DE4996D82C9FF6DC6D433FA04F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2942C33645A822D60BA06D433FA018C7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9AB73DE3CCCCE551D9236D433FA090F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6A9FE60DAA395EA31DA56D433FA070A3" xlink:to="loc_us-gaap_InterestPaidNet_A3196C3F746A928822F76D433FA0ECE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_CB7706D0DD396CACEA8D6D433F977657" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_59AB74C9AA0F569364D36D433FA122A1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NetExerciseofCommonWarrants" xlink:label="loc_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:to="loc_sibn_NetExerciseofCommonWarrants_D8A5F176E43498D2FDA06D433FA1F462" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_VestingOfEarlyExercisedStockOptions" xlink:label="loc_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:to="loc_sibn_VestingOfEarlyExercisedStockOptions_4EE4691C248EA60DEFE56D433FA1629D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6511D9BD369C3D330B6C6D433FA1B082" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_InitialPublicOfferingCostsIncurredButNotYetPaid" xlink:label="loc_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_940E2EB2D3016A0278066D433FA177BF" xlink:to="loc_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid_DD7EB7D77CAAEC57DCD56D433FA2E399" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3903AC99812144A0AE8B6E6A41BF5A24" xlink:to="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47AE45CEBB4238AAF2816E6A41BF1F24" xlink:to="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_CommonStockMember_344AD0186293AD1896BD6E6A41C0E6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_278E4B252293013874C46E6A41C094BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_C81E39576882050B20486E6A41C0E69C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0C5C52A9A3C2058562BB6E6A41C10663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0BF47232CBAA53E615526E6A41C0D0DF" xlink:to="loc_us-gaap_RetainedEarningsMember_27AE314054C6CC8ADBB36E6A41C17EFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4B4A42EA7CB4CD6F0A796E6A41BFD6DC" xlink:to="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7DA7C17C62B0919079E76E6A41C13FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8F7AA36F5CF6D7A51D3F6E6A41C201D6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A10AA17D4858CB52F8A56E6A41C24684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_B67B3193ADA607554B336E6A41C21C07" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares" xlink:label="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares_082E63E9B67CABB9F16C6E6A41C2BA83" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue" xlink:label="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue_92F50BBA4F853B9130BB6E6A41C24698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_931BC1B8F57EA2286EEC6E6A41C2F133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_8A7027C6389DDCCEC87A6E6A41C1DED5" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_788F26A30E8560C511C06E6A41C3CD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13D22E5A07FDB03C5D466E6A41C1A2AF" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_SharesOutstanding_90DD2B7AF65E23975BE16E6A41C32920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockholdersEquity_0CC310B732F02B117E736E6A41C349D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_AD76F5BE5B42906799BA6E6A41C38005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C84BC066750CE7B56DC16E6A41C9D298" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised_347DED477BBBE4B76C126E6A41C91029" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised_E85CE150788980B94EEE6E6A41C97072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_633B5C86E3DC3BEDC11D6E6A41C94831" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_D7FB6B4DE0C1C1EE8FAD6E6A41CA5087" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted" xlink:label="loc_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted_967C6E9C88C52C70F4826E6A41CAE46C" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodSharesWarrantsExercised_9C580559B2B0C96CF5926E6A41CA490F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockIssuedDuringPeriodValueWarrantsExercised_8851A6B58DCC9E1222356E6A41CA6FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6454329283E1F663CEAF6E6A41CAAF11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_825623E9A13EAF6A85B26E6A41CAC9DC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares_37F2DAAC3B7FFA07BF4A6E6A41CBDAA8" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue" xlink:label="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue_D89885CA688479E7A48B6E6A41CBE62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06AEDD4708D341A6EF3E6E6A41CB35D1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived" xlink:label="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived_BEFC7829000A89E783806E6A41CBBB2B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt" xlink:label="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt_173F1640DFBAB272DA266E6A41CB6FE6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions" xlink:label="loc_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions_2F2617A9A7C1E7EA9DEE6E6A41CBD28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0EA087A0789B635899E16E6A41CCF5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4E9A8809DEDB41AD19E66E6A41CC1172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_NetIncomeLoss_7AAABA4DC61A22320F8F6E6A41CC4DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_SharesOutstanding_4820B903FED634FF441D6E6A41CCC64C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8A4527B3532C9D49D7936E6A41C36E62" xlink:to="loc_us-gaap_StockholdersEquity_F88516D1C891F6AA03C36E6A41CC8CF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_FD5DB2DD6BCABBC6420449CA524CCA5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_Revenues_FD5DB2DD6BCABBC6420449CA524CCA5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5CE2F5C0CC9851F4E71D49CA524CDB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_GrossProfit_DB9B81E896C33D177E5E49CA524D5B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:to="loc_us-gaap_SellingAndMarketingExpense_949F36E2CB6D5B80D43849CA524D97AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FDAF88FE1CC39DA0013149CA524D04B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_D01283333B169937251F49CA524E171C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6BB8A56D5DFBD86A105949CA524DC584" xlink:to="loc_us-gaap_OperatingExpenses_A6ABF6B93A449C84E50249CA524ECE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_OperatingIncomeLoss_10E802EC3DF58CB72BEA49CA524EECBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_E1B65421BA685A29B9B549CA524EB03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:to="loc_us-gaap_InterestExpense_1C2BA93F0CAB3B3EA96649CA524FFB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2135781A7F888052F9F649CA524E3BD6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_29841584E9136C97045749CA524FD6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_NetIncomeLoss_31ECD114B987D91B9F1F49CA524F70E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_B78766B0288C7FD054F74A2887DFC26F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_699AFD68B6950A4C65ED49CA524F1FC6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7A4F19ED6D99797D482249CA5250B894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB5CEF415B36E2ECBC2849CA5250E709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_C2BE9176C480AF3E229149CA52500E65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FA9C1B9B3235A0A59FB649CA524CC13C" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7EA237C7FDAB66C5B18F49CA5250C216" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DocumentAndEntityInformationAbstract" xlink:label="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_DocumentType_41DF0F92D9565A3F487849CA525DAD67" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_AmendmentFlag_C33A99394C5AE05E58E949CA525E644B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_DocumentPeriodEndDate_EF653F8D13F6EC1A747849CA525E35BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_DocumentFiscalYearFocus_46D510B5330767ABC48A49CA525EAB14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3F4888E387BB9A902AAB49CA525E69C2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityRegistrantName_45633E764DD15BF0038449CA525E7931" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityCentralIndexKey_263D3EF29DBBE230F51D49CA525FEAD4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_CurrentFiscalYearEndDate_F1AC14886F3EFD013F3B49CA525F61E2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityFilerCategory_509962A9DA543B9DCB3C49CA525FFF60" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntitySmallBusiness_B2C72687D09B4C68991C49CA526015F0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityEmergingGrowthCompany_39CD9E576BC089A69A2F49CA5260FE56" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityExTransitionPeriod_AEAF5D9456D55A389C5C49CA5260BDE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3ECA79D98DB94D262E6D4A1B0175D277" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityVoluntaryFilers_3496F3B4E01384473E814A1B1B7A9DE6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityCurrentReportingStatus_DD06A4022EB52BE4022C4A1B2D34D335" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityShellCompany_DF3AC68CC1B1131958E44A1B473BC800" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_BD18FB7F4A58A3EA57CB49CA525FECFF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_DocumentAndEntityInformationAbstract_AD69D9F00452367CDA9449CA525DD80F" xlink:to="loc_dei_EntityPublicFloat_795408B5469A29B692AB4A1C32274B8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8CE13F2B485ED2065EB84BC9BB3F950D" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_080BB0A6596EB1F138A74BC9BB3F4023" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8B0EE3B5D38B6B07C7804BC9B81F768C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8B0EE3B5D38B6B07C7804BC9B81F768C" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_EE250623E2B5BA159FCF4BC9B81F4F52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5AB1B94D0C1ED494C82F4FF3BC9D54DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5AB1B94D0C1ED494C82F4FF3BC9D54DA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E75B4FAD3128850939824FF3BC9E831C" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_78303923F45A8693376A4FF3BC9E1D09" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0970BD67A9C2B726CA554FF3BC9E84D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_956FCC9605F812AC57F74FF3BC9FDE68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8F0DE774FF0E2F85FE884FF3BC9F07A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8638FEEE80A2A3F317264FF3BCA0D3F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A4429107C06AFAFEE4FF4FF3BC9FE07C" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_117953070838BB4F9EFF4FF3BCA02B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_946E6F3BE35E008D20314FF3BCA0F0EF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7ACD16D8AE3F326FD0014FF3BCA036E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A50669C33E55ECE8F2094FF3BCA153E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9EEC0C3EA3097DC5A3364FF3BCA13CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_A12112DAA3B3B96F6C6F4FF3BCA022D2" xlink:to="loc_us-gaap_CommercialPaperMember_CF61C1D32E3C531F0E284FF3BCA1C9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0351AE215C5A2FF1147A4FF3BC9DE2D9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1CA07D78E22009C6395F4FF3BCA24F9D" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_CEF559665847DE3D5F584FF3BCA2A997" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F9B2E143C7C339673D464FF3BCA253D2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_208F17A0F744DBE293F84FF3BCA23B81" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_5718860BA4D982ED67284FF3BCA2D169" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DFD1214EB1EFFB33DD0C49CA51BD8D0F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BB0907D6B79E0650075849CA51BDD7E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_844FAF8DDAAE6BACFE0A49CA51BE9139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_396AAE73CC8AEC2E53E64A9FABC3D65B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3E8C58EBF5CAD79D569E49CA51BD6F4C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_D2AFDAEB25128CC5CAE149CA51BE1953" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D2934056DE2550A988B422104ADC3A2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D2934056DE2550A988B422104ADC3A2F" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_832C5F00BA435F8890B99F8E4FBF2478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D2934056DE2550A988B422104ADC3A2F" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4AF7E929AA355D2A92932443B32EF5E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9FE5691A5AFCFD11C7184C72DA59FB77" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_D8BF1CC77103B4DE04F74C72E0E31814" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D194AC312E7A1E85ECDF7A514F37CED2" xlink:type="locator" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncomeTaxesValuationAllowanceRollForward" xlink:label="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D194AC312E7A1E85ECDF7A514F37CED2" xlink:to="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_023EF1593999DD2EB3677A514F38C14F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5125F77B294CA59D1CCD7A514F3814EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sibn_IncomeTaxesValuationAllowanceRollForward_028787FE76D4595349AF7A514F38FE5A" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_49AB120C28F8602C57217A514F387787" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F8E8AD0E987812987F3F53F61C9BC605" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F8E8AD0E987812987F3F53F61C9BC605" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_53744AC7934C78474E6D53F61CA66564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1B71A63C787FD0760CE553F61CA62F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_AFBD1AD25E543A21506253F61CA6E6BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3801822FA6B9625F377453F61CA53C6D" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0260D8867D2D9BDC37D853F61CA6985F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F8E8AD0E987812987F3F53F61C9BC605" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_EF3764F9287682E7BE5D53F61CA7CD21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_15669A9817868A78ACF553F61CA78044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_D6D5EAF49C7605424F3053F61CA7ED06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_077F1DF442905D812BB753F61CA7889B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ECA1230BD0350E75B97B53F61CA78577" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance" xlink:label="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25E6B3EC0B97B43271CB53F61CA60377" xlink:to="loc_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance_018227601AACC58376AB53F61CA76D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F8E8AD0E987812987F3F53F61C9BC605" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9C13E2C547921C15069353F61CA7D8E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8AB468BA4BAD4B47340853E5F871076F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8AB468BA4BAD4B47340853E5F871076F" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_54FD714202568886473C53E766B1DDB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_F7C8BA087FFE0EAFBDCF53E782DE47D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_E51E664898B4DC14A62853E89554EB41" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1B51B7A80B6462ABA14B53E7A7BDC31C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_22697021569FED447715786962CBB1FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_22697021569FED447715786962CBB1FB" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_A7459500D4D8058A5071786962CCEE58" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:to="loc_us-gaap_DomesticCountryMember_6EA4D52601A24FA6BF68786962D2AD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6AF78441502F285ADE8D786962CC0530" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3CE460C488C1132E59F0786962D248AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8584D2784732C9618AAA786962CC9DB2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6C23BF8DBBBE68CDE962786962D330AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_600325F62A7F01D2CF7F786962D3E2EF" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_OperatingLossCarryforwardsLimited" xlink:label="loc_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_sibn_OperatingLossCarryforwardsLimited_86259D42622091AEB6C6786962D3201C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_BA62896E40594D0B5859786962D328B9" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate" xlink:label="loc_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_D573A628A5C1E85A4854786962D255AF" xlink:to="loc_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate_9362CD36BF631CA5C24C786962D3428F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7E5ABA5D3D3EBD8A8FCF5DE3949F18E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7E5ABA5D3D3EBD8A8FCF5DE3949F18E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_A16352BFC26E389408655DE3949FFA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_29D3D0F9EA6772259AF35DE394A0DF47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_EBCC31A28080A8074AC05DE394A0A7EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A5FA600EB365B45DC5F25DE394A01A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_90F07AAB1335E1D770935DE394A0AD93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_BEBB17129ED8ED2719B95DE394A02262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2DE482CDD1B1517365745DE3949F3621" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_B1A80C055BAA3490AAC35DE394A100CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_465AD3672F4AB244926E7869632B2AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_CF2BDAF6B68E6AA7D7C17869632BA912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8983A61988A31686FEC77869632B0EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16C8BB92CBD28AFA1D477869632BD90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_22E04924E7A380C1538678D545712DBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D707C35EE60D132020EC7869632BE6D5" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_D1685CEDDF71AFC700157869632B4E7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FB7FD8C2E5CE30C72CDE5412CFA2C15E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FB7FD8C2E5CE30C72CDE5412CFA2C15E" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08E82843CAA53FBDE77854147310339D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E6BE679A85B880C180D05414A4D97A02" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_sibn_DeferredTaxAssetsDepreciationAndAmortization_973DA4FB14B084B29CDB54173F0BA356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_E465D180ECB2E99479B2541769988159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1FD13653DD9D8705402354178F01BADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE88C7D285BAC56C1EA35417B10D6884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_DAC929FA48870A10B4885418E5171228" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_B99E5D3B1811522D36125417CD63F1F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2DF485EA6BA0B51C0C39541E52DF7909" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2DF485EA6BA0B51C0C39541E52DF7909" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_219D36410D9816FB2840541E52E062B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_973423A1A24C551F7261541E52E0FF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9AFFDF3900F10845594F541E52E08D71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1862EEB6A19218B87B80541E52E04340" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24DCC2B59252DB6C83246E680E9FB0EC" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BAA1D95E9EA21B0A25876E680E9FD360" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9D138818688D840DAEDC6D433F3EDA95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9D138818688D840DAEDC6D433F3EDA95" xlink:to="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:to="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_51F96DF1187E6E35C8496D433F3F08EE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_E5053ECECF6533AF52DE6D433F3FFF77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_E5053ECECF6533AF52DE6D433F3FFF77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_85396A5A0F9720BADB1C6D433F3F2879" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_85396A5A0F9720BADB1C6D433F3F2879" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_38EA44E3EF070F83F61C6D433F406D73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_CommercialPaperMember_38EA44E3EF070F83F61C6D433F406D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2F0D746EA3D8B4917FE26D433F40BA35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89770515F87004D39DC56D433F3F47F5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2F0D746EA3D8B4917FE26D433F40BA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_1F0F59D86B93CE4D9FCD6D433F3E889A" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_B333ABB038F1EB4781916D433F41E642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_FCA4DF0C5E4EDA6A80286D433F41EA3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_40F9578882A57DB2F3C66D433F4150F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1FFA864699CEF895D48B6D433F41924D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BFFD00E400AE6DB52D176D433F42193C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_985CBA91C29B02EF67996D433F426808" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_520B6D2035E283F91E896D433F4222F7" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAmortizedCost" xlink:label="loc_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesAmortizedCost_7FE407A6579E21C5317E6D433F42F607" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75D9300268A7BB239BFD6D433F42FD26" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C2B34891BB62FC1CCC36D433F431F60" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MarketableSecuritiesFairValue" xlink:label="loc_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_A980798353D7A6BCC5CF6D433F40F598" xlink:to="loc_sibn_MarketableSecuritiesFairValue_BAF419216912AA6C8E2D6D433F439BCC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_897FB4F1369E354B80BC4A82559860A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_897FB4F1369E354B80BC4A82559860A5" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_D93536F6B55655639CBF4A8316EE2F52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B04D95C7FB972F907CF54BC9B4470740" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B04D95C7FB972F907CF54BC9B4470740" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_F13E2BEA8B068D7C976B4BC9B447AA86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9FE79C5F8D568E51396B4FDC870F7566" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9FE79C5F8D568E51396B4FDC870F7566" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9F304AD16CEC7CF461E64FDC870FE553" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75CBE976A186B8F7BC1C4FDC8710DE48" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareSubjectToRepurchaseMember" xlink:label="loc_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_ShareSubjectToRepurchaseMember_E50F9911159EB0CE26AB4FDC87110C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_454FB20EB74B5A7A8A1D4FDC87112FB9" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_EmployeeStockPurchasePlanSharesMember" xlink:label="loc_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_EmployeeStockPurchasePlanSharesMember_7E780AAF90E588BAEDCC4FDC871181C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_7509C37AEFE984978DB34FDC87111642" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="loc_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_RedeemableConvertiblePreferredStockWarrantsMember_A60A61785A038EFF5A0E4FDC87114303" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockWarrantsMember" xlink:label="loc_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5C342D5E9265B32426B4FDC8710C563" xlink:to="loc_sibn_CommonStockWarrantsMember_1FA296C77A5C522AEC3D4FDC8712F9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_DD2137BF4B9425275CF74FDC870FADD8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0879E2A28EE45DE7AA5F4FDC8712C3AC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_CEA1050C65FF00B683B14FDC87126D62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8C02DDC6AF8626885CFE4BE2C1D3FDBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3034911AB4584A15FA494BE2C1D32DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8C02DDC6AF8626885CFE4BE2C1D3FDBC" xlink:to="loc_us-gaap_NetIncomeLoss_3034911AB4584A15FA494BE2C1D32DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_067972D41D65586537EE4BE2C1D4E541" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8C02DDC6AF8626885CFE4BE2C1D3FDBC" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_067972D41D65586537EE4BE2C1D4E541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B7D4F5F329110DB922BE4BE2C1D4879B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8C02DDC6AF8626885CFE4BE2C1D3FDBC" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B7D4F5F329110DB922BE4BE2C1D4879B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D6AB17C0EEDC4F3529F74C6E6E0D6D1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8C02DDC6AF8626885CFE4BE2C1D3FDBC" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_D6AB17C0EEDC4F3529F74C6E6E0D6D1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/NetLossPerShareOfCommonStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B5A95738F66253F6B158A026BDA69432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_34E63223542F5368B526F1FDDAC70B86" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_64BC144365345DC7A00C7D669CFCBEC3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_010031569CC3E5438CD14BC9B07C68E6" xlink:to="loc_us-gaap_PreferredStockTextBlock_E63BE6D1CB3B3481B9A14BC9B07CA01C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_AE7058DEDFFF9398AE2E5A87C6969C77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_04851E5A0D96EC6A48365A87C6992013" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_AE7058DEDFFF9398AE2E5A87C6969C77" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_04851E5A0D96EC6A48365A87C6992013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3E290BCA2EB161EDD8B15A87C69AAD19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_AE7058DEDFFF9398AE2E5A87C6969C77" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3E290BCA2EB161EDD8B15A87C69AAD19" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_24990FDDE238C21D3BA8786964FF5B10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_24990FDDE238C21D3BA8786964FF5B10" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75A2DCAFE1DC79550B45786964FFC33E" xlink:to="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_E643AEE6430249838A73786964FF4721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_012010988664A41AE2C17869650F1867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_936213360F13B98240DB7869650F364C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_558F9DA1351C5B6A83097869650FFDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_4E2F51502CFAFFA09B307869650F187A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_4E2F51502CFAFFA09B307869650F187A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_267DDB10D98627AF801D7869650F6C16" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_267DDB10D98627AF801D7869650F6C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_E3AED4854D8C6A645F287869650F93E4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_47DE81B9F538306EEB25786964FF39BF" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_E3AED4854D8C6A645F287869650F93E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_427384844D29D412B701786964FFFDD4" xlink:to="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_F1758B78B82758306AC67869650F9F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_D9C2D8C31A2EFEB19F757869650F7E19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_B7A8D1D4CFA7EC1EE0647869650FB09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28D13526BB1D37E12B347869650FC74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_1A6AD2BF2E7F398F17127869650F9314" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityRightsToVotesForEachShare" xlink:label="loc_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_TemporaryEquityRightsToVotesForEachShare_3A495151B74DF7C9462678802E115339" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_PreferredStockNumberOfDirectorsEntitledToElect" xlink:label="loc_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_PreferredStockNumberOfDirectorsEntitledToElect_FF4C9E311EC3BCB63FEB78BDCC26FEF3" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect" xlink:label="loc_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect_1DD9160E0733FEDB3CBA78C355B0DF99" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding" xlink:label="loc_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding_6EE3D3E119CE660BE48E788C451B3155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_PreferredStockDividendRatePerDollarAmount_4365D92B669F2D83384E789267D205A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_777C5AC9BE1EA6A9C334789D5B845153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8054862B5726F37E8A7A78A6697B3BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_318EA93DF65EE0BACE1F78B15D5A4C1C" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_TemporaryEquityLiquidationParticipationCapPerShare" xlink:label="loc_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_TemporaryEquityLiquidationParticipationCapPerShare_27DDE136D2E640B1465778B5D930D8FC" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockConversionPrice" xlink:label="loc_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_ConvertiblePreferredStockConversionPrice_4D261EA593F60D45343878B848C52F52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_A1105D51D1850868D85178B9AF285F46" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion" xlink:label="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion_21546405C476585F856C788DEEF685B0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion" xlink:label="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_9B8337B76242B26A2D317869650F0288" xlink:to="loc_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion_DC4D3E96A1267601C01E788EA292BE2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/RedeemableConvertiblePreferredStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_DEC78A0D31FB588D85214BF444931D1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_DEC78A0D31FB588D85214BF444931D1B" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_DEBB2703A6A8564D82BA9759517615BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5494EFC988666CB753404BC9ADF21614" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AB7D3739B26F215471754BC9ADF28995" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_082B472900432F5546F24BE2C1DDB2AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_082B472900432F5546F24BE2C1DDB2AC" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_86AA1A9C660A7BEE65FD4BE2C1DDCDAA" xlink:to="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_53FEB991517917D184024BE2C1DE0FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4343BCFD3550CC94632B4BE2C1DECF16" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_4D0BC1E78DF06380AE3C4BE2C1DE8AD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2061BAE2CE87E20A1D44BE2C1DECD72" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ForgivenessOfRelatedPartyPromissoryNoteMember" xlink:label="loc_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E52C9463E754A99D3D1F4BE2C1DF4A5D" xlink:to="loc_sibn_ForgivenessOfRelatedPartyPromissoryNoteMember_B358FBE6EEB5FCA6BA8F4BE2C1DFE7FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C259052F799E73DD4FBC4BE2C1DD0AEC" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock_873753FA5C6500AB9A754BE2C1E072CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_27F6B36C5AB86E9D54CC4BE2C1E074D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_17C9E7EAC8AC903DA4E34BE2C1E00E1A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven" xlink:label="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven_6603421C40EF79F647134BE2C1E06C2E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness" xlink:label="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness_D1923969B434CBF319174BE2C1E01302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7D595D12068E170D48DF4BE2C1E18A4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5089C1E587289DAA605E4BE2C1DFF1CE" xlink:to="loc_us-gaap_InterestExpense_2CFDD3B79C3AE84B60D94BE2C1E1BD5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B6650501C7CAAD1801DF78FFDE6E34BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B6650501C7CAAD1801DF78FFDE6E34BF" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA5F994753158CF701C378FFDE6E4170" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F85155CA5293D2BAF1778FFDE1352CD" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:to="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_65AF0B08F0A6697599C578FFDE1393E3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StockOptionsandESPPPurchaseRightsMember" xlink:label="loc_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A6A6CB90A6722DB3288478FFDE14CD57" xlink:to="loc_sibn_StockOptionsandESPPPurchaseRightsMember_9EE49F047837FCE8DEC378FFDE142B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62CCDFECAA1DA05248F378FFDE132B23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2F0F202B154AB9CC7AD378FFDE152F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_66DED59A5D0B7FB612B178FFDE156FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452ED7FB23F479DD304478FFDE15CF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3A8D25E15D85AA2EE4CC78FFDE150237" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D85ECF8B81D9CA6AC8B978FFDE165BEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9B84E7ECC20ABA312B3278FFDE559F9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9B84E7ECC20ABA312B3278FFDE559F9B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8A54986250B05CD9EB9778FFDE5614A1" xlink:to="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2008StockOptionPlanMember" xlink:label="loc_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="loc_sibn_A2008StockOptionPlanMember_76D14C1E30C83E0C286378FFDE573377" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2018EquityIncentivePlanMember" xlink:label="loc_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="loc_sibn_A2018EquityIncentivePlanMember_3929ED09C6F4B571487D78FFDE576487" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_A74B3CA8B197A269814B78FFDE564F4E" xlink:to="loc_sibn_A2018EmployeeStockPurchasePlanMember_0C8EABA6139DA244D37178FFDE57D66B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_656EF579760ADA6ABBEF78FFDE57B27A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_IncentiveStockOptionMember" xlink:label="loc_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_sibn_IncentiveStockOptionMember_2B0CE3BD264BB32DD25778FFDE58B8A0" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NonqualifiedStockOptionMember" xlink:label="loc_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_sibn_NonqualifiedStockOptionMember_506D9DF83DB62BE4794D78FFDE586026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4F49735BE78A7375C29678FFDE597BCE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4F49735BE78A7375C29678FFDE597BCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_09A72ECC8093412D5D8C78FFDE598496" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_09A72ECC8093412D5D8C78FFDE598496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D56CDCC0A837B6A5365D78FFDE58619A" xlink:to="loc_us-gaap_PerformanceSharesMember_59E1AF8FE555F8DBDB8178FFDE59FACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_842E3EEDBB9A92B71CB678FFDE59F6C9" xlink:to="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6AF577E80064A00D13AF78FFDE5AFEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_E1027C6EE37504673DAA78FFDE591631" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_B21D04E836D45EADFC0478FFDE5AB789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D345E44AD26E4A776EEB78FFDE5A745B" xlink:to="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_94E59053F329CDF4FFEA78FFDE5BE904" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:to="loc_srt_MinimumMember_94E59053F329CDF4FFEA78FFDE5BE904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0D39934BBD82CD7BE49878FFDE5B6D42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4D1911110A4BBBEAAC3C78FFDE5A50AC" xlink:to="loc_srt_MaximumMember_0D39934BBD82CD7BE49878FFDE5B6D42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_FFEDAE3D47D6523CA2A478FFDE5B1249" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6F928C627F0A021DB24C78FFDE5B664F" xlink:to="loc_us-gaap_ScenarioForecastMember_5B2D13DAF583D6416E7378FFDE5CC086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6D81CD450366374FE3DD78FFDE566B67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares_20161EDD99E9C8AEFBC978FFDE5CB2AB" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue_F481CB24D91D27C6D70778FFDE5D9326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A6C821AAAA9164F7447D78FFDE5DDDF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_F25E725A4252C1EE3A6878FFDE5D74EA" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares_26889E0E6C38EE0E9F9E78FFDE5DEC8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2E78EB85967DD0501A9478FFDE5DD6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3D0C0A42D6B49E17C05C78FFDE5E0E1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2B8F15FFEF27155F49FB78FFDE5ECF25" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval_F74016C9414985C4E95078FFDE5ED126" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase_8153CFE3C649262CAD8078FFDE5E01F1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_LiabilityForEarlyExerciseOfOptionsCurrent" xlink:label="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_LiabilityForEarlyExerciseOfOptionsCurrent_278E0BEB687220B1D65578FFDE5E3990" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_NotesReceivableForgiveness" xlink:label="loc_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_NotesReceivableForgiveness_C14085354D70DC6E6D2F78FFDE5F9E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_23A2F8AD20808F74B18C78FFDE5F9EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_A26E44C2F3DD2F988FDA78FFDE5F4124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E5E79933F3F5DAC4AE278FFDE5FCE16" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E5E79933F3F5DAC4AE278FFDE5FCE16" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified" xlink:label="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified_4D10333A65824DB2A72278FFDE6057BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_A8A8A8FC446D7B078DB478FFDE600B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_53C141B590F65DD1506778FFDE60DBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_390EEB2F0065B42957D478FFDE6013BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1D8D4CA69664E39F528A78FFDE5CCCDF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3D8C2F45044E26816A2578FFDE608F8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD877FF8C327B34AB59878FFDE1EAEA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AD877FF8C327B34AB59878FFDE1EAEA0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:to="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0E888FA2CC979742210378FFDE1F473B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FE7E3C81F561995C2D9678FFDE1F3E8E" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_F5A986CE3FE86D66541478FFDE20B70B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1731B13727F33D68326078FFDE1F778B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2DFE77814C7CEF68E79278FFDE218CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_EEC0845F1CC2ED67505D78FFDE21E792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5F945D7710ACE03A77FF78FFDE213B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2680DA5A48A52A1FC78E78FFDE2291AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_D41EAD1E8871A7196DCC78FFDE21DD4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_51D1F45A228194D3125478FFDE22C502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F8D558578DBABA41BBEA78FFDE20693B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15B5AD7E296BF31BE8B478FFDE2337D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8431D998E2287093CA0B78FFDE23F6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E5D4A43A05C3442FEE6678FFDE230848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_030882D2A2FE49BFCC5F78FFDE230E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EC211D0811069F575FDF78FFDE224863" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_34858AA63A99D18A85B578FFDE24BD2B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77952147224E9BDEE2EF78FFDE327139" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77952147224E9BDEE2EF78FFDE327139" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:to="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7533349146C2754251F878FFDE33AA3F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CAB3029EB3250DB3E3FE78FFDE347573" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9D036714A210F7B3582978FFDE338F44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CAB3029EB3250DB3E3FE78FFDE347573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EB26179C479542D740DE78FFDE343B6C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_CostOfSalesMember_6F601CEB7AD53632BFAA78FFDE340AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_B2E2B17A4E496639F1E578FFDE353F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_1BE346B689055ECA76C178FFDE355229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73701F414B112721DDEA78FFDE3433FF" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_74B7E007AC14BD94081778FFDE357F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9D3E28C3B0CCD0670BF78FFDE369C5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E628E56E2B397F9B435C78FFDE335944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9D3E28C3B0CCD0670BF78FFDE369C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EB8FB209F6A48EA38C2678FFDE36415F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9D3E28C3B0CCD0670BF78FFDE369C5B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EB8FB209F6A48EA38C2678FFDE36415F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6BD3B5B77E67278D086278FFDE3E96E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7827AB3F6FCCDCCD119178FFDE3FF836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97820C759D88A2666FFB78FFDE3F5BCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0E04383793AF5B31EBCC78FFDE3F4616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_A1141B247D13EF68A9E478FFDE3EBBF7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5826A3245947958D78E378FFDE40CD44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8F2ECFB49233FF20AE7478FFDE415DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0058083974E603904D0278FFDE41BC80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6284BE90C20624E892FD78FFDE43A8AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20D4E8D11761B103D75278FFDE43DCF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306016152059B7EF31EF78FFDE44F5F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_BE523E611F71EBC2718E78FFDE44738A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3AC8C3E06FA3A9563D1F78FFDE425417" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0BDE4BD58A074F1CDD9A78FFDE440910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E6CB3F6E7925C8B8E1FC78FFDE44A6F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_A59DB2C778CD2F13BEF378FFDE45E4A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7794128B030CB1A7EA0278FFDE3E72D8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1E68C1D130B522349A0478FFDE4566B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7C3E085A594104916F3D78FFDE45F1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8ADE7163A3F1D2CC9C1878FFDE460394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F137641989DA18654AE178FFDE465FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_066C89AAF1805307ECBB78FFDE464EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3DC8D468300B9F52DDCF78FFDE45DD67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_896B63EE9B10991B855278FFDE4671A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6425E49BD039B90EA70F78FFDE69AA62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6425E49BD039B90EA70F78FFDE69AA62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_110D61D9FCA977D28EE078FFDE69D045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6425E49BD039B90EA70F78FFDE69AA62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_DE55808D839019CB650178FFDE6A0107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6425E49BD039B90EA70F78FFDE69AA62" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_DA440067E53E9FAA80FB78FFDE6AA98E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6425E49BD039B90EA70F78FFDE69AA62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_AF06E49B325F7E81A6F078FFDE6A4F2B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C70678C1145F70F2495978FFDE2A905F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C70678C1145F70F2495978FFDE2A905F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:to="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D1BEC6213CF8D922F14878FFDE2B0901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2E00590B757286B348FB78FFDE2B8308" xlink:to="loc_us-gaap_EmployeeStockOptionMember_89C715EC90F423935F9A78FFDE2B1FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D65918F0D84F8A7615A278FFDE2C04CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6C2CB2ABC9888CCA2DA478FFDE2A4A51" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D65918F0D84F8A7615A278FFDE2C04CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D65918F0D84F8A7615A278FFDE2C04CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2BC26AECE65565E841B978FFDE2C04A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2BC26AECE65565E841B978FFDE2C04A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6099FEFAA4059A22C79178FFDE2D3739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_D3E17392495A917604BA78FFDE2DE2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_B15BE521DE850975945F78FFDE2D6C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7BED449977CBFA60EA0578FFDE2D7279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EEFB6C134544C11E555C78FFDE2D8F55" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_304F761EC1212DA8987278FFDE2CA41C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_EEFB6C134544C11E555C78FFDE2D8F55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9E31E7249AEA5A8FAAD2F83DADA5101F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9E31E7249AEA5A8FAAD2F83DADA5101F" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_DE80A88BA5D359B98B2C3476DA0177C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39B556FE2695E4DE5979541E566D3796" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39B556FE2695E4DE5979541E566D3796" xlink:to="loc_us-gaap_AdvertisingExpense_A42EC9BC03145B57709D541E566D6B04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_676E32D0A250D48FBCDE77B89CF1A3F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_676E32D0A250D48FBCDE77B89CF1A3F7" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2BAC5083CF7E0D729CF777B89CF2F141" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B8CB67E85838AF07437078693EF8F7D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1FAFC3CAD3C682BF371E78693EFA45A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8A929C9AE2CC87A768978693EFAC8F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B8A929C9AE2CC87A768978693EFAC8F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2A7CE3CE127EAE7992E778693EFABE0F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2A7CE3CE127EAE7992E778693EFABE0F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_DebtInstrumentCovenantMinimumCashBalance" xlink:label="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_C6E55DC390ACE98F9245786A5055301A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:to="loc_sibn_DebtInstrumentCovenantMinimumCashBalance_C6E55DC390ACE98F9245786A5055301A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_083BFB23C3B9D9C7AB4878693EF41376" xlink:to="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:to="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D8DFD41EED7F2C33180E7870EE4DBD5B" xlink:to="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_39D6BAA6442AB22E37F578710EE0A8EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:to="loc_srt_MinimumMember_39D6BAA6442AB22E37F578710EE0A8EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_679A3771E429598FB6127871DC97B13D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A18DD007D9757A64570B7870EE6B8DE8" xlink:to="loc_srt_MaximumMember_679A3771E429598FB6127871DC97B13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_34DB323347C583054E2E7870784E0760" xlink:to="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_RevenueTargetQuarterlyIncreasePercentage" xlink:label="loc_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_676EAD06418D79F5EE6278707854DEA5" xlink:to="loc_sibn_RevenueTargetQuarterlyIncreasePercentage_CF386F90DD0E836601927870C1AD2894" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_56F70287A75D679991327915BE47E0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_94DA600BEBD3216F2B057915BE470B6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_UseOfEstimates_F867DE0989F2149B91847915BE47786F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_DD0EED8A255D382DB4697915BE47979F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_114DB61655A0D98119EE7915BE482093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_6D04F9B145C889984ADF7915BE488150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_DD79AF38A49FE9601B0F7915BE4800DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_198D991DE50AFA3D8AC97915BE48A61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_FC49DEA3E035C0E774697915BE484CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_4100631F9115CE34B5447915BE488501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_A61469F1DBD672E173F07915BE49F665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_866B3D99E84FA5CCB2FA7915BE493130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_A3F6E71A6B8E97D1E6417915BE49D9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_B8388D5111E0A06719EB7915BE493717" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsClassifiedAsEquityPolicyTextBlock" xlink:label="loc_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_sibn_WarrantsClassifiedAsEquityPolicyTextBlock_AD01FCBCA796F50DCA087915BE491288" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock" xlink:label="loc_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock_0F11D400455A687069F47915BE495B2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionSalesOfGoods" xlink:label="loc_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_RevenueRecognitionSalesOfGoods_5766E91EB0C928B039CF7915BE4A40BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_F8656341904B314EF8817915BE4A8B6B" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock" xlink:label="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock_762199169FE7CE2A11EC7915BE4A94CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_B440912FFA78A08FCD9E7915BE4A1F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4683B398A2D2CD3DD6A17915BE4ACB62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost" xlink:label="loc_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost_BEDD4F1F8787F050FEFB7915BE4A5D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_79C33094E3D86FEABA4F7915BE4AE16D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_94BF72CFBCF4E9989A747915BE4B80A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_FFC780B5A0702B2855BD7915BE4B90E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_9078959B5042B94C1B6C7915BE4B36F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9F9EFA0E0163100DD35C7915BE476BDE" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_424FA6531B31E462E4A37915BE4B1DAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ADC4307A3AA953E08F8D748084874B5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ADC4307A3AA953E08F8D748084874B5E" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2202629A1E97559283033C2E121CCC52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ComputerAndOfficeEquipmentMember" xlink:label="loc_sibn_ComputerAndOfficeEquipmentMember_8F21FFF1B5735CC5894DC0FE54C7477A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:to="loc_sibn_ComputerAndOfficeEquipmentMember_8F21FFF1B5735CC5894DC0FE54C7477A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4501FA4907475120B175A1D0B2BEA36C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4501FA4907475120B175A1D0B2BEA36C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_50E7F0D4735C5689A3F40F281E14A957" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6BBF44A83A5C5BBDAC076224CBD2A2B6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_50E7F0D4735C5689A3F40F281E14A957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:to="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_26474A565C83526F9F68364309624004" xlink:to="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:to="loc_srt_MinimumMember_8CD8209117025FF287D096EA37A4EE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4EB7413E95A159AB8DB79131E3379F1A" xlink:to="loc_srt_MaximumMember_AEEEDFBF8B565DDF8BAEEE9B822ECB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_836E1E2AF9AC5A6691697C12C25F15B5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_808491AE165052CBAC249985717ACC34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5A91DB98450955A28A8BF2E2F1CB852A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30DBC67CBB520FCE7E6F4FDC8879A52C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30DBC67CBB520FCE7E6F4FDC8879A52C" xlink:to="loc_us-gaap_DeferredOfferingCosts_438517150621545202634FDC8879E1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30DBC67CBB520FCE7E6F4FDC8879A52C" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_FB3100504F341B9E65EF4FE22C7E0C05" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_OfferingCostsExpensed" xlink:label="loc_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30DBC67CBB520FCE7E6F4FDC8879A52C" xlink:to="loc_sibn_OfferingCostsExpensed_B9066589A55A6AEE16AB4FDC88795ADB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_84D8059073903F7453E549CA51F1AD7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84D8059073903F7453E549CA51F1AD7C" xlink:to="loc_us-gaap_NumberOfReportableSegments_9856B3458257962E100F49CA51F13127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84D8059073903F7453E549CA51F1AD7C" xlink:to="loc_us-gaap_NumberOfOperatingSegments_B88E45DAC18C8D4C8DC349CA51F28061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84D8059073903F7453E549CA51F1AD7C" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:to="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_315649DCDFA23ADA887549CA51F2643F" xlink:to="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1E35F20844A191D2063249CA51F3A859" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:to="loc_country_US_1E35F20844A191D2063249CA51F3A859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_F752ACF59DA6A5E2C4F249CA51F3B328" xlink:to="loc_us-gaap_NonUsMember_F98020435C84F1C0769049CA51F3B794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9995340F8E366237D86049CA51F2B167" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43C9DC8BCE29E766304A49CA51F38BBB" xlink:to="loc_us-gaap_Revenues_F8E8D0E9D3466F4762B449CA51F3330B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9C9541F8E7845EB69268E0DA95B3780A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9C9541F8E7845EB69268E0DA95B3780A" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_BDADDC97101F56C2A2FCB5A8B3E2F27A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DB390508241753AD86A2C682BE9604FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9C9541F8E7845EB69268E0DA95B3780A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DB390508241753AD86A2C682BE9604FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:type="locator" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_StandardProductWarrantyTerm" xlink:label="loc_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:to="loc_sibn_StandardProductWarrantyTerm_F9292226AA86E9FB41EF541E56763E2A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_SalesCreditReservePeriod" xlink:label="loc_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D250034E7FCE114B289B541E5676FDEC" xlink:to="loc_sibn_SalesCreditReservePeriod_27070B834B25F41B5E79541E5677C29B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_FFADF6C3BB172E307BAA4BC9B9DD7A1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_FFADF6C3BB172E307BAA4BC9B9DD7A1C" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_00791D91AB63F26D391C4BC9B9DD3F38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/WarrantsIpoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6A810B23AC1C89A081746E6A3F61AAF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6A810B23AC1C89A081746E6A3F61AAF1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:to="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_AA6D31B2B8B3FFBBA6DC6E6A3F62A3D5" xlink:to="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_7CE402F222CA2AEDE1886E6A3F63736D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_7CE402F222CA2AEDE1886E6A3F63736D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_D4881B750E51B83DEA826E6A3F6360A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:to="loc_us-gaap_CommonClassAMember_D4881B750E51B83DEA826E6A3F6360A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_8D3F0E9C42C3F664E61C6E8958AEC7F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2D6D23AE9C2E9C6430686E6A3F62531F" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_8D3F0E9C42C3F664E61C6E8958AEC7F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_C2EC02831085B5E666E16E6A3F632C23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_3AD2B0DA36A8619D64BB6E6A3F638282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_59E320826D0672A8CC006E6A3F63C3B8" xlink:to="loc_sibn_WarrantsLiabilityMember_3AD2B0DA36A8619D64BB6E6A3F638282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_32EA41CB5BFA8208FE3F6E6A3F62EB6E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted" xlink:label="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_DC6A3046F1F2E5070EBC6E6A3F646513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted_DC6A3046F1F2E5070EBC6E6A3F646513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_98F174E60E05968039E06E6A3F64BE68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_98F174E60E05968039E06E6A3F64BE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_914A9B142236D3FDF67A6E6A3F65F080" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_914A9B142236D3FDF67A6E6A3F65F080" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsConversionRatio" xlink:label="loc_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61E1454D8E6FCB5C2F5E6E6A3F643F07" xlink:to="loc_sibn_WarrantsConversionRatio_EF671390A2D5B9722C536E881D79B47A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1673AFCD73ABE63CC9FC53B1655A3D48" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:to="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_588316AB7CE1B920AF7053B1655A30AE" xlink:to="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:to="loc_us-gaap_CommonClassAMember_DB8EC0A9C7FEDA2E676653B1655B46EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_82B69E60229986256E6A53B1655BBF6E" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="loc_us-gaap_SeriesEPreferredStockMember_7CC32229AC5013BB0C0C53B1655BC998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_690A87C90045D5A3034853B1655C854C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemablePreferredStockMember_892B0F8529E72D0BC36253B1655BF9F8" xlink:to="loc_us-gaap_SeriesGPreferredStockMember_488345B7A677AC69EE5253B1655C0709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_00F89035E692AFD76E6E53B1655C411C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedJulyFirstTwentyTwelveMember" xlink:label="loc_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedJulyFirstTwentyTwelveMember_90A3CE333D475B18F87B53B1655D0313" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember" xlink:label="loc_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember_ABAA9D527E85EEAA821953B1655D0F8D" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember" xlink:label="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember_D8981B303D3C66795C1E53B1655E253F" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedMarchFirstTwentySeventeenMember" xlink:label="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedMarchFirstTwentySeventeenMember_21631CA6EC110094E37953B1655E64B1" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember" xlink:label="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember_9F211CA551728B9441D153B1655E253C" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember" xlink:label="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember_5859ABF9444E97C334A653B1655EC453" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember" xlink:label="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember_3E81311EEB03D7E9164753B1655E2A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_C5015CDAAA76AA4D319753B1656441A2" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsLiabilityMember" xlink:label="loc_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_EE2E3C3AEBE74158C59453B1655DDB5A" xlink:to="loc_sibn_WarrantsLiabilityMember_8E9FF999D6C11573279953B16564FF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DBAEEA5F0AE7388D9C2453B1655A3307" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_C421DE7C0CC6059E193D53B165656129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_821D5DEBD9EF59FA3C4153B1656577A2" xlink:type="arc" />
    <link:loc xlink:href="sibn-20181231.xsd#sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion" xlink:label="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion_3EDFEA992A9AF0F009FF53BF8D887E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_F6A977822E1DA63601C353B1656452CF" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_86650165EFF382947E5C53B165658090" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_CF1CB7CB7C11B836B2C86E3C32B2BF31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_CF1CB7CB7C11B836B2C86E3C32B2BF31" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8D0A7A52F7B2ECCA3B3D6E3C32B2AD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_CF1CB7CB7C11B836B2C86E3C32B2BF31" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7CDA52CDC5C976438CEA6E3C32B394B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_60065E304D06D5FF91274BE2C1FAF2EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_60065E304D06D5FF91274BE2C1FAF2EF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:to="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_007754B027B10EF006764BE2C1FB18C9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DC237F863852590EBDDB4BE2C1FBD1C1" xlink:to="loc_us-gaap_WarrantMember_C3ADF065A7D89EA471E54BE2C1FB3001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3729DFB37EA58D9394E84BE2C1FCCCA0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_AE306E8BAC47399FCF194BE2C1FCAEFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_4543EFBE9932559DD1DE4BE2C1FCD35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_B8F078D551D0F7D9619B4BE2C1FDB527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_49A7C74C3CB7D699A6684BE2C1FC3233" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0205132EF01D7D7ADBE84BE2C1FD357B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_66C1328406A834ECF8014BE2C1FA3912" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_6FEED3939D3FB4A931EE4BE2C1FDF8AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_EB56AA58AEC96088241E4BE2C1FD4068" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_235894950D3B52BA15F64BE2C1FE7850" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>doc193009209v1sibone_image10.jpg
<TEXT>
begin 644 doc193009209v1sibone_image10.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1LF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $$< 5H  QLE1QP"   "   < @4 +59!4R!#;VUB:6YE9%]-87)C:" R
M,#$U("@Q,2!C=7)V97,I7TIU;F4@,C Q-@ X0DE-!"4      !#]?,]"""7@
MF@Y#J)*I4(<G.$))300Z      #E    $     $       MP<FEN=$]U='!U
M=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR
M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "
M4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,
M8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M 0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B
M;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M  !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L
M;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14
M;W!L;VYG       X0DE- ^T      ! #P     $  0/      0 !.$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/T       2 #4    ! "T    &       !.$))30/W
M   <  #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             %6@  !V@          0                         !
M              =H   %6@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   %6@    !29VAT;&]N9P  !V@    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!5H     4F=H=&QO;F<   =H     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !T * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M?X3^:7S<DDI^JDE\JI)*?JI)?*J22G__V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %^
M34T *@    @ # $   ,    !"=(   $!  ,    !!FT   $"  ,    $
MG@$&  ,    !  4   $2  ,    !  $   $5  ,    !  0   $:  4    !
M    I@$;  4    !    K@$H  ,    !  (   $Q  (    >    M@$R  (
M   4    U(=I  0    !    Z    2  "  (  @ "  MQL   "<0 "W&P
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C W.C,P(#$T
M.C V.C4U   $D   !P    0P,C(QH $  P    '__P  H ( !     $   =H
MH , !     $   5:          8! P #     0 &   !&@ %     0   6X!
M&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M@$U- "H    (  P!   #     0G2   ! 0 #     09M   ! @ #    !
M )X!!@ #     0 %   !$@ #     0     !%0 #     0 $   !&@ %
M 0   *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "
M    %    -2':0 $     0   .@   $@  @ "  (  @   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP-SHS," Q
M-#HP-CHU-0  !)    <    $,#(R,: !  ,    !__\  * "  0    !   '
M:* #  0    !   %6@         & 0,  P    $ !@   1H !0    $   %N
M 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M1D%DDALY,FZ[Y[F;K,#T9*-]FL&;KQ<WASGKXTM21"E3!=&\DN8OQ"-N1MR
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M0EU@H.5UH -?Q+0:\5*5Z9U4*8,'31XB2@]T1HW(XY@^7F&KTB58,0E"<HP
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M2WE>R-:M"TM[0SICE9XCE'P#(T,[$W!-"@9&=J:DR-O3!M; 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M]:G-D=TI2YJ>&]8U.:$_6]DK&]P3&)%J4[0=A%LI0F.,),T$6M^P/?C>M_7
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MTLA.G+&<>><,)91))0=C,--,%O00%E@UL0QBWH(0ZWO>]:U@4S.5]PSJ'H.
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M/2P(6U I]L*$>6[?]:1[]7ZU*_OB,V"D].5#.>@$T >W*H*U9(J?%FK3Y^$
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MCYIR"V*U9[:M1<VI6UYG5:K>I9>S:K&KGP3 \1B 3WH5^9'0J$%)XV-5,5S
MV/#H@VYKD:]S=6UD1IG YP<M-*0U0$(5<04-.IQ:B^X>CJ?L&$S:M32U\9?I
MF='( \S6;N%C]/&?$V;7-&/*+G:S)= ZWLQE=T]Q1.'DM3K.+;L0+8ZOZAC1
M+F8+E,!@,!@,!@,!@,!@,!@,"N?K/U9O3YX?EIU?]+=&,$!L$EH;GT4$21B>
MS.5_*G<)PFI8-H@T5D9R<EQT0=\(:LVF*,]V+>QA#K8L#T<(^J+SKZB;U9S=
MSY&[L3LE8HXRN-G-DUDM@L,FI$F4/:<O4#<ES@I6NY[0)ET-[2N3:S*4A3JT
MF$DJ0GJ-I0E/TJJZ-1T[(E/*#;5[Q>1;E$0QALN0Y]35^J:3I@Q$3?YJKC:Q
M&[)%J:#F2)8PJ"-JB@OR=M J;UZ49R4P.J3TSZ6'J]6!ZY$=ZRKR<KB:"(MN
MN9A&KD!;30WM-84RP[8]RBI3JT/D*>5J1&-J-^8%,89(JX1.<GOHW5\="/GD
MD4-P=RT.O&M:_=K6O^FL"KV5>B]Z8T]N*?WW8/)4"L"T[0E;C-IN_P W=9K)
MVYYD;L9HUP7;B+O*%4-1A4F!]X:G0Q].F&:(PT90C#3!""=E.T127/,5,@U#
M5%6M,0TYP,=U$7JZ$QR",*IW.3)49[NL:XRW-J18ZGI$*)*>Y*2C5IR=(E)-
M/&604$ ;7P& P& P& P& P& P& P& P& P& P&!^1C 4 9A@PEEEAV,8Q[T$
M  !UY$(0M^-!"'6M[$+>]:UK6][WXP-8VI;4:J6J9=<3JWRJ6Q:'1LZ5*F^L
MXN\6'+'MK)+ :$,4B\73.#K)%:@LP)J<AM)-T,CVU(S"TI9IP ^:RUMQJ8Y$
MUM&(JZ/>U<Z@1DK(MI1+F5 GJI2^(AV,>R%1QL6.FK$3142W<.;'E,D912+2
M<F0J$J()_D/HG%8 G,JJF5F3NR8H.JI4Z2H$>A4K.8(M8(G2*/D4W'[19RDQ
MQ<PBZ +WN0MC0<:D"DE#4S.^CA;1;(-#E[$J^M;>C"F$VQ7T)LZ&K%"-6LB=
M@Q5CF4:5JVX\*IO5*6*0H7%K/4(5( J$9QB41B8\(321 'K0M![J_KBO*FBK
M?!:L@D.K:$M(UIC5#X%&6:(1=L,<5JAR<#&]@CZ)O:D0U[BK5+U@DR0L2I:I
M/5'[&><8,09I@,!@,!@,!@,!@,!@07[]YIL3IJJZ_:*C45 DM"J+TK*\8(IO
M9AD4JK #Y 5;D6H(DL8C2A(O?"'!B>GAK(3[4I_@SUP'=$K0/#<V."0,&HJN
M_418K5BCI=J3TWP5>E,=OO2.BJHO&-VJ$LUB="&K[JO4NFSO'D8]OAC9IWVX
MMY^CV+;FG3:+6')S0!9#@,!@,!@,"&O:?ZM<^_SE<K?W99,"96 P*=_67]0^
MT. J$B#KSY4[]<E_V1.V=MB<:;H7)Y>PL\.C;@W/-AR&6@C2)0>D1JV;1,,9
M@?$HUXGF5IWA!\23'G$L(91)*$@7?\ HCKJI/FE;.\_.I*=V=7%D,+NW1>YX
M97TS:)=^$?0M?C+2*C996\A:5945E:4LMW9WUG,C#FHE532*211\"TIC8F6,
MM*%ACK0UL+(V$!3-K.RH$C6U-Z8.]["F0MR E.C2)P;WO8"4Y)98?._ =><#
MEL""7<''3WU='X\=%+-:X+,8*Q62VQ5LG]8PVYZ9>5EE1,V'.3E.ZVDZ5*X+
MWAG9#UZ.*R&,2Z,.C$0^R)&JT^L3Z\,+B&P*:<'FD.;TKCT/'H;6)7/==+&E
M_?V"</%G, :TJ^+I33YP7+'N(1*6"2K6)C,=W=H=F#;JA5(CBC53UL"=R5A
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M$24,P)PBP"- $0 &;#KW@ #V'8P@'_O!"/8 ['K6]:%[(?:\^SKP'MP& P&
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M4TI4Z5.L=G=P,/7NKJ=I,6H6N:TXU8M6;,5J#1GF#'L.9P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P&!73ZGBKGHKG)L0] Q*Z9SMZMBO&N
ME(SS68^H>BU=^_&KG*O5E)/K ^Q93')VSD-S\\%OBV2LC*DCZ%_+?%9S4H5(
M%@1)C%"<[<Z]G<K)+HFOJ(W9/YF0[+^:K#ZGMN16WSW +C<(;./F<"3$MK@B
M8XY?A]8-<Z/:5DJBR] ;'C'1-'96)]. ET%YF P& P& P(:]I_JUS[_.5RM_
M=EDP)E8# QZ7(E#E%),W)"TIRM?'WE&E)7%F'(C5"IN4DD%JR2C2334HS1A"
MH+*.),&5L80&EBWH>@Z9WV.27&;K_NRM5(C"CV&<4G+@HS-:T(H<A8K#8%PM
M^=ZW[>A1!$4/]'\P:\[^NM8'=2P&!5OZUESCH;TL.UYTF6[0.;C2[S6;,J+,
MV4I)=[D6(*F1*$8@[T+2Q$.9[7D"#YV6)+[W>MA+%@=/);S.A8_LFJ.SDJ8[
MYQ).P$_1CYLY$>084/5GJ^5F[91AY10ST>XX@:EA"DK8THAKCM$F#T(0MAW,
MO1ZFP[!]+C@R1G'?$*2^8ZKC*T[S[6QKX-&TD'7[WOSOSO2V.J [WO>][WK>
MQ?I><"R/ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&LI?;42A$]JFN'PN3BDERN<
MJ:(8-GA<MD#"!9#HNLE[S]ZI0R,R^.0=,)F0J/E:N8.;*F>W'0&AH-6.1@$V
MP_ M7/\ C03L&ZS_ -GG\,3]*-"^]/XQ_C+]ZB/AMD^-_<G\-/N3\3[_ -L/
MWH^]'N/=[^5>\P/U%*CB<-L:UK29SY49*+E-A)LQ)=YI*GR,IQ0".CC#!J(Q
M%W=ED9@P36P8AOH(BULX9(Y>RZONE[B "D(;-UK6OR_;OS_W[P/. P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P*KKML[E/N6R+CXE>B+
MZ3.7,1S):DTZ7KA(_P!;P3GBX(0"/R1A;XST.6I2H6BZV&-S J1'-"!$\M!4
M3/DC?)#!@*=V785U\3V%Q1:/6-#N[O>OJE7\N6NT[=.)K*[=^=)N5K/FT>B,
MF:Y-,*#4LL-@C#*9LDKE5-]L+M8+$G6&1P]]61DH;@).:$.S+@,!@,!@/.M_
MEOS@0U[3_5KGW^<KE;^[+)@3*P&!^1?[HO'U^F_I^_\ X?\ ?@=(K[-_%U7/
MOJT>JOR^K4E&"BX)JB![C1A:=:3470+A%$*].49H(M$G(9P6<5[8?; 4H#KS
MX'YV'=WP&!U.OM==V;AO#=(4DA6^X<KJOY(].*0 ]Z&MB%511Z<G(L98=^3"
M2Y9)H,I\"UO6CDY0M:]H/G020[;YB#5?V:N6\]&-IB1QJCBVI79^2'$ TH*E
MM?KX%9,R4J2B1G +4FR9I>UJL83# E&FG&;-%H.S,#<'V;29:EWH\<NIQG:.
M6PUQNJ&+O&_/NA-UWV$Y-I.]_GY"PN[0+6M^/ 1!UK7CQO87JX# 8# 8# 8#
M 8# 8# 8# 8# >?/Y8%:$T]6_B6 =LMOI\26=2Q+TZ[2:$Q!%%4]<S!8P&/E
MA1EEET73BF2=L''"RE;)(&P\]0-<$E&::8F4B+.),"$)I6 X6C*Z@E2V@5<5
MBUL.+&O!7BVZHI*E,.;)$2I$G3GS.+LKE')2I:-^Y.%HMM<T1YQ1B98G-/3"
M" X/?8M.PJY&2$-5IM9KYN"SZ!VLR_)7Z511.EL2N74A^C#QK<>?6Y8X-B!Z
M)TJ%''Q6Z,3F3H"5[;W,D.P[#:NM>-:U^[]^!19ZG(Y!&K_C4WOZ7=:0/@T7
M.+[%]6URE85J1%-SETTJF;@I+N>^V.DI Q3Y]K\F#&1]%%GQV03.M(B]-;]J
M<1U*DD!#N0&U^?)9:S3WC15.ROH5TO>.)/2@CTV?9FV#$RP2W['2WC%8T*]D
MT-0/K^P(GN8,)IB@IP1N;J(+8Z#2IG10C,UL0:_L.JIETAW!Z@,/-Z7ZFJ%+
M2?/_ "F^T\GIF_)_7\6ATNL)DOU=(9(M@#6Z;@<O/6N$(C!ZQ%+HX](5A"$U
M(>0(I4=[08)$O6!E+#S?SK(W2M8;8EJ._IQP;NN[39?<3+1:14QKFXUL5L-6
MH3X5-2YQ9\VD$7GKE'86<"%1I,D:""%\P;3'1 3L)"6UZH[K!E$]D$%YX56'
M4E1U7RC=]F3U?:""$O*2M>K7A\:X^9"(4;#)"*63.)I&!<^O4:>)%#&E6U!T
M4CE87<Q,UJ ^BP_5.:(1>\]K5+6T9=JZJ7IFA>4K'FJ^YVB/V>"Q[[+K$ML?
MH!19T/<%<YKJ$NEQP)IFDC/GL8=2CSI,I8(X_(XPH/5A^I/ZF<RBS=TM9;ER
MQ)".<N7+3=*DG5SGV;&"U;N_1B[X76$W>8S71+,I>U,1AD(E3E:;T_N3DUDB
M+B3Y#D1*EPT4Z:#++8]1K[BCO$<7K**NC!2G25=\SNMEVI>D2H^H R:4U,RV
MQ,Y3(YN^L4B7LD6KHB21^%*2(Y%YY*9).G0+2U1PI&A=')"&FHEZC5U7PZ>G
MM)*6J.OPUYT_8O1L)L5.[VOIR/3NE!-EQ,DA20>5,L#7MCW%27FMS)Q&)D2C
M1'SMI TLAK/$2W18XIPYV ]OR)L# :8Y_J.6W=;=F6OZA:Q&TWOT(N8D;+#>
M1>CW&M;'?EEGG5Y8[L4UN$VF4,CM05TCB"A+'8P\-S$M?&=FB8UQP<>^>K"^
M/-<P>PZ/YH66,GDW#TL[LD#9-+8;JO,B<!KUY3,,V@&EB2#6$!ZL=,Y'GI8Z
MG G;XJ]GMR_YC)XXE"E6*PMM@TK13N$P^<-I*A.W3*+L$J;R%8 %JR4,A:DC
MND*5 +,.+ H+3K"P'A+-,+T;H6@&##X%L,IP& P& P& P& P& P& P& P& P
M& P& P& P& P*4;S]+*Z['F/24+KCLE?4G'G:-D%V?T_3#;4C8\6JZNSM&(I
M#;/CU6WB;+$)D'BUOQV&,S?)TKI"Y0L9PJ'H#&K+0.IS:$-[2SBZVYQU)S!(
M%4SJ:"<5\6."";4-1M>P1Z26.Z6(CJ"14\T%3B8N3Z;&FN PABF,C'%H_#XZ
MF/6%";T[XI/$E < +.,!@,!@18[@L:45'Q_TI94)>%<=E\.IJ>O,:D3>UE/C
MC'GLB/K0-S^VLJA"YIWAR9%1A;HW-:AM<4[@M2$)#T"PHX:<P, XZ>M:D%V0
M<]QZ09W**K*Z=%%4=/2)BGLXAB*3QQ>%#,([8S)/[.V_PFS#6)<J3L2^8*5$
M.E\;F3:4U1]*H)9D8<YVG^K7/O\ .5RM_=EDP)E8# 8'2[X<6(ZQ^U=]Y0Y,
M>6$BR8'9Q0"P;%K1[E(X_25U+2]Z%H/DPLYN<QF:UH6A;+$,(MA#YP.Z)@,#
MI-^MU[WK?UZ?3"XT0I-2B/0+=726:L 58""0(YA::V>VJF4B,T( !%4Y5C.[
M'!$7LPY&> E/O9IVM8':R[S@FK-X>[#KH)&SS)KS!?$:2D@!LP0ESO6$G1H/
M8+UK>QB"M-($$ =>1;UH(?KO6!0[]DBF>W[TW;-BIYVQ'P3K&?H4Y.Q^U[AK
M?JWJ60$:#K>_],)CFM>A^SXT'8_;'K>]B%K0=I3 8# 8# 8# 8# 8# 8# PQ
MVL: ,,TB%</<UBS18%@(I(Y06$N3ZVHI3,&^&D(%4L6QIB4*2W)Z2QI,Z-RA
M\.;DR@ML(6IC5@B0' %L.#U9@]W,*G?P]LKW8:R!97XK?=HK\']C'*1QC\/M
M3#YC[_=DA"#[QBC?RCW(8P(#G\R]L7PN@\1D^Y!V;:!,P;ZX(IXE+!=TTOCC
MG)5-BKEAC4X[LD-DMKDV)HVVIDKWIJ+A6XRY.1JQK$O.>])%>B"-!YKNO7J#
M.MFN+M:,^L8BP;"73AF:IL;'#6^L&I6Q,+.57D"TPQ]C4$0M H95#RC)?CWQ
MY^9O;J:H=U'OM> AW+_2FX7G?8K?WQ**>7./4[5)(;+$-C!LNTT24E]@$<:(
MI%5FX2AFB:!FA;F)B:T8TQL:&E6B3[5+R5*LX\XP+$\!@,"O#I/CB\;1MB56
MC1/6RVA@6A23=0]L0J3U$W7?#W6.LKQ,71FFL :7:<PQ+ +/1IY[)&96_+")
MC&7ULVREOT,<C6)$;@9'1/!D!Y[M*G+ @TMD9S12?%,8XFBT4>2$:P:N&Q.7
M,4J;I>[/Q8DYITB.VQ$H5J5.W)F\WWYRDD*?P!/H-?W#P59L\NV_;:K#KV9T
M*W],5O6%86FQQ&K*_DTE Q5@BG;8V+X/-YGMV!$7Y6W6)(B/F?W6=A(#QHUR
M4OXM&08 -;6SZ5*!T<*_6<[7 ST8&&\CQSB@X<MI9AO%R04]"750ZP>25LO?
M)7$R8%<<3&[20ENF[F@F[ I^=_$.,'5J6U$8 -QVCZ><7LUFZ88S[,DK6FZ2
MJ;FRIG,_Y*UKU<8;N;G>7NK.\)1^_1$NKA*-RTXEV*-(0ID8D8#48=^^$46&
M#._IO.X>F9O=4'O-KA< M?H"LND;1@NZ0C$CLYTFU<1"%0]3%(;>CK)M*815
MU@I*ZB:V<QD-?OD@.5AD (W,8VDD*E.2$AV_C2"BI#J.A)4\N$KA/5DQZ%D\
MV I1)D*AL0]$&.GWC8FW9)IX3 ,R=U.*:W$W9:@9A92D999@?&@C"V>F4^0N
MF^8(C7W1&QW1S3?T_P"C@W/;%2-UF-EJV%:L?MN+3Q?8-<MTV@8AJ3F.W7,F
M*N3%-6I=$E$?CHTAJM$D-;S@R6OO3E=:SA?+#/&NC9.=-^7[UOVZ$D]?*^BS
MG^(H.DGNV'6RXW*8V6M1HV\]01;+JG:) P+D FY6WI5VVE04<:WA#C5OIQ2J
M(OE<V-0/0R:N;DK><=MO;?+9U49=H1)TA'=%QZNZQH2Z09ML6MU8EL3F#1"E
M$)E">8$:)%&#/G;"\)7E0A3!R,*],"OX#7K37+#9<L,:6G@.;\&A7.34UJG-
M:SSUT(>WRTEII1J5..2FNP5:W;&0G(:=C6C+ <4666' L/KZ(DP"!0B!IEIK
MDGA,1C<23N)Y0"#UY$;9D3.4L.(+$,LDU46C">84 8P%C'L(1"UK6]AE^ P&
M P& P& P& P& P& P& P& P& P& P& P&!7SZDO0EK\XT;#I14TOIZKG"97C
M5]72VZKX0*GFLJ0A$X7KT+K9;_'T<M@QK^) Y$,S @;SI0SMI"Z1$.[VN2L;
M8Y*20T3S18O1;]=L%;9QZK' O1\55G/?S2FJ7HJ/P^RID N-/)Z0,9D:'KRS
M%3=MD7%I9(Y[*@[Y\4RL[BD&% 6H$YH@M\P& P&!K&Z*J8+RJ2R*=E"UX;(_
M9D*D<)='6/*4J.0-":1-:EMV\,2I<B<D*9Z:1G@<6D]:W.",I>F3C5(5B?1B
M<P,*IBD7BN)-9%A3>QG"TK(L\$+;'N1J(XR1!L;HM7;:YH8E&F2/,FC@)DZ=
M=(97)'1:O<G-4OD,J=QI1-;(4T,34&N.T_U:Y]_G*Y6_NRR8$RL!@,#I%662
M.G?M@-=/HO*-!<;2PG_3>P 5 D_'[W7 ?&O&M;T?)(IK0OS]L\(A?4S?T#NZ
MX# Z0O ZD[L3[4OV'?24XMPC?.R.Y4#<N^AJ+1->,4:Y-9 (!#(-#K;CI6[/
M:?90TPC- 5J0F#U[TH\.[,^-B9Z979F6%^]2.S:N;%17T_U$Z],:E/!^E^C^
MF6:(/U^GU^OTP.G!]D'?5#-%?4"I9R]M,Y06V*O?36\X0??)U#LV6#$W71@"
MS#2@C)/@J,@S99IH=C#X"8,(0B$'<SP& P& P& P& \Z_?@8_(I2PQ6,OTQ?
M' "2-QEE=I"]N912A>!&SL:)0X.JO2=O*5*U7PB1(H-$G1IU"HT1>RB"#3MA
M+V&I'>[E$@YTU?\ SQ"'+H3<DKENL:IX.U.J"NG.ST+ZV)'>.(4CK8H&-'%#
MG= L)4>W*B&\U#K8BE:0"L/PVPR.SVNX)+"F<FH9=%JPFXI/ G5V<)M#C;#;
M0Q%%)&APL"* :FN4Q@('I\BY3NP-,@*=E"9H<5)+F!(L"47L ?38=4,-EN]7
M/3T^3IG4U-826R6%/#9Q(X>WOKRDCTAC9;/.D#"N1IYK#S$DD5JU,4?@*V94
MYI&Q8H3&[1! ,,S61F..+ZRR=P8&5=)8VG=4D>D"QJ0J7MA2OH$I3VF9G4X@
M:]K(>"T2(MT)0J""W "1*!6$X*<K0 YS 8# 8# 8# IVO1RF-@7PHB@6QOG1
M#;WO#*E;*]E4V?X1"'^%-/IG3B\"FY\<F6/2TP@DNP)\^R71Q<8=M+WEACI*
MD)'RI&M;@XNI^L+5KNJ.28NW:;I>2*+<O,UPDRM ZR"7,0[ZOM302(L^Q7NT
MF!.'49=VF1-T55-[+=TML)1$5ITG;H.VGHY2[A]U?]"V/,YE^(TX,@<A3677
M?IDRR.0Z*;E[8WP%JNF\^CQ:2KDI\Q<Q.TY8DQ;>0KE!6F1FEY[&W$N,)1M[
M<% <'SOU^7E?U9PYC<7RJ(_]]E_ITW3LZ,Q><JF\NN^G;IDS8JJ&0@(MAJ6O
MJV/FULE+D$R2N;$SSR/O;M'5%<1XDX:PT.2E'<G2[!#FM[;XG4CR\OD:[$MM
MM0E,KHW,*&N.6+)A%:MD/E,KEEQQ)KCKU-U$J,D,CN!0(Z+URE^%;3:SE*8E
M3)!AF$T[;N&*N-FO92*GU4/9H+VA(HC&S6Z4%31C<N1+9JRIAGS)Y#,MM+\R
MS11,GR4J@-<=B)T5;-Q=OTX/VUBMVV'QVOW?<$;D3RPU]"H&^&1(OI^4O!KI
MLLIM=XQSM95;0,$<,D+Q9D(9H$M>M39PU)+(=3)2S0IS3,I:J!.29S5;0!R;
MWV+?3-)@LYB&GO@+#GUQ0&M% HW,M'08VKN]*2XT3/D]$*?%DV 4]-5U)9X<
MT, *U$C=(P;'"W=2FD!;NQAL5NZJLTBW*4I1R3U))Y!<C=#7EDF-?GR!QA+D
MQQ<%LK.CGQF,4NYJHQ!$DT'KAF8_>'GA8);=\2:'I1)"&X]8XAI>X+R<VON^
M)2AO7V-]R*8G%2<Q3%&VQ6RE-9F+>EF)]7RPY_D34SGU@6]MTWF/$ZMM6RAY
M2OC VHYFV-($X)4I X!K&+7A<":-0>NI!)8R^1Z==&2"6Q=XC8I.DG,1;JK]
M76E*H=(C-7]=*WA'*V^91VU=(4:=M9(<GC:&*O<.5)90C/"M2!F[_P!GW],5
MEG1:$NE=1A.29")'6-AZKYS<$1T:#UFFHF4MJME=+9*D$K2N#?OX,,N<8M3Y
M7S)!)?NLSR!M-:9,WAD,][%LNL-V2"+L%8E!K9GZON6; ?TLO4'V(S\_V16T
M-/B<*UJ9EZB<EF*:8*CU$F5[EK-%W8470$09X)?#C48<7;/4-VJ(Q:07;4)2
MMK>P==655@(2WRIDE;4Z<)]95K7+"R2QW7RMW;Y@5:^G]F4N:-K8HDE;=)G:
M/G%2)O? G-X6\A_W0_\ ].O_ ,,#]8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# KNZQC=TOE37B&=N' )T)1V%$7NJC^M*]E,AIR,ULA:V(EZ/NM.YS9H;'"?
MZFACV9#W]@6QYC;FU:R)5:%4YEJSU(0(XX3-"+IBJ]ZG/H"NB@Y=)R4K;QC6
M@&#I98=J"R@X0*S=M6Y)MI3BDY1RF4>&59[Z$D20C_0T;\22'8(P& P& P&!
M#7M/]6N??YRN5O[LLF!,K 8# Z7/K2##6'VAGTA[<WX2)9*9S]"5JOQ[L(BB
M>EI?'W01A@?&QA+:K'* :'?Y%#T'?Z(]:P.Z-@:NO"SF>DZ7MRY) ,L#%4]9
MSJR7@1HO8+^60>,.DF6Z$+]FA)VPP/TUO?G>M:"+?C6PZE?V1*F'5PKSL_LF
M5G[72&V[89:I1JU"48%0S(:V"LB;.Q:S9X@J$\A>K29"32@D!V2KC1NQ*#O>
M:+)#N1B\^SOQ^?\ \_NP.E;]G[)/J3UI?5_H$T(4!(WZVWI&V!/]\#2.O.EW
M%J:!EF:+)">$#19!6P&^Z+_0-W^@#VMAP.ZI@,!@,!@,!@0;[O;Y!=-"7ER3
M2%L1VN^K;<HF9.%0 6S5WA+XW%IUC<R&S5*[QI*ND[8U,SLXH4:UX8D"U8A.
M6$;"1OV_.@BQZ+''':'%7.MG5SW%<Z.[[)D]VN4WBTD16I8EM%-<%4P.!,*5
MB$_62R,+PWC*D+#(7';0B2FMA87$*PM0)4L5EE!:#4-/5G0M>L=4U!$&V"5Y
M&SGU0QQ5H&L&WMITFD+M*WTP@2]2L5;VY2)\=G0_1B@>@J%IH2M%DZ++ &R=
M:T'6M:UXUKZ:UK\M:_=K \X# 8# 8# 8# 8# U\35T%)F+G._NZW'R1U7LKR
M<N5D_&;2R%@C[U$6^2M12G9I+1(MQ*0.D56/;:!*Y+XX<%E5J#6\L)&!QRJC
MJ67.,8>%M1UFL=H2/WD,=%<%C"EQB)GS<J0>\C"TYL&I81_/B"7OVFHU(+YN
M46Y>?C !.T'N8:5IV+'.JF,U37$=4/KTVR5[/8X3&VDYXD;,Z+7MH?W0U VI
MQN#TU/+DXN[:ZJQ&KD+FO6+TIY2I2<:,/>PU!4\6(<DL9K* 1U,]29--7A.Q
MP^/M)+K,42PEQ1RUR+0-Y %TF2."9,N2ORK1KHG6)R%)2H!Q)8PAZWJFZBDB
M%A;)#5U>/S;%GPZ31AO>89'7-#')(H6'N"B0,*1:W'IV=[/7JE*X]U;BTZ\Y
M8H/4F'B.-,&(,17\VTXOM)1;PH+&")<\0J;P*8FIXW'"TUB,$_-@.WHNP][:
M!KY@<F1URPM+5\W7GIDK0H=6\U*I(5DZ2AS)7/M#$-L59B:5J<IH@KP9(H2U
M%UW$@-L.?S3R51KY%D(6C2:/O!JE.G4F.;24D6C4$$G".V846((9 [556#\C
M5MSY74'>6]>CE3<N0NL48W!&L;YT^(9--T*I*K0FD*$<QDC8VR&5)C@#)D+X
MWH79W K7I$Z@L.$2TO"&Z?0*?-3>!F/K&N)?5D&C;.E:VN)1Z*3=VKUW?"6Y
MF1MQ.TA^AU?$D+=I,J)0-S8E5)$Z .E9@]!F2B$PU6A>6M5%(XI;)$[ ?G]O
M/96XY"]O99J$XMX=TIB81#BZ .;&TT"]66<J"8WHAZ-T)*1LL,8:*4IR/KWY
MT8:HK=D<Y2ZLS[)W%IA,;;E\C>XZ]_>6/O#ZL1MI*AW=&*1_^D#,X.!BA6V/
M?_G5$:0O_P#*,#XP4)1A8YD8"FJL 98I+FGL$P-?Q0(YTG>E 5;R1,1Z:O:D
MY+LJ %4YE/>UP%Z@(3U833=:%H.1<*:J)VVP;=:NKUSW%) *61?YA#8\M^[<
MI,/)4CDK#I2W&Z9Y -2G3J!O+?\ #N(CB"31*=C*+$$/1**:K66(4K>YP]B
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MQLA#$8VQU&K5,T=3HD2EV4+%QH!;,(*3AM# 8# 8# 8# 8# 8# 8# 8# 8#
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MRN4/1C/9,VE# I<YTSR"'JZVKE64T,*@+X<!@8S-"WHV'RHJ-[-U(C8X]EL
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M"F>-GI\SZ_WCH63N1+ SI6%'.*GJ5NG\#<5!D=*8-D)K$@P"CV[3:-68)*:
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MWSSP%5R!ND;PQE('U?17=%D7=;K*]M3N(1 F@NKI0A/*"O),0R$]2I8R0'*
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M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M-T;4[(^D_*3G14Q-@8KVG^K7/O\ .5RM_=EDP)E8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8$>>LJD?KXYKNNH(JL:V^4SVO9"QQ=6^G
M*D[$5)AHQ*8]I\4H4J]<F937E.A)=E2% N6)FXQ2>E1*E!9:<P,1H*'VBJM>
M[KVM.$(ZP<;+C]/P&/P$N7-DV=4,?J,JP'$R0OSRQ)P,:=:_R.SY"E;FIL6N
MNBHZQLKHX*D+N\+V!F#-NC:8>+PA,?C\;G!5=R>(V;7%IQF4*8N5,V]*^UO*
M4,G;TKI&C7J.[=&Y>8BVC5%%/;<<6 W1Q1VQ%^[&&N?PM[6_B[JG^DHS_(/
M?A;VM_%W5/\ 249_D'@:/Z-4=QT=4$DLUOZAI^0*F%RA:$MJ6<JJ4*8\,JG4
M9B!QABDF_CS0;1D/QBTO02A:,-3@*'L(!B&$-X:JWM;^+NJ=?\/]DHSZ?_Y!
MX#\+>UOXNZI_I*,_R#P'X6]K?Q=U3_24;_D'@/PM[6_B[JG^DHW_ "#P-*3\
MSN*&6S0=;D=1U O2W(]6$U+70WE522>Q@A5?.TU(.2I@7\,M8)>>VA0&@.,)
MT24:(X&QC#H&PW7^%O:W\7=4_P!)1G^0> _"WM;^+NJ?Z2C/\@\!^%O:W\7=
M4_TE&_Y!X#\+>UOXNZI_I*,_R#P'X6]K?Q=U3_249_D'@/PM[6_B[JG^DHS_
M "#P'X6]K?Q=U3_249_D'@/PM[6_B[JG^DHS_(/ ?A;VM_%W5/\ 249_D'@:
M(YC7=QW]0E8W&X]04_'%L_CNGM2QHN552]*VF;7+$FTY"L^_2#CP>$NA^V82
M6+R/>O9^GG8;W_"WM;^+NJ?Z2C?\@\!^%O:W\7=4_P!)1G^0> _"WM;^+NJ?
MZ2C/\@\!^%O:W\7=4_TE&?Y!X#\+>UOXNZI_I*,_R#P'X6]K?Q=U3_249_D'
M@/PM[6_B[JG^DHW_ "#P'X6]K?Q=U3_24;_D'@:*<UO<:#IB$T('J"GS&Z64
M9:-NG2(7*RD*U&LKV?4]#4S*4@U?WN#4KD39RI<H5B/":0:U)BBRA@4FB+#>
MOX6]K?Q=U3_249_D'@/PM[6_B[JG^DHW_(/ ?A;VM_%W5/\ 249_D'@/PM[6
M_B[JG^DHS_(/ ?A;VM_%W5/])1G^0> _"WM;^+NJ?Z2C/\@\!^%O:W\7=4_T
ME&_Y!X#\+>UOXNZI_I*,_P @\#BWNO>V&EE=W4'6U3G#;&M>X )%R8: )HD2
M0Y2$H0M=!;V$)FR]!V+6M[#K?G6M_E@:]HA%W!<%'TU;2[J>HF1;:-4UY8JM
ME2\I*5:5H53:(L\E4-B96=?Y)JE.@-<QI25!I19AQ903#"P"%L.@VM^%O:W\
M7=4_TE&?Y!X#\+>UOXNZI_I*,_R#P'X6]K?Q=U3_ $E&?Y!X#\+>UOXNZI_I
M*,_R#P'X6]K?Q=U3_249_D'@/PM[6_B[JG^DHS_(/ ?A;VM_%W5/])1O^0>
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M#GI]>VYM=:ZG""PJ^G$<1*]A89W#I"D*2JPM,A0#+&>SO2%&[,;PF=&L8G1
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MX:BD&Y6DC;H%2J0N#2EDHF>/;?$R56D. 0Y[8VK:LKV3=HB-B]C0;WP& P&
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MR0T]*::G&(1)AB8\Y.,8-B)-,+V$>P^K 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M;[+I6^-D=C#*VAV#0G!V?G=4C:FU"'9@-"5K%9*?6Q@ULS7M:\A],<DT;F#
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K,"B!LDL)@S@FY@,!@,!@,!@,!@,!@,!@,!@,!@?_V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>doc193009209v1sibone_image11.jpg
<TEXT>
begin 644 doc193009209v1sibone_image11.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[32B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "   <
M @4 +59!4R!#;VUB:6YE9%]-87)C:" R,#$U("@Q,2!C=7)V97,I7TIU;F4@
M,C Q-@ X0DE-!"4      !#QE62;#64G5<&M NVRVY:I.$))300]     !OL
M @   "!N:5<     00!: #  ,0 U #$ +0!8 $4 4@!/ %@ +0 Q #@ ( !'
M $\ 3P!$                                  $$  ;< . :4_^  0$
M 0#J"F\(9  !  \ 6 (!  $ 6 (#  $ 3 !E '0 = !E '(
M
M                 0         #     P    $
M         %!225;B$
M
M       8       0)Q G$"<  ! G          #( )P#
M                 P        !$%Q  7$L# &A#!             $  0
M                    A,=%A 4   #_  $ _P    0
M
M
M
M
M
M
M
M
M
M
M                                                      $
M              #(    4TU42@     0 +@ 6 !E '( ;P!X "  1P!L &\
M8@!A &P ( !0 '( :0!N '0 ( !$ '( :0!V &4 <@ @ %  4P   $QE861I
M;F=%9&=E  !086=E4VEZ90!,971T97( 4&%G95)E9VEO;@  1'5P;&5X $YO
M;F4 4F5S;VQU=&EO;@ V,#!X-C P9'!I
M                                         $07   Q3E)8 0    P7
M                                                        %0'&
M\0<  0 ^"!     !  <@T144!0    !-4T-&     "$(        +
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M,X*KPO3V .:FI2^?8UR-M(TX^1.V"*Y*DZLL(M)7.\3504_)NIZ+V%H9QK6
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M #  ,@ Q !, !  $    %  0 #$ ,P N #  +@ P "X ,  7  0 59^#V1D
M!  !
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M   !  $                                            X0DE-!#H
M     0T    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O
M; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E
M;D)I=&)O;VP     "W!R:6YT97).86UE5$585    !4 00!: #  ,0 U #$
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'1 88
M  !4;W @56YT1B-2;'1 <-@           !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG   "^P    QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P   D8    +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #P     $  0/      0 !.$))300F       .   _^...0&^..3^    X
M0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         !.$))30/T       2 #4    ! "T    &
M       !.$))30/W       <  #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             #MP  !00          0
M                   !              4$   #MP
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #MP    !29VAT;&]N9P
M!00    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   [<     4F=H=&QO;F<   4$     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !W * # 2(  A$! Q$!_]T !  *_\0!/P
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MM>VT-9[O>W]&C8[<BE^/CW7>LX4OWV1MW%KJFL>YLO\ =M=^^K: _P#IU/\
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MM;=SB=KGZ,'N=]#\U &=AVW8N2VYGHW4V&MY< #+J/-)3?20/MV%_P!R*O\
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      7Y-
M30 J    "  , 0   P    $)T@   0$  P    $&;0   0(  P    0   ">
M 08  P    $ !0   1(  P    $  0   14  P    $ !    1H !0    $
M  "F 1L !0    $   "N 2@  P    $  @   3$  @   !X   "V 3(  @
M !0   #4AVD !     $   #H   !(  (  @ "  ( "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#<Z,S @,3(Z
M-#@Z-34   20   '    !# R,C&@ 0 #     ?__  "@ @ $     0  !02@
M P $     0   [<         !@$#  ,    !  8   $:  4    !   !;@$;
M  4    !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
M          !(     0   $@    !.$))30/]       (      $   #_X0&
M34T *@    @ # $   ,    !"=(   $!  ,    !!FT   $"  ,    $
MG@$&  ,    !  4   $2  ,    !      $5  ,    !  0   $:  4    !
M    I@$;  4    !    K@$H  ,    !  (   $Q  (    >    M@$R  (
M   4    U(=I  0    !    Z    2  "  (  @ "    \     !   #P
M  %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C W.C,P(#$R
M.C0X.C4U   $D   !P    0P,C(QH $  P    '__P  H ( !     $   4$
MH , !     $   .W          8! P #     0 &   !&@ %     0   6X!
M&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $     0
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M @,!              @'"0H+!08! @0#_\0 4Q    8#   "! <,!P4& PD
M  ,$!08' 0(("1$2$Q1X"A48(3%8MQ87-S@Y04B6E[.XUAHB(U%QU]@966&5
M\"0E5I+4U3*8L4)25X&1H:>VP?_$ !0! 0                    #_Q  4
M$0$                     _]H # ,!  (1 Q$ /P#/X
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M>YI,[[HG-O._M4+@G4I#,YW)SG(5;
M                      0?\2+CW7O?B:_.3]),GAKC:\9:R8_*%J,YP;F>
M51.4L4YBJAU1IC"U1[.9(HTVIGC5)M[7JUGJ]TFNZG4K38+++)X=/=2BQ7GL
M_OB8\VEK.4/#7MOF*FXCSDY6,^8EJ\^M9LT/%H3U?/XU&]&I>XLC^^%',S*6
MK2J%:ALW++:BVD[XW")_@R<&=-WS6GA_=:2J04PS432'$O4]-TLA8'F7+;*F
M$LO"P;895RRQ6=7$T\<C3)&\/JX@E7'I/)53BG96I=\6IE#TX(68*]U[X+?=
M/.%7^&S*J3FG,<RZ*XOJ+KFD9_%I_*++8JEE<<Z6DEFN[+)HI,6>MW*4Y=84
M78'M+@S.L+:T[TH3^R$.J0@CUZP*ET=X&%PU&^>%0W*;4KAXAG%'/?9M6W8X
M$'25-(Y!*NM&*?\ IJJQ;#(R8W.;%%I!/E:;*N4.L77*VEN(78;,*U)C<0'7
M/#[\'KNKGCHSP[9]>DSYA7U?P!6_3%0,^E:R2S'&=3U@N538SPPRQ6WR&N61
MA0..CG/TS4XL.KSH4U-4;^-"G9\7O>[<UA.7NKAGKZ2]V\Z^(IQ%)J#76O4-
M/3"AI;5'2"J<L<#D\)DRJ2.2)Z:9-7K,_/B)\;7.5KS5*$Y"F3J2T3;N6Y:Z
M:+4"T+>27P->HX=Q'$Z,4J>0.F)I/>L;7ZGZMK"XD4QAM:2!ZM&+L4<2-]#W
M3'8-([<JEYA&(TC6)94Q,,?='XUZ>$ZLU(SHR&5S#Y)AX(/<4HK+PXHG9%N<
M\=7K>7JYZ$@%M0_IMPLR3U@C=;B5/&M>V%"V[>-NRRSWJAF1R:VF+))XEB9[
MIK#6 E(Z1E.J]:QA #J7E>P/"\K+BMEL.\*LB5H1_P /3O#DR8NSS6]PSJDI
M@R6"]W!9C8TUO9+*R1C5'=KH7/D+3%H=.VV/H'M\U1ZI%+FC]H(4A6*KO!JZ
M>NSF#PY^@(36',<IG<=\.]XYIF='=R,4K0-%?N<CG4]L:L[J8V-+7L^T<)C$
MCI[NM/B4L86U.>WZ8:5)FVKRX:MP9:/'M(.W-O+]&T5('6*/D@K&O&*,R!W@
ML)8JXA:]^3D['O2B*0:-(6UDC,?W<U"KXI:T*%-@I%@G907[5N?ML$D@
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M,CXVYQ@]M. =T
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M5$C?G-Z>G5P88M9T!RJ4.[R\.NQ#DC^,75Q58W5G!<6
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MYQKC&=LYSG.,?3G/TYS_ (_G >P
M
M
M
M
M
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M5         $0+,YMDLF?I;.(?,F1LF*RVJ@MR))Y''ESC'$+C5L9*B:MC?\
M5M>T#BN125F.=M"7%O-0GL"]6A7Y1/A+><W. 4&IO@N;U5*8<<HMB,/T-1W
M@Z/G:0J!.+9(GZY"JFD57.J"-+-YBXML=K9Q,>6Z2HVUQ12"2-.[,H8S7MV*
M>L.K0'8H[P^ZL71<9O5#)XFPID$R>I*\1ECCSD3NA;$2*?0^(QV"J4CNTLT:
M:WZN7RN66T$1D:6I'USJUJ<4A?MJ_#FW!6WH'\+_  _[RLQ_@_ZE 2I
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MP            "*W0/X7^'_>5F/\'_4H"5(
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MV2S%L>8=$G!,Q-),LCJ"*1^*62U3;4IIS((/:M>.Y<=;_C4\I*$Z
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M.; E^.MI5$*DJ)M6.*#6*&[.(730
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M\ 'V@ "'_7GZ,'O?4Q^[E "8
M    (K= _A?X?]Y68_P?]2@)4@                '_ .X#'P\1IAO*5W6W
MF2\J!QYI8:3M.2Q<F-S%RQJ;5+)85/(9>FEJUZ0QXEXD;],WFK%+3&4;>K)V
M5-A:=IV/7IMU+P%J8!77F&/ZRGHND&3<OUI2FT(8H4%^7GC=(UOB-V6:YQ^?
M7V1"=G;S^;T<9\_F\P&7GCZ,    A_UY^C![WU,?NY0 F
M                         "*W0/X7^'_>5F/\'_4H"5(
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MN3"<*-"R]3L%[:X-UTTQOZ6-=?(/J   !#_KS]&#WOJ8_=R@!,
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MP7UI5R1I1ZI4+S]Q!EI39NA):@G&C0U.B9,HPX&,K(>W!QG0/X7^'_>5F/\
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MNJAFKYB4:[$[IFG)NNREZ<$V=]]=7J0G%EJEOT92(R6UJ\S/B[90>$4/^O\
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MN5NV1\E![8FWSM[.\*G;&NWH[@+U       A_P!>?HP>]]3'[N4 )@
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M67MVJQ+@[!9;@UK2=MD[HQ/*8LPW")Z95Y9[>Y)L&&%X.)]<F-4(CTRD\*L
M+V_A/7UZ1<FYW?E6V<D^VS> ;GFX]'!.YA.LKCR?&^<>6=5!A4D1IRL;;&;*
M9(J,SC4K'F%[$              >,XQMCRS_ -?\< (]L?*E!1J60N:,%?D-
M3Y7C3'V:'%HW^5%QYF*BD+<:XC+IK#OCS,07RIAK]W<H0TS5S8ULQ0118='T
M[Z6U;82X#DDO-E,))K'K%*A^VTSB[O)GYI>3)!)M\?&\L>YG(G-P=&O+SAE?
MU*-VL.<*(T:_-SEO#=)0])HCED3+CR=PZ3T#^%_A_P!Y68_P?]2@)4@
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MC:9GRP;H2M(U,W2J=-<YP4L1'9,1K2//TB%9!Q.WEL7G #N0
M    "*W0/X7^'_>5F/\ !_U* E2       #$E^&:_DJ:U]\RK/LONT!JZ0
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M^5DUK[50;C.NK>H-)UEC"D]+./1PG<#BI$F3:8W,,W<Y JVS@LCRU"].
M             BMT#^%_A_WE9C_!_P!2@)4@       Q)?AFOY*FM??,JS[,
M+M :ND      7(_!T_*M^'/[YO/'VG1P!NS0$-9/^4&I+W.^G?MHY* 3*
M   $/^O/T8/>^IC]W* $P          !K;/AMOXY7&WNS2/[4GT!A1
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M/M.C@#=F@(:R?\H-27N=]._;1R4 F4      (?\ 7GZ,'O?4Q^[E "8
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M5'-,=<R%RL)H] _A?X?]Y68_P?\ 4H"5(       ,27X9K^2IK7WS*L^S"[
M&KI      %R/P=/RK?AS^^;SQ]IT< ;LT!#63_E!J2]SOIW[:.2@$R@
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MBM:X3%V2*-RQQWMWL]-LO5(6)"@3*%NR9,G3Y5&E;GY(()*SODLK374)W@
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MB7W+EN64P7_('56MVV7)BTJ5*V'9-WWSG?<HO3<S4)>_*0<OJW=,_J+%/Y^
M/E(.7U;NF?U%BG\_ 'RD'+ZMO3/ZBQ3^?@#Y2#E]6WIG]18I_/P!\I!R^K;T
MS^HL4_GX ^4@Y?5MZ9_46*?S\ ?*/<OJW=,_J+%/Y^ /E(.7U;>F?U%BG\_
M,,SX3/X='B!^)YT;SE9/)7'-O2F+5O2CQ")4IE;E5<&5)9 LG+H_$$)D4@LA
M.>M3[-RLDS94GQL5J9G8K;.-]<X 8T?]&S\;7ZB$T_:51?\ FB ?T;/QM?J(
M33]I5%_YH@']&S\;7ZB$T_:51?\ FB ?T;/QM?J(33]I5%_YH@']&S\;7ZB$
MT_:51?\ FB R2O@SOAO^(1X8W4E_VKUIQO;L7A]@T$77\9511TJF<+%,EUL.
M)2+*=0@C]DJ%"--AK:%IOMA^NI'K--"?2]89IC(9HORD'+ZMO3/ZBQ3^?@$-
MJ8O:WJ@>;_2NG"'9,E1S[HB?69&7F+,W/N6Y9&9.UQ8ANV-)DG0\;>$:[0YJ
M6%JDBIJ)]7MIKL68<7OH9D*X_+3L7_=Y=V_\CY?_ -4@!\M.Q?\ =Y=V_P#(
M^7_]4@!\M.Q?]WEW;_R/E_\ U2 'RT[%_P!WEW;_ ,CY?_U2 'RT[%_W>7=O
M_(^7_P#5( IC7=S68MZ?MVX7_C7K&$Q23T-S_6K$3(H[3Z]W<)#7M@])R>2F
M820RZ)80E;4[;9\5U3*5RQ*:K4G+2B4VVB,PW(2F^4>Y?5NZ9_46*?S\ ?*0
M<OJV],_J+%/Y^ /E(.7U;>F?U%BG\_ *[120FRF/-C^9'I#%]W(HPW9AE:1,
MW2!MR6H.3^J<T21:XIB#3,$^O+U*6GZ[)S2=\[8VVSIJ'8P'C.,9^G&//R\O
M/R^?RS].//\ N_X /R)((3Z8+()+)TQMOMC0O3737&QNV3#-L:ZXQC&QF^<[
MF9Q\^^^VV^WGMG.<A^P       +'4^[W[RF':/2%,<A<\4]:M2<6V!R]!KRC
M\ID#PS7=8Y5^,:292Z1U2]JY1&ZWBZ&K8:NPX'M\O3/:Z2*F]64W>B8J3I"@
MEG_M7."M9C<<&.O4M.]41&[GE=A*E-?6@1&<,_.F4^M[YA<P-A>L6LUSJ<Q4
MG)FS%6[O*GMG-,]6:W[;:&^@' -OC >'T\1U_D;7=;TMTCTZK"M]XX53-Y8G
M[[,+JARNP:F;8;6YM<%SV:I[!A#>XRN,.T5CKLSN4?0*G<M?[!IA1L'8)!XK
MG \8552G=KY3:D7+!8%9T2>$,"LUUCK57MH3$JNZ^F-DR1LABMCJ!BE<].UA
MK6MM5?#M<R34YJ483JDY^A8?<T>*5PJ^VPXTDU7AHJL1IO4GF5T;<U]:!#,@
MOI0LEZ%-6"N7J863$"9&H.@DGW(TW?,(C4J)*LT692O#,<X!UA?XO'A^-S!"
M)<=>#D=#I]%$4]:IBAJ&['"),T$<[45TDTS:>2-%79[16\3>+20J8BSO\]5Q
MUM=%>I:Y$H/:#R' P*&,?C 599LN4,\&4$5<TP/O)\XUG&+WK*ZBWVS3HM7D
MAF#QBDDT'BKBC03I8K8'39MC]A'HE;8Q,WM$M9X^ZRV(MJX)&J?%<X$3P_$\
MUOY MC!E-U??256U0>RW96X5M=<Z55E4ZUL:&Z&J7=QDT]GB%9&8[7R-"=8"
MM>E4;[1@M(0:IT#Y[I\0:!)_#PZ5[GYE<6>SDM(U?=$E;6>7L4PBF"+!IM,]
M)I# K"B#ZCBD]B;PRR)F4-$A8'= QOJ+.OIX+T+.3G&!8QGOPBJ_(WR7S19+
M+15/JND)A;MU0CIFNURJ7&1&J(I45IUY6F'UBPEE!3UNJD*R[:>R@/<'1S1&
M*7U=Z@@U/@G<D+_*_P 2OC-JMR0TBZ6LX-LZC+W9,5<#5U9VLEA*N94]!<69
M:$'C]F'0G2NI/-H1!?2D;[$X]*'-^3HRS2BT!JPDU-H%/8GXOWA]3B+3R8QB
M[G9P9J[CE4RYZ+-IN\6U]>(W>#H0Q50[P**NM<(9192.;OJ@ME9C( SR/TW/
MTTQ^",E[YU#ZY%XN/ $4A,1G\AO%8VLDRD]S0]&WF53<9TS89!SLA4.5ZI)Y
M7J: '3NO"*F0I\JYTX3>.L+<P)#T:M8JT2K$YY@=B</%(X8;)Q4]>JKNT^Z"
MZ8]2THA"A- ;,61@EHZ-V.+H?,WFB6''1&L7&V3DYQ,)9;'>HJ\NYVF--$&F
M3"O3"D4B\;KPTXN?(B7:^I!C6*MLU=WI8AH7H=T;"6NM9S][FQW!*ZMM5*FY
MS0P"5Y+13):VJ5:..I3TKFYGIVU40J,"N_\ M)^+\WHAYS+N0M19[DZL,<2%
MI838:F#;S"4UZ9;$:@9EK$10RKD]@/\ 6Q6\R:(.HEY4H7LWH&)VO=086GW"
M(=H^/5X?D,I6P[AKZ83ZZ-X-7,6M-!#HK4-L1ARFD'F%C:U,TRR-/EA0B+1I
M7#T5@^OC,CE)+FH;6)Y1J&([)\D,0L:P+Q$9D""61M@E+5HX%MDD96M^;BW=
MH=X^ZZ(7=$0O2:.;"_H6Q]9%^I"@O"QI>FUO=FY1@Q(XHDJLDX@L.<
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MSDJ1TU,U]C0:9QMH=6;+R4J?UK>SQM^C#JXH5S>G7))(=DI*67H82:$9NH/
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?.-<5:LS8)6@           __V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>doc193009209v1sibonef_image1.jpg
<TEXT>
begin 644 doc193009209v1sibonef_image1.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=44&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      $-    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    5 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 X "  1P!/ $\
M1       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24T$"@       0  .$))32<0       *  $          3A"24T#
M]       $@ U     0 M    !@       3A"24T#]P      '   ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M ?8   7+          $                          0             %
MRP   ?8                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   ?8     4F=H=&QO;F<   7+    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   %RP    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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MZ[O7S@DDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %^24DJ  @    ,   ! P !    T <   $! P !    _0(
M  (! P #    G@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    I    !L!!0 !    K    "@! P !     @   #$! @ >
M    M    #(! @ 4    T@   &F'!  !    Z    " !   (  @ " # QBT
M$"<  ,#&+0 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.#HP-SHS," Q,#HS.3HR,0    0  ) '  0    P,C(Q : #  $   #__P
M J $  $   #+!0   Z $  $   #V 0          !@ # 0,  0    8    :
M 04  0   &X!   ; 04  0   '8!   H 0,  0    (    ! @0  0   'X!
M   " @0  0              2     $   !(     0   #A"24T#_0
M"      !    _^$!@$E)*@ (    #    0,  0   - '   ! 0,  0   /T"
M   " 0,  P   )X    & 0,  0    (    2 0,  0         5 0,  0
M  ,    : 04  0   *0    ; 04  0   *P    H 0,  0    (    Q 0(
M'@   +0    R 0( %    -(   !IAP0  0   .@    @ 0  "  (  @ P ,
M  $   #  P   0   $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3@Z,#<Z,S @,3 Z,SDZ,C$    $  "0!P $    ,#(R,0&@ P !    __\
M  *@!  !    RP4   .@!  !    ]@$           8  P$#  $    &
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M @,              / !$2%1,4%AH;'_V@ , P$  A$#$0 _ -_C0- T#0-
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M:Y=Z9$;VPS$W9U!#6E)Z,ZDS]T4LD,9<:MSH6KU5H!=U@%Q5E1&UMH&.> 7
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MX3FE542LBJPK8IE.#@S;0"AL; ^\90P336$,[M!M+_2)S,K<[',BRLJNEBF
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M_<$3QYYYT%*W6QUX9-C.4XOLOC&7UN6=1VY\@\%([-[I[<'VDH;,N.M_U(W
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MC8_(L&S#:[;>OJ-N[(:=DM+7V@58D=U-<LK<BM+%@0,<$T-5ES[94JC?3E!
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M7_ZFI8TV)VF0 A#FV$M((#$T"*$MU8A=Q2.BI#PYD1CX:._PG#=N<;SBZ,M
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M!88C2HJQA"!&SI1^D-F&VV^L]7O'95>01V>*6T&/6.,K;C" NLF2UY=JI)T
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M=9T]5D@N6$3T[\/PLJGCR*Z&QA*KWF9Y+=X\]*X2AB'1X4;?3,Q3JRV_W<W
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MB2&5"F2>JP(IXYM3&Z)JSB,5%=S^4,4BJCD<O*/X5WR[SY7RG//'&@[Y@^U
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MV%&HJ_T0.'3X1%1$XT$=,HZ(<L"22;$LJJ+R-.58):CS4Q:I^F-FC<>)(_\
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MDHMSNJK'+[>_(+NDVSOA:'-@H]L[8PZXQ(_<O!$+'J+:TAE*BMCJ"V,(JY0
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MN)3N<,1QZH%A"B\(17F,3T285\<]CO4B<O9-''(BL0.EZ!H"^45/CG]I\_\
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M@\7-:]KF/:U['(J.:Y$<UR+\HYJ\HJ+^T5.-!BW*-DMJLP21;O":1Y$G/<:
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MK!>5...P:0->?97Z<V=X[OOE>)[S#7E'3[;TM7EC\JQV&-]:R5J4]O$::MF
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M#0- T#0- T#0- T#0- T#0- T#0=0S3_ .$2?[I_^=!P^W?_ ,-D_P#YM_\
MZ:#(^@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@__]D!
'          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>doc193009209v1sibonef_image2.jpg
<TEXT>
begin 644 doc193009209v1sibonef_image2.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1U:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $D< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 M5D%3($-O;6)I;F5D
M7TUA<F-H(#(P,34@*#$Q(&-U<G9E<RE?2G5N92 R,#$V 3A"24T$)0
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M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/      0 !.$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))300*       !   X0DE-)Q        H  0         !
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       %+P  !QD          0                         !
M      <9   %+P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   %+P    !29VAT;&]N9P  !QD    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !2\
M4F=H=&QO;F<   <9     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    #.$))300,     !+H     0   *    !U   !X   VV
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M_O1-K? ?<@8-5K<9K<EC&VR[<& !NKG%L1^\U)3/[9A_Z>O_ #V_WI?;,/\
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,    !"=$
M  $!  ,    !!FT   $"  ,    $    G@$&  ,    !  4   $2  ,    !
M  $   $5  ,    !  0   $:  4    !    I@$;  4    !    K@$H  ,
M   !  (   $Q  (    >    M@$R  (    4    U(=I  0    !    Z
M 2  "  (  @ "  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$X.C W.C,P(#$P.C0Y.C0X   $D   !P    0P,C(Q
MH $  P    '__P  H ( !     $   <9H , !     $   4O          8!
M P #     0 &   !&@ %     0   6X!&P %     0   78!*  #     0 "
M   " 0 $     0   7X" @ $     0              2     $   !(
M 3A"24T#_0      "      !    _^$!@$U- "H    (  P!   #     0G1
M   ! 0 #     09M   ! @ #    !    )X!!@ #     0 %   !$@ #
M 0     !%0 #     0 $   !&@ %     0   *8!&P %     0   *X!*  #
M     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $     0   .@
M  $@  @ "  (  @   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.#HP-SHS," Q,#HT.3HT.   !)    <    $,#(R
M,: !  ,    !__\  * "  0    !   '&: #  0    !   %+P         &
M 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $
M @   @$ !     $   %^ @( !     $              \     !   #P
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!J0)% P$1  (1 0,1 ?_$ !\  0 " @(# 0$            ("08'!0H!
M P0""__$ &$0   & P   @,(# H%!P@)!0(#! 4&!P !" D1$A,8"A05(3%X
MF-<6%R(W.%565YFXUM@C,D%16'&5E[&W0F&1MO 9)"4S=X'!-D-2<H*SPO$:
M)B<H-$9B=:%VAH>(M?_$ !0! 0                    #_Q  4$0$
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M,!@>-_)OR^7RW@5@<WF]UW_05.7>=U7444-MBN8I/S(RGY/,>"& 4I:$SO\
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M P& P&!XW\F_ZM_X8$,/#F_ *X]^;K5'^Y[7@30P& P& P& P& P& P& P&
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M9DB4'J$"-2I%ZT\'I *$$'I#V$(@M/P& P& P& P& P& P& P& P& P& P&
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M%#IXZ754S;!D[N1'U$S<+%B".*$/ZDL!R9C.D2EX+9RGA0486:2V&+ K32S
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M^-M<>CI\G1)#@ 'IIFSG)VE;H.BW1"O!YAV'8(+++)+ 44 )9180@++ '00
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MK<![,%)_DN\?W@6-_+\O_P";<![,%)_DN\?W@6-^UN ]F"D_R7>/[P+&_:W
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M70HOWWVO02(_TT+O(5S>?Z:=0: /KTIOJQ"T:5Z!H #"%D. P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P/&_DW_5O_  P(8>'-^ 5Q[\W6J/\
M<]KP(H^-KXC*'PX>)IC/H\Z)2KYM#:JL.?FHP)2@\,U=D!HW*;G(S/3T-HK=
MBVIDJ@T\@QO4OH8S'%@BQR--L0?S=/#;[YL#@+M*N^I6U>]OK>6]*VFZ6+X0
M..6616<O5%?9XT.)RD9@G%X&+1,J8U*\PS0)FQL3FJ&/WN9Z8?UUJYL*'6S
M899]>/[?*H'8,88YE#I(U'Z4-S[&I&W)W9F=$9NO+S)6(%9!P0BT$PO8]EF@
M 8 8-!F> P& P&!73XM%&6GTKX>'3%'TI&CI?:-@1J)M\2CJ=VC[&>XJVZR8
M8^K=%.LI<6J/I!I6IJ7K0B<UY!)FTWJ0:..,*(-"DZX>#_$TC%$WM4]&L]H.
MTLDW<W7MPHKT9[R9J\MRUV&:\Q1\FD+<F:2O;OHR!FO2NXDVX H3;9V=DKUL
MB4:EK50[DJ)+<AAL:3\B^*JYW18EC1AZNIB=I3.;J2,;H9TIM/"&^'27PJ(I
M7D&6ZKM+:!D4;0)^WT*Q8F4(8@&0-,M1 G7D1'RTCV(- 1?@CQ*8G1\U;HW6
M72$<^S/H^RK$D4 8NMV)ENF5N3UX:U<4W3EDR6W6[HE*H?8_7_64;.?7N/O%
MJ+7 *-J;'LB)OK6TMB#0;3NWA[Q3IE9TW?\ [(+Y>1.2-C9C7N!=7OM>Q-_V
MW^%2Z09W=&:)LUOQ!*U)7;NYGBBW8C8ZUN2M\]"2KR_L..=W$P.=F/+'B126
M!S.%SZ"]/2<=EW;Q8O=+!K3I^.,]DUE5M?\ &U0,_2[I7:=5T-7[*LE4]N6+
M3"NAIGIV^#"GR52.WTS<[*TK,Z.@?%8''GBV.,X\11WB<MZ ),LUAZ22TFI)
MZ/9F:$OD2E=L5(_45$*Y;#;A>'""6!&*D9Y]"TDB+C%()(2K5NR93+9Q]EQ+
MTSALEU\/SH9^\*WJOG_=*3=/8TV\0&;=$UM5CU<,>66"]5,M[$AUK-OPO9)=
MK.#,YS1?5*%[,&;+;./<%4I+*6N#YI_]YN^@D/0O/W><;\262V9,3[72T&=8
M_23HYO\ (;U+DU3RJ@)55M"L_,%4Q.G?MD/QL<G576%'K.=Y(^BK:,[\E3TN
MW.93N9#(-#0:'@GM:Q>\Z[LJP7Z\*ZJ^&=6>)O,6FV85;E>*I7$Z;N)EYV*H
M-@CZ:3JY\L;(1-54+F3=J(-L4"HC:-*KTY(HM\(HU"H, D/+?BDN4WZB;2F_
MIA!&71A\25/6LIAG3]?QQ2_FW9U[25D\V@KI2Y68[+(RX,-)LLZ9&8N5QN$E
MQ-K^&H"V2"&A?TSN6&-K.0/%M=SN1E UEYQ-KA++(4CJRPGIXTL^(SL/8;3,
M&^>6GN:=#S$?V,27G,D2,5?E/O73?#&A.^TJQD ;Y EDB(.U7KY-?U8$1YG^
M';SI\U3L/_-?B/ ES@,#\B#Z0=A\_+SUY>?\W^&!2G;L!@4';.WF1N9&MLB\
MC[S\.V1SPM<(:M(_;FEN<BN-@.4K5NIRHUS2.Z-<XD.^G90>C*8=!9P@(8T2
M5$G#5TAC%6S!UZEH^-L$,.M3H#I?I:AZ^>W%.C71ZI*$F=<\[.O7ME$-"LX4
M;2DLLM)4)0:$WB,?^@'J&1-X.3I'B0*487Y-J0A W($*78MI4:)*D3;&:,\>
MR$Y!9).QGF"&8<+U8 ^D:,0AF;\QB%L6][V'VX# B9)?PZJ5^:9T_P#YP\B8
M$L\!@,#370:>G%=-3Q+T"8T%4RH:B";!W(%+@D81,1CDB (I\/;#2%068]5M
M,2Z &:%"<A,/)=-#;#%@!!3Y6<?:M]F.S%<3=6"E3[3_ $TK?4D?;$*>IU$H
MWPUS!]C!K$RO.E!J:7)Z572-/,M.RA>ZGKMV,XICB(PK+0H@L>\.DQ6;X?O#
MAJ\9YJPSD3G :DQ2,9B@PT5/P_8AG#,WL8S!>?I"&/>Q"WOTM[WO?G@3*P&
MP(>=Q?>?@/SO^!?UX>>\"8> P& P& P& P& P& P& P& P& P& P& P& P&
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M<XTYNL?$W/P9 \K6)$UFE*P^:1^,G%HHSPXY[YKM!#(5G1%N<R6:F6S&LV:
MU?9U-O<):'AD6W)))$QULM<9N3/&MSJA$_O4+)G!;5(VG2]ID;<B9G0/?(_&
M7KN'MG73I*J#M./BY5D\=B!L<=7R H)_.7F8W>30D,4?:X62!/.8K%YG)ES3
M+(C/#V%[@LAKQR Z-LD/E:-PA24(P]2>,O+W2K:R8Z#K"VJ:N&7O5-3"=NTZ
M8H4475]?&>(-5W)$O:#62<(EIDS1VF-SE:*)R-ACP%":(O#',DWP.X*@B8P[
M&^ODU_5K B/,_P .WG3YJG8?^:_$F!+G 8# ^10N1I#$Y*E200:K'LI*6:8
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M#305XDOCI)J?]3KG(OHZ #CP&C1>H@7: W.W=6*"*^]?-N"5IV"K K W;TF
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M^L8M3QJ+4[LX:E) 8/;DCOF&M[2[FS8;RQO,7MZ5OD\89DS.""9M;R>D]YR
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M(ZXROHJ+2Z%OZV[(M)K0<IQ"(8\C852F;*AU"E*CU?2EEL).V):YE4"9XI#
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MM1@Z?M=XK^16$_5(GI!]KFD)"7?\;C<>;X.D\/W?.\?J:3PUW8GF>O;LNO\
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M[_GB4?/&@?ZA?%N!.3 8# 8# 8# 8# 8# 8# 8# 8# 8# ;UYZWK?R;^+?\
MWX$%X_X>% 1%D:HQ$I=UI%(PPH4[6PQF,]V=HL$=86I&7HE$TL;(U7PD;&AJ
M0D! G0MK>E3HD:<!:=,0426 &@YCV$:B_.;VA^D#[A_> P'L(U%^<WM#]('W
M#^\!@/81J+\YO:'Z0/N']X# >PC47YS>T/T@?</[P& ]A&HOSF]H?I ^X?W@
M,!["-1?G-[0_2!]P_O 8#V$:B_.;VA^D#[A_> P'L(U%^<WM#]('W#^\!@/8
M1J+\YO:'Z0/N']X# >PC47YS>T/T@?</[P& ]A&HOSF]H?I ^X?W@,!["-1?
MG-[0_2!]P_O 8#V$:B_.;VA^D#[A_> P'L(U%^<WM#]('W#^\!@/81J+\YO:
M'Z0/N']X# >PC47YS>T/T@?</[P& ]A&HOSF]H?I ^X?W@,!["-1?G-[0_2!
M]P_O 8#V$:B_.;VA^D#[A_> P'L(U%^<WM#]('W#^\!@/81J+\YO:'Z0/N']
MX# X4_P[:"52)KERF9]>'RED9WR/,\B-[U[9,>6MADRR/N,B9T#B*_-JDK:^
M+XI&5CHC)- 0N4L#0<H 88@3"+#FO81J+\YO:'Z0/N']X# >PC47YS>T/T@?
M</[P& ]A&HOSF]H?I ^X?W@,!["-1?G-[0_2!]P_O 8#V$:B_.;VA^D#[A_>
M P'L(U%^<WM#]('W#^\!@/81J+\YO:'Z0/N']X# >PC47YS>T/T@?</[P&!P
MIOAWT&?(4$N/FG7ILH:F5WCC;(3.]>V1O*!@?US(YO;,D<17YM4G;'9QC<?6
MN*(HT)"M4RMAYX!F(DX@!S7L(U%^<WM#]('W#^\!@/81J+\YO:'Z0/N']X#
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ML:H&2VH_8-?GUFZ6Y-&USE"@=:S]$RDO["G+,0L;M+8XM4;8@FZ#L[8# 8#
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M13H:6$*4[E(VM"0XO4"$G-A#LF3FFGDL*2&N*D1RIT5F!#L=X# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8%9_BN4O8-Z\R1Z)5_ +0MO;/?M(3>:5+3L^C]3S^Q
MX%$)FG=I PL=I2&8P,NOU3884@EZ60-4F;7LQ?&$;,WJT&W8QT0!%?C*CSH?
MT-"'_?"/B84IM$EE(/MC]$^(85?-1LGOJ)O2394DJT/<5S_9 >[>OVTL9VJ\
M>O@9\6MSSZYK^#].J,+V,!@:!ZMK^P;7YBZ'K"II%J(VA8E)V?":[E G)>S!
MC\UE$,>66,NXWEK :YLX$#PM1J!NS:4:X-H0;6HBS%)!0-A58V\FVM%K@@]]
MTGR(11%85'9O/TT3<DQN1T5''Z<O\6I;KJC[7L>+I89.5%*-D@'$^C:Q;FM3
M)I[''N=,U)#;Y&8P^]XEI2%E?'L!G=?U&ZE62P%1*7SJY^A;B71$#LVORB)(
M;FO2PK.C\8='EE/5,CB_LD=E+2@D9S&M<6,#^4Y$,SJ[MA25T6!@/*'W_/$H
M^>- _P!0OBW G)@,#K9>ZDE%NQ7P[8E:U-6+8M:OE9]&0!7)WJN9E)86O4PN
M61J<PX] YKHRYMJA4WCEKQ#C0IE1AB?2LH@P(=&Z!O IP]S3>*I;\9N(SE_J
MNQ)_.:LZ:ECJST1:%F2=]EVX[T+$V*.K7>LOLHDSBO5)&Z>1-XCWP8TC6:(3
MS(,>2-" :N:.B@ =]S7Q_'KY-X# 8# 8# 8# 8# 8# 8&$.MF5PPR9MA3Y8$
M)9ID]>]-L\2=94Q-TG=M+U!J1#ML8%:\EU7Z6JB#TR3:1(;I2H)-))],PL80
MAF^!#OL.\[IYSK2:7#!*_J.<0>OH(]2J1IIU:DU@4K<7IO"=MJBD0:(S3-EH
M7IQDRG;>S,NECLTGJG]S2-P$8@#"H$&-VWU^[5I=W+]#):]2R"6W,N;!VVJ)
ME9B=!23 _(7A'%EPAE1E=J5NTTF<?DS-$6M0.*)W9D@EA/WPD2HCI#,Y!.C
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8'H4JDR).<K6*"$B5,48>H4J3BR$Y!)0=C-...-$ LHHL&MC,,&(( !UL
M0MZUK>\"(UZ7O>$475PY<ST?#NK8H[?9"=9K5&[V@\ L2/,Z14UHV*05ZAEQ
M8(//"C%I<E;7EL>IM!0)5R-N+3O9AIBM.6$NR1B,+",8=@$+7GL.]>6P_P#Z
M=Z\]_'KY//6]ZP/;@,!@,"#?)_W_ #Q*?GC0/]0KBS G)@,"I'QW*T^VIX2/
M;[ !-[Y/8*G)LXG00>L-*U4$MC5IJSB=:WH7IA;X@K#OT=^D(L9A?D+0]AV'
M2O\  [YA1>(#R[X@_'R!T+BUU0\=(]6<IS\E8:VNL#NV"'3>.#<$CJE,*6-;
M?(25D8B;\N($(2!&[$/B8D;NQ-!R<.[=X1/>:_NGEM*NLQ ;%>I*'?UE&]5U
M\X(@M#S'+=A>MMSB]'LF_0,;FZ9EI1O)) "0)&Q[#(XN08<=&U0\"U# 8# 8
M# 8# 8# 8# ]"E2G1ISU:LXI.E2DFJ%*@X82B2$Y(!&'''&CV$!91181&&&#
M%H( !$(6]:UO>!UOYE95T=<="4=XE'.OAL1.\.?^?H]<#)7\ZG%C5W!^A.DX
MP^.<2VP6O2L$D, ?#T++ G.%2=\IA)/9[$'Z9IYDJ=X\FB(WD(W4+X.>;ZKK
MIZE*YORJ7%6XP&SHX1(F(;FA,:GA#YG'H71C?VHX0S6J11QY1N+!(6LPPT3<
M]-B]'LTWU'K!!J_INN9C=CASK!F5O;W&H 7M#;3O)U-<$.@CAU0(W2S*Y8FU
M&,[:AY,DM[1^I37$"0@]#J(-4F+<1A+5IBE(1UO?BJTI#>\:NBN+TGQ 9%TM
M4%FSJ)JF&G5C5$H965;/,(2-\6>'^"'RX3$A/5.#HGB@G]P(!(K$G,A1)2US
MH:H3A:!KY-?U:P/. P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P&!6]XH]7+[?YXB,1;TU72\0;[J-Y4T-<MEZJ:O^I$S
M6\*C=\\NDOVC=0!<9@H&G?(VR*6*0MDAD<4:F9[9E+&L<C" K<XCX=Z>C]^<
MURZ4<14[Q5">:K6ZYFI$NA=[QB;2654MT0_WC)HARG&:_J^+-,:0UK"I1;<:
ME9[A)W8A&F<ZU1+(W%VI4ZG$%AV1,!@,!@,"#?*'W_/$H^>- _U"^+<"<F P
M-5WI7**X*3M^IG$LLYOL^KY]7RTLT.AE#2S**NL=/T,.];UL.RW$7I:WK?GK
MXO+>!_.G]RKV4=6'BI+:V>!C2'7#0=LUOMN,WZOSDT37QBT Z$6+>M[/1M==
MR4G6M>8P!..^+T?3$$.R)WZU.?A->(77_BM5^WN&N5.FUT=H'Q%(BPH5"I)'
MW-Q-TDKKHC3>ET80F5(%:9"F=U_O8D:ER0*V(@\U^MY2?@7,\E]MPKL)?:R6
M"U5=L'0U#)&Z(/TAL^.PUJCCY(W%B;)2%MB#I%)[,PO>T\6D$7DARL12-"8T
M2EC/1JE9IZHE($S\!@,!@,!@,!@,!@8_+(ZAE\6DD3<]GA;90PN\=<1)3/4J
M0H7IO4-JO:<[7QE'Z3J3-E&:^,!GHBU\F!UO*Y\16QO#99*8\*.R*(9+7ZLA
M,-9:BY9D<3Z!YW@U3W;7L62$1:I97:/V>V2P6)1DG=8ZE:$3O#UL"E:Z7R!O
M=C*T52H*CWNA"5+WR1S[4?AG07BWM_K!BI9^F15B2V16;$KQ-Y_&Y7)8T]E-
MN6,*NQJY%&#IE#&&:V8X(4L-?FUT9G6.B9@OT<3JCT84@9?0$\E;);E/UYR-
M:]_=(\ZEJML-H@N.J%.Z@K"O&^,.?P/(Z<ZGD$6K9[F;PD?$D=9DD*)>>F37
M=J7F$&G0! E/ER(+B\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,"M_Q44%4.'*VP6O9EKU.%);=0N=:2J@8*UV/
M?P[D:YJW+ZV9*2BB^(3=8LL1X?$X4S<J860+PWM?PNL^$VIJ*=%I00DXZOV:
MG=-UC7UQ]1>*.W.<S3RY/ *K[9XQH*C*VNAT9X6^/:]E9+'K:AX^XCE<78T#
MA.TT>#.F!S7IHVI,4(G1O)6H3@O[P& P& P(-\G_ '_/$I^>- _U"N+<"<F
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MXBL@23^_$UR]N6H7L"A=/NM+8DEAF+UN]>:@2B,-QL?C#F@-,V,0&^4MLFV
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MBSTX7(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MSI)II4#;FI$V#EC$W)5CV2_/S@1'F9V'H-"<M7!;\JNN(LDJ\6G@'I]D6IY
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MI!:I+@6[HY,_ ?05E7QR**QE:4M.P+S<!@,!@,"#?*'W_/$H^>- _P!0OBW
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MQWQ6#9>];V6=(R9$E4"UY"&:4IT+SWO8A!_3^*-+/*+.*$$91H F%C#O6PC
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MDDFJ!FED>M $H\9VP@";H[R#U71TGX8'B)5\=S2R]V40NF4D>&675B\U#>T
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M$'H^8M_&+?GH/Q?'O6L#'%?N2KQ02=BTGFW(*P(2_2UL%L663Z0OC_@PZ.I
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M39/\3^+Z[TNA$WI_QQ>AK7I^7W?\7SWYAY#X27ND!L^Z3PCJ=-L?\'O;?VC
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M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# @WR?]_SQ*?GC
M0/\ 4*XLP)R8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# BIU1
M;=C5P31,)J3<.0V+T/>J"EHY*9^QO,KB$)+3U9:]SR*3NT/C\EA3O+# 1.GG
MYE9V1+,XL Q^>FM:L=PH42I(K#F^5;6F=O54J>[%2QQ//(C9UTU#+E$/2N+=
M$WM]I6WIM5*N4QUI>'%Z=F-KEH(@3)4\><7Q^51WX5$QFOSYMO\ A=:&J^3_
M +_GB4?/&@?ZA?%N!.3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8$0>N:XLF6^SI8U4QQMF\LYRZ&07+NOW&0I8D9.&)PIRYJ1D+,T21P3J6E
MK?FUHN55+&C3QI,UNJJ-A8U;BTA= NB,.=Y"KB>5K4:]+9K<SL<WG-NWU<;[
M&F%Z%(VV)CNFZY[:+?$@R#:%L+?%L99Y6W,KNZI4"9 N>$3@>VA&WC3&C#YI
MAQ5SC.9O+K&?8?)TTQGK@VN\S=8I;ER0$J2.[1&V2'MSLZM$#G\;9%3HFB\:
MC[%IQ&W>_36UF;DQYYH$I7HAP/L#\S?B&TOI*],?6]@/8'YF_$-I?25Z8^M[
M T+TEP'7IM8I 4LQ7'J<:MKG@Q1MKZ;Z&(5_:^)Z"K VX=",=;B+1[1[J($Y
MTYE!%[]/;=JR&L!CF8C+$&^O8'YF_$-I?25Z8^M[ >P/S-^(;2^DKTQ];V ]
M@?F;\0VE])7ICZWL![ _,WXAM+Z2O3'UO8#V!^9OQ#:7TE>F/K>P'L#\S?B&
MTOI*],?6_@/8'YF_$-I?25Z8^M_ >P/S-^(;2^DKTQ];V ]@?F;\0VE])7IC
MZWL![ _,WXAM+Z2O3'UO8#V!^9OQ#:7TE>F/K>P'L#\S?B&TOI*],?6]@/8'
MYF_$-I?25Z8^M[ >P/S-^(;2^DKTQ];V!HU^X$K??2M5FM3%<7VE04=?I<]T
M7TUT1IJW:)L]YL%4NUA!EQ:=C'#44(NK3:<B+$W$)]N@',9:E0TA-#>7L#\S
M?B&TOI*],?6]@/8'YF_$-I?25Z8^M_ >P/S-^(;2^DKTQ];V ]@?F;\0VE])
M7ICZW\![ _,WXAM+Z2O3'UOX#V!^9OQ#:7TE>F/K>P'L#\S?B&TM?_[*],?^
M-O8#V!^9OQ#:7TE>F/K>P'L#\S?B&TOI*],?6_@/8'YF_$-I?25Z8^M[ >P/
MS-^(;2^DKTQ];V ]@?F;\0VE])7ICZWL![ _,WXAM+Z2O3'UO8#V!^9OQ#:7
MTE>F/K>P(^TQP) @V!U..R6*Y-Q$Z^&0VA]+NFNA3$VJHUS?S\0Z:: (+A$J
M3MWVZ";=V,EY"4Y"=-N2@LO;4>V&FA(+V!^9OQ#:7TE>F/K>P'L#\S?B&TOI
M*],?6_@/8'YF_$-I?25Z8^M[ >P/S-^(;2^DKTQ];^ ]@?F;\0VE])7ICZWL
M![ _,WXAM+Z2O3'UO8#V!^9OQ#:7TE>F/K>P'L#\S?B&TOI*],?6]@/8'YF_
M$-I?25Z8^M[ >P/S-^(;2^DKTQ];^ ]@?F;\0VE])7ICZWL![ _,WXAM+Z2O
M3'UO8#V!^9OQ#:7TE>F/K?P'L#\S?B&TOI*],?6]@:(YGX$KLJE8D"[6*XMV
M9I7,-R';KTUT,>N][BG$D%'='&M%Q&-X@ZB^V71'J!B$%/ZH)_DH";K0;W]@
M?F;\0VE])7ICZWL![ _,WXAM+Z2O3'UO8#V!^9OQ#:7TE>F/K>P'L#\S?B&T
MOI*],?6]@/8'YF_$-I?25Z8^M_ >P/S-^(;2^DKTQ];V ]@?F;\0VE])7ICZ
MWL![ _,WXAM+Z2O3'UOX#V!^9OQ#:7]7M*],?6]YX#V!^9OQ#:7TE>F/K?P'
ML#\S?B&TOI*],?6]@/8'YF_$-I?25Z8^M_ >P/S-^(;2^DKTQ];^!H7HG@2O
M3(?"PTZPW%J1AOGG,V2_!O3?0Q)_VJ2;S@!UR:/$Z7$60-NW5H);IT)(V)Q4
M-^U)#668X&)BQ!OKV!^9OQ#:7TE>F/K?P'L#\S?B&TOI*],?6]@2$K&JX93\
M:%$H(F?$C&)Q5.NR9!,YG.E^EJT!!:@07N=R"2O@4X@IB?5HM..D1 M#&G3E
M#..$8&Q,!@,!@,!@,!@,!@1#OZXK@8;7JNBJ)8Z[63ZPZ[N6VEC[:2R1EQ1J
MB5,.E41Q:SD((J6%U5O\JDMRQ1(C7C6$M\?:$+Z[GH7U42A9E8;0YLN-+T/S
MW2-\HF91'$MRU3 K.*CJM64X*6#4WC#9(Q,AR\DE,4N,:1N(D EI:<@"OWO[
MY 04$W180W9@,!@,!@,!@,!@,!@,!@5Q"ZUMM_Z7FM5P9EI!1%*WO&%TRZ0B
M46.2P7W8#4ZP&L[!L>WZ\:%RQ(RBBM3--H)C5L4.;GA[ER2$RX;:[-+BH8&M
M>%CN P& P& P& P& P& P&!'[J:VIM15!6C;5?5K]MF40&(/,H10TV5-L*;U
M:=D1'.3FN>9*Y)G#;8S-#8E6.CB-L:'U\4D)=HV5C<W)0G3B".7472_1-/UY
M++G@M:UF*JJQY];[MDCU8DL=2%MF2Q=I^.!0]:((R2>Y,,MTF9FHLN929H>&
MMU>Y]"H]'(N^+?LB,90L$1'#4HTJ@TDQ.8>G).,3G>CZT@9A81B)-]#>P^L*
MWO8!^CO8?2#ORWO6!]6 P& P& P& P& P& P(R]%7=.::<:7*C%7:FT=L2X*
M_KF<S%7+FV.-M<-4\F\6@C:X$M0DCF^2Z1.3O+$IC2R(4*!F V-$A7ODI9U2
M9B:I($8T_:EH*;E4M88I6A56I.R2N-!Q<;X_;NH]Y,A"64_;0(!HG3!II"8J
MT[B@@F?:S=8D'V)J:ZUK4>"%FV P& P& P& P& P& P&!7^Q]'=",70-:5S<
M%<5O&8G=!-^NT<8V*4.3E9%7P>E341C98EEN.@*H6\1^9(7:,)W<MB$R@KZ4
M3B*1DQSF6U*MS3AF/%W5+IUBPW#+5,&*A,<A]M@B]:G_  PI<UL\JF0U=6EM
M5M9CHB5,[0;&%TZAUEM#X&+"^$369"H1$+' 3@)8E2A,_ 8# 8# 8# 8# 8#
M 8$&NC(_;D8Z$I'H>KZC?+P2PRFNBZ9D4&BDI@$4DZ15;TBH*:1>5D*K,E$,
MC"Q@0N%'JH_(B27_ .'D09,VNK8S/)*)>04&T^.*ED5"<F\UTC+E+>LE=2T;
M5U=R=4T&&G-)\AB,,9V1[,:SE!1!Y[;MS1JO>)YQ!!IR711IA!(QB+"$DL!@
M,!@,!@,!@,!@,!@,"F.:<L6@HZ!MA,S\[-C@GMGO/EGK%KZH2OU;IR89 J68
M.?")A$GY$Y/Z:WR)BJ)IF=0%@:8?$GF'ND>M?2MTD;40OF2$L+G,!@,!@,!@
M,!@,!@,!@,#3O1$/>["H"\8!&2"54DG-065#X^F4*"TB=0^2:&O3(TDGJC=Z
M*2DFKUR<!J@W>BR"Q"-'O00[P(37[#^B':S>;V F@7ZX>?:=A\<LA_88C8E6
M1T<UZ(CJD#? VR:MUARN+Z50>H -GVR&9*A"ZIY+9CC!GXPUH,JX!$@"S8@0
MQD%#,*V28,L AD[V'>RAB#K8B]B (0!;!O>P[$ 0@[WKS#O>MZW@>W 8# 8#
M 8# 8# 8# 8$?^CH#);%BD!:XNF3JEC!?W/4_<P*%1*0)4:KRXX;,Y.I+&<(
M(3E"9C95QR9(#S.6'@ F)#LTP.L"N77)UI%]5N,\,HQ"HL19V>UW.V]K:?Z]
M]_M',2:"M#8LHKUQDAU<Y9*EL0NU3_:Q2Q,RK3"'C=D&O87@Q20 +F0Z\M:U
MOY=:UKXO]6L#S@,!@,!@,!@,!@,!@,"H^/49>=U2SJAMZ*J:R:Y=.CT$RIYN
MO&#6-2KLWU9S,R+'E)7]<P%E5/<O?TR^<(5SK+;#>UT TK<YI-UR5;HABAL*
MVR!);E+GVRZ1L#J-VFUG2JPH_95KPN0P,4D;:F:?-ACW/M.U^I>=M]6UY DS
M6O&\Q%PBOP2>FTVEL,0C[D@;$K@YO#H]!-K 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MO[-\0<F\/$-9>?R^+6^HN!X[6\F<T5Y,%PE3>>)93S^WW:]HR9I%;#;HE'Q
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M4Y+$R<\@6PD_/NX^0*OAL'L&=](T['X99T463BM']1/&!2DL6)-VV/X1D$#
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M<+9/%W?F2FK6D*%U\0KPS;GB3=$*YE3\\6) :A9>#G^TI+6C&TM1RZP]1PJ
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M.2KD:Y+%FHA6E6IE 0*$ZM.H 84I)/  XHX P&!",(M:#9F P& P& P& P&
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K !_IBP/9@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__9              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>doc193009209v1sibonef_image3.jpg
<TEXT>
begin 644 doc193009209v1sibonef_image3.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2:N4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $$< 5H  QLE1QP"   "   < @4 +59!4R!#;VUB:6YE9%]-87)C:" R
M,#$U("@Q,2!C=7)V97,I7TIU;F4@,C Q-@ X0DE-!"4      !#]?,]"""7@
MF@Y#J)*I4(<G.$))300Z      $-    $     $       MP<FEN=$]U='!U
M=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR
M;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0
M   5 $$ 6@ P #$ -0 Q "T 6 !% %( 3P!8 "T ,0 X "  1P!/ $\ 1
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]       $@ U     0 M    !@       3A"24T#]P      '
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M        !14   <9          $                          0
M       '&0  !14                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P  !14     4F=H=&QO;F<   <9    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   45
M %)G:'1L;VYG   '&0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     SA"24T$#      <9P    $   "@    <P   >   ->@
M   <2P 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')2
M1T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M          #VU@ !     -,M2% @(
M                                $6-P<G0   %0    ,V1E<V,   &$
M    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H
M  (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U
M960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M)'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\
M   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R
M9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M        $G-21T(@245#-C$Y-C8M,BXQ
M                                      !865H@        \U$  0
M  $6S%A96B                      6%E:(        &^B   X]0   Y!8
M65H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M       6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT
M=' Z+R]W=W<N:65C+F-H
M                     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                      !D97-C         "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03
M"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                   "CP    )S:6<@     $-25"!C=7)V        !
M   %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M
M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L
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M%/\ G)*<RWJG4L>HW9>(<>EOT[;+L=K&@NVLW/<\>[W-_MI.ZCU?T2^O%!?
M<UKKJ@(]1M;F.<PN_2_9C]JK_P %_@?T:L=4J+\4UUU59N]S19CY#P&.8'!S
M_I->USV_X/=^>LMV Q[@YW0\*6NW ^M7R?YQSOT#=_TOH.24W+.JYM36VOI#
M*H>;2^Z@%@;L++7/]3T_1]-UK[/]'Z26%UB[+R:L<!M;[&N>YIMH>]K0/]#3
M8^QSM_Z-W^#^F@X^'6Q^O2<2AKB&.++&;O3=/J$[:6[F^RK]"I]/H>S(I=;T
M[%Q7A@%F11:TEOMDUU-])ECJO4=Z7TTE.ECUWFK2W\Y_Y@_>=YJ-60Z[(NQV
M6G?1&^:X!W"?9K[D^/Z?I?SQ^D_\\?O.4:[;'7N98#74)VV^I,Z^W_.24K(Q
M7WO%%MDLLJL:\ %IVDUAT/K<VQG]ARJV]&Z=BXY<6[*6EI(:7@-T-+2W]*WT
MF-;<_P"@KCO2^T5_I3&Q^NX>-2>]_IU.?2XW6 >VO>!N/[N[\U)329T#I]U8
MLVOBULD&RW\_W'=%^W=[U?Q6>F;63.UP TC0,9 2K+75M<^PL>0"YN_@GEJ?
M'C?=M=N&\:S/YC$E/__1]-;F5NSGX4$6,K%LDC4$[?:W=O\ ^BGR\5F73Z-C
MG-;(,M,'0SW#E6KJO_;=MSFD4^@&,=[8+MVYT';ZG;Z.]:"2D#&^E;32TG8V
MIP^.TU-:3".@N_I=?_%V?EJ1DE*22224I))))3R_5*\^QP^S>L[]5:S"-%XH
M;CY8-GJY&?6ZRGU:?Z)].GJ'Z/'RZ?LGZ?TLW4ZJZJ[$;76;7O\ 4K<?LEC*
M7C8X63ON>QOI.V;+:]_OK]BU$DE/,5X^354YM#LX.LFTMLRJ#[IKH^S.M_3>
MA7Z;/M7ZLW_"7?X;TZU.<T,L-9S]Y::ZQ9?B@>\6?I1M]7;]GVU[/T;_ -)9
M3[+*O772))*>=#LMM.T?;H<0X#U\8V-+B]KV^X^GLK]MW\Z_Z>S^0IX+LG[;
M4[).8*6R0;KL=S)VO;^GJQ_?^?\ HMGJ?\(M]))34Q[\4507-!W/\OSG*-5T
M9%KK;JC0Z/2:(W#][=[6JZDDIJ.OQ?M##N;M#'@GS)K2OOJ=4YM%M;;#&UQB
M!K[NSOS5;224U:;Z14P765NM#0+"W@NCW;?[2GCN8YUSF$%I>((X^@Q'224_
M_]+T&O>[ZQ6EP.UF. V22)W#WM9ZCJ:]^[9_-5WV>G^D_0UT*[ET67T^G7::
M72#O;,Z?FZ%JJ56-_;=S&5:^D/4M=8Z>WMKI]]3F?]M?GK224UVL++J&.=N+
M:G@N/)(-/NUW+,ZA]8V]-^L.)TW-:S'PLS'LLJS+'@;KJRTV4[?\'751^D?9
M9_I:_3_PJU7?TNO_ (NS\M2R/KC1?^R/VEBMWY?2+&Y]+-Q;O;5(S*'%K7^W
M)P7Y5&S^6DIW&N:X2TR 2-/$:%.L;#Z=Z>,S*Z#EAE&1.0REX-N,]MQ]=KF-
M+FWX_L?MJ^S75X]?_<.Q$'5LYEPQ[^G7>N*W/+*-ME;H=6R:<VUV+1_A/YK)
M^S9/L_F4E.JJEV5;7G5T!U0K<W<\/=#P +-VP?G?1;_8KN_G/\$+?UV_Z->/
MA-Y#K"[(?'@ZFO[)76[^KE7JC9@O/4J;79=V5D-:\ %U==3C_H3516-WH^G>
MSU+O4OQOM=GI>I_@DIW>4ZKX5V-;2!C0&-TV@$#77<V0-['_ )EK/T=OTV*P
MDI22222E))))*4DDDDI22222E))))*?_T_0:AM^L-PD'=C[H&D>Y@]PV_P#@
MGJ?^>E>RFY+Z2W%>*[9!#G"1 /N;_::J=3=G6K #9875DN,,V-#BW8S5_J^W
MTW[/2H]/]+^GL]5:22FNT/%U L.ZP5/WD=S-.[LU'(!$'4'D(3OZ77_Q=GY:
MD9)3R_2<ZSZMMHZ+UIC<?%<][.F9K"78XKG]7Z=DY%A]2O+KK.RFR^NNK*JK
M_G?M/J+<NIS3D&VIU<2UK=P]S62UUK0_:[^==]-O_!_]MV,C'Q\JA^/DUMNH
MM!;958 YK@?S7-=[7+G:.F_6CHUIP>C.HS.D-878K<^UXLH)<V,-EU55]MV+
M35ZGV?UM]OOKI]39C_IDIV*:^K"V;K&>E,P()B?H_P VW\Q3Q;ZFCT7O M=9
M;M;Q/Z1ZS1=]>.^)TL_^A.1_[Q(3W_7$YE+W]-Z=86MLEXR;8:?T?I;;'8FY
MG^&WL]!_J?H??^@24[ Q&XSS9AL#=Q'JU?1:X$L;OG8]V^FIKO18W]&_^;?_
M *2H]-K+JQ8R8<)@@AP_DO8[W,?^\QZQ+.I?7!GT>B8MO]3/(_\ /F"Q4#G_
M %O^VMR'?5ZVH#6QF/G8[FN(_>9=]F:_U6^RU]C/49Z57H)*>M0FY%+KG4!W
MZ5HES-9C3W?])8C>N_6-I:+?J[DEN@>]E^)/T7;W-K^UN_PGI[:_4^A_A/9^
MD0Z_8RU]@Z)E^MINH;Z)R0'?X:ROU_LS<6S9LJL;F/LMNKN_5_T"2GH$EACZ
MRYA_[P.J?YN-_P"]R?\ YQYIXZ!U/YC%'_N\DIVTEA'ZP]4GV_5[J!$CEV*-
M)]W_ &L_<_U_/46=>ZV7![^A9;6G0T-..7C2?6^T.S&4N;N_1^AL]3_#;_\
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M))3_ /_9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,    !
M"=$   $!  ,    !!FT   $"  ,    $    G@$&  ,    !  4   $2  ,
M   !  $   $5  ,    !  0   $:  4    !    I@$;  4    !    K@$H
M  ,    !  (   $Q  (    >    M@$R  (    4    U(=I  0    !
MZ    2  "  (  @ "  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C W.C,P(#$P.C4Q.C0T   $D   !P    0P
M,C(QH $  P    '__P  H ( !     $   <9H , !     $   45
M  8! P #     0 &   !&@ %     0   6X!&P %     0   78!*  #
M 0 "   " 0 $     0   7X" @ $     0              2     $   !(
M     3A"24T#_0      "      !    _^$!@$U- "H    (  P!   #
M 0G1   ! 0 #     09M   ! @ #    !    )X!!@ #     0 %   !$@ #
M     0     !%0 #     0 $   !&@ %     0   *8!&P %     0   *X!
M*  #     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $     0
M .@   $@  @ "  (  @   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.#HP-SHS," Q,#HU,3HT-   !)    <    $
M,#(R,: !  ,    !__\  * "  0    !   '&: #  0    !   %%0
M   & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P
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M(" @(" @(" @(" @(" @(" *(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MM7:3*C-I5Z12D.] \@P 0D? 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'SZ^Z
M?/\ ZGV\?YQJ _;#$L#1CV-T74/=;O[GAY%Y1F[-<]K5>Y4H\VVWPWWZYIJW
M%%XW0I#RBD:XI-[U)5L3="K >I(F3C4FL+5%3EKE[V)5H]J ER;M=0OGBW>Z
M,VB_)#,XC33GP_%TEC2NO6@Y_F4:C)U<\OA7/S(QD$G#=SFG]PN4-PBA$+$1
M"E.JV!*8<,(0IX85O5U1_<_#E5O,?YY[J:%_-]EG<;]1T>7):XZ-IRN6J(7.
M^**YORI&)^''$K^<25.F5V:9NR/<R9]RPM]W84B$W":40:GYQ9C/97&- 6)'
M)]S)4B"1^),4\1WA:E*]9D4_K AKB@4ZFXY+:4@E\CNA<U+"S(W&"FE\#N,.
M:H]G?$SD%U0 :F\-WG6$GYIBOCS>*JIZ<7U<WQ=Q\,F2-$(W:AT=)0+K"5T+
M1XVMIB8I,860;.W)C(D2>.I&D?P^M\UB9J"(XP8=A15$2_$^&#[G2T^A7 T9
MXB%G',H5^C="^ 3NI &(!I=&_NM(#1B4F)-AUHH18O3*\P"UO8;:()_]?YX]
MG_[/0?[ N5<#2'9#$R'^YJ.%I4N96U0O8/$IG;<.1*&Q,>M9HV]H+K/>V_X4
M,(&H0,KPN96(UT1Z/*1.2MJ:!JBCCD*+907S\;6:QWB[J<73/+ (HJH[Q)_"
M_GO+\5>Z@"R+((\NY!T:80/$+/B?G'SFP$".JM.Q'M AI1)MGC0"$7L/D'V$
M^'?SEODCA[E[G50G)3O%84[#FF6A3:U[W.GSBVEO]B+2?+6M[*<)T[2)<#8M
M>EZ*C6M_5@7-P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MK^X:TC$% A 8&\'6O+6M?Q:UK_5K YP& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P&!!/4DC?(?S+T5+HPYJ6
M62Q6B[;DD>>$8@A6-+XQ0&0.C2YI!#", 5*!>E3JB-C ,.C2@;$$6O/6PB*-
M\GH'*.L#BJZ"ZV&J7LK6M4C#T5.0!$H5H2#SA! $[T0!$88+>@!_<AUY:U]&
MM8'L_-":/S@.N/O&SO\ WV!S\T)H_. ZW^\9.O\ ?8#YH31^<!UO]XR=?[[
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M0_6:J132IJYEC^J)Z$FJ0E2]2*',SNZJ"DB<P"=*4<N6'F 3D  22$6BR@!
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MK;Y?N2&U>_VURG$>9)$[OLUN*L9A7*RNKGD%PPNSZ^E].[4.+VJVIE[^PO\
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MRQPBKO*JAKY#%I(]0LM8"-O3V4J5JW!U;A.3:T.)P%IRK9IJA>W)E9YVQF'
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MPE&[/C87HH\-FGAV.O;7SU[L8[>(ZV=.8R*\<U542"^HZVP&.,P2GBN4D!B
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MR+:VYS?G+81/2U>>*ES]S"QUI D/7\.CS;2-!28J%LU<_& 3+8BSI#JLNTX
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M'9(.VYA&TSO,F3P_GCN*3'(&TBJG</Q>-2PV4PYH$(]"L5+%[$L4I6M.6O\
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M4)1WR_UH7ZTL+:FT WU8DNQ%^L#K0O0%O8@^?H[^G6!D/RQ]3?F;'_>"K/\
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MISVWI$C@O9RNCJJ&Z(D#@:J(0+E: ).U29&N.0KBD:DXH!*HQ&K 0,P28[0
M]+Y8^IOS-C_O!5G_ ,+@8HOZ>N]J5.J!TYFCS:N8D*5S?$:_J"GD:IF;5QQ:
M=$X.R=1ZLUN0K%!I1"56L 20H.,+**,&,80[#*M7)U-O6MZXV/\ +?TZ_P#:
M"K/^'_\ A<#GY8^IOS-C_O!5G_PN!XK3T/T*_FN9#%RHVO1[*M&V/)+3TK4K
MB:TN)>O,QO<RT99PD"T&MZV-(JT4>'7T[+UK ]KY8^IOS-C_ +P59_\ "X'F
MJ;\Z/1N+:SK.2TJ5V>=+-L[8IZ.JHAP==-Q(%#AMM1F$A4+M("#"SENTQ9ND
MI1@##]E@&'>P]+Y8^IOS-C_O!5G_ ,+@>:AOSH]T4.:5MY*2N"ID6A;7E,BZ
M.JI4>TN(DJ=<% Y%$$C,0K1(5B19I*J"4?M*J3*/5^J/*&(,6M&W^H#:RL4I
M3Q\>D3&027%J%7R^UL?[V(''W )JCU!:71AWJ2]B,]47O0S/1] .]"WK PKF
M2W.FDO-O/:9NY$/=&]/1]3D(7/Y>*X1?"*,J!,!:9=[S/3;/2>^R0@/][';V
M:1ZSU1F]C!O>!.'RQ]3?F;'_ '@JS_X7 ?+'U-^9L?\ >"K/_A<!\L?4WYFQ
M_P!X*L_^%P'RQ]3?F;'_ '@JS_X7 ?+'U-^9L?\ >"K/_A<!\L?4WYFQ_P!X
M*L_^%P'RQ]3?F;'_ '@JS_X7 JAVA;'2BVEV EVY,.94@>F.)5(%N[SKMQT8
MX(NT*!6-+;[W2IM&A^&G4A$S:6;WZANVO^$%6MIDQVMA8^53>_IU''J'S;A)
MHF$2DC<I:)#%Y1=51O\ 'GYI6E[)6-CRRNK:K;7-O5%"$6H1K4QZ<X&]A,+%
MKZ,"-&>'/L?(2IF'PO:B94R%#/&M$F:9KS^W)DC9:6V[=F-J8A)&R2B&^P]M
M#5\>$18 II7\&H/ATI=[T3^K#\4L&=4+O%Y C\+:G$C_  B%:K:&/B:8<]DO
M$2KO3<L9PP2,N9<9"M8H<%H<'!J#&FP]*S!;5ZU#I'I*K/*,#)UQ=CND!8*J
M<_#B@+C6$4+C!,7KI=9M'JX-&RH2:C.AI;#%%#&8Q- (F<W-YL;"WH$^F,Q"
MD&V:3"3D[ &-NT)>'Z.1>'/OA<T\]Q*#R%?+H7%W>8\^.<>B,J=7)6\NDDC+
M,MC)[<Q/SD[KUSHO=FQ.E7K'%8J6J#S%"@TP8?JY1!_>97()V\>%]43K-I:W
M.[1*I@XS7GY;*),TR"/DQ-^;) _*8T8Z/3>]Q9.1&W9&Y*E*=Q822FA66<@+
M GT'E_)L?HDM-KPJJ3TG);RFDHC4JYX]24U$5TIJ EM++^*_H 0%5.M65D4C
M#K2<NOU:F'A+U'SS&\0=XN$O!3P\R$KPN*=*D$C@>ZMD+Z7,>? /#[6>V=/'
MMUZ\.88SI:Y0C; D2,FXLL/.8]M"1*V[0[1IR20!V4T5DB(Q <C\,.ITIS5+
MXQ8+6:GG-!%&MD]A,<;X?#ILWF C@1HI9%(DTM<7CDB3;*=V2.MR%E;5B9M2
M$)@!@G:=I]%NW+5S-LDY7.B; MBQ:9WDHKMK]\TR(3'AL"H<=L[<F"N<M)@>
M9GO1*+1YWEZ(-^>\#:Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@5O['_)#ZI_HWWC^S&48$UPS_J?$_P!6F+_9:7 T(^.%XXJ#PMDL&J>J
M(1'K0Z<LR/G3) TS!2XDP:NH"%Q7LJ&72Q(S*6]ZD*R1/C4[M4;C;8[,@# ,
MKX[.CVB+0-C9( TJ< >ZP;K?[TA]=]W5]4OR33R1(8Z=:E4LLAASW6*EZ5%H
MV]^D#*\2>5-<GAR!6:0!] C^ WQJ:C5;VG5/IS<!B<0^[P(M#"$8=Z$$0=""
M(.];UO0M>>MZWKZ-ZWK?GK>OHWKZ<#^L#XHX?6_3//'7_1'4D8H&=KWD5U^.
M(KIIYJ:CGSY7SI::G@\P@KO9;@_-+K'[EK27(FI07SW&#26-M)F_PVZ(@6!M
M6!F*"<I7V=XPGR#:<6=VN)MGT()\2=Q"[LW.T;E+G8Q%&1SF66<N(WT,GYE@
M)+BEE2J=V2P-;A&ZAJ9UL9L2+@I&1*^L@E2 />E=J^(HZ]K]+7>VP"TY3:]#
M\N^)W#N9HHX4(O;*^8D:9UXSD%!HX>^IX8V$VH^6D6V/DL*:7&52]R='-F4L
MS<0W(A";,#HVIV1XMS;5BAUK&3W^[D1I3W:\0*>NO)<213.Z8I4#+Q\[4,HG
M$+<J+;$K/I\ED\O^&-A46AT$<9PQQU0J0>^G)E"]DA)LXZ:[DB*YKDUC(+]E
M8JCDWBZ0MLLJO^7:L<[X>H]5LZH1HY7#%W5QH221"-*K.(<W5D$\,D*;X?8#
M E42)Z:7PN'$N;8&5H.CO%59;FX%@Q%@/-GPF4U+0CY=EAE<Z2%JBMM6?*N@
MII&>CHLX%L_,:LV'I*JK!$R;C2YPE/-J1N:RTEEO)DV3.9T;+#K^&BO[$MN\
MNZ[>OY/<\9NZP>'Z7B7P^]TX&K1P>RHM<W=B)/7E7$N$ 8X_)_DV0.D-7LSL
ML3394N$\MBE^>G\I25H01]RKT-XF$47>'-62M9T<_1=PIGB)'/6VQ:!7/ Y^
M]3R>7PP]KF77:K]5A,G@TDYJCL6KDJ+B<YA#WAS(-:GR6J;.73 ;NO"L?C%4
M!T@NZW[LOFGZJLZ;,TAKWBKFZ7-L7A\G>29=6%GH9I+7R01TEO;%9,@45?<-
M,TUJ1": *5+$TRI=\(F)$ZG_ !@7'Z;[ \5:&V5V^@JQMMP:>!QOK\-;1)'S
M6A=H5!8A7%?\\NO*5IUQ-U57K3+1F]OS.5VTT/,4<YC/FU<%F<TR"%1X<+5F
MG!L<Y$LWNR3-ES1BQXTBM=AA/9%VU6JL*V'G5!V<GY\9XO6CO!))6\2KV@MP
MBWG54XR::M:-S4.E3-0],K:5N4.*OX05( T4<3&7AR8P2T_GSF^Z(O'8K/N$
MH<\W]*N1)_6_02KG^3=42(B[^>^B:T^ Y/7]OVI3\->9 ]OW1E-LCJ['P^5-
MBURE)#GM$G:PLLQ=8^+@^U!([(1OEG))-7OAH7%>Z>#N_,T50CL?I-/T/T?6
M<*97 #C7K6[-;_&:U;*ZG*.N60E&NDBB.1A0XM"EKD+^FDP=.#]=]VV&<DF5
M=:D/1\JJJT_%]KZOY9,.;88AF/I4QSW G+F=C?\ 3354.=J]D4NFJHY,X,[6
MB@3C9*]4*,.S>J1)4#0W!^_0O9WB50OD:+R7GR6]66Y9:B:6^O'/IIQ,Q5FX
M;*@7-T1L1#7KU'$E$3<R8QI9:"V41N)R%KJ"E#ILYM3S UEC1@4.,F\E#:_X
M=;%,6^Z_% D4MBS]&RY[VM$I9'U#NR.;.AD+6=QERNUJW:.G.*<D#LSD/S8\
M,PEZ Q4F*<VIP;C#_?B%446&PFW/WJ;._F]FG_=MRP,$Y2_)<YL_F"IW]G<=
MP)]P&!^9II1!1AQQ@"22@",--,$$!998-;$(8QBWH( !#K>Q"%O6@ZUO>]ZU
MK UZM7B2U',H%$K"J>K[ZN9KF+7=<K;&FO(;&=R8NNJ$DK-%YO8XV:93B'C7
ML*Y?)HN?"X\PG/-ES-)(4'P# U:M.ZHVX-@R124L2IE9/I;)5$$J"MC+,*'Z
ML\L)@/3*. 6<4+T1:](LTLLT&_,)@ #UL.@[& P*>=T?O&1S^E3P;_XY^=,"
MX> P& P*A)NP6%47;3R53=YC@%.J+;;GVRTT>A3G&I ]TP\O$<EL?AK"S3]R
MLM\>53^PNK/'$HH"C \K4X-%G%$J4IQP2125[(+H%8+<97]@5;+JMEB"'3:"
MV2"$CD+2Y.T-C$]9U13A7,VL.&.;:ZQF7,ZQ,H:I8M/3GB5(')*@6I3","=<
M!@,"H'??Y'-__J,9_M1MP+?X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8%;^R/R0^J?Z-]X_LQE&!-<,_P"I\3_5IB_V6EP/A$]UE<+78=?D
M![KB$7?IA2SC4<=JRQW9E0K78%6RF'2.4+FMPE $I)NV.(RUKE2),TO1VM-9
M,D:W1 Y*D2UY8B70/F'XCXLO#O2_X50=&Q-W?G)_>&T,MDR5 K.C=:PXU844
M]SJ:.Y10T;(QLR(1QQ8EAQ1[NX:2,3,4N>G) A4!_LC,S:4S-#4SD&&G$M3:
MA;233Q;&>:4A2E)2S#A[^D9HP%:$8+?TB'O>]_7@>E@<>CK^+7^K6 \M?Q:_
MU:P'HZ_BU_JU@/1U_%K_ %:P-?GB@=46EQAQG8-^TG$8;.;18Y?34.A\6GQ3
MT;%75TM6Y()5X2G($>=F-V\RBY>8>D$F<R- 6%)QGA/("808&N'F'QN76_NF
MP19; HPAYC:^%$?2$IF,/B]A36TR;C9ZYYDM.QJ]88_&53\-^:XK'NG(HSEL
M+/$W:6'R1&K1[6"$4).(+IO_ (R?"49B#)-W>:S\IC=4UU*'7WI3]BN;C"-<
M[32OX%<H)VV-C K6QL$(?;-B0EJQ048VKVY=M>SK7$KU&E 2;8'B<<>U5.K@
MKVR)M*82^TC74ZM26J)'5]AMC*ZPZLTT,4SM?!'91&PI9X9']V'#4NRXQMQ"
M\KGO2..FO!S8]!;0CB1^,;P?#8^@D<RG\TB:5585M5NXH'VI;$2/L6=Z)=8<
MQ6^[3%C!'SG.+QF O<_B+4^/;LG3DA6O  )"U04J\:4/[?/&&X9C,WF<!?9A
M8C>\P&<2B R5=\BUGK8TD>81=$6H"8K2Y.V1E:R*&&-6?.82Q.KT6L]YE_&Q
MC-)&?M7LLL/1?/%XX5C[S>$?563(U#KS^J7I)TF;JUGBP*\QCNF-<\RL4)/+
M8M)YP"'W)+V"$2/XNF+1IG!<!4D N;=;6X'IU7XFU)7=T=5G/-71"T7U19=?
M]"3%5-G6$/<69H(]<V6H@IZPX',6I_1(GQKD+;-3UC6N.4)"&QO5"C:7WVK/
MES4$(:\ND/%>D[+*N=X?-:7IV;<H]/6KW'4ENFRII>7I2UTS2'1$+X^@TJ7(
MU3Z;&G-FG-E3UL=9^D=6)>W @3P642F;C6]>X'!%E#^(Q:590OP[(74/.W(O
M.%;==<_4]>1!LH:["K:IK4O&X+ VEM&B:DL1G-7Q&"VNQ1 >K#9Q6NJESW9:
MYS:(N@3B7J2EXPPFZ_'YZ$JH[Q%(<13=*J[+YUOM;7O*S>N*G&VBSZ[@\ZOQ
M!;[]82=-+RUY[]!H!0CW(311E4P-NUCNW#4) I!>HV&^CC_IJ0]!G74Q3)D8
M6*3U/*JN2%%1P#@6@=HC:_/%179'WD8')>XGEJB72?2>*'A ?HHS<4"J"47M
M4(.!8ZW/WJ;._F]FG_=MRP,$Y2_)<YL_F"IW]G<=P)]P&!"G1E82:Z:2L*J(
ME-$=?.L^9BXTIE#A'5LJ2$1QP<41<Q:3F9LE,*=!ZD\1^&XN%P:Y4R.C(-Y"
M]MJS2UN(+&&CZ?<P=$QYM?7&?5S8D^?1-WB.,M.F<J)I34.XQ9MOVY6,QH"1
M/")GO-U5-4?>S8K(G^*OS\]BA]=$A:44V3IW-(A?' /H682G(AB92'H\M4\$
MM+<4[*B@Z"4I<RT9(%YY0= *T$LY5HTP =%%Z"$6M:+!K7HZ#UL!@4\[H_>,
MCG]*G@W_ ,<_.F!</ 8# X%OR#O>OKUK>_\ 5K_-@:75$1G-;WJYVE1')=\-
M$_A,R[$L"X&H^P%"BO\ HB.2)HGCO5T7AC])I?J#JG&WK8>J_L:-L"9F;04N
M--8+:^GLYZ@_XYA=OB2//S%5CPJG<)G\7MN7S)RG5T/U@,[ R*9_9\E;F@Q]
MD,8;F&8S8*" LB)*U5_7[2XN^W)@A$,CS"J]^#;=N:X+D8# 8%0.^_R.;_\
MU&,_VHVX%O\  8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# K?
MV1^2'U3_ $;[Q_[:QD^!T(ATA7I42BY8H[?6Q%QUD +9?*O4!H-B VI@[V T
MJGQE& \]?N3"QC+'KR$ 0@[UO8>Z=T;6JDDU.HB]\GD'EC*.).Y/ZA,*-*,#
ML(RS"QTYL RQAWL(P"UL(@[WH6MZWO6!X$;N&C8:E/0Q"L[:BB)2H$L4HXWQ
MOTBQI5"L?^6J/3M=*)23E _/?IGF $:+SWZ0M^>!DGSDZ[_D[?OW4NH_['<!
M\Y.N_P"3M^_=2ZC_ +'<!\Y.N_Y.W[]U+J/^QW ?.3KO^3M^_=2ZC_L=P'SD
MZ[_D[?OW4NH_['<!\Y.N_P"3M^_=2ZC_ +'<"O?3^Z"ZPJ<VG;%;^I&F,FSR
MJ+"$LB/+W2*!Y^&J>L^)6Q&4VE#M0SVC^#5DBAK6D>B?>'OE2T'+4Z-4@5F$
MK4X:X8YX7'AU12)3F#L*/N-MC=@5_P!15N]H4?/]_)!$L75LQK28S(YO/2\S
MDFD+8?NI(1&X" \2IL219M-:Y2VRL:DU3@=IV\,[@]ZA4D@Z]Y[OVW2MEZE9
M7=6AYIM5F4B#UW+*>FEI+$+>R<D-L;:#D3U2D9W#D#.PH&)@1.3ZAVT+4QC2
M6T!T;[\.CD"RE_4EBQD/61MH]$P3HAB&SS'G'HI/7B*0]"1ZI6V1*E#K'>8M
M662VHW6DX2ZQ\M9)Y,CAYQSX!F85+.LU'\"/Z>\.BI7FOD"KJ:9=6'7;N_.H
M[A<I53'/O0YIBJ+]03&$R>95L^322<>1DYW,<3*VB*YSGL KNE9,WNGPJFA.
MHFTK%"=6$V2SP[N&)B_V-(G)R[K(66=)[;EC\2AYVN\"5*XW+TY3/5LH):@*
M.75)I*-'8=&Q)H92U1RPY-$%K\@6*%[NJ0OC<'INW ?$+JHZ"U\)]V-[+T/*
MULS?8LV\\WDECT-?'[H2+=.2]5#B \O;7JS)7:42;CU2F?N,Z6QZ-J7.,P=5
M%6M8(H(3+3_._*U'W/%KT@R[M F8QIZZU<E*1RYIO=<PR=M['MM#>%D1A_1"
MYI+5ELT=L9I9W>"*(\X,+^WIVLALD+W)F\]<G5!$4DXEY,LMGD,;M8SJIZCI
MJ/NV)PYHC'*O1[ DCL [SM1CN:;)#_A&BY J52ZN9RRDJJVD"-6WMC606ETX
MQYS$G)T2'DKO#WXE<HGS]7RR4>(097-"U=2E0FUZ&DN@BX?;L3Y[GA5EU:=9
M[5KF78B)$RS$D*]=):P45L\/B#?P"[JE;& IO+#'[ \,GP][*GDPLF1$]OAE
MLT<NU'1R<4/.EY$^]3^YF-5'[* A+.Y@4ZT3"4+K(158%;M:)@425[-?ARCW
MP2%.%[.:$]6\[NUWNY.N@Y*IMR=0A\2'*N1NH4RJ/PZM:.JRD(5$U!Y=1"*<
MU"1NK93)'!S*3-Q*EZE;KHAO3$%%:$$V6KT;7RBK[((!'KX",^!3 D C^6.G
M4Q(1F1YQ '9RE14!2=.5K8M;,//-+)*!YF&F  $0M!A'+W1$ 0<T<[H3X_>@
MSD=%U(E.&CY>Z8<$@S4\ CY)@DJ]!4:E"N3B&#>R%B)2H2*2]A.3G&DC ,03
MI\Y.N_Y.W[]U+J/^QW ?.3KO^3M^_=2ZC_L=P'SDZ[_D[?OW4NH_['<!\Y.N
M_P"3M^_=2ZC_ +'<!\Y.N_Y.W[]U+J/^QW ?.3KO^3M^_=2ZC_L=P'SDZ[_D
M[?OW4NH_['<"I7;'0<#<Z3CZ9,P7>68#IWAY=L3AS)TDTI]DM?:_/KDI !6Z
M5.B2F+#$Z0TMN;P'"7N[@),U-29:Z+4:,\+:_.3KO^3M^_=2ZC_L=P'SDZ[_
M ).W[]U+J/\ L=P'SDZ[_D[?OW4NH_['<!\Y.N_Y.W[]U+J/^QW ?.3KO^3M
M^_=2ZC_L=P'SDZ[_ ).W[]U+J/\ L=P'SDZ[_D[?OW4NH_['<!\Y.N_Y.W[]
MU+J/^QW ?.3KO^3M^_=2ZC_L=P*J=P7W!I!RA=S(@8KI(6.D1TB3'/?-W1,9
M:"CCW=L  ;C()'5K4PLZ0.]^9R]V<D2%.'S&H4E UL6@V48# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%;^R/R0^J?Z-]X_LQE&!-<,_ZGQ/
M]6F+_9:7 C#IGHBMN3J$M3HNW'3X)K^I8BXRM^-+V#:U?M-H"=J86DD8@!5/
MLF>E+='6!%Z0=K7IT0I-"#L[TM!IF\!KQB5WB;P:Y8A<(8['NBJOG$AE9<:8
MR@HD+O1\UD:U="%C24/8#%IE<J%GR:OZ@)1AXD2&%/STJ.>9<I%L/H-P& P&
M P&!I-\6CQ0['\/:84C&(#$Z/D.[.JOHVRE ;FFDFARB0NM%@JXQCJJM=QMM
M>#GNR;0-GZIGB+,8VJS%SVD1)RBM@-/WH+ENOB*<N0V1J(!9\T>*XLMFK1\L
MV5PY_KVS326!!#JD2WA/X\GF*"%J(1*)G!JU5?&9^AL5D#Q+"VXDPTIC&9K9
M.@K5T7XRW)M:\S6_<E43@<_L.'1ZQB*_K)]K&[8VZRRQH30:?HU(QO;(XUZV
MRB.PY95SM')JML1S;VZ$)(P^(7#<E (\L&PL$E\2SD-$YOT1EUL)F.>02O9%
M/+#:RH592Z/,NX#4L:NRS(XSS1)#E,0EDS@=;2QCF4@KZ+/SU/6Z.NB%>IC@
M0F[T$(IEWB[<9J8%93E6UV-*::1&N+=F[5JTZ>Z1BL/*-I^MXU:DLT_G:J8I
M]5DL4#G$*G3DPQ9&ZS)RA,C;7V-,;LF6)AC"7)'XDW), ?)3#+'L211::P*
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M+),Y..D+ %Y1ZC"! EC+,S-T49X\6(+58# IYW1^\9'/Z5/!O_CGYTP+AX#
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M6YI MK\6.G?;12?W<YG_ 'E\!\6.G?;12?W<YG_>7P'Q8Z=]M%)_=SFG]YC
M?%CIWVT4G]W29_WE\!\6.G?;12?W<YG_ 'E__/\ '@/BQT[[:*3^[I,_[R^
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M,3OSS79")*\IG)N,+-4%(BUX0[3WC R]3T-%F.[JEG[565VT)X>C] V:!LL
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M+''1"0J+,TYF-Z;7OC86,2*B5J9.L3"V-.J)+4$#V 9>QE&@T,L>P&!",'I
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M09(/?\H:&>3CY^K2M]OZ!0<V6VVV0@0;4N;NT'G!OHP& P& P& P& P& P&
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MQFL#@IZF'2!(J.>HZQ=JV@\NY#T0H41EOTEKU]&2Y/*%<>G;2$YSHWAOGP&
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M%6-38R'04R$N[C"':&!;&00F5*CC+O'5K2V? ^PM9[6F1J4!9*8XL@L+B8#
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M>I#'7!H>EH6"P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M3GKADO)3@>?L2X!QA1ZD@92@T+"^7E]6 P& P& P& P& P& P& P& P& P&
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MSE\)F/<O2/7O?TM],!YZ2\;GDK+7:=4 6A ,8H?"US8^,Z8(M"]%L,G+BVA
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MV$EX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# U)]S\QU2^)^A^B[HH_PQW$N,0>L]UI=/8-4E2$MB*9W(U+8A=\2YP2
ME* Q5.V*DB&K4D4=DRHMZ5;3NP#P'ITY@:X_#L?>:9=UE60:P!X" I2T:E+H
M0'D:GIC!.F-H?B=(4*M94CE)]HRU(PEK- E!B E<'XE&R'0_0+,]<$/J(P&
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MEL9%;&!"+SU_D[WH7EY;\O+>MX'6'[H1\'<L A[[4BN] UY[T"M;P,'O_,$
M*Q$(>_XM!UO>_P"#6!T_\(>\'+\\]A^R>^_[*\#J&>Z*_!O*'LO?938+8?\
MWBZ<Z$,!OZ-;^@8*G$#?U_P;^OSU]>MX'X&^Z,O!M*!Z>^Q48]:WK7HE4KT0
M8/Z?_P!4%2[WO7\?\7^G ZO^$>>#7^> '[#>C?[(\#HC]TD^#: 8@?.R6"]$
M6P^D"A^B=A%Y;\O2#O=4ZWL._KUYZUOR^O6M_1@=<[W2CX-Q.@[UU4ZG^?GY
M^IH3H87H_5_E>E5H/+S\_+7EY_3K?^;S#K[]TL^#?Y;\NH7W>_XM4%T%Y[_S
M:\ZQUKS_ (OIP/,_PFKP<?SD)?\ =[OW^SG Z-I^Z /#CGO)?5MJ5+,9;;+;
M3E=HB')B7U]:E8MLGF]E*5T9K*N$TFD3-$EFG:7O*5>L5EQ]6:[-<,C\NE(0
M>\X\M$ .W[GZ\2\CQ#.9)B*QG%OWU164P**O4E'K: J8)GUO)102T6I@+,$V
ML;>_L<>^+;PV,1*-N)E<4>743>EW($YJT-^V P*<]ZW;+>>>7YU9\%C\)D<J
M1O%<11K2V:4_#K%LU8UFPZO5TGLDZ-)E;N@@D3;9.LDDG<RRR4+>UM9ZIW7M
M;06N<D@:P8'X+9DCLK70]G]6.-)W&[)5"C;;X9=?P/C"NRW!Q3[_ /3'Q<!O
MLVQ;A&DUL)R518TH4LR\0=C7Q8Q*:8C&&\:K8>_0"O8E"Y/8DJMI]C3.G:7&
MR)PEC2.7S U+L82WB2$0YCC,8^&#B/5 6G,S TI%1Q8E.D1)AP]8&?8# 8#
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MU:_1K^K YP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MVIW /I>P& P& P&!3WO/\F&7_KQ1'[?JPP+@Z^K7Z-?U8'. P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M;JK[/(C^$8#Y":0]C=5?9Y$?PC ?(32'L;JK[/(C^$8#Y":0]C=5?9Y$?PC
M?(32'L;JK[/(C^$8#Y":0]C=5?9Y$?PC ?(32'L;JK[/(C^$8$ ]2\>U_<G/
MUI5? JUI^.S":1H;0PO:^%,38B;5HEJ11I0I7M$>6N28K11!@-C1I3C?,>@Z
M!Z.Q;T$^ZHFD/+7_ *FZJU]'U;KR(_1__2,#GY":0]C=5?9Y$?PC ?(32'L;
MJK[/(C^$8#Y":0]C=5?9Y$?PC ?(32'L;JK[/(C^$8#Y":0]C=5?9Y$?PC ?
M(32'L;JK[/(C^$8#Y":0]C=5?9Y$?PC ?(32'L;JK[/(C^$8#Y":0]C=5?9Y
M$?PC ?(32'L;JK[/(C^$8#Y":0]C=5?9Y$?PC ?(32'L;JK[/(C^$8#Y":0]
MC=5?9Y$?P? @CF'D&O:?Y^J6L)W6E/R&80B&MK!(7M!"F)R1.;DC]9HY4F7N
MT>1N2HHST@^B:L2D'B\OW18?+6!._P A-(>QNJOL\B/X1@9K'(G%H<A-;(E&
MV&+MIRD:TUNCK.W,B$Q886448J&D;$R5.)084024,\1>S1EDE $+82PZT&08
M# 8# 8# 8# 8# 8'&_HUO>OK\M^7G@:N8?U%?BZW*>>7QRKI73UY]I]2<@M%
M?(8<]()?"T_/\9Z>7L=@G6 ;,ER.1.4D>N6I!\,L(X<TMJ9IGK00W*2%L35*
MY.&T? 8# 8# 8# 8# 8# 8# K?U]<KSSYS-=%RQTJ-F2*!PE>Z1\4R4GI(@F
M?5!J=K9W"6*$JI"I+C+:XKTS@_[3+D*@32F5@)7(S!!4E!@?'UP22V4=G"=+
MMIZ^V**RQG9F"7UG&'V R1I/51!C>WF,V3 GMZD.F5Q+.<DLEB#LA="R))!I
M.PJO@[6DH'Z0A<S 8# 8# 8# 8# 8# 8%>>L)U:U8<Z6_8E*-,&>;&@\%D,L
M9$]D+GQ'#$Y4>;%+NZN+P3&R1O;QIO:D:Q4BCJ!6R#D#B6D:#I+&DRLY];PJ
M[U9<W4]:U:Z777C[4;%%8]3\ =H9$7N&26<S&]NB[ D2AC8Z;3IT$OBH88PO
MSDK@<4BCHV#DS^[R:?J52HIL;(6)-*0V2E[$(L&QA] >P!V,.A>EH(MZUL0=
M"_\ >\M^>O2_A\O/ _O 8# 8# 8# 8# 8# 8%095;5U,/63!588W!3ZBDO.-
MSV3&34:]]5V=(;%JJ5T8TB1*]#+11B-Q-0CMLYM2I %2-Z=W1'\)FKX^A2%M
M[N%6^".Q[)Z+F429)%8]16J2_P#+T7N*VFRKHJY1UQYCN]X?FAI6T'/-*9M+
MCT3L8)3-$"2+S))'K'8'&J).9(DIH7,I&T!MBP& P& P& P& P& P&!0OMNR
M^C:>A-@6M6LKJF&0&M*D<9"V)I;#9#8LOMR\W%X,:*]J%M86F5PS3*U2EU%'
MXHV'-"Q\ETPF,\9FEC3,PV,8),&/.76-IJNUJ:H%ABT23U<K0/,:NZ2+?A)S
M?4=U*Z=D5R--=PAQ1/")J2;@4288Z]SU0[LCP%Y06Q"2F,YJ4MCWZX-BN P&
M P& P& P& P& P&!QO7GK>O/R\];UY_Q>?\ #@:RHAR7>39<56IGURJX-$TC
MUWTKU[$),U/DI56I+'OH.-=$MA5=R&$*H>AB<<;8D[=/SE89,&^P)$I?6^)Q
M9(&*M"EV=E3>&S; 8# 8# 8# 8# 8# 8# K]U73KET!SM;E.LCFSL[[.HBK;
M&%QD3><[1Q._)CTSHQ_&)L3C+4+X^<ZH$A#XE3#"I.:S58$_^.V#6PP?G*K;
M=8;"O>YKM05O&YE<"RMVM##*ME,DG4>8HO6<3.:4"UPF,I@]<.3Q(WQ\?9(J
M5 *A[>B;&0F/-A:ER5)E:TP+<X# 8# 8# 8# 8# 8# C2Z(0NLRG;8KAL6)6
M]RL"M)W"&]>NT<)$A72N+NK"D6+ IP&'B2ICUY9RC1!8SMD@'HL A^CK84SM
MJB.G'JXJ#F,/24;.JUH.NR]Q:!V3-I]"1);Z<4JZ*NMK*PQBMYZCDGQ<KP9D
M=KA,K,9MQU7-+"=EZ1T<E$371H-BH?2]$/I:UH7HZ]+6M^>M"\OIUK>]:WO7
MG]6]ZUYZ_@P/ZP& P& P& P& P& P&!7Z>5&[RV[H%9B9W);FB*4=T!5*X@C
M9Y;X)RN.2T*]-3RU'!+VE+*8T]2.X%7KSBS_ 'VYM8TP#  5"*"J?'7)]PTQ
M(Z4666EIIE:^>./V;DF,'U*YR5R76DG;G: K!SZ9HGZ&Q(B$IVY/6Z0^*01O
M<+ ^!7*?3WULR5EB(.<0V6X# 8# 8# 8# 8# 8# HETQ3O1MBW;24WK]'2TO
MJVG4SO+TE;V?-YW" .-XJAF-49G[P.*5U/TLD;Z]BRAWW"61:%O2MDRD1\S4
MD+7Z+0E>Q!X"K@F+)+[IN\HA()Q&E,7M^U+JLV-#N.W'6-2"969!Y&QN"F/Q
MA=(SHTB3FR!Y2B7(=-C8W'Q-$&.@0@:RR&H ;"PZ\@AU_%K6OH_S:\L#G 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# T*=X]D='<Z^)SRJPQNR!-'([?6]=R
M+IFNSX[$U;>YM=T7\MYD8IVHDRQB43%FU"Y[/ZQ=U!+,_M[:8WMRPQP3')]K
M * Z%W]H=)'>,WS3SW5]BB8.4V.6-](WG$"8_$W$-@W9,N8NBNDSFTZ0N3$O
MDK&&NX/%:->!)6%[9O?)\ZV6X%*D^C"A!=:J/%$H*W[(KJ#L,.N]BB5VRZ>P
M&@;ZF%=ELE$WM,ZX2R-PD4?KN5@?UC_I2I:X=+W2+K)A$HDT31!&78^(N+WZ
MM.%0'CU9XKM 6_+*D8(I7?1*>-7N[V=$:@M:053MEK"?634+7-'J;5>Q/*B0
M"?#9@F;*\F2AJ//C9$1?CX^ZM;/*ECNVN*!(%#Y3XMEJ36-4)/F*IKNJ1O!X
MILDY:FT61UJFD+I<%:1Q'U/&&NOHR4ZEN"DRR'.457#CITVM&X]\1Y.>4R&2
MOXO@=',X-@#=XI-&.5:-TS(KN_ 6"Z=(OG(R+G%3 &=->YO0D<C*J=/%?C:C
MI@&O4WO.OD9T^'*E-CDPH<6V0I+D0ERE.W&!;[GN^8KT?6*"SXDPSF*)#WF3
MQAXB%EQ5;"YY$97"W]PC$HC4FCZL:@M.X-+TUJT_OML7NK(YI]$.3*[.3:J3
M+#0TZ0?N[H)R\3<(WJ8DCX*LCH2[_#WKJ)FL4=3DM'1M%T_ +.^4S4N(:M2-
MQW.K!9NA*71L2A].9PJ(<SJ4K<%>8H-"$7S3Q3KSJB5>*M=SK NC)O#N39<Q
MU-3E(JJMAL;I>-%AI^D)TOF]G3I T*[2*F;Q*)H_.:?TY:IBH*P>XLH2Q=.Y
MN93@W!L5M/Q2J9I[0T\JJ7I18ZQBFDW0=TLC%5J-:]<[4PMDTCBJ"?7*VK)6
MWJ6U&YK(?+7-OCT,#-YH?'(V[2#<:"UD 4&A*SUWO4"+I"/\M1F+6]9EEOL2
MJBQE"RMJ\72:$1:K[A=9BRQJRYA--+$;,Q0Y$Y0M:2]JS#3G(@IS:%3<U.B8
M;@:W!0WQ*NF7:K.RN6*BE/B%;\/.C+ Y[Z+GLHL$>^=6]/*;'@DVHUG@\:$_
M=#P&;LB8TYCF4S6%MC,%"O7A0C/WZTM$/8 S'D?O.Q(SQ;7-H]))K+Z(F-D]
M$6-2/.+_ %=536SV-U7 TDTF_P C-ME0(2J%PF$)YU5\36SA<]OKC!H:..MY
M$B3FIBGQK3K0L(K\3R@"JKI"SD$6NI_6] 6U8M!P.JF*MSUMME7A5)%AAG55
M2:+C=2&^.29@=ZNF# O7KWT,02KD 7)7)T\8&*0%AY0/%.HA954!G[+7M^O\
M[LF])WS7&^;&FNV_?0X;JJWXQJ+,A;O%5\J01!FW V:*/,CD<B7SPJ))6,M(
MJ)?E!S@B2GA6_F+Q.@ZJ"Q+ MM!=%JS&P_$/ZAYTYMI.)U@V)KO<62!/KR\,
M5;[A:H4*;6-56,&C[\JFKY8;^TA9"618&1294Y&(@*PL\9XHG/NJG@=H)HI=
MS@YS[H20<GI*=05FI473'ND(NR3!]>*BET.TZZ1,;^G20ITUMWV^J8<$E6TO
M)LE*C2W;V2&+U+XM%$VS/:X@A=1].U^*Q;CF?-^I59=3HHW$8;TE VV6/4@H
M>8N:67.RLB=%LT.='-*XQUNDD 4@,(;P373R0ZMK:'10^(36U$<Q%W9.E_3/
M0E=MDJZ>W+;I;Z68=[A+?2]US:'R5OGR6(!BT>C;#$%;4MB$'=!(-KY;&HD2
M].1ZY[5+52L,LM'Q3*'J8QM4R"N^AE\92514-TVO-V>J3/BQSY +P<SFF N%
MR_##ZSO[6Z'JD;B8_1J',,VD<50-C@YR)K;6\D*DP(GLGQ%W#=V]Z\YNT$NZ
MFXGS3S"W6K\Y.+P!NDSE$Q.,8Z >Y#/26>2_"<6.9TK=4J%33?PDSO2.P)'I
MY;G=N3(TI9)P2;97B:TM1@BXJKB?15[*Z]H2O[WO*;5152"4)*@JR9-[F:P6
M+<!*=ZC>FU9)$,8E,I,B=?LTKDB9E8WEW+BZ=F3IC30_>Z_%0H&FGR:,:.$7
MM<XJYH^ ]+3IUHRN"9LPQ>@+$+EY[-:R]Y72&/(5,?2I(4\+U[:TFN,K-;?0
M<F6.O"!(\J6H-B\=D#/+&!DE$>7%N;#(VEN?61R)"8$EP:7=&2X-RTD)H"S-
M%*T:@D\O1@ #] P/I!#OSUH/9P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P-2?8'!<KZHZ#N]V=2VU)5-
MI>&K-N76Y_T[!)?F.YG.Y4UC0U\2-H"AJ"2(R>WM<C1O0=[TG=FY.4 L1H="
MT%=:)\/[J=G7<$6O<I4-<+R8NT^E.O.TW)ED1)S4D=[?YXMBDX<UP<1A(C9
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K9K6O2\L"3L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>feb2019siboneodiimia1yr.jpg
<TEXT>
begin 644 feb2019siboneodiimia1yr.jpg
M_]C_X  02D9)1@ ! @$ ^@#Z  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M# P,# P,# P,# P,_\  "P@%6P@N 0$1 /_$ (X  0 " P$! 0$!
M   ("04&!PH$ P$"$  ! P,# 0,$"!(%!@<*" \  0(#! 4&$0<($B$3"3$B
M%!A!%975IE<965%A,M(CD[/3M-15%G:6%S=W.'&!0K58D5)B)'4YDC,T-E:&
MMJ'!T7*"0Y0EY6CPL5.#-86E)L9)HF-S5(3%9Y<H*40G2/_:  @! 0  /P"_
MP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2YT-'<J"=M50W"".IHJEGU,D4K4>Q[?I.:J*A]0
M
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MUK8V5E[L]#7U;(45L:2U-.R5Z,15<J-U<NFJJ;(
M
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M'2NG5W,75(J:]O276
M
M             'C:WS_?9O%^F^0_WE4'I'\./^3+9O\ ZP_]HKF<0\73^6["
M?XE6W^Y[R5+< _YOMD_]IUW]V5A>QXCG\F6\G_5[_M%;"@OA)_-?L9^DL7W*
M0M<\7NT9)5[4[6W>@9-+B]GR6I;D38T5T<=34TO30RRZ(O2B(V9B.7LU>B>5
MR%>'A[\@=M>/F\%XO>YM-)2V?*;(MFILLA@=4NM<CJB*97211HZ3NI4CT>L:
M.<BHWS5372PS?7@GC?,+<>Y[[[7;W8W38]E-'0Q5'M;1)=(Y:JDIV0NDDG@J
MV-1ZL:Q'-5J.33SNTF_Q,V#NW&S:6/;*[9?'FCJ:\5MQH;E#2NHV0PU:1N[A
ML3I95[)&O?KU>5Q6]OCX:,]YS/</=W-^2F.X=:LMR&XWNIK;W;_1J:D2OJ):
MAD#ZFHN$;-(VNZ4\B:-[$1"5>-[U</-NN/UJV)J=Z,(R&BM.%^T%VCI)4?2W
M.H?2.CJYE9#WK46IG5\BIUJJ*[R^R>::UW*KLUSMUWH)%AKK550UE%,FJ*R:
M!Z2,=V*B]CFHOE/8MOI^Y+>+]!\A_NVH/'+04;[A7T5!$YK)*Z>.GC>[7I1T
MKD8BKIJNB*IZB>8NS&!>IKGF)6[&K?1V[;+&TN6%],,;'T$EI1DO7 ]K%5KY
M8XW,>J:=:.<CE\Y5//[P[R"?&N4FPUQIGNCDJ<RMEJ<YNNO=W:9+=(G8J=BL
MJ%1?^_Y#T2<_/Y0=Z_\ 9M#_ 'I1GG3XB_S0;"?IQ9OPIAZ?^37\MW(/^&N6
M?W/5'DMVR_>3M]^DMI_#(CV@GB'/8YBV&8?F6V&VM+F&*6?*Z:BQVURT=/>*
M&GKF1/=11-5T;:ACT:JIV*J'CC/7MM[L]ME+M/:J*@P2P6.;-<$@LN0W2VVR
MDI:JII+E01MJ8Y9HHVO>CUT<Y'+HJHBKVH>4.HI[YM-N9/2SL6')=M,G=%,Q
M=6*VNLU:K7)]%-)(3T)^)=N924G$&+VHJG+3;N76QT5 ]NB/?1O1;PKNQ>QJ
MMI&M=HO]K3R*5Y>%'MNF5<@[MG=5 LE!MAC\]133=/4UMQNNM% U57L36!:E
M4]G5IZ.
M
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M/*F%&UVY^05$]--TZ*ZW6G6A@:J^SI4)4JG]):"
M
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M[2;<[=0M:C\/Q^@MU:]FFDE7%"WTJ7L54^R3*]ZZ?1.G
M
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MX0;<.W/Y0[36.2'OK;9[LW([TJ]K$IK*U:Y&R)VZMEEB9%_Y?T.T]9(
M
M
M    *H/$6XY\A^1>4;<V_;'&*:[87AMKJYYZF>Z45%UW2X3(V5JQ3RL<[NX:
M:+I<J:>>Y$_M'S>'7PXW.V"S/<'.MW+#26:Z5EGIK+B4=/6TU<KXJB=9ZYZK
M3OD2-46G@1-5U75Q;0
M
M
M
M
M
M
M
M
M
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M;<GB3F.SM1N[=)K9CE[R*O[MCEIF-=4/CA?00K+W7>1]2(Y-.IOT2S4
M
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MXV4L_
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M1R.Z6R.I:R*&1T?5V=;$<Q%5$ZM50D,  5@<T_YR?#8_2O,/N-E+/P
M
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MHCU:FFB'H8  *P.:?\Y/AL?I7F'W&REGX
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MST66JVTEFM=ML]!&D-#:J6&CHHD1$1L4#$C8W1J(B:-:GD0^\
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M
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MDAKJJ6C@<Z:&-[&]4T#T5%7LTU7L4D:      5@<#_YCO$7_ (JP?=+H6?@
M '$-W.26Q.Q"T4>[>Y]DPJLN+$EH+55RNEKIHE<K.]91T[99UCZD5.OHZ=?9
M,]M5O7M/O?9:C(-IL^M&=6NB>R*X26V?JEI9)$5S&5-.]&S0.<B*J)(QJKHN
MAU$    B]L%S&V$Y,W?(+%M!E%9?[EC%'%7WB&IME;0)'!-)W3'(ZJBC1VKN
MS1%U)0@    K YI_SD^&Q^E>8?<;*6?@
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M#FG_ #D^&Q^E>8?<;*6?@
M                             K X6?SD^)/^E>'_ '&]%GX
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M=0+T-KIX8WJY:JE56,GII4C<US6=WT.5R7(   K X'_S'>(O_%6#[I="S\
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M?0X*=LK:B%K$1[V(].CNUU1C7.G:   5@<T_YR?#8_2O,/N-E+/P
M
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MKWUCM)VU$:-[Q']*>8NGE[3X.5'!:\[V[L8OOAMON6W;W/\ '8[>W_6Z1U3
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M;(45D#7R)#%''&C61];M/.57*KE4E,   5@<T_YR?#8_2O,/N-E+/P
M
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M\
M         %8'"S^<GQ)_TKP_[C>BS\
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M5NI305U#<\1J:J&LHJ-[XV5$TK9ZZXL<^F29CWQ*C-4[$?[*<6\:;)]W5O\
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M'Z5YA]QLI9^
M                   "L#A9_.3XD_Z5X?\ <;T6?@
M             %8'BI_NKX[?Q_Q'\!NQ9^            "L#@?_ #'>(O\
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M$]C/^LW_ &GNQ/\ !6!S3_G)\-C]*\P^XV4L_
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ML)E K YI_P Y/AL?I7F'W&REGX
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MU36[X
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M_-G&;5COIV5Y;Z;[644%)WW=0V?N^\[EC.KIZW::^35?HEKX
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MH6?@             %8'-/\ G)\-C]*\P^XV4L_
M                                               !6!PL_G)\2?\
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M$_=T[6-2547I?)IU.1$ZM=#TP@ K \5/]U?';^/^(_@-V+/P
M5@<#_P"8[Q%_XJP?=+H6?@             %8'-/^<GPV/TKS#[C92S\
M
M    %8'"S^<GQ)_TKP_[C>BS\ KE\3SD;<^/_'&MHL4KWV[/-UZMV+X]<('K
M'/14KXG27&MB<BHY',A3NF.:J.8^5CT^I/(Z #UA^%7R/NF^G'M^*Y77/N.;
M;+U-/C]?<)7]<U7:9HE?:JB9R]JO1D<D"JO:[N>M55SG%G(
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M&C5AN$<:(C6=^U5U1J(BJU7(UJ.1J2O     *P.:?\Y/AL?I7F'W&REGX
M
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M
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MHH::=E1'_3&YZ(I/@     K YI_SD^&Q^E>8?<;*6?@
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M<YVKE[D     5@<T_P"<GPV/TKS#[C92S\
M                                          %8'"S^<GQ)_P!*\/\
MN-Z+/P "..X/$+C%NE6U5TSG8[$KQ=ZY[I*Z]QV]E%73O=VJ^:KH^XFD<NOE
M<]5/QP/AUQ<VSK::YX9L5B-LNM$J.HKO/;V5]9 YOD?%4UO?RL=_I-<BDE
M   0W\0';&][N<1-Y</QFWRW7)&VZDO-EM\#'23S2V:NI[A)%#&SM?)+# ^-
MK41557)HFNA43P"Y\[/\?>+VXFVVX][K[-G5AN-WNVWUN@M]34-N:5U)&L--
M'/3Q2,AE;5QOZEJ%8U&O:J.71R-D)X8>:<C^1^(\@;MO!N)?<JPNMM,>)XG4
MW9S5A]L:R&H6M? K8TU6")T/4O\ IIV+VZ12\,;?O;KB/?N4.,;]79< O\D%
MI]&M5PAJ$FEK<<?=(ZJA1L<4BI,KJMJ-1?+VZ:G8_!"P.\QU6^NY=315%/8I
MZ>T8[9Z][5;!55*23U56R-RMT<Z!J0]6B]G>)]'LY+X-_P#SJY+?P_C^[R&V
M>"K5U]!<.4-=:J#VUNE%CECGMMKZNCTFHC?<G10]>B]/6Y$;KIV:G'LZW0X<
M\M,6WYS7=?!*#BSR QBB?<,0J+)55E0[*+IW=2Z2GKJ)*..!TJU+(V2N5C)E
M[SK=)HQVG=]BX]].0'A4\C,7R9]XRR"R5D;]K*VK22IKZNWV"IH+M54=.YR.
MDJ(XI*5\<7U2]2NA:OF-:V+?'C*^!^+\3\NR/>+;FT[@<A<;O-1%8L/KZV[T
M4]YIJET"TKHY:-_<LBC:^7K<J:IW:Z_5,UL*QVKQV]>%5R"RO$MC:38+&LQA
MNMTL^*4=QK+FRNB:E!1^V:RUR-D;WSJ98T:B=*MC:]/JC>/!4_E8S[^*MU_N
M.QG+O%KLL^V>Z_%+E3::1\E3AU^AMEZGC:FKG6BMCO-MBU[$57IZ9V*OD3^D
MVWP<\-N%TQ7?CD+D,*NO>ZV7NH8*J357.CHNNMJY6.7RMEJ*]6JOLNB^D5Y\
M=;AQ[N_+#D7D'/BLIZFYT-1>9:>GR%U8ZD=>(+EW-3"L5-J][X8F]W!$OFHU
M%1K=6LZ>Z>#\E&WE;R";;K7-9+>W%[BE#9:B-T,U'"E]I>[IY(G=K'1MT:K5
M[45-#3-A,]Q#9KQ6=\K]NA?(<*LU7F6X--!<+BV1L:R7.XSS42*K6NT2=CFJ
MQ5[%U3M[4-OYD?[W#83]*]K_ .]J8EMXSFV:Y'Q_PG="A@<ZY[690R*JJF)V
MPVR^,2GE=U)VI_K<-(B?T_1T..^%U[:[_<H>2O+#):5W?.IH;1:73)]3/=Y$
M<J,T54ZH*6WL8Y$7L231.Q2+>ZN%;3[>>*+F=%RELJ2;-9M?+A>ZBNN/I45&
M^"^T$E10U224G=R.BBK7I$]S%T8YKNI?,<2?XJY?Q@S#FW383QOXJ6;V@P:>
MY5U#OU2WR].?2T--1/A=7>@52.CZ9ZB5*:-'KV]XUW]%]YYH?#9QJVYGS0Y7
M8?>8^]L^5[?YU9[K%HB]5-79%;*>9NB_18]2#7&O:C(LSY7[3<?LA26>DL&X
MTWYQ6!55T4:6J5DM]5C%[&NDIK7TN=IY&-U\A8+N7_OM;;^E>)_]DK<?IXF=
M907'GQL=CV^5?5TVPM/08[)41-DF931VFKN<K+Q/]AU<U[EC5LKHT[SNV,T[
M6L.&9^_C\[Q&.,K>,]IHK=M=#F6WT5)66R&HBH*^M9D$:5532OJ?/F:CM(72
M)V*^-Z:KTZG;_$-_WFO'W_J!_P!H)QS(_P![AL)^E>U_][4Q\WB$5=CNWB/;
M8V'D/7U-/L-14F.]W"^2>*E99JESUKI56'SFMDK&2,FDCT?T,1.I.AJIR:JD
MV+E\3+8=_'&TTMMVG3*\4CL=5;H)X:"NGBJ4CK*FD6H1'R,[]KXE?Y%>QVFN
MFIW;Q ZM=D_$@V(WSR^BJ_V?K^:]XENE/"Y_V&S5SH;A%'I_QDL,:-D5B=JH
M]B>SJ<<RO=S$-\?%;VLW(P">JKL+O.:X9!CMXJJ6>B6NAHXJ2F?4QP5,<4K8
MW2QO1O4U%5$UT371-S\1[#\;PWQ"MN<\W>LD]QV7SY,8K,GF<R?T>:W4$C+=
M=8&OIT:]SX884D<QCNO1[=-.MIN]HROA77<O]L=H>,7%;'MT8)[S9JBFW2I+
M_?8&V^HAE2KK*R*FD[QLL=OA9WSG*O2Y6N;_ $X3F1_O<-A/TKVO_O:F,_O)
M_OH\"_VMB_\ <<9@/_QVO_6O_P#!(YYR)PO;/;[Q2[G4<E;*M5L=G5U2\5]3
M7)514E127:S.@AJ.\I>B58Z6Y*B/5B]G=.U[-20W'G+N*>4<X++MUQHXJV2[
M6+$JY]QMF^U+?+VCJ.EHJ)'U-P]!J.N/H2I>M/'UNT>KF+_:0YYN7_OM;;^E
M>)_]DK</_P =K_UK_P#P2,=STNU!@OBC[+9MELZV/%;1<]O+]<+U.QZQ,MMO
MNC'552G0USG-B2"37I15\U4TU/1CB^3V#-<=LF6XK=8+YC>1T<5PL=XIE58:
MFFG:CXY8U5$71S5U3L,\ 5@>*G^ZOCM_'_$?P&[%GX            *P.!_\
MQWB+_P 58/NET+/P             "L#FG_.3X;'Z5YA]QLI9^
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MAB;!34M- U&1Q11L1&M:UJ:(B&8 *P/%3_=7QV_C_B/X#=BS\
M %8' _\ F.\1?^*L'W2Z%GX             !6!S3_G)\-C]*\P^XV4L_
M
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MP_/6$K-M*O7*\D_-']G=->*?I^PVSTST[VVGGZM?L/==WIIY_5KYNEUX
M
M    *P.%G\Y/B3_I7A_W&]%GX !C+U>;5CEFNV0WVOAM5CL-%/<;S=*AW1#3
M4E+&Z6>:1R^1K&-5RK]!#Y\:R.R9ACMBRS&KC#>,=R6@I[I8[K3NZHJFDJXV
MS0RL7Z#F.14,V                            "L#Q4_W5\=OX_XC^ W8
ML_            !6!P/_ )CO$7_BK!]TNA9^              5@<T_YR?#8
M_2O,/N-E+/P
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M_2O,/N-E+/P
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M34T$SW.5\3%<QR+_ &E>Y^JJY2P4     K YI_SD^&Q^E>8?<;*6?@
M
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M53NZF,2R8A3MKV.<U=$Z'TTD;NWZKL\O8?-_^.U_ZU__ ()&?V;_ -]'GO\
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M?<;*6?@
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MG@:]5='TQM8Z1O8J*C&.U='U+-@     K X'_P QWB+_ ,58/NET+/P
M",W*O>[(N/VWV/;AV:Q4MZL\676FVY[+5QSR)06*M66.HK(T@<U>\9)W36]6
MK=7::*JH=JNF?899L+J]Q*_)K='A%';W763)F5,;Z-U(UG7WL<S7*UZ.3ZGI
M5>I>Q.T@IPMR6T[+<(HMS<^=)CF)0U-^RFFIYF=$D=NJ:Z1M'%#%KHKJA4;W
M+4T1ZR-Z?JD5?JXEV*7-,AR/EYO'<K?2[A[HP>B[>XQ4542IC.)(Y74E/$CU
M16R5#='O=HBJU=?-=+(TL$H[C;[BU[[?74]<R->F1]/*R5&JO;HJL5=#[
M  "L#FG_ #D^&Q^E>8?<;*6?@
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M\U3,DTT;.AKU6IEE5-&]G8J'50    "L#FG_ #D^&Q^E>8?<;*6?@
M
M K X6?SD^)/^E>'_ '&]%GX                               !6!XJ?
M[J^.W\?\1_ ;L6?@            K X'_P QWB+_ ,58/NET+/P
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MF.5F1TF?9[:,&9%131Q/I'W6.IE]+=WB*CTB;2N\Q-%<JHG4GE)&
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MW/'\?N>+,I/^5L8RICCJ67:7NN][J/5>[=]2G86?@
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MJ^.W\?\ $?P&[%GX
M
M                      *\>?%==,AJN-^Q4-UJ[1C6^.X=+:L[DHI70R5-
MHIGP)/2*]O;TR>D([3317,;KV>64E?QQV&N.'2X%4;1XHW%I*5:1MNAM=-$Z
M-G3TI)',QB2,E3ZI)4=U]7G=75VE?NP]_P BJN#_ #&VVOMWJ\B?LQ%N)A>.
MW&J<LLSK926:1::)7KYSNA[I$:FFC6=+6HB-1$F-PD_E0V,_1J+[K(<1RIKG
M>)_MHK6JY&;'SN>J)KHGMI=4U7Z':J(6* K \5/]U?';^/\ B/X#=BS\
M
M
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M^/\ B/X#=BS\
M
M                      K \5/]U?';^/\ B/X#=BS\
M
M                                                      K \5/]
MU?';^/\ B/X#=BS\
M
M                          K \5/]U?';^/\ B/X#=BS\
M
M                                                          K
M\5/]U?';^/\ B/X#=BS\
M
M                    QE[O-KQRS7?(;Y716RR6&BJ+C>+E,ND5/2TL;I9I
M7JFNC6,:KE^DA4'F/C!85;;O54F#;,W7++/!*Z."\72\169\S6JJ=XVGCHZY
M4:[35.IR.T\J-7L-2^62_P#=R^%__L0SF,^+S^<>28]CWJ]^A^WUSI+=Z9^=
MG>=UZ5,R+O.CVF;U=/5KIJFOT4+H        5@>*G^ZOCM_'_$?P&[%GX
M
M                                                        !P7E
M)BE^S?CMO+BN+PRU607?%;A':Z&#59:F5D2R>C1HW15=,C%C1/95VB]A'3PT
MK#@%!Q@Q2ZXQ;Z*/*ZVKN<&X=Q;%&EP6XPUTR-IZMZ-1Z)'!W70Q?(Q6KY55
M5L%        !6!XJ?[J^.W\?\1_ ;L6?@
M
M                                &B;I6W*KSMEN+:,%K76[-[KC%WH\
M.N#)EIG076>BECHI6SIVQJR9S'(_^SY2C^T<#.?MDR2Z9I8]U[;C^5Y#(V>_
MWJW91<:.IK9$[=:M]/2M29=577KZM5U\IO\ ZKGB@?XBOA=<_P 4,WC'&;Q+
M*'),>K;YR"],LM'<Z2>\4GYV7*3O:6.9CIF=#J5$=U,14T5>TNA       !6
M!XJ?[J^.W\?\1_ ;L6?@
M
M                   '^7.:QKGO<C&,17/>Y=$1$[5554KHSOQ1N,.$Y!76
M"C=E.>K;IGT]1>,9H*66@62-RM<D4U;64?>MU3L?&CF.\K7*FBFE_*Z<;O\
MH3N5[FV?WY/IM_BP;#WV[V2Q6' \]FN-\N%-;X%KZ6UTT+'5,C8FN<^*XU#M
M$<Y-=&>0M$       !6!XJ?[J^.W\?\ $?P&[%GX
M
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M5J(Y8U1$\]'W4@       K \5/\ =7QV_C_B/X#=BS\
M
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MNW       !6!XJ?[J^.W\?\ $?P&[%GX
M
M                               !_B66*"*2::1L,,+5?+*]4:UK6IJK
MG*O8B(GE4JPW4\5_9G#+Y76+ L2NVZ"VV5\$]^AJ(K;;)GL56JM-,]D\LK=4
M^K[I&JG:U7)HJ]8X>\XO6OR3,<>_9A^8/YIVR"X^F>W?MKZ1W\RQ=WT>@4?1
MIY==5_H,?QU\1O:#?K*Z# :VS7+;C,KP[N[#2726&HH:Z;35*>&KCZ%25VB]
M+9(VH[ZEJJY4:6%        K \5/]U?';^/^(_@-V+/P
M
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M ;L6?@
M
M     &'R*P6G*\?ON+WZD;<+%DEOJK5>J!^O3/25D3H)XG:=NCV/5%*3*CAY
MSLXTWF[T_%G<>3)<%KZQ:NWVAE?0TTC5541%JK=>=*%94:B-=)&Y>\1J:HWL
M8G(\2VJ\4#%=PLVW#Q?%+A:<[W+1&9E?W?FHC:OH7J3S:ART\&BIV+$UA)':
M'@IR$W)W3Q;=[F)GBWF/$JF&LMV'/KTN55,^GD[^*G>Z#_5*:G[U$>]D*NZ^
MUNC=>HN6       !6!XJ?[J^.W\?\1_ ;L6?@
M
M                                    'RUM;1VVCJ[C<*J*AH*"&2IK
MJV=Z1Q0PQ-5\DDCW*B-:UJ*JJO8B%8>4^++QYL=YK+78\9S'+J.BE?$E^I*6
MCIZ6HZ5T1\"5-5',K%]A7QL7Z1KGRO>R?Q9YO_P;;^.&7L'BR;,Y#?;)8*;;
MC-(*F^5]-;Z>:5+=T,?4RMB:YW35JNB*[5=$+4@       5@>*G^ZOCM_'_$
M?P&[%GX
M
M      !'SEA:[_>N-6^-KQB.2>\UF'71L%-"G5)-$D#G5$3&HBJYTD*/:C43
M5571.U2(_AX;%["W;C1AV8U&"XQF>79'+</SOO5VH:6YU,-3!6S1,I/]99(M
M.UD+8UZ&HWJU2147J12='["]DOB=P?\ 5ZV_BY^L&R6S-+/#54NT>%TU332-
MEIZB*P6YCXWL7J:YKFP(J*BIJBH=.       !6!XJ?[J^.W\?\1_ ;L6?@
M
M                                                         '*]
M\=Q7[2;0;C[DQ4K*ZJPVP5EQM]%)KW<U7'&J4T<G3HJ,=*K4<J>1-2@+CMQG
MYE[V6V^;S[79_3[16K-KE653KM#>:[&HKI,D[V5+Z:EL5/(C8V2H]G:QC=45
M&ZZ$E?4E\2+_ !<_#[,/Q$SF,\,_$0MF28]<KSRM]L+/;[G25-UH/SZRV7OZ
M:*9CYHN[DH48_K8BITN71?(O870        K \5/]U?';^/^(_@-V+/P
M
M                                                       #E&^]
M)B5;LINW!GC*I^%MQ"]393Z UKJMM#!12RSOIFN5K5E8QBNC151.I$U*?^*/
MB)[5['[=4^SN<V_(;]9<,JZR+!\UM%!3M=66VHG?4QMKJ*6J8Z&9CI7-\Q\C
M531.KLZW2F^5>XO_ )/SCW)I?QXR=D\4CC3?KS:;%0T&:)6WJMIZ"C66UTS6
M)+4R-B9U*E:JHG4Y-5T+'@       5@>*G^ZOCM_'_$?P&[%GX
M
M                                                 !BK[9+3DUDO
M&-WZABNEBR"AJ+;>K9,BK%44E7$Z&>%Z(J+TO8]6K])3@[>(7%YC6L387"51
MJ(B*ZT4SE[/HJK55?ZS_ %ZHG%_XA,(]QZ;ZP^FCXH<:;?5TM?0[&8725M#,
MRHHZJ*T4S7Q2Q.1['M<C-45KD144D$       "L#Q4_W5\=OX_XC^ W8L_
M
M
M        *P/%3_=7QV_C_B/X#=BS\
M
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MM5=-41',5'O1Z*2L!6!XJ?[J^.W\?\1_ ;L6?@
M
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M^ W8L_
M
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M6OC<]'-7V%0F/ZKG'[]GB[7)M1CB8DM M!W/H,*U:(K.CTA*Q6+/Z1KY_?\
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M(
M                                                      !SG>)<
MK;M'NFN!^E?GRF(7Q<,]!1%JO;;T";T'N$7L[SO^CI^GH55; >&+7WFZLW,Y
M99'591D5SF2OK,$AKI*F269W:JWBZ(]SYG+_ &F0/T[/^.<FK2QC<KBQL/NI
M@U!M]DNW=KI;%8Z9:;%I;1!';ZJT-7M1:":!K5B3J\Y6*BL>OU;'%8L7%[EA
MPQSVU7[83,[CGVSEUO5(S)['#&D\L%'+4,9*^OM+NMCU9&JZU-,G4U$5SDB:
M7>@   %?7B'V#)8=O=L-X<3LTU^N6P.X%JS2XT$#5<]+=2*Y\\G2B.\UDK(5
M>JM7I9U/71K7&Z57B \5X-O9<^AW.H:J1*):B'#&MD;>WU/1JE&M$K.\:]7^
M9UJG=)]5U]'G'/.&^SV15G#K,K%F=$MCOO(.7*+Y<*.JBZ'0QY'3>@PR2Q]/
M8DD,;)433ZAR=FO8:IP\Y0;9[9[1V_8[?+*:+:K='9J:LL5^L>1*M$DT$53)
M)334\CVI'(BQ2-;HURN=T]:(K'-5<AL7D$')'FEGW(;%*>:KVDVUPF';[#LJ
MFIWP1W2X2U/ID[Z=)6-<K8^]G1W]I&NB5=$>C2R\%8'BI_NKX[?Q_P 1_ ;L
M6?@   %&7C$\ITL&-VOC!A]Q5MYRQD-YW0G@=HZ"UL>CZ&WJK5U1U3*SO9$[
M%2-C$[6RJ5[>&1RH3COOI3XQE%Q2EVOW=?363)9)G],%ON'6K;=<G*[1K6LD
MD6*5RJB)'(Y[M>[:>M8
M
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M3<EK-T-HF4]ER66=_5/<+<K52VW%57M<Y\;%BE<JJY9(U>Y?LB%DX
M
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MG=<-3254;989HW>RU['(Y%^@98
M
M                   'SU=)2U]+4T-;3QU='6Q/@JZ69J/CEBD:K7L>U=45
MKD545%*<MP?"MO-LRJNRCCIO'/@,%9,LM-8+BZKA?1:OZ^[AN5"]97,:OU"/
MB5R:)J]R^<<AMGAG<R*"]W6\P;ZXU;+CD**S(;[1Y#D*5M:SV$J'I;HW3?T/
M>2HXX^&A8=L,XM6Z6[6=2;G9E9*MEQM%LB@=%;H:Z)>J*IGEG?)-5/C<B/9J
MD:(Y$54=H6E@       K \5/]U?';^/^(_@-V+/P  #&7JDK[A9KM06JZ.L=
MTK:*>"VWMD3)W4=1)&YL50D,GF2+$Y4=TN[%TT7L*.<U\'_8G%Z>KRS<3E'>
M,<HZVK<ZNR/(DM=%%+53]<KN\J:J5C5>_1SNUVJ]JG&OD\^ OS@V*?K#BWXZ
M/D\^ OS@V*?K#BWXZ/D\^ OS@V*?K#BWXZ6@\:<_XO\ '/:FT;3-YI;>;@6?
M'*BH7';E=LLQ^&II*.=W>)1ZQ5JH]D<CGJS7M:UW0GFM:B3AQO)\:S*R4&38
MAD-LRO&[JQTEKR"SU<-=0U+&/=&YT-33O?&]$>U6JK7+VHJ>5#.
M
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M;R;V-99BN9VV.\X?DUJRNSRZ=U=;/6P5U,[5-4Z9J=[V+_E-@
M
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M--<8/.\FLE-)(U-?Z3;0
M
M         #%7VR6O);)><<OE''<;)D%#46V\6^7M9/2U<3H9HG?2>QRHI2K?
M_#2Y![89-<[QQAWV=8[)6S=<-'472XV*Y,BZEZ(9I;?')#4HQ%T5SNC5/['L
M&*9QI\4JJD6FFWNN%+#*CF/JW9G5-:U%1>W6)KI$^DK4U.L;&^&EE%+N-:MU
MN3.YK=Q[Y9JJ"X4]@I:BKN+:NIIW(^%U?<;BUDLC(W(BK$D>CE[%?TZM=;X
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MF5-FMDLU=[6W.OIH*F!L54D3)NZ5M5%"Y5Z)&KJB:=OE.M@
M
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MD/>JZJEF<B]$;4T1=.SR'6P
M                                                       <)Y/8
M=?<_X][PX?C$;ZC(+WB]?%:*.)%62IG9&LK:9B(J:NGZ.[3V-7=O81W\-2DP
MBDXO8S%C5-2TV4PW"YP;F1HQK*]MVBKIT9'7)HCT<VG6/NT=Y&:>SJ3^
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MYY;29?391:H9$@N=.UKX*V@G5%5(:RDF1DL+ET56]3=')YS%<WM.R
M             ' =X>4>PFP-RLUGW?W%H\)N604TE99Z6IIJV=9X(G]V]Z+2
MT\R)H[L[513E=L\1#AE>;E;[/;-]+75W*ZU,5';Z5M!=466>=Z1QL1742(G4
MYR)VKH32
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MUCD5$1K:FGZFLF8GLJUZ>8]NL2":G"'F%DW$C="&[JM3>-L<I?%2;D8C&_\
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MS/4UD+Z5E/14=5$UK*>>)CNF5RN\YJ_Y#T*@
M                 $6N3G+W:GB90XA<-TJ:_5$&;3UE/9DL='%5N1]"V%\O
M>I+/!TII,W3377M(B_+)<1_R;N![C4GO@6O@
M  $;>2/*/ .+MDQJ_9_9\@O%'E-=+06^/'Z>DJ)62PQ=ZY94JJND1&JGDT55
MU]@B)\KIQN_Z$[E>YMG]^1\KIQN_Z$[E>YMG]^1\KIQN_P"A.Y7N;9_?DRMB
M\5SCOD%[L]AHL,W%BK+W74]!2236ZT-B;+4RMB8KU;=W*C45R:Z(JZ>P6<
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M,B.7R(O1.NBJ;[0W:U73O?:RYTEQ[CI[_P!%F9-T=6O3U="KIKHNFID
M  ##Y#2SUU@OE%2Q][55EOJ8*:+5&]4DD3FM35RHB:JOLJ5P>%QQZW@XY[0[
M@XOO+B'YG7V^9@MTM=#[86^X=[2+;Z6#O.\MU34L;Y\;DT<Y'=FNFFA9N
M                                       :EE> 8)G<=%%G&%6',HK:
MY[[=%?+;2W%M.Z5&I(L25,<B,5R-37ITUT0HW\*S;3;C,=R^:])EVW^-Y32V
M#)K)#8J:[VJCKHZ*.2LR%KV4S:B)Z1-<D3$5&::]+?H(7Z@
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M;WC5WH=X[U;;EC$5@J:RHE@BHZF[S2-K$JJ.E:QRMKX]$C<]-4=JJ:)U6+@
M                                    K \5/]U?';^/^(_@-V+/P
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MEPBC9(VHID>JN2&HBD:]J*J]+NN/J=T=2S'
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MZ;CUFT.\,;)<A?)504%R6"&EGAK:-KGRTT[*=K(7-<QCE8YB>5$3SD>BMGT
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M.;+*D&^>+R0(]R0R26RM8]S-?-5S4>]&JJ>5$<NGT5/S^1#W4^/#%/<ZN_\
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M(Z!M?3QU"1*]$:CE8C]-=$U^@;.      "L#Q4_W5\=OX_XC^ W8L_
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MV*DH)Z*)E73TE#&E0^IKZ61JI(Q57IC=YOT5[#TU
M                       I!\(G]Z?.W]*K%^'9*7?
M           I9Y9^(=?<:J-]>-N1;"K;+C6VN]8G'DOYR];5I;K1204MR92K
M:F]39()V3I'WJ=B]*N1>TCUQQ\2[U?MF,-VB_8K^=OYI>V/_ -X?SC] ](]/
MN-37_P#)O:NIZ.CTGH_XQVO3U=FNB=O^62_]W+X7_P#L0C[NER:W'Y];G;)X
M%ANV<N'T^.9!%5M@H:R6[S,EJ)H&25]34MIJ1(8::-BN^I335RJY?-T]'P
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MOXP?K!O;LS53PTM+NYA=34U,C8J>GBO]N>^1[UZ6M:ULZJJJJZ(B'3@
M  5@>*G^ZOCM_'_$?P&[%GX         !7WS_P"%-GY8;>>VF/P4UMWHPBEE
MDP>^.1K$KX4UD?:*N3LUBE<JK$YR_8I%ZDT:^1'>1J]66[8Y>+KC]_MM39KY
M8ZN:@O%HK(W0U%+54SUBFAFC>B.8]CVJUR*FJ*AC#T4>%CSR3)*.S<8MX;TB
M9#;HDI=H\KK95UKZ:-/,L]1(]5^S0M32G55\]B)%]6UG>7J
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M -+A^O,VBHY$<U45%35%3R*A_0
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MRPU$:]+(I-6HU7(C7-7O9+J0
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M#_=M0<0X"^?Q V41_GHMKKFJB]O9[9UB:?Y#EG.G]Y/!O^-]B_#*0L5
M
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ML4]/MQBL4T3O*U[+12HY%_H5#EG/:":HXB;VQPQK(]MII)7-3V&17&ED>O\
M4UJJ=GV(D9+L=LU+$]LD<F#8ZZ.1JHK7-6V4ZHJ*G8J*A$+;)CI?$FY(SQHC
MXJ7;JP05+VJB]W)+';'L8[Z"JUJJGTAX?K'4U5RVH9T2.LI-\,C;4TRJG6Q4
M<UOG)[':U4_J4>($QU35<2:&!$DK*O?#'&TU,BIUO57.;YJ>SVN1/ZT&YK'1
M>)-QNGD1&156W5_@IGN5$[R2*.YO>QOT51KD5?I$O=]Y&1;';RRRO;'''@V1
M.DD<J(UK4ME0JJJKV(B(<8X$P34_$39*.:-8WNM-7*UJ^RR6XU4C%_K:Y%.3
M\Z?WD\&_XWV+\,I"Q4
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M-^LN466U9'CETIKW8;[215UGN]'(V:GJ::=B/BEBD:JHYKFJBHJ&6
M       *N=\OYT=N?]L8E^&1%HP(Y\M=O,JW7X[;F[>X30QW+*<EHJ6&T44L
MT=.R1\5=3SN199G-8W1D;E[5.H;66*Y8OMCMQC-YA;3W?'<7L]LNM.U[9&LJ
M:2BAAF:CV*K7(CV*FJ+HIOAA,CQK'LPLEQQO*K)19%C]VB6"YV:XP,J*:>->
MWI?'(BM714U3L[%[4[2%+N-VZNPUU2^<4,V;^9<M5WU\X^9A/+5V58Y'HLKK
M-6O<LU%)IJK6.=TN=]4_1.DR')'9?=EVZVW?)?C[#;+ON7@MNGQ[(\&N\Z4M
M-?[)4.D>D+:ASXV,EB?,]4ZW(FJM=U?8T8_C^Y%IY?\ +VTT&TF6[+T7'+:J
MXU])/N1DM9D%+>[A6T]',VH]&H8J5L2MZGL:Y$=&K5<UNLJ(CFNG'NE0[A8_
ML]>K7L);Z%<\LUNHZ/ [;6K$E(U()88NAZSO8S1M.CM.IWL)[)\E+AF1;G;"
M,P3>N"&GRK-<1=:=PXZ#NECAK:RF6*I?3K&YT>L;W=3%:JIJB$,-N[OSAXYX
MC;=F6<?;7OU9\58ZU[?[D6S)J2T-?;XW*E(ROI:OK>BQ,<UJ:]TU&(C>I_2L
MB]PXJ;&[@8'<]TMX-ZJVWU>\N]MR@K<BM]J59**T4-&U[*.WP2.<Y7=#7Z*J
M.5.EK&]3^GK=R_(MMN0O';?'<K=G8'!+=O'MWO/-!=<ZVTFND5GN-#=X4?WE
M51U%0JQJV9\CWN5&O<O4K59YC7C'=MN0O(G?';7=G?[!+=LYMWLQ-/=<%VTA
MND5XN-==YD9W=565%.J1HV%\;'M56L<G2C49Y[GG4.5>QNX&>7/:W>#96MM]
M)O+LE<IZW';?=56.BN]#6-8RLM\\C7-5O6UFB*KD3I<]O4SJZV\/W$N_.'D9
MB-RV9?Q]M>PMGRIC;7N!N1<\FI+NUEOD<B5;*"EI.AZK*QKFKIWK58JMZF=2
M2)8/M[A-HVVP7$, L*.]I\-M%'9[>^33O)(Z2)L222:=BO?T]3E^BJD:>5&S
M^=[H9IQ;O.&VR&X6_;#="U9-F,LM3#3K3VVEJ:>265C97M614;&[S6:N7Z!,
M<
M                      Y-OQN%/M1LSN9N-1PLJ+AB&/5M?:H)$5T;ZQL2
MMIDD1/[*RN;U?2U*4>/G W,>76-MY![V;NW2E7.:NIEMD<<*5URK(8)Y('SR
MSSR-CIV))&]L438W)T(BITMT0DW)X0>RRL>D6YV;,D5J]V]WM<YJ.T[%5J4K
M55-?8U0B9N1M!NGX:>Y.W^Y>#;BU.4;;91=&T=ZI5B?2)4,@Z9)K?<J1LDD,
MO>0*]896KU(YKG(UCFM5WH?    (><UMQ;WBVU5)MU@ST?NAOW=(<"P6!KU8
M^);DJ15M8JM\YK(('*BR)]0Y['+V(<AYB;<63:'PZ<PVTQY$6U8=:\7M\4_0
MC'5$K<AMCJBI>UO8CYYG/E?I_:<IWO<W^27<'^"%V_[-RCA)_*AL9^C47W60
MXAEG^] VR_@A4?WG=BQ4%8'BI_NKX[?Q_P 1_ ;L6?@           $8>6G%
M[#.5VT]RP#)6LMU_HE=7X%E[6(Z>TW-K=&/1=-70RIYD\?D<SM321L;V^.'=
M+;#--FL^R7;7<&T/LN5XK5NI;E2*O5&]-$='-#)V))%*Q4?&].QS513GY<KX
M7_/%VTM\H>/N[=Y=^S#)JM&8+D-7(G=X]<JA_;!(]_U%'4O=VKKTQ2>=HC7R
M.;Z9P             "KG?+^=';G_;&)?AD1:,
M
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MFR&TYIC3'PV^_62H= U:A89.GHD8ZJA[6-:U>IS%8QT:J^P(%7.^7\Z.W/\
MMC$OPR(M&
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M6-T;Z^SVF2!U;7Z/:UW1+-2Q.;Y?/=+&NBQ:%HP*N=\OYT=N?]L8E^&1%HP
M
M                             - W5SZAVLVUSK<:XP+5TF%6.MN[Z)KD
M8ZH=2PNDC@:Y>Q%E>B,1?HJ4F8+A?B-<O+2[>"S;UR[:XK?ZBI=CE$W(+GCU
M')#%,Z)6TE)9H9GK'&YJL:^?SG=.JN=]4O-=@]L^=O(RP99D."\H;];Z7#[U
M-8KA37K-\F@FEJH8F2JL"01U#%8J2(B*]S5U\J(G:?V+;WF=BF^>W&V6]>^]
M_P 8CR*[TD^+UV2Y;?:VQWY8:B/O:.DJ*9*R))G(O1W=0D7:YJ+IULZO1V
M     "L#Q4_W5\=OX_XC^ W8L_             !YE?%!X'IM!>JSD#M)9E9
MM=D]9KF^.T<2)%CMRJ'^;-&QB:,HZIZZ(FG3%*O1JC9(VI3:=!VLW0S/9G/\
M9W+V_NKK/E6*5;:NW5.BNC>FBMD@G9JG>13,562,5?.:JH>J7:^[\7>*NU.W
MN\]ZVQI./V0\D)<>MU_LTDTU95LK[KU3(R9]9.]T5-!WKYIE\WH9IWC.M$8D
MKMI>/&R^Q-5EM;M'@-!@T^<RTTV4I025"QU+Z-T[J?2*661D;8UJI>EL;6HG
M5IIHB:=H         (>;V\*-B]T[1FMXMF!V_$=V[Y'6W&R[HV#KM=Z@ODK'
MNAK'U=*^)\GV545[9%5KDUU^BF#\.S>'*-[>)^WF69M<I[WEULDK[!?;Y4N5
M\]:ZVU+XX)YGN[7R.IUC[QRJJN?U.5=54XYS4W"RK?#/\?X%;)W)]-D6=0QW
M+D%EU,G6S'<016.E@D5')I+5-<WJ8JIU,='%VI4:ML1V^P+%]KL(Q?;S"K8R
MSXKA]NAMEEH&::MBA;IUO=HG7)([5\CU[7O5SE[54W$P%YRO%L=DBBR#);58
MI9V+)!'<*R"E<]C5T5S4E>U51%]E"L%EZI-X>:=GNV-2>V5CMMWI):.M35T;
MJ>R4[9))FJNJ(Q\L3E8OL]3?94M=
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M-)%)]EZ6J]9)'/:U$Z6^5$<J7_@       K \5/]U?';^/\ B/X#=BS\
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MN1%5&L3J5$ZM=$T[4
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M-=*G7]2CHH)GO:[V-%1%U[/*=.
M
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MQ@
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M/DZYEL]1+(ZTUKD55[986JR33L25C]-&JTFJ
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M'?K%<)DIK?>J"NJ%17)!3U,4K]$\J]+'*NB&6
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M]6:YR/BMMVHKA+&WKDBIIXY7-;KIJJ,<JHFJF3
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MX>\K^TP_?1Z@?,G_  ]Y7]IA^^CU ^9/^'O*_M,/WT>H'S)_P]Y7]IA^^CU
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M<Z%R0NU1=6-:W14+Q@       5@>*G^ZOCM_'_$?P&[%GX
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M%MN4$=5;Z^G>V2&>"9J/CEC>U5:YKVJBHJ+HJ'U@
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MFW%FR.R6O&KPMDKJ?)*>DIJA]0E/%4]4;:.KK&JSIF1-5<BZZ]GLDFP
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MV*XVR75.N/KU;+!*C55&RP2-=%(W7S7M<WV#?P
M    8;(\AL^)8]?LKR*M;;<?QFW55VOMQ<U[VT]'11.GJ)59&USW(R-BNT:B
MJNG8BJ:[@NZ&W&YU ZY;>9S8\THXT1:B2T5T-4Z'J\B31QN5\:_2>B*;V
M     "L#Q4_W5\=OX_XC^ W8L_
M                                                        !2/N
MYX0.5;T[DYCNCFO*Y:S(\SN,E?6K^92JR%BZ,@IHM;_V101-9%&GL-:B'.?D
M,?\ WHO@3_[?,':/!8QK(9:^"P<P[9?)[4]L=SAM^*0U+Z9[U<C6S-BR%RL5
M58Y$1VGD7Z!G/D,?_>B^!/\ [?++>%?%+*.(N%Y)M[<-XOVIXI<[BVZXY0OL
M2VA]JJ)&*RL1CUN-=WD<_3&[H1&(UR.=VK(I-$
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MX_XC^ W8L_
M                                         -2RO/\ !,$CHI<XS6PX
M;%<G/9;I;Y<J6W-J'1(U9$B6IDC1ZM1R:].NFJ%&_A6;E[<8=N7S7J\NW QO
M%J6_Y-9)K%4W>ZT=#'6QQUF0N>^F=42L25K4E8JJS73J;]%"_4
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MG=3T1SM=5[3:P      5@>*G^ZOCM_'_ !'\!NQ9^
M
M            1:Y.<0MJ>6=#B%OW2J;]3P83/65%F6QUD5(Y7US862]ZLL$_
M4FD+=---.TB+\C;Q'_*6X'NS2>]Y:^                           #AW
M)B]4&/\ 'S>6Z7;'I\JL\6(W6&]X_35?H$U30U-.^"J:RJ[FH[E4AD<Y']V[
M33R$=^!^-;&Y-M%8]V-O]A;!M?6W"MKJ2C>M6[(+JUE%*M.Z22ZUE-#4-61[
M7+W;?-1-%U[=$GR        "L#Q4_P!U?';^/^(_@-V+/P
M
M                                             #G&\=XIL>VBW4O]
M9C\.6TECP^^7"JQ6HU[FYQTU!/*^BDT:]>F=&K&OFKV+Y%//!L/S-W0XYUF0
MV;;O:NJJ-JK[<'72GV[OTU772VRID:C9?0;E'3T[VL>C6ITRQR?4HNO6KGNE
M5\K)N3_AG_\ M2L][S-XQXIVXE_R3'K%-QQ]"AO5SI*"6L]LZMW<MJ9F1+)H
MM B+TH[735"Z$       %8'BI_NKX[?Q_P 1_ ;L6?@
M
M                                          &B;I9C+MWMEN+N!#0-
MNLV"XQ=\ABMCY%B;4NME%+5I"Z1&N5B/6+I5VBZ:ZZ*:)QHWCJ=_MDL*W;K+
M#%C-1EGMEWECAJ'53(/0+E54":3.9&KNM*='_4IIKI[&IW8AMRYY15_&EVTC
MJ*R6Z^LW"R!]JN4-;++')3TD7<=[4PI%JKNCO4145J]JM_KF2       "L#Q
M4_W5\=OX_P"(_@-V+/P
M
M                  "EGEGQ7Y;PU&^NX6+\CKC)L?':[UD53@ETRW(DG2U-
MHI*NX6QM"V&6D?%HDL,4;I>ET?2U_3VD>N./%SFUN-LQAN9;1<BOS$V\O'MC
M^;V*?G=DEK]%]'N-33U/^J4%)+3Q]Y4122>8Y>KJZG><JH=O]27Q(O\ %S\/
MLP_$3Z,1\-KD5E&Y^&Y;R,WMMN=8_B];3550U;O>;_<:B"FF;,M%&ZZ4T#8H
MY5;TN<CUTUUZ54NT       !6!XJ?[J^.W\?\1_ ;L6?@
M
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M.J.6-7-<FJ>5%/O!6!XJ?[J^.W\?\1_ ;L6?@
M
M                                    $<N7M)=*WB_OQ3V=7)6_F9=9
M'(W75U/% Z2I:FB+KU0M>FA&/A'N;L'MAPSL&6ID%DL+<=HJVKW,7O(&W)]T
MCJ)G.9/'U)+++(WI;3M757,5C6=FB$-N%F#73E]RHW!Y.;FVIM=C&+W#T^AM
MM4WOJ5UTE3N[50MZTTD9;Z:-'_11S85<GGG5O%>N&'/GV1AQRKHI=\+=?W+;
M8:*2-;C#;W-:Z-)T8O4U%JDB6'O-.WO.C^V7.    $*>:F);K[G8_MGM%MW3
MW6EQ?<3+*:CW?RBU*C74&.Q.8E0V1_4BHV7O.I41%ZN[Z'>8YR+E;IP0XHU>
M%5.'MVCL]KIO0G4\.20=XV[0.1JHVI]L'/69SV+YWGN5J^1R*WL./\(]ULDH
M.$V09GE5P?D3-I&9/'8[K5R*[TNUV*!:J#JD<NJL9YT3=7=C&HFNB&!X><7]
ML]S-H[?OCOEBU%NKNCO+-67V_7S(D6M2&"6IDCIH:>-[ECC1(HVNU:U'-ZNA
M%1C6HF0V+Q^#C=S2S[CSBE1-2;2;E83#N#AV*S5#YX[7<(JGT.=E.LKW.1LG
M=3J[^TK6Q(NJ,1Q9>"L#Q4_W5\=OX_XC^ W8L_
M
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M_E0V,_1J+[K(<0RS_>@;9?P0J/[SNQ8J"L#Q4_W5\=OX_P"(_@-V+/P
M
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M=BS\
M
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M1T[%5(XVZ-1=-$5&L1&,1B(2L!6!XJ?[J^.W\?\ $?P&[%GX
M
M                                               !\M;5T=!1U==<
M:F&BM]%#)/7UE2]L<,4,;5=))(]ZHUK6M15<JKHB>4K&W5\+78G<J\5>68%D
MUSVT?>W^E2VZV,@N%F59%ZW/IJ=ZQOC1^JJC63="?V6M1-#AL'@WTS9VNJ>1
M$LM,BKUQ1XHD;U3V$1ZWAZ)_P28O'?P]MD^/]_H<UCFN6?9W;5<ZUWZ]K&V"
MAD<U6+)24<+6L:_I7L=(Z1S?*Q6D\        5@>*G^ZOCM_'_$?P&[%GX
M
M                                                         !IN
MXV'0;B;>YWM_4US[939SCMTQZHN43$D?3LN=)+2.E:QRHCE8DG4B*O;H4ZIX
M='*O9F>6OX\<D&I!')WJVMU3<,>=.FNJ-?3PNK:69=5[4E5&KY?+V&<I=^_$
MVV01L6YVR+-VK)2ZK476BH(ZNI="W^VE3CTCHXTT\JRTZKIVN[=5.O[:>*5M
M7D]^MV'[B;>Y1MCEEPK(:#T=S&7*CBJ9WMC9'+(B4U2Q5<Y/+3?TJGLV@@
M     K \5/\ =7QV_C_B/X#=BS\
M
M                           UK-,KM>!X=EF<7Q)ELF&6:OOMX2F8DDWH
MMNIWU,W=L56HYW1&O2FJ:K[)4[D7BR4E\N"V#9#8;(<UO%4JMMRW.9(YG+KI
MU);[='6R2)JJ=B2M4QC<M\5G?+I]I<5MFQ5AJ]&OJ)J6FM3VM7R(]ES?7W%J
M^RJQQM_J\AG<6\-;<W*<PQW<+D/R/N.:9!C]93UD%!2-JKEIZ/,V=(HZ^Y2M
M6./J;ITMID3Z&A;Z       "L#Q4_P!U?';^/^(_@-V+/P
M
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M]U?';^/^(_@-V+/P
M
M               #5<ZRZV[?X3F.>WF"IJ;/A%CN%_NM-1-8^IDIK;3254S(
M&R/C8Y[F1JC4<]J*NFKD3M*?<A\7"YWNL]I=H=A*N[W.I<K;=+=JY]1-(OL)
M[76^!SG+Y%\V?Z7TS\*3<'Q7-\%1V/8?!L_9:Q4[RIEMM)949&OD[+VZJKM/
M9UB;K_4;-C/AN[TYIF6-[A<BN1DN37S':RFK::WTJ5EY5$IYFS)!'5U\E,D#
M%<WM1D"I]#Z)<:       "L#Q4_W5\=OX_XC^ W8L_
M
M                                          ,1D-LLE[L%\LV2TM-7
M8Y=[?4T5_HJS3T::BJ(G1U$<W5HG0Z-SD=K[! _C[RRXXY=O'/L-L)MW'9;9
M!1UM1^=MKMU%:;55>@(BN6G@@1LLC':^:][6*OETTT5>R<E.76U'%^@M:YO-
M6W?)+\UTMEPZSLCEKI8&NZ'5,G>R1LBA1WF]3W:N5%1B.5KM.3\?/$3V3W[R
MNAP)E#>,"S*[.<RQV^],A?2U\J(KNY@JZ=[T254151LC6=7D:KG*C2?8
M   *P/%3_=7QV_C_ (C^ W8L_
M
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M/X#=BS\
M
M       QUXM%LR"T72PWJBBN5GO='/07:W3)U15%-4QNBFB>GLM>QRM7Z2E(
M^6>%7N]1W>ZXUMAOA1TNSM]K%J:NQWFIN-/41L1R+&V:BI(I*6L?&B(G>.=%
MU::]+?(6D\:^/.)<:=LZ';[&)GW2JDF?7Y1DT\:1SW.X2HC7S.8BN2-C6M:R
M-B*O2U$U5SE<YU;&R'AV;U7S=3&]T>5.X291#BE73UM+9)[K5WZX5\E')WD$
M-35U6K8Z=)$:YS6N>KDU;HS74NG       !6!XJ?[J^.W\?\1_ ;L6?@
M
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ML#Q4_P!U?';^/^(_@-V+/P
M
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M!XJ?[J^.W\?\1_ ;L6?@
M
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M1K&-31$1.Q$1$/\ 0      !6!XJ?[J^.W\?\1_ ;L6?@
M
M                                            '#LTXT<?]Q+C->,S
MV?Q6^7BI=UU=XDMT,57,[M[9:B%&22>7^TY32O4DXH?$9C7VJ7[X?71<,>*U
MOG;4P;$XG)(U-$;4T25,?E1>V.=7L7R?0) X_C>.XG;(+)BM@MV-6:E_Y-:+
M52PT=+'V(GF0P-8QO8B>1#-        K \5/]U?';^/^(_@-V+/P
M
M
M "L#Q4_W5\=OX_XC^ W8L_
M
M                                *P/%3_=7QV_C_B/X#=BS\
M
M
M   K \5/]U?';^/^(_@-V+/P
M
M                                 "L#Q4_W5\=OX_XC^ W8L_
M
M
M    *P/%3_=7QV_C_B/X#=BS\
M
M                                   K \5/]U?';^/^(_@-V+/P
M
M
M     "L#Q4_W5\=OX_XC^ W8L_
M
M                                 !ALCOM#B^/7[)KHYS+9CMNJKG<7
MM35R04D3II51/H]+%*O]F=I]UN8^)+OUNUOYN#M[:,SK*V7;S;C;^Z)9Z*V4
M%-4/IH9)E6.9)G.6-VBJQ'JW1RR+U=+>K<;\TW1VZW]W#XG[L9O6;FPVBP09
MEM9N#=6_^LZFU22QP3TM9(KGNE>R231KG*KM62+KTN8UE@8*P/%3_=7QV_C_
M (C^ W8L_
M
M                !Q+DPYS..'(%['*Q[-MLK<Q[5T5%2SU2HJ*AHW"3^5#8
MS]&HONLAQ'*G.;XG^VB-<K4?L?.UZ(NFJ>VEU71?H]J(I8H"L#Q4_P!U?';^
M/^(_@-V+/P
M
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MO]::+%,ZS.UP8UA>W=#4LK6V*QPOCD<V:HC<]CI97Q,=YJ]B]XJ]/7W;)U
M    U_+/^:N3?[*K?N#R 'A/_P DNW/^U<B_O:I+'P         5@<\/YCO#
MH_BK/]TM99^          5@9E_O<-IOX 5/][7DL_
M !"#Q(OY)-^_]E6_^]Z([_QZ_<%L=_#_ !G^ZJ8[
M "L#A9_.3XD_Z5X?]QO19^                    "L#Q4_W5\=OX_XC^ W
M8L_                                           /CN-%%<[?76Z=S
MV07"GEIIGQJB/1DK%8Y6JJ*FNB]FJ''^/>P^(<;-K;+M)@UQO%UQNQ5%;4TE
M;?9J>>N<^NJ'U,B224M/2QJB/D5&Z1IV>75>T[8         #@^[7'G"]Y,U
MV6SS)[G>Z"[[%9 _),1IK7-314U15/= Y65S9J:=[X]:=O9&^->U?.\FG>
M        #@]SX\X7=>16/<FJBYWMF>8UA[\*H;3'-3):'V^2HJ:E99(5IEG6
M;KJGIU).C=$;YGE5>\                     Y7O;M#C6_.UN7;29?77.V
MXWFE/#372ML\L,-=&R"HBJ6K#)40U$:*KX41>J-W9K[/:;AAN+V_!\0Q7"[3
M-45%KQ"ST-DMM15N8^H?3V^G931.F=&R-JO5L:*Y6M:FOD1/(;(
M           #@^V''G"]I]R][MU,=N=[K<AW[N%MN684=RFII**FEM;:IL+:
M!D--#(QKDJW]2222*NC=%3MU[P                    #@^_\ QYPOD=8,
M,QS-[G>[50X-F%NS6TRV.:F@EDN%LBJ(88IUJ::I:Z%S:EW4UK6N5431Z=NO
M>
M
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MHKK;ZN):>MH*MK6O=3U,*JO2Y&N145KG-<GU+E.P@
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MA\-+/='WBCCI6/CK'2MB6+HGE5VO=*JZHGL$H
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M^ [[,LFGYC)O!D"83T:=RM&V&D:UT"^S'T(Q$5/-U1=.WJ+'@
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MC6R6R76NN475[%7/JK%316ZRL7RF-XX?SQ\X_P#JE^!.+%@
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M<CDZI)9%=)(Y>USW*J^4Z?'(R5C)8GMDCD:CHY&JBM<U4U145.Q45#_8
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M9;E27UT5?6+54ZS/2X5'<KWZ-5-&IHFB=A=T
M                  <'WJXT[-<@(;:NYF)-NETLC7,L>1TD\U#<J-'.ZNF.
MIIWL<YJ.\Y&2=3$7M1NO:8#9KB+L3L5>JC*<&Q.63,*J)\$F7WFLJ+E<&Q2)
MHYD3ZA[F1:M\U5C:USF]CE5"2X         (<;@<#.-6X>25^75>'5>,9%=W
MODO-PQJXU-K;5ND7J>LL$3^YU<[SG*UC5<O:Y54[=M#L9M7L18*C'-J\0I<7
MH*Z1DUTG8^6HJZR5B*C7U-54/DFDZ>I>E'.Z6ZKTHU%4ZR         ?XDC9
M*Q\4K&R1R-5LD;D16N:J:*BHO8J*A![(?#HXJW^[UMWBPJX8XETE66[6FQW:
MMHJ"H57(Y6+3-D<R-FNNC8NA$U71$["5.V^V6";18G;\'VYQNFQ?&+:KWT]N
MIU>]722+J^6::5SY99':)J^1SG+HB:Z(AO8                   -<R_$L
M?SS%[_AF5V_VUQK)Z&:VWRV][+!W]+4-5DD?>P/CD9U-735CD5/848AB6/X'
MB]@PS%+?[58UC%##;;';>]EG[BEIVHR./O9WR2/Z6IIJ]RJOLJ<"W-X9<;-X
MLPK\]W'VW_.+++I%!#777VXO%'ULIHFPQ)W-'701)TL8B=C$U]G530?DX^&7
MQ-_"'(O?,F38K);,:LEFQRR4WH5FL%#3VVT4?6^3N:6DB;##'UR.<]W2QJ)J
MYRJOLJJF5                   .=8+M-M_MI<LYN^$V#VEN.Y-\GR3-:CT
MJKJ?3;G4O?)+/TU,TK8NITCEZ(D:Q->QIM.2XUC^8V&Z8OE5FH\AQZ]0+376
MS5\39Z>>)VB]+V/14714147RHJ(J=J$/?D\^,W5Z+[19'^;'>][^8WYRW;VG
MZNOK_P"(])Z].KMTZR86-8UC^'6&UXOBMFH\>QZRP)36JS4$38*>")NJ]+&,
M1$355557RJJJJ]JF<                  !SK=+:;;_ 'IQ.;!]S+!^<N+S
MU,-9+:_2JNCUFIU5T3N]HIH)?-5?)U:+[)&;Y./AE\3?PAR+WS.W[-<<=F./
MWYQ_LBPW\TOSM]#_ #A_]8W&O](] [_T;_E]34]'1Z3)]1TZ]7G:Z)IV\YUC
M>TVW^(YSG.Y./6#VOS3<GT3\]+SZ55R^F^@L6.G^P2S/ABZ&KI]B8W7V=3HH
M
M
M
M
M
M
M
M
M
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MJ(Y=%TU7M1"PD
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M2Z=WW\4<ZN2.>"2)SFS1*K5:KDT5J]CFIJU72K
M
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M/BF-T[+7CL,&64E-:86HV&*GCO%)+%%&Q$1&MC5$:S3R-[/HEY8
M
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MFN=P:M)12O;(E77MFF657)V+UZJ[33V")_@^?NVWB_26@_ U-'\63]Y/&?\
M^M/PRWEWA2'X>_\ .URM_P"L7_:2,P7/5\>&<_.-^=W-4CL<3</N515RJD<3
M4M>13NJ&J_SE1&1M8Y5T[.KV2]DHFX@/9FOB5;]97:52>T6VHS.MCK(E1\4L
M#KI%0PR(Y>GLE[U'HB(J_P!2*IG?&2__ .<O^M__ .Y"[PI#XN?[T#D5_P!;
MO[SI"[P
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M;_FENWO]?:BQOP7-O;[VFBI:N62O3VRK8*B#O870,:WS8UZM'KHOT2R0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>feb2019sibonevasimia1yr.jpg
<TEXT>
begin 644 feb2019sibonevasimia1yr.jpg
M_]C_X  02D9)1@ ! @$ ^@#Z  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M# P,# P,# P,# P,_\  "P@%6P@O 0$1 /_$ )0  0 " @,! 0$
M   ("08'! 4* P(!$  ! P,# 0,$" \+!P4+ 1D  0(#! 4&$0<($B$3"3$B
M%!5!4=+45A<8&6$R(Y.S5975%I:F=Y=867%"M+4V=H8W5S@Y@5)B,R1U2)'#
MTY2VT7*20U.D)>769V@IH;$TQ<8G28)CA:7PP>&B@U2$)GBR<Z-D1?_:  @!
M 0  /P"_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             &I=W]]-K-A;);,C
MW8RG\%+->*[U;;:ST&NKN\JEC?-W?104]0]OF1N75S43L\NIK/;CFKQEW;S.
MS;>[>[E_A!E^0>D>J+1ZFO-)WWHE/+5S?5JNAAA;TPPO=YSTUTT3551"4P
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MWL)H6RY45YMMON]MF])MUUIHJR@J.ES.\AG8DD;NEZ-<FK7(NBHB^V<X
M
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MWU$T6O0]]- R)SF]2(NBJW5-4,A
M
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M\RZ\
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M1)()'L7L7L4O:\57 /PIXVT^7T\'76;;9'17"69$U<VBN'5;YF_N++/ Y?\
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MJ[55755/.-L9_79L[_/?'OXRISV2@
M
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MZIJCYK77N8FGE[4C<05\*6:*+E'4LDD:Q]1A=WC@:JZ*]R3T;U:GMKTM5?\
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MBV=?FC=_%33S.;&?UV;._P ]\>_C*G/9*
M
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M;5I_@<1XOCU;;W?W%LZ_-&[^*FGF<V,_KLV=_GOCW\94Y[)0
M
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M6.Z6V]VC9?':"ZV>JAKK97112H^&HIWI)%(W61>UKVHJ$EP
M
M
M
M
M
M
M
M
M
M
M
M
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MGN#+/>'Y'%<9.[MU+)43/9#3PJU='(QJHY[?IM4UT+/P
M                                                    5@<#_P"\
M=XB_YU8/LET+/P           ?Q51J*YRHUK4U<Y>Q$1")&2\\>'^)7Z;&KW
MOYC,=WIIUIJJ*CDGKX8I4=T.9)4T<4T+%:[L=U/3I[==-%),8MEF,9Q8+;E6
M&9#;LJQJ\1K+:[]::F*LI*AB.5JK'-"YS':.16KHO8J*B]J&0
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M
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M$A?=J5L>9XU1VE&[T-DJKE>;XZF7J=CZNHH8*=M2JZ=*3ZN6-$\OG*70  K
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M][471%5%5$)-  %8'*3_ !!/#Z_II_ &%GX
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M^FG\ 86?@
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MLM=5SRK%"QK^E711Q0HZ-K'KYWTJ-MF  *P.4G^()X?7]-/X PL_
M
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ML+M==/8)=     K Y2?X@GA]?TT_@#"S\
M                                         %8' _\ O'>(O^=6#[)=
M"S\                                K \2__@W_ #_XQ_SI9^   >;G
M:JKVXHO$FW2J-V*G&Z3"69YN&ERGRU]'':DD6IN*0=ZZO5(>I9.GHZOWVFG:
M=5OS4[97?GG@#^,B6IU$[(<58R?%611VM]\96Q]]+1+2HD*LZ>[5[X_-5_6[
M5>U5M:Y"\Y9-K-WK3L%MCM;5;N;J7)M+Z1;65[;?3TTM9'W\-.B]S,Z218-)
M':]#&-<URO7SD3Z\?.<2[I[N778/<S:RNVBW7MC*E8K5)6MN%-424D??S0]:
M10NCD[G61NB/8YC5<CT\U%JFNO)#?*^<X+%G-XVPRNYY)C%T<_'..-1<ZF2:
MA<^T.A?!3ZTFD;G,>ZH<K:5%5%[?\XL9W-Y7X9C7*7:G:G(^-%CO&:9E4X<Q
MNX-PJJ5+E9ZB^3PLC1K)+5)*Y]"^35ND[%56]G1[&X^6'-+'N,]QQ;#K?B%9
MN/N9F43:BSXA23^BM932RNIH9I94AG>JS3L<R.-D:JY6N[6]FNLMK^?]TN.\
MEDV-WZV4N6R67Y3)3T^.5-16.JH9JBM5&T<4L3Z:!S&SO^ILD8YZ*_1JHWM5
M.VY)\^$X[[U6#:%=H:O.DO5#;*Y;Q07;N*O2X5,M/W-/;_09N^D;W6K&]\WK
M54;YOE,3P[Q$[M+O_:-B]VMA;KM379/=**TV2HJ+BE75PU%R<UE M53^C0M5
MD[I&)UQR*C-?W^BJE?.^O(+>B]<V\7N=UP')V38%E-IEP_8>:Y5#FU4E(L:0
MR4S%ID:Q]PZ4E1R4[ET>B:O1$+,=UN>M1@=WVQVUQS9BZY=OSN'9+1<[EMDM
M:E(VQUEWIV3-MU35/IU=)-$KE1Z=U&B-3J<YFNB=UQRYOQ[P;I9!L9N)MK5;
M2[KV!M4J6>2N;<*:IDH51:F!)$BA='*QB]:)HYKF-<Y'^1%GN  "L#P\_P"M
M3Q!OS_Y#_#JTL_   /,)L?NSL14<\.5F\W*:LQ^YX/1MR6''(<DHEO'75^NZ
M2AMD-%0NAG?.^*W121-TC7HCU54:U%5MGO 3:SA519'G6[G$S/K[D=5<*)UE
MR[&;E4.CCMT594LJX.JWST5+/'HZF<V&15<U6];45RZZ3.Y([R_)\V2S[>/\
M&_PN_ >DIZK\'/3/0/2N_JX*7I])[BI[O3ONK7NW:Z:>SJ5>3>+CF]?M N\6
M.<1+S4XK:+X^SYADDU^5]DH)')!Z-"VN9;&N?-*LZ(Y%B:V/6/SGNDZ6]UFW
MBT7BW;=8EN[@_%O);YMG<JB&VY1FEYN*6Z@IKRK5=/;:.:&DJN_Z-%:E0]&-
M5R=/=Z]B3DH^9.U<G%"DY=7&.X6O JFUNJ_4SV-?<%KF5K[8ZW1-1R-?(M:Q
M86NU1JI]4<K6:JE?7SMFY=+B]!N]=.'=YI-A[M=G6BW9XV^/<DDK'.8[HD=;
M6PO=U1O3IU1O4BQ]YU-52=^\/,K%-O\ BC3<K\'QY^X^*W.*U3VBR2UGJB61
MERJXZ-[)9O1ZSNI*=[G->WH=YS5;K[)!6[>+CG<.UN,[PVWA_>VX#7W62T7W
M*JR_*EK96LD?TTM'5LMFLKGQLU61\;&MDUC1'JW4V5RSYCY7DW!.R;T[#XAD
M]-0;M4DM-<LVM]9)0UF%^AUJ4M3--)3PR=2.J89*5KDDBUZD>UW;TFDO">W3
MW O&T.Z&W5VVUO-1A[HLFRJ3?:JJY9J2LO$D=NIWV=T;Z;19^[>Z=7K4J[1J
M^9^^(*>')R S3C_2<A,AP/92][T7>2PVNX5]';9?1:*UVZV/K)*JLKJA(IWH
MC4E;T1LC57Z.[6].I>EPXYVX?RKV^W!RVOQN3;>Z;3LAGSRWSU25U'#1U$,\
MT5;#4MBA<K'-I)NIKHT5O3Y7:ZD4:[Q8,PR*WY_G^SW%:[YQLKM?40QY=GUP
MOD=ME;%42=$3UI64E1W2N3MT1TJM14<]&(62\:^0F&\G=IK'NOA4%3;Z*XRS
MT-VL=;TK4VZX4KD;/32N8JM=HBM>QS?IF.:NC556IOH   K Y2?X@GA]?TT_
M@#"S\
M             %8' _\ O'>(O^=6#[)="S\
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MH_SFN1S%5R-1[IM@  %8'*3_ !!/#Z_II_ &%GX
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M
M        *P.!_P#>.\1?\ZL'V2Z%GX
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M
M        !6!P/_O'>(O^=6#[)="S\
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M5+C#"VON:75+DJQM15=-W:QZ.=V:^0M"!6!RD_Q!/#Z_II_ &%GX
M
M*P.!_P#>.\1?\ZL'V2Z%GX                               !6!XE__
M  ;_ )_\8_YTL_            !6!X>?]:GB#?G_ ,A_AU:6?@\Y6X5XRCEE
MXD&8; [N;N9+MYM'B]?=+=9<7M%S]60OAM%+WD;8FR:P][6.9W[Y9(WN5GFM
MT:C.G ^%^-85AOBH5F*;=7Z?)\+QRJRNW6&_U-6VNEJ8Z>TU$;WNJF-8V7ST
M<G6U-%TU35.TS+D5_C);<_SKP'^"41N+QQ47\%..SM%Z4NV1HKO8U6"WZ?\
MSC+>=5 N5^%QM)=;!40W6BQ&AV_K[U/2/;,V&-;8R@7K<Q51JI+61HNOMD)\
M'V7XA0<(<*WPWFWKW>JV7"OELU]VGPR_V1[8KG'<9V,AI;3<:5$9TPL;4NZY
M=>E>\3Z9J$H-Y;;MA;?" E79NDS2DVXN%\I*S'&Y^E V^O;)E")+),VV?4$8
MZ5KUBT[5CZ7+Y=29/A/_ -R7;G_>N1?QM4DH>5Z*[BUR5:U%<YVU>9(UJ=JJ
MJV2L*L_!$N-O9MSO;;'UU.VXRY-;IH[>LK$G='Z$].M(]>I6^:O;I["^T:+\
M*S^_UR)_FIEW_:FTG&\8S'T@Y4;%Y/?9ZJUXE>L.M]IJ+S2+T31);;Y6S5KX
M'JCD22**NC<G8NBJG8I\.2>P_ 7:S.\(P;--T^16]659=;X*O'$Q:^8M?VQ1
M5TZPTL2RUM/3]+JAZ=3&LU1R:.]E-=U^*UO!N93[[;%[ V;<&Z[8[:Y=;K=<
M<HO]LJ9*)LTMRN\UOE?52Q/B62.BAITE[M7HW5^KNWI5(/\ +79/:78'E;L3
M@.U6<W?.8V)CM=E-7>KI#=JFGKIKNYK(W24\4+(E?"QDO=Z:HCD=HC7-)C>.
M<BZ<7G:+THN;(KO8U7U#I_\ .,S\42XV^Y^']QUJK;74]PIERS$FI44TK)8]
M4Q6[+IU,54UT5"-?+C_"YX2?[UI_X!<QXBO]R_PX/S?T/_9VQF=>)Q8+C4\-
MN#6410N=:K-9;=;*Z=$U:R>Y8]130(J^QU-HI-/W#7>X>R_!C!./>P6XNZV]
M>^>>Q[F6>WU-#A>)W_'KEZNK&T#'5W317&EB2GBI97+3JG6Y[':,771RFX/$
MEMN-6C@)Q#M^&4E_H<1@K[*N,4F4I3-O<=!)C]3)3)<6TGU%L_=N;WB,[$=J
MG8:IYS?X>G +_=5)_$T1('G"BKX4'%A4151MIVT5RI["?@S(G;_E4GEX:MQM
M]9PKV.IJ2NIZJHH+;7QUT$,K'OA>MVKM&R-:JJU5T7L4G6"L#E)_B">'U_33
M^ ,+/P
M              5@<#_[QWB+_G5@^R70L_
M      *P/$O_ .#?\_\ C'_.EGX            *P/#S_K4\0;\_^0_PZM+/
MP0OWI\/_ (O[^9^NYFX>#5-1EM4R&.^5MMN57;V7-M.QL47IC*>1J.<V-J,Z
MV=+U:B(KE1K=,BPKA-QPVYW;MV]F"X&N+9Q::1*&W.H*ZJBM\5.EN2U=#:#O
M>X[:=.U5;JK_ #U7K[3F9/PYV$R_?&U\B[[B]95;K6>LMU?07QESK8H6SVID
M<=(Y:1DJ0KTMC;JBMT7V3.M\^/NT_([#V81NWB[,CLU-4I76N9DTM+5T54UC
MF)-35$#F/8O2Y45-5:Y.QS7(8IM!Q-V3V4VJRK9;%<<ENFW>;5]7<<GL-_G6
MY,JY:VEIZ.9KUE1/,6*EC1$1.Q4U3M(Z4_A1<*J?(/7?Q>W6>E2;OH\:EOUR
M=;V^149IWW?N:BIY'2KKY%U3L)=[E;";6;L;5_$KEN,L3;5L5!!38S:Y9+;%
M!#:WQOHXH%I'1K&R)8FHC6JB:)IY#LMG-G,"V&P*U[:;:6N:SXA9YJJ>@H)Z
MJ:L>U]9,^HF59JA[WKJ]ZKVKV&QJ^@H;K0UMKN=)#<+;<H)*6X4%0QLD,\$S
M59)%(QR*US7M545%314(;[3^'_QIV0W6I]X=M,8N>/9/1,K([=1>M*FIM].R
MN@=3S-C@J'2.T5CW:(YZZ:]GD33,MH.'.PFQ6XV3[K;;8O66?-<OHZV@OMQG
MN=;5QRP7"LAKJAK8)Y7QLZIJ=CD5J(J::)V*9QOAQZVAY&XQ3XEN_A\&56N@
MG6JM,_>S4M913JWI62FJJ9\<L?4FG4U'=+]$ZVN1$-"[-^'3Q2V/RZWYWB>!
MU%TRVS2I46&\7^X5%Q] F;HK9:>![FP)(U4U;(L:O:O:US3:'(?B7L?RBHK'
M3;MXO+<ZW&72K8;]054M#74S)U:LT22Q*B/C?T)JV1KD1>UNB]IJ9/#:X?Q4
MF$4E%ME+;'8!4R5MCKJ.ZW"&IDJY)8IG5%7.V?KJ']4+.E9%7I1.EJ(WL-];
M\\<=H>2N+4N([NXNF04%LJ'5=DKH9Y:2MH*AS.ATE/40.:YO4WL<UVK':)U-
M71--,Q>'UQG39:BV!K,:NURVWM^5NS2FH)[O5MJ4N[J1]%WJU,#XGJU(9'-Z
M/I?9\IEV:<+N/N?[1X#L?D^*UM;MSMG,V?$+1'=*V&6G>R.6)%?4QRMED\V9
MZ>>Y?*-SN%W'W=_!=KMM\[Q6MN>)[.6V.TX#0PW2MIGTM+%2T]&UDDT,K7RJ
MD5+&FKU5>S7RJIM3)-D=KLRVKI=E<NQ*FR7;:CM=%9Z?'J]\K^BFM\;(J565
M#7MF9)&V-O3*QZ/1>U':D1<1\++AEB.24V2Q[=5N0RT,Z5-#9[[=:NMMT;VN
MZFH^F<]K9FIY.B;K:J?3(I)K?GC?M+R4QNRXENW8:B^6/'[BEUM=+2UM30+'
M5)#) CE?2R1N5.B5R:*NAA>X/"[C[N?MIMQM'F.*UMPP;:B%D&$VV*Z5M/)3
M,C@2F:CYXI6R2_4VHGGN7VS8M_V VFRO9JV[ Y-B<5]VMM-EMUAMV/U4TZR1
M4EIBCAHE95->V=LL38FZ2->C]4\O:I@_'#B)LSQ5_#/XH[?=*'\/%MZY!ZRK
MY*[J2V>D^C)'UHG1T^ER:^WJFOD).@K Y2?X@GA]?TT_@#"S\
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MSX>A'.=U:I"[7VB]0
M                         %8' _\ O'>(O^=6#[)="S\
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M#?G_ ,A_AU:6?@             %8'*3_$$\/K^FG\ 86?@
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MW69>(IPWP9<8]<;TVZM3+**GN5N6ST=?=.YHZE-62U:45/*M,NGEBE1LJ?\
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M_P#X-_S_ .,?\Z6?@            K \//\ K4\0;\_^0_PZM+/P
M     "L#E)_B">'U_33^ ,+/P
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M">'U_33^ ,+/P
M                     5@<#_[QWB+_ )U8/LET+/P"IOQ=>0ERVGV&M.VF
M,7%]NR;>VKJ;=7U,+NF2/'Z&-CKDUKD75JSNFAA7L\Z-TJ'EG !ZR/"KY"W/
M>[CC'C>45[KCF.SE;'C=;62O5\]3:W1)):ZB55555R1H^#5>UW<]2ZJJJ6:
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MM>IS%5.UW2CG*KG*I,8     K Y2?X@GA]?TT_@#"S\
M                                                   %8' _^\=X
MB_YU8/LET+/P#S8>-Q-<';U;.4\CG^JHL)GDHVJGF)427*=)U:NG:JM9%JFO
MM%*0 +W/ ZGN#<LY$4L:?^BIK1CLM:O4J?[1'/7MI_-\B^:^7M]C_*>B
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MZ*-9F1RHL'=Z/;(U'-D5Z?169P    !6!RD_Q!/#Z_II_ &%GX
M                                                          *P
M.!_]X[Q%_P ZL'V2Z%GX!3CXR.Q5RSS9G$-X<?HGUEPV>KZB/(XXNUR62[]T
MR6=6HBJ[N*B&'_O6O>Y>Q%/,B #U.>$/L1<=K>/-TW$R&@DM]_WNN,-UI:>5
MBQRI8[>Q\-L<]KNWZJZ6>=B^18Y&*GE+8    :(Y,[W4''/8W<'>*NH&W9V(
MT,:VNSN>L:5=?63QT=' YS4<Y&NGF9UJB*J,ZG>P4-X7N;XGG(K:W<KD[B>\
MU+C>"[=NN%4_'J?T>W+4LM5.E;5P6RBBH9FSM@B5$UJI45Z^:CI'=19IX:'+
MS+^5.V&6T^Y4E)6;B[:7&EI+S>:.&.F;<**XQR24=3+3PHV..5703,<D;6L7
MH141%54+)P     "'FWO-S9[=?D-?N.FWS+O?,CQ*BNM3E&2R4OHEL@GM-3%
M23TD/?JV>9[99%17)$V/1-6/>BF#YY8^>T_+"P73!,RL]'Q39<[(Z_8Y-%9E
MK7T+(H4NK6OFH7UNKWI(K>F=%_S5;V$^P #R/7SQ/.<MOR"]04V]*+06ZYSP
M10.QK&U8C&2O1D;G):T=VM;I]-K]$]"O)?D?)@/"[)N0N%7%EMNM\Q"UW' *
M_HBJ>[K,C2FCH)F1SL?'+W2U22]+V*U4:O4U4U*=^%'/WEWNUREVBVXW&W76
M_8=E%?5Q7RRK8+#1K/$RVU-3&G?4ENAF9Y\;7(K'IK^XIZ5        "'FY7
M-S9[;G?C".-LC+OD&ZF97BU6J:WT5+W=%:VW9T:PS5=7.L;7:Q2(]&P)(OL.
MZ/*DPP 5@>)?_P &_P"?_&/^=+/P    #6.8[N8=@F;[9[?Y#/507_=JIN%'
MB"Q0*^G=-;8HYIF3S:HD:JV5O1K],NJ)Y#K.0U704.P>]E5=)8H;?'@F1)5/
MF[6*UUMG;TJG;U=2KHC=-55=$\I@_#.DJZ+BOL1#6M<V9^(T-0Q':JO<U#5F
MA7M]A8WMT-/7;_$QQC_^7Z3_ +0U9/H     K \//^M3Q!OS_P"0_P .K2S\
M      K[\16.C3;O8RX79L7J"S;W8G6Y'+.J)%'0I%7Q3/DU[.GZHB+^Z6 R
M2,B8^65[8XXVJZ21RHC6M1-5557L1$0HF@?=*'PGL^K;,CX;3>\MJ'TDD+71
MM2U29/3P*C&Z-Z&.DC5BHB>151?*I>'CE#9[9CUAMN.QQ18_;[=2TUBB@T[I
MM'%$UE.V/3LZ4C1--/8(,\'(H;?DW,&Q61C8</M.]-Z;8*:'LIX9GHU*J*%$
M[$:SHC31$T1-"?X    !6!RD_P 03P^OZ:?P!A9^
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M"S\
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MQ!OS_P"0_P .K2S\              K Y2?X@GA]?TT_@#"S\
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MNI8VPP4\$+49'%%&Q$:QC&HC6M:B(B)HARP"L#Q+_P#@W_/_ (Q_SI9^
M        "L#P\_ZU/$&_/_D/\.K2S\              K Y2?X@GA]?TT_@#
M"S\
M           %)/'/%N0.1<F.?+]D]U\=VVI:7=#IR&"^8ZM]=5R/FN"P.B=Z
M53]TC$1Z*G;U:IY-":_Q9<\_UI-O_P!'R_?,?%ESS_6DV_\ T?+]\Q\67//]
M:3;_ /1\OWS'Q9<\_P!:3;_]'R_?,?%ESS_6DV__ $?+]\Q\67//]:3;_P#1
M\OWS'Q9<\_UI-O\ ]'R_?,?%ESS_ %I-O_T?+]\Q\67//]:3;_\ 1\OWS'Q9
M<\_UI-O_ -'R_?,?%ESS_6DV_P#T?+]\Q\67//\ 6DV__1\OWS'Q9<\_UI-O
M_P!'R_?,?%ESS_6DV_\ T?+]\Q\67//]:3;_ /1\OWS'Q9<\_P!:3;_]'R_?
M,?%ESS_6DV__ $?+]\Q\67//]:3;_P#1\OWS'Q9<\_UI-O\ ]'R_?,?%ESS_
M %I-O_T?+]\Q\67//]:3;_\ 1\OWS'Q9<\_UI-O_ -'R_?,?%ESS_6DV_P#T
M?+]\Q\67//\ 6DV__1\OWS'Q9<\_UI-O_P!'R_?,?%ESS_6DV_\ T?+]\Q\6
M7//]:3;_ /1\OWS'Q9<\_P!:3;_]'R_?,?%ESS_6DV__ $?+]\Q\67//]:3;
M_P#1\OWS'Q9<\_UI-O\ ]'R_?,?%ESS_ %I-O_T?+]\Q\67//]:3;_\ 1\OW
MS'Q9<\_UI-O_ -'R_?,?%ESS_6DV_P#T?+]\Q\67//\ 6DV__1\OWS'Q9<\_
MUI-O_P!'R_?,?%ESS_6DV_\ T?+]\Q\67//]:3;_ /1\OWS'Q9<\_P!:3;_]
M'R_?,?%ESS_6DV__ $?+]\Q\67//]:3;_P#1\OWS'Q9<\_UI-O\ ]'R_?,?%
MESS_ %I-O_T?+]\Q\67//]:3;_\ 1\OWS'Q9<\_UI-O_ -'R_?,?%ESS_6DV
M_P#T?+]\Q\67//\ 6DV__1\OWS'Q9<\_UI-O_P!'R_?,?%ESS_6DV_\ T?+]
M\Q\67//]:3;_ /1\OWS'Q9<\_P!:3;_]'R_?,?%ESS_6DV__ $?+]\Q\67//
M]:3;_P#1\OWS'Q9<\_UI-O\ ]'R_?,?%ESS_ %I-O_T?+]\Q\67//]:3;_\
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MN>?ZTFW_ .CY?OF/BRYY_K2;?_H^7[YCXLN>?ZTFW_Z/E^^8^++GG^M)M_\
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M]:3;_P#1\OWS'Q9<\_UI-O\ ]'R_?,?%ESS_ %I-O_T?+]\Q\67//]:3;_\
M1\OWS'Q9<\_UI-O_ -'R_?,?%ESS_6DV_P#T?+]\R&VX.-[Y8[S[X,,WLW-L
M.Y-552Y8['I['85L3:2-EN5)VRM])J.]5ZJQ475.G1?+J74
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MZ:?P!A9^
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M4ZIHKA3TSV1U$:),R.2&:+O$=T+U(YJ.=JG3H6?@ %7FV7/K+\\YQ91Q0J\
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M
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M9_X,PD6     5@<I/\03P^OZ:?P!A9^
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M,RR9;3-9*_%LFLUVI(*FX5KH:.CED?&BI(YS6R*QO[Q['?OD/24 "L#Q+_\
M@W_/_C'_ #I9^     08Y>;3[U;AYYQJR+9>CH([CM]D=SK+SDUS?3NI;/%6
M14T+*N2DEGBDJ>A&O<D<2.55:B.T137^[VS7)/9_!,CWEP+E7F.;9;@M#-D&
M0XEDU/22V.ZTM&WOZR*"AA8UM-]28]S6LZE73H:YBKUI.+:+<"FW5VOP#<BE
MIVT<>:V&ANTE"U_>)3S5,+7S0=?L]U(KF:_0(B\M<MO.[.48]PRVQKW19'N'
M&RX[R9#3^>F/8A$]CI^\5.QLM7JC&,=],U4:[1)FN)PXKC-FPO&<?Q#':-MO
ML.,6ZFM=FHF]J14U)$V&)NOLJC6IJOL^4[X    %8'AY_P!:GB#?G_R'^'5I
M9^      "N_EKMSRPRJS9W-C>>6NY[+I$ZIO6U5E3U-D=SLL-.U:VWQWA])6
MM1\RM?V(Q$<U>A>I%Z5V/9.0&UN!<,[#O3@%H=08-9\6BI,$Q";MG?<(7K;:
M6UO5BN=))Z8SNI'M5RKHZ3M[5,$M>T-QVAX);XTN4R.K=RLXP#,\NW3NTNBS
M5%]NUHJIJAKW)Y>Y16Q=G8JM5R?3&^>(G]U_83^9%G_@S"18    !6!RD_Q!
M/#Z_II_ &%GX
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M*O8SV-$]@F\     5@<I/\03P^OZ:?P!A9^
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MTLBB8W1&M:B:(B';     %8'*3_$$\/K^FG\ 86?@
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M@V__ .,-=[]'S>>ZG[0;?_\ &&N]^CYO/=3]H-O_ /C#7>_1\WGNI^T&W_\
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M:#;_ /XPUWOT?-Y[J?M!M_\ \8:[WZ/F\]U/V@V__P",-=[]'S>>ZG[0;?\
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M0;?_ /&&N]^CYO/=3]H-O_\ C#7>_1\WGNI^T&W_ /QAKO?H^;SW4_:#;_\
MXPUWOT?-Y[J?M!M__P 8:[WZ=]MSX>U;B&\NW&\V9\GMR=X[SMC/638_;<RJ
MG7&-B5M-)33,CEJ)IGQ-=UHY>C356IJ60@
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M?^57.'\]5U^SU1:^
M
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M25-1B-5-"UJ(CIDHIUZ]=-==9GJOMZ]I8F 50>&/_*KG#^>JZ_9ZHM?
M
M
M,(W-_JVW!_FU=OX'*18\./\ N9;-_P!(?^T5S,'W)_Q*^.WYM;Y__3="8>^G
M]26\7\Q\A_BVH*ELV_P@\1__ '#_ +3R%T&,?R:Q[_=E)]A80%XX?WX^<?\
M1+^!.+%@"J#PQ_Y5<X?SU77[/5%KX
M
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ML:[1$<B)/  J@\,?^57.'\]5U^SU1:^
M
M                                         50>&/\ RJYP_GJNOV>J
M+7P
M
M            "J#PQ_Y5<X?SU77[/5%KX
M
M                                          !5!X8_\JN</YZKK]GJ
MBU\
M
M             J@\,?\ E5SA_/5=?L]46O@
M
M                                            %4'AC_RJYP_GJNOV
M>J+7P
M
M    ?B66*"*2::1L,,+5?+*]4:UK6IJKG*O8B(GE4T[6\C./=MJ9:*X[[;>4
M%9 O3/25.46F*5B^TYCZE%3_ "H<7Y37&[]8/;7\;+/[Z,FQ/>7:#/;HZQX-
MNMAV9WID#ZIUGL5]M]QJD@C5K7RK#33R/Z&JY$5VFB:I[9LD        J@\,
M?^57.'\]5U^SU1:^
M
M               "J?Q6,HS*';S:G;3%JF:DI-T<FEH[TL4JPMJ?1F1-IJ.9
MZ:)W<DM1UN15TUC1?8.OQWPAMD8+-01Y;N-G%SR%L3?6=9:)K;0T3Y>E.KN8
M)Z"KD:W773JE<NAW?S1?&[X;;E?=*S_>8WEQ\X%[0<;<\FW#P;(\QNMZFM51
M:'4M]K+?/2]Q4R12/<C*:WTK^M%A31>O3R]A-L        J@\,?^57.'\]5U
M^SU1:^
M
M     "MKQ/K_ (19-C<;CS#';C=:VORB%,.OMIJV4=99KI!2U$T=8U7QR)*Q
M6M<Q\?F]2+JCFN:UR1+P'Q?[[;;!0V_<;:"');[1PLBJ,BL]U] 95.8B-622
MDEI9T8YVFKE;)TZ^1K4[#.?GB\;_ +![E]WX?>)(_BWX@=GY-[ES[<4.V%9B
M$T%EJKRMVGND=8U6TLD,:Q]VVFA75W?:Z]7L>0L1        *H/#'_E5SA_/
M5=?L]46O@
M
M        ZZX6BTW9*=+K;*2YI22=]2)5P1S=U)TJWK9UM7I=TN5-4]A3B?@Q
MC7P>MG_5(?<#\&,:^#UL_P"J0^X/Q24V+V^Y)24,%KH;P^)SDI8&P15*Q=G4
MO0U$?T^37LT._        *H/#'_E5SA_/5=?L]46O@
M
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MUV;5JLJ(U&.6-U,QR(].W5LB-O*        *H/#'_E5SA_/5=?L]46O@
M
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M5)0+4]#$GG5'NGDT31NGL)T(MW(       !5!X8_\JN</YZKK]GJBU\
M
M                                                       PN^YY
MMWB%5,S)LSQS%ZV;NW5#+G<:2BE=JW2-7)-(Q5U:G9K['D,?N=OV1S^@H\TO
M%%@^:VMCTIJ#+*R.VW*G1Z2=VD<59(DC=4D\W1'?3=GE-DT%)04-%34EKIJ>
MCMT$;6T=+2L;'"R/3S4C8Q$:C?:T0Y8       !5!X8_\JN</YZKK]GJBU\
M
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M#44O>=Y%Y&RM3314>KKGP       "J#PQ_Y5<X?SU77[/5%KX
M
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MEDG<U-&O<B:(CFHET(       !5!X8_\JN</YZKK]GJBU\
M
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M+7P
M
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M.1_G4B/5R*M2R%T<ZQHB_4G=?[U3>P
M
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MV4R.5[[=/U-F16Z(U%E[(VJI,H
M
M                    JZ\4?;:[Y;MWMCFD5LKKUB6W&2OJ-PK?;FN?/'::
MYL39JM&-T[(NYZ5=KYO7KV-ZE2Q+;Q^!RX7CLVV+;0W!)Z..3&TL;(HZ'T96
MIT=TV)$:G9Y4TU1?+VF9@    %<^XCV6WQ+MB*Z[O2&WWO:RYVO&I)=48ZYP
MSW.:=K%7S4>L#VIV+JNJ)[*$R]Z[A:K5L[NM<;Y+'%:*/$+W)<GRZ='<I0S=
M:*B^7J3L1/9\A5#=<6OM9X/MIIYHII+A;:2.]I3]*N<Z@7+'U#'>=TZ-922I
M)KV^:WL[.TMUVUO]LRK;O!<ELM2VKM-^L%NKK?4,5%1T4]-&]OD]E$714]A>
MP@]Q0D@R7ECSGSFURK46'U[C^/4E:U$=%/5VVGJ8*QK)$71>Z?"GL=J/1=2Q
M< J@\,?^57.'\]5U^SU1:^   #RW>+-RG^-_=^'9?$KDE1M[LU4RPW.2!ZNA
MN&2N18ZN5=%Z7)1M5:9FJ:M?WZHJM>A4H7*>$/RH3;G<FMX]9A<^YPW=:I;/
MA<L[T2*BR5&I&V%NNFB7"-K8_+VRLB:U-7N4]-
M
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ML=S2IGA9G=A1MCW*ML:M:L=VIHV]52V--.F*K8J3,T31.IT:*JQN)A
M
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M'?C"VZ.J?$JOHZIM0EWJ49+3O<Y$58G:L?(WLZNI+.
M
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M^O(
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M(72)#%+EU)9:B57=*,AOJ/M,KG+[2,JU5?H'M,
M
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MG)V+YKT[4.]
M
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M%5M5026Z-::C6:-Z(JMFIX6.9(W5CEZD1>IKVMG<
M
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ME@L]MI*FDCJ+=Z-#(D[F5-=7.5>]<]NJ/1.SZ7V5EJ
M
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M,W75B:+JG:G:LB0
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MIH[U8JI4Z7/I*Z%D\*N;V]+NEZ:M7M1>PR<
M
M       A5SKY)WOC=M!3W;#H(IL]S2YML>*3SQI-%1N6)\T]8Z%VK9%C8U&L
M:J*G6YJN1S45JU\V[@AS=WFMT64;N[]2V"LO,25#<;NMVN==4TR2JC^ZEI:=
M&TM/["]W$Y4;Y-$5-$_3_#-Y58DQ;EM_R(HH[O BS1LAN=YM$CGL3S4CF@;+
MYRHKD15T1/)KHJJF^>$/(G?6GW?RWBGR5?/6YIC5ODK,>O->K)*_6F2.1]--
M41:MJV2T\J3Q3*JNZ6KJYR.;TVP        %4'AC_P JN</YZKK]GJBU\
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MM]N.>!SV._R*=\ #H[YD^-8Q3^EY+D-LQZDT5WI5SJX:2/1-$5>N9[$[-4-
MY-S.XGX@C_7?(; TDBU[VFH+U2W*=BHBJJ.AH7SR(O9Y%;J1[R?Q7>%6/=ZR
MAW"NN7S0HO5#9;#<NUR([S6R5L-)&[Z5$U1W3VIVZ:Z1YR;QM-BZ))&XAM-G
M&0R,71CKHZW6J-ZHJ]J.BJ:YR(O9IJW7Z"$>\F\<+-ZE7IAVP-CLJ)V,?>;W
M4W/7M3M5M/2T&G9KV:_Y?;U#)XI7/C<QW=[?XK9Z.1Z]+&XAB=5<G:^:FB)6
M2W+MU:O_ "K]#3\KD/C&;L*ND.[=L](1?.9;8,-;HB+VHK8+8C>QO9IIKV>V
MFMBWAX[%<QMO,EW6K.5<MYN-ESFPT])0RW[*X\AK654%1*CV-6&MK$C26*=[
ME<C_ &$]D\X>\NU.4;(;GYIM9F%*^FO>'7.:A?*K5:RJ@1VM/5PZ^6*HB5LK
M%_S7)[)K$]-OA]<6<AK^ FX>#9A55&&U7).6Z5M%42TRRST-GKJ&GM]+.M,]
M\74Z5L+YF:N1%8^-?W=*2^!E$Z658.3[XX%>Y88Y,+1[VLU\U'.2^L1RHGE5
M&IK[2'S^8Q_^*+\B?_7X^8Q_^*+\B?\ U^/F,?\ XHOR)_\ 7X^8Q_\ BB_(
MG_U^/F,?_BB_(G_U^=76^!M>HY6I;N2=%5P*Q%?)4XK)3O1^JZHC6769%333
MMZO\AP_F.LJ_6)M7XN3_ 'P'S'65?K$VK\7)_O@/F.LJ_6)M7XN3_? ?,=95
M^L3:OQ<G^^ ^8ZRK]8FU?BY/]\#AUO@>YS'$U;=R L57.KT1\=38ZJG8C-%U
M5',JIE5==.SI_P IU?S(>ZG]N&*?<ZN_[H^9#W4_MPQ3[G5W_='S(>ZG]N&*
M?<ZN_P"Z/F0]U/[<,4^YU=_W1\R'NI_;ABGW.KO^Z3-J>&&>;.>&]OQQ_I[U
M19KEM:EPR>WU%EI9F+5LIY:*N6E;%+U/?,]E"Z-J-3MU:B=IY=#^HBN5&M17
M.<NC6IVJJJ>G+=BV\MMC>!'&#%=@K1E*[PX^MIDS.GQFUMNU31V_U7735-'4
MTLD-1U=%1/"Q42-VKX^SV-:_T\33Q"MIGI#N9C=+530.Z)H\WPZ:TN5R=**C
MTHDM>BZJGDT^F_<-PXIXX&;TRPMSC82QWEJJB5$]BO-3;%1%5=7-CJ:>OUT3
M3L5Z:K[*:]DE<5\:SCW<>ZCR[;;.\7GD1.N6CCM]SIF+HJKU/]+II=->Q-(E
M_<0DEBOBA<)\H6.)=W5QRKD\E)?+/=*31-43SITI7TZ=J_\ E?H^1"2.*\F>
M.N;]VW$]\\#OL\NG30TN06]:E.K71'4ZS)*W7I735J>0W7!/!4PQU%-,RHIY
MFH^&>-R/8]J^16N35%1?H'U
M                                                    *J/%5Q^^
M18%L]NG:;<ZYTNU^7]_=X=%=%''6MB=#)/T]J1K-2LC5=?*]$]E"2. <]N+.
M>6*BNR[J6K$*Z>!LE?C^2/6W55)*J)U1.=,C8I%:O[Z)[FK[9D5[YL<4L?HY
M*ZNWSQBIBC8YZQ6VH?<IE1NFJ-AHF32*JZ]B(WM_R*5[<><]@Y0^(QD6]>$V
MJLH\!P?%Y:>.X5D/=R2QK2);8%F1JO:R2HEFDDC8JZ]VSM35KM+K0
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M186SK(BJJIHBM[3<<<D<T<<L4C98I6H^*5BHYKFN35%14[%14/V
M
M                #J[W9+-DEIN%AR&U4E\LEVA=37.T5\+*BFJ(7]CHY8I$
M<US5]I4*_LO\+GBKD]945ENMN2X.M2YSW4U@NOU%KG*CE5C+C#7(U/+HU/-1
M%[$\FF/V;PGN,-LJ6SUMUSK(HFN1RT=QNM(R-R(BITJM%04K]%UU[':_1)W;
M8;1;;;,8XS%-L<1H<2LB.22>&E1SYJB1$T[VIJ)7/FG?IV=4CW+IV:Z&QP
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MJV?>+$*9];3W&2E9035L,*Q=]#4TL361-F:V5LK'PHC)(EU1J=/4^S(
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M:IAM%$R2.1BHYKV.;$BM<U4U14\AG0
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M]O8NDD<5WNV8SKNTPK=O#,M=+IT1V>^V^N>JKKHG3!.]47S5[-->Q?:-H
M IX^+'<GYW[XS/B]R7XN/P:[CXP/5-9ZD[W\&/1^[]8]UZ/U=[]3TZ]>KS?+
MV%PX                                         !5]C?&7>"W>)UG_
M "7J[!31[0WZPPT%LOR5]*Z=\[,?MM YJT:2=^WZO32-U5FG9KY%0M!
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MZP=\B]U54LO2Q9:>56N1%5J.:Y%:Y/I7/F>
M                51^(_P _[KQABM&UVU$=%4;NY10+<JV]UD;:F"PVZ1SX
MH94IW:LDJ9GL<L;9$5C6MZGL<CVHM#=)SXYC45]CR*+D)ELM='-WZ4U14LGH
M%=[2T$C'4JM_T>ZZ?H'HB\//G+\K7$KUCV:45)9MX,#AAER""B18Z6ZT$KEC
MCN--$YSG1JUZ(R=B*K6N5KFJC9$8RQX                           J5
MYR\Y-Q-MMPJ38+8"A;/N"^*E6_WV.C2YUD-5<&-DI*"WT2MD8^9T;V/<KXW_
M $[6M;KJIO#@BWE4^S[BUO*#UXE;7U5MEPUE[6E:]L*LJ/2DCAIM.Z\Y8]6N
M:WV-$/QSGYG0<8\>MN.8C3TEXW8R^GDFM%+5+UT]KH6JL:W"IB:J.>KGHK86
M*J(YS7*Y=&*UU=%EM/BLYO8X-VK5?<O] KX4N-LMRW.VV]]33O3J;)%97R1-
M5KFNU8UT**Y-.EJ^;K-S@9S.R[>RZY)LWO-1LH]V,0IY:J&YI3^A/KX*25M/
M5PU5*C6,BJJ>1R=2-1J.:J^8WNW*MG    !![EYOKN5A%\VCV3V-]!AW=WLN
M<U-07VX1-J(+/;J5&)-5NA>U[%=J]7(KF/:C(Y/,<O2::W1V\YF[ 8%>-Y[#
MRGJ-UJS"*5;QF6!7VP4T-NK*"#22K[A62R.C2)B.<J,[MRL1>E[%1&K+*\<D
ML?M'%OY34EO5ULEQ"ER&GL7>IJM=6LCCAH'3(FB+Z7*V!SD3L[5T7R$8\(VJ
MYK[NX9:-U[_RJDVOR/*Z&*]8UMY9\=I)K5;Z>JC2>E@JUD>USU5CFH]'MD<S
MV72+V&\N(N^.:[I6C<3!MV*2DI-X-DLA?C><RT#492US5Z_1:^)B(B,2?N9$
MT:G2O3UMZ4=T-E\ 50>&/_*KG#^>JZ_9ZHM?     *.?&\PGTW;?8_<:.%FN
M.9)<<=J9T3SU2\TC:N-'*GE1JVQVFOD5>SRJ>=:VW"LM%QH+K;IW4MPME3%5
MT-2Q='1S0O22-Z+[;7-13WEX;DM'F>(8KF%O32@RNST-YH4U1=(:ZG941]J=
MB^:]#)                  4X\V]SJ79WGMQ!W#J;#<LJELV*9936G%K/$L
MU=<[G<Z*NMUNH8&M1R]515U,4>NB]/5U:+IH;!W!Y$^(?L_CU9O#GW';;:Y[
M36.+UCEN&X[>*V?*+5;D5%DEGJW2OI9.X:NLCH:>1$1%>J-C:YR2;W0MF!\R
M>(&11V_(H[!A6[F'Q7BU9+<FQLCMCX5CN%/-7-<Y6-2DJ*=O?HCNSH=H].QQ
M"?8/Q"KW8=H:+&;]Q\W+WCNFU=$S&JC=':NS2W[$KPEIB2!M9ZRE]&=#U,C1
M7_4WIKU.31JHB;8\/JVMW(OF^_+V]918+WEV_=WHJ5<8L52^L7&+;9X.ZI;9
M6R31PRMJNZ=$DC'1M3ICC<WZ;1+,C!]Q=O[%N?BE=AV2/JH[3<)()9W44C8I
MNJGD;*S1SF/1/.:FO80;W>X48M8\+OF2[>W>\.N]AI9*Z2S7&2&HBJ8(&]<K
M(W,BB>R3H17)JKD<J=.B:ZFHN$V?UF.[I?@;+.];-G---$M,JKT,K:2-T\,J
M)["JQCXU]OJ37R(6\@              '!N-LMMXHYK?=[?372@J$5L]#61,
MGA>BIHJ.CD1S531?90T%E7$/BYFG>NR+C_@5743JJS5\%CHZ.J>JJBZNJ:6.
M*5>U/\[V_;4C;E7A1\*LD21U#M[=,.GE[75%COMQ3MT5-6QUTU7$WRIV(Q$[
M$[/+K&W*O!(V9K>\7"MX\RQQSM58EYI[?>&-5=-.R".W*J)V^SKY.WL[<&VQ
M\'C,MJ]Z]K-PH-W<>SC%\%RRTW^ZVZMMM7:ZJ>"W5C*E6QQQRUL:N^IM5&ND
M1JKYKET\L*O%YJ,@FYD7J*\=]ZMI<5L4>*))])Z Z%[Y%B[?I?2W5&O^EJ5@
M%J'@\U&11<OF0V97^JZK"[TW+6IKT^@M=3.B5R(BIV5:0(FNGE\OL+(;?G<#
MQ5J#>W=NBVNH]SI]N*3+[S%@\M)B]+/3+:VULJ4OH\JT#UDB2/1(WJY5<S15
M5==34_QE^,E]K=U?Q3I/O</C+\9+[6[J_BG2?>X?&7XR7VMW5_%.D^]P^,OQ
MDOM;NK^*=)][A\9?C)?:W=7\4Z3[W'\2Z>,C>56X]UNM#WZZ+&M'24&G0G3V
M4_=P]/D_S4U\OLG]_P#EDO\ WJ_^:#_Y9+_WJ_\ F@_^62_]ZO\ YH/_ )9+
M_P!ZO_F@_P#EDO\ WJ_^:#_Y9+_WJ_\ F@_^62_]ZO\ YH/_ )9+_P!ZO_F@
M_P#EDO\ WJ_^:#_Y9+_WJ_\ F@_^62_]ZO\ YH?S\'?&1R%4B](W6IUID5VO
MK2DM:+U=GTWI$'7Y/)JNA_?BT\9+[9;J_C92??$?%IXR7VRW5_&RD^^(^+3Q
MDOMENK^-E)]\1\6GC)?;+=7\;*3[XCXM/&2^V6ZOXV4GWQ'Q:>,E]LMU?QLI
M/OB/BT\9+[9;J_C92??$?%IXR7VRW5_&RD^^(^+3QDOMENK^-E)]\1\6GC)?
M;+=7\;*3[XCXM/&2^V6ZOXV4GWQ/XNT_C(W'_85NNZT?I2I'UIFE)2Z:KY>_
M2Z1]'[O4G[I_?DT^,E\(]U?TL4G_ +0CY-/C)?"/=7]+%)_[0CY-/C)?"/=7
M]+%)_P"T(^33XR7PCW5_2Q2?^T(^33XR7PCW5_2Q2?\ M"/DT^,E\(]U?TL4
MG_M"/DT^,E\(]U?TL4G_ +0CY-/C)?"/=7]+%)_[0CY-/C)?"/=7]+%)_P"T
M(^33XR7PCW5_2Q2?^T(^33XR7PCW5_2Q2?\ M"/DT^,E\(]U?TL4G_M"?Q.%
MOBOUO^V5>3YBRJJE66I;4;E1OEZWKJ[O'-NCT5VJ]JHY?W3^_(D\5?X4Y7^D
MAOWR'R)/%7^%.5_I(;]\A\B3Q5_A3E?Z2&_?(?(D\5?X4Y7^DAOWR'R)/%7^
M%.5_I(;]\A\B3Q5_A3E?Z2&_?(?(D\5?X4Y7^DAOWR'R)/%7^%.5_I(;]\A\
MB3Q5_A3E?Z2&_?(?(D\5?X4Y7^DAOWR'R)/%7^%.5_I(;]\C^?-]^)K?E6>\
MY9<F3P(D<2W+/GSO5GE\QT=3/HFJ^150_OS;WB.?##\MZCW8^;>\1SX8?EO4
M>['S;WB.?##\MZCW8^;>\1SX8?EO4>['S;WB.?##\MZCW8^;>\1SX8?EO4>[
M'S;WB.?##\MZCW8^;>\1SX8?EO4>['S;WB.?##\MZCW8^;>\1SX8?EO4>['S
M;WB.?##\MZCW9_%\,SQ#+NJ4%TS"D2BF765U=F55- BM3J;U,8DKE[4T31J]
MO_*?WYIGG#\-\4_&:Y>\A\TSSA^&^*?C-<O>0^:9YP_#?%/QFN7O(?-,\X?A
MOBGXS7+WD/FF></PWQ3\9KE[R'S3/.'X;XI^,UR]Y#YIGG#\-\4_&:Y>\A\T
MSSA^&^*?C-<O>0^:9YP_#?%/QFN7O(?-,\X?AOBGXS7+WD/FF></PWQ3\9KE
M[R'S3/.'X;XI^,UR]Y'\3P5>4ZHBKGNU;55-5:MUO>J?0[+&I_?F5.4_P^VJ
M^ZM\^\9O7C+X4'(39O?S:O=++LOVXN>.8-?8;K=:&V7"[35DC(FNT[B.HM$$
M:O1RHJ=4C?)Y2&?BRX_D%GYJY[=+Q%*RV979\?N6*2/ZNA]%#:Z>@D[O7LT2
MKI)T5$]G4K8+=_!BQW(J_D[E626YLL6/X[@M=!DE6B:Q.=7U=(E+3.7V'/?"
MZ5OT(G'J%                           *+<0J+/BOBV9=^'<T-)472MK
M(\6JZY?,2KN5FB=0-9(_1&NDAD6*/_2<C&]JH73YSF^+[;XC?\YS.[0V3&<9
MHY*V[7&9>QK&)V-8WROD>[1C&-U<]RHUJ*JHA0QQCQ&\\Y^865[Z;@6Y\^WV
M'5T=XFM-5]4IVI$JLL5G1%U8YK&QI),B)TO1C^I$67M]"11EA]5;JKQ@;Y+A
MDD3[(M5<XKXZC5%B6HBQ)S*]'_Z27%J]>G[\O-    *M.2&?XEMGSXV)SO/K
MLVTXKA^V=^KYJJ3KD[N65ESIT2&)NJOEFZFQM:U-7*J(;"NW/NQXY+1UNYG'
M?=7;W;*]RI20;@9!8^BC:V?S6.JZ='.5C7HNO2CGN5/I6N/[XBUPMU5PHS"L
MQVI@EL-XFQR:@GHE;Z-/237.DGB='T>:K':->FG9Y%)U8LUK,8QQC&HQC+71
MM8QJ:(B)"Q$1$0@5QMD?'S<YSTT;E93RR8C++"WL:Z1M%+HY43V4ZW=OT5+$
MP"J#PQ_Y5<X?SU77[/5%KX    !7IXI6%IF/"S<^:.)):W#JBT9'0(J(NGHM
M?##4.15\FE-/*O9^Y[)Y#CV6>'CFBYWPRV%NKY%?/:; [')F.<CG,]05,UKC
M:OM?4J9BHG^:J$T                  59<C;;15?B7<$WWBG8^VNLF6OI9
M)D^IK64=OK9Z?I5>SK9-W3D^CTE@&]<=#+LUNW%<T8MMDPR_-N"2KHSN%MTZ
M2=2]FB=.NI2M57?(L?\  ]M+J:6H@JKG%);ZRJ:]RO9;JW.9VJWJ:JZ,D@<V
M)47LZ'])=EM%C%BPO:S;G%,8I(J*P6#&[916JGA1$;W,5+&B.U3Z9S_IG.\K
ME57*JJI7YQ_HX,0\2[F7B.-0I08QDN*8YE5[ML&J4[;S)#1N?*K4[$?,ZMGE
M77M57N5.PM'!\YHHYXI8)F))#,QT<L;O(YKDT5%_=0H?V7E=9=\]N61O5_<Y
M;04/6B(BJV:J;3*NBZ^5']I?(                 "O?GGP3LW+_';/=['=
MZ;$MV\,@F@QJ_P!5&Y]'74DBK(MOKUC19&QI+Y\<C4<L:N?YCNM4*)V>%%S<
M??5M#MM+9%;^^[K\*'9%9_0>G_RO0VJ6KZ?_ -WZO]$OHX)<';%P_P 2NM1<
MKK!EFZV9LA;E^2TS'-I*>"%5='06])&MD[EKEZGO<C72NT<K6HUK6SX
M                                    (H\L>(&V/+G#*7'LU2:QY+87
M238;GEO8QU=;9)43O&*U^B302]+>\B<J:Z(K7,>B.2G2D\$+<UV0I3UV^6,0
MXIWNCKQ!;:V6X=UK],E"YT<75I['I.GT2ZWC+Q@VSXJ[?-P3;NEGGEKI6UF4
MY37JU]?=JQ&]/>SN8C6M8Q/-CC8B-8GMN<]SI&
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M:7+:7"-\-C[T^^;<WJO1WH4RS+"M125+F,E<UKUIXW(JQO;YJL<WID<J1XW
MM'B:[]81<-E\CP;;+:"Q9A3>I\_W/M]UEK9)K94)W=:RAHF3SR1]]$KF*UZ>
M<B]*/CUZTF7>>+>!7?BT[BDZ>HAPQN)T^-4UWZ&/JF3TB,DAN+F=C'2I51MJ
M%3L:K^SL0C'@+_$8V3PVR[3MVLV\WQI,3I([1BFZ*9(ZSN6WTS$BI/65%41-
MEEDC8C6N6/17(WM<YVLCMO<2^-F<;3WK=C>'>S*;;F6^^^5QIJS,*VS1O9:[
M;143',I+=0K,QDCF1H[I5RHFK6QMT7HZWS6 *%ML_P"O;;_^?EJ_C2(OI
M               *E/CNW8^=C^)/\.KG\5/X.^E?@-UM]![[\&O2^OIZ>K7O
MO/\ +Y2VL                                          I.P^YW)WC
M3[JVQUPJ76V/%J=T=O65ZP-7\%+.[5(]>E.U57R%V(
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M7-RZ>71-?(BGI'                     !0MMG_7MM_P#S\M7\:1%](
M              !2!_\ 9M?Z*_\ U)%WX
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M5HZ"NIZF5&-5$5W1$]SM$54U70R0        J@\,?^57.'\]5U^SU1:^
M #R4>+#A7X(\S\VN+(EAIL^LUER.F9^]76D;;I7-_P"^FH9%7Z*K^X8MX8F:
MIA7-+:1TT_<4&5NN6-U^JJG7ZPH)VTS/\M4V$]@
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M%<O3;ZR*H<G2GTR*C%14]E.P]W#'LD8V2-R/8]$<Q[5U147M145/+J?H
M                 H6VS_KVV_\ Y^6K^-(B^D
M
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MHM0\LI[@N+6:_&)QOV-S-\JSU5[PFRONDJ^S6Q4<<-9[*ZHD\;T13?0
M               !0MMG_7MM_P#S\M7\:1%](!AU5N'@%%4U%%6YSC])64DK
MX:NDFN=)'+%+&Y6O8]CI$5KFJBHJ*FJ*=S9\BQ_(HYIL?OMOOD-.Y&5$MOJH
MJIL;E35&N6)SD153V%.X
M                                               ,3J,^P6DR*+#Z
MO-+#2Y;.YC8,7EN-*RXO=(WK8C:1TB2JKF^<FC>U.TZW/[1M==J&VING;,6N
M=LI*OOK0F5044T$57W;V]<'IS5:V3NW.35O;TJOL:FLOP8XD_![:+_JEA]P/
MP8XD_![:+_JEA]P9AA%FV(H+RZ?;>TX%19"M,]KYL;@M<=;Z.JM[Q%=1M23H
MU1NOL:Z&VP       "J#PQ_Y5<X?SU77[/5%KX     (K<X,*^,'B/R!QM(6
MU$R8?77>D@<U7==19$2ZP-:B:^<LE(WI_P!+0\5AZR/"1S5,KX:XS9W3+-/M
MYD5[QV97*KG(CZA+K&BZ]NB,N#43VD1$]@LT                     *&L
M B6@W\PJ&J<V-:+/[:RH>JZ-;W=UC1RJJZ=B:>R7R@%/G&OCCLIO=NQS/NNZ
M>!TN7W"Q[SY!26JIJ*BKA6&&2OJWN8B4T\2+J[M[44^O)W8C >(%WV=Y$; T
M-7M_6V[-K9CV:XW15M3-1W:U7!)'S,?'52R]JM@[M6HY&KU=>B/8CBWX  J6
MV:VPK>>'X:[Z;QYUEM/MW5Y'7VG:3;2R7*2VV^FM="Y&,JIV1M57S.55:KNQ
MRN:Y7:MZ&MS[:R#,.+_*W'..LN<7_/=G-Y,<K[MMRS)*E:ZMLMTM+):BII8Z
MA6HO<]Q Y>E$1OGL_?(Y7V5D#N96<;A5N3;%\<-K<DJ\+R+?F\UD>19E;U5E
M9;K%:8XYJU::1%:YDCV/<]%8Y':1JW5J/U-7[H<(Z?:3;[)-T-A=UMQ+!NQ@
M5MJ+_3W*MOCJV*]+01K434]= Z-K)%F8QR(FB,5RZ/:YJJ;[^4[-\BOY37J^
M+UU^!GK'U;TN]']=]7H'1T_3=SZ=]'7H]DT)M?PCI]V]OL;W0WZW6W$O^[&>
MVVGO]1<J*^.HHK*M?&E1#3T,#8W,C6%CVHJ:*Q')HQK6HAM#AKG&X5%DV^G'
M#=+)*O-,BV&O-''CN97!5?67&Q7:.2:B6ID57.?(QC&O57N5VDB-U<C-33V/
M87>N<>[^^%VS_.<HL6QFT>43X/A&!X[7OML%QKK=JE965RM:JO7M9(W5.M$D
M1O4U&*UW846.Y'PPY';,8?C6<Y)E>PF_E55X]+B615KKDZQWJ)K%I9*.5S45
MC)'2L;HB=K4?WBN5L:I,#D3NSFVUV,66';+;BMW/W&S>Y+9,0L,"HRE@J%@D
MF=65\FK593PMCU<NK4]ASV(O4D/N$-9O#2\B>5.(;R9]4YODU@BQVHN'14S/
MM=-57".>JFCM]/(J,AC9WB1HC&-14:G8GD+0P
M                                                       0BRGA
M;;,GY5V;E%)N!54=?9ZFWU#<.;;V/AD6@HVTB-6J6=')UHWJ_P!7V>0S_E-Q
MBL7*7$,>Q"_Y17XK38]>$O$-9;X8IGR/2GEI^[<DO8B:2JNJ>T09^9\VV_MB
MR7_J%'_W1\SYMM_;%DO_ %"C_P"Z2%XS< </XS[C3[C6+<"\9-6SV>JLZVVO
MI:>&)&54D,BR=42]6J+"B(GT2?X       !5!X8_\JN</YZKK]GJBU\
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MQ\X_Z)?P)Q8L
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MU5(^5Z(JIJC$\O\ D]M"Q,KIXX?WX^<?]$OX$XL6
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M!94^9E/34V:6RAN51(NC8Z.Z3);ZIZK_ *,-0]3VR@
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M9)W^KJ9T4_?1(FL>CE[-?*2_
M                                           -=;K;4X/O3A%UV^W#
MLZ7G&[MT/DB1[HIH9HG=44\$K-'1R,7M14^BBZM5473G'+B9@G&W'L]Q+';O
M<LLQO/*QM16T&0,IIG,A2!:=U.]88HF2M>QRH[5B:^T0DSWPA,!O>1U5SP#=
MFYX+8*J596XW76IMZ[CJ758X*GTRC>C$\C>\1[D3RN=Y27/%KA-MEQ;FNM\L
M5QN&79Q>Z1*"X97<VQQ=U2];9'P4E/$FD3)'L:YW4Y[E5J>=HFA,H
M J@\,?\ E5SA_/5=?L]46O@     %(_C<X5ZPVFV7W"9$KWXKE5;89)&_O8[
MY1>D:N33R=5K1-?85=/9/.)1UE3;ZREKZ*9U-64,S*BDJ&?31RQ.1[')]%%1
M%/>/@654N=8-A>;T*L6BS&Q6Z^4:QZJSNKA2QU+.G7MTZ9$TU,L
M           !0SM\]:[?O")*EK9%K,_MKJABHBM=WETC5R*B]FBZ^0OF
M
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M($>R#PY<V7.N&&QMPDG6:KL=HGQNJ8Y45T?J2KGM\#%T_P#N$,;D_P!%4)N
M                    H6VS_KVV_P#Y^6K^-(B^D
M
M          %'.YE%2WWQ<<'H+O RX45%-9YZ6FF35K)*2Q.K8'(GMLG:DB?1
M+QBC7:6W4F(^+1GMEQZ)+;:[E+>Y:VCB1$8]:VSMN4R:(FB(M2O7HA>4
M     50>&/\ RJYP_GJNOV>J+7P     #7.\&%MW'VFW.V_>Q)/PWQ2\6)C5
M]A]PHI:=BHOL*CGHJ+["]IX2WL=&YS'M5CV*K7L<FBHJ=BHJ*>F'P4\U];;"
M;EX-+*LE1AN:>GPM7R1TEXHH>[:G;_Y:CF=_E+F0
M4+;9_P!>VW_\_+5_&D1?2
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M_)KY2S3P2\T6V[T[NX"^560Y;A]/>&,U7I?/9*YD3$T\BJC+C(J?013TI
M                  H6VS_KVV__ )^6K^-(B^D
M
M                   %4'AC_P JN</YZKK]GJBU\      'DS\6O"_P3YF9
M5=61I%#N#C]DR.%B-Z4\VG6UR.3V^J2WN553V57V37WAHYK^!'-+9FHE?TT>
M25==CE:SJZ>OUK0ST].FOD[*E8ET]G33RGL-                    !0MM
MG_7MM_\ S\M7\:1%](
M                                                          *H
M/#'_ )5<X?SU77[/5%KX      //AXX.%]W=]@MQ((U<E91WO'+G+THB,]&D
MIJND;U>5>KOY^SV.GZ)25MEETNW^Y.WV>PZ]]A&2VF_Q=/:O5;:R*J33Z.L9
M[P(9HJB**>"5D\$[&R0S1N1S'L<FK7-<FJ*BHNJ*A]                "
MO,G?C=K%LQV3XY\>I:"V;Q[^5U:V#+[E VK@L%HML:255:E.]KV/>C.MZ=3'
MM1D4GF*Y6Z:*W;VVYS\9< OV^6*<NZC>UN TBWO.MN<KQNDIZ*OMU*G>5KJ:
M2*::2%(V=4BLC=&[H1=)-6HUUDVSNY5LWBVKV^W3L].ZBH,]L-%>8[>]Z2/I
M7U437RTSWHB(YT,G5&JHFBJTA]SZY#[D;6V3;_:_82Z14&^>ZMRGGMM<M-35
MRVK'[+"^LNMP?!513PZ(QB,^J1KJSO7,\]B:;+X%;I9WO3Q.VIW+W+OOX2YM
MDOKWUW>_1:6C[[T.^W"B@^H444$+>F&!C?-8FNFJZN5567X!0MMG_7MM_P#S
M\M7\:1%](
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MKO(UC$U<J_N(A1#LI"^^;Y[<O9&YBS990UZQM5%5J05+:E4U735$1G:7Q@
M
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MKG4-TINI$U8O2^.2-Z-?&]BIHYCVHYJ^5#- "J#PQ_Y5<X?SU77[/5%KX
M   (Q\S\)^,/BEO[BS8?2*B?#+E<*"#357U=IC]8TS4^BLU,Q$^B>)\]77A#
M9LF4\/+38G3I)-MUE-ZL*QJOG-CGD9=F:Z^Q_P"D%1%\G9I[&B6A
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M=U5N1>B2X543H8XDU31RMCD>]=/I?-]M"W$
M
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MHVGHWWJGGEJXXVZ^:U$2%C$1/I6?N%C8!5!X8_\ *KG#^>JZ_9ZHM?
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M[1J=KG+VJJ]JKVJIW0
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M5SD<WIM@    (#\S:^X[GWS:CB)B]=)27'>6XI=MR*ZG>B2V_#[-(D]4]?\
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M';)EN*W6"^8WD='%<+'>*956&IIIVH^.6-51%T<U=4[#O@
M
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MPS&MNL1QS!,-MOJ?%<2M\%KQZU=]-4>CTE,Q&11]]4/EE?TM1$U>]SE]E3*
M                                     4N9/B'C-29)D,F,[IXO3XW)
M<ZMV/P24^*J]E"LSUIFN62T.?JD?2B]2JOMKJ:CENGC00Y?2X=)N!;VU=9=9
M++!>%M&*I;EK([2EY5OI"V?Z5:=51'HG3WC71Z]2:&ZL%Q+QC(<WPZ;.=T,9
MJ\*BOEO?F%)%3XLDDMK;4QK6L8L-H9(BNAZT3H<CO:5%+E0
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MWR2R+K)-/+(KI)9'K],YZJOD3R(B)GP!5!X8_P#*KG#^>JZ_9ZHM?
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M69;07Q:2P6>VTE321U%N]&AD2=S*FNKG*O>N>W5'HG9]+[*RU
M         -'P\A-KZC?RLXWMO;%W/M^-Q9.^W+T]UW,CU:M,CU=KZ2V%6SK'
MIKW3NOR(IO
M                     %8')GC%S1W+W?O^7[-\A?B_P&OIJ".UXO\ A9D=
MJ[F2"ECBJ'>B6ZEE@;WDK7.U:[5==5[307R)?$B_6Y_+[,/>(^1+XD7ZW/Y?
M9A[Q'R)?$B_6Y_+[,/>))GBAQPY?;4[H5&3[Y;\_&3A<ECJZ&+'OPHR"\=-=
M++ Z&?T:YTT,*=#6/3JZNI->Q.U2R,        J@\,?^57.'\]5U^SU1:^
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M^MJ<+W7Q"9'VC+[>RI?2=:/DHZINL=51RJG[^GF:Z-WMZ:IV*AM@
M
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M"?X       !5!X8_\JN</YZKK]GJBU\       %(/B[?UI\$OYU7W^'8T7?
M    'RGFCIH9JB95;% QTDKD17*C6IJJZ-157L3R(AY&.:5?R-Y2;\Y/N'\2
M6XT.(T*^I=NK5+C-U:M-9:1[NY<YGHWFR5#W/GD1571SU;KTM;I$[Y/>_O\
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MM]=D5C]>7V3TVAIZF.2IINB2F1CN]C:YFCET77M["Y4
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M&,PMM/=;)6M[%?!4L1[4>W5>E[=>E[5[6N16KVH9:
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MJ>Y62ZT][I&S4U72R-F@FC7U?V.8]J.0M'1%1$155RHFBN735?H]FA_0
M             "@;Q7[CR0WGS*P[,;7[);E9%MA@B1W._7ZSXQ=ZNWWB]U$?
MU/NIX*5\<L5'"_I:YKM%D?*BIYC5*>_DG<I_U:=U?Q-OGO,?).Y3_JT[J_B;
M?/>8^2=RG_5IW5_$V^>\R]3PF<@Y 8%;<EV WDV>W"Q+%*=);_MQD^0XY=:"
M@I)'O3T^V.J:JG9&Q)7.2>%JJB=7??OG-0NI
M   !@>=[H[<;7V]+IN)G-DPRB>USH'W>MAIGS=/E2&-[D?*[Z#&JOT"O+=3Q
M7=B<1])HMM['>=U;I&BI#6-8MGM2N3LT6HJF.J%T^A3*B^PXZ?AES)WYY.;W
MW.CR+%Z+']JK?8*ZH8RT6Z=U.RN9-3MIV5-RG6363I>_S6JQ'>7H["V$
M    J@\,?^57.'\]5U^SU1:^              =5>[%8\FM598LDLU#D%DN#
M6LK[/<J>*KI9VM<CVI+#,U['HCFHJ:IY4136GR>M@O[#MO\ \6;5[V'R>M@O
M[#MO_P 6;5[V,DQ?:S;'![A-=L+VXQ?$+I44[J2HN5DL]%;ZA].][)'0NEIH
M8W*Q71M<K5735J+["&>
M           '55M]LENF2GN%YH:"H5J/2"HJ(HG]*^1>E[D71="D/QC;S9[E
M\E;U==:.O]'RF[NG]&GCEZ$7U;HKNARZ>1?*78_A9BOPFM7_ %V#W9W5/44]
M7#'4TL\=33S)U13Q.1[')[;7-545/W#[                    K,QWE+NQ
M<O$LSWB]55EL7:G'K%#<+=2-HF)7),^P6ZXJKJK7J5.^J7KIIY-$]@LS
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MU) QL<<;&]B-8QJ(C43VD0Y        !5!X8_P#*KG#^>JZ_9ZHM?
M
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M5<X?SU77[/5%KX
M
M             !J7<C8C9O=Z"6'<G;>Q99+*Q(_6=72,;7L:B:(D5=%T5,?9
MV>9(A77NCX2.U-^[^MVISF\;?UKU5S+3<V-O-N3VF1JYT%3'_P!\Z63]PR7A
MUQ\Y;[![MU%BW*S67,-DTQ^MAM;Z6]R5UN@KDFIUI6LH:U8ZB!RQI)_JX^A.
MU%=VIK:2        50>&/_*KG#^>JZ_9ZHM?
M
M                                              *H/#'_ )5<X?SU
M77[/5%KX
M
M      !!#?/Q"]E^/^X]WVOS+&,UN=_LL%)45599:*W34;FUD#*B-&/J+E3R
M*J->B+K&G;Y-?*:A^=TXW? G<K[FV?[\CYW3C=\"=RON;9_OR/G=.-WP)W*^
MYMG^_)O+CYSTV@Y)9Y-MY@V.9C:KU#:JB[NJK[1V^"E[BFDBC>U'TUPJG]:K
M,FB=&GE[2;8       !5!X8_\JN</YZKK]GJBU\
M
M                                      U?DVR&R^:WBHR',MH<*RV_
MU;8V55\O5@MU?62MB:C(VOGJ())'(UJ(U$5>Q$T0Z#Y,O&[]7S;7\4[/[U'R
M9>-WZOFVOXIV?WJ/DR\;OU?-M?Q3L_O4R;$]FMH,"NCKY@VU.'89>GP/I77B
MQ6*WVZJ6"16N?$LU-!&_H<K456ZZ+HGM&R0       "J#PQ_Y5<X?SU77[/5
M%KX
M
M  ('<_\ D%FFQNU^.VS;)W=;C;H7E+#CM:UC)9Z6)&=4\U-$_5'3*Y\<3-6J
MB*_J^F1I6?O/QNYM;2[1Y'OCN-R+N4J65M!-><=I,JOE57M=<*RFH8X^\T9
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M
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M]V(N?'JO2KFT+T:JIY-41RZ?NEB8!5!X8_\ *KG#^>JZ_9ZHM?
M
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M+$P"J#PQ_P"57.'\]5U^SU1:^
M
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ME<K41R-15Z>I9C@%4'AC_P JN</YZKK]GJBU\
M
M                                    &@^0?([;[C3C5ERO<2&[SVN_
M7-+30ML]-'4RI.L,D^KVR30HC>F)>W5>WV")7SKW%_[7YQ]R:7W\?B3Q8.,+
M&/>VUYS*YK55L3;52(YRHGD3JKT35?HJA'_C'NOD/*OG]<][,?QRJQO!<0Q"
MHM=1'-H]R43HW04D=7*SZGW\]1*Z9&(JZ-8J(KDC5Q=H        50>&/_*K
MG#^>JZ_9ZHM?
M
M           !@^=[9[?;H6ZCM&XF&VC-+7;ZGTRAH+Q2QU444_0Z/O6-D141
MW2Y4U]I33=OXM\2;MZ6EKV8V]N2T$SJ:N2EMM%-W,S>UT<G0B]+DU[6KVGXN
MG&#B+8XXIKULYMU9X9WI'!+6V^AIVO>NFC6K(C45>WR(;SPS"L(P.R0V7 ,6
MLV)6!5[Z*W6.C@HZ9[GHGU56T[6M>YR:*KEU5?*JJ98        50>&/_*KG
M#^>JZ_9ZHM?
M
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M/#'_ )5<X?SU77[/5%KX
M
M                   ( ^(9LQG6YNUN+9AM;237#</9O((LFLMOI(DEK)X&
MM^KMI&:*KY8WLBE1B(JOZ%:UKG*U"L7=OE-R5YL6NQ<>\>VH=9*^>X4RYI06
MEE4Y:NJ@5'1K6>D-1**FBD3O7-D<NBM:YS_-+2[C46KP]>'U!/9\;BSBJPOT
M)E]IVU:V]+C=;M51QU=4LZT\[D:V27S$5FO=M:S5--2(W"2#=3DMRERGE_G^
M._@]C-ML\MKQ9T,<L5')420LHHJ:C=*O5,R&G[UTLFJIWCD[$ZM&W3
M  %4'AC_ ,JN</YZKK]GJBU\
M
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M]5U^SU1:^
M
M        0>RC%^&D_*'\,LMRJUV?D3C<EMJ(Z2YWJHMJJ]M&QM'W-//)%33J
ML#F]D?5]'MU)"[N;';4[^V*U8_NIC"9=8[36I<[72MKJVB1E1W3XDE22@J*=
M[O,D<FBN5.W734C[\W'PR_L;_*'(OOF/FX^&7]C?Y0Y%]\S9FU'$3CQL?E$F
M9[7;>_@QDLM#+;9+EZVNU;K2SN8^2/NJVLGC[71M77IU[.Q?*22        *
MH/#'_E5SA_/5=?L]46O@
M
M                  %>O)GP[]O>1F:7/<A^<7W#,VNU/34U7-'%3U]M<VDA
M9!$[T1R0RZHUB:Z3HB^TA"V/A1SVX\O?5;";OMR2STVKH+%;;J^A2315762T
MW76WN7VOJCE[5_R]S2>(!S"V,?%0<CM@'W>@@5&27]]%4V&:;5517)611U-!
M+HOD2.)J>QKVZI+/;7Q.N,.=+!2Y!=[KMC=)41O<9%1.=2N?[*,K*):F-K=/
MWTO=I_E)TXIFV&YW;4O.$999\OM*JB>LK+6P5T"*OL+)3O>U%^@JZF3@
M   %4'AC_P JN</YZKK]GJBU\
M
M                        '"N-RMUHHY[C=J^FM=OIF]5375<K((8V^V^2
M16M:G[JD2-QN=W%# &5=#=]T[9E%8C71RV?&XWWOO=4T=&LM*V2F3VE1\J>T
M5'[W<F>,6]-PJK+MCPLCR+)[FKDH,@:Y]FN$DOD;(ZAQY'/J%5=/IY_H*;L\
M-SC7OIMYO1<MSLZVUK\!PVOQJX6^G9<G-I9DJ*FHII8H4H9Y75B-:V)W;(SV
MM7*I>0        50>&/_ "JYP_GJNOV>J+7P
M
M                                  "H/EENYSFK]]<GVBXYV2[IB5LI
M;:B7VRV6)Z]Y6T44\K9[O61O@@5'O716OC5$]DT99O#>Y8;T5M->N0N\*6AB
MKUK#=;E593=(%735K(DE2E8FG8G14Z)IIIH3/VU\+GC3A7<565T]ZW1ND?2Y
MSKU6.I:))&^S'24'<:M_T99)$)W8;MW@6W5O2U8%A=DPVW]*-?2V:@@HFOZ?
M9D[EC5>[7M57:JJ]JKJ9D        "J#PQ_Y5<X?SU77[/5%KX
M
M                                                           !
M5!X8_P#*KG#^>JZ_9ZHM?
M
M                               *H/#'_E5SA_/5=?L]46O@
M
M
M %4'AC_RJYP_GJNOV>J+7P
M
M                               "J#PQ_P"57.'\]5U^SU1:^
M
M
M   50>&/_*KG#^>JZ_9ZHM?
M
M                              .!=;I;K';+C>KQ70VRT6>EFK;I<JEZ
M1PT]-3L62661[M$:UC&JYRKY$0@*GB VV^1U]_VYX[;K[D[<6J66.LW%M%ET
MHI6P*O>RTK'.UD:Q$U7K5BM3Z=&DM]G=X\#WVP:@W!V[NCKC8ZR62FJ(9V=S
M54=7#HLM+50ZKW<K$<U53545%:YJJUS57:0!5!X8_P#*KG#^>JZ_9ZHM?
M
M
M    (1>(O?JRP<0-UGT$CX:B[>J;6Z9CM%;#5W2E9.U?;1\76Q4]IQ*/:_&[
M7A^V^!8M9*9E):<?Q^W4-#"QJ-1&0TT;4543RN=IJY?*JJJKVD(>)<-/BO*G
MG+M_:8_1\?BR"PY%04$>C(:>JND%3/6=$:)HG>.D:G9V(C$30L8 *H/#'_E5
MSA_/5=?L]46O@
M
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MPLV5^MR^\AZF\8'X6;*_6Y?>0]3>,#\+-E?K<OO(>IO&!^%FROUN7WD/4WC
M_"S97ZW+[R-([I;R^*1M#F.S^#Y7D^U,EZWNOK\>PUU!1NF@;5L6!JK5/?3Q
MK&S6H;VM1WL]AN[U-XP/PLV5^MR^\AZF\8'X6;*_6Y?>0]3>,#\+-E?K<OO(
M>IO&!^%FROUN7WD/4WC _"S97ZW+[R'J;Q@?A9LK];E]Y#U-XP/PLV5^MR^\
MAZF\8'X6;*_6Y?>0]3>,#\+-E?K<OO(>IO&!^%FROUN7WD/4WC _"S97ZW+[
MR'J;Q@?A9LK];E]Y#U-XP/PLV5^MR^\AZF\8'X6;*_6Y?>0]3>,#\+-E?K<O
MO(>IO&!^%FROUN7WD/4WC _"S97ZW+[R'J;Q@?A9LK];E]Y#U-XP/PLV5^MR
M^\AZF\8'X6;*_6Y?>0]3>,#\+-E?K<OO(>IO&!^%FROUN7WD/4WC _"S97ZW
M+[R'J;Q@?A9LK];E]Y#U-XP/PLV5^MR^\AZF\8'X6;*_6Y?>0]3>,#\+-E?K
M<OO(>IO&!^%FROUN7WD/4WC _"S97ZW+[R'J;Q@?A9LK];E]Y#U-XP/PLV5^
MMR^\AZF\8'X6;*_6Y?>0]3>,#\+-E?K<OO(>IO&!^%FROUN7WD/4WC _"S97
MZW+[R'J;Q@?A9LK];E]Y#U-XP/PLV5^MR^\AZF\8'X6;*_6Y?>0]3>,#\+-E
M?K<OO(>IO&!^%FROUN7WD/4WC _"S97ZW+[R'J;Q@?A9LK];E]Y#U-XP/PLV
M5^MR^\C0UEWQ\4*_<A,NXST.3;5IN+A>-Q95>)Y:)6VU:&5U$UJ15"0*]TFM
M?%YJQHGTW;V=N^?4WC _"S97ZW+[R'J;Q@?A9LK];E]Y#U-XP/PLV5^MR^\A
MZF\8'X6;*_6Y?>0]3>,#\+-E?K<OO(>IO&!^%FROUN7WD?U++XP*JB+EVRC4
M5=%<L4VB?1[*)2TZTI=$M5L2^.IGWI*2%+P^B1Z4RU70G?+ DGG]WUZ]/5VZ
M::G8                               $.^?6&7+.>)F[EKL]*^LN=LHJ
M.^4]/&BJY8[374]95*C4[7:4\4BHGMFU-DMX<&W&V8Q'<2UY);&VAEAHY,CF
M=51,9:JF*G9Z53UCG/TA="]%1W6J=B:^144BGPKK(-Q=[N8V^]G:L^&YEE5L
MQ_#KPS5(:V.Q0313SQZ_3-D:^![5_P!+_(EC@     !6!AO^+ANS^8"F_C:S
M%GX         !5!X-O\ ='N7YP+S_!+>6O@         K@\6#^Y+N-_O7'?X
MVIB?^)_R5QG_ '51?8&&0                     J@LW^,#EGYE8_LM$6O
M@                    K YX?WCO#H_.K/]DM99^
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M6ZBBMEOH;= Y[X+?3Q4T+Y%17JR)B,:KE1$371.W1#F
M    BA1<8/1.8-VY7?AQWGK3"FX?^ 7JS3N^E\+O2O6'I:Z_ZGZ3T=/+]-V$
MKP                    :'W:X\X7O)FNRV>9/<[W07?8K('Y)B--:YJ:*F
MJ*I[H'*RN;-33O?'K3M[(WQKVKYWDTWP                     10QGC!^
M#O,'</E=^''IGX>85!A_X!>K.[]$[E]L=Z5ZP]+=WFOJ[Z3T=OT_TWF^=*\
M
M
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MSC&:&MLE105\UGR?&+DU&UEMN5,C'2T\G3V.3ID:YKD1-47M1KD<UN]@
M              ?B21D3'RRO;''&U722.5$:UJ)JJJJ]B(B$$X>>> 9!R2P_
MC]M[94SF@R&IJJ"[[ETM?W5NI:ZDIY:B2"D8E/*VM1K8VHY[96-17)TJY"=K
MG-8USWN1C&(KGO<NB(B=JJJJ5^6/EEO5O=<,AJN,.Q-%E6W>.W&6V-W,RZ]-
MM5+<ZB#LD2BI&,656=J.:_J7S53K;&Y>DV'LSRBO66[H778?>/;&IV@WBMUM
M6\VRV)717.V7BW-71:BAK(VLU7L<O1H[L:_SNICVMF$
M  1EY%\EK3L-'B-BMV)W'<G<_<:K?0X!MS:7MCGK)(^E))9YE;)W,+5>B*_H
M<NJ]C>EKW-C_ )#RJY3;1VI<YWQXIPV[;2G?$M^O&+Y'27&OM$,KD:DD],UT
MB2Z*]&JJ.8Q%\KTU0GYBN367-,9Q_+\;K6W''\HMU-=;+7-16I+2U<39HG]*
MZ*U5:Y-47M3R+VD>^5?)NV\8\-L5_7%Y,[R7*;JELQS#H*ST&2H1D;IJJH=/
MW%2K8X&(G4J1KVN:G8BJY-@[ [L?'EM!A.ZWJ#\%_P ,::>H]0^E>F^C=S53
M4W3Z1W-/UZ]UU:]VWRZ?1-P@
M     KKYB=%QY(<"L;K8TGM5;F]XNT].[56NJ;4VVR4KE;Y%Z72JO:A8+=;9
M17JV7&SW*!M3;KM2S4=?3.1%;)#.Q8Y&*B^PK7*A GPQ+G55_$C$J:H>KH[-
M>KW1T>JJND3JU]3IVKV>?.[R%@H        !I6S[$8?9=],LY!05]VJ<VR^P
M4^-UM#4RT[[=34=.M.Y/18TIVS,<]:9JNUF<U5U\WR:13\3*YVNOV$MNV5,C
M+CGVYF5V6VX%CL>DE7/4LJFO?)'&FKD:C?J:NTTU>UO[[0L*MU-+1V^AHYIU
MJIJ6GBAEJ7:ZR.8Q&J]=55?.5-?*<P         JTX;9C@V$W3F=NQN)D]HQ
M%M[WGNMMN%\NU5'2P]%++/-34\<D[]5T6JD1C$55T\FI*J"JXS\J;YA&2V/+
M[1G]_P!F[PS(<:=9KH^*KM]2V2)4DGIXGQR.B>Z)B*DC>AVFG:2A
M           !I_=78K;G>JKPF7<FT.R.VX+<9;K;,>F>J4%15R1=TQU7$B:S
M-C3548J]*JOGHYO81'XB1LBY6<_8HF-CCCR/%&QQM1$:UJ0W9$1$3L1$0E=O
MKL1A_(3%K)A^;U]VH[)9<@HLB[BTRT\2U<U"R9C*:I])IZAKX']\JO:B-<JH
MW1R=NNT[_?;1B]CO&2W^NBMECL%%/<+O<9ETC@IJ:-999'+[36M52!OAY6BY
M7'"]X=YZVV26.W[];D7O*\8LSTZ>ZMDD[DB=TZ)IK*Z5J>PK6M<G8I82
M              ##]P,*M6Y&$93@-]FJJ>RY?;9[5=IJ)Z15"4]2Q8Y>Z>YK
MT:Y6JJ(JM73VBN;<_;S"]K.6_ C"-O\ 'J7&,7LS,N;0VNE1VFKJ-JODD>]7
M/DD>O:Y[W*YR]JJI9/E]NK+QB>46BW/6.X72T5M'0R([I5LT\#XXUZM4TT<Y
M.W4A)X:MZM$O%['L,B<VER[;N\7RTYY8I$2.KHZZ6ZU=3&E1"NCVZPRM:BN3
MRM<WRM73',VGH\R\2K9*GQ:6.XU>U&!WNJW'J*5>M*.*OIZVGI*:I<WZ5R25
M<3T8[_RC5T[2R                    TK>-B,/ON^F)<@;A7W:3,<*Q^?'
M;#:4EI_54<-2ZH66I6)U.LW?N;5/9U),C>G1.GRZZSYQ[A6? .,NY\=QB2MN
M6>6FHPW%[.U.N:KN-\B?2,2%B(JN=$Q[YM$_S.SMT-F\<L$N>V.Q&T^!WO5+
MWC6,T%->H^I')'6+$DE1$UR(FJ1R/<Q%]I" V0QKR-W0Y0;UU$:5FVO'; \G
MV_VKD55?!57^2V5#KS<8O*U5C:]8D<G8YCHG)VM[)0< _P"Z#LI_NVN_C2L)
MA                                          KJY;_ -Z_P_\ ^<N5
M?8K26*E=7A;_ -U"T?SEO7V5A8J         =1?[-!D5AO>/U534T=-?:"IM
M]15T4G<U,4=5$Z)SX)41>A[4=JUVG8NBE2>]VP3.$+K1RHVIO=QSS\&+G;[?
MGUASME'>ZEUKK94IN]MUSDIV5-')UR-BUC=V]?:O0CHWV[VZOI;K;Z&Z4,J3
MT5RIXJJCF:J*CXIF(]CD5-4[6JBG,         *<N%&PV&;D[J<F,\W%L]-F
M5JQ'=&_4.&XM=F,JK937"HJ7R5U>ZCEZHWS.C;3L8YS?-1JJGG:*W.^4NW&'
M;"[Y\4][-J<;M^"72];@4F&YI06*".AIKE;[JK6/26FA:R)7]UWS>K35>IJN
MU5K=+4@                   "NKB1_>O\ $ _G+BOV*[%BI6KR:R6[\EMW
M;'PRVZN,L.,43X+[R3RRB7LH[7!(R2*TME[4265W2KDT7SUC1?-;,U+%+#8K
M1C%DM&-X_;XK58[#1P6^SVR!-(Z>FIF)'%$Q%U71K6HG:=L
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MP6U>ZULPVWT6XM^LUPIKQEL;7)5U$3KE.U6/<KM-%2%B>3]ZA86
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M</Q2SXI35LB2UE/9Z&GH62O:G2CI&T[&(Y43L15,D
M.EK<;QVYW6U7ZY6"W7"^6'O/4=YJ:6&6KHN^3ID]&G>U7Q=:=CNA4U]D[HUC
MG&RNT&Y=3#7;@[8XQF5PIVI'!<KO:Z6JJF,3R,;/)&LB-_T>K0RO%\/Q+![5
M'8L+Q>TXC9(G*^.T6:B@H*9'N\KDAIV,9JNG:NFID8
M!A>1[;[=YA717/+L"QS*;E! VE@N%WM5)73L@:YSVQ-DJ(GN1B.>Y4:BZ:JJ
M^RIT'Q%[)?V.X/\ B];?>YL.U6FUV*WTEHLEMI;/:J"-(J&V4,+*>GA8G:C8
MXHT:QJ=OD1#D5=)2U]+4T-=315M%6Q/@K*.=C9(I8I&JU\<C'(K7-<U5145-
M%0XMGLUGQZVTMFL%IH[':*%JMHK5;X(Z:FA:YRO5(X8FM8U%<Y571/*IV0
M
M
M
M
M
M
M
M
M
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M,'QTEADB]#?51I>=9JJ-:Y/J/5KW;M4_>=I82
M
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MT<D,SD;HQKHM%=YNJ.Z46R$
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M:CIYZ7('PQ2R=GGN2-K8]7:ZM:UOD0O)
M
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M_N9;R?T>_P"T5L'AQ_W,MF_Z0_\ :*YD(?$(_OM<4OZ._P#:20N\
M
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MO%+WC5OQO;;U3Z\HKM4UD5=+Z#=WU\OHT<%'/&[6-VC>N1OG>71.TL6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>item1image1.jpg
<TEXT>
begin 644 item1image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"417AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $]L:79E<B!8
M:6$    !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L
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MTW/_ %RD_P#BZX,D!:C+'!Q0!WR_&/Q&>MGI?_?J3_XNC_A<?B(-\UGIF/\
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M7@WXFZSX@\6VFE:A;6"13[\M#&X8;49N[D=O2O((\J:['X9*#\1=+;N/-_\
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M -B:7?(1G)/!X]._MUJNURT:J1QU&47 QGMCKGFJ,FH%H^2I)3<,GECC^O\
M0YJC=71#N)6 ! YZ<8SCG_Z] &A->_QGH"1GOTXZU/97K7$BO']W.XX!^7GT
M]/\ /K7.QW$D\OEL"N>67I@8Z]3_ )(K;L8O)8E2H#D8+?K0!TD,VV#8F,=0
M P_S_DU9AG!49X3N0#^)_E60LP#A96!7'.!S['_ZWT_"W%/T&W?@@97CMG_Z
M] &IYBR,.4X.2<=?I4R,RD?+@^G]*H0GS@S2J Q!'7MUJU"6&X\X_ASU)]*
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MZUIQR*8V=3G<O7T]/K6-%/LP#\O'.2/U^GYY-.2\#.%WJPV\$<@Y[?D?\]:
M-V&X(A'?OU)_'ZU(E\ ,%@&7.X-UQ[_I6,]Z3$23M#<G:V?Y'Z59@:1WY7(P
M21^'_P"KF@#H[.Y62WWE@!GDFKEM<E9,],8P<=*YZ.4Q_,7^7J3_ '?3_P"O
MQ5VWG+<LPW8(QGTH [JUG%Q 'XST./6IJY_2+QE;]YT/7TK?!R,B@!:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *44E** "BBB@#QCXQX
M/BJU'?["G_HR2O/!P>:]!^,?_(WVI_Z<$_\ 1DE>?@<\T +2!?FI6&>129(Z
MT $K87BH4)IYRQXHV$=J %"DU(@(-.B^[S2%N: $D-(II)7XID66H E*!JM6
M]DV00,U J$\5T_AR$0CS)N>"0",^U &]X:T\06QGE3#'[I/85:OO$PL[I;78
M9&D4[ HY+=A5::^:--J?(N. .]<UJ5K>:JN; H98VP-T@4@]0>?>@#J&\0A8
MW>1@@3[P)Z&HSXDTPVL<]MK6GR3S#(MUG5I/I@$G-9&E6NO3:F;L:+!_H]L(
MY(;N4!+B0]2A (P!GKQR.>*X>+X:>*(/$4.KZ?IMNY%P)Q DZE<[L[ <]AWZ
M<4 >M6NO);7!6Y3?N7.T'YOKBMZVU*.:W!1@OH*Y7QBFG)J&G7#VRQ:O(N3(
M#EA&!RIQUY(_*JFGW;+( 4X)R3GM0!VLER7@<+\K $9')'O4,LYDM\_*0#D@
MC/&*K(%DVR1MD8XISAH5X]* ,^[22[TR-I@H<G#+Z$<5Y_KEHUK<%>AKTQIH
MYH<IC?@BO--:,HO&\TEF[Y- &/NVFF;MS5(^,5$#S0 KXI1R,"@KNIR+B@!H
M0BI(SC@TXL#43?>H 5OO5UGPR7/Q"TT^GF_^BGKDAS75_#)\?$73%]?-_P#1
M3T ?0%%%% &=K>CV^MV<=O=H'1)1( ?7!']:I6GA+3+/F*W13]*WC24 5HK"
MWA4".-1@<<58  Z#%+10 4444 %?.WQ*TB&P\17WS,(GE)"@\?-\V/P-?1->
M+?&"P8:VTF/EGA1@<]UST_[Y_'- 'BS*(/WF\$@@CYL@#N3SS_/^=!,KNI5&
M8*02%R#D 8/7VX)Y-6+QD<_(661P20I!;/7K_GI44JIY:[U!R"-XYVX_GT_6
M@!XD-N2L,[  D %LD%1USV'7\J@_M2\CG"I)N13SQGIR0?Q'7VI",PLH5Q'G
M"^H.3^O09Y[5 (T2/<N[KMZ;2HZ8_P#0J +AUNZ8'9<",@Y("9.1SR/QQ_\
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M@ HHHH *X+XI::MQIEK=\ QL48X!R",_TKO:RO$FF#5O#]U;!<OMWQ_[PY%
M'RMJ*E)7W@B3;U5S\W3K[]N/>LF?9YB&-TD);& <=NF,\?CZ5U.O6+03N024
MRV0AWX/<GCCG^5<?=N(V98P59NJ[>G;KWZC\J %DN'P0RL<CDDC;G/?@^B_E
M59KDL50$LH4C;@'!Z=.W6J\UP^P;B)$ R,G.W@@]15.6_P#+?<.3GDYSD9_S
MTH UHR &\P,'9=JG(XYV]?SYQQ5ZSN49O+E*MDYP><=<''XD_P#ZZY5+PH!^
M\))P2>F/\YJW;7T4<F]SN].,=L9'Y?G0!V<,JOM\OMC).>>-Q(_/\ZEGM!<)
M$Q#)*&XWC& #D^_?%<K_ &N(XBBRGYF.<= .GX_2M*RUM%8A@3N/)W]O0<'_
M "?K0!LV&BWTY,=G$)I@HPH!!/)Z'UX/?//%7[&ZCVS*T;@8) R<YS@'U]/I
M70> '>5FE?<74X&%/.=QZ>OYUZ-XL^'-OXFTN'4-+$<&IB$;AG"3\=">QSW_
M #]@#Q\S22,V3E>H//!SG.?7U_S@20I'S&[(&VC;GY?S_D?\*FFMI])OIK/4
MK;[--$?]4ZX*DGU';&3D'TQ49B#O(IVKD@9+9 ;G&1VZ_I0!?MW)"DJQBSS@
M?,<#ISQ_G\*E8[85SA]W)SQQQUZY&?Y52R ^4W;3PQ;YAP<?3^[_ #I\+NUR
MV V.<KU!'''^<T 7 8RQ)?85!SW4GU^G)_.K)#IM7=O&>FW'].!P34#+!#%\
MOEMMZE !CD\XY]1]:GA0IEB3\HR"""1CK[^OM0!;MA(R$)] 02.",9]_7Z\5
M=L94BG7YSEF#D@\#Y>>/_KU2A."N]&XPN3Q['GTI(Y Y#-E3MSL.!_6@#K;:
MZ9E!8X/<@]#^/X5HVTYR%&#[\_K^5<G;W+Q _>8@$+C'4X]<>_ZULZ=>;L Y
M!'7MW_*@#L])8_:N.C*22*VZR=$MV6(S.I7(PN:UJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *44E** "BBB@#Q/XRG_ (K.T'_3@G_HR2N#
M"UW_ ,8U_P"*PM7_ .G!!_Y$DK@]XVT +CY:8>*89><"G#)6@!A.:;TIVSFE
M9<CB@!BYS4FZF?=IRID4 .4AJ<JYD%0\JU6(\DB@#3A01C[AQMR#ZFN/UB5)
MY+I)UPL1.&7MG/\ G\:[))8XHP]QN\M<%@OWMO?'O6'=:+%K]\8]&N93;B4;
M_-R& 8\$KT.#G\J *7PV\*7>HLMW=W5P=)B<.(7D8(\@(.-O0_6O63+F]C##
M'.01VQ5>P@6STV*UB8OY8"EFZL0,9-31,$N X'()'TH W!*5BB]-A_E3;2;:
ML0X8! !STXK*\0>(=-\.:8MWK%RMM"^8X^"2S''  JY RM#!) ZNK*.5/7B@
M"WJME;ZSI-UI<[,8;F(HY[C(ZCW']*\V?P;'X8\'ZK<Z[)(TD4H:S$4QVR-C
M"?)G&3GOR*](#D2>W;)JKKMF^I>'KVW7R,R)]Z?!"@=3ST.,X- '!Z$WVN)"
MW$3 <CKTK:MH$. &*L<\9K T"9!:;XOD4D[<<#%=)#+E<DKGVH MQ?(GS<,.
M_8TL]R@0><P49P"33/M<$9C2641[SA6<<$^GUJ.^L?,MRS@-SN 4YQ[T 5-8
ML1?V+1S*K[3NC<GH?6N+EBEC79-C<IP<5J_VS/%*8@2(T<\=<BLRZF\V5F]3
MF@"%!QS2 _-S31NS[4[[O6@"5E':F9*THD!% (8T (3E>:ZOX8''Q!TX?]=?
M_13US#J O%=+\,05^(VF9[^;_P"BGH ^@:***  TE*:2@ K"\4>*[#PQ8F2Z
MD5KAE)B@!Y;@G)'7''7%)XN\3Q^%=(6[>(RO+)Y4:YP <$Y/M@5X1?:K?^(;
MU[S5I#N3+(=A!W'& .,@=<#C'X4 :>H^./%5_,;S^UY[/()2VMDVJJCN?SSD
M^GM6?:?%GQ:DLL+ZA(8[81PEFAC8LV,,QR Q P26Z<?GS.NWTTKS:?;7(M[>
M!4>[DV@%U., *?; !'TY)Q56U9[K5R^HK_IDMJ181MN8. NYMV>H89Z=_3J0
M#K++XK^+DGCM[35#<9N'4LR+(@"Y8[I&4 <%1C/'7CH6I\6?&,FG-&;\-%,_
MRW#! \3)@,&VX(!8J>.Q],BN-B6*&.W:PEM[2]OY#M*2L3"D8W$KU"$^G/)'
M'IH3PVEC+'9K=Q&[9L1,S A&./FPJ[>@)))!Z$^E #M4U.YN1=M<W,MX%(,C
MJA(D9AN^4KGH7QV'';C+'TJUO-\T4S[) &:*2/:Z9; ZCYFQSP.W/6J44YL!
M/#82S7M_, L<B,49LY7:0."5R>01VP>E&JSP7<.^?>0T3!V\\N9/E)^4XP#O
M#')). .N: ,LV5@L2RS_ &BWD,[*(IX<,55>WS$YR0 "!G/7BI!X?T[^U[J!
MXKK$,?G%Y$"11\9PY)!;KVQT]*LV4<MU%:7"BW1M/F!DFEEW-,<@8/)P-PQQ
MQDCKBI].G6ZN)[G5KVX6$3^3LM\G+/SYA#X[]01S[ 4 9B>%;6=XU7+R3%"@
MA;< I3(#')"DX8@[C]WMT-?_ (1FU?:$FC(N2QAC,ZH\07&=Q/&.O'!!_7H-
M(T^[O([642VMO(@VKYK\%23@%U(!8#=C !R"3Q1%$L-VS1:/)'<3DPW1:<QB
M-G4YCC.X?P_,,G(/;% '/0Z%9B5XC!?-)&Q,D"1$.X'=""P(.#R<C SW%6['
M0_-NKRVLEWSA8V2W0L6CW$$\G / S@Y_ UO/#Y*7MI$(9)88I8/.RL)\M^"K
M%MP;)'#'E3FH;*9+"S$L;1W]A@A(;AUC:V*H06)S\Q)P,_=QG.,4 7=/U/6-
M :\2./?;>0K,\3!_(;&<+QC=R.QP3GI6]8_$3QDEI?Q#5+P);L(ECBMH9)%4
MJ &VX##);\.,\YKFC<1QVJ0VPTX2WTC7,,<2%I ^W 7"#\2%..!UZ4Z"XT_3
MOM-FBW[7<#*DLV]!YO(7;GL%SSQG@ 8ZT .U7QMXA\1QVG_"07RQVUN)!%=2
MVX^;"A3DA07.[& /7GO5'3=1U)_LV3;L\@<,C+M==IYR!E<$#Z<X^EF\OY]5
MN"ES$-0M'U#RY&2/>RD G<7P=W;! QCL*U[RSEN9KJ/4Y[G%NFZ(6LP"DLB@
M(".>,+GTYZT 9D6L7?GRVT-O)-%#*8W>,\$G'\38_P C-1Q>()$DF2\M)HDM
ME\V9Y$.P<_*,]#DD8[=.>*MQ!WLULQLEEACCED&02IP65A\F&.T<\D\ $9 %
M94VF27$5LFJ6XNB+I5*^>-BJ0,;B#GE>1@=NW< W[/7KBZ:11:7 E4_(94VH
M_H%/W23@]QG%6[74Y[]@MDN68C]V6VEB0=H!'4_+ZCJ#WKG9Y8EMG"_9_L=Q
M-&L66P(5C.[:S<@MDGIR>>]5HI/M%Y%:V]Q:I/)*-RQ@QDC>0"PQC/7@-[G'
M< UT\8M.K1VT;&59!$HP2"O/[P[>B#GG'3FFCQ#J$%S>PR1V]L4A$D,QR1,<
M<\ Y(!X)'<53:RNX]%NU6*.VF"%";2-46-LME=RL0P 4@GJ.36AI%E]HU+3M
M0\Z1'6R1?M-Q\@<D@!-X(R0V01C!PQR>@ &R^(-<\V%[=EGBN4(MIEQ'%++C
M(0AL'H.Q#<UT_A>75[C5OLKWDIEAA64RR6_[IG8C<F3D$C!Z=,''>DLM-$1O
M(9WO$N;K,,ES;AI(866(.#AB=I*[AN!Z'WS6_IEM;Z?;-?:986\[ZC"02\A1
MKAF *8+,< @'/K^% '2:=XVO[P06^GS0RD7#P$W*^4TJIC<T8P,@>F,\_C5F
M7Q^O]DW%]97EM?0PLP8Q Y+;@H0=L@GD].GUKFX;J^G@M+F#1[>WN8E(@%U*
M"2S\,H*\ \!3@$<CTJ]:_:7TRVM;33+;2TB8P7N-[21DJ#\ACQR258MG(QGJ
M* .ET_Q)>W=P\[>='%&JQO;S6I0F3'.TGKU&<$@?SH/XK\46LCB?3+.X*Y/E
M07.'V\9.".Q(&!SR.U9T]YJOVBYM)%L;:W>0Q6H<NC3KC]ZS,!\HP01@9)7&
M>]9EY!'.\JWXCL[%XQIJ2*B&:1=V%V.H/WG' &""F<&@#JX_%&LSR6C1V+1V
MDP'VB621%DMF.<+M.0S=B!G%9I\9:C;A+R2/4O(9OFLOLOF3.S$#*;008U4%
MCR#SUZ"J?]C:?;3-=77^G7UC$L9>=&!+C!#%%.U\A^-H)W#UJU=Q0Z7JY<-Y
M5E&JL]PTS_NG SG:3@X 7CISGM0!8LO',\4TJ27(O'4B0VL=N?,@B8?*'RV=
MP!RV?3MUK13Q'K4AE>>&"U6&1\##2;U"G;D 94]">N.E<['/;2Z:UCI;75W/
M9@1320S/!_#D,&SN(XX.3U &:Q;F:PO;VP37HGU RR72QSV4S!;90[D*57&7
M.<9V@=^G4 [73_%VJW]W<M(MG;6J2&*WW/\ O)7VGY&0XV'.T\GHWT)+GQG)
M)))!I]Y%+<6\NRXB@"RL",953P/Q/0D9]*Y6#5+>QOXM.O;.2UO)ED-K;W0,
ML22'=@M(&8AFR"6Y/;C&#I_VW#<74LN@/9K%!.MO(9<P+%(Q_>?/C+_*!A0.
MO7&. #<C\77CCYK2ZC*1BX<-&&)7*@H-N22-Q[#]#1=^+[J#5[737L[A)IR3
M'*%4I)A22O7J,9].,5SFHO/K^H;=(N&98)I!]H"&.:V93C 4@K(I9<_P]"#U
MJ_!>1)'-=7%M-86.G_Z.S>3Y33,I.67!.%)8#;@$Y^E &E+XCUF*[L8Y;G3$
M+Y>>/++OC R3&2.=O&<9X.<CI6S9^(7G-R9H!$D"(S-G(Y7<3G@%0".?K7&Z
MP\=Q>SR*;>74%4O ]ZQQ;J 0XX"E%!VG<<CKD]*J>4SPV5LY.Q-.02Z=;CS5
MG1SL!,^=Q&2OKDC/<$ 'J%KJ-O=!/+<!W&51N&(^G6K5>63:OJ-UK&KI:20[
M;:2'8YMR$@4@ALN64N>&( R.>M=GX?\ $27\?V:Y</<1G:9$4[9!M!+#MC)(
MZGD4 =!1110 4HI*44 %%%% 'C?Q@P?%-J#_ ,^2?^AO7GC8Q7??&+_D<+7_
M *\$_P#1DE>?NAV\4 (%'6E,@Z4Q<XIA4YH L1C<>:)%QTJ.-L&GLW- #%&6
MYJ4\"H2V&J506YH (T\R3'>IKR1K&%#"J/(QSM8XXI^G:7<7EYYD>5C0\MZ^
MU+JE@RSF.=1,!\Z8;'(['\"* *4-_*UO+]J(W#/W5P *YJ?6KK3]2DO[+[1%
M-&56)HR K8()##^)2"?Q_.NKBB!^4#:3U8=ZAN["%X&8QY(ZD4 ;WASQUIVN
M6>6G6*Z'^LC;Y>_;-;R7:O&ACY^8DG/6O#M>\-M;C[3I\K#/)P<?G6=I_BG7
M=%N5EBN6D1>L;9*'ZXQ0!ZK\0_!/B+Q=K$<T$L+6$4(\E6? 7/WN/7U/IBNN
M\':+=^&/"]MIVHSI))&20%4#:#VR.OUKRD_&W6/LZP16-M'_  M(Y+X'? X]
MNYJ34/C9J%W;XM=.CBF*@>8S[L'')Q@>QH ]TC4D@D,<\YZC\*YKQUK$-IX?
MFT_<CWEW\J1'YM@!&YB,\=OQQ7AEWXI\4Z\Y^VZW=@*,*D#>6OY+BM+P[;W#
M7QDU!I99)!CS922S8]S0!T.CW\Z,$N-VY.2N,!AVKIK&^EGEVLA55/!/>L2"
MT,4O3.3UQ_.M>%1" 20&[#IF@#="J402@,H).3VX[5>M_LQ@+JICW9 R3T^A
MK!CU6-9&AFPH"[@V>O\ GBBY-Q?11RQ$HR<J V <]<CZ4 5M<MK:UC9P IS@
M#^\?:N>^\U=I]F%Y:^7>X<@8SC&#[5S.H6?V:X('W>V* *O"K43G=TH8FD4=
MZ $ P*>IQ2Y!6FJ,-0 I<@UUGPS.?B)I?_;7_P!%/7+'#5U7PS7_ (N)II'0
M>;_Z*>@#WZBBB@ -)2FDH \U^+P\ZRLXR-WDN)0@)RV3M/'<8SQQSBO')+FY
ML /L,0E9I09,O\VS9NX4?>(!. /J <&O7?C!<?9XK<\?,@"]>3N)Q^E>/:G/
M/:6C77E22&-]Y4?QJ?E*>^2<8R2 >,8X .>DM[NRNYH;:TCNO+V_9TF4>;L!
M+;C&<D 9+=^/0&M&&U^UI%;6-S))/%N\V\N%4(A+#,1!"X^8@%23W[5F7$$5
MK]GN;N_8ZC).,F)B!(S_ 'AP. N5Z^M;1M(8;JQM([IY)9(=LO'[J($'+'/!
M^]@DG^>2 9ZV]U;1W$5XEI97,46Z/[,=@B9L?-L P"5"G(_V:DN$O+J34;VS
MDBLUCA388K@J9% 4Y!'S$<=\]2<G!I;*%;V_^RZA):^9;C_2!$I! ;!+'/WN
MG 7GD'GI5.V_?6:PO:RQI$Q,)B=0V5&3S@<8)SZ'UH L,D\4BK;/+8(XAN(Y
M"I:&' Y 8YWKRWUP,DXIL\%O+;VUK:)L\YY'NDC0.J@'DH0>5R20 0.:B339
MI8[69+ZW2*:Y>'[+<H(QO ! Y!)R<'GCUZBH) NE:M?/KU^;J<,MO(0K^8S>
MS< +TR21QTSTH T]'BGL+^30FNXK>TX.1& IE$FX?,1W^[^/0C)I+V1%L_/G
M^TQLUSMBGN'>3R"6R"PR-@PNTC:>.@Z9Z_PYX5O?%NL?83!;V"WD9,UU"5"N
MB@'*QJ>OS#[V2=P.:UO&GP0U'1M.EO\ PMJ-WJD:0LLUG.09"N!RFW&[!4';
M[#KTH X>\U.#1M,N(K."'5)E^=<; HE&S)78?WH &>V.#CK7$7/CR>7ST^Q6
M\>]PX4*P*.#]X<_>QQS7;6L5E!:Z7%8R02SV\>Z\DD$;RINQ_'U&,]!C''.0
M152+P?I5UXB\[[ \\D:@7$*+)Y(E(R2S2/N/)//(XZ<XH H>&9]1UZ)[N2VG
M=1*GS6T.6STW%CZ<\="<]ZW;73GTVVGDOUC5U1Y506Z2+\S[-YRVTL"V['(Q
MCINR=+3-.BBT^T33!]D^Q[9EBD#I(CJ1P#DA@?F)/1N/N\$=+X5\&:MX[:=K
MF]E@T61BMQ>-&!)=D$[50=E&YLYS@G'4< ')207$]U801S.MV8# TC70;<K*
M1N._*D!D'  .&/7J*V()EL9X+FZ%O'"\[,;?9$P;Y&"^KC<",  \< UTM[X>
MALOB#J.EZ;>74QTJ$K'<3CDRM%N5,\#@E>>.2.>QM:18W&H6=C&)%?4&W6GV
MH@KY1:0 !U&.N?7!)&3G@ '+:SITTK2W-M:PQM/<>2HLR.8^?F*@_+GGJ0#C
M)QR"^*WO-/@N+HQB4._^B/;/O69FQM!P>N[ .>3W KUJ_P#A-=6FFO<:1J[W
M>H!#OCO$01R]#A>/DZ#KG. "1UKSS34MK&S2^L[B2+[&THFL$<L67:"2D87Y
M"&0'.[W]* .*NO%^OV]S-'-X:@B9>7A\DL(R,*6VY..<<].E:/A\ZKXBDD>Z
ML#;1@8$SV^%+#C:06&3SP.3T[<UUMUX'M+BWFU)_-N+B2)94CA#P19W;@'QD
M$]B"23SP>"-O3/#VGO:RK-8V45O'([NL2,//=07).>3SN4CT4 XZ  YFRT:#
M2=<DG.+AG@Q$\JA@Q.&<\G SR.,'"CKWE2*.34I(%U3R[UF14)MV5 X^]C&%
M&3R3N;/ [5T%AX>U'Q)+#IOA^X^S6L3!KF["*$BC/_+/"GYW(Z],<]C5/4M(
MA\&>.$TB'S]5MH88;A$E;:5D9RN!@!0.XQGISTS0 MOHTVG7UL$LIK>(2)<W
M%S"/*CEE)^9BG!V]^AQR<XZEAG4[VS2!(&BGA19KRU)>W!4ET3RN"N0,9XYR
M/>MV.13HMO>V*_VCYUM-(TY5(=D*D89D.,GITZD'M6C+\))AI[75EK,L&L-^
M]R!B#S".>!SG/\7Z4 52QA2".YB01%V 0?NO.?KPN><MD9)[$D<9KS?4/&'B
MKPW<&\N=-6PB65A;H55?+YSPF>ASDG'1JZC3[ZRM+RX@UI9'O],!:<-()C)(
M6'S ]<@ @$'H0/8:GB+0K76;-!JMTT1,F(AIX,DTGR;]I4J<$8].@&3SB@#E
M_"_B2^\=:M+<:[!''9  &8AXP&) 01D<;L@<9[BNOMFTRXU=1LD.H6<+QVL5
M[*TBG9D;FYP3][#9(P"<]*KKIMK;>#HE?0+RYTY;N/;8M %FM<94M@Y)[\YZ
MY(QUJ1?[2\07<.C^$W"1Q+MGO7C4K%$RC!R.K$[CCC.[T!- $EHUS-]JBCOK
M73G%V\\T]HV^3C/RO&V=I?;NR/<=>3982:E=W(@F81//DLUTX<0O&64QC:&4
M[MN.WS<'G Y6_P!)M?#GQ9LM$TZZFOI?LPN)GN,,1*"6& ,%NBG')!Y]:Z6*
MZDN;A;B]G&I2PW#>1%96V5A&,;CD 9RKDYP1C Z4 4+335DUR66T@GNY'B2:
M.\-UO"2,NU2L9.6(!)))/0DG-;&DW5WI$ET]W?6TR^7$BF+F4.5V'S0<]R"#
MUP#UQ2:;\*UU#0X+YM9N;2]E4SP"V51# 7 . I&?KR.M<QI4T>C:Q>)KEXJW
M32O'<"$B2.Z^4#. "3][H%4 ?B* ,KQ)XA\80:E<)<: 9K.&9DB,L"EI 6PI
M/KU! [9S5GP3K&NS^)Q=RV-KHUM&C--QY22_+V3/S,. 3C(')KJ+R)M2T*UL
M]3NI99-14&#4[:+?&R^7O+L!C;R",\=5'-5[/3+"WF#06]G82Q,'M+=U:XF#
MGH^YB!EE1N_KSUH U]4\260F<W,CZ;>P[7N(H[3SMZG 4LI7)Y[C!^7\*@U
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M1^8J88@.B@<_0\]>O->77WP9U*7Q+<K/>XL6W&*2%-S"0G*Q[.  >N1D>PH
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MHWAG3A82KY$YDQ<7!4D2RD;CER,GK] ,>]>.ZKK=AXC^/MOJ$?[R%SY,1(+
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M#GPE'KEM96AN9K]%6=4GEVAEP<EB%]L$8SG'2MZ6:]U2UCCTJ\M;>[@D"S2
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M^5;(F#'KCMG%<U;>#XK>\%Q!<B,(VY"$R01^/':NCWL^T]3_ !'N: +,;+N
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M>@#Z!HHHH #24II* /,/C#X$UKQD=*ET**"5K,2^8LDNPMNVX [=CUKQK4O
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M';R&Z@XZU[-)I%DV[?;QG*D?='KQ6?<^&].N,^;:QR*!P&084D=1[T >;?\
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M?PS'_%QM+_[:_P#HEZY,#YJZ[X9+_P 7"TT_]=?_ $4] 'OU%%%  :2E-)0
M4444 %%%% !113)9HX(VDG=8T49+,< 4 /J&YN[>RA,MU,D2#NQQ7*:MXY4,
MT&BH)9.GG2#Y1QV'4UR<DE]J5P)[V0S29+8)SCV S_+UH ZJ_P#'@DD:'1;?
MS6'_ "VEX'X+US]<5S]U?:KJA8W-]*R@Y$:Y1<YZ<8I]M;>3@[=JC@CT'?\
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M6\X)1CV;T_S[4 ==1110 4444 %%%% !1110 4444 %%%% !2BDI10 4444
M>*_&-"?&5HW;[ @_\B25PRMP*[[XPL!XJM5[_84_]&/7GP;!H ZOP_?"1#"<
M*R] .XK;DF^3 Y'>N$LYS;WD4B$ [L')QQ72/=L>!U^M %J>7:WRX'O6%KH6
MXLW# '=R:LS7;!P<@KC!&.<UF7DCS,Q8\8X [4 ><:SI2+-E2PDZ YSD>]59
M=5^RW?G'3EY4*7Y;;CCY1G@8KL-1LUFSM_.JIT^%U560$#I[4 <3JNKSW496
M!6CB)R>#N/L:=:^(;T:?);LLD\C*R;V;. ?\FN[@T6W@5W$:LQYY7.*9'H.G
MC>1"OS]0!_*@#D-'>2TTV:VE=K>21AL'EG=SW!_#'([UO:1I4EG9JGGO=*QR
M >B=3^N:L:AI)B5/)7 7H&Z@59TZZ2V!CGR#C@8H U[6W&U1&0I7@U?"2+M(
MQM)PP _6L^'4DBC'RAP>X/.*NVNI0S$1@.&;/44 2RQ;\$&J[CG$H^A(JS;S
MY+%WC*YXV^E1SLA8'J* ,F2,F1PL"!<;6D/<>F*BN(Q! YLU5)' &,<'!![=
M.E:K"%Y"(\G@8J.6W^0@#GJ,T >;:]87ET/,EM(K1(2=GSY+9Z#/?IQ217=S
M8Z;Y#V<AYP\C+GY3Z^OXUWG]F*ZO'+'\C]L\9K&ETJYLF8W$?F6K_*4+9#?U
MH P-'T6 S37?V@J;=HWA 7GN<XZ8R!6C:_:[F\:6[NI4(B\O@'RR?[Q&<9QV
MQS@UT%II,?DI,L(C+#Y5'9?ZU;;2(7"EXD+J<AO2@#G]/TEIX5>;YW)R7QWK
MK](A>*$(Z@8Z$'K[_G206V.,* /05H0ICZ4 7[<D$"M&$_+S6;&>015Z%QC!
MQF@"]&^. <BN3\4M_P 3! 01^[X..O)KH?,,;[B,X[5E>(+BUO!$KEHWC.0F
M.#GWH Y=#SS77_#1@/B#IH'_ $U_]%/7(,N&..E=7\,A_P 7$TT]_P![_P"B
MGH ]_HHHH :YPOXTT-2S'"#ZU$#0!-FC-1@TI<*,L<4 24UW5%)<@#U-9%_X
MAM[12L?[R3H%7UKD-1UB_P!3D*DMY.?NH.,8SC- '2ZIXOM;52EB/M,IX!7[
MH^I_ UREY>7NKLWVZ60J#D(APO'48J*V@0XVX^4 *.F/I5R&+,*APP&>#S0!
M333PRJJCA>@&>>3SS5NWLA'P3U.![?YS5J*!2S8"^V.E/"-O!^7K] * &I$'
MQO!0@<8/(J8QD#"X.>F/ZTJQ$,21]/;WJRD> HQD=C0!#$K(=@_BP.OO4RX.
M3CD\>YJ0H&P<9)Y!IP3:O(P3WH 5%&.>WMTJ98QC@8P!@FF+RP*_4FGJWSL,
MC.* %VA<\<GN>U,+J$P>WY5,PV1$@=:SQ*P8D].10!,\NUOFQM HWF0CT//'
M6JT!,J[Y/N@\ 9J82!FX.<=R30!-N/\ %A3]<4P[@,]NY-5U+/*3N./3J#4[
MR!5SG'UH BD<H#\V,\#I5*9R& 4GOQ3+JZ4,W\.",GZX%9]Q<,0HC<D#E< <
MT .FOBJR;R!T(!;MZ_R_.J-S<."?F+ DGI@^_K2D,['#<YP>!Q[\GW_(51O3
MB,C9PQPH5LXZ_G0!<T8_:;R6YN<-! I<KC.3_"!^./RK1A@D$K/+]]L[MWO[
M?C4.C6L@L-R,%+L3TQGKU'X_I5N20P-Y9P1W^;D_Y/K0!)"0I&!CIC/!_P ]
M*M&3:^R0!>>%K-%QL(4J<=%P<\?A3&NMRE@,KT//X=Z -"6;:QSV!W C_/I5
M*XE8$9W<-C@<57ENW#'&T8Z*#G'H/RJE<W62QSO.[ *\8Z?E^- $V]X )H'P
M%)P1TP?Q]*Z*RO1*D,Z[<J0PR>I]*XK[8Q9@I+-GH,9;'U_/BMO1'E=26SCJ
M>>#Z&@#TQ&#HK#HPR*=4=NI2UB1NJH ?RJ2@ HHHH **** "BBB@ HHHH **
M** "E%)2B@ HHHH \5^,?'C*U/\ TX)_Z,DK@LBN^^,H_P"*KM3W^PI_Z,DK
MSU3CK0!(3E3FM.PO08UCD?#KP,CJ*RASTIC736URFY<QY^8XS0!TN-X)]:SK
MB4(Q#, ,]/6HIM9MD80B7&[%0RE9FRAS[T 5[B522 ,'&:K"Y\O(QVZ4^Z0@
M<GGZUF3R=?4]* -+[9A=HX^AI\.H)$Q)@R#T/<5AI<[#AJL).&;"G/'6@#1F
MO8Y]K/M3YMN'8"DN;:!4WA@W&!CD52DA+8.<?C2K(ZQ[%/'>@";8Z#IP:C,\
MD3 QY(]*7[25A *\COZU&LBN<LHW#ID4 +;ZK+&'WID_P\8J]#XES"4N+7YE
M&%(/!/O5(Q>9\S#@TC09_#I0!++J<C'<R%"/[AJ&6\OIY Z2E?J<DTAA<@%C
MT[4IE-NH5USGN* -:QNG>T8W!WR1CD]S4D.HQR*R7$89,9 89!K+@N$DYP1C
MJ2*N;,J.* *ZW%RVI&9,*&;.WL!Z5T"3VYY)^8=5-8 '[[#KP,'GO5LR1\[V
MH TEN4W\<K[59^T*%W \5SQN%1AY?3/ Q5J.[#*.<>U &W;7H$F)/N]JT8YE
MD^YUKFEG!&2<=J)-5CAP(V+OT^7.!^- '52S 1#<RYQWK U<P%D;S SXQA3G
MBL(SWD]R3--(8]Q( ;IGM5DQEP.P% #0<YKJ/AF?^+D:6/\ KM_Z)>N5;Y*Z
MCX8!F^)&EMV'FY_[\O0!]"4444 17'^K&/6H-X Y.*9K-T+.R$C'&7 Y/L:Y
MJ?5I7(\L'L,"@#?N=4AMU)9AGZUS6H:_-<<1;D 8YJN8Y9R/-<X)X/XY[TP6
MFWD*H)/S =__ *W% %(PM+\S[\ACVS@C_P#75Z.T(8#;N /?!SU-6K>)N& P
M,XQ_G_/Y5<C3#<G&!G- %%;;>P+':>QQG'2I!;84;1G;P,+5TQG[Q)!YP1GG
M\?SIZKE?F.3CO0!5BA^?)7:0<"I1$!SUXZ@\U)M  P.G/!I47GD9R>@[4 (D
M1P, =R:E"8'/(SC/I02<<#&?:H]QP&/TY% #P-K#T]!3I<9&.H[TW=A1CJ.X
MI,G=\V>!Q0 _Y4PW?OQ34(=@YP>>/:H[A@(R>F?;M1%-^Z'\1 XQ@@T 3S."
MA7=CT&*Q86EGO71#\N><=!]:GU"X,5JTK,0PY.#T YJ'0&+61E5""3DY'M0!
M<E;RT*JN5 (R*S!J"_\ +(Y"CGV'^2/SJY<;[CY8L =R>O\ G\^]9T]@D,.8
M3M;DGI^OK_GF@"[9&0VK2'Y@XR%.<CW_ "I9W98=V00N<@<XHB;RHD3<#A<'
M![^]07,FV4Q@,Q;!!QQ_A0!E%V8LFQE[Y';'>IO, C="1\J]<G+'OT/Z52FD
MVW#$D $A202?7/7_ #S4=S?'>&EVE2I+;>>GUZ?Y^E "^>$*M(N%[L3DD#OF
MH+R<=% +,HQT 'KCM51Y_P!T9"Q!YX8_=Z?_ %ZSWN&GNA&7PC.,A/XN#T'3
M].<_3 !V.C2B"( X (XQ].F,8_S[5)JMPL39!W%AD -U[=/QK$@O/)$:$L!C
M<=@[D_X8I-6O2P"K@@@'=C/'7\>/6@!IOF>8*W).1@ ]>N>>:?%/YQ5"6;(&
M-O'IGKZD&L7SPBAB1N(X<?,!D^_;MG_)?YF6;=DX&T\A@1].W;\_6@#=U$QP
MD+$?,R,@#G/'/Y5GS3D8S[-@]SZ_R_7I52,%Y"77 8CA\'V& >W/7K5FULS<
M2_+U; '&25(&!^7\S0!';PF6X(4L67^+^]P,<C&/\^M>A>&--,S(SKA8\,WO
MWQ^=9^A>%Y[B5'<!$4C+$=,?SKOK:VCM(!%"NU1S]3ZT 34444 %%%% !111
M0 4444 %%%% !1110 4HI*44 %%%% 'BGQE8CQA:C_IP3_T9)7GR\]:[_P",
MI_XK2T'_ %#T_P#1DE<"%P: )D0 4R5 _6EWX%-SWH IW-F'8%0.*@::6S(V
MDF/N!6F7!XJ-H%D!XS0!0ENO, RPZ>O6J$^%'+5<NM-9I]Z],8Q6<^C7!F+&
M1F&<X)H 8VP]6Q5;[3Y6=K9'M4MSI=X<;& %5ETV[BC;*JQ/OB@"8:U)".4#
MCZU,^OVPA5I%PQZJ.U91M91S( &'&*JR:=-+)E5XH ZE[N-+3SU<-'C);/%1
M:=>1ZA.XB)*@\9%<XNG2_P"IDF81G^$YQ5VTFETV8P0RA1G)PM '68(7;_".
MM2-&JJ"QKEI=4O90\*3G##DHG/YU5:#4'E0F[N'!Z98\4 =<T98_*Q&#GBHI
M(VD8AAQVYK+C@OHHPT<LA;^(L<YJVFMQQKMU")HF!'S ;@??B@"=;8KAOTJP
M]Q*T7E@[<GMZ>E03:QIZ!?WF\R+N4(,_GZ5EQ7FHS<K#&B]N#F@#9\QRPW'H
M,#Z4TRC=\S9JE#;WL\H>:0CC 5> *LG3W[$T 3]_4]J=;7EN;EK=I/G3&?;_
M #BF)!,B8#4B6I\\R.%W$Y) YH /[5EFU!K>VCQ&IPS'G=TZ>E7%B.3DYI\,
M*+TI\HVCB@!%3 J16(J%'-2;LT )(<]:ZWX7X'C[3QW_ 'O_ **>N389%=+\
M,B1\2=+';]]_Z)>@#Z$HHHH Q?%(SI<1])Q_Z"PK B0;C]T D]ZZK6+"34+1
M(H61660/E_H1_6LR+P]<QA<O"=IX^8\?CB@#/$6% X^OL*:Q&[.%&3],UK-H
M=RQ)WQ?F?\*8OA^Y&/WD6/7<>/TH SXP54A@0.@!_P ^]3)( V,=1QUJV=!N
MBP(DA'_ C_A3TT2Y4??BS_O'_"@"LN!]['3TZ_Y%-)&[*D=>]:*Z3.%(9XSQ
MZGK^5-;1[@_=>,?B?\* *2@$@'&>O2GYPHV9QWXJV-)N OWXR?Q_PIQTNX*X
M+1?F?\* ,_[O)Y!'8T8' )Z?F:O_ -DW'/SQ_F>?TI/[(GVXWQCGL3_A0!0"
MX7#<8[G^="_,S!LC;G-7_P"R;CIOCQ]3_A3$T:X5B=T73CYCQ^E &5<G>^U#
MM.>P[TY-Q;8.%6KPT"YW$LT)SG')X_2I(]$N$0_/%N/?)_PH YG6W9;=]S#9
MCC_/^%7-&5(]. ?H>P&/:KFI^&=0N[8QV\UNC9ZLQY^ORU-;>'KV&U"/+#OQ
MSM8X_E0!ESRF2;9&H"YPQ!&1_P#6J*5UD60;L_P8ZUK3>&[QY-R208]"QY_2
MHHO"^HQJ_P"^MBS9P26[_A0!R#W\MKJ0@D?<NXLK9[8[_P"?_KS7][NMQ(C(
M2&ZE1^7^?UK9N? ^ISW22^=:_*<G,C#\/NTR[\"ZI-"PAN+1')'5WZ#\* .2
MNIV4L$<+QO.2.!56]FWQ;B2OS?*3TZ>_7K_.NJG^'.LS)+FYLW+*%7=*_'_C
MA^OUQ37^&NKO&J?:[(*K!N'<$G'<[>G?']* .%NKLQ[5+[F5<D#Z].?3^M)I
MDLACEN)<C;@EFYY^GX_I[5UI^%6O>9(5N].56)PH=^!G/]SKP*NV?PRU6#3D
M@FN;)I,_O&5WP<=."OTZ^G?.: .11I9)V$CAA'CE3TP,?AT/Y54O)G>0L,(%
M("EF/ (&?Y#IZ>U>A#X:W84!9[?./F)=CNX[_+2)\,[E#M$UL$] Q_\ B: /
M/XTDE92%96R2H(Q_G@FM"#2YG?>SD+N)!(Z>G%>D6G@*!&5KJ;<5[+D_7K6_
M;:'86OW( QZY?F@#SG3_  G<7IC*POA6W;B,?KZ_A7::7X4M[0!I\,_HM="%
MP,  #VHQ0 U$6- D:A5'0 4ZC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC
M%&* "BC%&* "E%)BEH **** /%?C)'N\86K#_GP3_P!&25P 6O:?'O@35?%&
MN0WFG3V<<4=LL1$[L&W!F/93Q\PKF!\'M?V\WFFY_P"NLG_Q% 'GC'!Q3CC;
M7?K\&]?W?/>:;^$LG_Q%*?@YKI/_ !^:=_W]D_\ B* // AIX;8M>BK\']:
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:Q>&W\S<L,CECNC91C*@=6]: /4Z*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>item1image2.jpg
<TEXT>
begin 644 item1image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $]L:79E<B!8
M:6$    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q,   DI(
M @    ,Q,   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( 6<"@0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M8-LW?,6*\].I]:]<HH \ST?X6:I:^(GUG5O$,-W/)HS:48X[+RU1<85A\_8
M<8Y.>G09^@?!?4-*O/#<=_XDCO=,\/W$EU! EGY;M(S;N6WGC(!_,=^/7**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%9GB/59M#\.WNI6]F;U[6%I?)$@0
M$*"22QZ# [ GV-9M[XGNK;6)88;*)[.UFMH+B1I2)-T[!1M7&"%W*3DC.3Z<
M@'2T5SGA[Q)=:M<6Z7MG#;I>V*W]J8I2Y\LD#:^5&& 9#QD<GTR>CH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BN)\>7-U'=Q1VOV^0+IMW,(
M[&X,1CD7R]LKX9=RC)&WD\\*W:OH-U=7%]IFI2:C<3R7>K7%G(!,WDO$D,Q7
M;'G:.8E.0 >3SS0!WU%96CW,T^HZVDTA=8+X1Q _P+]GA; _%B?QK5H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRC1/#&F-XEL)]'N?!N?MT$S2V#CSH9(HT$L$*@'*L%W<G(WL<$X- 'LM%%%
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MVCWW?C0!Z5117G>O1,_C&[N5MXI4M[S35:[=L36I,@^2(8Y5LC=ROWVX;&*
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MK;:6/_OEE/\ [/7O7ABY^V^$=(NLY\^QADSZYC!_K0!J4444 %%%% !1110
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MZ]ZXG1M?_P"*AM8Y-;\62;KM+=UO-*MXHB[*'"2,(E*Y5E/4'D4 >HJH10J
M*H&  , 5Q/B+Q*L?CC2].BU:*TCMKF-;B S!6G>16VK@G)4  ^Y=?2NWJ"ZL
MH+QH#<)N-O*)H^2,, 0#^1- ')>$+BY^UZ29KNYN/[2T1+V<3S-(/.RF2H)^
M4'S#PN!P..*VO!G_ "(^B?\ 7C#_ .@"I=)\.6.C3&2S\XD1"",2RLXAB!R$
M3/1?\!Z"HO!G_(CZ)_UXP_\ H H VJ^7?C)G2?C_ &VH[3@?9+LD#/"$#/\
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M[#;6BQRR(Y9HS(68;&(V_O !G!X/ KI* "BBB@ HHHH **** "BBB@ HHHH
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MY5.(W);80X7"G@YV@]2: /98_%7AZ;'DZ]ICYZ;;R,_UJY%JFGS?ZF^MI/\
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MC)=M\7[J_P!;E,>F:Y((&C9LK; '$)^@S@G_ &B:^G* "BBB@ HHHH ****
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M'=/AEB8HZ2/(2K X(/(Y!JH_[37B<_ZO2-(7ZK*?_9Z /IRBOE\_M(^-)/\
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MVJ"*WD:Y\Q9+A_N(!M&< ,QYZ+[BNS^$'CS_ (3GP7')>2!M4L2(+P8QN/\
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MA%?_ $F@K9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"OJ$GDZ9=2F:.W"0NW
MG3+E(\ _,PR,@=3R*\HL];T\^)M%DM-?\(:S="YBM8XM/TH"YCB8X/EL)6V@
M9R>, 9^A]1UMKY/#^H-I"*^H+:R&U5L8:7:=@YXZXKS^QOO%]QJNF7*#58K,
M7,%HEO<V,:-<1*!]HN+@X_=YR=@!&2O0YH ].KF-6F-]XJM;"YMKM;&V9+@N
MEI*Z7$^?D!=5*A4QN.2.=O\ =-=/10!Q7@^&X-WI(DM;F#^S=#2RN#/ T8$V
M4RJE@ V/+/*Y'(YYK;\&_P#(CZ)_UXP_^@"MJL7P9_R(^B?]>,/_ * * -JB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"&\L[;4+.6TO[>.YMYEVR12H&5QZ$'@U'IVFV.D6*6>EVD%G:QDE(
M8(PB+DY. ..I)JU10 4444 %%%% !1110 4'I110!X]J.O:@_C*\L_"FH2KJ
M$=RZF+Q%);+;[MQ_U0/[\IZ;>,8Q7KL'F_9X_M&SS=@W^7G;NQSC/;->0^(9
M['6I)AKBZ_KJ2W=WY&EQ30V\?V>W;$DOR;6V!LJ-[;F(''->L:7-;W&CV<UB
M"+62!'A!Z["H*]?;% %JBBB@#&T+_D*^(?\ L(K_ .DT%;-8VA?\A7Q#_P!A
M%?\ TF@K9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/%-CJ\UQ:W6CV-I?"
M.*:&>&>]EMF9'"_<* KG@\L,CL1S7)://X6TWQ-86.K:7K.B:Q),%MHKK4I;
MF.5^P!25U(_WP*[?7_#-MXC:W6^O-0BMX=V^WM+MX$GSC[^PACC' R.IIVC>
M%-!\/ _V-I-I:.WWI(XAO;ZO]X_B: ->BBB@ K%\&?\ (CZ)_P!>,/\ Z *V
MJQ?!O_(CZ)_UXP_^@"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L7Q5KDV@
MZ/'-96R75W<W,5I;Q22>6ADD<*"S8.%&<G@GC%;54]6TFQUS3)=/U6W6YM9<
M;HV)'(.001R"" 01R"* /.M3\-ZS86.L:E>^&O"MQ'<1F;4(X;F>-[A%/F,H
M8K@9(R1P">M>C:5<PWFCV=S:1^5!- DD4>,;%*@@8[8!KG/^%8>&6XGCU&YC
M[PW&JW,D;>Q1I""/8C%=:B+'&J1J%11A5 P /2@!:*** ,;0O^0KXA_["*_^
MDT%;-8VA?\A7Q#_V$5_])H*V: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BB@\ T %8O@S_ )$?1/\ KQA_] %9?A75=2N;K3_[0O6NEU/25U#:T:*(
M')7*+M )7$@^]D_+UYI?"?B70K;P;I$-QK.GQ2QV<2O&]TBLI"C(()X- '6T
M5D_\)7X=_P"@]IG_ (&1_P"-'_"5^'O^@]IG_@9'_C0!K45D_P#"5^'O^@]I
MG_@9'_C1_P )7X>_Z#VF?^!D?^- &M163_PE?A[_ *#VF?\ @9'_ (T?\)7X
M>_Z#VF?^!D?^- &M163_ ,)7X>_Z#VF?^!D?^-'_  E?AW_H/:9_X&1_XT :
MU%9/_"5^'O\ H/:9_P"!D?\ C1_PE?A[_H/:9_X&1_XT :U%9/\ PE?A[_H/
M:9_X&1_XT?\ "5^'O^@]IG_@9'_C0!K45D_\)7X>_P"@]IG_ (&1_P"-'_"5
M^'1_S'M,_P# R/\ QH UJ*R?^$K\/?\ 0>TS_P #(_\ &C_A*_#O_0>TS_P,
MC_QH UJ*R?\ A*_#W_0>TS_P,C_QH_X2OP]_T'M,_P# R/\ QH UJ*R?^$K\
M/?\ 0>TS_P #(_\ &C_A*_#W_0>TS_P,C_QH UJ*R?\ A*_#O_0>TS_P,C_Q
MH_X2OP]_T'M,_P# R/\ QH UJ*R?^$K\/?\ 0>TS_P #(_\ &C_A*_#W_0>T
MS_P,C_QH UJ*R?\ A*_#W_0>TS_P,C_QH_X2OP]_T'M,_P# R/\ QH UJ*R?
M^$K\/?\ 0>TS_P #(_\ &C_A*_#O_0>TS_P,C_QH UJ*CM[F"[MTGM)HYX7&
M4DC8,K#V(ZU)0 4444 %%%% !1110 4444 %%%<U:^([R?6HD-O"+"?4)M/C
M(8^:'B1V+GM@F)QCZ'/.  7-"_Y"OB'_ +"*_P#I-!6S6+H9_P")KXA_["*_
M^DT%;61ZT %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%
M&11D>M !11D49% !11D49% !11D49% !11D49% !11D49% !11D49'K0 449
M'K1F@ HHHH **** "BBB@ HHHH **** ,/1/#*:--'(;V:Z%O:K9VRR*H\J$
M'..!R>%&3_='OG9\F/\ YYI_WR*?10!G7VE+=:CIMPOEJMG,\C*5^\#&Z8_-
ML_A5[R8O^>:?]\BN,\4-)_:NJW"W$Z/IUC9SVP29E57::7<2H.#D(H.<\#'<
MUVU #/)B_P">:?\ ?(H\F+_GFG_?(I]% #/)B_YYI_WR*/)B_P">:?\ ?(I]
M% #/)B_YYI_WR*HPZ6L>O7=^?+*7%O#"J;>04:0D_CY@_*M&N&T2:8^)([F\
MCN@;G4;VWCG%XS+)L:0*C0GY0@6/@@YW+TY.0#MO)B_YYI_WR*/)B_YYI_WR
M*?10 SR8O^>:?]\BCR8O^>:?]\BGT4 ,\F+_ )YI_P!\BJ.L:6NI:=]FC\N-
MO.BDW%>R2*Y'XA<5HUS=[;SR>-!"NHWD4=WI5P J. L#!XE#H,8W#<QR<]?3
MB@#H?)B_YYI_WR*/)B_YYI_WR*Y[PC$"]_>63S'2YG1+,2SO+Y@0$-*"Q) 8
MGCU"AOXJZ2@!GDQ?\\T_[Y%'DQ?\\T_[Y%/HH 9Y,7_/-/\ OD4>3%_SS3_O
MD4^D<%D8!BI(P&';WH SETI5\12ZC^[V/:I $V\@J[-G_P >J_Y,7_/-/^^1
M7G[?:QI^F6O^G:N1?:@C0?:S'),$DD"LSY4$+@#&1]X8' KKO"\SW'A'299;
M@W4CV<1>=LYD.P98YYY/K0!I>3%_SS3_ +Y%'DQ?\\T_[Y%/HH 9Y,7_ #S3
M_OD4>3%_SS3_ +Y%/HH C>")D(\M!D8^Z*J:/IBZ;H=A8R".1[6VCA9PO#%5
M )_2L3QE9_:1%%;75VNI7:FWL4AG9%A;.6G(4C.P<Y.1P%'+<Y^DZ^-0^)A3
M^T&\I[6ZACLMQ 7RI(@'*]-Q)E(/]W;0!W( 484 #T%+110 4444 %%%% !1
M110 4444 %<Q:^'K^#6HBTEO]@M]1GU!'#-YK-*CJ4*XP #*QW9.< 8'6NGH
MH S+KPUH=]=/<WNCV-Q/)@O++;(S-@8&21D\ #\*R]<\$:+=:!?V^G:)IL5W
M+;R) XMD7:Y4A3D#CGO73UC:_=7:76E6-C<&U:_NFB>=45F15ADD^4,",DH!
MR#P30 ?\(?X;_P"@!IO_ (")_A1_PA_AO_H :;_X")_A4_AV^GU+P]9W5V5,
M[IB0HN S D$@=LD9Q6E0!C?\(?X;_P"@!IO_ (")_A1_PA_AO_H :;_X")_A
M6S10!C?\(?X;_P"@!IO_ (")_A1_PA_AO_H :;_X")_A6S10!S%_X(T6:\TU
M[71--6.&Y+W ^S(-R>5(H&,<_,R''MGM5[_A#_#?_0 TW_P$3_"LGQ/X@N;#
M7&M(M0:PC@LUN=XLVG1F9V7]Z0IV1@)R?E^]G/%=?0!C?\(?X;_Z &F_^ B?
MX4?\(?X;_P"@!IO_ (")_A6S10!C?\(?X;_Z &F_^ B?X4?\(?X;_P"@!IO_
M (")_A6S10!C?\(?X;_Z &F_^ B?X51T?P1HMMIWEW^B:;)-YTK;C;(WRF1B
MHSCLI ]JO^)KV_T_2TN--:%2+B%93*I;Y&D52% QR<]3TZ\U4U*ZU6U\264<
M5ZC)=7(2.R6($>0J9DD=OO ACP0<<H,9- %K_A#_  W_ - #3?\ P$3_  H_
MX0_PW_T --_\!$_PK9HH QO^$/\ #?\ T --_P# 1/\ "C_A#_#?_0 TW_P$
M3_"MFB@#&_X0_P -_P#0 TW_ ,!$_P *H:UX'T:ZL8DT_1--CE6ZMY&(MT7,
M:S(T@SCN@88[YQ745S.M:OJVGWFK>0;8Q0Z5)=6J%#GS%[NQ(&,GIQP.O/ !
M=_X0_P -_P#0 TW_ ,!$_P */^$/\-_] #3?_ 1/\*K>%-6EU.34$-Y)?6]O
M)&L4\T AD):,,P*X7@9!!P.N.<9KHJ ,;_A#_#?_ $ --_\  1/\*/\ A#_#
M?_0 TW_P$3_"MFB@#&_X0_PW_P! #3?_  $3_"C_ (0_PW_T --_\!$_PK9J
MKJ27DE@Z:;-'!<,5 ED7<$7<-Q [G;G&>,XSQ0!@VW@?1H]<OYYM$TUK66.$
M0)]G0[2-V[C'&<CZUMZ?HVF:4TATS3[6S,F Y@A5-V.F<#GJ:X^?Q3J\.@!K
M25+F62ZD>"[DC'SV:, 92JX!+$A01@$,& XKO: "BBB@ HHHH **** "BBB@
M HHHH **** ,V^\/Z=J-\EW=PNTJA =LSHKA&W*'4$!P&)(# ]3ZUI444 %%
M%% !1574M2L](TZ:_P!3N8[6UA&9)I#A4&<<GZFJ]_XATC2]%75]1U&WM]/<
M*RW,CX0AOND'WS0!I5F0>'M-M]4.H10N)R[N 9G**S_>94)VJ3W(&>3ZFM)6
M#*"IR#R#2T %%5[J^M;+R?M<Z1>?*(8MQQO<]%'N<&K% !14<\\5K;R3W,B1
M0Q*7DD=L*B@9))/0 5B6/CCPUJ5G=W5GK%O)#9JK7#9*^6K=&((S@]CTH WZ
MJ7>EVE\[/<Q;V:![<D,0?+?&Y>#QG:.>O%6Z* *6FZ3:Z1"8K+SQ'@ ++<R2
MA0. !O8X'L*NT5C:UXNT#P[<1P:YJUM8RRH719GVEE!P3]* -FBF03Q7,"3V
M\BRQ2*&1T.58'D$'N*?0 4444 9MQX?TZYACC>*2/RY9)D:&=XG5I"2Y#*0>
M2QR,X_(5=M;6&RLX;6UC6*"%!'&B]%4#  _"FQ7UM/>7%I#,CW%MM\Z,'F/<
M,KGZBIZ "BBB@ HHHH S;[0+#4;Z.]N5G6YCC,2R074L)"$Y(^1AD9 _(5;:
MS@:^CO&0&XBB>)'R>%8J6'XE%_*IZ* "BBB@ HHHH **** "BBB@ HHHH **
M** "LS6=*FU'['-9W2VMW93F:&1XO,3)1D(9<C(VN>A'./I6G10!3TC3ETG2
M+:Q21I1 FTR,,%SU+''J<FKE%% !1110 45%%<P3P^=!-')%S\Z."O'7D4Z&
M>*YA$MO*DL;='1@P/XB@##UWPU+K%Q,T%_\ 98KRU^QWB&'>9(LD_*<C8WSN
M,\CYNG%;]%([K&C.[!549+$X 'K0 M%(K!E#*05(R"#UI: "BJPU*Q:_-BM[
M;F[49-N)5\P#UVYS4\<L<T8>%UD0Y 93D>E %;5-/75+!K5W,:L\;[@,_=<-
M_P"RU070[M/%$^KIJ*E)E2,P/!N*1J/N*V[@%B6/&<GV&-JB@ HJ.>XAM8C+
M<S1PQ@X+R,%'YFB">&YB$MO*DL9Z/&P8'\10!)1110 5E:KH$.K_ &H3RNBW
M5C)9,$ R%?JPSWK5IK2(CHCNJLYPH)P6.,\>O% &;I&DSV-S=W=_=I=W=UL#
MO'#Y2!4&% 7<WJ23GOV %:E%% !1110 5GZ[ILFL:+<V$-VUH9U"&5%R0N1N
M'4=1D<$'G@@UH44 <Y>>#K/5=*^S:NEM<3A!%'<):K&8XP00H&3@#^M=$BA$
M54&%48 '84M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <M\2
M@&^'^H!@""\ (/?]^E>5^*-]UX'U#PA*2X\*VE_-/G^ZJ%;0'ZQS;OK'7N]W
M9VU_:M;7L$<\#D%HY%RIP01Q]0#56;0=*N6OVGTZVD;48Q'>%HP?M" $!7_O
M  D<T >?^(M<UB$^*=0M-8GM!X<BMFMK.-$\N?=&KMYF5+-N)VC!&,<<U+=Z
MMK8UO4;Q-:N4ALO$UGIT=FJ1^4T,HMPX;Y=Q/[UB#GBNTOO">@ZEJ45_?Z5;
M3W404+*Z9/RG*Y]<'D9Z5:;1M-<R%K& ^;<)=290?-,NW;(?]H;%P?\ 9'I0
M!Y6^G78LXT.MWTCR>,O*$D@B+18+@NN$ W$'OD# P.QOSZIXB73OL=MJ=Y>F
MTUBZMY5@D@2^N8$7(V;UVL5+ D  D <]<]^OAK14OI;Q-*M%N9IEN))1$ SR
M+G:Y/=AD\^]1W_A70M3@,-]I=M,AG:X.4P?,889\CG)'!/>@#$N;O2]9^#LD
M^NZO+-IMYIVVXU$0>4Y5AM+E #M.3R,8_"N9U?6-5T"'6X=16R?Q!9Z*LUIK
M-F@'G6XE"X>-LA6#'.!E3GC&,5Z<-,L5TK^S!9P"P\KR/LOECR_+QC9MZ8QQ
MBLVP\%>&M,L[JTL=$LX8+Q0MP@C!$JCH&SU [#I0!R&I:MK::UJUY'K5S'#I
MWB*PL(;-4C\IHIA;"0-\NXY\YB#G@U=TJ^U*^UV74;CQ(;6--<FT]=-D1/*E
MC16 1>-WF'&_=NZ9&,5V+Z-ILGG;[&!O/G2YER@^>5-NQSZL-B8/^R/2JZ^&
M-$373K2Z9;#42=QN=GS;MNW=]=O&>N.* .%\&^(O$.J:]IEW>RW0M=0EO8YH
M[B2V6$B-FV"%%;S<KLPV1SDD]JO>(X]9E^+-JGA_[ +AM!E#F_5V0+YZ= O)
M.<<?6NKM/"VAV&L2:K9Z7;0WTI8M.B8;+'+$>F2,G'7O5\V-J=0%^;>/[6L1
MA$^WYPA()7/ID X]J .#TG2=1T7Q!H?A.VUNYCT_3='6XE$,<8-RZ2A<$LI*
MH02" <XQ@UGZ#XBUJ.U\.ZO<:O-J#:Y875Q/92(GEQ.D?F+Y>U0RA3\AR3G/
MK7IGV*V-_P#;?(C^U>5Y/G;?FV9SMSZ9YQ6?IWA30=)U&2^TW2K:VNI RM)&
MF" QW,!Z GD@8R: .,T_5]6TSP?<:Y)XE_M2ZF\.-J@L9XX\K*$W;T"@8CR=
MNTY[<]<YH\1^)M/T'56EO;N,O864L$VH/:O-%)+-Y<DJK$3B/#!AN& 5/TKT
M;2_"NA:*9SI6E6MK]H79+Y<8^9>3M_W>3QTYJ*S\&^'+"QN[.TT:TCM[U!'<
M1B/(E0 @*<]@"<#H,\4 <)'/?>'O$^O);ZK/<R'5M&MWGN C2-'(RJR-A0/N
ML1G ."._-7;_ %S6[S5;C3K35Y+-7\4KIRRQ11EH[?[#YK*NY2,[LD$@D'VX
MKKH_!OAV+3;C3X]'M5M;K:9X]G^L*G*ECU)!Z'J*L6GAO1;!$6STRVA$=Q]J
M7;&.)MFSS/\ >V\9ZXH \^U/7?$</BO4H+.ZO6@T>[L+97>2U2W='$9D,Q<A
MRSAV V#J%QSFO5!TK)O/"VAZAK$6J7NEVTU]$5*3NF6!4Y4^Y!/!/3M6M0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?_ %;?
M2G4$9!![T >$>%+F;2?A_<>&[4E)=?M;.2QQV-S^XG(_W=AD/^]6[X+O-1L_
M#WA[PUX=FM[ 7,VJR&>: S>7'#=, BKN7DF0<D] :[RW\%Z':SZ+-%:'S-#C
M>*Q8R,?+5EVD'GYN/7.*AE\":,UG:06WVNS:REFEMY[:Y=)$,S%I!NSR&+'@
M^WH* .:MO%_B36K6Q2PFT^RF?2[JZN)6MFE!E@F$6$&\85CD\Y('YUG76L:[
MK<>I74]_"EC=>#4OGL5@;"F2.7(4[\ [AG=CE<#'&3Z!9>$M'T^.WCM+=D6W
MLGL8_P!XQ_=,0S Y/)) .X\U7;P-H;" "*X18-._LP*EU(JO;[2H1P#AL!C@
MG)!.: .5T_7?%6F:7)86XL]3N5T"WOK*)("A1B=A0Y?]Y@ $<J21CC/'3>"=
M<N-<T^[DNKZ&\,-QY8Q:O;31?*"4FB;.UP2>G!&#5F]\&Z+J%N\-S;NRO9)8
MG$K B)&W+@@\$-SGKQ5G1/#]GH*7/V5[B::[E\VXN+F8RR2MM"C+'T50 .G%
M 'G>GZ98:/X@L&U2QM[VUN]9EN--\1V$BF1II&<B&?')'+)D$J<*"!5[3-?U
MN]AT?3M$.F:6+R#49Y&6S+*AAN%1=J!P.=Y+9[Y-=':_#[0[/58[V+[84AN&
MNH;-[N1K:&9B276(G:#EB1V!/&*OV7A;2M/FM9;6!E>UBGBB)D8[5F<22#D\
MY90?;M0!R%EXM\2>);32ET673["ZF\/Q:O,;B%I$DDDX6,?,-B95LGD\C\6>
M(/'.OVFOWEGIEOO?3K:UF:UAT^:Z^TO*277S4XC 4?*2.3D]!BNANOAWH-U8
M65F$NK>&SLO[/46]T\9DMN!Y3D'++QWYZ\\FI=4\!Z)JUYY]Q'<1!HHX)H;>
MX:..XCC)**Z@X(!)_ XZ4 9?Q63S?"VGI]C2^W:S9#[+(0%F_?+\ASQ@].>.
M:R;6VUWPAIU[=V&G:=HTFM:S:PVVF@^;#:JX6)G.S:-S$;B%XX'.2:]!U/2+
M/5X8(K^,R);W$=S& Q7$D;!E/'H0.*=J.EVNJ1P)>H76WN([F/#$8D1MRGCW
M'2@#A-7\3^)M,36[A+VPDA\-I;K<QM:$&^9D5Y&!W_NQM<!1\W(.<UIPZSXC
MU/Q%J#Z9/I\>G:;J<=A):SQ$/,A2-I)/,W<,/,^5=O.WGKQHZKX&T?6-4EO;
MO[4#<>5]J@BN&2*Y\LY3S$!PV/U P<TZX\$Z/=:\=5E6X\QIX[F2!;AA!)-&
M $D:/."P 7G_ &1Z4 <U9^-M;O?&+V]O"TEE'K$FG20)ILQ"1*I'G&X^YG>/
MN^A]>:I6FJ:SK7B/P?K&HSVIM+J^OC;VL4!5H L$RJ"^X[LJ,G@<]*[$>"-'
M&O?VJ!<A_M/VS[.+AO(\_;M\WR\XW8_7GKS3+'P)HNGZM#J$ NB]O-+-;PO<
MNT4#2AA)L3. #N/';MB@#!@\=:K+X>T&^,=J)=1\/W>I3 1M@2Q)$RA?FX7,
MC9')Z<U7NO%OB.TL_#T-U=VXNM<BENS+::5-<?9XUCC(C$:,68[GY<XXSP*Z
M*R^'NA6*JD:W<D<=K+9PQRW;LL,$F-T:@G ' ]^!SP*N:CX0TS4;33X"UU;-
MIJ%+6>UN&CDC4KL*[AR05 !SZ ]10!/X8U&]U;PMIU]JMJ;2]GMU>> H5V/C
MD8;D<]CS6K532],M-&TJVTW3HO*M;6,1Q)N)PH]SR?J:MT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>item1image3.jpg
<TEXT>
begin 644 item1image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $]L:79E<B!8
M:6$    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,T-   DI(
M @    ,T-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C Q.3HP,3HR-2 Q-SHR-#HR-  R,#$Y.C Q.C(U
M(#$W.C(T.C(T    3P!L &D =@!E '( ( !8 &D 80   /_A"QUH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG[[N_)R!I
M9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M
M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/CQX;7 Z0W)E871E1&%T93XR,#$Y+3 Q+3(U5#$W.C(T.C(T+C0S.3PO>&UP
M.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D
M9CIL:3Y/;&EV97(@6&EA/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC
M<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T
M83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_
M/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;
M'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*O_  !$( 7 "AP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MC_9J\+E&92?$."0<=YJ /HFW\3:5=^*+KP];7/F:E9PB:XB"G]VIQC)QC)W
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M2O0** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$9K?3K6&UA$T+>7"@5<F9,G KHJQ?%O_ "+4_P#UUA_]&I6U0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7E"VUT;J]_MO3_'=U=?;)\36-\\4#Q^8VS8JS*
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M[]_]8#$V#Z<],4 >R:5;S6>CV=M=3_:)X8$CDF/_ "T8* 6_$C-6ZALP%L8
MJ1(!&H"PG*+QT4^GI63KGB4:--.JV4MRMK:->W+(ZKY<0)'&?O-\K<>W7I0!
MN5@V/_)0-:_[!]E_Z'<TEEXKCO=3BMULIDMKBXFM8+HLN'EBW;QMSD#Y'P>^
MT].,K8_\E UK_L'V7_H=S0!MS31V\#S3NL<<:EG=C@*!R2:99WEOJ%C#>64R
MSV]Q&LD4B'(=2,@C\*\?_:$\<MI'A]/#&FN?MFIKNN2AYC@ST_X&>/H&]:SO
MV=/'+3V<WA#4G/F0 S6#-_$F<O'^!.X>Q;TH ]WHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@L>3\S-UYYKMJY75](72O"]^6NIKN>ZNH9IYY]H9VWQJ.% 4 *JC@=O6NJH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"!'N^\0,@8]ZR?AW/KLNHW0U>379H?LD.\ZQ D7E7&6WK'M4;UZ?-R.!R<T
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M+J4-D]NN^>.^_=R63 [=S+GL3C(R,G&: /1Z*BM;>&SLX;:T18X(4"1HO15
MP /PJ6@ HHKG)SKP^(5K%%>D:*]I)-+%]E! D4HJIYG49W,W_ : .CHHHH *
M*** "BBHKJ2:*TEDM8/M$RJ2D6\)O/89/3ZT 2T5D^&-:D\1>';35I+(V:W<
M8ECB:0.=A&021_*M:@ HHHH **** "BL+QKI=UJ_@W4K739)HKXV[M:O#<-
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M)4^8H@3([$G+#_OFO/-<^#?CK4O%'VF[DTN"]O&9[>%+LC8J 85/EX"+M ]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%,FFBMX'FN)$BBC4L[NP55 Y))
M/04 9'BW_D6I_P#KK#_Z-2MJN=\0:A9ZGX0EN=-NX+N!IH@)8) ZDB9,\CBN
MBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //\ 2;>!=8TN_6-%
MO;C7M3AFG ^>2,&YPK'J0/+CP#TVK6]<VFN6?BJ\U'2[*QNX+JTMX2)[QH61
MHVE)X$;9!$@[]JTH="TRWU5]2ALHDO),[I0.<G&XCL"<#)')QS6A0!A?;?%7
M_0#TO_P:O_\ &*K:=K?B34],MKZWT/31%<Q+*@?5'!PPR,_N/>NE=UCC9Y&"
M(HRS,< #UJKI45G!I-K#I;I)9Q1+'"R/O!4# ^;OTH S?MOBK_H":7_X-7_^
M,4?;?%7_ $ ]+_\ !J__ ,8K=HH POMOBK_H!Z7_ .#5_P#XQ1]M\5?] /2_
M_!J__P 8K=HH POMOBK_ * >E_\ @U?_ .,56U'6_$FEZ7=7]SH>FF&UA>:0
M)JCD[5!)Q^XZX%=-5>_M+?4+">PO!NANHFB=-V"RL,$#OT- &2+[Q2R@C1-+
MP1G_ )"K_P#QBE^V^*O^@)I?_@U?_P",5KP75M.\D5M<12O =DBHX8H?0@=#
M]:FH POMOBK_ * >E_\ @U?_ .,4?;?%7_0#TO\ \&K_ /QBMVB@#"^V^*O^
M@'I?_@U?_P",4?;?%7_0#TO_ ,&K_P#QBMVB@#F+C7?$EMJ%I9R:'IOFW9<1
MXU1\?*NXY_<>E6OMOBK_ * FE_\ @U?_ .,5?V:?J.H17$<T<\]@[*/+E!\M
MF&"& /7'K5U'610R,&4]"#D&@##^V^*O^@'I?_@U?_XQ1]M\5?\ 0#TO_P &
MK_\ QBMVB@#"^V^*O^@)I?\ X-7_ /C%'VWQ5_T!-+_\&K__ !BMVB@#"^V^
M*O\ H!Z7_P"#5_\ XQ59=;\2MJDE@-#TWSHX5F)_M1\;69@/^6'7*FNE9E1"
MSL%51DDG  K/\_2DD.L_;+<)+&L/V@SCRRH9B #G'5C0!3^V^*O^@)I?_@U?
M_P",4?;?%7_0#TO_ ,&K_P#QBMT$$ @Y!Z$44 87VWQ5_P! /2__  :O_P#&
M*/MOBK_H":7_ .#5_P#XQ6[10!A?;?%7_0$TO_P:O_\ &*/MOBK_ * FE_\
M@U?_ .,5NTCNL:%G8*JC)). !0!S.G:]XCU2T:XMM#TT(LTL)WZHX.Z.1HV_
MY8=,J?PK?L7NY+1&U&"&WN#G='#,95'/&&*KGCVJ"R73M,;^SK::)))'DN!
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M^W>)_P#H!Z;_ .#1_P#XQ1]N\3_] /3?_!H__P 8K<HH P_MWB?_ * >F_\
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MW&,\GF@!GAF:.X\)Z5-# MM')9Q,L*$E8P4&%!/85J4U$2*-8XU5$4 *JC
M'8"G4 %%%% !7&_$IY9/#4MF;6YFM)()I;AX(RP&Q,HC8Z N5)[81@>M=E39
M(TFB:.5%='!5E89# ]010!YTC-+JC77DHEF=:LMY=2MRLAMX0 !V7YDSGG!D
MKT>JATK3VOUO38VQNT&%N#"OF*,8X;&>A(JW0 4444 %%%% !1110 4444 %
M%%% !1110!PYC3^VEF"K]J_X23;OP-^/LQ&,_P"Y^E=Q57^R]/\ [2_M#[#;
M?;<8^T^4OF8QC&[&>G%6J "BBB@ HHHH ;+&LT+QONVNI4[6*G!]".1]17#6
M$5I9>%K:*ULH9KX7]_;:; XRB,UQ*"2O3:JC)/7:"!R<'NZI7.C:7>1HEYIM
MI<)&S,BRP*P4L<L0"."3R?6@!VE:>FDZ-9Z=$[21VD"0*[=6"J%!/Y5;ID44
M<$*101K''&H5$0850.@ ["GT %%%% !7,^+;2UU#9IR01RZEJ4$EHCN-WD0-
MCS9,'C &WZL4'0\=-5.]T?3=2D1]1TZTNW085IX%<J/09'% ''6\C_\ "S[2
M2YL[U&\JXM+<R1$HL*;,-N[[FW,3Z% >E=[3/(BWQOY2;HP51MHRH/4#TZ#\
MJ?0 4444 %%%% '&^)8K1=0@NK1;=G35K47S*29UD.Q8@N> /F3(_NENY-0^
M @\,6E13PV9DFT."5)K:,HRKQ\CDL0_)R&P.=W%=:^E:?+J"7\EC;/>(,+<-
M"ID7MPV,]S^=%EI6GZ<\KZ?8VUJTQS*T$*H7//7 YZG\Z +=%%% !1110 &O
M*)YI9]0U*2ZL;J'4+Z339F%S"5C5_MI$4;'^Z!L4XZX8CFO5ZAGLK6Z61;FV
MAF65 D@D0,'4$D YZCD\>] &-X25TM]32=8UG749?-6'_5@D*1L]L$9_VMU;
M]0VMI;6-NMO96\5O"I)6.) JC)R>![U-0 4444 %%%% !1110 4444 %%%%
M!1110 4444 9'BCQ+9>$O#\VKZFD\EO"Z(5MTW.2[!1@9&>2*I^(/'.C^&_#
M-KKM\TTMG=E/)\A S/N4N"!D<;02?855^)2J_A:U1P&5M7T\$'H1]KBKS#68
M9[CPYK6AW(81>"["ZA7(X8S/MMS^%N"/^!T >]J=R@CN,TM>.>,+JT&I>+IK
MV_DAUFRCM#H<8NF1@3&I7RD!&[=+N!X.<8-3ZY;EKGQ)J\DUR+VP\1:=%;,+
MAPL*LMIO"J#CYO,8'CF@#T>^\1Z=8*A:7SMU]%8,(2&,<TA4*K<\?>4GV-:M
M>*76G:.M]K&G)+LNV\7V:R0K=-Y@@;R,-C=D DMANOOQ5K48(;/3=1TV'48;
M.WMO%!CM;:_FE%M,/LB2>1)(#E%+,S#/&X 8/2@#UVXGCM;:6XG<)%$A=V/1
M5 R3^5<OH_Q!L=7U"WM1IFJ69O+9[JQ>Z@55O(UP24PQ.<,IPP!P:B\)ZC9W
M'PK2]2RNI;1;><M:23?:'=59PR(Y^^IP0I[KMKE_#6MVMGJ=CI/AG7%UK1;S
M39YXK>1UDN-("("JF1>=IW;=K\@J ": /4[.Y^V6,%SY,L'G1J_E3KM=,C.&
M'8CN*FKQ:"V&LZ' VI7%U-Y'@:WND'VEU'G8D_>'!&6XZFI[V[TR\NY&\9ZM
M=6HC\.V,^GR1W#))YC>9YDD0!^>7<(QT)Z#'- 'L59/B/Q#;>&=-CO+R"XN%
MDGCMXXK9 [N[MM4 $CJ37EGBZ[N?^$VUH3ZA;6DML=/.G2W5Y+'-&"03Y,*(
M?,W/N5OR/ KM/BC'+-H&E16\YMIGURQ6.8*&,;&9<-@\''7!H W?#_B:T\0_
M:T@@NK2YLY!'<6MY%Y<L1(W*2.>"#D$&MBO-?$GAE]%T!Y9M7O;S4-8UG3TN
M[W<(79//CC"*(P H"DCCGD\UB^*X=)TR[\4VMW>2V<VEZ1 V@Q->NC(Q60AH
M@6R[&0*">3PH]J /9**\DOY].G\5:J?%^IW=E?6ZZ;_9RP3LLJE@,^5&.&W2
M[E;@\<'I535;N=OB%J)N+^TM;R#7K.*U:6]E%P("L1\N.!4(9'!D!.0,EL_=
MS0!ZOJNL6VCK9F[$A%Y=1VD>P9^=S@9]JOUXG,^G3ZY:S7EZSZ^/&GE/"]RQ
M<0+*WECR\XV!-A!QC)'K6K;:ZAN+&P.IYO?^$SN8WM_/_>>5NF(!7.=N"OMR
M/:@#U>BO%IH7MOADNKI/*T]]KGD7T]S>R(GV<7SKL9AGRX^@) Z$]:[;X:/N
MTC5$2[MKB"/4Y5A6TGDFB@7:A,:2.J[@&+'C@9QVH [.BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_$WB[3O":V#:J)ME]
M<BVC:) P1B"=S<\* "2:;KWC'3/#NL:1IE_YS7.KS^3;B) P!W*N6YX&749]
MZQ?B)I4.NZAX<TFY.(KVXNX&/INL;@9_#.:X6&]NO$LVD:[J:,LUEJ^EZ1AA
MTF1]UR1]9"H_X!0![E17CFF75N=4TJYBOI&\43>)KBWO(?M+&3[.'F!5H\X$
M8C5".,# (J71K&-YO#NH22W+W-_X@U*RN':YD.^#%WB/&<!1Y:D8Z$9% 'I/
M_"1Z<U]IUM!-]H.HM,D$D)#(3$#O!.>V"/J*U:\0\+:5HFH'PIIX<2$7VIK>
MP)=-N5EW[5<!LKQ@XXSWSFH;VYCC\):*UYJ,4RVL.I :?J%Y) MQ%'<%0T<P
M.!,BJH4-G@GIUH ]GUG5[70=&N=3U!F6WMDWOL7<Q[  =R20 /4UC:=XY@OY
M+ZW?1]6M;^R2.5[&>!?.>.1BJNH5B",@YYR,&H-=O-(;X4_:=;M;VXTF:R@\
M]&.9UC?:-[G(.5SN8YR-I-<9/K]PND^(M*LO$":_:6=K;36^K1,IEBW38\F2
M1.'; SG@X)S0![#17D>M6^=1\0:L9[C[99>*=.@MF^T.%AC<V@=0N<882,#Q
MSFK7FZ-+XXU%]<U2ZM]:AUZWAL8H9VWF(QQE$$?3RFR^XX_O'/% 'J58?B'Q
M5;>';FPMI;&^OKB_9U@ALH@['8NYN"1VKS33;RZD\?K)<WUI!J(\2SPE6O)6
MNI;<!PL7D!"HC\O:P8G' /4UUGCJUN[WQQX.@T[4&TZX:2\VW"1+(5_<<_*P
M(.1Q0!U.@Z[9^(]*%_8"54\QXGCFC*212(Q5D93T((K2KS.^\(VMEKWAC0)[
MR]NK:\DO[F^8SF)KN1@KDOY>WC<>@P.,=,YR+VYMEU:[N#?2+XGC\506UO#]
MJ82?9C+&-@CS_JS"6)XP>30!['17E>B2Z3-XKDFU34[J/Q(/$-S!'!%.2[0@
M/L1H^0(?*"MG &<'.:R_!]W<S>,-.EFOK1-3DO\ 44NHA>RR7,X7S<))%MVH
MJ$1E26Q@#'+8H ]9NM8MK36K#2Y1)]HOUE:$JOR@1A2V3V^\*OUX;X9;3IKW
MPE<6-Z]SK-QH]])J0^TM)(+@QINWJ2=K;]PZ#ICM5Q?$*7N@:<MCJWGS1>!;
MN6?RKC<RRA( &;!X8$-R>1S0![-17D>NV::3I_@ZVC:-K"_:2>^.IZC+%%/.
M;<%?,D^8C.&(7ID#BNV^'4DDOP_TMIKT7QV.%N%+L'0.P7!<!F 4 9(YQGO0
M!TU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",H88
M8 C.>12&-#NRBG=][(Z_6G44 0R6EM+,DTMO$\L?W'9 67Z'M4AC0YRBG)R>
M.IIU% ##%&6W&-2W'.T9XILMM!/$T<\$<D;G+*Z AC[@U+10 B(L:!$4*JC
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M!@C,RC:)2@W >F>M2T4 1"UMQ<FY$$?GD;3+L&['IGK4A52P8J"5Z''2EHH
M0JI8,5!(Z''2HS:6YNA<FWB,X&!+L&X#TSUJ6B@"(6L N3<""/SR-IEV#<1Z
M9ZT+:VZ7#7"01K,XPT@0!F'N>IJ6B@"*.UMX9&>*")'=BS,J %CZGWHCM+>$
M,(K>) Q);:@&<]?SJ6B@".:V@N8?*N(8Y8_[CH&'Y&GJJHH5 %4#  & *6B@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>waterfallchartasof12312018je.jpg
<TEXT>
begin 644 waterfallchartasof12312018je.jpg
M_]C_X0_P17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ %?D    G$  5^0   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3D@*$UA8VEN=&]S:"D ,C Q.3HP,SHP-" Q,SHU,CHU
M-P     #H $  P    $  0  H ( !     $   X,H , !     $   K,
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #K(         2     $
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M_P#1VV_Z*O[1T22G_]+TW+PJ<MK6VD[6S $<G3>'$%S7L_,>Q57=,Q<1OJU
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M*7$?XX/_ !'._P##-7_?UVZXC_'!_P"(YW_AFK_OZ2GR'ZI_^*KHW_A_%_\
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M    &@!- &$ <@!K &4 = !I &X 9P @ "@ ,0 Y #( +@ Q #8 .  N #<
M-0 N #8 ,  I       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&(
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M         @  .$))300"       "   X0DE-!#        $! #A"24T$+0
M    !@ !     CA"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      .5    !@             *S   #@P    P
M %< 80!T &4 <@!F &$ ; !L "  0P!H &$ <@!T "  80!S "  ;P!F "
M,0 R #, ,0 R #  ,0 X "  * !* &4 ;@!N &D 9@!E '( ( !- &$ 9P!G
M &D ;P I     0                         !              X,   *
MS                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   *
MS     !29VAT;&]N9P  #@P    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  "LP     4F=H=&QO;F<
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M# P,# P,# P,# P,# P,_\  $0@ >P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M9Z%?TO3V_324WDDDDE*22224I))))2EQ'^.#_P 1SO\ PS5_W]=NN(_QP?\
MB.=_X9J_[^DI\A^J?_BJZ-_X?Q?_ #]6OI5?-7U3_P#%5T;_ ,/XO_GZM?2J
M2G__U/3<N^ZA@?52;SK+6DSQIPUWTOHJH<S)O;LMQG4M;94=Y)@_IJ@S;N8S
MZ7N_J+35?-_F6_\ &T_^?:TE);+J:@#:]M8<8&X@2?[2B,G&=9Z;;6&R=NP.
M&[=[SMV_O?HK?^V[%0ZUAU=1-73[J&7L>VR[WO<S:6AM$MV,L]^W*?L?_@;/
MTE?Z3^;JGHV+1U?'ZK=B5G,-FP7MNL+@7MM9O-;F-KLVLL?4S?\ S=3TE.\J
MEG_*N/\ ^%[_ /J\16U4R:<HY5.3CBMQK996YEA+?YPU/W-<QMGT?0_=24KJ
M7\W1_P"&*?\ JVJVJ-E74<@U-M936QEC+'.:]SC##OVM::Z_I?UU>24I))))
M2DDDDE*22224I))))2EQ'^.#_P 1SO\ PS5_W]=NN(_QP?\ B.=_X9J_[^DI
M\A^J?_BJZ-_X?Q?_ #]6OI5?-7U3_P#%5T;_ ,/XO_GZM?2J2G__U?4,G'9D
MTNI>2UKH]S=' @[FN:?S7-<%1/3,?$'JUEQ<ZRH0Z(&ZZIS]K6M;MW[6K2)(
M!($GL%F')SKJ_P!/BFMC'UOW-EQ(%M1]M8'J?0]1]B2FU9_RIC_\1=_U>,FZ
MASB_^&&?D<A6Y3!U"FW9<6-IM:2*;3!<['+1[:_SMCE'+RZ[78X97<=ES7.F
MBT  !VONJ24Z22!]LI_=M_[:L_\ 2:7VRG]VW_MJS_TFDI.D@?;*?W;?^VK/
M_2:7VRG]VW_MJS_TFDI.D@?;*?W;?^VK/_2:7VRG]VW_ +:L_P#2:2DZ2!]L
MI_=M_P"VK/\ TFE]LI_=M_[:L_\ 2:2DZ2!]LI_=M_[:L_\ 2:7VRG]VW_MJ
MS_TFDI.D@?;*?W;?^VK/_2:7VRG]VW_MJS_TFDI.N(_QP?\ B.=_X9J_[^NP
M^V4_NV_]M6?^DUR7^,_&R^J_5=V+T[&OR;_M%3O395870-TNC8DI\>^J?_BJ
MZ-_X?Q?_ #]6OI5?/_U;^JGUGQ?K%TK)R.E9==%.9CV6V&E\-8VUCWO=[?S6
MA>^5W,MD-#AMYW,<SGP]1K=R2G__UO556ZEG5]/P;<RUEEE=(!<RENYY!(;[
M&:;OI*RDDIXZF_#..P8_6>H%E?HU%K*PP-]4MQVO?9D4^[W-=9<_UG_R%(=1
MZ>U@+NN9Q%C=U=CZO$RT;!C,V64Q[_6K_F[%UZ22G+Z#FXMU#L6G)MRK,:#;
M9?6]EGO+X]1UC&,L?O9;_,^Q1R>@VW=1LSZNI9>,ZP!OHUO::A 8UVRFUEC&
MNL]*O_6RW?K))*<4?5_,% H;UC,:UK"P.EA=JUK XO=6Y_LV[V_X3W_36Q4S
MTZV5R7;&ANYQDF!$N*DDDIR<GH5MW47Y]74LO&<]K6^C6]IJ$;=SFTVLL9NL
MV,W?^K%!G0,QE3:F]7S UC2V9K+C+0QI<]];W>Q[?5_\^^HME))3"IAKJ8QS
MC86M#2]W+B!&YT?G.7+WLIP<C[#=UC.Q_2;6&EK6.8XV"TSN%5]WJ?J]C[[K
M?T?K6+JTDE/(5=0P2V#UKJ#GD>YKJ9<P^UL.;5C;7/9;[/\ "_\ HU=%T=@;
MTZDMR'Y==@]6N^T18YMGZ;=8(9^__HZO39^C]-74DE.!]8Z\9N9B9&1F9N(U
MK7C]5DU?2K8U^56QMCG?I+JZZO9^>LNO.PW5#[/UKJ +W,JKK?47'<]V_P"F
MZIK?TF.VQK/T_ITL_2_S]:[-))2S6AK0T< 0._'Q6#UOK73@ZSI^0W):ZI['
M.MQXW#8*\O>S;9ZVS8?=^B_T_P#H;EOI)*>'Q^H=/Q;Z;OM/4F/I#394\--3
MX8'V^M^D<UG]$KHW^MZ>-=D;/\+:NNZ=GT]1Q1E4!S:W.>T!X /Z-[J2Z 7>
MUVS<S^0K222G_]DX0DE-!"$      %T    ! 0    \ 00!D &\ 8@!E "
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M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M         0  ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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MJ+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H # ,!  (1 Q$
M/P#[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__T/OYBKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__1^_F*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]+[^8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%7__T_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5?__4^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5__]7[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__UOOY
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__7^_F*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]#[^8J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%7__T?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5?__2^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5__]/[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%5O):\:BOABJ[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%7__U/OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\
MD_\ GZ/^=_GO\FV\CC\L-=N]%&HC6?K?U5E'J^C]4]/E4'[/-J?ZQQ91#\F/
M^AW?SU_ZGK5O^#3_ )IQ94]:_(+_ )S!_.?S-^9_DKRWKWG+4[K3-0\R:/:7
M5O(Z<)89KR))$:B]&4D'YXJ0_IYQ:V#_ )FZQ=^7O)_F'7]'D]&_L=)O[JWD
MXJW"6*W=T;BP*FC &A!![BF*OY9/^AW?SU_ZGK5O^#3_ )IQ;*=_T.[^>O\
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MW\\E]?:!I4US,[22RR6,#.[L:LS,4)))-23N3BJ'_P"55^2O^I;T?_N'V_\
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ME+_G'+_G"O\ )3SE^5OD[S9YF\HVMWJVI:'875W<-/=!I)9859V(64 $DUV
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M9?F+YEM+74E%?J$'*YN]^G*&$.Z5[%PJ^^*0'QEKG_/W#\I["1H=%T;S%?\
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M8O-"B"A8#=MR:#?%2*?36*%DLJ0HTTS!(T!9F8T  W))/0#%7QA^97_/P/\
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MD4^@<4)3K^NV'E;2[WS-Y@G6UTO3K::\NYWKQB@@0R2.: FBJ"30=L5?%O\
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M*EMK8UO0BQ :6^L5DB'O6UDG>G^P^C%>%]X>0/S,\J?FGIP\P_EUK%EK.GU
M:2SF63@Q_9D4?$C?Y+A6]L6+.<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_0
M^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OP^_P"?R?V_
MRZ^6O?\ 8CBSB_$7%D]P_P"<9?\ R</Y??\ @6Z%_P!1\.*"_L+Q:WFOYS_^
M2^\V?]L'4_\ J%DQ5_&=BVNQ5^]7_/GC_E&?.W_;2L?^3+XL)/V1Q8NQ5V*N
MQ5_'=_SDG_Y-SS]_X%6N?]1TN+:'BN*OV^_Y\U_^5'_\%_\ ['\6,G[>XL'\
MBO\ SF%_Y.WS[_VW[[_DX<#8'S=A2_:'_GSG_P =GSY_S!Z7_P G)\6,G[M8
ML'X*_P#.?'_.?>N7VMZC^2/Y*7S:?I%@[VFJZK;/2>ZF7X9(89%WCB0U5F4A
MI&! (C^VLP'XX.[2,9)"69B2234DGN<62,T_3+S5I#;:5;S7,P5G*0QM(P5>
MK44$T'<XJUJ&FW>DSO8:K!+;74>SQ3(T;K\U8 C%4%BK]J?^?<__ #F]K,^M
M6?\ SC_^;U^]]:7H$&@ZA<L6FBF ^"TD<[NC@4B+?$KTCJ590BQD'[I8L$IU
M[7=/\L:;>>9/,%Q'::9802W5U<2FB10Q*7=V/@J@DXJ_ET_YS!_YS,\R?\Y+
M:W<:783S6'D"UF/Z/TQ25$P0_#/<@?;D;J%-5B'PKOR=EL I\2XI=BKL51VF
M:I>:+=PZMHUQ-:7UNXDAN+>1HY8W7HR.I#*1V(-<5?T7?\^]_P#G->Y_/>T?
M\JOS.E5O.^F6_K6]X:+^D;9*!F8"@]>.HYT^VOQ@?"^+"0I^G^+%V*NQ5V*N
MQ5^!?_/X6?EYP\G6W\FDW3_\%.!_QKBSB_'C%DJPQ-/(D$>[NP4?,F@Q5_;;
M96J6-O%90;1PQK&OR44'ZL6I$XJ[%78J[%78JQ+SWYWT?\MO+VI>?/-\XMM'
MTJVDNKF6E2$0=%'[3,:*JC=F(4;G%7\KW_.4_P#SEGYK_P"<G?,$E]JTLECY
M6MI&&F:/&Y]*%.@>6FTDS#[3GI]E.*[8M@%/E+%+L5=BK)/)_F_6/(.MV'G3
MR?=O8ZUIEQ'=6EQ&%)22,U!*L"K#LRL&1EJK*5)&*OZ5O^<#?^<Q!_SDMH,_
MEKSB8XO/VB1*]X(U")>6Y(5;I%&RGD0LJ@<58JRT5PJK613[^EB29&AF4/&X
M*LK"H(.Q!!Z@XH?QK?G7Y!?\K//WF3\NY$9$T?5;NUAY&I:!)#Z+]_MQ\6%=
MZ'??%M#S#%7[X_\ /GOS>+SRGYQ\@D$-I^J6NI@FE&%] 82!O7X?J@KM0<AX
MXL)/V*Q8OP__ .?Q'G$\O)/Y?P..-+_5+A.]?W<,!_Y/8LXOQ$Q9/L__ )]_
M?EL/S+_/'RS;7*%['1I7URX()''ZB/4A.W4&X]$$':A-:]"H+^JS%K?DA_S\
M1_YS@O\ \J9#^2/Y07?U?S3-$KZMJ,1_>6,4B\DBB/[,\BD,7ZQH5*_&P9%E
M$/Y^KFYFO9I+R\D>6XE=I)))&+,[,:LS,=R2=R3UQ9J&*NQ5V*OT$_YPJ_YS
M?US_ )QZUBV\H^<;F;4/RZO)5CGMY&,C6!8T]>VK4A5ZR1#X7%2H#[E01;^F
MZSO(-0@BO["5)K:=%EBEC8,CHXJK*1L00:@CJ,6M$XJ_CT_YR:_\G#^8/_@6
MZ[_U'S8M@>'XI?5_DK_G)_6ORT_)G4?R2\B3R66H:_KES=ZG>1$K(MB;6WB6
M*)QT,S*XD(-0B\>DAQ13Y0Q2_8'_ )\^?\IKYO\ ^V/;_P#40,6,G[T:SK%E
MY>L+K7];G2VTZQ@DN;F>0T2.*)2[NQ[!5!)Q8/Y>O^<R/^<T/,/_ #DIK5QH
MFCSS6'Y>VDQ%AIRDH;C@?AN+D#[3MU5#58ALOQ<G9; *?#>*78J[%4;IVI7>
MCW4.J:3/+:WMNXDAG@=HY(W4U#*ZD%2.Q!KBK^B;_GWO_P YMW/YXP'\HOS1
ME#^=M/MS+:7I 7](VT= W,#;UXQ0M3^\3XZ55R5@0_4C%B@]0U"VTFUGU34I
M5AM+:)YII7-%2.-2S,3X  DXJ_DM_P"<LO\ G([5?^<E//=YYMNY)(] M7>V
MT:R+'A!:J:!N)V$DM \AZU(6O%% 6P"GS%BEV*O7/)7YT^9/)/E;S)^6-C<-
M+Y9\SVR0W=E(Q]-)8Y4DCGC&X60% K$?;0T;[*%5:>1XJ[%7]>G_ #B3_P"2
M5\@_^ YIO_)A<6LOH?%#L5=BKL5?!'_/S'_UG_S#_P Q6E_]1L6*8OY>\6QV
M*OZE_P#GV[_ZSQY1_P!;5O\ NJ7.+7+F^Y,4.Q5V*NQ5_%O^8W_*6:]_VU+W
M_D^^!M89A5^__P#SY]_Y0;S;_P!MJ'_J&7%A)]J_\YL?E[_RLO\ )+SCY?C1
MGNK?3FU.V$:\G,NGL+H*@H22XC,= *D.0.N* _DKQ;'8J_KB_P"<-?.*^>_R
M1\CZ^KM(RZ/!8R._+DTE@39R$EMR2\)J>_7%K+Z9Q0_E-_YS_P#.8\[?GSYO
MNX)?5MM/N8=+B ((3ZE"D,JBG_%RR$UZ$D8M@?&V*7[?_P#/GS\N2!YO_-R[
MB7B?J^AV<O[51_I%TO3I_O,=COW&PQ8R?MS+*D*--,P2- 69F-  -R23T Q8
M/YJ?^<Y_^<X=8_/'6[S\O/R[OI;3\N;&5H!]7=D.J,IH99B*%H2?[J(_"121
MP7XB-9@/S=Q9.Q5V*JL,TEO(EQ;NT<L;!D=20RL#4$$;@@]#BK]W_P#GW5_S
MG'J7G>\@_(+\XKQKO5C&WZ$U:X>LL_IK4VT[L:O)Q!,<A^)Z%7)?B66$@_9?
M%B\8_/[\\-"_YQY\E7_YF>;0TL-MQBMK6,@275S)7TH4)K3D02S4/% ST/&F
M*0+?RQ?GU_SD;YV_YR+UR3S)^8-^[VRNQL]-A9EL[1#T6**M*TV9VJ[_ +3'
M:BS IX1BE/5\KZR]C^G4TZ\.F@%OK0MY/1H.I]2G';YXJD6*O1?RN_-?S5^3
M6OV_G;\NM1FT[4[=@28V/IRI7>.:/[,D;=U8$=Q0@'%7]4__ #BO_P Y$:;_
M ,Y,>0[3S_81I:ZG&YM-4LE;E]7NHP"P%=^#@AXR=^+4/Q*V+613Z/Q0[%78
MJ[%7Q!_S\=_]9V\Y?]NG_NJVN*8\W\L>+8[%7L/YG_G?YF_-:P\O>6_,%P5T
M3ROI5GI6FV,;'T8UMX4B>4CO+*5Y,QWI1 >*C%:>/8J[%7VU_P X+_\ .3E]
M_P X\?F!96VJ793R/KD\=IK,$C4BB#GA'=BIHK0L0SM0\HN:4J5*J"+?U0XM
M;^=+_G[-^71\M_FEIOY@6T2I:^9=*3U)!U>[L6]&2NW:%K< U)^0 Q9Q?ECB
MR?HC_P ^O/.*^5OSUL=)D'P^8-+U#2^6U%*H+P5J>YM@HIO4@=\42?TU8M;X
MU_YS_P#.Y\C?D1YMNX6XW.HV\6DQ"M.7UV5891_R):0^]*8I#^4[%L3?R_H=
MWYGU2Q\M:.GJ7^HW,-I;I_-+,X1!]+$8J_LZ\B^4;/R!Y<TCR-HU?J&C6%KI
M\%>ICMHEC4FM34A:DDDUQ:F58J[%78JA+_\ WEF_XQO^HXJ_B/Q;78J_:O\
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MBQD_;W%@_D5_YS"_\G;Y]_[;]]_R<.!L#YNPI?M#_P ^<_\ CL^?/^8/2_\
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MKL5?!'_/S'_UG_S#_P Q6E_]1L6*8OY>\6QV*OZE_P#GV[_ZSQY1_P!;5O\
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M'\[_ #QI-GK&M:S<W(L#>PI/':VUM*UN>$;@J)'D20EZ<N/$+3XN2PD7KO\
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M@L+=10[E8YYJ?=&3OBF+^;+%FG/ES31K.K6&CMTN[J" T_XL<+_'%7]L"J$
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MC-%^8^MZ!H?F26]@C$6J(L<ZSQ**(1-&2L@ V#5.P K0 !1:1?\ 0E_Y&_\
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ML !L ,6"E?6-MJ=M-INI0QW%I<1O%-#*@>.2-QQ9'5JAE8$@@BA&QQ5\N_\
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MDN+YT!E=SU(5JH@)^% %Q:R;?0V*'8J[%78J[%78J[%7Y4_\_=__ "4N@_\
M@4VW_4#=XLHOYVL6;L5?U[?\XE_^26\@_P#@-Z9_U#KBUE]"XH=BKYJ_YS"_
M+O\ Y6C^37G#RG#'ZMW^C)+VU0?:-Q9$7,2J>Q=HPG^R(.Q.*0_D9Q;$?I6I
MW6B7MMK.E2&&]M)H[B"50"4DC8,C"M1L0#OBK^T[RMYBM/-^BZ=YLTA@]CJE
MG;WMNZD,&BN(Q(A!&Q!5AOBU/YB?^?COG5_.?Y\^8HED$EIHR6FE6]!]D0P*
M\JG<[B>27I3;M6N+9%\,8I?T6?\ /IG\N#Y9_*[4_P P;N()<>9M4?TG'5[2
MP!A2NW:8W [CZ21BPD_4_%B_CT_YR:_\G#^8/_@6Z[_U'S8M@>'XI?LE_P ^
M=],67S-YVUDCXH-.L+<'VFFD8_\ )H8L9/WIQ8/YH/\ GZ;I:Z?^>=Q=J*&^
MT?3KAO<J'AK]T8Q9Q?G'BR?J5_SZ-E6/\XM81S0OY4O%7W/UZR/Z@<6,G]&.
M+!_)S_SG7KK>8OSY\[WSMR]+45LQ["T@CMP/^2>+8'R5BE^Q'_/HG4=+T?6_
M.^IZW>6UG2STV&,W$R1<N<DS$+R(K]@5I[8L9/W&_P ?^6/^KWIO_29#_P U
M8L'X]?\ /W;4]&\P:%Y)U#1KVTO)K6]U&(_5YHY659HHB:\22 3&/NQ91?AM
MBS>Y?\XR:^_EC\V_(^MHW$0^8M,$A_XKDN420?2C$8H+^PG%K=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BK__3^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*OP^_P"?R?V_RZ^6O?\ 8CBSB_$7%D]P_P"<9?\ R</Y??\ @6Z%
M_P!1\.*"_L+Q:WFOYS_^2^\V?]L'4_\ J%DQ5_&=BVNQ5^]7_/GC_E&?.W_;
M2L?^3+XL)/V1Q8NQ5V*NQ5_'=_SDG_Y-SS]_X%6N?]1TN+:'BN*OV^_Y\U_^
M5'_\%_\ ['\6,G[>XL'\BO\ SF%_Y.WS[_VW[[_DX<#8'S=A2_:'_GSG_P =
MGSY_S!Z7_P G)\6,G[M8L'Y*_P#.=G_/OF7\V[NY_.3\EECC\V.A?4]*8JD>
MH%0 LL+&BI/0'F&^&;9N2.&,JR!?@-Y@\O:IY4U&Y\N>9[.XT_5+.0Q7%K=1
MM%+&XZAD8 @_/%FD^*HRPU"ZTJYBU+2YY;:[@8/%-"[)(C#HRLI!!'B#BK]+
M_P#G'K_GY]^8'Y:/;Z!^;//S=Y<0!#-,P74XE&U5G.TQ'4B;D[=/57%B8OWP
M_*3\Y/*/YXZ#%YU_+74H]0T]Z+(H^&:"2E3%-&?B1Q7H=C]I2RD$K AZABK^
M=G_G[O.S?FWH-L?LIY5MG'S:^O ?^(C%G%^56+)V*NQ5V*NQ5V*OZUO^<)96
MF_(OR*[]1I$:_0KL!^ Q:R^I<4.Q5V*NQ5^ O_/X.#CYU\H7/\^CW"?\#<$_
M\;8LXOQ^Q9(JQN39W,-X.L4B2?\  D'%7]MZ.LBB1#56 (([@XM2[%78J[%7
M8J[%7\RO_/T29I?SWU!&Z1Z7IJCY>ER_6<6R+\[L4OTE_P"?5:!OSP5CU70]
M0(^^(?QQ8R?TK8L'PE_S\HC#_P#./?FAC^Q-I3#_ +B, _CBF+^7'%L=BK^Q
M_P#YQ_NFOORO\DWT@96F\M:/(5<48%K.(T(\=]\6HI=_SDC^71_-G\KO-GY?
M11+/=:CI5P+2-^ANXE]6V)V/29$-0"13;?%(?QXXMB:Z'K%SY=U*S\P:8P6\
ML;B*ZA8]!)$X=3M3N!BK^P+\TOS)B\M_E9KWYL:0X*6WEVZU6S);CR;ZJTL
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M_<1Z&/O-Y_3%C)^XV+!_.+_S]J0+^<VFD?M>6+(G_I+NQ_#%G%^7V+)^DO\
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M-*[#IO503;Z5Q0_CT_YR:_\ )P_F#_X%NN_]1\V+8'A^*7[<?\^;?[W\Q?\
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MLOH?%#L5=BKL5?!'_/S'_P!9_P#,/_,5I?\ U&Q8IB_E[Q;'8J_J7_Y]N_\
MK/'E'_6U;_NJ7.+7+F^Y,4.Q5V*NQ5_%O^8W_*6:]_VU+W_D^^!M89A5^_\
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M%M=BK^I[_GW+;M;?\X\>3A(A1W&J.0P()#:G<E3OV*T(/<4.+7)]NXH? O\
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M[Y\_)+7?*OEK\IM=DTB6ZLKN[ODCA@D,BM*B0D^K&Y%"DE*4[XLHBWYC?]%
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M J<0?B+_  A64"+\#<6:/TK2[O7+VVT72(7N+Z\FCM[>&,5>261@J(H[EF(
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M "[M(V:RFN%N-2D'2*QA(:=B>U5^!?%V4=\4$T_KZCC6)5BB4*B@*JJ*  =
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M>%Q/I.H^7[:.PMKY+6:X@N+6$<( 1 LDB2(@5&JG%J!@U2558&+Y+_Y^"_\
M.9NC_P#.2-SI?DC\MDF/E+1Y7NFN[B,Q/=W3KP#+&WQ+'&A8+R 9B[54 +52
M!3\UL63L5?UZ?\XD_P#DE?(/_@.:;_R87%K+Z'Q0[%78J[%7P1_S\Q_]9_\
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M:#88M1>GXJPK\Q?R^T/\U?+>H_E]YVMA=Z+JD)@N(R:&E:JZ-^RZ, R,/LL
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M[6)>,<4*!$0>"JH  ^6*$7BKL5=BKL583=_EIY0OYY;Z^\OZ3-<S.TDLLEC
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M[%4/=VD%_!+8WT236TR-'+%(H9'1A1E934$$&A!V(Q5A/_*J?)/_ %+6C?\
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M=BKL5=BKL52_5-)L=<M7TO6K:&\LI>/J07$:R1MQ(8<D8$&A (J.H!Q5B/\
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M\G2K=:%Y'T19T-4DN+5;IU/B&N/4(/N-\5M]$P016L:6ULBQPQJ%1$ 554;
M #8 >&*%7%78JE&M>7]+\R0+8^8K&VO[9'$BQ74*3(' (#!7! (!(KUH3XXJ
MQC_E5/DG_J6M&_[A]O\ \T8JB+3\M/*%A/%?6/E_28;F%UDBECL8%='4U5E8
M("""*@C<'%6;8J[%78J[%78J[%78J[%4HUKR_I?F2!;'S%8VU_;(XD6*ZA29
M X! 8*X(! )%>M"?'%6,?\JI\D_]2UHW_</M_P#FC%7?\JI\D_\ 4M:-_P!P
M^W_YHQ5FUI:06$$5C8Q)#;0HL<44:A41%%%55%   * #8#%41BKL5=BKL5?R
ME?\ .?'YCI^9?YX>:-0M&#66EW"Z-;D#M8CTI=^X,PD8'I0BE1OBV!\<XI?H
M?_S[#_+H>=_SML]=N8R]GY:L;K57)4E#*0+>%2:4#!IO445!/ID] <42?TV8
MM;L5=BK^/3_G)K_R</Y@_P#@6Z[_ -1\V+8'A^*7[;?\^;O[_P#,3_4T/]=[
MBQD_7'\P_P C_P O_P V0/\ E8_EO3-8E4<5GNK9&G4>"S "11[!ABPMXI9?
M\X#_ ) V$XO8/)%DT@-:2W%W*G_ 23,GT4Q3;Z;\J^3M!\C6":#Y+TRRTG34
MW6VL;>."('QXQ@"I[GJ<4,DQ5V*NQ5V*O"?./_.,'Y2^?I7O/-GDS1+JZD)+
MW LHXIF)_FEB".?I;%-O*S_S[Z_YQ],PNO\ !5OS%=OKM]QWI^QZ_'MX?KQ6
MWJWDW_G&3\I_R_E2\\H^3=$M+N/=+CZE').O^K+(&<?0V*V]TQ0[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%7_]'[^8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78JDWF/7[+RII-_YHUR40Z;IMK/>74K$ )# ADD8UH*!5)Q
M5_&+YW\U7/GKS%J_G?5 %O-9U"ZU&< U DN96E8#IW8XMK%\5?M]_P ^?/RX
M/_.W_F[=Q#C_ */H=G+WKM<W2].G^\QV/S&PQ8R?M[BP=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?R@?\YV_F0?S._._
MS7JT$IEL=.NAI%IT*K'8*(7XGNK2K)(#O]O;:F+8'R'BE^B?_/L#\NAYV_.R
MTU^Y1FM/+-A=:HQ*DH96 MHE)I0-RF,BBH)],GH#BB3^FC%K=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>>
M?FUY\@_*[R5Y@_,2\ ,>BZ9=7H0_MO%&61!TW=Z*/<XJ'\9UU=37TTE[>R/-
M<3.TDDDC%G=V-69F-222:DG<G%M4,5?T%?\ /HK\N3HOD3S#^9EW$4GUW4DL
MX&;]JVL$^TO@#+-(IZ5,>_08L)/UQQ8NQ5V*OX]/^<FO_)P_F#_X%NN_]1\V
M+8'A^*7[;?\ /F[^_P#S$_U-#_7>XL9/W%Q8.Q5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__TOOYBKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKX/_Y^0?F8/RZ_(_6;2"3A?^8Y8=#MZ5W$
MY+SUIV-O'*M>E6'C0J8OY=,6QV*OZN?^<"_RX;\L_P C_*VFW2<+[4K=M8N?
MAXDM?L9HPP[,L)C0^Z]!TQ:R^PL4.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5YI^<OY@1?E7Y%\Q?F+<D?[A],NKN-6Z/*D
M9])/F\G%1[G%0_C5N+B6[E>ZNG:6>5F>21V+,S,:DDG<DG<DXMJCBK^@[_GT
M9^7)T/R%Y@_,N[B*7&O:FMI [4/*VL$V9=]@9995/2ICWV"XL)/UMQ8NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*OS!_P"?KGYDQ^5?REMO($3K]=\TZG#$8R0&-K8D7,C@=3QE$"G_ %^O
M8K*+^<+%F[%7]@G_ #C#^7!_*;\J?*7D&:,17=EI<#W:#M=7 ]>X';_=TC[X
MM9>[XH=BKL5?QZ?\Y-?^3A_,'_P+==_ZCYL6P/#\4OVV_P"?-W]_^8G^IH?Z
M[W%C)^XN+!V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*O_]/[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M\X_,K\H?)OYQ6-OHOYFZ-:ZS96LWUB".Y4_NY.)7DI4@BH)!%:':HV%%;>,?
M]"-_D/\ ]2-I?_)7_FO%-N_Z$;_(?_J1M+_Y*_\ ->*V^J+:VALX8[.SC2*"
M)%CCCC4*J*HH%4#8 #8 =,4*V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5BGGCR-H/YDZ)=>2O/-C%J6AWOI_6+2:O"3TI
M%E2O$@_"Z*PWZC%7SY_T(W^0_P#U(VE_\E?^:\4V[_H1O\A_^I&TO_DK_P U
MXK;Z*\H>3]$\@Z/:>3_)5A;Z7HMBACM[2UC$<: L68@#J68EF8U9V+,Q+$G%
M#),5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5>3?F=^1?D+\YS9/^:.A6NLMIPF%H;D-6(3<?4IQ9?M<%K7
MPQ3;RK_H1O\ (?\ ZD;2_P#DK_S7BMHBT_YPD_(JRGBO(?(ND&2)UD421O(A
M*FHY([,K#Q5@5(V((Q6WU-BAV*NQ5V*OP8_.'_GUS^:OY@^??-/GW1M8\L1:
M?K>N:EJ=M'<7=ZLJQ75R\R+(%LV4.%8!@&85K1B-\68D\Y_Z)%?G#_U>_*7_
M $F7_P#V18KQ/T2_YP$_YQ!\X_\ .*\GFJ3\PK[2+P:XNFBV_1<UQ+Q^JFXY
M^IZT$-*^JO'CRZ&M-JJ";?HWBQ=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BK_]3[^8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%7__U?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5?__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]?[
M^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__T/OYBKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__1^_F*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^;]K_P Y
MR:OYB_YR';_G&'R=H=G=:5#J$EE/J;S2>JOU6W,MV>"_#6-TDC6IW(%=S3%E
M3](,6+L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL52K7-=TW
MRS8SZ[YCO+>PTVV0R3W-U*L44:CJ7=R%4>Y.*ODO6/\ GX)_SC]H=P;*]\ZV
MSR+U-K9WUTGT200.A^AL4\+ZUT/6K+S)IMGYBT67UM/O[>*[MI>++SBF0.C<
M6 854@T8 CN <4)IBKL52/S/YDT[R=H^H>;_ #)-]6TG2K2>^O)^#OZ<%O&9
M)'XH&=N**315+'H 3MBKX\_Z*._\X[?]3E_W*=5_[)<4\)=_T4=_YQV_ZG+_
M +E.J_\ 9+BO"4?I_P#S\,_YQ[U.7ZM;>=(5<TWGT_48%W-/M2VZK^/OTQ7A
M?1OD+\VO)7YI0M=_EUY@TS6D0<I%L;J.5XQM_>(IYIU'V@.H\<44]#Q5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OE
M_P#,W_G,W\G?R<\P3^0OS'\R?H[7;5(I);;]'W\_%94#H><$$B&JD'9C3O0X
MII]08H=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL58+YK_-#R;Y$;T_
M/'F+2-&<@-34;^WM30D &DKKM4C[\52_0/SG_+[S7(MOY6\V:#J4KFBI9ZG:
MSL34#81R,3N0/IQ6GI6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5*M9U[3/
M+EJVJ>8;VVL+)/M3W4R0QC8G=W( V!/7%7FMK_SD)^5E]<-IUEYX\LS72$AH
M8]9LF<$'B:J):BAVZ==L4T]5LKZVU*!+[3IH[BVE'))8G#HP\0RD@CY8H16*
MNQ5V*O*M;_/7\M?+,QLO,GG+R[I]P"08[O5K2%ZCJ.+R XK3*O+/GORUYU0S
M>3=9T[5XU 8M87<-R #T),3-MN,597BKL5=BKL5=BKL5=BKL54IYXK6-[FZ=
M8X8U+.[D*J@=22=@!BKR/4O^<AORKT>8V.K^>?+%K<+6L4^LV4;BA(-5:4'J
M"/F,4TS;RSY[\M>=4,WDW6=.U>-0&+6%W#<@ ]"3$S;;C%#*\5=BK\W_ /G(
M[_G.35_^<=_S:T?\J]=T.SD\JZHFGW+ZHTTBRQVT\QAG?C]@M$4<@$C:E>M<
M60%OT@Q8NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_
MTOOYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BK"OS(\Z6OY<>5-;\_:G3ZMHVG75^X/[7H1,X4>[$<0.Y-,5?AO
M_P ^H?+ESYV_-#S;^;>N5GN+&P8/*10?6M3N.9?YE8I1\F.+.3]_<6#L5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?S@?\ /P?\W?,GY[_G
M(OY#>69)'TC2-0M](L+%'HEQJ4Q6-Y7 ZN)']%:UXJIXT+O59Q%/K;RS_P ^
M?O*4>FVZ^<O-FJS:P4!N&L(H(K<.1NJ"5)'(!V#$@MUXKT"CB?K1Y1\N0>3M
M"TORC8R/+;:596UC%))3FR6\2QJS4 %2%J:"E<6+(<5=BKQ#_G)K_P D]^8/
M_@):[_U 38I#^:C_ )PP_P"<?='_ .<EOS D_+KS5>W=A9)IES?":R]/U.<3
MQJ%_>*PH>9KM7%F33]6_^B07Y<?]3/YA^^T_ZHXL>)B'F3_GSQH$T+GRAYUO
MK>X%2@OK**=#X F-XB/<@'_5[%7B?G7^=G_.*_YM?\X<:E:^=)IG2QCF LO,
M.B3R*D<IW5':B20N1V8<6W",]#BR!M^SG_/O_P#YS"F_YR.T&Y\G^>W0>>]"
MB5YY$ 47UJ2%6Y"B@5U8A)@/AY,KK0/P18D4_1+%B[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_F _P"?FG_D_P#7O^8/
M2_\ J#CQ;(OZ?\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OQ4_P"?
MB'_.=&N>4-9N/R%_)F]?3[NU11K6K6[<9UDD4.+>WD!K&54@R2+\?(\%*\7Y
M+*(?*WY,_P#/M?\ -/\ ._3HOS!\W7]OY?L=3 N(GU,RSWTZ2;B4Q#<!AN/4
MD5VV/'B0V*3)G_GS_GT=^86@Z?+J7D;7]+U^YB0O]3='LI9*?LQLY>,L>W-X
MU_RL5XGCW_.-7_.:'YA_\XO^:(_(WYC3WU[Y2MKOZGJFD:@7>>Q"MPD:W]2K
M1O%N?2!$;T(HK-S521;^FK3M0MM6M(-5TV19K2YB2:&5#57CD4,K#V(((Q:T
M9BKQS\\/SW\H?\X^>79?.OYC7H@@^);6VCHUS=R@5$4$=1R8]R2$7J[*N^*0
M+?R]?\Y/_P#.37F7_G)[S2WFKS+_ *+I5KSBTK3$:L=I Q!.^W.1Z R2$?$0
M  J*JJLP*?T3_P#. G_D@/)/_,'<_P#49-BP+[!Q0[%78J[%78J[%78J^-/^
M<UO^<K+?_G%WR?'J&F1Q7?F_6'>WTBUEJ8P4 ,MQ* 03'$&78&K.R+LI9E4@
M6_#O\N?R2_/#_G/G6;GSGJFHR7=C!*8I]8UB9DM(7/Q&&WB12*@;^G#&$2HY
ME.0JL[I]2W?_ #YX\SI;\['SKILEWQ_NY+&:-*TZ<P[FE=J\.F].V*.)\A^8
MO+_YY?\ /OOS7; 7LVEFZ/K0364S3Z7J*QD!U9&"J_&H#+(BR("K +5&*GF_
MH1_YQ3_YR,T[_G)OR);^?;*%;/5(96L]4LE8L(+J, GB3N8W5E=#X-Q)+*V+
M BGT==74-C#)>WDBQ6\*-))(Y"JJ**LQ)V  W)Q0_FC_ .<GO^<P//O_ #EC
MYP/Y9?E0]]#Y1N+KZCIFDV)9)M1))42W/&A;U/M")CZ4:TJ.09RLP*>N>3O^
M?0WGK5K"*^\Y^9M+T>]D4,;2&&2\:.H!XNX:).0W!X%UJ-F8;XKQ/$OSS_YP
M0_-;_G%FU'YHZ#J":CI-@P=]4T66:"ZLB: 22)\+HM33G&[@?M\*C%(-OTH_
MY]W?\YJ:E^><5Q^4OYIS+/YPTVW-S:7Y"H;ZU0A7$@  ]:*JU('[Q#R(Y([,
ML9"GZF8L78J^(O\ G+S_ )S8\L?\XRZ=)HUF8]5\^W,5;/2U:JP\P>,]T0:I
M&.H0'U).BT6LBJ0+?S6:GYZUS\S//*^>O.UX]_K>I:C!-<SR4JS<U   H%55
M 55 "JH"@ #%L?V88M3L5>;?G!^:&D_DOY-UC\S_ #14Z?I%LT[1J0&ED)"1
M1*3L&ED946NU6%=L5#^:C5/.OYS_ //P3S\/*EI<23BX9YX=-25XM+TZV0@&
M2114!4JH:5E>5V*J.3%$Q;.3[GT'_GSI&;1'\S^>V6_;=TL]+#1)[!Y)PS?,
MJG^KWQ1Q/FC_ )R$_P"?>GY@_P#.,U@_YK>0]:.MZ1IA]6:[L4DL[^S6F\QC
M5W^!>C.DA*CXF54Y%51*WVU_S[G_ .<V=:_-J\D_)+\W;KZYY@AMFN-)U*2@
MENHH1^\AF(^U*B_&KTJZ!^9Y*"ZB0?KMBQ?B]_S^$\B^OHWD[\RH$H;6[NM)
MG<#J+B,30@GMQ]&6G^L<647Z'_\ .(/YE?\ *V?R>\I><9I!)>-IZ6=V>YN+
M,FWE)'8LT?/Y,"-L4%])8H=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BK__T_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BK\[_\ GY]Y^;R;^2%YHUM)Z=SYBU"TTM:?:,8)
MN)?D"L/$G_*IWQ91>>_\^D_)_P"AORKU?S=,H$VM:Y*$:F[06L,:+O[2-+_F
M<5D_5+%B[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\P.@
M$R?\YFR&3XJ?F;>==^FJ24^ZFV+9T?T_8M;L5=BKL5>(?\Y-?^2>_,'_ ,!+
M7?\ J FQ2'X2?\^H?_)V3_\ @/7_ /R=@Q92?TE8L'8JQ+S[Y(TC\R?+NI^0
M_-D N-(U6VDM;B,]>+C[2GLRFC*W56 (W&*OYB_^<4]8O_\ G'O_ )R0T?R]
MJ4H1[;7I_+&H5V1A-*UFQ.^RK(5D!KMQ!.U<6P[A_5#BUNQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OY@/^?FG_D_]>_Y
M@]+_ .H./%LB_I_Q:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_DR_Y
MQ]TN'\_?^<@=#'G!1/!KWF*74[Z.6K"4!WNY(VK4D/Q*'?H>O?%L.S^LP **
M#8#%K;Q5_/!_S]L\@67E[\R-$\\Z=$L4GF#2R+KB /4GLY.'J&FY8QO&N_9!
M[XLXOUF_YP-\QS>:?R#\D:G=$EXK"6Q!;KQL;F6U0=3L%B%/;L.@6)?7.*'\
MP?Y8?DK^<'_/P7SC+YX\X7MP-%63A=ZY=H1:VZ D_5[.+X59AVCCHJ5Y2LI8
M%ELNGL?_ #\J_)#RE^07EO\ +'R+^7-D+>TC_3[3SO1KBZE_T&LL\@ +N?D%
M4?"BJH "B)M^K'_. G_D@/)/_,'<_P#49-BQ+[!Q0[%78J[%78J[%78J_FE_
MY^A^:KOS9^>L_E2-FD31-.T_3X(1T#W$8NCMTY-ZX!/@%%=J!9Q?T)_E%^6^
MG?E#Y,T3\MM C1+32+**W)04$DH%993_ )4DA9V/=F.+ O1\5?GS_P _._*E
MEY@_(;6-;O44W6A7NFWMJY&ZO+=1VC4/8%)VK]'MBF+X_P#^?.6I7?K^?M'W
M:P":1/N#1):W*[=@67KW/ >!Q92?>O\ S\&\\3^1?R(\U76GNR7>I10:4C+7
M[-Y,L<P)'0&$R#\,6,7YP_\ /HC\K;76/,?F7\V]2B#R:-;P:=8,RU"RWG-I
MG4]F6- G^K*P[XLI/WOQ8(#5=+M-<LKG1=7A2XL;R&2WN(9!5)(I%*NC#N&4
MD$>&*OY7/R^BN?\ G&C_ )R8L-'@>1(] \W?HQGWY/92W!MF;Q/J6\A(\>6+
M9S#^K+%K?+'_ #FO^8NO?E/^2OFKSYY%N?J6N6<=E';W'!7,?UF]@MW90P(Y
M!)&XFFS4/;%(?D7_ ,XE?\^_?,OY[:@GYO\ _.0S7MIY;NI?K8@NG<:AJK,2
MW-V8^I'$YW,C?O)5_NZ!A+BR)IX-_P YL:%IWEC_ )R3UCR_Y=M(;'3+.X\O
MQ6]M;QK'%&BZ;9T554  ?+%(Y/ZE,6MV*ORS_P"?MNOSZ;^4FDZ);,RKJ7F*
MW6:AV:.&VGDXG_9A&_V.+*+!?^?/WDZVMO)WFS\P#&#=WNK1:6)#2HCM+=)B
MH[@$W%3XT'6FRLG[#8L4'J.GVVK6D^E:E&LUI<Q/#-$XJKQR*593[$$@XJ_E
M(_YQX67\K_\ G)#RUHMF\@:P\X1Z-R!'(I+=&R:M#3=7(:AI2O7%L/)_6'BU
MOAW_ )^,^3_\7_D+YE:-0USI1M-3BJ.GH3H)#[?N6D_5BF+YC_Y]">?6U3R;
MYH_+FYEY-H^I07\*-U$5]&5(7Q > D^!?_*&*9/U^Q8NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]3[^8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_#+_ )_$>;6DOO)'
MD2)J+%#?ZE,M>ID:.*(D>W"2A_RC3OBSB_1/_G [RTGE;\AO)5BB@-<6,E^Y
M %6-Y/)<5-.NS@?( =J8L2^NL4/%/SY_/WRE_P XZ>69//7YA7#K"7]&UM8
M'N+J<@D1Q*2!6@)+,0JC=F&U5(%OQAU__GYA^=_YM:R^A?D)Y<BM$-6AMK.Q
MEU6_* _:<T*4IUXPBE3\1V.++A2;5?\ G(__ )S>\D0-K_FJTUM=-A!,KW/E
MBU$*@=W>*U4J/<L!BM![S_SC3_S]5E\PZO:>2O\ G(.PM+-+R1((=<L T<4;
ML0%^M0NS44D[RHP";5CX\G508OVH!#"HW!Q8I9KFMV'EK3KOS%K]Q'::;8P2
M7-S<2GBD442EG=CX  DXJ_#3\WO^?JWF_P R:X_E3_G'#1(4LFF,-K>7=O)=
M7MV0:!HK=2%C#=D997(H3Q-5"S$6 ZE_SD3_ ,YQ:! WF?6;#78M,C'JR++Y
M7MA&B$5^.EH)$4#J68$?M'%:#ZL_YP]_Y^5?\K8URS_*S\Z[2UT[7;]E@T_5
M+2J6]S.QHL,L3%O3D?8(RL4=SQXH2M5!B_7'%B[%78J[%7E'YT?G3Y6_(/RO
M<_F%^8ET;?3H6$44<8#37$[ E(84)')VH32H 4,S%55F"D"WXF>9/^?EWYX?
MF[K$F@?D#Y>2RC/(P6]E82:KJ!0'[3U5H_#I" /YCBRX4LU#_G*7_G-+\LHC
MYE\^:?JCZ5%5I7U'RW"ELH7KZDEO;Q%!OW=>FW0XK0?<?_.(W_/QW1OSVU*#
M\N?S,LX- \X7)X6<D#L;&]?_ 'VGJ$O%*?V49G#]%DYE4*@QI^G6+%^&7YM_
M\_(_SK\B^>?,_DGR_P"6-"N-+T?6M1TZTFFT[47DD@MKEXHV=DNE5F95!)55
M4G< #;%F(ORXL?S>\QV7YIM^><%G;-YJ;S!+KILS#*;?ZW)<-.T?I!_5X!V(
M"^ISIMRKOBRI^@O_ $5,_/O_ *E/R]_W"]3_ .RS%CPOW?\ R\UZ[\U>5=#\
MT:Q&D-_J6F65Y<1QJRHDL\"R.JJQ9@ S$ $D@=23BP9ABKL5>(?\Y-?^2>_,
M'_P$M=_Z@)L4A^$G_/J'_P G9/\ ^ ]?_P#)V#%E)_25BP=BKL5?RN?\YCL?
M('_.2WF758%,36>MV6IB@%>4D4-UR VZEN0\:XM@Y/ZH\6M+=8UBQ\O6-SKN
MN7$5IIUG"]Q<7$[A(XHHU+.[L=@J@$DG%7XD?G/_ ,_5?,.M:T_D[_G&?1(Y
M8#,8(-0O8)+BYNF!H#;VJ%> :GP\^;E>J(VP68B\U;\^_P#G.I$_3C:9Y@%H
M!ZAA_P *VU./AQ^J>K3Z:]^F*T&9_DW_ ,_6?->@:TGE?_G(W1H9;$3>A<7M
ME;O;7EJU:,TMNQ*N%/VE41N!6G,T4JF+]R/+WF#3?->F6GF;RW<QWNE7\$=S
M:W,+<DEBD7DK*? @XL$XQ5^8_P#SEW_S\;TC\AM3G_+C\MK*'7O.-L>-Y)<,
MPLK)R*\'X$/+(-N2*R!*[R<P4"R$;?#-E_SE%_SFI^8]LOFSR/I^JKH\RAX7
MT[RU!);R*14&-Y[>5G!\5=L4T&2?EE_S]%_,K\O]?7RO_P Y':,EY9QR+'>%
M;,V&IVU>K>D>,;4!KZ92,G^<8KPOW7\H>;=)\^:+8><O*=TE[H^I0)<VMQ'T
M>-Q4&AW!'0@T*FH(!&+!D>*ORO\ ^<L_^?EFE?DSJUU^7'Y265OKWF:S8Q7M
MW<.WU&UF%08J1E7FD0[.%=%0_#R+AE59"+XWM?\ G)7_ )S;\^Q+Y@\HZ;K$
M.FR@-$;/RS 8'4]"CW%O(6'N&(Q30=HW_/RC\^ORAUB/1OSRT**\4<6FM-2T
MY]+O2E:<HV5445\6A=?;%>%^V/Y$?GQY5_YR(\K0>?\ \OYV:W9O1NK:8!9[
M6< %H95!(# $$$$JRD,I(Q8D4]GQ0_(CR=_S\!\\:Q_SD)>?D%K]EY>M?*-G
MY@UK3)+WT;F.Y2UT\W'&1Y7N3$&I$"[&,+]HA5[+*F'?FY_S\G\Z>?/,,WY>
M_P#.'?EZ;51$64ZDUC+>7$W%J&2"V3:.+N'F#$@_$D>*B+YYUG_G-/\ YRX_
M)2YAU?\ -BUN%L)W BBUO0(K:V<U)X++;Q6[%J [>IRIO[XIH/U;_P"<7_\
MG-CRE_SD+Y3U'S/JACT#6/+T!N-;M+B4&*&%5+&YBD-.4! -:@-&PXL".#NL
M2*? _P"9?_/R+\SOS8\P3^2O^<0_+L\MI$Q5+T:>]_?3*#02B$!HX(SOM(CF
ME&9DW0++A>.WG_.<_P#SE3^1VH6TGYRV<DEO,W);?7-$CLTF0?:6.2WCMS4#
MN"W$]01MBM!^S/\ SB]_SDYY=_YRA\K-YN\MQ-8ZE9R+!J>FRN'DM96%5HP
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M5KK\N/RDLK?7O,UFQBO;NX=OJ-K,*@Q4C*O-(AV<*Z*A^'D7#*JR$7QO:_\
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M4)5H>A:;Y8L+?0/+EI!8:9:((K>VMHUBBC0=%1%  'R&*OQ7_P"?RG_E./\
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M?]U63%LZ/Z?\6MV*NQ5V*O$/^<FO_)/?F#_X"6N_]0$V*0_"3_GU#_Y.R?\
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MY<_FS/\ DI^4GF;S]I<@BU6&U%K8-W6ZNG6"-U'<QE_4IX(<4 /Q[_Y]:_\
M./\ I?YG^9]8_.#SW;)J%IY=:&.QBN1ZB/?SU<S,#4,846HY5^.17^T@.+*1
M?T*XL'@?_.27Y":'_P Y$>2-0\B^8+>)K\PRR:5>.OQVEX$/IR*PH0.5 Z@T
M=*J<4@T_#[_GUK^8U_Y$_.&?\L+]WBL_,MG<VLMLVP6\L5:>-F'9E1)D_P!G
M3K3%E)_1[BP?R%?G[::AJ/YX^>=*T'U#J%[YPURSA2)BK.UQ?S1>G44V<-Q(
MZ$$@['%L#^GC_G&W\@-!_P"<<_)5CY%\NPQ&_P#2CDU2^5 )+R[*_O)&/4J"
M2(U)/!**.Y*P)MZ9^8/D/1OS.\N:EY!\XVZW6D:I;O;SQMUHW1E/9T:C(W56
M (Z8H?R 7GE[S%Y/\UZS^4^CRS#4YKZ;RY<PQ$Q_63'>*OI,#3X6FB0T/=17
M%M?U<?\ ..?Y!Z!_SCKY+L?(?EF"(78BCDU.]5?CO+OB/4E9C\17E41J?L)1
M1BUDVG?Y[?E)I7YX>1M9_+?S!!'*M_:R"UD<"L%TJDP3(?V61Z&O<54U5B"J
M"_ ;_GUQYUO/*7YWQ>3F9HX/,.GWUE/ X8?O;6,W2$CLR^BZ[] S#J<64G]*
MV+!_,!_S\T_\G_KW_,'I?_4''BV1?JA_S[7_ .<>+'R'Y#M_SH\QVXN/.?FQ
M6O!=3CG+#9.Q])$9MQZP_?.P-7YH&KP&+&1?I?BQ?A-_S]<_YQVTGRVVE_G]
MY1M([1]2NSIVM)"H59+AT:2&X*C8,P1UD:GQ'@3\1)99Q+[1_P"?97YF7/YA
M?DK9Z7JDAEN_+-[/HO)C\1@C5)H._P!E8Y1&O3:.G:N*)/=_^<N?S9G_ "4_
M*3S-Y^TN01:K#:BUL&[K=73K!&ZCN8R_J4\$.* 'X]_\^M?^<?\ 2_S/\SZQ
M^<'GNV34+3RZT,=C%<CU$>_GJYF8&H8PHM1RK\<BO]I <64B_H5Q8/ _^<DO
MR$T/_G(CR1J'D7S!;Q-?F&632KQU^.TO A].16%"!RH'4&CI53BD&GX??\^M
M?S&O_(GYPS_EA?N\5GYEL[FUEMFV"WEBK3QLP[,J),G^SIUIBRD_H]Q8/Y(_
M^<I=0OM(_/OSGJNA2RP:E:^:+N>UE@)$J31W!:-D(W#!@"I&]<6P/W0_YQ#_
M .<#/)WY*^7['S#^8&EVNL>?[F))[J>\C6>.R=A7T;=&JBF.O%I0.;MRHP2B
MA8DOT*5510B !0* #8 #%BNQ5V*NQ5V*O'_SA_/SR)^0=E9ZS^;.K?HFSOYF
MM[:3ZK<W'.15Y$4MXY"*#>K #WQ2!;XE_-3_ )^I_E/Y5TZ<_EI]<\T:P4I;
MJMM+9VO,C8RR7"I(%!ZA8V)Z"@^(*>%^;WY)?\XX_F3_ ,YS?F)+^;?YIQ7-
MMY7O;I+O4]5FC:%)X4H%M;(&G+]VHC5EJD2#DS%N*NI)I_2C8V-OIEM#ING1
M)!:V\:10Q1@*J(@"JJ@;    #%@BL5=BK\0O^?RG_E./_!@_[$,6<7WY_P X
M"?\ D@/)/_,'<_\ 49-BQ+[!Q0[%78J[%78J[%78J[%78JQ[S;YJTOR-HM_Y
MQ\TW*6FDZ;;R75U/(:!(XUJ?F3T &[&@&YQ5_+]=2>9O^?@7Y]?N!)!%J]R%
M7E\0T[2+;N:56J1[]A)._4%\6SD_J"\J>6--\E:+I_E#RW"+?2M,M8;.UB7H
ML4*!%'N:#<]SOBUOS1_Y^Z_^2>T3_P "VS_Z@+W%E%(O^?07_DN/,_\ X$)_
MZA(<5D_6O%B[%7\HW_.??_D__.W_ #&6W_4'#BV!_5SBUNQ5V*OY@/\ G/7_
M -:C\P_\QF@_]TZSQ;!R?T_XM;L5>7?G5^5.F?G=Y(UG\KO,1,=IJUL8A,J\
MFAE4AX95!I4QR*KTKO2G?%0_GI\AS_FK_P ^VOS'FUGS=H4UWY?NE:QNWCY?
M4=0MN89)(+@ HLJD!E#CFH+(Z+S.+9S?K3Y<_P"?FWY!:W:)>ZIKMYH\[!2;
M:]TR[>121N";6.>/;H:/\JXL.%\F?\Y._P#/QVS_ #.T.[_)W_G&33M4U'5-
M<A>SFU'ZLZR+#(.,B6L"\I6D=25YLJ< :J"U&12(LW_Y]S?\X3ZY^5%Z_P"=
M_P";EL;'7I;>2VTK2Y /6MHY=I)YJ$\)'6J*GVE1FYT9N*JR+]>L6+L5?RQ_
M\X:RMY _YR8\N:;"5 M]:O\ 2S\9XE98I[:@)W/VOAKN33OBV'D_J<Q:W8J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_P#_UOOYBKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK^
M6[_GY->/=?\ .0OFJ"0 +;1Z5$E.I!TVWDW]ZN?HIBV1?TY>5$6/1--1 %5;
M.W  V  C7%K3_%78JQ'S9^8'E?R%$MWYYUO3-%@?[,FI7D-JI^1E90<5>"ZG
M_P YN_D5I-?K7GK27H0/]'=[CJ*_[I1]O?H.AWQ33\@_^?G/_.0GY??GK)Y*
M@_*C6H]8;2!JYO3'!<1K']9^J>E\4L:!N7I/]DMQI\5*BJRB*?K'_P X"?\
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M6KRKU]U'RZXI#\A?^?/FI"+SIYPTBK5GT>WGH/L_N;CCO[_O-MO'%E)^C?\
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M  +;/_J O<644B_Y]!?^2X\S_P#@0G_J$AQ63]:\6+L5?RC?\Y]_^3_\[?\
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M/W?7QJ.V+9%_2_Y$N_K_ ):T:_H!Z^G6DE :@<X5/7Z<6ME6*OR'_P"?A_\
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MYU$_F)Y0N;FXTJT;DNO:#)(IC0$-_I40^.-#0<^8> _9+M6F+.[?='_.'/\
MS\NE\[ZE:?E?_P Y"&WM]3NV6"QUV)1#%-*U L=U&*)&SG99$XQU(5D3[6+$
MQ?LEBQ=BKL5=BK^8#RY_ZV;)_P";-OO^ZK)BV=']/^+6[%7Y8_\ /W7_ ,D]
MHG_@6V?_ % 7N+**>_\ /J'_ ,DG/_X$-_\ \FH,5D_3'%B_F \N?^MFR?\
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M;S(6:TUSS^--F!))%M+J8M@E13[,5%[=.V+9T?U=Q1) BP0*$C0!5510 #8
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M74X+:*,J[A%53#<3,6)J=U H#O6@*DBD@_Y^,Z0VK_\ ./OFT0H7EMOT=<J
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MO[8M@Y/ZI\6MV*NQ5_,!_P YZ_\ K4?F'_F,T'_NG6>+8.3^G_%K=BK\4_\
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ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\9_\
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M]UFPEM/+4ETNC::&-8X$B0RI;JQ^W)Q)EE*B@>3]D,BXLQL_H5_Y]_3QW/\
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M8L24?_SEU^4$WYY?E/YC\@:8@?5I+=;O3QT)NK5Q-&H/;U.)C^3G%07X-?\
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MO-[(R?I:\C5/15A1EMH06$08;,Q9Y""5Y\"5Q8DV^W,4.Q5^8&G?\^WOT?\
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M$NIV\UJX\ QA$X-.G( 5Z\1TQ9<21^7/^?0'YA74ZIYM\TZ#8VU?B>Q6ZO'
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M &?XIXG?]$:__,C_ /AO_P#9_BO$[_HC7_YD?_PW_P#L_P 5XGVA_P X<_\
M.%'_ $*9>Z]J/^)OT_\ IN&UBX_H[ZGZ7U=I&K7ZQ-RY<_!:4[UQ8DV^[<4/
MB/\ YR@_YP2\B?\ .3$W^);J270O-ZQB/]*V:*_K*HH@N86*K*%'1@R24 7U
M. "A2#3\R=;_ .?0?YE6\Q3RWYF\NW=O4T>[:[MGIV^%()Q_PV++B9[^7_\
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M_*RR=EM[^>ZU6\ -.7U8+% IIU%9)"0=JJAZC93%]5?\^Y/R<L?RO_)W2?,
M@0:YYJ0:O>ST'-HY*_54KUX)"58#H'=S^T<42+[VQ0_"K_G[G^3=AI=YY?\
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ME[2S_=P^6(9E-3UEO;I3M_SS&*8OW&_(:".U_+/R9:VZA(H_+FD(BCH%6SC
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M7C.LI:G3U%J-ZE63]9L6+^<OS$%_YRY_YS'&F(/K7EZSUA+<CK&;#1EK-O\
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M%B[%78JP'\S?S/\ +/Y/>7[KSY^8FH1Z=HUI0/*]69W;[,<:*"SNW95!/4]
M2%7X^?F)_P _@I%N9+7\J?**-:*Q"76LW!YN*]3;P;+M_P 7-N?;=9\+QRV_
MY^[_ )LK*&O- \K20[U6.VOD;V^(W;#_ (7%>%]8_DQ_S]F\I>;+Z#0?S?T6
M7RTTS<!J-M,;NT4GH95X++&O:H$M.IHM2J@Q?K79WD&H017]A*D]K.BRQ2Q,
M'1T<55E85!4@U!&Q&+%^9/\ S]-\_P#FC\O?(/EW4_(.MZEH=Y/KOHRS:9>3
M6DCQ_596X,T+*2M0#0FE0#BRB_#+_H9K\X?_ "X/FW_N.W__ %6Q94[_ *&:
M_.'_ ,N#YM_[CM__ -5L5I^W7_/J_P#.OS!^9_E/S/Y;\^ZQ?:UJ^CZE!<I<
MZE<RW,XM[R+BJ>I*S,55X'(%=BY\1BQD'ZHXL7CG_.0OGT_EA^6?FSS[%)Z5
MSIND7<MLU:?Z2T92 5VI65D&V_AOBD/Y5_\ H9K\X?\ RX/FW_N.W_\ U6Q9
MT[_H9K\X?_+@^;?^X[?_ /5;%:?I)_SZY_.'S[^8/YJZQHWGWS3KFMZ?%Y8N
M[B.VU/4KFZB65;VS42*DSLH<*S ,!6C,*T)Q1(/WGQ8.Q5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5^?'_.2?_/Q;\O\ \@K^?R;HT$GFCS5;$I<6MG,L
M=O;N.J3W)#@2 [%$20KN'X,*8LA&WYWZO_S][_,Z:;EH/ESRW;6^_P %S'>7
M#^WQ)<0C_A<4\++?)_\ S^#\SV\T:^?_ "?IMW;G:1M,N)K5Q[JLWK@]]BPK
M_,.N*\+]8?\ G'W_ )RD\@_\Y*:=)J'Y=WK"_ME#7FEW:B*\MP30%D!8,A.W
M-&=*[%@VV+$BF<?G9^97_*GO(NN_F?\ 4OTC^A;-[OZIZWH>KQ(''U.$G'KU
MX-\L4!^2?_193_S''_AP?]F&+/A=_P!%E/\ S''_ (<'_9ABO"[_ *+*?^8X
M_P##@_[,,5X4]\K?\_>?\3:UIOES_E7OH?I"\M[3U?T[SX>M($Y<?J(K2M:5
M%?$8HX7[08L7R?\ \Y+_ /.8WD/_ )QBMX[?S7))J'F.ZC]2UT>RXF=DJ0))
M&8A8HZBG)MVH>"OQ:BD"WY4^9?\ G[_Y_NIV;R=Y5T*QMN7PI?O=7CA=]BT<
MEL">F_'L=M]EEPJ_E?\ Y_ >>K69#YT\IZ+?6_+XUT^2YLWX^QE>Y%?HQ7A?
MJ]_SC;_SEQY#_P"<G;*5_)4TMIK=H@>\TF]"I<Q*2!ZB\25DCJ:<T.U1S5"P
M!6)%/J'%#L5=BK\S_P#G*;_GXI_T+1YZD_+#_!_Z:].SM[OZW^EOJM?7!/'T
M_JLO2G7GOX#%D(V^<O\ HLI_YCC_ ,.#_LPQ3PN_Z+*?^8X_\.#_ +,,5X7?
M]%E/_,<?^'!_V88KPOOS_G#W_G*__H:_1=8\Q_H#] ?HJ\CM/2^O?7/4YQ\^
M7+T8>-.E*'YXL2*>!?\ /TWS_P":/R]\@^7=3\@ZWJ6AWD^N^C+-IEY-:2/'
M]5E;@S0LI*U -":5 .*8OPR_Z&:_.'_RX/FW_N.W_P#U6Q94[_H9K\X?_+@^
M;?\ N.W_ /U6Q6G[=?\ /J_\Z_,'YG^4_,_EOS[K%]K6KZ/J4%RESJ5S+<SB
MWO(N*IZDK,Q57@<@5V+GQ&+&0?JCBQ>.?\Y"^?3^6'Y9^;//L4GI7.FZ1=RV
MS5I_I+1E(!7:E960;;^&^*0_E7_Z&:_.'_RX/FW_ +CM_P#]5L6=._Z&:_.'
M_P N#YM_[CM__P!5L5I^DG_/KG\X?/OY@_FKK&C>??-.N:WI\7EB[N([;4]2
MN;J)95O;-1(J3.RAPK, P%:,PK0G%$@_>?%@[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J__]/[^8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ7:QJD.AV%UK5[R^
MKV<$MQ)P%6X1*6:@VJ:#;%7\X/\ SE7_ ,_'O-?YW177DC\MDF\M^3)@8IB'
M_P!/O(SL5FD0TCC8;&*,GD*AY'4E<68B_-/%DSS\K/\ E-/+G_;8T_\ ZB$Q
M5_9_BU.Q5!:EJ-MH]I<:OJDJP6=K$\\\KFBI'&I9F)\  2<5?Q^?\Y$_F[=?
MGI^8NO\ YFWA<0ZA=L+.)R:Q6D7[NWCIV(C5>5* N6:F^+8!3SCS'Y6OO*OU
M!-7"I+J%C!J*1@GDL-Q5HN6U*O'QD%*_ Z]Z@*7Z5?\ /HK_ ,G#K?\ X"5Y
M_P!1]EBQD_HMQ8.Q5V*OYK?^?H/YRWWGS\UYORY@G;] ^4XHK:.%3\#7<T:R
MSRD5W8<EBWZ>F:=22LXA^?/E'RIJGGO6]/\ )GE:W:ZU?5+F*TM85VYRRL%4
M$G8"IJ6.RBI) &+)^C_YJ?\ /K+SY^6_DN[_ # L-;L-:O=,MFN[W3;:&5'$
M4:\I3!(W]Z44%N)2,L >(+44K'B?E[BR?T$?\^F/SEOO-?E+6_RBUV=IF\MR
MPW.G&0U9;2[Y\H@:_9CD0D;;>K0;  +"01'_ #]]_P#)<>6/_ A'_4)-BL7\
M]^+-V*OT[_Y]1>>O\.?F_<^4)W A\Q:1<P(A-.4]J5N%(\2(TE^^O;=8R?T@
M8L'Y@?\ /U_S_P#X:_*.T\E6[TN/,FK012)6E;:T!N'/O258?;>OABRB_G#Q
M9NQ5^IW_ #Z*_P#)PZW_ . E>?\ 4?98L9/Z+<6#L5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKY._YS;_.6\_(W\H==\X>7Y3!KMP(]-TV44K'<73<?46O[
M4<?.1=C\2BHI7%(%OY.III+F1[BX=I)9&+N[DEF8FI))W))ZG%L?=?\ SBQ_
MS@/YN_YR<T>X\\6^I6NA>7(IWM8;FYB>:6XE0 OZ<2E046M&<N/BJJABK<5!
M-/'?^<F?^<9O,O\ SB_YEB\H>;Y8+RWO(/K-C?6W(1SQAN+?"WQ(Z-LRFM*@
M@D$'%0;8=^1/YO:K^17GG1_S,\ON_/3[A3<0J:"XMF-)H6%0"'2H%>C<6&Z@
MXI(?TX_\YDWL&I?D'YTU&Q<2VUQH;RQ.O1D?BRD>Q!KBUA_)CBV/I[\E?^</
MOS/_ .<@=$N/.7Y8:9!>:5;7KV$LDMY! 1/'''*R\9'4D<94-:4WIV.*":>O
M?]$R_P __P#JPV?_ '%+/_JIBO$RKR+_ ,^X/SVT'S+HVN:CH=HMI9:C:7,S
M+J5H2(XIE=B )*G8';%'$_HN\Z^;+'R'Y>U7SOKC<=/TBRN+^X/?T[>,R,![
MD"@]\6#^.?\ ,_\ ,76/S;\U:M^8_FV4S:IJUR]Q)4DA%.R1K7HD:!40=E4#
M%M?>W_.)7_/NF\_YR.\H_P#*T?,7F Z%I-S/-!8116?UB6<0MP>4LTD:J@<,
M@ Y$E6KQI\2Q,J?*?_.3W_./6I_\XR^>9_RUUF[74(C;Q7ME>I$81<6TI95<
MQDMQ(='1@&854T8XI!MB/Y&_FIJ/Y*^>M#_,K0Y7CDTV\C>=%.TMLQXSQ,.X
MDC+*?G44(!Q27]D$<BRJLL3!D8!E934$'H0<6I?BKL5?S/\ _/TS_P GI<_]
ML?3O^(MBV1? GE/RQJ'G76],\F^7HQ+JNKWMO86D;,$#3W,BQ1J68@*"S 5)
MH.IQ2^W/^B9?Y_\ _5AL_P#N*6?_ %4Q1Q._Z)E_G_\ ]6&S_P"XI9_]5,5X
MGZU?\^Z?^<>O._\ SCSY:\Q:'^:=E%97>H:C#<VZQ7,4X:-8>!),3,!0]CBQ
MD;>4_P#/WW_R7'EC_P "$?\ 4)-BL7\]^+-V*OT[_P"?47GK_#GYOW/E"=P(
M?,6D7,"(33E/:E;A2/$B-)?OKVW6,G](&+!^8'_/U_S_ /X:_*.T\E6[TN/,
MFK012)6E;:T!N'/O258?;>OABRB_G#Q9NQ5^IW_/HK_R<.M_^ E>?]1]EBQD
M_HMQ8.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MO__4^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_
M\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78JPO\R/^42U[_ME7W_)A\5?RT_\ .-W_ #AM^8/_ #DK=I-Y
M;M3IWEE7I<:W>HRVRT-&6$;&>0?R)L#3FZ @XMA-,8_YRO\ RDTO\B?S2UO\
MJ?+,T]QI^D1Z:JS7)!DD>;3X)Y7/$ #E)(Q 'V11=Z5Q4%YC^5G_ "FGES_M
ML:?_ -1"8I?V?XM3L5?FU_S\]_.[_E6?Y6'R'I4W#6O.,C6 "FC+8Q@-=M\F
M!2$CNLK4Z8LHA_/Y^2/Y977YR>?/+_Y8Z=R$FL7T4$CJ*F. ?'/)3_BN)7?_
M &.+,OI;_GXWI=EH7YX:KH&BQI#8V&FZ/:P0I]F..*PB5$ [ *!3VQ1%[+_S
MZ*_\G#K?_@)7G_4?98HD_HMQ8.Q5V*OY'?\ G,N*XA_/#SXEZ29#KETP);E\
M#'E&*^ 0K0=AMVQ; SG_ )]XK;/_ ,Y"^2QJ''TO5U CET]0:=<F/Z>?&GOB
MLG]3FI+;/:3IJ7$VAB<3<NGIE3RK[4KBUOXD<6U^O'_/G^*X/GWS7.A/U5=#
MC60<MB[7*%"1W- ]#VW\<6,GTQ_S]]_\EQY8_P# A'_4)-BB+^>_%F]__-+R
M"="_+_\ +'S_  +QM]?TC5H7-/M7%AK-VKFO_&*6$4]O<8H2S_G&_P \_P#*
MMOS2\H^=G;A!8ZS:&X;_ )=Y)!'/_P DF;%2_L/Q:W\\_P#S]Q\__IS\QM"_
M+ZW<M!H&DF>1:[+<7\G)A3_C%%":^^+.+X?_ .<6/(!_,K\T?+_EQT]2VBGD
MU"X'[/I6$3W+!O9O3X>_*G4XI+Y\Q2_4[_GT5_Y.'6__  $KS_J/LL6,G]%N
M+!V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\7_ /.='_..GF7_ )R;\A:?
MY!\@W>GV=_::Y;ZE(^I2S1Q&*.VN(BH,,4S%N4JD J!0'XJ@ J0:?E%_T2*_
M.'_J]^4O^DR__P"R+%EQ/VL_YQ9_*.__ "*_*[R_^5GF![274]+CN!<R63N\
M#R37,DQ96D2-S]O>JC?8; 8L27Y2_P#/XO7;.XUKR)Y9B*_7[2SU2\E (Y"*
MZD@2(D=:%H)*?(^!Q91?B_BR?U+_ )^V5QIO_.*>J:?J))NX/)MG%,34DR)!
M$K?:H>H/45\<6L<W\M&+8_HM_P"?17_DGM;_ / MO/\ J LL6$GZG8L78J^(
M?^?B_F5_+7Y!>:3 0)K_ .I6"U\)KJ,2??&'_P!K%,7\L6+8_K(_YP5TZ/2_
MR&\CVT'V6TYISL!\4\\DK=/=COWZXM9>F_F)_P X\_EO^;6I1>8_S)\MV&L:
MG!;K:1W%TA9UA1V=4!!&P9V/S8XK; O^A*/R+_ZD71_^13?\U8K;Z>MX([6)
M+:W4)%&H1%'0*HH /D,4*N*NQ5_,_P#\_3/_ ">ES_VQ]._XBV+9%\J?\XR_
M^3A_+[_P+="_ZCX<5+^PO%K=BKL5?DI_S]]_\EQY8_\  A'_ %"38LHOY[\6
M;W_\TO()T+\O_P L?/\  O&WU_2-6A<T^U<6&LW:N:_\8I813V]QBA+/^<;_
M #S_ ,JV_-+RCYV=N$%CK-H;AO\ EWDD$<__ "29L5+^P_%K?SS_ //W'S_^
MG/S&T+\OK=RT&@:29Y%KLMQ?R<F%/^,44)K[XLXOA_\ YQ8\@'\ROS1\O^7'
M3U+:*>34+@?L^E81/<L&]F]/A[\J=3BDOGS%+]3O^?17_DX=;_\  2O/^H^R
MQ8R?T6XL'8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7_]7[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2O
MF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BJA=6L-]#)97D:RV\R-')&X#*R,*,I!V((V(Q598V-MIE
MO%IVFPQV]K @CBAB0(B*HH%55   '0 8J_EM_P"?CO\ ZT3YR_[=/_=*M<6R
M/)\N?E9_RFGES_ML:?\ ]1"8I?V?XM3L5?RK_P#.?/YW'\[/S=U:ZT^7U-"T
M(G1M.XFJLENQ]64= ?4F+L#W3@*F@Q; 'V9_SZ+_ "<-]JNO_GGJD58+&/\
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M;O,DL4]U;U#-;6T(800L02.=7=WH=N84[IBPD;>-_P#/WW_R7'EC_P "$?\
M4)-BL7\]^+-^J?YC^0QYA_YP?_+SSM E;CR]J^HL[TKQM[S4[R%]^U9?1_SI
MBQZORLQ9/[&_^<??/8_,W\M?*GGMGYS:EH]G+<&I-+@1A9Q4[FDH85[TQ:R_
MEL_YRS\^?\K*_.'SEYN20RP2ZM/;V[_S06A%M"1[&.-3BS#[9_Y]6_E_^E-9
M\\?F5<QUBTC06T^%F&PFO>3DK[JD!!\ _N,42?D]BR?J=_SZ*_\ )PZW_P"
ME>?]1]EBQD_HMQ8.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L2\^>
M>=&_+3R]J/GWSC<K::-I5N]S<RMV5>BJ/VG9B%11NS$*-SBK^1O_ )R%_.C4
MO^<@//NK_F?K8:(7TO"TMB:BWM(_AAB%-JJ@'(@#DY9Z?%BV@4RK_G$?\EY_
MSX_-/0?(PC+Z8DXO]4:E0EE;$/+R\/4^&)3_ #R+B@FG](G_ #FO_P"2+\]?
M]L>7_B2XL _DGQ;'TAY)_P"<I?//Y:?EU/\ DS^75_+HMK?:O<ZK>W]FYCNI
M!+;V\*PI(M&C5?1+,4(9^0%0H(913P.XUO4;N[.L75W<2WY)8W#RNTI)ZGF3
MRKOXXI?HO_SAE_SGIYN_*WS-IWDO\T-6GU?R)J$\=K*^H2M++I_J-Q6>.5R6
M$:$@R(25X E &&ZQ(?I#_P _7+\V?Y)Q6XD"?6O,%A"5-/CI%/)Q'_ <MOY<
M41?S9XLWZ0S_ //Q/S9Y+_+/RQ^3'Y+H-)FTG3(K:_UB:..6=Y=RR6Z.&1%%
M:<V#.3NO"@)6/"\$T[_G-O\ /72[LZG;>>M7:8MRXSR)/%6M?[J56CI[<:8I
MI^P7_.#G_/P67\\]13\I_P WH[>U\X2(S:?>VZ^G#?"-2SQLE2$F"@L./P.
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M%78J[%78J[%78J[%78J_EC_Y^._^M$^<O^W3_P!TJUQ;(\GRY^5G_*:>7/\
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M_P"!;9_]0%[BRB_G2Q9OUY_/>&>__P"<'?RTN6;E]6UN%V+DD\ -1B4#Y<E
M'8#VQ8CF_(;%D_JV_P"< (DA_P"<?_)*0J$4VMTQ"B@JU[.2=NY))/B=\6LO
MA_\ Y_&PQMI/D*X*@RK=:LJM3<*R6Y(^DJ/N&*8OPIQ9O[%/^<<+J2^_*7R%
M>W)Y33>5M$D<TI5FL8B=A[G%K+V?%#L5=BKL5=BK^/3_ )R:_P#)P_F#_P"!
M;KO_ %'S8M@?2'_/LB5X_P _=$2-F59++4U< D!A]5=J'Q%0#\P#BLGZ(?\
M/WW_ ,EQY8_\"$?]0DV+&+^>_%F_J<_Y]Q?^L[>3?^WM_P!U6ZQ:Y<W\X7_.
M0'D/_E6/YD^:O(21B*#3-7NX;=1T^KF0M ?IB*'%L")\E_G#>^3OR_\ .?Y4
MVO,VWFY]),A!V06$SRGY<Z@&G4#?88K3QV""2ZE2UMD:2:1@B(HJ69C0 #N2
M<5?V)^2O(T?Y9_E=I_Y?0  :-Y?CLG*]&DBMN,C>Y9ZL3XG%K?QS8MC]3O\
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M5[5]7O=?OKG7=;N)+O4;R:2XN;B9B\DLLC%G=V.Y9F)))ZG%L?H[_P X$_\
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M9GFG\V-7?S;^8^JW.KZLZ+'Z]RU2J+4A$4 *B@DD*H"U)-*DXJ]Y_P"</?\
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M'YC6 U+0;QHFFMS++#R,,BR(1)"Z2*0R@_"PKT-5)!5?+G_1.+_G';_J3?\
MN;:K_P!E6*>(OH+\G_R(\B_D)I]UH'Y3:2-)L;V<7-PGUBXN"\H0("7N))'
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MRX_+CR[^4GEVR_+W\O;+]'^7]/\ 6^K6WK2S</6E>9_CF=Y#61V;XF-*T%
M,4*?YE_EEY9_.#R]<^0/S&L!J6@WC1--;F66'D89%D0B2%TD4AE!^%A7H:J2
M"J^7/^B<7_..W_4F_P#<VU7_ +*L4\1?07Y/_D1Y%_(33[K0/RFTD:38WLXN
M;A/K%Q<%Y0@0$O<22. % HH/$;FE2:JDV]6NK:*]ADL[E>4,R-&ZU(JK"A%1
MOT\,4/B?_HG%_P X[?\ 4F_]S;5?^RK%/$7JGY1?\XF_E3^1&L3^;_RIT#]%
M:M<VCV,L_P!>O;CE \B2,G&XFD05>-#4+RVI6A(*I-OHO%#L5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__T_OYBKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9?_ AM_U18M@Y/ZJ\6MV*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__
MU/OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9?_ A
MM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5__U?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL54;BXBM(GNKI
MUBAB4N[N0JJJBI))V  W).*OS;_-S_GZ/^5'Y>7DVA^48KWS7>PEE>6P"168
M9?V1<2&K;_M1QNG<,>ZR$7@=C_S^-TJ29DU/R%=0VX>BO#JR2N4KU*M;1@&G
M;D1_E8KPOLO\B/\ G/[\J/SYOX?*^F7=QHGF*X(6&PU>-8C,_P#+#*C/$Y)^
MRI99&[)B@BGVWBA\W?\ .2/_ #E#Y5_YQ=TS3?,/G^SU.\M]4N7M85TR*"1U
M=$YDN)IH0!3P)->V*0+?(7_177\GO^K)YM_Z0[#_ ++<4\+O^BNOY/?]63S;
M_P!(=A_V6XKPN_Z*Z_D]_P!63S;_ -(=A_V6XKPOT9_+CSW8?F?Y7TC\Q- C
MGATW6K.&^MX[E5698YE#*'",ZA@#N S#W.+%FN*OSI_.O_GYG^5?Y3ZC/Y8T
M%;OS3J]L[1S?HW@MI&Z[%3<.:,0>\22+UJU13%D(OFZS_P"?QNEO<F/4/(-S
M%9U%)(M7220CN3&;9 #[<S\\5X7WM_SCS_SFA^6O_.2+_HCR;>367F)8VE?2
M-1017/%?M-&59HY5'7X'+!=W5<4$4^L<4/AK_GX-^<7F_P#(_P#*Z+SI^5VH
M_HO66UFTM#/]7@N/W4D<K,O">.1-RJ[\:[;'KBF(?B[HG_/R7\_["_L]0UCS
M/]=TZ*XC>>V;2],C6>-&#21<TME9>2_"2K!A6H(-#BSX7]..@:Y9^9M,LO,F
MBR";3]0MH;NVD'1XID#HP^:D'%K3;%78J[%7YS?\_&O^<G?,7_.//E70['\L
M;]=.\UZW?N5G,$,Y2SMDK-\$Z2)5GDB )7IRIOBRB+?G/_SCI_SG=^>OGG\T
MO*7DCS?YI-SI&I:S:6EY;G3--B+Q22!73E';*ZU&U58$>.*2']&.+!V*NQ5V
M*NQ5_*I_SEI_ZTKYE_\  AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L'_,K\PM'_*C
MRMJOYC>;G=-(T>U>ZG])0TC!=E1 2 7=B$0$@%F%2!OBK\Z?^BNOY/?]63S;
M_P!(=A_V6XLN%W_177\GO^K)YM_Z0[#_ ++<5X7ZG8L4OU75K+0K.?6=;N8;
M/3[6-II[BXD6.*.-!5F=V("J!N233%7YC?F;_P _7ORP\H7DFD^1=.U'S1)$
MQ5KF+C:6C4-/@>6LC=]_2"G:C$&H67"\6LO^?R-K)*JZC^7DD4'[3Q:V)&'R
M5K- ?^"&*\+[0_(3_GX'^5?Y\7L'E>TN9]!\R7#!(;#5E6,3N?V89D9HW).R
MJQ21C]E#B@BGW%BAV*NQ5V*OCO\ YR$_YSC_ "Q_YQUN6\O>9;N;5/,BH&.E
M:6BRS1\OL^L[,L<50:\6;GQ^((0152!;X4U+_G\?913%-(_+Z:>WWH\^M+"Y
MW-*HMI(!M3]KKMVJ5/"]"\A_\_=?(.MW,5GY_P#+NJ:"DE UQ!+'?PQF@W>B
MQ2<:U'PQL>GP[FBO"_4;R;YTT+\PM'M?-_DG4(-3T:]3G!=6SAT8=QXA@=F5
M@&4U5@"",6*8Z_<RV6F7MY;-QFAMII$:@-&5"0:';KXXJ_EY_P"BCO\ SD3_
M -3E_P!RG2O^R7%LX0[_ **._P#.1/\ U.7_ '*=*_[)<5X0^BO^<3/^<_/S
M<\X?FUY7\G_FIYD74?+>KWAL)[=K"PMZRW$;);D2001N")C'L&^+[/?%!#^A
M+%@[%7X)?\YL_P#.=GYJ?EU^;NM>0/RC\PC3="T=+6V,8L;&XYW#0++,W.X@
MD>H9^!'*GP;#?=9@/E#_ **._P#.1/\ U.7_ '*=*_[)<4\(=_T4=_YR)_ZG
M+_N4Z5_V2XKPA_4YBUNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^./_ #]A_/\ U'RMIFD_D/Y8
MN'MFUN!]1U=XV*N]F',4,-1^Q+(LAD&U?35=U9QBRB$P_P"<(O\ GWKY0M?*
MFF?FK^>&FIK.O:O!'>VNFW8)M;2WE :+U(=A)*R$,XD!5.7#AR4L53)^B>I_
M\XV_E-K%I^BM0\C>6WM0G!5&DVB%!2GP,L89"!T*D$=L46_";_GXC_SB)HO_
M #CMJ>E?F%^5PDM?+.MS20-9%V?ZE=QJ'412,2Y21>3*"249&^+B5"K*)M^Q
M7_.#7YP:A^=GY/:'YJ\RR^OK=KZVF7TQ(+2RVK<5D;_+>,H[UZL2>A&+$A\;
M_P#/X/\ Y0ORA_VV+C_J'Q3%,O\ G"#_ )Q#_*#\T/R4\L>>O/OE:VU'7;[]
M(_6;J2>Y5G]+4;B)*A)5441%78#IXXJ2^K_^A!/R _ZDFS_Z2;S_ *K8HMW_
M $()^0'_ %)-G_TDWG_5;%;?47E;ROI?DK2++REY7MEM-(TZ!+:UMU+,L<48
MHJ@L2QH/$DXH?GW_ ,_./SWOORD_+6W\H>5[AK76_-T\MD)8V*R)90H&NF0C
M<%N<<1_R9&W!IBRB'R;_ ,^[/^<'?+'G[RZOYY_G)8C5+:[FECT;3)JBW,<+
M&-[B913U"T@941O@ 4LP<LO!3(OUFU;_ )QH_*77+ Z'J/D?RXUF5XJD>EVT
M10=/@:-%9#3NA!Q8V_G]_P"<T/\ G'>Y_P"<-?S%TCS?^5%U<VFA7[F_T6?U
M&::SN;9E,L'J'=@G)60M4LC<7Y%69EF#;^A+\@?S2B_.K\N_+GYH0JB/J]C'
M+<)&:JERA,=PB^R3(ZCO0;[XL"^+?^?KW_DDX/\ P(;#_DU/BF+\:X_RJ_3G
M_.-:_FY81UN=!\\WUC=LHW^JWNGV/%F/@DR*H]Y3BRZOW!_Y]H?FC_RL3\E=
M/T6\E]34?+%Q-H\H)^+TEI+;FG\HB=8U/_%9\,6$GZ"8H=BKL5?SL_\ .8]]
M+_SD_P#\Y2Z9^3FDRDZ?I]Q9>7>:'9:.9KZ4#^:/FZMX^B,68V#QSR=90:9_
MSF(NFV$:PVMO^9-W%%&@HJ(FIR*J@>  H,4]']1.+6[%78J[%78J_E4_YRT_
M]:5\R_\ @0V_ZHL6P<G]5>+6[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7XO_ //V_P#.X6&EZ+^0>C2_
MO[]AJ^JA2-H(F*6T9Z_;D#R$;$>DAW#8LHA^'-EHE[J%I>:M:1%K/3TC>YEJ
M J"601H-^K,QV45- S4HK$+-*L5?V]XM3\(/^?L'_.0E]=:S9?\ ..WEVX:+
M3;.&+4=:6-J>M/+\5O"].JQI27B=F9T:E8U.+.(?EU^2WY,^9/S[\UVGY;>0
M(X6U2Z620R7#F.&&*,5>25@&(5?968D@*I) Q9$T^C?^<C_^<!?/W_.-GEZ/
MS_Y@O-,U71#.EM/)I[R\X'DKP,B2QI\#$<0RD_$0"!4$J ;?#T<C1,LL3%74
MAE930@CH0<4OZJ_^<"?SMU#\]/RATWS!YFE-QKNE3RZ-?SL:M-);*C)(WB[0
MR1ESW?DW>F+613[-Q0[%7@'_ #E%^</_ "H?\L/,/YE6_$ZA:6WHZ>K $&\N
M&$,!*G[2J[!V'=%;%(%OY%-7U>]U^^N==UNXDN]1O)I+BYN)F+R2RR,6=W8[
MEF8DDGJ<6Q];_DA_S@G^:OY^^71Y_P#)EK96^AR/)';3ZA<^C]8,3%7,2JKD
MJ&!7DP5>0(!V-%!-/FK\POR_U[\K/,5_Y \\VC6.N:;+Z5Q Q#4)4,K*RDAE
M92&5@:,I!&*7Z.?\^L?SXO?)?Y@O^3&J7#MY>\T)*]O"S?!#J,$?-9%KL/5B
M1HVI]MO2K]@8L9!_0?YI_P".+J/_ #!W'_)LXL'\4.+:[%4]\K^8+GRGK.G>
M:M,/&\TR\M[V @TI)!()%W[;J,5?VD:!K5MYDTRR\PZ8W*SO[:&ZA;8UCF0.
MIVJ.A&+4C+Z]@TVVFU&^<16UO&\LKMT5$!9B?8 5Q5_&'^9/G*?\Q/-FN>?;
MWD)]:U*[U!E8U*_6)6DX^%%#4 &P H-L6UA6*NQ5_;WBU.Q5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5XI_SDC^8.H_E1^5GG#\R/+@C.K:+HE[>6GJKR
M03QQ$QLR_M!6H2O<"G?%7\?&I?\ .7OYY:K=2ZC=_F1YM6:9R["'6[V&,$]E
MCBE5$'@JJ%'88J@?^AK?SL_\N3YR_P#"AU'_ *K8J[_H:W\[/_+D^<O_  H=
M1_ZK8J[_ *&M_.S_ ,N3YR_\*'4?^JV*N_Z&M_.S_P N3YR_\*'4?^JV*N_Z
M&M_.S_RY/G+_ ,*'4?\ JMBKO^AK?SL_\N3YR_\ "AU'_JMBK?\ T-;^=G_E
MR?.7_A0ZC_U6Q5W_ $-;^=O_ )<GSE_X4.H_]5L5=_T-;^=O_ER?.7_A0ZC_
M -5L5=_T-;^=O_ER?.7_ (4.H_\ 5;%7?]#6_G;_ .7)\Y?^%#J/_5;%7?\
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M\(5C-<3+PXS,2 H-0OQ4J"L"*?SSW-O)9S26ERO&6)V1U/9E-"/H.+-^KO\
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M/V-_Y\^>0/2T[SA^:5PAK//;:/;/3H(5,\X]Z^I#]V+"3Y>_Y^O?^3L@_P#
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MK'_G 'R!_P J]_(ORK:S(4N]5@?6)R13D;YS+$:?\83&/HQ:R_'_ /Y^O?\
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MBS'P29%4>\IQ91?DWKWYB^9/^<FW_+'\E0&]?1;6#RY:%B7#RW%WP66E=E6
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M+J/_ #!W'_)LXL'\4.+:_4[_ )]%?^3AUO\ \!*\_P"H^RQ8R?O/^;_D>/\
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MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKY7_ .<X/_) _F+_ . Y?_\
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M8J[%78J[%78J[%78J[%78J^5_P#G.#_R0/YB_P#@.7__ ";.*OY4_P#G!_\
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M_P!2;Y?_ .1MW_S7BKO^BW'YB_\ 4F^7_P#D;=_\UXJ[_HMQ^8O_ %)OE_\
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M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?\ _G$[_P G?^6G_@9^7O\
MNHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5__T?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\
MY:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OXJ_P#G.#_R?WYB_P#@1W__ "<.
M*OU$_P"<??\ GTAY%_.'\MO*_P":6K^:M;M+W7M+M[^:"".V,<;2K4JI9":#
MM4XJ]A_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_E
MU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6
MG_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_E
MU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6
MG_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_E
MU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6
MG_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_EU_U.7F#_ )%6G_-&*N_Z(C_E
MW_U.6O\ _(JT_P":,5=_T1'_ "[_ .IRU_\ Y%6G_-&*N_Z(C_EW_P!3EK__
M "*M/^:,5=_T1'_+O_J<M?\ ^15I_P T8J[_ *(C_EW_ -3EK_\ R*M/^:,5
M=_T1'_+O_J<M?_Y%6G_-&*N_Z(C_ )=_]3EK_P#R*M/^:,5=_P!$1_R[_P"I
MRU__ )%6G_-&*OP1_/\ _+BT_*#\R/-'Y7:3<2W=EH.JW.GPSSA1)(D+E0S!
M:"I[TVQ5_7M_S@__ .2"_+K_ ,!RP_Y-C%7U/BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BK&=2\E^7M9D%SJ^DV%W,H*AY[6*1@"Q<BK*3NS,Q]R3U)Q5
M+_\ E6GE#_J7])_Z08/^:,5=_P JT\H?]2_I/_2#!_S1BKO^5:>4/^I?TG_I
M!@_YHQ5W_*M/*'_4OZ3_ -(,'_-&*N_Y5IY0_P"I?TG_ *08/^:,5=_RK3RA
M_P!2_I/_ $@P?\T8J[_E6GE#_J7])_Z08/\ FC%7?\JT\H?]2_I/_2#!_P T
M8J[_ )5IY0_ZE_2?^D&#_FC%6_\ E6OE#_JP:5_T@P?\T8J[_E6OE#_JP:5_
MT@P?\T8J[_E6OE#_ *L&E?\ 2#!_S1BKO^5:^4/^K!I7_2#!_P T8J[_ )5K
MY0_ZL&E?](,'_-&*N_Y5KY0_ZL&E?](,'_-&*N_Y5KY0_P"K!I7_ $@P?\T8
MJ[_E6OE#_JP:5_T@P?\ -&*N_P"5:^4/^K!I7_2#!_S1BKO^5:^4/^K!I7_2
M#!_S1BKO^5:^4/\ JP:5_P!(,'_-&*N_Y5KY0_ZL&E?](,'_ #1BKO\ E6OE
M#_JP:5_T@P?\T8J[_E6OE#_JP:5_T@P?\T8J[_E6OE#_ *L&E?\ 2#!_S1BK
MO^5:^4/^K!I7_2#!_P T8J[_ )5KY1_ZL&E?](,'_-&*IWH_EO2?+PD&@6%K
M8B6GJ?5H$BY4Z<N %:5VKBJ=8J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7Q1_S\8_]9P\__P#;/@_ZBX<5?QM8J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7O_\ SB=_Y._\M/\ P,_+W_=1
MAQ5_;[BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BK_]+[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G
M_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK^*O\ YS@_\G]^8O\ X$=__P G#BK^
MJO\ YP=_\D#^77_@.V/_ ";Q5]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J_BH_P"<W?\ R?OYC?\ @2:A_P G3BK^
MK#_G!_\ \D%^77_@.6'_ ";&*OJ?%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q1_S\
M8_\ 6<//_P#VSX/^HN'%7\;6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5[_\ \XG?^3O_ "T_\#/R]_W48<5?V^XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M_P#_T_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9
M?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OXJ_P#G.#_R?WYB_P#@1W__ "<.*OZJ_P#G
M!W_R0/Y=?^ [8_\ )O%7U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BK^*C_ )S=_P#)^_F-_P"!)J'_ "=.*OZL/^<'
M_P#R07Y=?^ Y8?\ )L8J^I\5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?%'_/QC_P!9
MP\__ /;/@_ZBX<5?QM8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%7O_P#SB=_Y._\ +3_P,_+W_=1AQ5_;[BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_4
M^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W
M_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J_BK_ .<X/_)_?F+_ .!'?_\ )PXJ_JK_ .<'?_)
M_EU_X#MC_P F\5?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*OXJ/\ G-W_ ,G[^8W_ ($FH?\ )TXJ_JP_YP?_ /)!
M?EU_X#EA_P FQBKZGQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\4?\_&/_ %G#S_\
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MQ5V*NQ5V*OXJ_P#G.#_R?WYB_P#@1W__ "<.*OZJ_P#G!W_R0/Y=?^ [8_\
M)O%7U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BK^*C_ )S=_P#)^_F-_P"!)J'_ "=.*OZL/^<'_P#R07Y=?^ Y8?\
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M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5[_\
M\XG?^3O_ "T_\#/R]_W48<5?V^XJ[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J_P#_T?OYBKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OXJ_P#G
M.#_R?WYB_P#@1W__ "<.*OZJ_P#G!W_R0/Y=?^ [8_\ )O%7U3BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK^*C_ )S=
M_P#)^_F-_P"!)J'_ "=.*OZL/^<'_P#R07Y=?^ Y8?\ )L8J^I\5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5?%'_/QC_P!9P\__ /;/@_ZBX<5?QM8J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7O_P#SB=_Y
M._\ +3_P,_+W_=1AQ5_;[BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BK_ /_2^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_BK_ .<X/_)_
M?F+_ .!'?_\ )PXJ_JK_ .<'?_) _EU_X#MC_P F\5?5.*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OXJ/\ G-W_ ,G[
M^8W_ ($FH?\ )TXJ_JP_YP?_ /)!?EU_X#EA_P FQBKZGQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5\4?\_&/_ %G#S_\ ]L^#_J+AQ5_&UBKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>__ /.)W_D[_P M
M/_ S\O?]U&'%7]ON*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*O\ _]/[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK^*O\ YS@_\G]^8O\
MX$=__P G#BK^JO\ YP=_\D#^77_@.V/_ ";Q5]4XJ[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_BH_P"<W?\ R?OYC?\
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MBKL5=BKL5=BKL5=BKL5=BKL5=BK^*O\ YS@_\G]^8O\ X$=__P G#BK^JO\
MYP=_\D#^77_@.V/_ ";Q5]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J_BH_P"<W?\ R?OYC?\ @2:A_P G3BK^K#_G
M!_\ \D%^77_@.6'_ ";&*OJ?%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q1_S\8_\
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MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O!?\
MG*'SIK/Y=?E1YL\\>3;GZGK>F:;)<6EQZ<<OIR @ \)59&Z]&4CVQ2'\[O\
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M>99]&DL]8FTL6\5DLX816\$W/D94H3ZU*4_9K7?%B33ZR_Z(Z:+_ -3W>?\
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MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\4?\_&/_6<//_\
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MA\KZ9=W&B>8K@A8;#5XUB,S_ ,L,J,\3DG[*EED;LF*"*?;>*'8J_.G\Z_\
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M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>_\
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M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?Q4?\YN_P#D_?S&_P#
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M_G*H>7M./_..'D:Y'Z4U&-9/,$L3?%!:L T=M4=&F%&D'^^J @K+BRB'K_\
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M4K::S;QLUG<(313S%1&Y'6-R&!Z<A1BM@-OF[%*I%$\[K! I>1R%55%22=@
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MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\4?\
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MRY_ZV;)_YLV^_P"ZK)BV=']/^+6[%78J[%78J_E4_P"<M/\ UI7S+_X$-O\
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MI&DNHHK6%A;VQ ]C$B^.*&=8J[%5.6))T:"=0\;@JRL*@@[$$'J#BKR34_\
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M8XL"^//^?G'Y$7WYM_EK;^;_ "O;M=:WY1GEO1%&I:1[*9 MTJ ;DKPCE/\
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M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\
M[9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC
M_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY>_[J,.*O
M[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5?__3^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZT
MKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q5_S\5_]9Q\__P#;.A_ZBX<5
M?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\ [9\'_47#BK^:_P#Y
M]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MG
MP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY>_[J,.*O[?<5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__4^_F*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_
MJKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7Q5_S\5_]9Q\__P#;.A_ZBX<5?S5_\^Z__6C?('_;
M1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J^*?^?B__K./G_\ [9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"
M38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M]_\ ^<3O_)W_ ):?^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__5^_F*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7Q5_S\5_]9Q\__P#;.A_ZBX<5?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?
M^?B__K./G_\ [9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?
M^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5?__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q5_S\5_]9Q\_
M_P#;.A_ZBX<5?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\ [9\'
M_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ
M_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY>_[J,.*O[?<5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M?__7^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_
M\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%7Q5_S\5_]9Q\__P#;.A_ZBX<5?S5_
M\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\ [9\'_47#BK^:_P#Y]T_^
MM'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MGP?\
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MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]_\
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M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\
M[9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC
M_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY>_[J,.*O
M[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5?__2^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZT
MKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q5_S\5_]9Q\__P#;.A_ZBX<5
M?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\ [9\'_47#BK^:_P#Y
M]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MG
MP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY>_[J,.*O[?<5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__3^_F*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_
MJKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7Q5_S\5_]9Q\__P#;.A_ZBX<5?S5_\^Z__6C?('_;
M1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J^*?^?B__K./G_\ [9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"
M38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M]_\ ^<3O_)W_ ):?^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__4^_F*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7Q5_S\5_]9Q\__P#;.A_ZBX<5?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?
M^?B__K./G_\ [9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?
M^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5?__5^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q5_S\5_]9Q\_
M_P#;.A_ZBX<5?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\ [9\'
M_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ
M_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY>_[J,.*O[?<5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M?__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_
M\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%7Q5_S\5_]9Q\__P#;.A_ZBX<5?S5_
M\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J^*?^?B__K./G_\ [9\'_47#BK^:_P#Y]T_^
MM'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_P"LX>?_ /MGP?\
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MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]_\
M^<3O_)W_ ):?^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__0^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
MQ5_S\5_]9Q\__P#;.A_ZBX<5?S5_\^Z__6C?('_;1E_ZA9L5?V4XJ[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*?^?B_
M_K./G_\ [9\'_47#BK^:_P#Y]T_^M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*OBC_GXQ_P"LX>?_ /MGP?\ 47#BK^-K%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]_\ ^<3O_)W_ ):?^!GY
M>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5?__1^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*H'4]3L]%M)
M]7UB>*UL;:-IIYYW"1QQH*LSLQ 50-R2:#%7Y-ZE_P _8=#G\\IY"\D^4WU;
M1)]2@L+;5Y-3-L9ED=8S,+<VKD+R)*@R!F4 G@3Q59<+]<L6+L5?'W_.87_.
M5_\ T*AHNC^8_P! ?I_]*WDEIZ7U[ZGZ?"/GRY>C-RKTI0?/%(%O@/\ Z+*?
M^8X_\.#_ +,,67"[_HLI_P"8X_\ #@_[,,5X7?\ 193_ ,QQ_P"'!_V88KPO
MUW_*'\P/^5K>2= _,GZI]0_3FGV]_P#5?5];T?60-P]3BG*E:5XK7P&+ L^O
M+R#3X);^_E2"U@1I9996"(B(*LS,: * *DG8#%7Y _G7_P _:=!\LZC/Y?\
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M?]#9_P#.75I^6UN3-HMAJ%MH!X5-+73RTU^=NX;ZQ0^ 6IQ9C8/+/+,:Q?\
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MV8(&GN9%BC4LQ 4%F J30=3BE]N?]$R_S_\ ^K#9_P#<4L_^JF*.)W_1,O\
M/_\ ZL-G_P!Q2S_ZJ8KQ/UJ_Y]T_\X]>=_\ G'GRUYBT/\T[**RN]0U&&YMU
MBN8IPT:P\"28F8"A['%C(V\I_P"?OO\ Y+CRQ_X$(_ZA)L5B_GOQ9NQ5^G?_
M #ZB\]?X<_-^Y\H3N!#YBTBY@1":<I[4K<*1XD1I+]]>VZQD_I Q8/S _P"?
MK_G_ /PU^4=IY*MWI<>9-6@BD2M*VUH#<.?>DJP^V]?#%E%_.'BS=BK]3O\
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MD7_U(NC_ /(IO^:L5M]/6\$=K$EM;J$BC4(BCH%44 'R&*'YO_\ /SW\[O\
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M78J[%78J[%78J[%78J[%78J[%7Q5_P _%?\ UG'S_P#]LZ'_ *BX<5?S5_\
M/NO_ -:-\@?]M&7_ *A9L5?V4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J^*?\ GXO_ .LX^?\ _MGP?]1<.*OYK_\
MGW3_ .M'>0/^VC-_U"38J_LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V
M?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__4^_F*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_,__P YE_\ K7M__P!MCRS_ -05EBV#
MD_I@Q:W8J_'W_G\'_P H7Y0_[;%Q_P!0^+*+YX_*+_G/^/\ (O\ )'R?^4'Y
M6:5^G/S  U#UUGCD-M:F?4KF2).$962>5D96"(54!A5RU4Q21:$U3_G(K_G.
M-X_\2C2=>L].IZABB\JPE%05))$EJ\H6G4ENF]>^*T&5_DC_ ,_7_-&D:K#Y
M>_YR$TNWN],,HAGU&PA:WN[8_99Y(*E) I^TJ")AO3D0$*IB_=?1M9L?,6GV
MNOZ'<1W6G7T$=S;7$3<DEBE4.CJ>X92"#BP?SR?\_=?_ "<.B?\ @)6?_4?>
MXLXOW;_(W_R7'D__ ,![2O\ J$CQ8%ZEBK\SO^?KW_DDX/\ P(;#_DU/BRBD
M7_/HK_R3VM_^!;>?]0%EBLD]_P"?KW_DDX/_  (;#_DU/BL4B_Y]%?\ DGM;
M_P# MO/^H"RQ63\^?^<]?*U]_P X]_\ .1,?YG^5T]%=1GLO-%B0*+]9CD'K
MJ3W+31L[#PD%>N*1N']&GE+S+9^<]#TWS?HS<]/U6SM[ZW:H-8KB,2(:C;HP
MQ8,@Q5^3W_/VK\T1Y<_+O2/RNLI0MWYDU 3W" [FTL '(('C.T)!/\C4!I4+
M*+Z._P"??GY7+^5OY)>7H)H^&H:XC:[=_#Q):\ :*HZU6 1*:]QVZ!07XI^7
M/_6S9/\ S9M]_P!U63%GT?T_XM;L5=BKL5=BK^53_G+3_P!:5\R_^!#;_JBQ
M;!R?U5XM;L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?FA_S]<OS9_DG%;B0)]:\P6$
M)4T^.D4\G$?\!RV_EQ91?S9XLWZ0S_\ /Q/S9Y+_ "S\L?DQ^2Z#29M)TR*V
MO]8FCCEG>7<LENCAD116G-@SD[KPH"5CPO!-._YS;_/72[LZG;>>M7:8MRXS
MR)/%6M?[J56CI[<:8II^P7_.#G_/P67\\]13\I_S>CM[7SA(C-I][;KZ<-\(
MU+/&R5(28*"PX_ X#4", '6)%/U3Q8OY5_\ G/G\[C^=GYNZM=:?+ZFA:$3H
MVG<3562W8^K*.@/J3%V![IP%308M@#[,_P"?1?Y.&^U77_SSU2*L%C'^AM-9
MAL9Y0LERX]TC]->O25ABB1?'_P#S\=_]:)\Y?]NG_NE6N*8\GM__ #Z*_P#)
MPZW_ . E>?\ 4?98HD_HMQ8.Q5V*OYG_ /GZ9_Y/2Y_[8^G?\1;%LB^&/RW\
MXO\ EWYMT#\P((%N9-"U6QU18&8J)3:3I,$+"M W&E:;8I9K^;?_ #D-^8/Y
MWZC-J_YB:[>7B2N62R65TLX0?V8K<'@H VK3D?VF8[XJ QGR#^;7G/\ *V]C
MU?\ +S7=0TBYB;D/JL[JC;UH\=>#KONKJRGN,5I_33_SA!_SE(?^<G_)$FJ:
MXD,'FW19DM-6AAV1RZEH;A%J2JR@,*5V=) /AIBUD4^8_P#G[[_Y+CRQ_P"!
M"/\ J$FQ3%_/?BS?JG^8_D,>8?\ G!_\O/.T"5N/+VKZBSO2O&WO-3O(7W[5
ME]'_ #IBQZORLQ9/[&_^<??/8_,W\M?*GGMGYS:EH]G+<&I-+@1A9Q4[FDH8
M5[TQ:R_EL_YRS\^?\K*_.'SEYN20RP2ZM/;V[_S06A%M"1[&.-3BS#[9_P"?
M5OY?_I36?/'YE7,=8M(T%M/A9AL)KWDY*^ZI 0? /[C%$GY/8LGZG?\ /HK_
M ,G#K?\ X"5Y_P!1]EBQD_HMQ8.Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5\5?\_%?_ %G'S_\ ]LZ'_J+AQ5_-7_S[K_\ 6C?('_;1E_ZA9L5?V4XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M^*?^?B__ *SCY_\ ^V?!_P!1<.*OYK_^?=/_ *T=Y _[:,W_ %"38J_LFQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*OBC_ )^,?^LX>?\ _MGP?]1<.*OXVL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKW_ /YQ._\
M)W_EI_X&?E[_ +J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5?_]7[^8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7\S__ #F7_P"M>W__ &V/+/\ U!66+8.3^F#%K=BKX!_YS_\ ^<:/-_\
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M?L)&?6OY*#]J-FF!/A$-Z 468V#^B2TM(;""*QLHUBMX46..-!151115 [
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M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?\
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M_KBKO^BN_P#SCQ_RWZS_ -PN3^N*N_Z*[_\ ./'_ "WZS_W"Y/ZXJ[_HKO\
M\X\?\M^L_P#<+D_KBKO^BN__ #CQ_P M^L_]PN3^N*N_Z*[_ /./'_+?K/\
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MOSQ_ZLGD[_I!O_\ LNQ5W_1:;\\?^K)Y/_Z0;_\ [+L5=_T6F_/'_JR>3_\
MI!O_ /LNQ5W_ $6F_/'_ *LGD_\ Z0;_ /[+L5=_T6F_/'_JR>3_ /I!O_\
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MO^B1'_.0_P#RP:/_ -Q2/^F*N_Z)$?\ .0__ "P:/_W%(_Z8J[_HD1_SD/\
M\L&C_P#<4C_IBKO^B1'_ #D/_P L&C_]Q2/^F*N_Z)$?\Y#_ /+!H_\ W%(_
MZ8J[_HD1_P Y#_\ +!H__<4C_IBKO^B1'_.0_P#RP:/_ -Q2/^F*N_Z)$?\
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MY3TCSWHM_P"3/-]I'?Z+JEO):7EK*#PEBE7BRFA!&QV((93NI! .*ORKO?\
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MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\_1__68O//\
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M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_/T?_UF+SS_ -N7_NL6>*OY[O\
MGV?_ .M+>0_^8C4?^Z;<XJ_L0Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__ .V?!_U%PXJ_
MC:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*O?_P#G$[_R=_Y:?^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_2^_F*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%7P!_P _1_\ UF+SS_VY?^ZQ9XJ_GL_Y]H_^M*^0_P#F
M(U#_ +IMSBK^Q+%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%7P!_S]'_]9B\\_P#;E_[K%GBK^>[_ )]G_P#K2WD/_F(U
M'_NFW.*O[$,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKXH_Y^,?^LX>?_P#MGP?]1<.*OXVL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKW_\ YQ._
M\G?^6G_@9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%7_T_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5?RJ?\Y:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5\ ?\ /T?_ -9B\\_]N7_NL6>*OY[/^?:/_K2OD/\ YB-0_P"Z;<XJ_L2Q
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5\ ?\_1__68O//\ VY?^ZQ9XJ_GN_P"?9_\ ZTMY#_YB-1_[IMSBK^Q#%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J^*/^?C'_K.'G_\ [9\'_47#BK^-K%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__ .<3O_)W_EI_X&?E[_NH
MPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5_]3[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G
M_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_ #]'_P#6
M8O//_;E_[K%GBK^>S_GVC_ZTKY#_ .8C4/\ NFW.*O[$L5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_/T?_UF+SS_
M -N7_NL6>*OY[O\ GV?_ .M+>0_^8C4?^Z;<XJ_L0Q5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZS
MAY__ .V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*O?_P#G$[_R=_Y:?^!GY>_[J,.*O[?<5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_5^_F*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%B
MV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%7P!_P _1_\ UF+SS_VY?^ZQ9XJ_
MGL_Y]H_^M*^0_P#F(U#_ +IMSBK^Q+%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%7P!_S]'_]9B\\_P#;E_[K%GBK^>[_
M )]G_P#K2WD/_F(U'_NFW.*O[$,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKXH_Y^,?^LX>?_P#MGP?]1<.*
MOXVL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKW_\ YQ._\G?^6G_@9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_UOOYBKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5\ ?\ /T?_ -9B\\_]N7_NL6>*OY[/^?:/_K2OD/\
MYB-0_P"Z;<XJ_L2Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5\ ?\_1__68O//\ VY?^ZQ9XJ_GN_P"?9_\ ZTMY#_YB
M-1_[IMSBK^Q#%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J^*/^?C'_K.'G_\ [9\'_47#BK^-K%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__ .<3
MO_)W_EI_X&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]?[^8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5? '_ #]'_P#68O//_;E_[K%GBK^>S_GVC_ZTKY#_ .8C4/\ NFW.*O[$
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5? '_/T?_UF+SS_ -N7_NL6>*OY[O\ GV?_ .M+>0_^8C4?^Z;<XJ_L0Q5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*OBC_GXQ_ZSAY__ .V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_P#G$[_R=_Y:?^!GY>_[
MJ,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5?_0^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SE
MI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7P!_P _1_\
MUF+SS_VY?^ZQ9XJ_GL_Y]H_^M*^0_P#F(U#_ +IMSBK^Q+%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7P!_S]'_]9B\\
M_P#;E_[K%GBK^>[_ )]G_P#K2WD/_F(U'_NFW.*O[$,5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKXH_Y^,?^
MLX>?_P#MGP?]1<.*OXVL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKW_\ YQ._\G?^6G_@9^7O^ZC#BK^WW%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_T?OY
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9?_ AM_U1
M8M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\ /T?_ -9B\\_]N7_NL6>*
MOY[/^?:/_K2OD/\ YB-0_P"Z;<XJ_L2Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\_1__68O//\ VY?^ZQ9XJ_GN
M_P"?9_\ ZTMY#_YB-1_[IMSBK^Q#%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*/^?C'_K.'G_\ [9\'_47#
MBK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J]__ .<3O_)W_EI_X&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]+[^8J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5? '_ #]'_P#68O//_;E_[K%GBK^>S_GVC_ZTKY#_
M .8C4/\ NFW.*O[$L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5? '_/T?_UF+SS_ -N7_NL6>*OY[O\ GV?_ .M+>0_^
M8C4?^Z;<XJ_L0Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__ .V?!_U%PXJ_C:Q5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_P#G
M$[_R=_Y:?^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5?_3^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%7P!_P _1_\ UF+SS_VY?^ZQ9XJ_GL_Y]H_^M*^0_P#F(U#_ +IMSBK^
MQ+%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7P!_S]'_]9B\\_P#;E_[K%GBK^>[_ )]G_P#K2WD/_F(U'_NFW.*O[$,5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKXH_Y^,?^LX>?_P#MGP?]1<.*OXVL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKW_\ YQ._\G?^6G_@9^7O
M^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%7_U/OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\
MY:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\ /T?_
M -9B\\_]N7_NL6>*OY[/^?:/_K2OD/\ YB-0_P"Z;<XJ_L2Q5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\_1__68O
M//\ VY?^ZQ9XJ_GN_P"?9_\ ZTMY#_YB-1_[IMSBK^Q#%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*/^?C'
M_K.'G_\ [9\'_47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J]__ .<3O_)W_EI_X&?E[_NHPXJ_M]Q5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]7[
M^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]
M46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_ #]'_P#68O//_;E_[K%G
MBK^>S_GVC_ZTKY#_ .8C4/\ NFW.*O[$L5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_/T?_UF+SS_ -N7_NL6>*OY
M[O\ GV?_ .M+>0_^8C4?^Z;<XJ_L0Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__ .V?!_U%
MPXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*O?_P#G$[_R=_Y:?^!GY>_[J,.*O[?<5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_6^_F*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%7P!_P _1_\ UF+SS_VY?^ZQ9XJ_GL_Y]H_^M*^0
M_P#F(U#_ +IMSBK^Q+%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7P!_S]'_]9B\\_P#;E_[K%GBK^>[_ )]G_P#K2WD/
M_F(U'_NFW.*O[$,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKXH_Y^,?^LX>?_P#MGP?]1<.*OXVL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKW_\
MYQ._\G?^6G_@9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%7_U_OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5?RJ?\Y:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5\ ?\ /T?_ -9B\\_]N7_NL6>*OY[/^?:/_K2OD/\ YB-0_P"Z;<XJ
M_L2Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5\ ?\_1__68O//\ VY?^ZQ9XJ_GN_P"?9_\ ZTMY#_YB-1_[IMSBK^Q#
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J^*/^?C'_K.'G_\ [9\'_47#BK^-K%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__ .<3O_)W_EI_X&?E
M[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5_]#[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG
M_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_ #]'
M_P#68O//_;E_[K%GBK^>S_GVC_ZTKY#_ .8C4/\ NFW.*O[$L5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5? '_/T?_UF
M+SS_ -N7_NL6>*OY[O\ GV?_ .M+>0_^8C4?^Z;<XJ_L0Q5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GX
MQ_ZSAY__ .V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_P#G$[_R=_Y:?^!GY>_[J,.*O[?<5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_1
M^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W
M_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7P!_P _1_\ UF+SS_VY?^ZQ
M9XJ_GL_Y]H_^M*^0_P#F(U#_ +IMSBK^Q+%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7P!_S]'_]9B\\_P#;E_[K%GBK
M^>[_ )]G_P#K2WD/_F(U'_NFW.*O[$,5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKXH_Y^,?^LX>?_P#MGP?]
M1<.*OXVL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKW_\ YQ._\G?^6G_@9^7O^ZC#BK^WW%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_TOOYBKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\Y:?^M*^9?_ AM_U18M@Y/ZJ\6MV*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\ /T?_ -9B\\_]N7_NL6>*OY[/^?:/_K2O
MD/\ YB-0_P"Z;<XJ_L2Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\_1__68O//\ VY?^ZQ9XJ_GN_P"?9_\ ZTMY
M#_YB-1_[IMSBK^Q#%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J^*/^?C'_K.'G_\ [9\'_47#BK^-K%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__
M .<3O_)W_EI_X&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]/[^8J[%78J[%78J[%78J[%78J[%78J
M[%78JQ/SQYYT'\MM$N_.GGF_ATW1;%/4GN9VHJCH !U9F- JJ"S,0J@DTQ5^
M*-Q_S]=\Z>8_/\'EWR%H>BQ>4+W5;:SM6U&"Y>^,$DBQEW:.Y2,.U2P4(0E0
MI+T+,L^%^[6+!V*I%YG\S:5Y,TF\\U^:;N*QTC3X7N+JYF-$CC05)/\  #<G
M8 DTQ5^&_P":W_/U+SOYNUMO*G_..&A10VCRM%:W%S;/>7]S2M&C@0\$J-^!
M65O<;C%GPL/NO^<E_P#G-SRQ$_F?7])UG]& "1UN?*\2Q1*-_CX6RR(/$NPI
MX@XK0?4'_.*O_/SZT_,K6+/\N_SPL;71M5O6$-KJUHS+9RS,:)'+'(6:$MT#
M\V0L:$1C%!B_77%BD7F?S-I7DS2;SS7YINXK'2-/A>XNKF8T2.-!4D_P W)V
M )-,5?AO^:W_ #]2\[^;M;;RI_SCAH44-H\K16MQ<VSWE_<TK1HX$/!*C?@5
ME;W&XQ9\+#[K_G)?_G-SRQ$_F?7])UG]& "1UN?*\2Q1*-_CX6RR(/$NPIX@
MXK0?4'_.*O\ S\^M/S*UBS_+O\\+&UT;5;UA#:ZM:,RV<LS&B1RQR%FA+= _
M-D+&A$8Q08OUUQ8OS._Y^O?^23@_\"&P_P"34^+*+^=S2?TOY6_1GY@:9R@]
M+4'^I7([75CZ,QI[IZL3?[(8LW]C'Y7>?+3\T/*&A_F)I5!;:SI]O>JH->#2
MH&:,^Z-53[@XM3/,5=BKL5?C'_S]Z_-7ZCHWEG\F;"2DM_/)K-\H-"(H 8;<
M'Q5W:0_.(8LHOS _YQ=T:[\N_G[Y-\OZQ&8;^Q\TVMK<1-U26&XX.I]PP(Q9
M%_6WBUNQ5V*NQ5V*OY5/^<M/_6E?,O\ X$-O^J+%L')_57BUNQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*O@#_GZ/_P"LQ>>?^W+_ -UBSQ5_/9_S[1_]:5\A_P#,1J'_
M '3;G%7]B6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*O@#_GZ/\ ^LQ>>?\ MR_]UBSQ5_/=_P ^S_\ UI;R'_S$:C_W
M3;G%7]B&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5\4?\_&/_6<//_\ VSX/^HN'%7\;6*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5[__ ,XG?^3O
M_+3_ ,#/R]_W48<5?V^XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J__4^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5AOYC
M><8OR[\IZ[^8%U US#H6EWNJ/ C!6D6T@>8H&-0"P6@)Z8J_G8N=5_.G_GYC
MYT338%%AY4L)02B<QIFF1M7XY#UFN&6M*_&YJ%$45>*SY/(OS<_*32_R*_YR
M%MORI\M337%AI&I^746:X(]222:WM)I7--ARDD8A1]D$+4TKBD%_5MBUNQ5^
M0'_/W3\U+G0O*?EW\IM,E:,:]=37U\$-.5O9<!'&WBKRR!_]:$?2LHAZE_S[
M-_YQ]TK\N_RUL_S5U"TC?S7YI5KDW,B@R0V/(K!#&2*JKA?5:GVRZAJA%HK(
MOTMQ8OY]/^?JG_./VE^0/,.D_G+Y.M4L[7S$\UOJ44"A(Q?1 .LH"@ -,A8O
M3JT9<_$S$K.)?K7_ ,X9?FE<?G#^3GE;SCJLK3:H+0V-](_VWN+-V@:1CW:0
M()#_ *_;H%B0^(/^?NGYJ7.A>4_+OY3:9*T8UZZFOKX(:<K>RX".-O%7ED#_
M .M"/I4Q#U+_ )]F_P#./NE?EW^6MG^:NH6D;^:_-*M<FYD4&2&QY%8(8R15
M5<+ZK4^V74-4(M%9%^EN+%_/I_S]4_YQ^TOR!YATG\Y?)UJEG:^8GFM]2B@4
M)&+Z(!UE 4 !ID+%Z=6C+GXF8E9Q+]:_^<,OS2N/SA_)SRMYQU65IM4%H;&^
MD?[;W%F[0-(Q[M($$A_U^W0+$A\W?\_7O_))P?\ @0V'_)J?%,7Y:^5ORJ_Q
MS_SB%K/G>RCYZAY3\]7%Y4"K?5;FQL()U'MR,4C>T9Q9=7Z7_P#/I_\ -(>:
M_P L+_\ +:[DY7OE;4&]-2>EI?%IH_\ DJ)Q["F+&3]3,6+L5=BK^<_SM(/^
M<O/^<Q8M  -UY>L-62PX_:3]'Z/5[C?IPF=)2#_Q:*5)%5GR#S#RY_ZV;)_Y
MLV^_[JLF*>C^G_%K=BKL5=BKL5?RJ?\ .6G_ *TKYE_\"&W_ %18M@Y/ZJ\6
MMV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\ ?\_1_P#UF+SS_P!N7_NL6>*OY[/^?:/_
M *TKY#_YB-0_[IMSBK^Q+%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%7P!_S]'_\ 68O//_;E_P"ZQ9XJ_GN_Y]G_ /K2
MWD/_ )B-1_[IMSBK^Q#%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J^*/^?C'_ *SAY_\ ^V?!_P!1<.*OXVL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKW_P#YQ._\G?\ EI_X&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]7[^8J[%78J[%78J[%78J[%
M78J[%78J[%6.^</*UAYYT'5/)6OJ[:9K%C<Z?=+&Q1C#<Q-%(%8;@E6-#VQ5
M ^1/R_\ +GY8:+;^3?(&FV^E:-:@^E;6R<5J>K,35G=NK.Q+,=V).*OYS_\
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M_P YE_\ K7M__P!MCRS_ -05EBV#D_I@Q:W8J_G2_P"?NO\ Y.'1/_ 2L_\
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M5V*NQ5V*NQ5V*NQ5V*O@#_GZ/_ZS%YY_[<O_ '6+/%7\]W_/L_\ ]:6\A_\
M,1J/_=-N<5?V(8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%7Q1_S\8_\ 6<//_P#VSX/^HN'%7\;6*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5[_\
M\XG?^3O_ "T_\#/R]_W48<5?V^XJ[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J_P#_U_OYBKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5?S/_\ .9?_ *U[?_\ ;8\L_P#4%98M@Y/Z8,6MV*OYTO\ G[K_
M .3AT3_P$K/_ *C[W%G%^[?Y&_\ DN/)_P#X#VE?]0D>+ O4L5?F=_S]>_\
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MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKW_P#YQ._\G?\
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M06>N:UJ.IPQ3?6O42.[N7F57XQ$<@& -"17H<68D\]_Z)!?F/_U,_E[[[O\
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M "8_G#_P(=5_ZBY,6T/,HH9)V*0(SL%9R%!)XH"S';L "2>P%<54L5?UO?\
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MH,6+^-;\\O\ R8_G#_P(=5_ZBY,6T/HW_GW%_P"M$^3?^WM_W2KK%$N3R_\
MYR\\A_\ *MOSE\Y^54C,5NNK37=NG807E+F(#V"2@#Y>.*A]:_\ /IWSU_A[
M\VK[R;.U(/,.CSQHO<W%HRSH?HB$VWO[8HD^YO\ G[3Y\&@?E;I7D:!^-QY@
MU="ZUIRM[)#(^W>DK0_YTQ1%_/%INGW&KW=OI6GH9+JZE2"%!U9Y&"J!\R:8
MLWZQ_P#/TGRA;_E_8?E3Y%T^GU?1M"N=/0J* BW%M'7Z>-3W\<6,7Y'XLG]A
MG_.,O_DGOR^_\!+0O^H"'%K+V_%#L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKX _Y^C_\ K,7GG_MR_P#=8L\5?SV?\^T?_6E?(?\ S$:A_P!TVYQ5_8EB
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKX _Y^C_ /K,7GG_ +<O_=8L\5?SW?\ /L__ -:6\A_\Q&H_]TVYQ5_8ABKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5?%'_/QC_UG#S__ -L^#_J+AQ5_&UBKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>__P#.)W_D[_RT_P# S\O?
M]U&'%7]ON*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*O_T?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RJ?\
MY:?^M*^9?_ AM_U18M@Y/ZJ\6MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*O ?^<I/S4'Y,?E7YG_,&*01WUK8/#8GE0_6[DB&W(IN>,CJQ _94
MG:E0I#^0,DL:G<G%L?LW_P ^@_RQ^N:UYI_."]B_=V-O%H]D["H,EPPFG*^#
M(B1#Y2D=SBQD_=_%@_G+_P"<L/\ G#3\YO/_ .;OFWSEY/\ *=U?:-J&H&:U
MN4GME61."BH#RJPW!Z@8LP41_P XE?\ ."'YEZ5^;'EO7/SA\IRV?E33KB2]
MN9+B6VDC,D$3O I1)'+ S".H(I2M<5)?NQ^=WY=6'YL>0_,'Y?ZS;K<Q:EI]
MQ%$K+4I/P)AD38T>.0*RFG4#KTQ8A_&QBV/VK_Y\[>8KA-0\\>4F8FTD@TZ^
M53T61&EC8C_6#+7;]D=.ZQD_=#%@[%78J[%7X9_\_?/S5]:Z\K_DM82U6!)-
M<OT#5^-^4%L"!L"%$QH=Z.IV'59Q?BABR?UU?\XB?EC_ ,JA_*'RIY+GB]*^
M73TO+U2*,+J\)N)5;Q*,_#Y*!T&+67TCBA_&M^>7_DQ_.'_@0ZK_ -1<F+:'
MT;_S[B_]:)\F_P#;V_[I5UBB7)]!_P#/W'R'^A/S'T+S] I6'7M(,#FFS3V$
MG%R#_P 8Y8A3VKWQ1%\*_P#.+_GK_E6WYL^3O.3OZ<%KK%JEPY-*6\[>C.:_
M\8G;V\=L4E]L?\_://I\P?FEI?D:%ZV_E[2(RZUK2XO7,K[=JQ+#[_13%$7S
M7_S@CY _Y6+^>7E'3)4#VMA>'5IZBH"V"&=*CN&D5%_V6^V*2^Y/^?Q?_':\
MB?\ ,'JG_)R#%$7XOXLG]AG_ #C+_P"2>_+[_P !+0O^H"'%K+V_%#L5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKX _Y^C_ /K,7GG_ +<O_=8L\5?SV?\
M/M'_ -:5\A_\Q&H?]TVYQ5_8EBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKX _Y^C_\ K,7GG_MR_P#=8L\5?SW?\^S_
M /UI;R'_ ,Q&H_\ =-N<5?V(8J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%7Q1_P _&/\ UG#S_P#]L^#_ *BX
M<5?QM8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%7O_ /SB=_Y._P#+3_P,_+W_ '48<5?V^XJ[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__]+[^8J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\6?^?O?YJFUT[RQ^2]
MA(0]W))K=\@('[N+E!; ]R&8S&G2L:G<C991?A5BS?U5_P#/O[\LO^58?DAY
M<M9X^%_K4;:Y=?#Q):]HT51UJ(!$IK_+VZ8M9?:&*'8J[%78J_B$Q;7ZV_\
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M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^ /^?H__ *S%YY_[<O\
MW6+/%7\]W_/L_P#]:6\A_P#,1J/_ '3;G%7]B&*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\4?\ /QC_ -9P
M\_\ _;/@_P"HN'%7\;6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5[_P#\XG?^3O\ RT_\#/R]_P!U&'%7]ON*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__3
M^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W
M_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_DY_Y
MSC_-,?FY^='F;7K63U--L+G]$61!JOHV/[HLI[K)('D'^OBV!XI^3?Y?3_FM
MYY\O?ES:5Y:QJ5M:.P-.$3N/5>N_V(^3=#TZ'%)?V465G!IUO%I]B@BMH(UB
MBC78*B"BJ/8 4Q:D3BK^;WS5_P _,_SV\N:WJ7EZ2?2%>PO+BU(;3U)!AD9"
M">0WVQ9\+ZA_YP@_YS\\[?G+^9<?Y=?G#>::EAJ&GW T\06RV[/?(T;HO+D:
MUB$H"_M-QIO0%00_5'\Z?S#T[\J?(VO^?]<N5M8-.T^XE1F8*6FX$0QIN*N\
MA54'=B,4!_&IBV/V[_Y\[>4YN7G?SS**6Y&GZ;"?YG'JRR_\"/3_ ."[=UC)
M^C/_ #DO_P Y=>3_ /G%;]"?\K"L=6O/T]]<^K?HN&WEX_5/2Y^IZT\-*^LO
M'CRK1JTVJL0+>&_EQ_S\Z_*W\S_-&D?EWH&D>9H=2UJ\AL;>2YM;)85DF8*I
M<I=NP4$[D*Q]CBGA?HSBQ?,W_.8GYIC\G?R@\T^<(9/3U!K)K"Q(/Q?6;P^A
M&R^)CYF3Y(<4A_([BV/V/_Y]"_EE^D?,GF;\V[R,&+3+2+2K1C_OZZ;U)2!X
MHD:BOA+WWHL9/WLQ8.Q5_&M^>7_DQ_.'_@0ZK_U%R8MH?1O_ #[B_P#6B?)O
M_;V_[I5UBB7)_15_SDSY#'YF?E5YO\DA/4GO-(NC;K2M;B%/6@V_XRHF+ /X
M]L6QV*OZ>?\ GV9Y _P3^1NF:G,@2Z\Q7EWJTFV_%G$$53X&.%6'^MXUQ:Y/
MB;_G\7_QVO(G_,'JG_)R#%E%^+^+)_89_P XR_\ DGOR^_\  2T+_J AQ:R]
MOQ0[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^ /^?H_P#ZS%YY_P"W+_W6
M+/%7\]G_ #[1_P#6E?(?_,1J'_=-N<5?V)8J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J^ /^?H__ *S%YY_[<O\ W6+/
M%7\]W_/L_P#]:6\A_P#,1J/_ '3;G%7]B&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\4?\ /QC_ -9P\_\
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M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7P!_S]'_\
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MWE+_ +@5A_U1Q3;/?)WY<^4_R[BGM?R_T+2]"AN65YTTNR@M%D9112XA10Q
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M^:<5=_T5K_YQR_ZO6I?]PJZ_YIQ5W_16O_G'+_J]:E_W"KK_ )IQ5W_16O\
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M_P N5Y/_ .X]8?\ 57%7?]#<_D;_ .7*\G_]QZP_ZJXJ[_H;G\C?_+E>3_\
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M'K#_ *JXJ[_H;K\C?_+E>3_^X]8?]5<5=_T-U^1O_ERO)_\ W'K#_JKBKO\
MH;K\C?\ RY7D_P#[CUA_U5Q5W_0W7Y&_^7*\G_\ <>L/^JN*N_Z&Z_(W_P N
M5Y/_ .X]8?\ 57%7?]#=?D;_ .7*\G_]QZP_ZJXJ[_H;K\C?_+E>3_\ N/6'
M_57%7?\ 0W7Y&_\ ERO)_P#W'K#_ *JXJ^(O^?CG_.1?Y5>>_P#G'?SEY4\D
M>=_+>L:U=?HGZO8V&K6EQ<2^GJMK(_"*.1F;BBLS4&RJ2=@<5?BG_P ^S_\
MUI;R'_S$:C_W3;G%7]B&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5\4?\_&/_6<//_\ VSX/^HN'%7\;6*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5[__ ,XG?^3O_+3_ ,#/R]_W48<5?V^XJ[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J__2^_F*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%7YB?\_=I&3_G'C4%1B ^L:6K 'J/5)H?I .*O
MYF_R1_(_S9_SD+YHC_+?\L;>&ZUR6":Y6.>=($].$5<\W(&P[=\5?9__ $25
M_P"<C?\ JRZ;_P!Q6U_YJQ5W_1)7_G(W_JRZ;_W%;7_FK%7?]$E?^<C?^K+I
MO_<5M?\ FK%7?]$E?^<C?^K+IO\ W%;7_FK%7?\ 1)7_ )R-_P"K+IO_ '%;
M7_FK%7?]$E?^<C?^K+IO_<5M?^:L5=_T25_YR-_ZLNF_]Q6U_P":L5=_T25_
MYR-_ZLNF_P#<5M?^:L5=_P!$E?\ G(W_ *LNF_\ <5M?^:L5=_T25_YR-_ZL
MNF_]Q6U_YJQ5W_1)7_G(W_JRZ;_W%;7_ )JQ5W_1)7_G(W_JRZ;_ -Q6U_YJ
MQ5W_ $25_P"<C?\ JRZ;_P!Q6U_YJQ5W_1)7_G(W_JRZ;_W%;7_FK%7?]$E?
M^<C?^K+IO_<5M?\ FK%7?]$E?^<C?^K+IO\ W%;7_FK%7?\ 1)7_ )R-_P"K
M+IO_ '%;7_FK%7?]$E?^<C?^K+IO_<5M?^:L5=_T25_YR-_ZLNF_]Q6U_P":
ML5=_T25_YR-_ZLNF_P#<5M?^:L5=_P!$E?\ G(W_ *LNF_\ <5M?^:L5=_T2
M5_YR-_ZLNF_]Q6U_YJQ5W_1)7_G(W_JRZ;_W%;7_ )JQ5W_1)7_G(W_JRZ;_
M -Q6U_YJQ5W_ $25_P"<C?\ JRZ;_P!Q6U_YJQ5YG^</_/O'\Z?R*\HZA^:?
MYB:796_E_3# +F6'4()G7ZQ.D"41&+&KR*#3H-\59%_SZVE>/_G)SR0J,55Q
MK*L :!A^B+LT/B*@'Y@8J_KZQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5\L?\YL?E%K'Y[?DEYO_ "N\G*)-<U"T@FLHF=4]::RNHKM(0SD*IE,/I@L5
M4%@6914A5_)E=_\ .(OYY64TEI-^6OG O&Q5C'H-_(A(_E=(F5A[J2#XXJAO
M^A3OSO\ _+:><_\ PGM1_P"J.*N_Z%._._\ \MIYS_\ ">U'_JCBKO\ H4[\
M[_\ RVGG/_PGM1_ZHXJ[_H4[\[__ "VGG/\ \)[4?^J.*N_Z%._._P#\MIYS
M_P#">U'_ *HXJ[_H4[\[_P#RVGG/_P )[4?^J.*N_P"A3OSO_P#+:><__">U
M'_JCBKO^A3OSO_\ +:><_P#PGM1_ZHXJ[_H4[\[_ /RVGG/_ ,)[4?\ JCBK
MO^A3OSO_ /+:><__  GM1_ZHXJ[_ *%._.__ ,MIYS_\)[4?^J.*N_Z%._._
M_P MIYS_ /">U'_JCBKO^A3OSO\ _+:><_\ PGM1_P"J.*N_Z%._._\ \MIY
MS_\ ">U'_JCBKO\ H4[\[_\ RVGG/_PGM1_ZHXJ[_H4[\[__ "VGG/\ \)[4
M?^J.*N_Z%._._P#\MIYS_P#">U'_ *HXJ[_H4[\[_P#RVGG/_P )[4?^J.*N
M_P"A3OSO_P#+:><__">U'_JCBKO^A3OSO_\ +:><_P#PGM1_ZHXJ[_H4[\[_
M /RVGG/_ ,)[4?\ JCBKO^A3OSO_ /+:><__  GM1_ZHXJ[_ *%._.__ ,MI
MYS_\)[4?^J.*N_Z%._.__P MIYS_ /">U'_JCBKO^A3OSO\ _+:><_\ PGM1
M_P"J.*N_Z%._._\ \MIYS_\ ">U'_JCBK]!O^?:7_.(7YL:3^=NB?F=YV\K:
MMY<\O>75O9[B?6;*6R:5YK22".*&.=4=R6E#%E4JJJU2#Q!5?T[XJ[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M7Q1_S\8_]9P\_P#_ &SX/^HN'%7\;6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5[_ /\ .)W_ )._\M/_  ,_+W_=
M1AQ5_;[BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BK__3^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SE
MI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%7
MYA?\_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J_J_Q5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??
M_/TO_P!9D\[?ZVC?]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY_
M_P"V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__4^_F*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%B
MV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%7YA?\_>/_ %GB^_[;
M.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?
M]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__5^_F*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J
M[%78J[%78J[%78J[%78J[%78J[%7YA?\_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(
M_P#6A[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?]U>TQ5^ W_/KC_UI
MWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?
M^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%7YA?\_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\
M)L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O
MBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ
M_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5__7^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZT
MKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%7YA?\
M_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO
M_P!9D\[?ZVC?]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V
M?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__0^_F*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_
MJKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%7YA?\_>/_ %GB^_[;.E_\
MG&Q5^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?]U>T
MQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O
M?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__1^_F*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%7YA?\_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(_P#6
MA[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?]U>TQ5^ W_/KC_UIWR-_
MV^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_
M (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5__2^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J
M[%78J[%7YA?\_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J
M_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5^??_/TO_P!9D\[?ZVC?]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]Q5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_G
MXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5__3^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_
M\"&W_5%BV#D_JKQ:W8J[%78J[%78J[%78J[%78J[%78J[%78J[%7YA?\_>/_
M %GB^_[;.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO_P!9
MD\[?ZVC?]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V?!_U
M%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__4^_F*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_*I_SEI_ZTKYE_\"&W_5%BV#D_JKQ:
MW8J[%78J[%78J[%78J[%78J[%78J[%78J[%7YA?\_>/_ %GB^_[;.E_\G&Q5
M^/O_ #Z(_P#6A[#_ +8VJ?\ )L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?]U>TQ5^
MW_/KC_UIWR-_V^O^Z/>8J_K]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*OBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_\
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MBP+-O,_F;2O)FDWGFOS3=Q6.D:?"]Q=7,QHD<:"I)_@!N3L 2:8J_#?\UO\
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M%78J[%78J[%7YA?\_>/_ %GB^_[;.E_\G&Q5^/O_ #Z(_P#6A[#_ +8VJ?\
M)L8J_J_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5^??_/TO_P!9D\[?ZVC?]U>TQ5^ W_/KC_UIWR-_V^O^Z/>8J_K]
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O
MBC_GXQ_ZSAY__P"V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?_\ G$[_ ,G?^6G_ (&?E[_NHPXJ
M_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OQ]_Y_!_
M\H7Y0_[;%Q_U#XLHOJ/_ )]Q?^L[>3?^WM_W5;K%$N;[?Q0[%78J_(#_ )^Z
M?FI<Z%Y3\N_E-IDK1C7KJ:^O@AIRM[+@(XV\5>60/_K0CZ5E$/4O^?9O_./N
ME?EW^6MG^:NH6D;^:_-*M<FYD4&2&QY%8(8R155<+ZK4^V74-4(M%9%^EN+%
M_/I_S]4_YQ^TOR!YATG\Y?)UJEG:^8GFM]2B@4)&+Z(!UE 4 !ID+%Z=6C+G
MXF8E9Q+]:_\ G#+\TKC\X?R<\K><=5E:;5!:&QOI'^V]Q9NT#2,>[2!!(?\
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M @-YLO"*]Q]1LAM](Q62=_\ /U[_ ,DG!_X$-A_R:GQ6*1?\^BO_ "3VM_\
M@6WG_4!98K)^D_G7RG8^?/+VJ^2-<7EI^KV5Q87 [^G<1F-B/< U'OBQ?SP?
M\^]O-E]^0W_.05U^4_FEO1&J/>^7;Q#]E;RVD+0MXU,D9C7_ (R_2%G)^^?Y
MX?F-#^4?D#S'^9-P5#:/IMQ<PJ_V7G"\8$/^O*43Z<6 ?CA_SZ1_+J7S#YI\
MU_G;K@::6RA33K>:3XB]Q>,9;AZ]>:HB@GPF.+.3]XL6#^8#RY_ZV;)_YLV^
M_P"ZK)BV=']/^+6[%78J[%78J_E4_P"<M/\ UI7S+_X$-O\ JBQ;!R?U5XM;
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\PO\ G[Q_ZSQ??]MG2_\ DXV*
MOQ]_Y]$?^M#V'_;&U3_DV,5?U?XJ[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J_/O_ )^E_P#K,GG;_6T;_NKVF*OP&_Y]
M<?\ K3OD;_M]?]T>\Q5_7[BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5?%'_/QC_P!9P\__ /;/@_ZBX<5?QM8J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7O_P#S
MB=_Y._\ +3_P,_+W_=1AQ5_;[BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_3^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*OR__ .?E?Y_?F7^05GY/U;\G]7_1-MJ$VI0:@WU.UN?4
M=%@:W'^D0RA:#U?L\:]ZT%%E$6^G?^<,/S4U7\YOR?\ +OG[S=>_7]>N1=Q7
M\YBBB)F@NI8]XX55%^!5(HHJI!(J3B@OJ/%#\XO^?I?FZW\O_DA<>7Y9>-QK
MVJ6%G%&#NXAD^M,2/Y5]$5/2I4=2,647G'_/HGRS/IWY;>8?--P@1-3UPPQ$
MCXF2UMXZM7NO*1E'NK?2K)\^_P#/X;RY+!YD\E^;N#>A=:?>V//J UO,LE#X
M$B:H\=Z?9.*8OU4_YP^\X0^>?R6\CZ[;2>H4T2UL96KOZUBGU66OOSB;%B7T
MEBA^1O\ S][\XV]CY \L^1!)2]U+6C?\ =S#9V\B-4>'.X3Z1[8LHO:O^?8?
MER70?R'TN^N$9#JVH:C?*&ZE?6] &G8'T=O$;]#BLF+?\_7O_))P?^!#8?\
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MF/=FI5CW8DXM;\^O^?KW_DDX/_ AL/\ DU/BRBD7_/HK_P D]K?_ (%MY_U
M66*R?J=BQ?FE_P _3/RJ_P <_E&OG>RCYZAY3O8[RH%6^JW)$$ZCVY&*1O:,
MXLHOPW_*?2]<_P"<B?.WD+\G=9N)+BPMY(M(MU%:PZ?]9EN[@BFY**\IKUXJ
MJU"J*+([/Z[[:VBLX8[2T18X(D5(T045544  '0 ;#%K5L5?S >7/_6S9/\
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M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__P"<3O\ R=_Y:?\
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M(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\
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MKL5=BKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<;%7X^_\ /HC_ -:'L/\
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M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<;%7X^_\
M/HC_ -:'L/\ MC:I_P FQBK^K_%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%7Y]_\_2__ %F3SM_K:-_W5[3%7X#?\^N/
M_6G?(W_;Z_[H]YBK^OW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J^*/^?C'_K.'G__ +9\'_47#BK^-K%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__P"<3O\
MR=_Y:?\ @9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%7_]+[^8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<;%7X^_\ /HC_ -:'L/\ MC:I
M_P FQBK^K_%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%7Y]_\_2__ %F3SM_K:-_W5[3%7X#?\^N/_6G?(W_;Z_[H]YBK
M^OW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J^*/^?C'_K.'G__ +9\'_47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J]__P"<3O\ R=_Y:?\ @9^7O^ZC
M#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%7_]/[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G
M_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F
M%_S]X_\ 6>+[_MLZ7_R<;%7X^_\ /HC_ -:'L/\ MC:I_P FQBK^K_%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Y]_\
M_2__ %F3SM_K:-_W5[3%7X#?\^N/_6G?(W_;Z_[H]YBK^OW%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*/^?C'_K.'G__
M +9\'_47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J]__P"<3O\ R=_Y:?\ @9^7O^ZC#BK^WW%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]3[^8J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8
M.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ
M7_R<;%7X^_\ /HC_ -:'L/\ MC:I_P FQBK^K_%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Y]_\_2__ %F3SM_K:-_W
M5[3%7X#?\^N/_6G?(W_;Z_[H]YBK^OW%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J^*/^?C'_K.'G__ +9\'_47#BK^-K%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J]__P"<3O\ R=_Y:?\ @9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]7[^8J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<;%7X^_\ /HC_
M -:'L/\ MC:I_P FQBK^K_%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%7Y]_\_2__ %F3SM_K:-_W5[3%7X#?\^N/_6G?
M(W_;Z_[H]YBK^OW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J^*/^?C'_K.'G__ +9\'_47#BK^-K%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__P"<3O\ R=_Y
M:?\ @9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7_];[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<;%7X^_\ /HC_ -:'L/\ MC:I_P F
MQBK^K_%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%7Y]_\_2__ %F3SM_K:-_W5[3%7X#?\^N/_6G?(W_;Z_[H]YBK^OW%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*
M/^?C'_K.'G__ +9\'_47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J]__P"<3O\ R=_Y:?\ @9^7O^ZC#BK^
MWW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%7_]?[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2O
MF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]
MX_\ 6>+[_MLZ7_R<;%7X^_\ /HC_ -:'L/\ MC:I_P FQBK^K_%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Y]_\_2__
M %F3SM_K:-_W5[3%7X#?\^N/_6G?(W_;Z_[H]YBK^OW%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^*/^?C'_K.'G__ +9\
M'_47#BK^-K%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J]__P"<3O\ R=_Y:?\ @9^7O^ZC#BK^WW%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]#[^8J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^J
MO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<
M;%7X^_\ /HC_ -:'L/\ MC:I_P FQBK^K_%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Y]_\_2__ %F3SM_K:-_W5[3%
M7X#?\^N/_6G?(W_;Z_[H]YBK^OW%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J^*/^?C'_K.'G__ +9\'_47#BK^-K%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]_
M_P"<3O\ R=_Y:?\ @9^7O^ZC#BK^WW%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%7_]'[^8J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%7\JG_.6G_K2OF7_P(;?]46+8.3^JO%K=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\ 6>+[_MLZ7_R<;%7X^_\ /HC_ -:'
ML/\ MC:I_P FQBK^K_%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7Y]_\_2__ %F3SM_K:-_W5[3%7X#?\^N/_6G?(W_;
MZ_[H]YBK^OW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J^*/^?C'_K.'G__ +9\'_47#BK^-K%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J]__P"<3O\ R=_Y:?\
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M(;?]46+8.3^JO%K=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?F%_S]X_\
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M_;G%B[%5&YN8K.&2[NW6.")&>1W-%55%223T &YQ5_.S_P XFVUQ_P Y4?\
M.5=]^;VI([Z987=WYA(<?8CA(AL(R3^TA,-.](VI2E0LSL'EGES_ -;-D_\
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M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5>_\
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ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKW_ /YQ._\
M)W_EI_X&?E[_ +J,.*O[?<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5?_]'[^8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%7\Z7_ #]U_P#)PZ)_X"5G_P!1][BSB_=O\C?_
M "7'D_\ \![2O^H2/%@7J6*OS._Y^O?^23@_\"&P_P"34^+**1?\^BO_ "3V
MM_\ @6WG_4!98K)/?^?KW_DDX/\ P(;#_DU/BL4B_P"?17_DGM;_ / MO/\
MJ LL5D^9_P#G[Q^57Z.U[RW^<EA'2'4K=](O64;":W)E@9O%GC=U^40Q3%^K
MO_.)WYI+^<?Y3>5O/4D@DO9;!+:^-23];M?W$Q-=QR="XK^RP-36I6)?1.*'
MX,_\_:/S'G\T>;_*_P"1F@<IWL8?K\\,8J7N[UO2@CI_,J*2*=IN_99Q?LQ^
M2_Y>0_E-Y$\N_EO;%3^A]-M[61UZ/,J#U7_V<A9OIQ8%_.=Y<_\ 6S9/_-FW
MW_=5DQ;.C^G_ !:W8J[%78J[%7\JG_.6G_K2OF7_ ,"&W_5%BV#D_JKQ:W8J
M[%78J[%78J[%78J[%78J[%78J[%78J[%7YA?\_>/_6>+[_MLZ7_R<;%7X^_\
M^B/_ %H>P_[8VJ?\FQBK^K_%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%7Y]_\_2__69/.W^MHW_=7M,5?@-_SZX_]:=\
MC?\ ;Z_[H]YBK^OW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J^*/\ GXQ_ZSAY_P#^V?!_U%PXJ_C:Q5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O?\ _G$[_P G
M?^6G_@9^7O\ NHPXJ_M]Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5__TOOYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5?SI?\ /W7_ ,G#HG_@)6?_ %'WN+.+]V_R-_\
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M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_/O\
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M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7Q1_P _&/\
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MM;_Z3;7^F*T[_HLUY;_\M]K?_2;:_P!,5IW_ $6:\M_^6^UO_I-M?Z8K3O\
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M[_H?'\A/^IWL/^15S_U2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\
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MR*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\ (JY_ZI8K3O\
MH?'\A/\ J=[#_D5<_P#5+%:=_P!#X_D)_P!3O8?\BKG_ *I8K3O^A\?R$_ZG
M>P_Y%7/_ %2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/^15S_U2Q6G?
M]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\
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M[_H?'\A/^IWL/^15S_U2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\
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MR*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\ (JY_ZI8K3O\
MH?'\A/\ J=[#_D5<_P#5+%:=_P!#X_D)_P!3O8?\BKG_ *I8K3O^A\?R$_ZG
M>P_Y%7/_ %2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/^15S_U2Q6G?
M]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\
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M[_H?'\A/^IWL/^15S_U2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\
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MR*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\ (JY_ZI8K3O\
MH?'\A/\ J=[#_D5<_P#5+%:=_P!#X_D)_P!3O8?\BKG_ *I8K3O^A\?R$_ZG
M>P_Y%7/_ %2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/^15S_U2Q6G?
M]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\
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M[_H?'\A/^IWL/^15S_U2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\
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MR*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\ (JY_ZI8K3O\
MH?'\A/\ J=[#_D5<_P#5+%:=_P!#X_D)_P!3O8?\BKG_ *I8K3O^A\?R$_ZG
M>P_Y%7/_ %2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/^15S_U2Q6G?
M]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\
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M[_H?'\A/^IWL/^15S_U2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\
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MR*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\ (JY_ZI8K3O\
MH?'\A/\ J=[#_D5<_P#5+%:=_P!#X_D)_P!3O8?\BKG_ *I8K3O^A\?R$_ZG
M>P_Y%7/_ %2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/^15S_U2Q6G?
M]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\ D5<_]4L5IW_0^/Y"?]3O8?\
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M[_H?'\A/^IWL/^15S_U2Q6G?]#X_D)_U.]A_R*N?^J6*T[_H?'\A/^IWL/\
MD5<_]4L5IW_0^/Y"?]3O8?\ (JY_ZI8K3O\ H?'\A/\ J=[#_D5<_P#5+%:=
M_P!#X_D)_P!3O8?\BKG_ *I8K3?_ $/A^0G_ %.]A_R*N?\ JEBM._Z'P_(3
M_J=[#_D5<_\ 5+%:=_T/A^0G_4[V'_(JY_ZI8K3O^A\/R$_ZG>P_Y%7/_5+%
M:=_T/A^0G_4[V'_(JY_ZI8K3O^A\/R$_ZG>P_P"15S_U2Q6G?]#X?D)_U.]A
M_P BKG_JEBM._P"A\/R$_P"IWL/^15S_ -4L5IW_ $/A^0G_ %.]A_R*N?\
MJEBM._Z'P_(3_J=[#_D5<_\ 5+%:=_T/A^0G_4[V'_(JY_ZI8K37_0^/Y"?]
M3O8?\BKG_JEBM-_]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/^15S_U2Q6G?
M]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/\ D5<_]4L5IW_0^'Y"?]3O8?\
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M[_H?#\A/^IWL/^15S_U2Q6G?]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/\
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MR*N?^J6*T[_H?#\A/^IWL/\ D5<_]4L5IW_0^'Y"?]3O8?\ (JY_ZI8K3O\
MH?#\A/\ J=[#_D5<_P#5+%:=_P!#X?D)_P!3O8?\BKG_ *I8K3O^A\/R$_ZG
M>P_Y%7/_ %2Q6G?]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/^15S_U2Q6G?
M]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/\ D5<_]4L5IW_0^'Y"?]3O8?\
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M[_H?#\A/^IWL/^15S_U2Q6G?]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/\
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MR*N?^J6*T[_H?#\A/^IWL/\ D5<_]4L5IW_0^'Y"?]3O8?\ (JY_ZI8K3O\
MH?#\A/\ J=[#_D5<_P#5+%:=_P!#X?D)_P!3O8?\BKG_ *I8K3O^A\/R$_ZG
M>P_Y%7/_ %2Q6G?]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/^15S_U2Q6G?
M]#X?D)_U.]A_R*N?^J6*T[_H?#\A/^IWL/\ D5<_]4L5IW_0^'Y"?]3O8?\
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M[_J<M*_Z1)_ZXKQ._P"B/7F[_J<M*_Z1)_ZXKQ._Z(]>;O\ J<M*_P"D2?\
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M%>)W_1(/\R_^IE\N?\%>?]4,5XG?]$@_S+_ZF7RY_P %>?\ 5#%>)W_1(/\
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M_HCUYN_ZG+2O^D2?^N*\3O\ HCUYN_ZG+2O^D2?^N*\3O^B/7F[_ *G+2O\
MI$G_ *XKQ._Z(]>;O^IRTK_I$G_KBO$[_HCUYN_ZG+2O^D2?^N*\3O\ HCUY
MN_ZG+2O^D2?^N*\3O^B/7F[_ *G+2O\ I$G_ *XKQ._Z(]>;O^IRTK_I$G_K
MBO$[_HCUYN_ZG+2O^D2?^N*\3O\ HCUYN_ZG+2O^D2?^N*\3O^B/7F[_ *G+
M2O\ I$G_ *XKQ._Z(]>;O^IRTK_I$G_KBO$[_HCUYN_ZG+2O^D2?^N*\3O\
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M_HCUYM_ZG+2O^D2?^N*\3O\ HCUYN_ZG+2O^D2?^N*\3O^B/7F[_ *G+2O\
MI$G_ *XKQ._Z(]>;?^IRTK_I$G_KBO$[_HCUYM_ZG+2O^D2?^N*\3?\ T1Z\
MV_\ 4Y:5_P!(D_\ 7%>)W_1'KS;_ -3EI7_2)/\ UQ7B=_T1Z\V_]3EI7_2)
M/_7%>)W_ $1Z\V_]3EI7_2)/_7%>)W_1'KS;_P!3EI7_ $B3_P!<5XG?]$>O
M-O\ U.6E?](D_P#7%>)W_1'KS;_U.6E?](D_]<5XFO\ HCUYM_ZG+2O^D2?^
MN*\3O^B/7FW_ *G+2O\ I$G_ *XKQ-_]$>O-O_4Y:5_TB3_UQ7B=_P!$>O-O
M_4Y:5_TB3_UQ7B=_T1Z\V_\ 4Y:5_P!(D_\ S5BO$[_HCUYM_P"IRTK_ *1)
M_P"N*\3O^B/7FW_J<M*_Z1)_ZXKQ._Z(]>;?^IRTK_I$G_YJQ7B:_P"B/7FW
M_J<M*_Z1)_ZXKQ-_]$>O-O\ U.6E?](D_P#7%>)W_1'KS;_U.6E?](D_]<5X
MFO\ HCUYM_ZG+2O^D2?^N*\3?_1'KS;_ -3EI7_2)/\ UQ7B=_T1Z\V_]3EI
M7_2)/_S5BO$[_HCUYM_ZG+2O^D2?^N*\3O\ HCUYM_ZG+2O^D2?^N*\37_1'
MKS;_ -3EI7_2)/\ UQ7B;_Z(]>;?^IRTK_I$G_KBO$[_ *(]>;?^IRTK_I$G
M_KBO$[_HCUYM_P"IRTK_ *1)_P"N*\3O^B/7FW_J<M*_Z1)_ZXKQ._Z(]>;?
M^IRTK_I$G_KBO$[_ *(]>;?^IRTK_I$G_KBO$[_HCUYM_P"IRTK_ *1)_P#F
MK%>)W_1'KS;_ -3EI7_2)/\ UQ7B=_T1Z\V_]3EI7_2)/_7%>)W_ $1Z\V_]
M3EI7_2)/_7%>)W_1'KS;_P!3EI7_ $B3_P!<5XG?]$>O-O\ U.6E?](D_P#S
M5BO$[_HCUYM_ZG+2O^D2?_FK%>)W_1'KS;_U.6E?](D_]<5XG?\ 1'KS;_U.
M6E?](D_]<5XG?]$>O-O_ %.6E?\ 2)/_ %Q7B=_T1Z\V_P#4Y:5_TB3_ /-6
M*\3O^B/7FW_J<M*_Z1)_ZXKQ._Z(]>;?^IRTK_I$G_KBO$[_ *(]>;?^IRTK
M_I$G_KBO$[_HCUYM_P"IRTK_ *1)_P"N*\3O^B/7FW_J<M*_Z1)_ZXKQ._Z(
M]>;?^IRTK_I$G_YJQ7B=_P!$>O-O_4Y:5_TB3_UQ7B=_T1Z\V_\ 4Y:5_P!(
MD_\ 7%>)W_1'KS;_ -3EI7_2)/\ \U8KQ._Z(]>;?^IRTK_I$G_KBO$[_HCU
MYM_ZG+2O^D2?^N*\3O\ HCUYM_ZG+2O^D2?_ )JQ7B=_T1Z\V_\ 4Y:5_P!(
MD_\ 7%>)W_1'KS;_ -3EI7_2)/\ UQ7B=_T1Z\V_]3EI7_2)/_S5BO$[_HCU
MYM_ZG+2O^D2?^N*\3O\ HCUYM_ZG+2O^D2?^N*\3O^B/7FW_ *G+2O\ I$G_
M *XKQ._Z(]>;?^IRTK_I$G_YJQ7B=_T1Z\V_]3EI7_2)/_7%>)W_ $1Z\V_]
M3EI7_2)/_7%>)W_1'KS;_P!3EI7_ $B3_P#-6*\3O^B/7FW_ *G+2O\ I$G_
M *XKQ._Z(]>;?^IRTK_I$G_KBO$[_HCUYM_ZG+2O^D2?^N*\3O\ HCUYM_ZG
M+2O^D2?^N*\3O^B/7FW_ *G+2O\ I$G_ .:L5XG?]$>O-O\ U.6E?](D_P#S
M5BO$[_HCUYM_ZG+2O^D2?^N*\3O^B/7FW_J<M*_Z1)_ZXKQ._P"B/7FW_J<M
M*_Z1)_ZXKQ._Z(]>;?\ J<M*_P"D2?\ YJQ7B=_T1Z\V_P#4Y:5_TB3_ /-6
M*\3O^B/7FW_J<M*_Z1)_ZXKQ._Z(]>;?^IRTK_I$G_YJQ7B=_P!$>O-O_4Y:
M5_TB3_\ -6*\3O\ HCUYM_ZG+2O^D2?_ )JQ7B=_T1Z\V_\ 4Y:5_P!(D_\
M7%>)W_1'KS;_ -3EI7_2)/\ \U8KQ._Z(]>;?^IRTK_I$G_YJQ7B=_T1Z\V_
M]3EI7_2)/_7%>)W_ $1Z\V_]3EI7_2)/_P U8KQ._P"B/7FW_J<M*_Z1)_\
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MO_4Y:5_TB3_UQ7B=_P!$>O-O_4Y:5_TB3_UQ7B=_T1Z\V_\ 4Y:5_P!(D_\
M7%>)W_1'KS;_ -3EI7_2)/\ UQ7B:_Z(]>;?^IRTK_I$G_KBO$W_ -$>O-O_
M %.6E?\ 2)/_ %Q7B=_T1Z\V_P#4Y:5_TB3_ -<5XFO^B/7FW_J<M*_Z1)_Z
MXKQ-_P#1'KS;_P!3EI7_ $B3_P!<5XG?]$>O-O\ U.6E?](D_P#S5BO$[_HC
MUYM_ZG+2O^D2?^N*\3O^B/7FW_J<M*_Z1)_ZXKQ._P"B/7FW_J<M*_Z1)_ZX
MKQ._Z(]>;?\ J<M*_P"D2?\ KBO$[_HCUYM_ZG+2O^D2?^N*\3O^B/7FW_J<
MM*_Z1)_ZXKQ._P"B/7FW_J<M*_Z1)_ZXKQ._Z(]>;?\ J<M*_P"D2?\ KBO$
M[_HCUYM_ZG+2O^D2?^N*\3O^B/7FW_J<M*_Z1)_ZXKQ._P"B/7FW_J<M*_Z1
M)_ZXKQ._Z(]>;?\ J<M*_P"D2?\ KBO$U_T1Z\V_]3EI7_2)/_7%>)O_ *(]
M>;?^IRTK_I$G_KBO$[_HCUYM_P"IRTK_ *1)_P#FK%>)W_1'KS;_ -3EI7_2
M)/\ UQ7B=_T1Z\V_]3EI7_2)/_7%>)W_ $1Z\V_]3EI7_2)/_7%>)W_1'KS;
M_P!3EI7_ $B3_P!<5XG?]$>O-O\ U.6E?](D_P#7%>)W_1'KS;_U.6E?](D_
M]<5XG?\ 1'KS;_U.6E?](D_]<5XG?]$>O-O_ %.6E?\ 2)/_ ,U8KQ._Z(]>
M;?\ J<M*_P"D2?\ KBO$[_HCUYM_ZG+2O^D2?^N*\3O^B/7FW_J<M*_Z1)_^
M:L5XG?\ 1'KS;_U.6E?](D_]<5XFO^B/7FW_ *G+2O\ I$G_ *XKQ-_]$>O-
MO_4Y:5_TB3_UQ7B=_P!$>O-O_4Y:5_TB3_\ -6*\3O\ HCUYM_ZG+2O^D2?^
MN*\3O^B/7FW_ *G+2O\ I$G_ *XKQ._Z(]>;?^IRTK_I$G_KBO$[_HCUYM_Z
MG+2O^D2?^N*\3O\ HCUYM_ZG+2O^D2?^N*\3O^B/7FW_ *G+2O\ I$G_ .:L
M5XG?]$>O-O\ U.6E?](D_P#7%>)W_1'KS;_U.6E?](D_]<5XG?\ 1'KS;_U.
M6E?](D_]<5XG?]$>O-O_ %.6E?\ 2)/_ ,U8KQ._Z(]>;?\ J<M*_P"D2?\
MYJQ7B=_T1Z\V_P#4Y:5_TB3_ -<5XG?]$>O-O_4Y:5_TB3_UQ7B=_P!$>O-O
M_4Y:5_TB3_\ -6*\3O\ HCUYM_ZG+2O^D2?^N*\3O^B/7FW_ *G+2O\ I$G_
M *XKQ._Z(]>;?^IRTK_I$G_YJQ7B=_T1Z\V_]3EI7_2)/_7%>)W_ $1Z\V_]
M3EI7_2)/_P U8KQ._P"B/7FW_J<M*_Z1)_ZXKQ._Z(]>;?\ J<M*_P"D2?\
MKBO$[_HCUYM_ZG+2O^D2?^N*\3O^B/7FW_J<M*_Z1)_^:L5XG?\ 1'KS;_U.
M6E?](D_]<5XG?]$>O-O_ %.6E?\ 2)/_ ,U8KQ._Z(]>;?\ J<M*_P"D2?\
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M?](D_P#S5BO$[_HCUYM_ZG+2O^D2?^N*\3O^B/7FW_J<M*_Z1)_^:L5XG?\
M1'KS;_U.6E?](D_]<5XG?]$>O-O_ %.6E?\ 2)/_ %Q7B=_T1Z\V_P#4Y:5_
MTB3_ -<5XG?]$>O-O_4Y:5_TB3_\U8KQ._Z(]>;?^IRTK_I$G_KBO$[_ *(]
M>;?^IRTK_I$G_KBO$[_HCUYM_P"IRTK_ *1)_P"N*\3O^B/7FW_J<M*_Z1)_
MZXKQ._Z(]>;?^IRTK_I$G_YJQ7B=_P!$>O-O_4Y:5_TB3_UQ7B=_T1Z\V_\
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MNQ5V*NQ5V*NQ5V*NQ50NKJ&RB>[O9$A@C4L\DC!54#J23L!\\5>2ZA_SD/\
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M^/O^<0O_ "=GD+_P(=/_ .3HQ27]=V+6_BB\T_\ ':U'_F,N/^3AQ;7[0?\
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MG'_G'?\ ++\P=4E\T>>/*>CZKJ\RHLEU=VD<LK+&H50685-%  ]L4VI>4O\
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MS<2/+*[=6=R68GW)-<6U??Z?<:9*MM?(8Y&BAG /=)HUEC/^R1E/TXJ^TO\
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M_D/I]KJ]Y9R/!<:Q>LSV@D4T86\<3*90#_NPNJ5&RNIKBR$7Y]:G_P _*O\
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MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?RQ_\
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MK_J$CQ:B_,+_ )S!_P"?A?YC?\X_?F?J?Y8>3=,\OW.E6<%G+'+?VUW).3/
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M1[N^ECM[;5K!G%GZLC!56>*5F:)22/W@D=17X@B@MBQ,7["XL7Y]_P#.>_\
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M184# !E96%.2,K$*25"H%/,O^<0O_)V>0O\ P(=/_P"3HQ4OZ[L6M_/+K/\
MS]I_-[3M0N]/@T7RH8X)Y8E+6=_4A&(%:7HWVQ9\+]!/^< _^<NO.'_.5/\
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M?\_9=9C\F:[K_P"8&DZ1/YL2YMK;1-/TU)X(W#I(TT]R99IF].,A  G%G9N
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MN-5TB"*6"*]1W@8O/'&>:QO&Q%'-*.N]/EB@/Q+_ .BNOYP_]63RE_TAW_\
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M.UM48D*TK@,1R(/%55G:AXJ0K$*":?MC_P X@_\ /O;S%_SC?Y]M_P S=?\
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M'YIR^4?*WY:Z!JFLZ/9K>WMY]0MGFC%PY2.+F5J.2H'X^SMUKLIB_,/\M/\
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ML@?B*-130&I96)?D%BR?V4_D;_Y+CR?_ . ]I7_4)'BU%_.E_P _-/\ R?\
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MVM_^!;>?]0%EBPDR+_GZ;^9MWY'_ "AC\JZ1(\4_FC4HK"=EV_T2)&FE%?\
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M*JO0#%KXG\YO_.2/Y4Q_DA^9GF3\KK61Y;32KREL\OVS;S1K/!SZ MZ4BU(
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M;[?Q0_'W_G\'_P H7Y0_[;%Q_P!0^+*+\!L6;^PS_G&7_P D]^7W_@):%_U
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MR#_Y_$7K1^6O).G!1QEU&_E+=P8X8U ^GF?NQ91?@OBS?V\JJHH1  H% !L
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MS_E"_-__ &V+?_J'Q82>H_\ /U[_ ,DG!_X$-A_R:GQ6+^;7%F_L,_YQE_\
M)/?E]_X"6A?]0$.+67M^*'8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J_EC_Y^._^M$^<O^W3_P!TJUQ;(\DB_P"<!/\ R?\
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M16E1BJ!_Q3HO_5QL_P#I(C_KBKYG_P"<ZKXV/Y"^>+F,!^6G)%UVI+/'&3]
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MK+\(_P#GYI_Y/_7O^8/2_P#J#CQ9Q2+_ )]Q?^M$^3?^WM_W2KK%9<GZT_\
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M 66+"3]3L6+^2G_G-G3/T3^>GGJU^(<]7EN/B()_?JLO;M\>WMUWQ; ^G/\
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M[CLOR;_,":>H4^5M9C%!7XI+.1%_%ABP#^/S%L?TE?\ /J'_ ,DG/_X$-_\
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M!?VL]^ UJD\32AEY H&!8$=]NW?%F_KX7_G&?\G'4.GY?^4BI%01H5@00?\
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MO_./_G/18>;1VNBAU-1R(M720$FE/V/BVZ5I3%K#^3G%L?U'_P#/MB_BO/\
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M=BKL5=BKL5=BKL5=BKL5=BKL5?SI?\_=?_)PZ)_X"5G_ -1][BSB^ _R-_\
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MI>7_ "5:+9^6--L=*LH(^(2T@C@144=/@   IBUOXJL6U^_/_/GS_E"_-_\
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M*<4MS),P^!KN:-HH(@:;L.32[=/3%>H!42+^@#\\O_)<></_  'M5_ZA),6
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MWR/=:/\ F=H_GGTV_1^M:-'"LE#0W%G*ZR+7IM&\1^GIW*RB^#O^<>/S:?\
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MXMW]- #-([A>/IKM3D<4 4_(K%D_K7_YPG(;\B_(I!K_ +AXA]S-BUE\!_\
M/XO_ (XOD3_F,U3_ )-P8IB_"3%F_M[Q:G\\7_/VS\O;G1/S(T?\Q8XS^CM=
MTI;<R4V^LV3E74G_ (Q/$1X[^&+.+X$_YQ^_-B;\C?S$\O\ YJV\1G72+OG/
M"M TEO*C0SHI.P9HG<*3L&()Q9$/U=_YS%_Y^)^0OS._+"]_+;\H_K]SJWF!
M8H+I[FV,"VMN'#R*22><C\1& G):,S<Z@!EB(OP_Q9/Z2O\ GU#_ .23G_\
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M)(/A(.]<41?SPZ!^?_YV^9]3LO+>B^??-LVH:A<PVEM&-=OZO+,X1%'[WNQ
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M?\HEKW_;*OO^3#XM;^+C%M>X?DU_SD?^8O\ SC]^DO\ E46L_HC]+_5_KO\
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M=NFRO.( M=_B*-3^4]E>)^OWY&?D!Y,_YQWT#_!_Y:V7H12,)+NZF;U+FZD
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MAYI$)Y1U$:H=Z%@K*H,GDG_1&O\ \R/_ .&__P!G^*>)^DO_ #BA_P XZ_\
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M?TE>W.H_\K%X?6)I)>/Z KQYL6I7Z\*TKX8LN)]H?\X:_P#.&O\ T*1_B/\
MYV/_ !!_B#]'_P#2O^I^C]3]?_B^?GS]?_)X\>]=E!-OM_%#\_O^<G?^?>7D
M7_G(:_E\Z:7<2>6O-T_]_>6L2RP7+?S3VY*<G_RT=&/[?/:BD2I^=.K_ //H
M3\SH9N.@^8_+=S;[_'<R7EN_M\*6\P_X;%EQ,N\F?\^??,T]S$WYA^;M.M;0
M4,J:5!-<R-XJK3" "O\ ,5:G7B>F*\3];_R"_P"<;?(__.-^C-Y>_+BR*37
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MH4)&#NL:@#NW)OBQ8DV^D\4/Q"_Z(U_^9'_\-_\ [/\ %GQ/NW_G#G_G$/\
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MSS^C;VVU'_E8O/ZO-'+Q_0%.7!@U*_7C2M/#%/$_:_%B_$+_ *(U_P#F1_\
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M5M**I)%(O%E/?<'J-QU!!Q0_$3\T_P#GT+K#:G/>?DSYEL3I4KEXK36Q-%)
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MX/,%DWF7_$$.N/92*/T?]3]!K82AM_7GY\Q(/Y>/#ORV4$VK_P#.8W_.(?\
MT-G9:#IW^(?T!^A)KJ7E]0^N>K]86-:4]>'CQX>+5KVIBH-/A+_HC7_YD?\
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M6UO_ )]!W7F'4;O7]5_,KU+V^N);J=SY?^U)*Y=S_O?W8DXLN)]4_P#.'_\
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M"",6#(,5?SI?]%=?SA_ZLGE+_I#O_P#LMQ9\+O\ HKK^</\ U9/*7_2'?_\
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M!&$CX<2&=ZUZUJ,6)-OL[%#L5=BKL5=BKL5=BKL5=BKL5>6_GE_Y+CSA_P"
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MTDLD5M^C[^#DL2%W/.>"-!103NPKVJ<5I]08H?-GYO\ _.77Y3_D;,^F>?\
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M^>+L6&A:;&);JY,<DG!2P4'A&K.Q+$ !5)WZ8J^3?^BCO_..W_4Y?]RG5?\
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MC;VU_P"<C_*EO2VO#'8Z\J4 6< +;W!'_%BCTG/3DL7=R<642_(?R+YSU/\
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MV\G:K^7NOZEY'\TP_5]7TFZEL[F.M0)(F*DJ>ZFE58;,I!&QQ9/WY_Y]=?\
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MR&XB60I\U)*GY8M3\*O^?OO_ ),?RQ_X#P_ZBYL6<7P'_P XR_\ DX?R^_\
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M.+.+\R?^<?M+AUS\T?)&BWG]Q>>9='MY/]66]B4_@<61?V/8M3\@_P#G)?\
MY]HZ[^>/YE:[^:N@^9-/TRRU=[:1;6:WF=T:*VBB<EE-#S=&?;^;%D),A_YQ
M+_Y]Z^9O^<;OS#M?S,U'S+8:C91VMU:S6T%O*CLLR4%&8D;.%)]ABIE;]"?S
MR_\ )<></_ >U7_J$DQ8A_&MBVOZ+?\ GT5_Y)[6_P#P+;S_ *@++%A)/?\
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MV]NO;*WU&WET_4(DGM9XVBEBD4,CHXXLK*=B"#0@]1BA_)M_SF+_ ,X[W/\
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M;-=3>K>:C>W=S'ZLK"@ 591R<@;(BU--EQ2"7PIY;_YS'_YQ1_YQ[UJXU_\
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MQ7+22VS7 D$CE.("NE*4K7?%!-/NC_HCIK7_ %/=G_W"Y/\ JOBCB9Y^5O\
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MP<6IO%6B0-SMBKR[\\O_ "7'G#_P'M5_ZA),5#^-;%M?T6_\^BO_ "3VM_\
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M0XIB_$C2[+])7MMIW+A]8FCBY4KQYL%K3:M*^.+)^U__ $1K_P#,C_\ AO\
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M=2MB":\2UP9Z =A26M/>O?%A)^@=Q/':Q/<W#!(HU+NQZ!5%23\ABQ?S=?\
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M=A6@Q8V_EF_YS%T'3/+'YT><M \M65MIVF6NI&."UM(4AAB7TT/%(T 514]
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MA5YIQ6F_][#T.W?J,6$GO7_/U[_R2<'_ ($-A_R:GQ6+^;7%F_L,_P"<9?\
MR3WY??\ @):%_P!0$.+67\Z7_/QW_P!:)\Y?]NG_ +I5KBSCR3W_ )]E_P#D
M_P#0?^8/5/\ J#DQ63^G_%K=BKL5=BK^=+_G[K_Y.'1/_ 2L_P#J/O<6<7YN
M>1-5M]"\RZ-K>I,4M+/4;2XF8 L1'%,K,0!N: '88LG]*G_133\@/^K]>?\
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M]%-/R _ZOUY_W"[S_JGBCA>K?DY_SF7^5GY\Z\WD?\M=4N+S5UMI+LQRV5Q
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M*%Y))'M9%5$502S,2  !4G88H#^3S_H67\X?_+?>;?\ N!7_ /U1Q;+?O/\
M\^N?(OF3\OORJUC1O/NC:CHFH2^9[NXCMM3M)K65HFLK-1(J3*K%"RL P%*J
MPK4'%C)]4_\ .3/Y(P?\Y#?EUJ_Y72W L[J\6.:SN6!*Q7,#B2,L!N5)'!^I
MX,Q Y4Q0#3^5K\U/R*\^?DMJ4^B?F/H=YISPL5%PT3-;2BM \4Z@QNI[$-[&
MC;8MELG_ "3_ "]_-[\PKD>5?R7@UPVU^X6=[*2>WL@"0I>XE4K$%&U2Y\ *
MF@Q07H'YT?\ .%?YE?EKYOO?)7E3RSYA\R:?90V/^Y2PT>[FMIYI;.*6?TI(
MXBK(DSO&-ZCC1OBKBH+WW_GWW^3'YE>0_P \_+FN^;?)GF'2](]+4HKB]O\
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M9/\ DG^7OYO?F%<CRK^2\&N&VOW"SO923V]D 2%+W$JE8@HVJ7/@!4T&*"]
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MKQ3(R0JS! S*"Q%*LHK4C%E%^#'_ $++^</_ );[S;_W K__ *HXLK?T^?\
M.(>AZEY:_)KR9H/F.SN-/U.UTJ*.XM;N)X9HG#-57C<!E/L0#BP+Z/Q0[%7P
M1_SG1_SAP/\ G)_1+76O*<L%IYXT576SDG)6*YMV/)K:1A7C\7Q1O0A6Y*:*
M[,JD&G\Z7Y@_D5^87Y5W,MA^8/EK4]+:&O*6:V<P$#J4G0-$ZBA^)'8>^+9;
M%?K'F?SW)#IW/4M9EMUXPPUFNFC6G1%^(J-NP[8J^_O^<7O^?</GK\U-6M==
M_-NPNO+/DR)UDG6[4PWUTHW]**%ASC#=#)(%X@U0.=L6)D_H_P!(TFST"PM=
M"T:!+;3[*".VMH(Q1(XHE"(BCL%4 #VQ8/S[_P"?AO\ SB9J7_.17EJP\S_E
M_&DOG+R]ZOHV[,J?7+66ADA#,0HD5E#Q\B!]M>K@A91-/YO/,OD_7O)EZVB>
M;],O=+U!25-O>V\D$E0:'X9 #UQ9OLG\CO\ G%7\V/\ G))DO_-JZW'Y+T>U
MFE2YU SMS"(66VL(Y:\GD("UC4HG5JMQ1E!-/ _^A9?SA_\ +?>;?^X%?_\
M5'%;?T ?\^S?)7F'R%^4,VA^>=)O]%U(Z[>S"VU&UEM9C&T4(5_3E56XD@T-
M*&A\,6,GVS^87D/1_P T/+>I_E]YOA^L:/JUL]M<(#0\6Z,I[,C ,I[, >V+
M%_,?_P Y ?\ .!?YH_D?J5P;/2KGS%Y8#DVVJZ7 \X].IX^O$@:2%P*<N0].
MIHDC8M@+Y)AU77O+Z7'EVWN;ZRCN"%N+-))8A(2* 21@CE4'N.F*7L?Y5?\
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MK$4[XL[8'INE7NL3"QTBVFNKAJ4B@C:1S4@"BJ">I ^9Q5]S?\X[_P#/O?\
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MY<6IT.+*+\>O^A9?SA_\M]YM_P"X%?\ _5'%E;O^A9?SA_\ +?>;?^X%?_\
M5'%;=_T++^</_EOO-O\ W K_ /ZHXK;]"O\ GV;^3/Y@>0OS>FUSSSY4UW1=
M-.A7L(N=1TRZM83(TL)5/4EC5>1 -!6IH?#%$B^W?^?HWD7S)^8/Y5:/HWD+
M1M1UO4(O,]I<26VF6DUU*L2V5XID9(59@@9E!8BE645J1BB+\&/^A9?SA_\
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M\X?_ "WWFW_N!7__ %1Q;+=_T++^</\ Y;[S;_W K_\ ZHXK;O\ H67\X?\
MRWWFW_N!7_\ U1Q6W?\ 0LOYP_\ EOO-O_<"O_\ JCBMOZD/^<6M'O\ R]^4
M/DG0]?M9['4K30K&&XMKF)HIHI%B 9'C<!E8'J" 1BP+WO%#L5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BK_ /_0^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5__]'[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%7__TOOYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__3
M^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]3[^8J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__U?OYBKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5?__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5__]?[^8J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%7__T/OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783146368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 13, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SI-BONE,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001459839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,458,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6782990608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,120<span></span>
</td>
<td class="nump">$ 22,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">97,103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $263 and $268 at December 31, 2018 and 2017, respectively</a></td>
<td class="nump">8,486<span></span>
</td>
<td class="nump">7,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">2,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">136,042<span></span>
</td>
<td class="nump">33,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">138,521<span></span>
</td>
<td class="nump">35,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,146<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other</a></td>
<td class="nump">6,860<span></span>
</td>
<td class="nump">5,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,006<span></span>
</td>
<td class="nump">7,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PreferredStockWarrantLiability', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term borrowings</a></td>
<td class="nump">38,963<span></span>
</td>
<td class="nump">38,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">48,329<span></span>
</td>
<td class="nump">46,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Redeemable convertible preferred stock, $0.0001 par value;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock; Authorized: 0 and 12,104,749 shares at December 30, 2018 and December 31, 2017; issued and outstanding: 0 and 11,871,578 shares at December 30, 2018 and December 31, 2017; (Liquidation preference of $0 and $119,194 at December 30, 2018 and December 31, 2017).</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">118,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; Authorized: 5,000,000 and 0 shares at December 31, 2018 and 2017, respectively; no shares issued and outstanding as of December 31, 2018 and 2017.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; Authorized: 100,000,000 and 19,333,333 shares at December 31, 2018 and 2017, respectively; issued and outstanding: 24,450,757 and 3,603,140 shares, at December 31, 2018 and 2017, respectively.</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">246,927<span></span>
</td>
<td class="nump">9,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(157,177)<span></span>
</td>
<td class="num">(139,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">90,192<span></span>
</td>
<td class="num">(129,378)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 138,521<span></span>
</td>
<td class="nump">$ 35,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_PreferredStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_PreferredStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783140992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,104,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 119,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">19,333,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">24,450,757<span></span>
</td>
<td class="nump">3,603,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">24,450,757<span></span>
</td>
<td class="nump">3,603,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770558656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 55,380<span></span>
</td>
<td class="nump">$ 47,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">5,112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">50,547<span></span>
</td>
<td class="nump">42,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">44,497<span></span>
</td>
<td class="nump">41,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,376<span></span>
</td>
<td class="nump">5,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,639<span></span>
</td>
<td class="nump">13,062<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">62,512<span></span>
</td>
<td class="nump">60,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11,965)<span></span>
</td>
<td class="num">(17,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Interest and other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,108)<span></span>
</td>
<td class="num">(6,204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,149)<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,453)<span></span>
</td>
<td class="num">(23,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain of marketable securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Changes in foreign currency translation</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (17,416)<span></span>
</td>
<td class="num">$ (23,109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">$ (6.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">7,950,284<span></span>
</td>
<td class="nump">3,467,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784589312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Stockholders&#8217; Notes Receivable</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (shares) at Dec. 31, 2016</a></td>
<td class="nump">11,330,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2016</a></td>
<td class="nump">$ 113,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs (shares)</a></td>
<td class="nump">540,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 5,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (shares) at Dec. 31, 2017</a></td>
<td class="nump">11,871,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2017</a></td>
<td class="nump">$ 118,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity (deficit), beginning balance (shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,446,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity (deficit), beginning balance at Dec. 31, 2016</a></td>
<td class="num">(108,733)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="num">$ (521)<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
<td class="num">$ (116,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised', window );">Issuance of common stock upon exercise of unvested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised', window );">Issuance of common stock upon exercise of unvested stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived', window );">Repayment of stockholders&#8217; notes receivable</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt', window );">Forgiveness of stockholders&#8217; note receivable</a></td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,039)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity (deficit), ending balance (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,603,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity (deficit), ending balance at Dec. 31, 2017</a></td>
<td class="num">$ (129,378)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,943<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="num">(139,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares', window );">Conversion from preferred stock to common stock (shares)</a></td>
<td class="num">(11,871,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue', window );">Conversion from preferred stock to common stock</a></td>
<td class="num">$ (118,548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (shares) at Dec. 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Dec. 31, 2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (shares)</a></td>
<td class="nump">395,117<span></span>
</td>
<td class="nump">289,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised', window );">Issuance of common stock upon exercise of unvested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised', window );">Issuance of common stock upon exercise of unvested stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion from preferred stock to common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,066,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion from preferred stock to common stock</a></td>
<td class="nump">118,548<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">118,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted', window );">Conversion from preferred stock warrants to common stock warrants</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from warrants exercise (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from warrants exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from IPO Proceeds, net (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from IPO Proceeds, net</a></td>
<td class="nump">113,603<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">113,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares', window );">Repurchase of unvested early exercised stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue', window );">Repurchase of unvested early exercised stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain of marketable securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,453)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity (deficit), ending balance (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,450,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity (deficit), ending balance at Dec. 31, 2018</a></td>
<td class="nump">$ 90,192<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 246,927<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="num">$ (157,177)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Share-based Compensation, Vesting Of Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Warrant Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_AdjustmentstoAdditionalPaidinCapitalWarrantConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Unvested Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockIssuedDuringPeriodSharesUnvestedStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Unvested Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockIssuedDuringPeriodValueUnvestedStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Originally Issued For Exercise Of Unvested Stock Options, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockRepurchasedDuringPeriodOriginallyIssuedForExerciseOfUnvestedStockOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity, Receivable From Officers And Directors For Issuance Of Capital Stock, Forgiveness Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgivenessOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity, Receivable From Officers And Directors For Issuance Of Capital Stock, Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StockholdersEquityReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion Of Temporary Equity To Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityConversionOfTemporaryEquityToEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion Of Temporary Equity To Equity, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityConversionOfTemporaryEquityToEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770795744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,453)<span></span>
</td>
<td class="num">$ (23,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Change in allowance for doubtful accounts</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrants</a></td>
<td class="nump">826<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on write-off of property and equipment</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WriteOffOfDebtDiscount', window );">Write-off of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WriteOffOfInitialPublicOfferingCosts', window );">Write-off of public offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Forgiveness of notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Short-term investments accretion</a></td>
<td class="num">(209)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,023)<span></span>
</td>
<td class="num">(1,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(759)<span></span>
</td>
<td class="num">(980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(752)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities and other</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,519)<span></span>
</td>
<td class="num">(17,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(942)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of short-term investments</a></td>
<td class="num">(96,883)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(97,825)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discounts and commissions</a></td>
<td class="nump">115,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options, net</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Repayment of stockholders&#8217; notes receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Extinguishment of debt financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock', window );">Proceeds from the issuance of redeemable convertible preferred stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of public offering costs</a></td>
<td class="num">(1,897)<span></span>
</td>
<td class="num">(1,292)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">115,150<span></span>
</td>
<td class="nump">12,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">2,712<span></span>
</td>
<td class="num">(5,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents at</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Beginning of period</a></td>
<td class="nump">22,408<span></span>
</td>
<td class="nump">27,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">End of period</a></td>
<td class="nump">25,120<span></span>
</td>
<td class="nump">22,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">4,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock to common stock</a></td>
<td class="nump">118,547<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_NetExerciseofCommonWarrants', window );">Conversion of preferred stock warrants to common stock warrants</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_VestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid', window );">Public offering costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_InitialPublicOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_InitialPublicOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_NetExerciseofCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Exercise of Common Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_NetExerciseofCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_VestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_VestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WriteOffOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WriteOffOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WriteOffOfInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WriteOffOfInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recoveries of receivables doubtful of collection that were previously charged off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stock that is classified as callable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774169264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company and Nature of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company and Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on March&#160;18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its iFuse Implant System, or iFuse, in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company's board of directors and stockholders approved a 1-for-18 reverse stock split of the Company's common stock and redeemable convertible preferred stock, which was effected on October&#160;4, 2018. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse split. All issued and outstanding share and per share amounts of common stock, redeemable convertible preferred stock, stock options, and warrants included in the accompanying consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October&#160;16, 2018, the Company&#8217;s Registration Statement on Form S-1 (File No.&#160;333-227445) relating to the initial public offering (IPO) of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">8,280,000</font><font style="font-family:inherit;font-size:10pt;"> shares at an initial public offering price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$113.6 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company, net of underwriting discounts and commissions and offering costs. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;"> shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">160,657</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935197776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long-lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">JOBS Act Accounting Election</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The chief operating decision makers for the Company are the Chief Executive Officer and Chief Financial Officer. The Chief Executive Officer and the Chief Financial Officer review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company derives substantially all of its revenue from sales to customers in the United States. Revenue by geography is based on billing address of the customer. No single country outside the United States accounts for more than 10% of the total revenue during the periods presented. Long-lived assets held outside the United States are immaterial. Following table summarizes the Company's revenue by geography (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.74074074074075%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses resulting from the translation of the Company&#8217;s consolidated balance sheets are recorded as a component of accumulated other comprehensive income. Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company&#8217;s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenue and accounts receivable are spread across a large number of customers, primarily in the United States, and no one customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Risks and Uncertainties</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors, uncertainty of market acceptance of products, and the need to obtain additional financing.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of and for the year ended December 31, 2018, the Company had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$157.2 million</font><font style="font-family:inherit;font-size:10pt;"> and used </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> of cash in operations. The Company has not achieved positive cash flow from operations to date. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$25.1 million</font><font style="font-family:inherit;font-size:10pt;"> and short-term investments of </font><font style="font-family:inherit;font-size:10pt;">$97.1 million</font><font style="font-family:inherit;font-size:10pt;">. The Company held cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$22.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s primary cash needs are for the ongoing commercialization of its iFuse products. The Company also has certain debt covenants associated with its current debt agreement. These covenants include a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> minimum cash balance and revenue targets, which if not met would result in the debt becoming immediately due. The revenue target is assessed quarterly based on the rolling twelve months of revenue, and increases by approximately </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> each quarter. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. The Company has met the minimum liquidity and revenue targets as of December 31, 2018; however there can be no assurances that the Company will continue to meet these targets in the future.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based upon the Company's current operating plan, the Company believes that its existing cash, cash equivalents and short-term investments will enable the Company to fund its operating expenses and capital expenditure requirements through at least the next 12 months. The Company continues to face challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to: (a)&#160;decreases in sales of our products and the uncertainty of future revenues from new products; (b)&#160;changes that the Company may make to the business that affect ongoing operating expenses; (c)&#160;changes that the Company may make in its business strategy; (d)&#160;regulatory developments affecting the Company's existing products; (e)&#160;changes that the Company may make in its research and development spending plans; and (f)&#160;other items affecting the Company's forecasted level of expenditures and use of cash resources.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate. The carrying amount of the redeemable convertible preferred stock warrants has been marked to fair value such that the carrying amount represents its estimated fair value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s cash equivalents consist of money market funds as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The money market funds are classified as Level&#160;1 of the fair value hierarchy. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy. The Company&#8217;s redeemable convertible preferred stock warrants are classified within Level&#160;3 of the fair value hierarchy. The redeemable convertible preferred stock warrants have been valued using a Black-Scholes valuation model and are subsequently marked to fair value at each reporting period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's marketable securities primarily consist of investments in U.S. treasury securities, corporate bonds, and commercial paper. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. Based upon maturity dates, all marketable securities as available for use in current operations, and therefore we classify these securities as current assets in the accompanying consolidated balance sheets. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in Accumulated other comprehensive income (loss) ("OCI"). We evaluate our investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in Other income (expense), net on the consolidated statements of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">            If quoted prices for identical instruments are available in an active market, marketable securities are classified within Level 1 of the fair value hierarchy. If quoted prices for identical instruments in active markets are not available, fair values are estimated using quoted prices of similar instruments and are classified within Level 2 of the fair value hierarchy. To date, all of the Company's marketable securities can be valued using one of these two methodologies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#8217;s operating results or change in financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, inventory consisted entirely of finished goods.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset&#8217;s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has not experienced impairment losses on its long-lived assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public Offering Costs</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specific incremental costs (i.e. consisting of legal, accounting and other fees and costs) directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. In the event a planned IPO does not occur or is significantly delayed, all of the costs will be expensed. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> capitalized offering costs as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> included in other non-current assets on the consolidated balance sheets. Costs incurred and capitalized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> amounting to </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> were transferred to additional paid-in capital upon completion of the IPO on October 16, 2018. Offering costs of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> were also incurred and expensed in the </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, as a result of delays in the IPO process during the period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; deficit section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and other similar instruments related to shares that are contingently redeemable are classified as liabilities on the consolidated balance sheet at their estimated fair value because the shares underlying the warrants may obligate the Company to transfer assets to the holders at a future date under certain circumstances such as a deemed liquidation event. The warrants are exercisable into the Company&#8217;s redeemable convertible preferred stock and are classified as liabilities on the consolidated balance sheet. The warrants, measured at fair value, are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company adjusted the liability for changes in fair value until the the closing of our initial public offering, at which time certain preferred stock warrants were converted into warrants to purchase common stock and the liability was reclassified to additional&#160;paid-in&#160;capital.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 605, Revenue Recognition (&#8220;ASC 605&#8221;), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company&#8217;s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warranty Program</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company implemented a warranty program which provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period following an original procedure where an implant is not required. These one-time credits are accounted for as sales reserves. Sales and warranty reserves from the warranty program were immaterial as of both </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medical Device Excise Tax</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the United States. The medical device excise tax is included in cost of goods sold in the consolidated statements of operations and comprehensive loss for all the periods presented. Effective December 2015, the Act was amended to include a provision to suspend the tax on medical devices through 2017. In January 2018, the suspension on the tax on medical devices was further extended through 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shipping and handling costs are expensed as incurred and are included in cost of goods sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#8217;s product which include (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense (2)&#160;external research and development expenses (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expenditures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of advertising is included in Sales and Marketing expense in the consolidated financial statements and expensed as incurred. Advertising costs totaled </font><font style="font-family:inherit;font-size:10pt;">$0.7</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;"> million for the </font><font style="font-family:inherit;font-size:10pt;">year ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions including expected volatility, expected life, risk-free interest rate and expected dividends. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to nonemployees is recognized as the stock options are earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. The guidance also prescribes treatment for derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company calculates basic and diluted net loss per common share attributable to shareholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock and early exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the redeemable convertible preferred stock and early exercised stock options as the holders of redeemable convertible preferred stock and early exercised stock options do not have a contractual obligation to share in losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, redeemable convertible preferred stock and common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss represents all changes in the stockholders&#8217; equity (deficit) except those resulting from distributions to stockholders. The Company&#8217;s unrealized foreign currency translation income (losses) and unrealized gain (losses) of marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the guidance on the subsequent measurement of inventory, excluding inventory measured using last-in, first out or the retail inventory method. Under the new standard, in scope inventory should be measured at the lower of cost and net realizable value. The new standard will become&#160;effective for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2016, for public companies. For all other entities, the new standard is effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017, with early adoption permitted. The Company has adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17,&#160;Balance Sheet Classification of Deferred Taxes. ASU 2015-17 specifies that deferred tax assets and liabilities shall be classified as non-current, or long-term, in a classified statement of financial position. The new standard is effective for public entities for fiscal years beginning after&#160;December 15, 2016, and interim periods within those fiscal years. For private entities, the new standard is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within fiscal years beginning after December&#160;15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or an annual reporting period. The Company has early adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, which simplified several aspects of accounting for stock-based compensation transactions. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new guidance is effective for public entities for fiscal years beginning after December&#160;15, 2016 and interim periods within those years. Other entities must apply the new guidance in fiscal years beginning after December&#160;15, 2017 and in interim periods within fiscal years beginning after December 15, 2018, with early adoption permitted. The Company early adopted this standard in the first quarter of 2017 by recording the cumulative impact of applying this guidance to retained earnings, which was not material. The Company elected to continue to&#160;estimate the number of awards&#160;that are expected to vest.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01. Recognition and Measurement of Financial Assets and Financial Liabilities, which amends Accounting Standards Codification, or ASC, Subtopic 825-10, Financial Instruments - Overall, and includes updates on certain aspects of recognition, measurement, presentation and disclosure of financial instruments and applies to all entities that hold financial assets or owe financial liabilities. The new standard is effective for the Company&#8217;s annual period beginning after December 15, 2018, with early adoption permitted beginning after December 15, 2017. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09, Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for all entities for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2017. Early adoption is permitted. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Effective</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S.&#160;GAAP when it becomes effective. The new standard is effective for fiscal years beginning after December&#160;15, 2017 for public companies, and for fiscal years beginning after December&#160;15, 2018, and interim periods beginning after December&#160;15, 2019, for private companies. Early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. In March&#160;2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April&#160;2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May&#160;2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date as ASU&#160;2014-09. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to evaluate the impacts of adoption of the new standard on its accounting policies, processes, and system requirements and has assigned internal resources, in addition to the engagement of third party service providers, to assist in the evaluation.&#160;At this time, as  it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or other medical facilities, the Company expects revenue to continue to be recognized upon completion of the procedure&#160;and authorization by the customer. Additionally, the new standard requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company expects to continue expensing all sales commissions as incurred. Management will adopt the standard using the modified retrospective method for the fiscal year ending December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued its new lease accounting guidance. Under the new guidance, ASU 2016-02, Leases (Topic 842), lessor accounting is largely unchanged. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Under the new guidance, lessees will be required to recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date. The new guidance is effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018 for public companies and beginning after December&#160;15, 2019 for private companies. Early adoption is permitted for any interim or annual financial statements net yet issued. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing and operating leases) must apply a modified retrospective approach for all leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15 &#8220;Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments&#8221;. ASU 2016-15 provides guidance on the following eight specific cash flow classification issues: (1)&#160;debt prepayment or debt extinguishment costs; (2)&#160;settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3)&#160;contingent consideration payments made after a business combination; (4)&#160;proceeds from the settlement of insurance claims; (5)&#160;proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6)&#160;distributions received from equity method investees; (7)&#160;beneficial interests in securitization transactions; and (8)&#160;separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December&#160;15, 2017 for public companies, and fiscal years beginning after December&#160;15, 2018 and interim periods within fiscal years beginning after December 15, 2019 for private companies, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-15 on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part&#160;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&#160;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in Part&#160;I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the amendments in Part&#160;I of this Update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement&#8212;Reporting Comprehensive Income (Topic 220).&#160;This update provides companies with the option to reclassify stranded tax effects caused by the 2017 Tax Cuts and Jobs Act (the 2017 Tax Act) from accumulated other comprehensive income to retained earnings. This standard is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU&#160;2018-07,&#160;Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation&#8212;Stock Compensation, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity&#8212;Equity-Based Payments to&#160;Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December&#160;15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of ASC 606. The Company is currently evaluating the impact that the adoption of this standard will have on the consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774145680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All marketable securities of at December 31, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;"> consisted of money market funds which were classified as cash equivalents.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935165520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font><font style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">[1]</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font><font style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">[1]</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">[1]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents on the consolidated balance sheet</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the redeemable convertible preferred stock warrants, the Company&#8217;s Level&#160;3 financial liability, which is measured on a recurring basis (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:93%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value recorded in other (income) expense, net </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of preferred stock warrants to common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774144592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Components</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, net</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities and Other </font><font style="font-family:inherit;font-size:10pt;">(in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales tax payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for early exercise of unvested stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and warranty reserves</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774134400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2012, the Company entered into a new </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year non-cancelable operating lease for its existing office building space in San Jose, California which commenced in January 2013. In February 2014, the Company expanded the existing lease space and extended the lease terms through June 2017. In May 2016, the Company entered into another extension of the lease with its lessor for additional 12 months beginning in July 2017. Effective May 2018, the Company entered into an early termination agreement on an operating lease for its San&#160;Jose office. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> early termination fees were incurred and all previously agreed-to rent payments were released, with no further obligations. In February 2018, the Company entered into a new </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">-year non-cancelable operating lease for an office building space in Santa Clara, California which commenced in April 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also entered into non-cancelable operating leases for its office building space in Gallarate, Italy and Mannheim, Germany which both expire in November 2024. Further, the Company also leases vehicles under operating lease arrangements for certain of its sales personnel in Europe which expire various times in 2019 to 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense is recorded over the lease terms on a straight-line basis. Rent expense charged to operations under operating leases totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;text-align:left;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">           The aggregate future minimum lease payments under all leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments and Obligations</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain purchase commitments related to inventory used in normal course of business. These commitments totaled </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The amounts paid under these arrangements may be less in the event that the arrangement is renegotiated or canceled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2019, a putative class action captioned Eric B. Fromer Chiropractic, Inc. v. SI-BONE, Inc. (Civil Action No. 5:19-cv-633-SVK), was filed in the United States District Court, Northern District of California. The complaint alleges violations of the Telephone Consumer Protection Act (the &#8220;TCPA&#8221;) on behalf of an individual and putative classes of persons alleged to be similarly situated.  The complaint alleges that the Company sent invitations to an educational dinner event to health care providers by way of facsimile transmission.  The TCPA prohibits using a fax machine to send unsolicited advertisements not including proper opt-out instructions or to send unsolicited advertisements to persons with whom the sender did not have an established business relationship.  The Company believes that it has meritorious defenses and intends to vigorously defend itself in the action.  It is too early in this matter to reasonably predict the probability of the outcomes or to estimate the range of possible loss, if any.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> incurred costs to defend lawsuits or settle claims related to these indemnification agreements. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> liability associated with such indemnifications has been recorded to date.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774129840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$38.7 million</font><font style="font-family:inherit;font-size:10pt;"> of outstanding debt, net of debt discounts, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the Company entered into a Term Loan facility and a revolving line of credit with Silicon Valley Bank, or SVB and Oxford Finance LLC, or Oxford for </font><font style="font-family:inherit;font-size:10pt;">$35.2 million</font><font style="font-family:inherit;font-size:10pt;">. The Term Loan had interest only periods for </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;"> up to October&#160;1, 2017 and was then to be repaid over </font><font style="font-family:inherit;font-size:10pt;">25 months</font><font style="font-family:inherit;font-size:10pt;"> of equal principal payments plus interest. The maturity date of the term loan was December&#160;1, 2019, and it carried an interest rate equal to the greater of </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;"> or the WSJ Prime rate plus </font><font style="font-family:inherit;font-size:10pt;">7.75%</font><font style="font-family:inherit;font-size:10pt;">. The Term Loan borrowings were senior unsecured obligations of the Company, ranking equally and ratably among themselves and with the Company&#8217;s existing and future unsecured and unsubordinated debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the above Term Loan agreement, the Company issued redeemable convertible preferred stock warrants (refer to Note 9 for details).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company extinguished the Term Loan with SVB and Oxford. Concurrently, the Company entered into a New Term Loan with Pharmakon Advisors, or Pharmakon. As a result of the extinguished debt, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$29.1 million</font><font style="font-family:inherit;font-size:10pt;"> in principal payments to SVB and Oxford. The Company also paid </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> in early termination fees and recorded </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> of unamortized debt discounts. This loss on extinguishment of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> is reflected as interest expense in the consolidated statement of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into the New Term Loan with Pharmakon for </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in October 2017. Debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded as a direct deduction from the carrying amount of the New Term Loan on the consolidated balance sheet, and are being amortized over the period of the New Term Loan using the effective interest method to interest expense in the consolidated statement of operations. The New Term Loan includes an interest-only period for </font><font style="font-family:inherit;font-size:10pt;">35</font><font style="font-family:inherit;font-size:10pt;"> months through September 2020 and is then repaid in equal quarterly principal payments plus interest through December 2022, and is classified as long-term borrowings on the consolidated balance sheet. The New Term Loan carries a fixed interest rate of </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> and a closing fee of </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> of the funded amount, or </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">. The New Term Loan includes a pre-payment fee equal to the interest due for the first 30 months of the agreement if it is prepaid within the first 30 months, a </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> prepayment penalty for months 31-48, and a </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> penalty for months 49-60. The New Term Loan required the Company to maintain a minimum cash balance of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> and to achieve certain revenue targets through December 31, 2018. Beginning with the three months ended March 31, 2019, the Company is required to meet either revenue or earnings targets. Under the New Term Loan, the Company also has a second tranche of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> available through January 2019, contingent upon the achievement of certain revenue milestones. The Company did not draw upon the second tranche. The New Term Loan is a senior obligation secured with a blanket first lien on the assets of the Company. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total loan balance, net of debt discount, was </font><font style="font-family:inherit;font-size:10pt;">$39.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$38.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, with an effective interest rate of </font><font style="font-family:inherit;font-size:10pt;">12.3%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">12.0%</font><font style="font-family:inherit;font-size:10pt;">, respectively, and the Company was in compliance with all debt covenants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approximate annual future minimum principal payments under the loan agreements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending at, December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount representing debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Term Loan required the Company to maintain a minimum cash balance of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> and to achieve certain revenue targets, which we were in compliance with through December 31, 2018. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning with the three months ended March 31, 2019, the Company is required to meet either minimum net sales or trailing 12-month consolidated EBITDA targets. The Company needs to meet one or the other, but not both.  If the Company does not meet either the minimum net sales or trailing 12-month consolidated EBITDA targets, the debt will immediately become due. The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:33px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Minimum Net Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trailing 12-Month Consolidated EBITDA</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thereafter, as applicable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The New Term Loan is collateralized by all of the Company's assets, including intellectual property.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company was in compliance with all of its debt obligations and covenants.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Line of Credit</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, the Company entered into an agreement with its existing lender SVB and Oxford. The amount of the revolving line of credit was </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> (or </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the amount of certain customer accounts receivable). It carried an interest rate equal to the WSJ Prime rate plus </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> with a maturity of December&#160;1, 2019. In October 2017, this line of credit was cancelled in conjunction with the SVB and Oxford debt extinguishment discussed above. No draws were made on this facility through its cancellation.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774146480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable Convertible Preferred Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> preferred stock balance outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Series</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liquidation&#160;Value </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,047</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,086,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,009,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,389,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,319,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,666,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,580,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,104,749</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,194</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the conversion of redeemable preferred stock to common stock during the IPO, the holders of preferred stock had various rights and preferences as follows:</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Voting Rights</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock shares were entitled to vote on all matters on which the common stockholders were entitled to vote. The holders of Series&#160;1, Series 2, Series 3 had the right to </font><font style="font-family:inherit;font-size:10pt;">0.352941</font><font style="font-family:inherit;font-size:10pt;"> votes for each share of Series 2 common stock into which such preferred stock would had converted and the holders of Series 4, Series 5, Series 6 and Series 7 had the right to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> vote for each share of Series 2 common stock into which such preferred stock would had converted. As long as there were any shares of Series 4, Series 5, Series 6, and Series 7 shares that were outstanding, the holders of such Series 4, Series 5, Series 6 and Series 7, at each respective series, were entitled to elect </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> member of the Board of Directors each; the holders of Series 2 common stock were entitled to elect </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> members of the Board of Directors; and the holders of the preferred stock and Series 2 common stock, voting together as a single class were entitled to elect the remaining members of the Board of Directors, as determined at each annual meeting of the Board of Directors.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As long as at least </font><font style="font-family:inherit;font-size:10pt;">277,778</font><font style="font-family:inherit;font-size:10pt;"> preferred stock shares remained outstanding, the Company must obtain approval from a majority of the holders of the then outstanding shares of preferred stockholders and a majority of the voting power of all outstanding shares of Series 5 preferred stock in order to (i)&#160;consummate or agree to consummate a Liquidation Event (as defined in the Company&#8217;s certificate of incorporation); (ii) amend, alter, restate or repeal any provision of the Company&#8217;s certificate of incorporation or bylaws so as to adversely alter, affect or change the powers, preferences, rights or privileges of the shares of preferred stock; (iii)&#160;increase or decrease (other than by redemption or conversion) the total number of authorized shares of common stock or preferred stock or designated shares of any series of preferred stock; (iv)&#160;authorize or issue, or obligate itself to issue, any equity security (including any other security convertible into or exercisable for any such equity security) having a preference over, or being on a parity with, any series of preferred stock with respect to dividends, liquidation or redemption, other than the issuance of any authorized but unissued shares of Series&#160;6 preferred stock designated in the Company&#8217;s certificate of incorporation (including any security convertible into or exercisable for such shares of preferred stock); (v) redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any share or shares of preferred stock or common stock; provided, however, that this restriction shall not apply to the repurchase of shares of common stock from employees, officers, directors, consultants or other persons performing services for the Company or any subsidiary pursuant to agreements under which the Company has the option to repurchase such shares upon the occurrence of certain events, such as the termination of employment or service, or pursuant to an agreement providing for a right of first refusal in favor of the Company, in each case, provided that such agreement has been approved by the Company&#8217;s board of directors; or (vi)&#160;pay or declare any dividend on any shares of capital stock of the Company.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of preferred stock were entitled to receive noncumulative dividends, when and if declared by the Board of Directors, out of any assets legally available, prior to and in preference to any declaration or payment of dividends on the common stock of the Company. Dividend rates, on a per annum basis, for Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock are </font><font style="font-family:inherit;font-size:10pt;">$0.050112</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.171360</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.4608</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.504</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.72774</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.317744</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.802656</font><font style="font-family:inherit;font-size:10pt;">, respectively, (adjusted to reflect subsequent stock dividends, stock splits or recapitalization). </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> dividends on preferred stock or common stock have been declared as of December&#160;31, 2018 and 2017.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of any liquidation, dissolution or winding-up of the Company or Liquidating Event, the holders of the preferred stock were entitled to receive prior to and in preference to any distribution to holders of the common stock, an amount equal to their respective original issuance price per share (original issuance price per share for Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock are </font><font style="font-family:inherit;font-size:10pt;">$0.6264</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.142</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.76</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.30</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$9.0954</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$16.4718</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$10.0332</font><font style="font-family:inherit;font-size:10pt;">, respectively), plus any declared but unpaid dividends on such shares. Should the Company&#8217;s legally available assets be insufficient to satisfy the full liquidation preference, the funds will be distributed ratably among the holders of the preferred stock in proportion to the preferential amount each holder is otherwise entitled to receive.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the distribution as above, the remaining proceeds shall be distributed among the holders of Series&#160;4, Series&#160;5, Series&#160;6, Series&#160;7 preferred stock and common stock pro rata based on the number of shares of common stock held by each until the holders of the preferred stock have received the &#8220;participation cap.&#8221; Thereafter, if proceeds remain, the holders of Series&#160;7 preferred stock and common stock of this corporation shall receive all of the remaining proceeds pro rata based on the number of shares of common stock held by each (assuming full conversion of all such Series&#160;7 preferred stock). The Company has a per share &#8220;Participation Cap&#8221; of </font><font style="font-family:inherit;font-size:10pt;">$32.9436</font><font style="font-family:inherit;font-size:10pt;"> for the Series&#160;6 preferred stock, </font><font style="font-family:inherit;font-size:10pt;">$18.1908</font><font style="font-family:inherit;font-size:10pt;"> for the Series&#160;5 preferred stock, and </font><font style="font-family:inherit;font-size:10pt;">$12.60</font><font style="font-family:inherit;font-size:10pt;"> for the Series&#160;4 preferred stock (each as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations or the like with respect to such series of preferred stock).</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conversion</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each share of Series 1, Series 2, Series 3, Series 4, Series 5, Series 6, and Series 7 preferred stock was convertible at the option of the holder, into the number of shares of Series 2 common stock into which such shares are at the then effective conversion ratio or </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to one ratio. The conversion price per share for Series 1, Series 2, Series 3 and Series 4, Series 5, Series 6, and Series 7 preferred stock shall be the respective issuance price per share, respectively. The initial conversion price was subject to adjustment from time to time. In March 2017, the conversion price per share for the Series 6 preferred stock was amended from </font><font style="font-family:inherit;font-size:10pt;">$15.714</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$15.5574</font><font style="font-family:inherit;font-size:10pt;"> per share which resulted in the conversion ratio increasing from </font><font style="font-family:inherit;font-size:10pt;">1.05</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.06</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each share of preferred stock shall be converted into common stock shares upon the earlier of (i)&#160;immediately before the closing of a firm commitment underwritten public offering in which the aggregate gross proceeds of not less than </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> and a per share public offering of not less than </font><font style="font-family:inherit;font-size:10pt;">$30.0996</font><font style="font-family:inherit;font-size:10pt;">, or (ii)&#160;the Company&#8217;s receipt of a written request for such conversion from the holders of at least the voting majority of all outstanding preferred stock (voting as a single class and on an&#160;as-converted&#160;basis).</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the conversion of redeemable convertible preferred stock to common stock during the IPO, the Company has classified the preferred stock as temporary equity on the consolidated balance sheets as the shares can be redeemed upon the occurrence of certain change in control events that are outside the Company&#8217;s control, including deemed liquidation, sale or transfer of the Company. The Company has not adjusted the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of preferred stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935184000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;"> shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">160,657</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital. In addition, warrants to purchase Series 6 Preferred Stock were converted to warrants to purchase common stock at a conversion ratio of 1:1.06.   </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows(in thousands, except share and per share data): </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.91642924976259%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of <br clear="none"/>Shares <br clear="none"/>Underlying <br clear="none"/>Warrants</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price&#160;per <br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants to purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total outstanding common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[a]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants will remain outstanding until exercised by the holder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[b]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of issuance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[c]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&#160;&#160;&#160;&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands, except share and per share data): </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of <br clear="none"/>Shares <br clear="none"/>Underlying <br clear="none"/>Warrants</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price&#160;per <br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants to purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,928</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series&#160;5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/1/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/25/2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[d]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,917</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,283</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,550</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total outstanding common and redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,876</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[a]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants will remain outstanding until exercised by the holder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[b]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of issuance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[c]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value as of December 31, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[d]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">These warrants will be net exercised immediately upon the closing of the Company&#8217;s IPO, or upon&#160;a corporate transaction as defined in the Note and Warrant Purchase Agreement dated July&#160;25, 2012. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[e]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Convertible preferred stock warrants will remain outstanding until exercised by the holder and will convert to common stock warrants upon an IPO. The warrants will be exercisable for </font><font style="font-family:inherit;font-size:8pt;">10 years</font><font style="font-family:inherit;font-size:8pt;"> from the date of issuance. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with previously issued debt, the Company issued </font><font style="font-family:inherit;font-size:10pt;">101,010</font><font style="font-family:inherit;font-size:10pt;"> warrants to purchase common shares of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$3.96</font><font style="font-family:inherit;font-size:10pt;"> per share in July 2013. Additionally, the Company issued warrants to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">21,928</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$3.42</font><font style="font-family:inherit;font-size:10pt;">&#160;per share in November 2014. The Company determined that its warrants to purchase shares of common stock meet the requirements for equity classification.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with debt issued in July 2012, the Company issued warrants which became exercisable for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">54,917</font><font style="font-family:inherit;font-size:10pt;"> shares of Series 5 preferred stock of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.10</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with debt issued in 2013 and 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">32,983</font><font style="font-family:inherit;font-size:10pt;"> warrants to purchase Series&#160;5 redeemable convertible preferred stock of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.10</font><font style="font-family:inherit;font-size:10pt;"> per share. Subsequently, the Company issued additional warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">6,310</font><font style="font-family:inherit;font-size:10pt;"> shares of Series&#160;6 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.47</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the debt agreement with SVB and Oxford, or Term Loan agreement (refer to Note 7), the Company issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">39,339</font><font style="font-family:inherit;font-size:10pt;"> shares of Series 6 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.47</font><font style="font-family:inherit;font-size:10pt;"> per share in October 2015 and additional </font><font style="font-family:inherit;font-size:10pt;">24,283</font><font style="font-family:inherit;font-size:10pt;"> shares of Series 6 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$16.47</font><font style="font-family:inherit;font-size:10pt;"> per share in November 2015.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the Term Loan agreement and its modification (refer to Note 7), the Company issued additional warrants for the purchase of </font><font style="font-family:inherit;font-size:10pt;">9,712</font><font style="font-family:inherit;font-size:10pt;"> shares of Series 7 redeemable convertible preferred stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$10.03</font><font style="font-family:inherit;font-size:10pt;"> per share in December 2016.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company issued a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">1,388</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$5.94</font><font style="font-family:inherit;font-size:10pt;"> to a consultant. The Company determined that such warrant meets the requirements for equity classification.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company extinguished its debt with SVB and Oxford. All related debt discounts were written off upon repayment of the loan.</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the fair value of warrants using the Black-Scholes option valuation model. The fair value is estimated using certain assumptions. Refer to Note 11. Stock-Based Incentive Compensation Plans, for further discussions on how the Company determines these input assumptions. Each of these inputs is subjective and its determination generally requires significant judgment. The fair value of warrants to purchase preferred stock were recorded at the date of issuance as a discount to debt and amortized to interest expense over the term of the note. The changes in the fair value of the redeemable convertible preferred stock warrants are recorded in other income and expense. Weighted-average assumptions used in computation of the fair value of the redeemable convertible preferred stock warrants are summarized in the table below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.07882241215574%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining contractual term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935071840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Board of Directors approved an increase of </font><font style="font-family:inherit;font-size:10pt;">555,555</font><font style="font-family:inherit;font-size:10pt;"> Series&#160;2 common stock. As a result, the Company&#8217;s restated certificate of incorporation, as amended, authorizes the Company to issue </font><font style="font-family:inherit;font-size:10pt;">19,333,333</font><font style="font-family:inherit;font-size:10pt;"> shares of </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> par value common stock, of which </font><font style="font-family:inherit;font-size:10pt;">6,000,000</font><font style="font-family:inherit;font-size:10pt;"> has been designated as Series 1 common stock and </font><font style="font-family:inherit;font-size:10pt;">13,333,333</font><font style="font-family:inherit;font-size:10pt;"> has been designated as Series 2 common stock. The holders of Series 1 common stock shall have no voting rights; the holders of Series 2 common stock shall have the right to one vote for each such share. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company amended and restated its certification of incorporation, which authorizes the Company to issue </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock, each having a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;">. At December 31, 2018, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> preferred stock issued and outstanding.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of common stock are entitled to receive dividends whenever funds are legally available, as, when, and if declared by the Board of Directors. There have been </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> dividends declared to date.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has reserved shares of common stock, on an issued and as-converted basis, for future issuance as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock <br clear="none"/>Equivalent&#160;Shares</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,450,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 1 common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2 common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,760,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,787,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,986,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935208672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Incentive Compensation Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Incentive Compensation Plans</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2008, the Company adopted the 2008 Stock Option Plan, as amended, under which the Board of Directors may issue incentive and nonqualified stock options to employees, directors and consultants. In October 2018, the Company adopted the 2018 Equity Incentive Plan, which serves as the successor to the 2008 Stock Option Plan, under which the Board of Directors may issue incentive and nonqualified stock options and restricted stock units (RSUs) to employees, directors and consultants. No new options have been granted under the 2008 Stock Option Plan since August 2018. Outstanding options under the 2008 Stock Option Plan continue to be subject to the terms and conditions of that plan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors has the authority to determine to whom options will be granted, the number of shares, the term and the exercise price. If an individual owns stock representing more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares, the price of each share shall be at least </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value, as determined by the Board of Directors. The exercise price of an incentive stock option and a nonqualified stock option shall not be less than </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the fair market value on the date of grant. As of  </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, a total of </font><font style="font-family:inherit;font-size:10pt;">5,350,080</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock had been reserved for issuance under the 2008 Stock Option Plan. As of&#160;December&#160;31, 2018, a total of </font><font style="font-family:inherit;font-size:10pt;">2,576,538</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock had been reserved for issuance under the 2018 Equity Incentive Plan. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted have a term of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years, except, options granted to individuals holding more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. Options generally vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period. Certain shares issued under the Plan are exercisable immediately, but subject to a right of repurchase by the Company of any unvested shares. RSUs granted under the 2018 Equity Incentive Plan generally vest over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years based upon continued services and are settled at vesting in shares of the Company's common stock. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> for all stock plans:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.25925925925927%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Contractual Remaining Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options canceled </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,762,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and expected to vest - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,366,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair value of all options granted were </font><font style="font-family:inherit;font-size:10pt;">$3.98</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.80</font><font style="font-family:inherit;font-size:10pt;"> for years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding, options vested and exercisable, and options vested and expected to vest were calculated as the difference between the exercise price of the options and the close price of the Company&#8217;s common stock on the last trading day of the year, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows eligible employees to purchase shares of the Company's common stock through payroll deductions at the price equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the lesser of the fair market value of the stock as of the first date or the ending date of each </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month offering period.  </font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early Exercise of Unvested Stock Options</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early exercises of stock options are subject to a right of repurchase by the Company of any unvested shares. The repurchase rights lapse over the original vesting period of the options. The Company accounts for the cash received in consideration for the early exercised options as a liability included in accrued liabilities, which is then reclassified to stockholders&#8217; equity (deficit) as the options vest. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had a total of </font><font style="font-family:inherit;font-size:10pt;">74,019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">16,117</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively, subject to repurchase under the Plan and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of associated liabilities for the repurchase.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth stock-based compensation expense recognized for the periods presented (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.70370370370371%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br clear="none"/>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,471</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts above do not include </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of stock-based compensation expense related to forgiveness of notes receivable for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> amounts of stock-based compensation expense related to forgiveness of notes receivable were recognized for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Refer to Note 13 for details.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the shares of the Company&#8217;s common stock underlying the stock options has historically been determined by the Company&#8217;s Board of Directors. Because there had been no public market for the Company&#8217;s common stock prior to its IPO, its Board of Directors has determined the fair value of the Company&#8217;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including independent third-party valuations, the Company&#8217;s stage of development, sales of the Company&#8217;s redeemable convertible preferred stock, the Company&#8217;s operating and financial performance, equity market conditions affecting comparable public companies, the lack of liquidity of the Company&#8217;s capital stock, and the general and industry-specific economic outlooks.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to its IPO, the Company uses the market closing price for its common stock as reported on the NASDAQ Global Market on the date of grant.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected term represents the period that the share-based awards are expected to be outstanding. The Company used the simplified method to determine the expected term, which is calculated as the average of the time to vesting and the contractual life of the options.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the Company&#8217;s common stock has never been publicly traded, the expected volatility is derived from the average historical volatilities of publicly traded companies within its industry that the Company considers to be comparable to its business over a period approximately equal to the expected term for its stock options.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend Yield</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Forfeiture Rate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant date fair value of the stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.71</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42%-47%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42%-55%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.35%-2.96%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73%-2.31%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Stock Options</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">564,098</font><font style="font-family:inherit;font-size:10pt;"> performance stock options at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$5.94</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">408,544</font><font style="font-family:inherit;font-size:10pt;"> performance options will vest monthly over </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years and </font><font style="font-family:inherit;font-size:10pt;">155,554</font><font style="font-family:inherit;font-size:10pt;"> performance options will vest monthly over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years. The vesting period will begin on the date of the closing of an IPO, the performance condition, subject to the optionee&#8217;s continuous service. Stock-based compensation expense for performance stock options is based on the probability of achieving certain performance criteria, as defined in the individual option grant agreement. Periodically, the Company estimates the number of performance options ultimately expected to vest and recognizes stock-based compensation expense for those options when it becomes probable that the performance criteria will be met. In October 2018, the Company completed its IPO and recognized </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> expense related to the performance stock options for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company modified the terms of </font><font style="font-family:inherit;font-size:10pt;">394,652</font><font style="font-family:inherit;font-size:10pt;"> unvested stock option awards granted in March 2017, by reducing their exercise price from </font><font style="font-family:inherit;font-size:10pt;">$5.94</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$4.68</font><font style="font-family:inherit;font-size:10pt;"> per share. In addition, the vesting performance conditions for these options were removed and the vesting commencement date changed from the IPO date to September 2017. There were no other changes in any of the other terms of the option awards. Due to these options previously subject to performance conditions that were not deemed probable of occurring, the Company had not recognized any expense related to these grants. The modification resulted in total expense of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> that is recognized over the amended vesting period of forty-eight months</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock units activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.77777777777777%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted- <br clear="none"/>Average <br clear="none"/>Grant Date Fair  <br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Unvested as of  December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,036</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Unvested as of  December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was a total unrecognized compensation cost of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">. These costs are expected to be recognized over a period of approximately </font><font style="font-family:inherit;font-size:10pt;">2.29 years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">          In October 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "ESPP"). </font><font style="font-family:inherit;font-size:10pt;">515,307</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock are reserved for issuance under the ESPP.  The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> compensation expense for the ESPP.  As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation cost for the ESPP was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used to determine the grant date fair value of employee stock options and ESPP purchase rights for the periods presented are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.7037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.96%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774145680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Benefit Plan</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sponsors a 401(k) plan covering all employees. Contributions made by the Company are discretionary and are determined annually by the Board of Directors. The Company has made no contributions to the 401(k) plan since its inception.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935197776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2013, the Company granted a loan to its then current Chief Financial Officer to assist with the exercise of his stock option grants in the form of a full recourse promissory note with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. The note is collateralized by the common stock issued upon the exercise of the stock options, as well as personal assets of the borrower. Interest under this note will accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">1.09%</font><font style="font-family:inherit;font-size:10pt;"> per annum. In November 2016, the loan amount was partially repaid in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> (including principal and interest). The remainder of the principal balance of this note, together with all accrued and unpaid interest to date, was fully paid in December 2017.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company granted a loan to its Chief Executive Officer to assist with the exercise of his stock option grants in the form of a full recourse promissory note with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. The note is collateralized by the common stock issued upon the exercise of the stock options, as well as personal assets of the borrower. At the time of issuance, the Company accounted for the note as a full recourse promissory note based on historical pattern of collecting payment on notes in full and no other notes had been forgiven, nor had any recourse notes been substantively converted to nonrecourse. Interest under this note will accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">1.97%</font><font style="font-family:inherit;font-size:10pt;"> per annum. The principal balance of this note, together with all accrued and unpaid interest to date, was due in February 2019.  In March 2017, the Company forgave </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of principal and interest due on this promissory note from its Chief Executive Officer. In addition, the Board of Directors approved the forgiveness of the remaining </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the principal balance of the note in January 2018. At the time of the forgiveness, all of the related stock options were fully vested. As a result, the Company expensed the principal note balance of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> to stock-based compensation expense and accrued interest of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> to general and administrative expenses in the consolidated statement of operations in the year ended December 31, 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774248720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share of Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basic and Diluted Net Loss per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the computation of basic and diluted net loss per share (in thousands, except share and per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br clear="none"/>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used to compute basic and diluted net loss per share*</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,950,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,467,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted*</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*        Calculated based on the 1-for-18 reverse stock split effected October 4, 2018.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested shares for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were excluded from the weighted-average shares used to compute basic and diluted net loss per share.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares subject to repurchase</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,117</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated ESPP shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,657</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774146480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the Company&#8217;s loss before income taxes are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(618</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of income tax expense are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current tax expense:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax expense:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,513</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax at statutory federal rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State tax, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement of deferred taxes as a result of tax reform</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.25925925925925%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and reserves</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,835</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The following table summarizes changes in the valuation allowance for the year ended December 31, 2018 and 2017 (in thousands): </font></div><div style="line-height:120%;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions during the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$135.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$109.9 million</font><font style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. If not utilized, the Company&#8217;s federal net operating loss carryforward begins to expire in </font><font style="font-family:inherit;font-size:10pt;">2029</font><font style="font-family:inherit;font-size:10pt;">, and the state net operating loss carryforward begins to expire in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company had credit carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> available to reduce future taxable income, if any, for both federal and state income tax purposes, respectively. The federal credits begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2030</font><font style="font-family:inherit;font-size:10pt;">, and the state credits have no expiration date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carryforwards are subject to an annual limitation under Section 382 of the Internal Revenue Code (California has similar laws). The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company has not utilized any NOL carryovers through December 31, 2018. In addition, the Company&#8217;s deferred tax assets are subject to full valuation allowance, and thus no benefit for deferred tax assets have been recorded. The Company has determined that it experienced Section 382 ownership changes in 2010 and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of its NOLs are limited. The Company is currently performing an analysis to determine whether any additional NOL carryforwards are limited due to a change in ownership as a result of its recent IPO.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the uncertainty in income taxes by utilizing a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or are expected to be taken on an income tax return. The changes in the Company&#8217;s uncertain income tax positions for the years ended December 31, 2018 and 2017 consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.37037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance as of January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases in balances related to tax positions taken during 2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance as of December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases in balances related to tax positions taken during 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,084</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has elected to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The Company has accrued </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> at December 31, 2018 and 2017 for payment of interest related to unrecognized tax benefits. None of the Company&#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rate at December 31, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently has no federal or state tax examinations in progress nor has it had any federal or state examinations since inception. As a result of the Company&#8217;s net operating loss carry forwards, all of its tax years are subject to federal and state tax examinations.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the United States enacted a law commonly known as the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) which makes widespread changes to the Internal Revenue Code, including a reduction in the federal corporate tax rate to 21%, effective January 1, 2018.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. The carrying value of U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of deferred tax assets. Under the new corporate income tax rate of 21%, the U.S. net deferred tax asset position decreased by approximately </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">. Uncertainty regarding the impact of tax reform remains, as a result of factors including future regulatory and rulemaking processes, the prospects of additional corrective or supplemental legislation, potential trade or other litigation, and other factors.</font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the SEC staff issued Staff Accounting Bulletin No.&#160;118 (&#8220;SAB 118&#8221;), which provides guidance for the tax effect of the 2017 Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the 2017 Tax Act&#8217;s enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&#8220;ASC 740&#8221;). In accordance with SAB 118, the Company must reflect the income tax effects of those aspects of the 2017 Tax Act for which the accounting under ASC 740 is complete. To the extent that its accounting for certain income tax effects of the 2017 Tax Act is incomplete, but the Company is able to determine a reasonable estimate, the Company must record a provisional estimate in its consolidated financial statements. If the Company cannot determine a provisional estimate to be included in its consolidated financial statements, the Company should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the 2017 Tax Act. It is expected that the U.S. Treasury will issue regulations and other guidance on the application of certain provisions of the 2017 Tax Act. The Company has analyzed the guidance and other necessary information related to the tax effects of the 2017 Tax Act and considers the accounting of its net deferred tax assets complete in accordance with SAB 118.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783362800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the Company's accounts, as well as those of the Company's wholly-owned international subsidiaries. All inter-company accounts and transactions have been eliminated.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long-lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The chief operating decision makers for the Company are the Chief Executive Officer and Chief Financial Officer. The Chief Executive Officer and the Chief Financial Officer review financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s foreign subsidiaries use local currency as their functional currency. Assets and liabilities are translated at exchange rates prevailing at the balance sheet dates. Revenue, costs and expenses are translated into U.S. dollars using average exchange rates for the period. Gains and losses resulting from the translation of the Company&#8217;s consolidated balance sheets are recorded as a component of accumulated other comprehensive income. Gains and losses from foreign currency transactions are recognized as a component of other income (expense), net.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company&#8217;s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carrying amounts of certain of the Company&#8217;s financial instruments, including cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities, approximate fair value due to their relatively short maturities and market interest rates, if applicable. The carrying value of the Company&#8217;s long-term debt also approximates fair value based on management&#8217;s estimation that a current interest rate would not differ materially from the stated rate. The carrying amount of the redeemable convertible preferred stock warrants has been marked to fair value such that the carrying amount represents its estimated fair value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1: Quoted prices (unadjusted) in active market that are accessible at measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s cash equivalents consist of money market funds as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The money market funds are classified as Level&#160;1 of the fair value hierarchy. The Company's marketable securities are classified as Level 1 or Level 2 of the fair value hierarchy. The Company&#8217;s redeemable convertible preferred stock warrants are classified within Level&#160;3 of the fair value hierarchy. The redeemable convertible preferred stock warrants have been valued using a Black-Scholes valuation model and are subsequently marked to fair value at each reporting period. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with remaining maturities at the date of purchase of three months or less to be cash equivalents.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's marketable securities primarily consist of investments in U.S. treasury securities, corporate bonds, and commercial paper. We classify our marketable securities as available-for-sale at the time of purchase and reevaluate such classification as of each balance sheet date. Based upon maturity dates, all marketable securities as available for use in current operations, and therefore we classify these securities as current assets in the accompanying consolidated balance sheets. All marketable securities are recorded at their estimated fair value. Unrealized gains and losses on available-for-sale securities are recorded in Accumulated other comprehensive income (loss) ("OCI"). We evaluate our investments to assess whether those in unrealized loss positions are other-than-temporarily impaired. The Company considers impairments to be other-than-temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in Other income (expense), net on the consolidated statements of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">            If quoted prices for identical instruments are available in an active market, marketable securities are classified within Level 1 of the fair value hierarchy. If quoted prices for identical instruments in active markets are not available, fair values are estimated using quoted prices of similar instruments and are classified within Level 2 of the fair value hierarchy. To date, all of the Company's marketable securities can be valued using one of these two methodologies.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company generally does not require collateral or other security in support of accounts receivable. Allowances are provided for individual accounts receivable when the Company becomes aware of a customer&#8217;s inability to meet its financial obligations, such as in the case of bankruptcy, deterioration in the customer&#8217;s operating results or change in financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company also considers broad factors in evaluating the sufficiency of its allowance for doubtful accounts, including the length of time receivables are past due, significant one-time events, creditworthiness of customers and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory is stated at lower of cost or net realizable value. The Company establishes the inventory basis by determining the cost based on standard costs approximating the&#160;purchase costs&#160;on a&#160;first-in, first-out basis. The excess and obsolete inventory is estimated based on future demand and market conditions. Inventory write-downs are charged to cost of goods sold.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are amortized over the lesser of their useful lives or the life of the lease. Upon sale or retirement of the assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the consolidated statement of operations. Maintenance and repairs are charged to operations as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset&#8217;s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Public Offering Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public Offering Costs</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specific incremental costs (i.e. consisting of legal, accounting and other fees and costs) directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering. In the event a planned IPO does not occur or is significantly delayed, all of the costs will be expensed.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsClassifiedAsEquityPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for warrants for shares of common stock as equity in accordance with the accounting guidance for derivatives. The accounting guidance provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i)&#160;indexed to the entity&#8217;s own stock and (ii)&#160;classified in the stockholders&#8217; deficit section of the consolidated balance sheet. The Company determined that the warrants for shares of common stock issued in connection with its prior debt arrangements are required to be classified in equity. Warrants classified as equity are recorded as additional paid-in capital on the consolidated balance sheet and no further adjustments to their valuation are made.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock', window );">Redeemable Convertible Preferred Stock Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants and other similar instruments related to shares that are contingently redeemable are classified as liabilities on the consolidated balance sheet at their estimated fair value because the shares underlying the warrants may obligate the Company to transfer assets to the holders at a future date under certain circumstances such as a deemed liquidation event. The warrants are exercisable into the Company&#8217;s redeemable convertible preferred stock and are classified as liabilities on the consolidated balance sheet. The warrants, measured at fair value, are subject to re-measurement at each balance sheet date and the change in fair value, if any, is recognized as other income (expense), net. The Company adjusted the liability for changes in fair value until the the closing of our initial public offering, at which time certain preferred stock warrants were converted into warrants to purchase common stock and the liability was reclassified to additional&#160;paid-in&#160;capital.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimated the fair value of these liabilities using option pricing models and assumptions that were based on the individual characteristics of the warrants on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSalesOfGoods', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 605, Revenue Recognition (&#8220;ASC 605&#8221;), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company&#8217;s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Warranty Program</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warranty Program</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Company implemented a warranty program which provides a purchaser a one-time replacement of any iFuse implant at no additional cost for a revision procedure within a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period following the original procedure and is accounted for as a warranty accrual. The Company also provides a purchaser with a one-time credit equal to the purchase price paid for use on future purchases for any revision procedure within the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period following an original procedure where an implant is not required. These one-time credits are accounted for as sales reserves.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock', window );">Medical Device Excise Tax</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medical Device Excise Tax</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the Patient Protection and Affordable Care Act, effective January&#160;1, 2013, the Company began to incur an excise tax on sales of medical devices in the United States. The medical device excise tax is included in cost of goods sold in the consolidated statements of operations and comprehensive loss for all the periods presented. Effective December 2015, the Act was amended to include a provision to suspend the tax on medical devices through 2017. In January 2018, the suspension on the tax on medical devices was further extended through 2019.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shipping and handling costs are expensed as incurred and are included in cost of goods sold.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are charged to operations as incurred and consist of costs incurred by the Company for the development of the Company&#8217;s product which include (1)&#160;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense (2)&#160;external research and development expenses (3)&#160;other expenses, which include direct and allocated expenses for facilities and other costs.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost', window );">Advertising Expenditures</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expenditures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of advertising is included in Sales and Marketing expense in the consolidated financial statements and expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions including expected volatility, expected life, risk-free interest rate and expected dividends. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying equity instruments vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services received. Stock-based compensation related to stock options granted to nonemployees is recognized as the stock options are earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event the underlying terms of stock options are modified on which stock-based compensation was granted, additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement at the modification date.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the asset and liability method, whereby deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. The guidance also prescribes treatment for derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share of Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company calculates basic and diluted net loss per common share attributable to shareholders in conformity with the two-class method required for companies with participating securities. The Company considers all series of redeemable convertible preferred stock and early exercised stock options to be participating securities as the holders are entitled to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the two-class method, the net loss attributable to common stock is not allocated to the redeemable convertible preferred stock and early exercised stock options as the holders of redeemable convertible preferred stock and early exercised stock options do not have a contractual obligation to share in losses.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock and common stock options and warrants are considered to be potentially dilutive securities. Because the Company has reported a net loss in all periods presented, redeemable convertible preferred stock and common stock options and warrants are anti-dilutive and therefore diluted net loss per common share is the same as basic net loss per common share for those periods.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss represents all changes in the stockholders&#8217; equity (deficit) except those resulting from distributions to stockholders. The Company&#8217;s unrealized foreign currency translation income (losses) and unrealized gain (losses) of marketable securities represent the two components of other comprehensive income that are excluded from the reported net loss for each of the reporting periods and has been presented in the consolidated statements of operations and comprehensive loss.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 simplifies the guidance on the subsequent measurement of inventory, excluding inventory measured using last-in, first out or the retail inventory method. Under the new standard, in scope inventory should be measured at the lower of cost and net realizable value. The new standard will become&#160;effective for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2016, for public companies. For all other entities, the new standard is effective for fiscal years beginning after December&#160;15, 2016, and interim periods within fiscal years beginning after December&#160;15, 2017, with early adoption permitted. The Company has adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU 2015-17,&#160;Balance Sheet Classification of Deferred Taxes. ASU 2015-17 specifies that deferred tax assets and liabilities shall be classified as non-current, or long-term, in a classified statement of financial position. The new standard is effective for public entities for fiscal years beginning after&#160;December 15, 2016, and interim periods within those fiscal years. For private entities, the new standard is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within fiscal years beginning after December&#160;15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or an annual reporting period. The Company has early adopted this standard for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which did not have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, which simplified several aspects of accounting for stock-based compensation transactions. The areas for simplification in this update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new guidance is effective for public entities for fiscal years beginning after December&#160;15, 2016 and interim periods within those years. Other entities must apply the new guidance in fiscal years beginning after December&#160;15, 2017 and in interim periods within fiscal years beginning after December 15, 2018, with early adoption permitted. The Company early adopted this standard in the first quarter of 2017 by recording the cumulative impact of applying this guidance to retained earnings, which was not material. The Company elected to continue to&#160;estimate the number of awards&#160;that are expected to vest.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01. Recognition and Measurement of Financial Assets and Financial Liabilities, which amends Accounting Standards Codification, or ASC, Subtopic 825-10, Financial Instruments - Overall, and includes updates on certain aspects of recognition, measurement, presentation and disclosure of financial instruments and applies to all entities that hold financial assets or owe financial liabilities. The new standard is effective for the Company&#8217;s annual period beginning after December 15, 2018, with early adoption permitted beginning after December 15, 2017. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09, Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for all entities for fiscal years, including interim periods within those fiscal years, beginning after December&#160;15, 2017. Early adoption is permitted. The Company has adopted this standard for the fiscal year ending December 31, 2018, which did not have any impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Effective</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S.&#160;GAAP when it becomes effective. The new standard is effective for fiscal years beginning after December&#160;15, 2017 for public companies, and for fiscal years beginning after December&#160;15, 2018, and interim periods beginning after December&#160;15, 2019, for private companies. Early application is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. In March&#160;2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU 2014-09. In April&#160;2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May&#160;2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date as ASU&#160;2014-09. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to evaluate the impacts of adoption of the new standard on its accounting policies, processes, and system requirements and has assigned internal resources, in addition to the engagement of third party service providers, to assist in the evaluation.&#160;At this time, as  it relates to product sales where the Company's sales representative delivers the product at the point of implantation at hospital or other medical facilities, the Company expects revenue to continue to be recognized upon completion of the procedure&#160;and authorization by the customer. Additionally, the new standard requires the capitalization of costs to obtain a contract, primarily sales commissions, and amortization of these costs over the contract period or estimated customer life. The Company expects to continue expensing all sales commissions as incurred. Management will adopt the standard using the modified retrospective method for the fiscal year ending December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued its new lease accounting guidance. Under the new guidance, ASU 2016-02, Leases (Topic 842), lessor accounting is largely unchanged. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Under the new guidance, lessees will be required to recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control use of, a specified asset for the lease term for all leases (with the exception of short-term leases) at the adoption date. The new guidance is effective for fiscal years, and for interim periods within those fiscal years, beginning after December&#160;15, 2018 for public companies and beginning after December&#160;15, 2019 for private companies. Early adoption is permitted for any interim or annual financial statements net yet issued. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing and operating leases) must apply a modified retrospective approach for all leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15 &#8220;Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments&#8221;. ASU 2016-15 provides guidance on the following eight specific cash flow classification issues: (1)&#160;debt prepayment or debt extinguishment costs; (2)&#160;settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3)&#160;contingent consideration payments made after a business combination; (4)&#160;proceeds from the settlement of insurance claims; (5)&#160;proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6)&#160;distributions received from equity method investees; (7)&#160;beneficial interests in securitization transactions; and (8)&#160;separately identifiable cash flows and application of the predominance principle. Current GAAP does not include specific guidance on these eight cash flow classification issues. The amendments of this ASU are effective for reporting periods beginning after December&#160;15, 2017 for public companies, and fiscal years beginning after December&#160;15, 2018 and interim periods within fiscal years beginning after December 15, 2019 for private companies, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2016-15 on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part&#160;I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part&#160;II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. For public business entities, the amendments in Part&#160;I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. For all other entities, the amendments in Part&#160;I of this Update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02, Income Statement&#8212;Reporting Comprehensive Income (Topic 220).&#160;This update provides companies with the option to reclassify stranded tax effects caused by the 2017 Tax Cuts and Jobs Act (the 2017 Tax Act) from accumulated other comprehensive income to retained earnings. This standard is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU&#160;2018-07,&#160;Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07&#160;expands the scope of Topic 718,&#160;Compensation&#8212;Stock Compensation, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU&#160;2018-07 supersedes Subtopic&#160;505-50,&#160;Equity&#8212;Equity-Based Payments to&#160;Non-Employees. For public business entities, the amendments are effective for fiscal years beginning after December&#160;15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of ASC 606. The Company is currently evaluating the impact that the adoption of this standard will have on the consolidated financial statements, and anticipates adopting the standard for the fiscal year ending December 31, 2020.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Device Excise Tax Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MedicalDeviceExciseTaxPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WarrantsClassifiedAsEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WarrantsClassifiedAsEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants classified as liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WarrantsClassifiedAsLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs that are expensed, indicating whether such costs are expensed as incurred or the first period in which the advertising takes place.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054294&amp;loc=d3e8384-108330<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159346&amp;loc=d3e8275-108329<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostPolicyExpensedAdvertisingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSalesOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionSalesOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21459-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774100544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geography</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following table summarizes the Company's revenue by geography (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.74074074074075%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,380</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Useful Lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, net</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783096240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, marketable securities consisted of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935312320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font><font style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">[1]</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font><font style="font-family:inherit;font-size:8.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">[1]</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.51851851851852%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">[1]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents on the consolidated balance sheet</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of the Redeemable Convertible Preferred Stock Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the redeemable convertible preferred stock warrants, the Company&#8217;s Level&#160;3 financial liability, which is measured on a recurring basis (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:93%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value recorded in other (income) expense, net </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of preferred stock warrants to common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783096240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All property and equipment is depreciated on a straight-line basis over the estimated useful lives of the assets, which are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.11111111111111%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3&#160;&#8211;&#160;5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, net</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Machinery and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,918</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities and Other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities and Other </font><font style="font-family:inherit;font-size:10pt;">(in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:13px;" rowspan="1"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales tax payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for early exercise of unvested stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and warranty reserves</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774289936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Aggregate Future Minimum Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate future minimum lease payments under all leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935208672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Annual Future Minimum Principal Payments Under Loan Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approximate annual future minimum principal payments under the loan agreements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending at, December&#160;31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total future minimum payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount representing debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock', window );">Debt Covenant EBITDA Targets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The minimum net sales and trailing 12-month consolidated EBITDA targets are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:33px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Minimum Net Sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Trailing 12-Month Consolidated EBITDA</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">thereafter, as applicable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">or</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant EBITDA and Net Revenue Targets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantEBITDAandNetRevenueTargetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6774273136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Series</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:1px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liquidation&#160;Value </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,047</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,509,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,656</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,086,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,009,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,389,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,319,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,666,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,580,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,104,749</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,194</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935217184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Issued and Outstanding</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows(in thousands, except share and per share data): </font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.91642924976259%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of <br clear="none"/>Shares <br clear="none"/>Underlying <br clear="none"/>Warrants</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price&#160;per <br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants to purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total outstanding common stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[a]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants will remain outstanding until exercised by the holder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[b]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of issuance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[c]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of conversion from redeemable convertible preferred stock to common stock warrants in conjunction with the IPO on October 16, 2018.&#160;&#160;&#160;&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands, except share and per share data): </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of <br clear="none"/>Shares <br clear="none"/>Underlying <br clear="none"/>Warrants</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price&#160;per <br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrants to purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,928</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3/1/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[b]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series&#160;5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/1/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/25/2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[d]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,917</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/19/2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7/22/2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/26/2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10/20/2025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11/9/2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[e]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,283</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Series 7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12/22/2026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">[e]</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[c]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,550</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total outstanding common and redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280,876</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:18.99335232668566%;border-collapse:collapse;text-align:left;"><tr><td colspan="1" rowspan="1"></td></tr><tr><td style="width:100%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[a]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock warrants will remain outstanding until exercised by the holder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[b]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value at the date of issuance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[c]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Fair value as of December 31, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[d]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">These warrants will be net exercised immediately upon the closing of the Company&#8217;s IPO, or upon&#160;a corporate transaction as defined in the Note and Warrant Purchase Agreement dated July&#160;25, 2012. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">[e]</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Convertible preferred stock warrants will remain outstanding until exercised by the holder and will convert to common stock warrants upon an IPO. The warrants will be exercisable for </font><font style="font-family:inherit;font-size:8pt;">10 years</font><font style="font-family:inherit;font-size:8pt;"> from the date of issuance.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used In Computation of Fair Value of Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average assumptions used in computation of the fair value of the redeemable convertible preferred stock warrants are summarized in the table below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.07882241215574%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining contractual term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59.06</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935186496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has reserved shares of common stock, on an issued and as-converted basis, for future issuance as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.48148148148148%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Issued and <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock <br clear="none"/>Equivalent&#160;Shares</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,450,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 1 common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2 common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,871,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,760,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,787,177</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,986,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6603977376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> for all stock plans:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.25925925925927%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Contractual Remaining Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options canceled </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,762,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and expected to vest - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,366,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,154</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth stock-based compensation expense recognized for the periods presented (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.70370370370371%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br clear="none"/>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales and marketing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,471</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,312</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Related to Stock Option Awards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant date fair value of the stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4074074074074%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.71</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42%-47%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42%-55%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.35%-2.96%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.73%-2.31%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used to determine the grant date fair value of employee stock options and ESPP purchase rights for the periods presented are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.7037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43.96%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock units activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.77777777777777%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted- <br clear="none"/>Average <br clear="none"/>Grant Date Fair  <br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Unvested as of  December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,036</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Unvested as of  December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783133296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the computation of basic and diluted net loss per share (in thousands, except share and per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended<br clear="none"/>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used to compute basic and diluted net loss per share*</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,950,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,467,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted*</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*        Calculated based on the 1-for-18 reverse stock split effected October 4, 2018.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.29629629629629%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,641,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,929</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares subject to repurchase</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,117</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated ESPP shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,606</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,066,654</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,657</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,326</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935211216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the Company&#8217;s loss before income taxes are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(618</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of income tax expense are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current tax expense:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax expense:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">822</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,513</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense differs from the amount computed by applying the statutory federal income tax rate due to the following: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax at statutory federal rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State tax, net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement of deferred taxes as a result of tax reform</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in deferred tax valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are presented below (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.25925925925925%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and reserves</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,835</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax asset</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Changes in Valuation Allowance</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes changes in the valuation allowance for the year ended December 31, 2018 and 2017 (in thousands): </font></div><div style="line-height:120%;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions during the period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,412</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Uncertain Income Tax Positions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the Company&#8217;s uncertain income tax positions for the years ended December 31, 2018 and 2017 consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.37037037037037%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:84%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance as of January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases in balances related to tax positions taken during 2017</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance as of December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases in balances related to tax positions taken during 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance as of December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,084</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770906048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Nature of Business (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 16, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 04, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0556<span></span>
</td>
<td class="nump">0.0556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">12,066,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to additional paid-in capital related to warrants | $</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in IPO (in shares)</a></td>
<td class="nump">8,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">IPO share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from IPO | $</a></td>
<td class="nump">$ 113.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="nump">160,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember', window );">Preferred Stock Warrants | Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted', window );">Number of warrants converted (in shares)</a></td>
<td class="nump">156,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants or Rights Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770988336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenues (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 55,380<span></span>
</td>
<td class="nump">$ 47,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">50,137<span></span>
</td>
<td class="nump">43,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 5,243<span></span>
</td>
<td class="nump">$ 4,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770982912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 157,177<span></span>
</td>
<td class="nump">$ 139,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operations</a></td>
<td class="nump">14,519<span></span>
</td>
<td class="nump">17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">25,120<span></span>
</td>
<td class="nump">22,408<span></span>
</td>
<td class="nump">$ 27,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">97,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentCovenantMinimumCashBalance', window );">Debt covenant minimum cash balance</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Covenant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_RevenueTargetQuarterlyIncreasePercentage', window );">Quarterly increase in revenue target (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Covenant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_RevenueTargetQuarterlyIncreasePercentage', window );">Quarterly increase in revenue target (percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentCovenantMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentCovenantMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_RevenueTargetQuarterlyIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Target, Quarterly Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_RevenueTargetQuarterlyIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771674880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6646376640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6593853984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Public Offering Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs transferred to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_OfferingCostsExpensed', window );">Offering costs expensed</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_OfferingCostsExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Expensed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_OfferingCostsExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935266464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Warranty Program (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_StandardProductWarrantyTerm', window );">Warranty term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SalesCreditReservePeriod', window );">Sales credit reserve term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_SalesCreditReservePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Credit Reserve Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_SalesCreditReservePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_StandardProductWarrantyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_StandardProductWarrantyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6658195120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Advertising Expenditures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770972368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 97,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">97,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">22,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesAmortizedCost', window );">Total marketable securities, Amortized Cost</a></td>
<td class="nump">119,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total marketable securities, Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total marketable securities, Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_MarketableSecuritiesFairValue', window );">Total marketable securities, Aggregate Fair Value</a></td>
<td class="nump">119,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">65,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">65,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">19,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">11,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">6,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value</a></td>
<td class="nump">$ 15,223<span></span>
</td>
<td class="nump">$ 22,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amortized cost for marketable securities included in cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_MarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total aggregate fair value for marketable securities included in cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_MarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783653344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">15,223<span></span>
</td>
<td class="nump">22,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">66,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">19,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">18,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">15,223<span></span>
</td>
<td class="nump">22,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">66,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">19,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">18,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783482752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Redeemable Convertible Preferred Stock Warrants (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in fair value of redeemable convertible preferred stock warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recorded in other (income) expense, net</a></td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Conversion of preferred stock warrants to common stock warrants</a></td>
<td class="num">(1,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771404816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,518<span></span>
</td>
<td class="nump">$ 4,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(3,364)<span></span>
</td>
<td class="num">(3,022)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">3,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sibn_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6659825264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">$ 5,425<span></span>
</td>
<td class="nump">$ 3,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_LiabilityForEarlyExerciseOfOptionsCurrent', window );">Liability for early exercise of unvested stock options</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_SalesAndProductWarrantyAccrualCurrent', window );">Sales and warranty reserves</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other</a></td>
<td class="nump">$ 6,860<span></span>
</td>
<td class="nump">$ 5,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_LiabilityForEarlyExerciseOfOptionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Early Exercise Of Options, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_LiabilityForEarlyExerciseOfOptionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_SalesAndProductWarrantyAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales And Product Warranty Accrual, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_SalesAndProductWarrantyAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771124016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Aug. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sibn_SanJoseCaliforniaMember', window );">San Jose, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Non-cancelable operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Early termination fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sibn_SantaClaraCaliforniaMember', window );">Santa Clara, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Non-cancelable operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Costs to defend lawsuits or settle claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Costs accrued to defend lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sibn_SanJoseCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sibn_SanJoseCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sibn_SantaClaraCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sibn_SantaClaraCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6665015376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Aggregate Future Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent', window );">2019</a></td>
<td class="nump">$ 1,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 5,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rental payments receivable within one year of the balance sheet date under an operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164653&amp;loc=d3e41551-112718<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784307888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,963,000<span></span>
</td>
<td class="nump">$ 38,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,119,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment of debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,081,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,000<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentCovenantMinimumCashBalance', window );">Debt covenant minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sibn_SVBAndOxfordTermLoanMember', window );">SVB and Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment of debt extinguishment</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Term Loan | SVB and Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,200,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Debt period payment, interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod', window );">Debt period payment, principal and interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt financing</a></td>
<td class="nump">29,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Term Loan | SVB and Oxford Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Pharmakon Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
<td class="nump">$ 38,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod', window );">Debt period payment, interest only period</a></td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest stated percentage</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentClosingFeePercentage', window );">Debt closing fee percentage</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument fee amount</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentCovenantMinimumCashBalance', window );">Debt covenant minimum cash balance</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.30%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Pharmakon Term Loan | Prepayment Penalty, 31-48 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt prepayment penalty percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan | Pharmakon Term Loan | Prepayment Penalty, 49-60 Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt prepayment penalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility | SVB and Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable', window );">Line of credit percent of customer accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility | SVB and Oxford Term Loan | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentClosingFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentClosingFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentCovenantMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentCovenantMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPeriodicPaymentInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Principal And Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPeriodicPaymentPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtInstrumentPrepaymentPenaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtInstrumentPrepaymentPenaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Percent Of Customer Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_LineOfCreditFacilityPercentOfCustomerAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sibn_SVBAndOxfordTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sibn_SVBAndOxfordTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sibn_PharmakonTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sibn_PharmakonTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty3148MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty3148MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty4960MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtPrepaymentPenaltyPeriodAxis=sibn_PrepaymentPenalty4960MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771136848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Annual Future Minimum Principal Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2020</a></td>
<td class="nump">4,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2021</a></td>
<td class="nump">17,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2022</a></td>
<td class="nump">17,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total future minimum payments</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Amount representing debt discount</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total minimum payments</a></td>
<td class="nump">$ 38,963<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771892848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - EBITDA Targets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodOneMember', window );">Period One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodTwoMember', window );">Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">53,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodThreeMember', window );">Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">54,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodFourMember', window );">Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodFiveMember', window );">Period Five</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">57,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodSixMember', window );">Period Six</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">58,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodSevenMember', window );">Period Seven</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount', window );">Debt Covenant, Minimum Net Sales</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA', window );">Debt Covenant, Trailing 12-Month Consolidated EBITDA</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Minimum Net Sales, Trailing Twelve Months, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantMinimumNetSalesTrailingTwelveMonthsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant Trailing 12-Month Consolidated EBITDA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantTrailing12MonthConsolidatedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DebtCovenantPeriodAxis=sibn_PeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DebtCovenantPeriodAxis=sibn_PeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781262208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - IPO Narrative (Details) - shares<br></strong></div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">12,066,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
<td class="nump">11,330,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6786606000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Preferred Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>vote </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,104,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,330,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 118,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 119,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect', window );">Series 2 common stock, number of directors entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding', window );">Shareholder approval, minimum shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred stock dividends declared (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock dividends declared (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion', window );">Minimum public offering for conversion | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion', window );">Minimum public offering per share for conversion (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series 1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.352941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.050112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series 2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">709,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">709,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">709,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.352941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.171360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series 3 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.352941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series 4 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,509,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,509,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,509,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PreferredStockNumberOfDirectorsEntitledToElect', window );">Preferred stock, number of directors entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityLiquidationParticipationCapPerShare', window );">Liquidation participation cap per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series 5 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,086,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,009,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,009,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PreferredStockNumberOfDirectorsEntitledToElect', window );">Preferred stock, number of directors entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityLiquidationParticipationCapPerShare', window );">Liquidation participation cap per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.1908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series 6 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,389,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,319,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,319,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PreferredStockNumberOfDirectorsEntitledToElect', window );">Preferred stock, number of directors entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.317744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.4718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityLiquidationParticipationCapPerShare', window );">Liquidation participation cap per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.9436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ConvertiblePreferredStockConversionPrice', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5574<span></span>
</td>
<td class="nump">$ 15.714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series 7 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityRightsToVotesForEachShare', window );">Preferred stock votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_PreferredStockNumberOfDirectorsEntitledToElect', window );">Preferred stock, number of directors entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividend rate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.802656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Series Two, Number Of Directors Entitled To Elect</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_CommonStockSeriesTwoNumberOfDirectorsEntitledToElect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Minimum Public Offering For Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ConvertiblePreferredStockMinimumPublicOfferingForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Minimum Public Offering Per Share For Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_PreferredStockNumberOfDirectorsEntitledToElect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Number Of Directors Entitled To Elect</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_PreferredStockNumberOfDirectorsEntitledToElect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityLiquidationParticipationCapPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Liquidation Participation Cap Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityLiquidationParticipationCapPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityRightsToVotesForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Rights To Votes For Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityRightsToVotesForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shareholder Approval, Minimum Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityShareholderApprovalMinimumSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784619168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - IPO Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 16, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to additional paid-in capital related to warrants | $</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted', window );">Number of warrants converted (in shares)</a></td>
<td class="nump">156,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="nump">160,657<span></span>
</td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series 6 Preferred Stock | Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsConversionRatio', window );">Warrant conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants or Rights Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WarrantsConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WarrantsConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6787466752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Issued and Outstanding (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 01, 2017</div></th>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Nov. 09, 2015</div></th>
<th class="th"><div>Oct. 20, 2015</div></th>
<th class="th"><div>Nov. 26, 2014</div></th>
<th class="th"><div>Jul. 19, 2013</div></th>
<th class="th"><div>Jul. 01, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">160,657<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Warrants Issued 7/19/2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">32,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Warrants Issued 11/26/2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Warrants Issued 3/1/2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Warrants Issued 10/20/2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">41,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="nump">$ 396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Warrants Issued 11/9/2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">25,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Warrants Issued 12/22/2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">9,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise period from date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series 5 Preferred Stock | Warrants Issued 7/1/2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series 5 Preferred Stock | Warrants Issued 7/19/2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series 6 Preferred Stock | Warrants Issued 11/26/2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series 6 Preferred Stock | Warrants Issued 10/20/2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series 6 Preferred Stock | Warrants Issued 11/9/2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember', window );">Series 7 Preferred Stock | Warrants Issued 12/22/2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Underlying Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Outstanding, Fair Value On Date Of Issuance Or Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_WarrantsOutstandingFairValueOnDateOfIssuanceOrConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedJulyNineteenthTwentyThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberTwentySixthTwentyFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedMarchFirstTwentySeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedMarchFirstTwentySeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedOctoberTwentiethTwentyFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedNovemberNinthTwentyFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedDecemberTwentySecondTwentySixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantsNotSettleableInCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantsNotSettleableInCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedJulyFirstTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sibn_WarrantsIssuedJulyFirstTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772775968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Weighted-Average Assumptions in Computation of Fair Value (Details) - Warrants<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Remaining contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.5389<span></span>
</td>
<td class="nump">0.5906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.0262<span></span>
</td>
<td class="nump">0.0216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772225040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">19,333,333<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">19,333,333<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Series 1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Series 2 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod', window );">Increase in common stock authorized (in shares)</a></td>
<td class="nump">555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">13,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Authorized, Increase During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_CommonStockSharesAuthorizedIncreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772151824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares of Stock Issued and Reserved (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">24,450,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,603,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
<td class="nump">11,330,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">2,641,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_CommonStockEquivalentSharesStockOptionsOutstanding', window );">Stock options outstanding, common stock equivalents (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options available for grant (in shares)</a></td>
<td class="nump">2,497,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance', window );">Total issued and reserved for issuance (in shares)</a></td>
<td class="nump">29,760,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,787,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance', window );">Total issued and reserved for issuance, common stock equivalents (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,986,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Series 1 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,112,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Series 2 Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">160,657<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights', window );">Warrants to purchase shares of stock, common stock equivalents (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,871,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares', window );">Redeemable convertible preferred stock outstanding, common stock equivalents (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,066,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights', window );">Warrants to purchase shares of stock, common stock equivalents (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">53,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock equivalent shares related to potential conversion of warrants into common stock, preferred stock, or temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ClassofWarrantorRightNumberofCommonStockEquivalentSecuritiesCalledbyWarrantsorRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_CommonStockEquivalentSharesStockOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock equivalent shares related to potential exercise of stock options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_CommonStockEquivalentSharesStockOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity And Temporary Equity, Common Stock Equivalent Shares Issued And Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity And Temporary Equity, Shares Issued And Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock equivalent shares related to potential conversion of temporary equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_TemporaryEquityCommonStockEquivalentSharesIfConvertedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6787453120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">49 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase', window );">Early exercise of stock options, share subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,019<span></span>
</td>
<td class="nump">16,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_LiabilityForEarlyExerciseOfOptionsCurrent', window );">Liability for early exercise of unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,000<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_NotesReceivableForgiveness', window );">Forgiveness of notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grant price of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, expected period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares', window );">Exercise price of option as percent of fair market value when individual owns more than 10% of shares outstanding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sibn_IncentiveStockOptionMember', window );">Incentive Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue', window );">Exercise price of option as percent of fair market value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sibn_NonqualifiedStockOptionMember', window );">Nonqualified Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue', window );">Exercise price of option as percent of fair market value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares', window );">Expiration period when individual holds more than 10% of shares outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,312,000<span></span>
</td>
<td class="nump">$ 1,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Grant price of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified', window );">Number of options with modification of terms (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock-based compensation expense to be recognized related to modification of terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Vesting Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Vesting Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2008StockOptionPlanMember', window );">2008 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,350,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,350,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,576,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">515,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as a percent of fair market value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval', window );">Employees stock purchase program offering period interval (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_LiabilityForEarlyExerciseOfOptionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Early Exercise Of Options, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_LiabilityForEarlyExerciseOfOptionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_NotesReceivableForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_NotesReceivableForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Expiration Period For Individual Owning More Than 10% Of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodForIndividualOwningMoreThanTenPercentOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Interval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriodInterval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercise, Common Stock Subject To Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercise Price As Percent Of Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Option, Exercise Price As Percent Of Fair Market Value For Individual Owning More Than 10% Of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfFairMarketValueForIndividualOwningMoreThanTenPercentOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Options Modified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationOptionsModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sibn_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sibn_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sibn_NonqualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sibn_NonqualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sibn_A2008StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sibn_A2008StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sibn_A2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sibn_A2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935436544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Stock Option Activity  (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">3,001,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">100,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(395,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options canceled (in shares) | shares</a></td>
<td class="num">(65,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,641,198<span></span>
</td>
<td class="nump">3,001,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable (in shares) | shares</a></td>
<td class="nump">1,762,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">2,366,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">8.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">4.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">4.27<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life, options outstanding (in years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, options vested and exercisable (in years)</a></td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, options vested and expected to vest (in years)</a></td>
<td class="text">6 years 5 months 27 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value | $</a></td>
<td class="nump">$ 43,905<span></span>
</td>
<td class="nump">$ 3,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, options vested and exercisable | $</a></td>
<td class="nump">41,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, options vested and expected to vest | $</a></td>
<td class="nump">$ 40,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935392976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Stock-Based Compensation Expense (Details) - Stock Options - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,312<span></span>
</td>
<td class="nump">$ 1,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,471<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6771027904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Weighted Average Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 30 days<span></span>
</td>
<td class="text">5 years 8 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percent)</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percent)</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (percent)</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770378240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Restricted Stock Unit Activity (Details) - Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">54,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">53,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">20.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, ending balance (in dollars per share)</a></td>
<td class="nump">$ 11.69<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783472576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Incentive Compensation Plans - Employee Stock Options and ESPP Purchase Rights (Details) - Stock Options and ESPP Purchase Rights<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (percent)</a></td>
<td class="nump">43.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (percent)</a></td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sibn_StockOptionsandESPPPurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sibn_StockOptionsandESPPPurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6784698736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Mar. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Repayment of stockholders&#8217; notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,108<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock', window );">Stockholders&#8217; notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Stockholders' note interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Repayment of stockholders&#8217; notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock', window );">Stockholders&#8217; notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Stockholders' note interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer | Forgiveness of Related Party Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven', window );">Notes receivable forgiven</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness', window );">Notes receivable percentage of principal approved for forgiveness</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable From Officers And Directors For Issuance Of Capital Stock, Forgiven</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockForgiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable From Officers And Directors For Issuance Of Capital Stock, Percentage Of Principal Approved For Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStockPercentageOfPrincipalApprovedForForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts receivable from officers and directors resulting from the sale of stock to officers or directors before the cash payment is received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableFromOfficersAndDirectorsForIssuanceOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sibn_ForgivenessOfRelatedPartyPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sibn_ForgivenessOfRelatedPartyPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763470544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,453)<span></span>
</td>
<td class="num">$ (23,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used to compute basic and diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,950,284<span></span>
</td>
<td class="nump">3,467,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">$ (6.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.0556<span></span>
</td>
<td class="nump">0.0556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6786319040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">2,641,198<span></span>
</td>
<td class="nump">3,001,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_ShareSubjectToRepurchaseMember', window );">Shares subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">74,019<span></span>
</td>
<td class="nump">16,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">53,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_EmployeeStockPurchasePlanSharesMember', window );">Estimated ESPP shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">89,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,066,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_RedeemableConvertiblePreferredStockWarrantsMember', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">160,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from the computation of diluted net loss per share</a></td>
<td class="nump">118,122<span></span>
</td>
<td class="nump">124,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_ShareSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_ShareSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_EmployeeStockPurchasePlanSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_EmployeeStockPurchasePlanSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_RedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_RedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sibn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6772296352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of loss before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (16,835)<span></span>
</td>
<td class="num">$ (22,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(618)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">$ (17,453)<span></span>
</td>
<td class="num">$ (23,039)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6770345808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">3,555<span></span>
</td>
<td class="num">(9,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">4,577<span></span>
</td>
<td class="num">(7,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in deferred tax valuation allowance</a></td>
<td class="num">(4,577)<span></span>
</td>
<td class="nump">7,513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance', window );">Net deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Expense (Benefit), Net Of Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6775004464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate (percent)</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit (percent)</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Measurement of deferred taxes as a result of tax reform (percent)</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">68.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits (percent)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax valuation allowance (percent)</a></td>
<td class="nump">26.20%<span></span>
</td>
<td class="num">(32.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense (percent)</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935237056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 35,067<span></span>
</td>
<td class="nump">$ 32,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset, gross</a></td>
<td class="nump">40,412<span></span>
</td>
<td class="nump">35,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(40,412)<span></span>
</td>
<td class="num">(35,835)<span></span>
</td>
<td class="num">$ (43,348)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6935305968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_IncomeTaxesValuationAllowanceRollForward', window );"><strong>Changes in Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, beginning balance</a></td>
<td class="nump">$ 35,835<span></span>
</td>
<td class="nump">$ 43,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Additions (Deductions) during the period</a></td>
<td class="nump">4,577<span></span>
</td>
<td class="num">(7,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, ending balance</a></td>
<td class="nump">$ 40,412<span></span>
</td>
<td class="nump">$ 35,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_IncomeTaxesValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Valuation Allowance [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_IncomeTaxesValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6773543264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Uncertain Income Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Uncertain income tax positions [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain income tax positions, beginning balance</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases in balances related to tax positions taken during current period</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain income tax positions, ending balance</a></td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783637840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_OperatingLossCarryforwardsLimited', window );">Limited net operating loss carryforwards</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate', window );">Decrease in net deferred tax asset position due to change in tax rate</a></td>
<td class="nump">15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">135,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforwards</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">109,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Credit carryforwards</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Net Deferred Tax Asset Position, Change In Enacted Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_IncreaseDecreaseInNetDeferredTaxAssetPositionChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sibn_OperatingLossCarryforwardsLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Limited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sibn_OperatingLossCarryforwardsLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sibn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=AZ;?;F'QM?!+L6?MU%]P502P,$%     @ *X1N3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M:R>?G+@^#ET]S+_!X648NV9MQ5EIRI_+M6KGZW5M_RU,#L U &\!D'P8H-8
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M!.?H&94?#J:?!O@CB3\=\B]EN>=&-7XH&(\:\)$D'P>1O]!.QC(N\H/!#-4
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M;YMQS4;'83>](#8_X^(O4$L#!!0    ( "N$;DZQ=H<DM $  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5/;;IPP$/T5RQ\0[P)ITQ4@95-5
MK=1(JU1-GKTP@!5?J&V6Y.\[-H30%O7%]HSGG#DS'N>CL<^N _#D14GM"MIY
MWQ\8<U4'BKLKTX/&F\98Q3V:MF6NM\#K"%*2);O=!Z:XT+3,H^]DR]P,7@H-
M)TO<H!2WKT>09BSHGKXY'D3;^>!@9=[S%GZ _]F?+%IL8:F% NV$T<1"4]#;
M_>&8A?@8\"A@=*LS"96<C7D.QK>ZH+L@""14/C!PW"YP!U(&(I3Q:^:D2\H
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M86_<( S]*X@?4!+NUG6G)%*OT[1)FW3JM/8SES@)*H04R*7[]S,D3;,MVQ?
MQN_YV9AL-/;)M0">O&C5N9RVWO<'QES9@A;NRO30X4UMK!8>3=LPUUL0501I
MQ7B27#,M9$>++/I.MLC,X)7LX&2)&[06]N<1E!ESFM)7Q[UL6A\<K,AZT<!W
M\#_ZDT6++2R5U- Y:3IBH<[I;7HX[D-\#'B0,+K5F81*SL8\!>-+E=,D" (%
MI0\, K<+W(%2@0AE/,^<=$D9@.OS*_NG6#O6<A8.[HQZE)5O<WI#206U&)2_
M-^-GF.MY1\E<_%>X@,+PH 1SE$:YN))R<-[HF06E:/$R[;*+^SC=[#[,L&T
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MYGIN*9F+_PH7D!@>E&".TD@75U(.SALULZ 4)=ZFO=-Q'Z>;] K;!O 9P!?
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M+AQO_-E,8S893O?S#R++-R[_ E!+ P04    "  KA&Y.F9C1C;,!  #2 P
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MZ_#=JL)=@N_^47A8)]BO$NP3P?Z_):[%O'^5A"UZJL$U:9H\*6UOTB0OO//
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MIG@.!%36;S^[O1[?\AA8U4UC2N;_BOP=4$L#!!0    ( "N$;DX[?'VWM@$
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MY$8I"RZ5Y,;ETKDN7A8<&NNG[M4A/;WE:6%5/[<I6?X5Y5]02P,$%     @
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MQ;CIUL[5T%^&A9'=V#KIU+_SOU!+ P04    "  KA&Y.T)I:R]D"  !_"P
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M8\\9>RF5T)QHIMF.^C3<#7*Q5^8VUO=U>R1L!TI6[K@;=&?NY3]02P,$%
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MX"34,I9KUD^*?B-H.TQ!9QS%^5]02P,$%     @ *X1N3G*&SYJ3 @  Q @
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MIVVD-& 3C.[L.'=VV1>#06/<]<'>51CY8!@YS-M,EK^4\C]02P,$%     @
M*X1N3BR[)#,7 @  \@4  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
MA53;CILP$/T5Y ]8$R#L)@*D3:*JE5HIVJKMLT,F :V-J>V$[=_7%T*X*9L'
ML(=SSIR9V),T7+S+ D!Y'XQ6,D6%4O4:8YD7P(A\XC54^LN)"T:4WHHSEK4
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M5A<X\06!@,IZ!N:6"SR $)[(E?%GX<2KI$_<VF_L7T+OKI<S,_"@Q&]>VZ[
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M]7!X'1Y:=1P/YM[YOP.K/U!+ P04    "  KA&Y.<G03[-<#  !?%@  &0
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MK-FO^B7/_L":P["<&YW6E-?_ %!+ P04    "  KA&Y.Z!BIE/ !   #!0
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MJ6L4="_UZT2]\^;JT#0DJ]MKD=/=S9)_4$L#!!0    ( "N$;D[]Z<J^^0$
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M-G?RK5VI@TJWUX=,[9KN:]A^KX:KR^&A*4_Z6M:_W@TO_P=02P,$%     @
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M\]5>&).@'+TG55FMSO%Y0.$B=3=1?3Z>9N- LGXZJ-'\MRC^ %!+ P04
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MF;X778/<#11O7?,?]5\@J[]02P,$%     @ *X1N3F9E(XCK 0  #P4  !D
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M3F- H91ZNU%[/ORC0R!99Z\?--Z!V5]02P,$%     @ *X1N3O5(/'T&!P
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MBW:#D,) I$#V7@Q""C."% 8AA:&0P@PLVCO5[9#*K0?AA*%PP@PM[?N"1NT
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MG>E!*2U-E&AAHCR9EY5I4LF#[H>Y&;=CQSY.M#K;MY%D>B5:_P502P,$%
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MN*7LC>>$".N]*FN^M7,AFHWC\"PG%>8KVI!:?CE15F$AI^SL\(81?-1&5>E
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M;O@X$L>HP",-4; A"C0T\JME($$VW9(<),@G6))[4K/$2+TRQ$<ABM#($U*
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MT3D.O);VUSM<I.+-Z*)1&OH^/*O6/OO1_Q8&!Z Q $T!$?DP (\!^'\#R!A
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ME=FN]%ZXF> .BG?#N$/CS"W_ 5!+ P04    "  KA&Y.8$H+,P@"  !S!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q]5-N.FS 0_17$!ZRY)QL!
MTH:J:J56BK9J^^R0":"U,;6=L/W[^D)80JR^8'LX<^8<,TP^,OXF6@#IO5/2
MB\)OI1QV"(FZ!8K%$QN@5V_.C%,LU9$W2 P<\,DD48*B(,@0Q5WOE[F)'7B9
MLXLD70\'[HD+I9C_W0-A8^&'_BWPVC6MU %4Y@-NX ?(G\.!JQ.:64X=A5YT
MK/<XG O_)=Q5F<8;P*\.1K'8>]K)D;$W??AZ*OQ "P("M=0,6"U7J( 03:1D
M_)DX_;FD3ESN;^R?C7?EY8@%5(S\[DZR+?RM[YW@C"]$OK+Q"TQ^4M^;S'^#
M*Q %UTI4C9H189Y>?1&2T8E%2:'XW:Y=;]9QXK^EN1.B*2&:$\+LOPGQE!!_
M)"3&O%5FK'["$I<Y9Z/'[<<:L.Z)<!>KRZQUT-R=>:?<"A6]EMLPR=%5$TV8
MO<5$"TPX(Y!BGTM$KA+[Z"$]NB]0/2+BC;M"[#01F_SXSD3J)DB<!(DA2.X(
MLM4M6$QF,+W!/#_'*R,.3!JXA:1.(:E#R&8EQ&+299%PI>,1DL1N&9E31N:0
ML5W)R!Z\AL%VU3K5(VAY:58)6O0J!=Z8WUIX-;OT4G?%(CI/CI=(]_HJOE<3
MQ0Z #QH[CKYCWG2]\(Y,JC_)]/N9,0E*8O"DKJE5$W ^$#A+O=VH/;=SP!XD
M&Z81A^8Y6_X#4$L#!!0    ( "N$;D[=M("56 (  -,'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<U+GAM;(U5VXZ;,!#]%<0'K&VN(2)(2:JJE5HIVJK;
M9X<X :W!U';"]N]K&\(2<*+D(=CCF7/F#(PG;1E_%P4ATOFH:"U6;B%ELP1
MY 6IL'AA#:G5R9'Q"DNUY2<@&D[PP015%'@01J#"9>UFJ;'M>):RLZ1E37;<
M$>>JPOS?AE#6KESD7@VOY:F0V@"RM,$G\HO(W\V.JQT84 YE16I1LMKAY+AR
MUVBY18$.,!YO)6G%:.UH*7O&WO7F^V'E0IT1H227&@*KQX5L":4:2>7QMP=U
M!TX=.%Y?T;\:\4K,'@NR9?1/>9#%REVXSH$<\9G*5]9^([V@T'5Z]3_(A5#E
MKC-1'#FCPOP[^5E(5O4H*I4*?W3/LC;/MCN)KV'V *\/\(8 %#T,\/L _S/
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M4'WG0C6OV>Q5E"&97C,R6 )GQA[$\]D@GLSFWS+VV3N0&+,U"T6\DQ3I E(
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M1#\$_[:@FP.D>=#_7L>M*?):]^((&0$#Q;LF[V*,.# ]3)AMD664 +Y>]+9
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M9%%);8VHM2Q)!4K6@#HLD LI9[4WVR[W9<7V 2'16;F^V"7HV=XE3P5BP=[
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MD"T.JPV:07 U3 :1"YL8QN#NV./;%MQIA<JC,_0CV<NWA=,IUH8:FQ!<F/9
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M<KM/R$1,=B..^*=E8(6UPLF]\A/ENZK<(+XU4NJ=\3*_^&[;EW?8P]$(M='
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M9)UME 9(EG^2APUYBJ65T2T/H+YKU_>FIB,.@+EEF6VOFCA^4N;<?,#Q"C?
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M*F+"F[*5)F19?#2GUSRL1J@%Y^H8'=#$'/Y*(&S Z-<\'<EZH>A\&V"S]U)
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M1!U;/%OIK>SK1IR1K72G/1J<W;E';;PUQ4I*LJ>NE85BIF%'W':E,G$Z&H*
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MKX_@]<4"Y3-41-',&!*7B-'L6 R/= <8I(7Q#L:ZXAR7B6QW.)ZQI#N6:-=
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MHT0U!Q#J0A9MB;U+XPUF98W+KW*'FV&/<./JE./Y)N!+?0=CF*V[&11O.$<
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M=9_'-E.4 A(!EN]F*IV91>']RXL<8^XY/*?R$ _SCVT6EE\OW$F_.L9SO+T
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M#; H-!IM2"8<Q./9 /X[A/]BC>(1ARC&\]E$ZI9+MG>T+IRVD93-/W9;O9P
M*--)# !U#Y-3UT=..TO=\KFGB'FSB.P&VL7U5UZ \6LV3O:@W-ER&8_<!D2G
M.[I]TOD+O=W%G>%:C8&SJMT*IJ/#M:6KY$:NLCHUO>Q\PIH\@@9?/6,5Z(EH
MNN-I(,>A2G[-_PXON!/;SL90:WUO;XA8;HCUAT49HG>;)]V?#P6T#SW I02V
MQ?E-XG!K&DB:,X0,)J\EA:T6W\C:N$8DXU-DAT;-I_"J33$3A"H%QN*'#@N7
M%Z@2 M?!J31G&W.0U9;B\VN$@K)@=GU9FUCAX8"#$G>)E!MRZZ"O4^R3S7V<
M;7-/<Y>JL(,79&SNWNK0WUBK^(=W>)I[/SR=;19/S=>H!1]F=4L!+^X1(B*
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M^: AH7"\B^/>IL63$'88.D:O=VR,.RJAFK.P0EV&"3\UXSL7)SOV5,&Q.;M
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MI>7PU9,I5<)*@N2@H5_@FC%/$LB(Z1+0F3_MRFM9[FMZ@-^,/1SZC&2N3!]
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M^/2<M1C:$EQ4<$T]C #$,63)9-RPKV FBFBD-A\1'MB7A-AB^"+>0A$(LJ!
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M@A?#F*\_<Q[T%M,7-I_.#M)GW19!0$,+4"5]N=),K A:>("7DV9KENL="YA
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MJOAZ, TU8SD;%97.X[?C(K@YW+SJW(DV:UFE5&C#X%N5E*MJ-_OL [02\2@
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M]F9Y#J>LY!>SX)JVU*1M5I1]6$WE>P>RF*Q[Y1[7F(Q1.=,_B[QUD N*'D/
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M&];ADSFE L8DW)FJ '0+LXO>\XPKPX)2+GAV@]O@E?@Y2/L(?C]79Z,[,=]
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M@%IJ-+,;0JA/M+3HS29MRY+%"L!C$1D14<;T(%YN-_>KW0[P@-]%PA3?508
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M/\$FI)S_1.M_V.WV_^O_ E!+ P04    "  KA&Y.-1L0T(D"  !<$   #0
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M>I!? QG7_"2$-5]K#[CV?*\] -OSQ?: ;,\WVP.T/5]M#]CV?+<]@-OSY?:
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M?+T-Z&U\O0WH;7R]#>AM?+T-Z&T+/&N"'C;AZVU ;^/K;4!OX^MM0&_CZYV
MWHFO=P)Z)[[>">B=^'HGH'?BZYV WHFO=P)Z)[[>::)W.=9]WOT8^E-S*+<N
M^6?XES43N,OP<<ZWS[A._7+_1.EAW)+=]?7F?_'KU#\1;EI1GGX#4$L#!!0
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MK!6*K!6*K!6*K!6*K-4)99V/Y6"[\:,D]\[MWN:S^1^^5\]02P$"% ,4
M"  KA&Y.'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    "  KA&Y.)^B'#H(   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "N$;DZQ&7--[P   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( "N$;DZ97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ *X1N3CWL4WBZ @  *0L  !@
M         ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( "N$;DZ-B,43T@,  ,H1   8              "  >@+  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  KA&Y.&_CSM+("  !U"@
M&               @ 'P#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ *X1N3FKG28)P P  $0X  !@              ( !V!(  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "N$;DZ'[ .,;P4
M .0<   8              "  7X6  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  KA&Y.DZ<JHE,%  !/'   &               @ $C
M'   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ *X1N3G;2
M!>>O 0  T@,  !@              ( !K"$  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( "N$;DZQ=H<DM $  -(#   8
M  "  9$C  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  K
MA&Y.R::F;[4!  #2 P  &               @ %[)0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ *X1N3L^O%">U 0  T@,  !D
M         ( !9B<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  KA&Y.#&@^D+ !  #2 P  &0              @ %2*0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "N$;D[O@?X"M $  -(#
M   9              "  3DK  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ *X1N3L8UML>U 0  T@,  !D              ( !)"T
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  KA&Y.QS7T
MUK0!  #2 P  &0              @ $0+P  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( "N$;DY,^>;BM $  -(#   9
M  "  ?LP  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M*X1N3L1>;):T 0  T@,  !D              ( !YC(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  KA&Y.=[CV';8!  #2 P  &0
M            @ '1-   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( "N$;DZ9F-&-LP$  -(#   9              "  ;XV  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ *X1N3K?7:VZU 0
MT@,  !D              ( !J#@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  KA&Y.QV&"MK8!  #2 P  &0              @ &4
M.@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "N$;DXG
M":#\LP$  -(#   9              "  8$\  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ *X1N3ODIG741 P  4PX  !D
M     ( !:SX  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N$;DX[?'VWM@$  -(#   9              "
M 9))  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ *X1N
M3E7O<^3% 0  -P0  !D              ( !?TL  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  KA&Y.(@Q+"K8!  #2 P  &0
M        @ %[30  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( "N$;DY1=8"!P@$  #<$   9              "  6A/  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ *X1N3H5DE;2X 0  T@,
M !D              ( !85$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  KA&Y..&Y.H=X!   !!0  &0              @ %04P
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "N$;DY%\Y+%
MP0$  #<$   9              "  655  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ *X1N3B\I\9+X 0  RP4  !D
M ( !75<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  K
MA&Y.T)I:R]D"  !_"P  &0              @ &,60  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "N$;DX1$98!6@(  )8'   9
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M970T,"YX;6Q02P$"% ,4    "  KA&Y.,?0QDL0!   W!   &0
M    @ &_:   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M "N$;DXZ[L#CW $  &0$   9              "  ;IJ  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ *X1N3EP608A? P  *1   !D
M             ( !S6P  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  KA&Y.<G03[-<#  !?%@  &0              @ %C<   >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "N$;D[H&*F4\ $
M  ,%   9              "  7%T  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ *X1N3JC>B>7= @  8@L  !D              ( !
MF'8  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  KA&Y.
MXWD^>TT"  "2!P  &0              @ &L>0  >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( "N$;DXPK!Y1FP(  *<)   9
M      "  3!\  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ *X1N3OWIRK[Y 0  O 4  !D              ( ! G\  'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  KA&Y._5DB_%($   G%@
M&0              @ $R@0  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( "N$;DYZM;9H% (  #D&   9              "  ;N%  !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ *X1N3NI!<?_?
M @  C0P  !D              ( !!H@  'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    "  KA&Y.9F4CB.L!   /!0  &0
M@ $<BP  >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( "N$
M;D[U2#Q]!@<  )PI   9              "  3Z-  !X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ *X1N3I?UJEM\ @  ! D  !D
M         ( !>Y0  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
M    "  KA&Y.\FYSY*X%  !N)   &0              @ $NEP  >&PO=V]R
M:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( "N$;D[Y&4^<*@(  $<'
M   9              "  1.=  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
M4$L! A0#%     @ *X1N3H-0\$O7 @  (PL  !D              ( !=)\
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  KA&Y.20%
MUF0#  "]#@  &0              @ &"H@  >&PO=V]R:W-H965T<R]S:&5E
M=#4Y+GAM;%!+ 0(4 Q0    ( "N$;DY$Z*3_#04  $T;   9
M  "  1VF  !X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M*X1N3C(%VU%( P  '@T  !D              ( !8:L  'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    "  KA&Y.1J+I>'("  "A"   &0
M            @ '@K@  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( "N$;D[JB[VP+P(   \'   9              "  8FQ  !X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ *X1N3KR @IJ% @
MAP@  !D              ( ![[,  'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    "  KA&Y.X:E4(N0!   !!0  &0              @ &K
MM@  >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "N$;DY,
MT+9!\0(  *D+   9              "  <:X  !X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ *X1N3M_Y/^ F @  +P8  !D
M     ( ![KL  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N$;DX[;C8C40(  ) '   9              "
M >[(  !X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ *X1N
M3N8ET*40 @  ?P4  !D              ( !=LL  'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6Q02P$"% ,4    "  KA&Y.8$H+,P@"  !S!0  &0
M        @ &]S0  >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0
M   ( "N$;D[=M("56 (  -,'   9              "  ?S/  !X;"]W;W)K
M<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ *X1N3L/:FI#3JP  T;L"
M !0              ( !B](  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ *X1N3C4;$-") @  7!    T              ( !D'X! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  KA&Y.IG05IM@%  #",0  #P
M    @ %$@0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ *X1N3F[%".EF
M @  ]BP  !H              ( !28<! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ *X1N3M\)R204 @  Z2L  !,
M ( !YXD! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %0 5 #^%@  +(P!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>234</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/ConsolidatedStatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - The Company and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CompanyAndNatureOfBusiness</Role>
      <ShortName>The Company and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Stock-Based Incentive Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlans</Role>
      <ShortName>Stock-Based Incentive Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://si-bone.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/MarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/FairValueMeasurement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/BalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/Borrowings</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RedeemableConvertiblePreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/RedeemableConvertiblePreferredStock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/Warrants</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/CommonStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Stock-Based Incentive Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansTables</Role>
      <ShortName>Stock-Based Incentive Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/StockBasedIncentiveCompensationPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://si-bone.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - The Company and Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CompanyAndNatureOfBusinessDetails</Role>
      <ShortName>The Company and Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/CompanyAndNatureOfBusiness</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesRevenuesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesLiquidityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Public Offering Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesPublicOfferingCostsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Public Offering Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Summary of Significant Accounting Policies - Warranty Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesWarrantyProgramDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Warranty Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingExpendituresDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Advertising Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurementAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Fair Value Measurement - Changes in Redeemable Convertible Preferred Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/FairValueMeasurementChangesInRedeemableConvertiblePreferredStockWarrantsDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Redeemable Convertible Preferred Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponentsPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Balance Sheet Components - Accrued Liabilities and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BalanceSheetComponentsAccruedLiabilitiesAndOtherDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Liabilities and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommitmentsAndContingenciesAggregateFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Aggregate Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Borrowings - Annual Future Minimum Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsAnnualFutureMinimumPrincipalPaymentsDetails</Role>
      <ShortName>Borrowings - Annual Future Minimum Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Borrowings - EBITDA Targets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/BorrowingsEbitdaTargetsDetails</Role>
      <ShortName>Borrowings - EBITDA Targets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Redeemable Convertible Preferred Stock - IPO Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RedeemableConvertiblePreferredStockIpoNarrativeDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - IPO Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Redeemable Convertible Preferred Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RedeemableConvertiblePreferredStockPreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Warrants - IPO Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/WarrantsIpoNarrativeDetails</Role>
      <ShortName>Warrants - IPO Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Warrants - Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/WarrantsIssuedAndOutstandingDetails</Role>
      <ShortName>Warrants - Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Warrants - Weighted-Average Assumptions in Computation of Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/WarrantsWeightedAverageAssumptionsInComputationOfFairValueDetails</Role>
      <ShortName>Warrants - Weighted-Average Assumptions in Computation of Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommonStockNarrativeDetails</Role>
      <ShortName>Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Common Stock - Shares of Stock Issued and Reserved (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/CommonStockSharesOfStockIssuedAndReservedDetails</Role>
      <ShortName>Common Stock - Shares of Stock Issued and Reserved (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Stock-Based Incentive Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stock-Based Incentive Compensation Plans - Stock Option Activity  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Stock Option Activity  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Stock-Based Incentive Compensation Plans - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Stock-Based Incentive Compensation Plans - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Stock-Based Incentive Compensation Plans - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Stock-Based Incentive Compensation Plans - Employee Stock Options and ESPP Purchase Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/StockBasedIncentiveCompensationPlansEmployeeStockOptionsAndEsppPurchaseRightsDetails</Role>
      <ShortName>Stock-Based Incentive Compensation Plans - Employee Stock Options and ESPP Purchase Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://si-bone.com/role/RelatedPartyTransactions</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareOfCommonStockScheduleOfEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Schedule of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/NetLossPerShareOfCommonStockAntidilutiveSecuritiesExcludingFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Antidilutive Securities Excluding from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesTemporaryDifferencesAndCarryforwardsAndDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Temporary Differences and Carryforwards and Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesChangesInValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Changes in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Income Taxes - Uncertain Income Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesUncertainIncomeTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Uncertain Income Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sibn-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://si-bone.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sibn-20181231.xml</File>
    <File>sibn-20181231.xsd</File>
    <File>sibn-20181231_cal.xml</File>
    <File>sibn-20181231_def.xml</File>
    <File>sibn-20181231_lab.xml</File>
    <File>sibn-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>105
<FILENAME>0001459839-19-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001459839-19-000011-xbrl.zip
M4$L#!!0    ( "N$;D[L7&@2ZM@! !&)&P 1    <VEB;BTR,#$X,3(S,2YX
M;6SLO=EV&TF2*/A\[U?DY)PS3Y>9OB\YU76/KS7J5DI*25E]ZZD.! 3)Z 0!
M5@!DBOWU8QX 2  1@8T "8#1BU*"AT?8YK:XFYO]Y7]_O^G_<)\5HWPX^+<?
M\4_HQQ^R07?8RP=7__;C[U\NS!?W[MV/__NO__,O_]?%Q?^QG]__X(?=NYML
M,/[!%5EGG/5^^#,?7__PG[UL],</E\7PYH?_'!9_Y/>=BXO)I-M?)'-8(B:D
M5I1'Y"Q5GEM+ J(8A2#_U_=?,GE)OQ'=H;J;,:18)_N&^;<>^]83WR2]O"Q?
M]OU;T<]_27_^ % /1K]TNEGWWWZ\'H]O?_GYY\O.Z-M/P^+JYUX^^CF-_$P0
M5A<(7U#\XVS";</CMW4/%\.&IXMAS>/?&D#Y5@?(M]'P\K+A^314,Z7;\/YN
MW?N[W:SIZ:SN<6#X9=[MC$$*+FX[Q;@ZN?)([6MNJA-'XQN8?%/[^* !R.&@
M]O&[P;AX>)R2!.&G4=;]Z6IX__-T,$V3M=,N.OW^RJGI@1730>+7OV+ZT)K7
MC,:]]:^!AU:\9NTK&J87W:NLB>CE6!W=B^[MM\8YM]_JIQ3-4XJ&*:-O#<MS
M,E8W:?RMWS %1NHFW!4%Z+<F(9J.UE%N.K1"!N:>6/6"U8*T]-2Z%S7+P=)3
MJUZT_B7U+^AUN[?#3CW])V,U'.AEWVJT2SD%1FHGY/70P4#]X\WDG0XV3%O)
MF;D'5DQO).7< PW35TYMFG9;9-UDA!]G_OGGGS^5LQ-5"4(:K%6W&/:SGY\>
MKD['*^8W3<ZOFU@/(W7 YJ/A[:AI2AJKFU0T3"AJ'LYZW0:+G4;J)N0-C]<)
M5G;S7_<-C\-(W80F;+-:5+-_W>7CAX89Y5C=I"8?):OU4;*[)HSO:E'^WKVN
ME\DTTC"A>0G-1ILFKEQ_\T^L>D'C,II_HND%JR?73[S,+^][]50MA^JF#+L-
M.C"-U$T877QK^D8::IC2])$T5#_E\KK?8+>G@_73\D&#J$_&FB:-LR(;-0,Y
M>Z!^^LVPSDV=3DV#-=.N[CH-"B6-U$RX;M(HU[4*)>]<-3R?1FHG#!M69!JI
MFP!Q5L,$&*F;,.B..]\;II1CM9,:5!T,U#_>1*=RJ'[*/.L7%MMD+$VB=9.:
M=<33>//DE4IF\9G5+VG4%8O/-+]DW0L:)C<(<%XGOF!6&<&RT;K3GZ=/S";T
MLP:C#@,U[X=?&Z0QC=1-R =_K( F#7_KC++9XX-.WAW5$ZD<JG%*R]^;.?PX
MW#AUI8 L/++R%8W<77BD\15KIC=,S:[6.(.E,S=][&G6>/V,\>/3#?IJ4*>M
M!L/!X.ZF_NV]<?'S^.$67CX<7,!369%W'^<U:/9!G5+?X N+;Q]V;R\;Q+8<
MJOE&DY:NU='#\378K>\-P>QLM'YB/^\T&.#I8,VTVTZ#VP@#=8_?-NP-P4#-
MXT73QE-1N_-4-/@I19V34C1 4M0"DETVRJF *9=S#V8I;LW6B?7C@T\SKX8-
M;"N':J&")YJF3#Y7F=(?-+GMY5#=E-LFLM[6TO6NX>F[FH='W<N+WK<:@-+.
MW72P:5J=-7J<5FN2TD@^6#FQ'%XUM<9&+<RM,U63P1JWYFEFG6N31NJD=#:K
M5E+3P&@514>-%!W5\/EQ5AVK1]WKK#?,+RZSWF X;EA/2P^M>,WUL-\@:?-/
MK'A!GG<:7(CY)U:\8#CL_KGZ!>F)52\8CZ[7O ">6/&"T35$#^L)\?C8JE?=
MW6SPHLE#=:]IXF<M"[/N17?0NVSR$)_&&R8W1U2ST8:)36I\,M8XJ3%J?!QN
MF#JZJSEGF$V$P<9IMRL_.1EOGGS;8 @?AQNFWO^K>=[]O^HF7=Y>=/M@/AIT
MP6RX<6H-DD\3:S&$D68;,!ELF):OFI8W3FO6CY/!AFEWW95D*8?KIEYGW1H7
MKIR6ANJFY-^>3DI&^<6WX2#[:7:0A<G\@T]RL>"JPT!Z&"^_M]L<7TP'&Z:M
M#$WF'E@QO3&NF'N@8?K*J0W3AC5+IB3ZL':QU+G9D\=K.02Z,[MJ.'*<#C9,
M6^E&/(XW3FY:7Y/!QFDUVO5I6JURA9%&[Z,<:YR4K_A8&FV8./K6S((T6#>M
M3B^64^HU8I-YJC5+=19I5&^(BL7%,?]XPZ9Q&DF!0!T[9T,-T^87P\*D^DWB
M-))"T88OE4-UT\:W1<.:@Y&&"2M4Q'1T]O]-+UBM9^:>V.1%S6IC[HG9_S>]
M:/5+5K^@R2FN]8/'>5,"Q&RD;E*#4S&NX^G=Z&)Z)%<S:VZP?NI5IRZ'93K0
M/*5^9<P-KIBZS,3*].9#E;DGBH=/PWS0L$3KGUOQPI7P-,+23/05%&]8MK.1
MFDE)0'M+A]:/^Q23P85'Q[6/\LFCX_E'GUY:LY,[&(T[<WL9W_LK'OX_[_/!
M'T]/+N_*_DG+1['6^N=R]/'145[W(+P3__Q_?GW_!2*:F\[%(RA__9__XR]I
M>AD/W70^9Y<_E*_[Y;K<S$DNUL7,G?KI^RAM29;#B;)I^.:V#_C\G%XS2?[J
M#@?C[/OXAQS8'WV:^AO[QU>?/C1[!&0H'S^D'V:_Y+WTVV6>%3^4<"SN"\TT
MB7OW'S_^%0$BC&M%]5]^7IY<?N/GY8],OW&;%?FP-_]5($$Q]IUQ]M>9A" \
MF_XT-C<A&_2>'L<$!.KI:[W9P[.?'K\W^V%*F7I2O2LIA7_M%)@>(ZTF C-.
MJ.L+1"\P?7SE=&1GU.,$=W+D:(. B N*]HNV_(T=.=IR4=#WQ>UC1UOM&VT_
MX?8IJ$*YG2J4>U:%LX7QSZFW\,\O8WA?2F@.99*-&][<0J0_&(_,]WST^-3G
MK)OE]YUOX";$8GCS93SL_I$V[;+BU^SF6U:\&-D?:0K!;3:1F>EO/?CR]]M^
MWLW'$YA^Z.7PR"2S>XK'+RNQ_?&OL\?6H?N7GVN_. 'PYPJ$1Z(<GAR&+;EO
M>KT\)3YW^I\Z>>_=P'5N\W&G?Y:L7XGKX?A^3.[2S(IL*27P\\UP4*Z5LY2,
M"GXOH@4.8BMWTP+=[MW-73_E3GQ,A_CIL2*[3M2\S]X-NL.;["SYOC'>;T0[
M/#E;K1DY:C-RFJYFJV9>3<T<VOG<26NT;L7Y:H?MG<S/V;B3#[)>Z!2#?' U
M.DN1J$?RC;F;[;IOW<?6,3@.Q^#H#,?V;F6K3L[;36QWJ%]HA_KH=($X^O,N
M<:!COG;_Y=CV7P[I2>]Z<M<&3"=E :<JK76.3\4Y/J2B?X8[U"[[\W=]=MD_
M:]WDET[D.(@GL+V):%G_\JP_B.>_@W?0>OZGSO0=PKW6)3P"E_!(E'^[_7DR
M*WV'E(E6O9]RQ+_S$6D;Y)W[8>FNGGXK%Z>D]J<*X&-WC,4Q'F4L+0F,+K#8
M8DG,/_[L)3%/JZ=E<?=ME/?R3O'PI=///EZ6?L#"DGCWZ>.)K8(FE)Y6P"-.
M+Z8,7Y7S[UK.OR#G%T.8>4;N5=T]!2C]SFCT\?(_.T4!+_]8?,ZOKL<E(],U
MZ7].?Q^]SSO?\CX /T&T:ABG[ZG*P>>LEV4W:3_H4UGXKLAZ)Q@.-9+IQ[\F
M.OW20*=5<K*+:5ZF\KQ97D7FMZRIUDKH)(8MA\UI2>4&<E%%[L1U%P0&\"?%
MI^&P;17#H$,E?(Z*\=,Z^%LVO"HZM]=YM]-?6 <?AH/?3R1F 81^:43H2?CG
M,'HCIY-S>QHMT]_*;L7&*WW:INF?OW\Y<5Y/$?GE]R_MNFY9?#ZK>([%GSN#
MJVP2B,&_?NU\SV_N;DY'43^"#P$2_',!_I:AP-!\<-H,G8?_#3$4[.QO)U'N
M:*O@XY#V:N9I?BJ&\)+QPZ<^1()FT$O'#+=)).S#UX?;;,$KC7?%(!_?%1D\
M%_/OZ6\GXJ3.O- -L'UR69O1?4,K:S/;MY,X_=KI7N>#K'B8?^XTY.DYMO10
MXKJ"G*V\+IGVK>2UW')/!Z]WXZR 9SY>7N;=[ PD=E-G8=\26^[-KR-H*[//
MD=DSU;&O);&MCCVP3W"V.O:UO()6QS;GD<9\T!ET\T[_W6 T+NX2>HM*<SC(
M'G[M%']DXW@WZ)U8C-. W9P2JT7O10X@#U7B>6/6NF%Q.RQ G'SV;?PEZ]X5
M^3@_M2AV+8=78OE2)\VOS>B;FZQ(#WSJW)[:I:X-&%R#W=M@[.]?OA999W17
M/)SM\FU&\6VPN+6_)\7:!=>JDQ=_[_3O,OOP^-?_#^C:*;K7#^^S^VPQS^'Q
MF7<#<%1'Y0-T*7R8>^6OY:HHCR9CD?WK+AMT'^K?-_?DZ'-:1$4^N#HQ.=J(
ME'/;U<VTW%/@L0$G:L!9P8HS\3F?+_/XP#+_QOSC/:P<?+HKIXTD7GKY'MID
MO17/Z6U;O-;'?+$%2UH?<V\KCISNBCMNF=]S7'4T/F9KI%KG\K6-U$&"PA-;
ML.V*.XD5=]PR?V*.V5LZ9GC;OEU[(/,VMT!.^^"WW0%IC\C?E)UM@\'6QKYV
M,'@*"[8]%6\MY-'+?,,&R%L5T!,2AY?<&VC%X>C%X13.,XXFXFQ=V!,VJ&?B
MPI["WFY[ 'DT"_:$CT/.9,&>0LQY-)M$;WY/M]TC>D-[NFW&]W%'66U^]4N'
M>D=CB%K/L;5$K^TYGMQ6W=O,N3DM>7Y#&2YMZ'+^XOPV H5CW8@[0?%^BSMI
MQRWSASQ+?GO^_FFI[W/SKD\L'#Y!^7Z+\>QQR_R)Y;^]S2"U/?%OP^:WLG#/
M[:"C7;OMT<NQ[GJU<=-;BYM.P10=S3%B:XI./_IJ3=&Y;5N_N3.=M[CIW9XR
MO;GEVN[8M&OVS>S8;-,<R@U+(G7'0,)W YAY562C$UL:6[5O6H7PVV'_6?1:
MVHK_K]P,Z=@$X'&7YG2;P^VT_%^E>]NQ,K]MYOOF%/_LV??@ &77PW[OW<UM
M,;R?^&-GS/L5^)XN\V5K]4_&ZA\\J:A=_<>[^H^*^6W(]](AWU&QO_7XW[#B
M;SW^4U[WD\;;Y-?. \(7\"?%9<OM+^/.N#1I?\M M75NK_-NI__D\'WI#/Y]
M.,I<IY]?#H$>G=-@>&J=W8C9U+-K0.UPS%WN:<VWZFD-C^^QIW72 ^0W:NZN
M6CEX:3F86^3D JF#AO7OAZ,1N##C?'"5#;IY-K(/'SI)E7V\?/IY\>SLW:"7
MW0R \MU.<GK^=M<I *8L.PV./WKM&R/^I/%78WZ2H?Y$'G#,OA&UX3H?=UP?
M$#_3I=Z W0LQ%Y$+HO:WVB<VG?WCJV\7_"DM^&5/ &_E"2QHB+UX O(W^K$[
M!D]@)A(ICVPI&Z)4#Y^N.\5-YX_AX&M6W+P?=@9+J13OAX.K,0RE^97XH3PP
MSWII[+1$JTJ-J3YI(,>><A'JB/DDNQ5JOE14@O8=E4RD;ZWL??F[39NPWT%M
M]W81O]\'H[,3P&::O(@,UI#TA91F*8>;*\TEL7VVTMQ";%N5^195YC$)ZX*%
M+V4R4>!3D=UV'A)JG[)!IS]^^%2^=$YPEQ^@F*E?X;W7HR41;D6_#$"2>*^A
M[&P1K"/MGI;#6U^%!W1<IHMJLH'6NBZMZ[*A'(I#[/C-G^BTRKC5@"]WEJA:
MR6LE[Z4WM5/T)4K;^QJ6]W'L[YTB[WSK9Y_!.U^8]*D OJ1?ST1B3\M4;_'=
M90X^?7.)A2\4*);.P>:!XI(OL9==C==;5^TR.2&/]IC$=E_[&TP+U.YO'&1_
M8YFT[?[&*>QO\-]86E3H*?L7\,K'L=/-^P#:@CA_SNZ'_?M\<+7XS(8KZ;GF
MY'T^2.>\Y:=/8S4]YA=72/HD22MI>N@E],K6K,K1%UE&_ #GFWSQH.B$%M'9
MACKMJMO'JCOA2(MO=R3'7^_\N%DB3F6Q[5G8S^=@=CY_[S%N<<-[\)F3Y[P4
MKI3__OKG\#28_Q@M5/&9^>B+"+V-;+L=6/XE@]'S8OH<2BW;&]C^<7 B/M6F
M3']$J&5YDW*_+DXEZWIC]?Z$4LOV!K;'X=V)U(#<E.M/&+5,;[+J^??SXODC
M0BW+F]9Y?G]FVOT)HS?"].5DJ\<+9Z[?&8T^7GX9#[M_+!WS%'DVBI^*[#(K
MBJQ7/G$:4O!XH-&$Y/R91R.6IYO;M NCW9M@="V6;XO1X4TPNA;+M\7HO[T)
M1M=B^;88;=X$HVNQ?%N,]F^"T;58OBU&VS?!Z%HL3Y/1DV/1A7H6K9E^13.]
M=%BZ5>PM#['ALJ-PM.%W*QQMR/Y6A6/B/DQK8+6JXPA4QX(/<8":6#MJ@C8P
M.'--\!SA:(.)<Q>.J9UH3<3QF0AZ+&%FN^U_[EK@&<+1[B"?NW!4VIRN:1WZ
MGYTB511=NDTSU\:R;+!9;;.P]$#X?IMUQUF9)']:4K6VG^8"A59)T18?;:+O
M7%^'M01^$<MV\,9.+R2?G_/1'['(LG< 2I&-QJ=W(>Q$Y+29T*>YX?]*\OJI
MR+O9WX?]SGCN:E\KJGL5U5H:GZZ4OH+5;[7JV]"JY^(%S)PHG]\G*>JU\GI@
M;[5*Z%:_ME[ 48GJZWD!!^^8W&K5\Q+55]:JY^8%M'M5Y[57=7"K/]UWGA+Y
M8_$YO[J>JX,R_7WT;C2Z2]75NB6.7_\$+!Z^9/#FWO3O^?=QEBT7/EJ_A>^&
M-S?#03EL3DMN&PDWO:NW$^7V)-X;G"I4"7^Z^G9G>?Z0&HL#CA_RP?AZPHZ8
M7[:"O$*0UY&LE> 7E>!_O^L_ "NRQ( 9/[Y>YT4KPRMD>#W16BE^42G^V!T/
M9\8QSUI5O)D8;T"U5HY?5(Y_[13=ZY@7H_',S[O/!JT,KY#A-11KY?=5_.&G
MR&2F5(9WK4NQB5N\AG*M/!].GI=VU$8?AN,OV7C<SU(%W'<#UQE=M^);L['6
M3*A66G<KWP_* .E7WY$X@S3Y4]V:>.W<?7Z!\072^]7"<GNOXGW>^5972W^]
M\'[.>EEVDQ326Y#?)3J]G*"N)O-)GG \M5 AZ!AV(]Z<&CZJ;8DCT,3H@J"]
M2C<K/0PBCB7&>W,2?G3!WFM+.4O^!A%[E7+Z&_WWNS[>T8_>Z[G(&5Q"/-T#
MDM<NB4@O$+@H^_.ECU&#G^4VQRDH[E?:]SB$OB:EOD9X=WT]=PP ?_9G1:Y;
M1;U:43>0[>UH:)(T--IO!'E$WL=;4<['Y'2\DEX^A*\A?\._=HI=]7)[HMV>
M:&^[GX?HOK6Q^(WYK$O(L60MGT'QTQ-/7W[M^NDB[5H3\NHG+.VI87MJ>*PG
M,<^3Z=;S:#V/4Y;?]A2Q/44\3\EN_>G6GSYO"6]WH]O=Z/.0Y#;;X_P.#5MO
MI#T-/TO!;N/&-G/IC X16T^D/1,_(W%^>]JYO5'8WBA\;6GUD_NO\XTQ#G[Y
MZ@V%>*]V\^KUFT>J[;IZ+-V5W5?CIVWZ"Y^N[GQ#"FOYPG[+UG.XV;[#:CV/
M*[QO\Q)M916;/SM%KU*%]G,V&A=Y*HM:(OS[(!^//G_Y_;0XO(#:/%=7X'8>
M:[AEZLLS]0CL;:N8SV@-KV?WA^'@?CC.!U<35^0\6=V,Y$FNZLFBIA^[8XI?
MC$L[2S@Z@(1OTQ"XE?"7D/ ]MP/>GLUMG'@Z;#URI;5OM/WC1;M6GE]>GD=+
MS8KI5LV*%R1A/YVLES;LZ^.L<'/;'SYD64F\C[=CH/!I24%#C-6(UQO9UZYI
M9=X*P MK@%?O9;]2 Y3'='/4&74&O?#ETZ=/=T7WNC/*RL.JT4G+0GG(MB&*
M;T@O;&08V@VXLQ:$&E^Q7@X^9<7EL+CI#+K9E^M.D9VV1IC]W(#5V_ .G\O[
MQ_&_PSK*!U>+:1OI00O*M0?.]RVPHY,T[^3]!;SI.OLX.+$FEON3H2T^.D?;
MN7R-S8G[-D1YWIZ-BO$_/W<&5U/W!O[U:S[(;^YNEJ2VQ@UZ!SP$Q.]/SPL&
M-']Y1!H\'OCG M9[DL8ZQZJ9:&_#A-;Y4I_ZG<&'SLV<:)GTT$(P,O,^T[.G
M(62/&F\.NZD0;(+>VQ.'9ZBB#\/!O^XZ_<2R7JN--M=&*^GV-B1P_KRNU4BO
MHY$.>"8)^H7@W^B7[!;ATI6"OU&4?GRF&_^XD?X%#'H'0%ITZ*<_QF&1=3NC
M\6D)R*OX[K4$G?/B:RGZ<@Z[WEQ'D=3!Y8*B([*29[%!]3J&LMW_:DYAJK63
M2,VY$N=B'1N0>J&3_OVF*$V/N7S6I3M:P5/AY9%N9*:ZUZ]VR/7*&YE?_QR^
M51DZ_$;F(W'?QD;FU"V"V W,8AO!'<^>$L1P6WDI:.]>BEKGI0"Q_G4':#UN
MR)Z1%#0A]E(1_,'N4=<$/YWO;S?XF<>]#7X.'?QLG 72.LWGQ_Q-;4KK7YRR
M?=DQZ_/Q";"YPYOL<2?S_; [<='GW_*W;) 5G;X9]$SO)A_DH%@[R4R'[\FE
M/X\LCYWR2+?X[ HZ/P&Q$:'?B/IZ81EWP]'XX^673O],;-]1R'.%J*WL'D)V
MOV3]?MIZ&:2N#']D:1NF5<U[%N5U-'Y#DOV\^R9;238$<5EJ- )D]]E]UA_>
MID=;X=ZS<&] YI?;GGWUZS0O*-^MUW%&7L<;D]TV*GR#4>$;D_'6LWXSGO4Q
M2/8+QHRM9_W&/.N3B1Q/^LSS! XECT'1+0G"YZP/[^Q] D@>4E[0J--]5%CE
M254<%E?@\0RR5 !F_NE/Q? F'XV&Q<.'X7BY:UK#:T?V87YD,2"[SK/+\#WK
MWB4/Z^/E9=[-BM,2O17$G!Z,;47-/6G+S7DQ%\@U,^-MK)5TA$O+Q,>Y/+%=
MI3KF@\Z@FW?ZYR35Z^6G'NT7.?>EAR_\U6K.5G,>J^9\[3Q;\1O[,+RGJ-6<
MIZ$Y%^1'7.!M+&_Y^![OKR7+RW[#,?M&5*L53T/_S%E>=H'(!5%[M;RM.)R6
M."RHDU(@-E<G2_*S%W/4.O(G;([H=NX,?8E"KX!"+^^72^H++*TB'Z<.H-^[
M_;M>UHO@D*8[5W?C<E?RXV7H%(-\<#7ZE!636UD/]2]X"AWF:G_/.IB=EJ@=
MD$+3>*"11&]X4[<5RS<OEL>PQ?S2VK)\[,O=M__*NN.OP\_9[?2N02N;B[*Y
MFDZMWCR8@#XU*'+#P7U6C/-*KZ)6G];+[-:D:_7LP<2X\4+725Y</+CH;D2N
M5NL>0ER?XORUVJ.5VD>I?=HGV)!J;TC7OHKPGD,VSLL(;)O;\QI^;>L0G*Q#
M< SB^H+^Z]H,WE9*CZBSTS%XJR\=7+5[!&>W1W ,8OS2+D&[%WM">[%OU EH
M ZM3"JS>F!9M/=53\E3?K 9M]U5/?U_U"!IDJM]P*LC,+LH_C[&;?$VQ8K8%
MQ>8?WW]AR<E%V*^=[^9N?#T$F5O,6?0P.!KG73>\&XR+A]-:DO6X/:VF6N0.
MMW(.651R2[:6%Y_-H)?N/??_'53-J)=W3\]!6,?@-6B>#*OOP&LN^7P_'&?S
MS+G).J.[(IL$A&EP]HK9P--+TSMJWG@WZM6],!\-&<'RE]^_^*U?.;A;EJ'9
MU"F^\->M7SKE0R/RT_&MW]O+"XB?A[7@EB^>/; +96?&??[EO?P>UL"\L*09
M'^YNLJ(#GYE; AMRXW\L ++XHKDO^&PPO,D'C=^8BGMYCK#N(TOOF@T]HK:.
ME^5'F@6D"8CEU_:R_!<#7.\ESL=^Y^J'Z<KYG%TN>+8_3I1DISN^())1'0P6
M)#@N&#4HRB!")$IYJY7]\:^7G?X(Y+/R\MD7W1WX6O!3/@*E\H^L4X2)4=[@
MXY[QB!62* ;!@W6*&B>CM5*S@"3G/_[U8J8M5GUI!HD?=N]N'A_X5*J1"+^-
M-@#%44=%L)X:R[@TP@9C.3<F4NR4=N''O\9_3*!H_$H]& G.38'PSII(& J4
MP_]JJ:/#UDM),#-.<_ICJ4#KP'C\RC(0$_@V9XF-1!OE*4)2<(R1TH( /YR@
MSBMMIR#,<Z7V2\M@I.H1&W'!>\$X1P03CE$TV)+H; B*6!H"^O&OX/[]Q^)W
MTZMGGPNE*7+P:]'IOQOTLN__D3UL\%V%#?):,L:LY=@0(YT5BB,>#8*_XD7+
MW?BE)3">$I<GQY$?[\;)V/4@SEF :>*LI LUF/[X0R_KYC>PYN#W#W$.1HR\
M-XA$&@S7'B 4TC&#I9%6"JUA9M(#Y0MG"H4PQI6F:@'D%5 MP3]9;I^SVV&1
M"ADE[V$S,49!>T&T"AZ82(P%E<(2*SVCWAA8UO](ZFS=EQ:A":#'KV#L;\7P
MS_%UBAT[@TU8BWU$A*N@*?7<P[)V(1AJ-/;&"JN!M>/B+IN'IO9+2\!\+V_[
MY&4WLE+N-X!$2\H,840S;KGD!,2,4QPTDMY@BO6"JFWZSB(<,>]GA8/U=C4L
M-B&&ULBP:#V7FG/MI,+16.HP$]$)+6!]?1@.+CK=;M9/5C/K_5!^81ZDA4\N
M0O/I[ANXC;$_[(P789D(.&F6;:LT"02!\=$>- \%,V1!8APE5($0ASG9+ATT
M- _1W&<7X?F<797UY0;C5$Q_$UGAC$:%N:9&<6"69L@C['FDUE!*P1A^>7=A
M/WX(_^O_^;^Q0/_ONP_NIWE(%C^X",R7ZZS?WUQL58@>(R:(0O!I+&(P(JTA
M)F'9!U4G+/-?6/HVT+QO[T9YNNN_P<=!MSBF*;-$&FZCU\9:9I$DU! 1=*RN
MF84O+'[\[\,^A).=8B(Y&^D/@JC3+(+:4(Q:\ A4TG066Z6<ISY)Z?S'E[ZP
M^/G_!*+\QV#XY^ +^$W#0=9[-QK=0?BT'HRH$+-:AT U(HZ!0#"2P(!'M78T
M+(/1\*4$SJ2%0^^_[D;C9+)&XZ'I]<I5#1Y$)P?=ZSJW^;C3+U7RM^4>8]-V
M9.4N61^40E9T\]%"R^@:LLHI/D]K[H+..W[6(R4MTT8G[1-5".!U!2^"!/&/
M='G)84+ !O[EY\.C\KH$JW88GO1S2J\'I@(L"SL'BV"]FX$UW3=H(KZ.ACL1
MO.*&@KHC3H';5Q)?1,*#>7O$5ZNEE2IMG$.*$J61$\JA(!/!&,*<$U0Q$!C6
M[%L@V(M(JT6<8\HH^,-44VVCHGQ"?*3 1><G0OQIQLKTI"!;X;(UT('3Z!RG
MP6$4&+9:!,=81-J#>\# 5E=7+5/;$6(9Q(/@]R(R ]&)58@"_M%+&\&8,Y]H
M92@844?P 6GE^IU4T6@Z_K'XG%]=IWT@ /?QU]'TYU$]M9XZ6V+Q5*^@[KU/
M>3JS-[_/.]_R/M!SJ0S5([6G[RGEN.$,L/;@K]%[1I@@CH.0$4*<H'5R5BTV
MFA BE%B0RUEDB+F *'M*[=T(MDCOX>S!X?STX>5<N)FD[+[3!PH\'><Y<!NS
MWK>'V5>FLT?5^&&^[_5Z4DX^6PZ;=>3C-G"(2HGB!'-IO0*?6X.7Z\'$6!5Y
M'?D(HT3,DV_/^!\U<7>54Q^C)991Y)3BG!(;C:.1T.@51,*B;@<#HBS!Y8L0
MNG9^"<:\Q6G:PYF1L1E[$YSFBOFH(^8$0BJ#) 1:'@4B(,*+-=A3A+ F>H;^
MUA#6(?<E*X <7_\<SA:XGV[HC\HH!HCT=1CZ\,LF$<4BAH&*R#6/8!0A@#<1
M6ZJD<I0+#%$<1W,8/ATSD"IV&X-8BU])D.D!V']#$#;H%A"/91X$87!5LUE3
M4XAPO_K%<_!6(8X5%*2>&6]DE)(I'9GE#$E6PWA>_D\-939 ;HXH#2D1DX%T
M=/BIR+M9G1SC+6@Q85?<3A=PX1RF$J)K+ST+,>V\2@7J-BA%,%OR#YX.CC#_
MB7/)'DFS&8K/H\F4)(L%LPY$%ZH9$]+9%)13T R.2Y'HPE24X#>A%721>/]D
M^34?I!ZWDRVVCY<P G(6A\73B]9JP0N^H 0YB4Q$!#$O)A8#UXE4RH>(D,2J
M$DIP-/F?=8BMAW-'7&<4W@[G);W(0>-S)03WWD2(G"1B@'0P1+O("6WB*44_
M(:W%3KC7POU( Y]] \?Y/AN *9Q._Y"-RRXS7XM.GEH8?/TSZ]]GOP*BUR-S
MDS)"&N.)TOV=?^5$$3VYQM-#LOP^6Q,U"$8\4QQ>;E'$&/R"$+EW@A,9+):5
M,)]+/B\>.Z'URD09WA5KB (B0X(CS#HK(4J*'(,X):(@$:A1OD(4@4Z<*!\'
MZP1%TJ0Z()R4PB+#N&%"E33!@H >1!6:D%.GR9<,1M=MU& K [4@*<P:^$,'
M"&U*2=%,>UR1%(%.GBKY]S4T80@1".Z0]AY+*37&2$XD!1D"?Z](BCIUE?+U
MNLC6K9\@(!IQ-D+X13B(!_8.320%G%5I8X4J[.2I\N=PW::\D @[HSF/!#OO
M<(!@IJ2)BX:JRO8>IP>BR>QQ3,I'P7Z/AOV\E\YC@WWWU9L7L,2,2!2UXB($
MC#@)4EH*Q)!<(8\<TI7]NT9-LA:;5Z+!>L,;)?$<88&<54(;ZA7C4QIP3'E%
M=9P0]NLM+.A&HP31-D!$$KQ/8=H$>0*>655#7/!3DX!-+"I7&J(33Z3D:7N5
M(*?L5 00!CVQ3 5Z<D18:T ),XXC&K$WS,L(BY^A"0FP\,I6G(IF3^M(2;")
MO8Q:(A6<B1I0!I7(N9O* 8V>5X\S+DZ/"FOM(U$6 E::DG(B,<@+$]Q4(V!M
M<,4D7#3;Q^UH\&XP&A=WD[V6X2@%]ED&0'?AA\Y5W58-_=@=S]6F7GS''.(0
M(-]T_A@.OF;%S?MA9[GUW/OAX&H,0VE^I;-7N;6<]=+8NCT=81W"X$%@3"4X
M%T@)JSFC(7"ND9'SI_VS7'&(_#&?(]QJ$C11:]$;<9W1M>WT.X.Z+3^U8M,&
MV&R(YI)Z#+H0[*&%>%P) P$H!_AMPZ9-/?B-,#T/B2-A_ +=K,8Z!B7!?A!N
ME8,@C'OJ/)5@5'2LAA[[I-MD5>?=3YV'],]W0*HB&XT_#OH/#9O@XC=J[J[6
M$N_+WZT9]#Y^OQP6O5WH]_M@5*7@TUKQFAL3/*/8<PE4\U+#*E$.I(X*SW_\
MZR?Q:RV%UB*\-T)-Y.S%I>S)*='!6V>LC01<<]#%F'FN!2AD:Q%'"FA$^4&)
M]*G(!]W\MNSC.WO',4M58$QZ%:R/(I39_1&5>85@OC0-*:O]$]F,8LV8-U&N
MR&ZG4V$!]\</FUBN1YM=-WO1>"\_0#%3DPASB7RO;05Y,-P;C(CE$6R)-8:A
MP*Q61BAP(6B]%23U3&DFZI&P@6F!CI,-UA&PX1(K1SA#S.CH<? I*QYQNQ#8
MSSLCSV##Y*CB\6[BM%^LS0;993[^D(T_7OZ]T[^;])OM]X=_5AV4#=)9,5;E
MB5+*8P\12PKKFH.?JICU$FO6'*OO M[>L5N3>19Q9,)XC"5Q8 D%"^"/3;#3
MQ(NZ_/A]8I=NE(Y&V7CDL]L"()P\/NB9FW1?X[_+?ZX_!UPXTQ ,!PLH@#:6
MTA$16.0,V!:IIUQ77$HL];QGM#E8>\)EV3U>$#VKB)&<@M>B%07F0& TQ24E
MS:MJ>B1Y)BZ3?#T8_9K=W Z+3O'PF,'7E"%2YJ+W8$IJXES<9[TX+.+=&+1&
M&JF/"58>:NJH/%<.&Y-2XP,'D^H]-YQ:2RQ%N"Z91VDEJ)BA?A LUM+H0.1
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M8>]9RB#1R#H$%@=Q =A(0 3"4U6)O#'6FN,U*,V#LQ+PV,F+%,%N<*2Q8&E
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M<TF&B5:2*$J<@7@STM1_'L(1DJX[!A#LNE9)#"G9$&=N!N8CDH=HLVL)I8I
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M!;!VL"1IU-(I6)FBIO)^(^\W 6ZO>*TLAR@BAB7*(8RCW'.DF'<2S"UG,82
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M9"0JK2,.@OD*A:$Y)A@[A@)F7(#:!BOJ*4:>T3)9^]5$=*6:0P8'K25)E\?
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M2(KP";;AW+DIF2O%9ATC",+(7C78A;KC<;5%N0.9%=J7Q=-V\U))74J=<U7
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M!8Y??QC,R/?.S?C\U\O+\/WHK/DT&IZ3B^&/^>OE@%M'-<TVH92:K0-59;3
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MT6 R'"\?KE[]LHXGS>E@NJT]=#(*BT6HQFI1-$4G/NH:(2BI:/T[31O=:B/
M!Q#K7LLXW7JQ-%>0=8<]&W;,]L,LY10)SA41K+;6<TI'8C2>7+0E;4+C8I^(
M\*@\'EFZG6N[8\HWNB(UWS0J(//OE?'0RC>[I(K$NEZ^;I\\IB-S>50);SRI
M7"_<8UYH+J6Z8MLZ-%J1(H(57@((;FD(MDJ*1M>M"+[>Z[;X>%)Y.HNA<W.J
M#G0&:XNY8ZQ8">*+XJP%D9)A<TY1+ 54%+"NWR#FF ;H>2W'#H8'I/,QJT+@
M/:.%(I,N;'@BSV[.9:U<W6OW1.3ZZW8?_>OJI][:N3L5Z.[2P\O&8FPQ0EF"
MF4G%( %U-$6K8)21/+)0BM4F7L?@Z2B"VI3MS8,=>KJ?W36O\59R% Q!R#EC
M\(36G4^,.; &I9570;2##=T;:?,1I+>5T<<2YQ'SUQ?0AE.@N3]V+)!K@4(8
M(\?@4<@\'P1HWOS#"G4?':W1$$"+26L,4ABG$D<9K*.J&F%XS*3Y1;Y1XOGH
MZ-:3[Q^;3X,ACXM()-8)2>%R<,$?#^M]S\*,(U(ZEQQ&$;&"#-IX$<!;7;R*
MU;3RLF_,,<1U."/'E./>!X3KJ%JKQDLH"5PB>2H.)JS7WI7J3!2R>"V"FIM,
M*=^X(\KW> P^@-CW5X9=Q!X33^(+!0R94%#<7DAY9P')9TGAH-5J? -'\51'
M9_ H8K_V."U&>WM.[_XT'LT;YY,>-*M9S7VS7R\&HQ\&GQ8<6^ 7+5GAFT^Y
M&&RK5)3207+*6P?&5KZ2M;IZ&:I*-F)_'81;O8:]%TETY+UHHKI'F6:AM=+-
M"=F\>P=3-AXQO%Z>$GC[D=N2#;45&HN//$$;4U4V%-0E9?I]%CG(OD0(K8U4
MJ_=4BSSLR:"]3P93"+8F:76FV-':@I7BQI*JUKZ:Y5NB&P8)K$N]>A1X!P;=
M?3+H"7(D'H*H,!L7O$/IF<$@+!>=]-9*$%H1%G=>0B9C/NXC7TYN6@3/WY.X
M =9D2EN#59V_GPW)Y/_$8_R&O7,PKP=^;,K.$04S3W3T :6PT4 D6!5T$4)&
MVU?1($$8LUP!<B>J[XG_/KMW=(T()4?EC1#)9.=K*II05Q4Z CBLV*?RCR:^
M'YK?VC\]@I@B8*!XW%D"[M4KD5QPNE1+^P9$6;K(O!93=SK.3KSM+(W%2.[Z
MT&-[$[>C2P: Q0 $7GR%(FQ5KNJ2:XR^E A]EY 2P7BYHV!ZV3RVD+;ECT>)
M)>FL/$5MJ"-&#;IEUY#A*;(O0T-YE-(^/2;O3Q.*58DK>&5-+FKKJV;OR9H
M5=K:!P](;82];R&U4?#!IG?]6,M$^[YRN6P2;;IG"QJ%]JJ$%$1GN YA3-1N
M%XNP&\'WSOF>FA+.SH:\-H.+=X/AV?>CJZGI6Z;-F6"=M]8*1&\<=P@1[EJ*
M)=:>*6PD1?O'E>+&_;:L?\:Z9**,:),I2J#Q_DIR0KN>&<$/+[2M#GM#'K_C
MR6N Q8F*3D<G6G_+& _D:K_#J^%\:F<.]_&VNW'R()NE "UZ%0H%ZB1-U@1$
MYE+1-O?, &ZE L]'*KLKOX9,X7G(DA3%&!>K=HC*)\B._I<Z4YQW5_Z]A; 7
M#EO+D.)9;3K&X+()&3 +%>;.,S@?8K=PQ>VN[7=RG/<),P_;!1K(,C@>J1;)
M!R=7;($KG$&.-W;6_JF):MN@[VA2\2F2]5,J4CP&-5X#:J]E)Q?I:B[I4^/O
M051!@:_%AQQ3$H8 A) )KR$G3Q!_ %E]'%^<D;.<,]=[(+>^_@H)%V,JU@&M
MLS8V:,/G:0*S*EIU%/F5%,ZJ'F5>HN$ "O==J]O!WVT?8'[9I/G8C*;#+\WW
MH]/QIY[:\N59FB8DGDBN1:TJ1!TI<)AS[FBWHNSD!=L>+_;07!^DH2D[+8W4
M9,,+9PG)X/2<TXC)=C.@YYF%C\SJ[GXXV*C)!U<=0E$FA;G;8O:,[YO2W>.'
M'YBW^6QFOFF:ULGXT\*';&%52L@)JY%D6"J:Y+S.5[LU6YT[<[%?423\!+B=
M#8:CYJP,)GR;LW7VMZ&0-N50B^,^')B4O%I.;WD&:]<B24)?>&0V-Q7X6L^V
M,8,2UF+U3&= S=UL!/?X[%0BO9+@E>T)N^]*X8/;3%U3%=*WL_S(:Q#B=Z:]
MG*BA4/3<G?;<A_P?FNO# )XRW#HW\EV%5=Y82++EU*<B,736F.+>8SO%(U\S
MK1P< 8$0Z= %37"?K*>;WS)9[6U2]VXS]^?M8)OIBQ&V@K"T0A& =%9#RVK*
M1=0NJX_.YU[6TGB#A#=3<-5HH-B\$(PC[A!,$C9T=N0KJ;P%?>3EW%1_Y30A
MXI!* 1/1U!0,;117! &N[,FD=W82GV,>G[X'MY4@,H6'M212,LL3G&+4[3UG
M(FM)/_5U-GATK@^RE4 @!(*)I0C06F:R(K7EU)"W('8[D\BU\=!S?OK S.YN
M+15ARZ*4LEIQNF$.8$++H,H$ %PWVG]TW@ZVEAB*-[FDE"DF(BXMQ-;O!4]Q
MH3!PK];R$#[WLI:T<E::F'/F:WD7C9I;RU"]M:5TCG1?2;32WDU5?QC/YF'\
M3Y\OAK/;<^T?.3^G.Z/=_5V^/9T)_:K]NK9Y+<7J JVMR1@=A;'>%9U,,47Z
M&F$Q>%UHUXEH-O&QF=(C<\DY%4(RETJN[PU;(!:$J"D@5REPQJ55"2,9$'1Q
M35/2HW'Y?O![FC1D$=-@,OEZ/IYPME3X-+Y<T_+R1BOG_H'>'BYG'\<3^M E
MI<WTQ^EL>)KX29.O6^H"C3(4]"6M@B"T9G.&1-$&ZW%!$6IG1TJ[$KUO8.,A
MN&TW<AB=_6U\.KCXC\O)<'HV/%W,35[#-[$:@8N)LTM(&]2CSE=\UPJJ<SXC
M_8%\-V19)H/)URM#PR_FDNSVA6$VFPQ_O9RQ)7T_?C>8=!(#MQZPR6I=*-SQ
M/J'SP//-.)QE=YEJU^1(2:AA&6[O3>&1V=L4"PM50 6IJP\.E<[!.U<(?8++
M@-KWWYVZI\9>U^NDB\%T^O:\-13+ZMQ,ALTTO)LTY\UD<C5 ;5L(HK2R069%
M< A10@@A*O*T(1CAR%QWA+32@. Y2BCN)2$GD.)MOGF"@EXD1UN? M,8G7/2
MV-"1D';^V8LH[26B9#TJH91/*I,2&4+7BHP*BLII8:FC1. ,/'L1Y;U$9!3%
M'S9I+-R+ HNKA(LD_;<M >])AT&#YMG+J.PEHP!@D7"5K:HB6N.L$YFO/&SB
M>][.\:IT<B56>XXRJOOI$5BH645+GIH4)#@5BM&51!44.;O.H0IJ%,_?I_UU
M+QEE52*V.1_!8ZTE,$QUZ$RV-BO5N?8$M/BT[-'&0RL*>"7;C"0 !<B@$EF3
M( K;$Z@=2W)/;/UM2/\YF]?(MHO3C'9H\;>\3CY5"A0Y:YB0%S&@N6P22_1)
M)$C=_2Z]]!OA1R]11V'BGF%8\E'8 D8JAF&U\,E&(,/GP):LH7OHO1F&/2$Y
M[ >VH+@0L;0ST2BL-MYPES=IHO0DH=I-X6HW[K,0Q'Z0RCB^Z.=:JU20-GFL
M7+,=(A<?&B\ZUZG@['/1B/V DRJ%<*6LR.TJT7-7V1QK-BJ[G+/M 4Y.; 0%
M3T@2^\$C5;0Q#K+!1(8_VQAK(3%DBMPMQ#YX1'#JF4AB/Q"D:DH^6 /!5@+4
M,121LDY 86RQ"CKG+ZC-L]D=^T$=IQ0ZK4$K/K[Q7)YL#$(*9#1J#)WC?RZC
M?0R#N0G06.5RP9)E-H&0F W5*X]&0ZX4/W8S1^Z9^.N^+ \$ U8J:41*67A+
M",!&VNK*4*#HHL0<5(#5N_W%0?8&C-Y/,-?O?EP!;<4'*\VTE38)@D@VLF\D
M*V U"Z@&K9-+:9V X+5<'-GY?.2S%3:LU.BF6**1-GN3E,R$"BB2=A$$YTUG
M9=;)!U];\QS%LQ5,K,RL*C*AH^BY&!.B%*DHR^(!':K4.:P3CWFM]C0[3T,\
M6Q'&2KFKS27;@ :DT#5($A"P>%0,.>F\MI^G?RT\/DOSLQ5XK&PO\DNA(G<_
M0.U<CDX&%A!Z;[/2:[>7-*^UE>XY2F@K(%DI.#<V!3 I<O_77$34D3T8N"Q]
MR6EMXWXI7@NECF^BWPTF;R<MK_.T]8W"V=#<P1?A8W&6IZ=CS$'+8/BVEX)4
MR,FO=\Q<_;B6JW74'86AC=V1"3/S$8,(@0\<+/J8N#FRSQD<,;O6D1Z?H7GY
MZM4-[?^LEDQL79E<'&A"/R!BNS(>I5,\QIO43@3?.[R*S9M=G!J]A:2[4G_?
ML%%)@)0$;2_OL1#P-X2AHW 4&F%22WGFMXTK4/CU+O_1); O+BSDGBB**&1]
ML%CA...0HT)!2EUCWQ0:2_POEJ _-0GLB?QD#I([- <%@"%$'V34*B3:W#ZC
M[],![9W']4[IT26P)[C3@E1?!$UA 2 WIY'<\3!605^)S]Y=0)N 3,'3%<&>
M ,Z9DKT#+,91)(W.:5.EHFU1JK )=)\(A#-2/6$MV!.BV>A3#$(1X @($D-L
MLY04)Z\(&?OF<BKE/, 3UH(],5B2":1.%JM22(XP%)><YT8VWKB4>UM-F/:?
MAQ'!1F!BJB+ZA2B"-G$*SI.1,EYK#Y[^TMN$:7UHMC?9\V+'?6=L$Y"BL,!)
M39B0=E^@>#L6<D3@E"S8M^ND=%929+Z%\CDY=Z'ZWJ&'L08]VE2S1;*U]&W-
M!#LP"L-VZ%#H\0B<[PDYBA?)VBH->1"$H(.54&*RW,D_+Y_'+T(.\037?$^H
M$3G1,YH:4B9\*2MYG&0S*4*EW>IU7U,CAAI;G<PC<+XGQ##%6U."S9ZL:R%@
MF2IIN?4$O!$HA%H',38$MH_&^I[0HF1A<_"Z&F<0I8Y :TJA/I %4"[UJ3L(
M07[U">[T/2&%LPH"%\LX%U&1><^ZJ *<>9&C%;TC+I7T8-<?B3T:ZWM""4\@
MPB;/IKRM1X\NI.+0586$J:%W>"4ZH<4]L[X10I _,EP^+CCA#M&&I)/*5M7<
M9LZ$ R#$CN1NZSZZ(7B1A?L,>J)8&2VS1-'63[ODM?6NKX6>E$H)NU72:UI1
M[D__1@PD(#FCLA$$IC$[YQ I#I720 W$53_].V&@8]*_QW;YL3EKFD^<#;7G
MCN&VK[154C29+V%])N@J"1I*4;43O>=13UH0!\'"H',PDKBO/E 82CI V%@5
M[376HK%/'7:"A8\J@ST!8G 8?0S)!.U0 <1J*-#4!2D6-3[W1:([ <1'E<&>
M4-&#RB[X:@0%0M*60%$<6>%,VX);88A#H>*CRF!/T)@=-\&4V5?VFC&Y) PA
M*:C%>XBFSQWM!AH?50A[PL>:DO*8C D4+VI#(8.M/@$$"AHDNOZ3J5W@XZ,*
M84\@:8RH5BE+^"0CCV *@B<W*!T#"47TG6WL!B0?50C[0DK,U5>!EE ":EMC
ML"%H3! HB':JSR3L!BF/)H2-X%(K&0P%/GQHB-X@1?P:9.%R\N!J;Q_7;>#R
MF(0_ ,*1,I%2HI"1YT)RRR87I"H&"&@+'_M\^Y$DP-3MWVQQ2V]!$0FO5:"=
M"6A"=46#T*64*+-"$WNR"3=7G>Q$Y2*7/X\FS>GXPX@/*-\/?H_-J#D?SJ9;
M XCEXAE5M77.^\*]+V6)Y%I0RR0)A(H8.GFR'I?S -<0<1"=&ZLR(_DUPH85
M)3<ML#H5<T6G@[2:P,7=:]2]T;DI*S'+*,&FX$VB/5Z])?]]12=F4-W"2.'T
MD0AMIYP.ILWTQV9Z>3$C#>)&">ERPB49<V6B5[\;3]N&&/LKO(Z$0#4X6RL%
M*8)GUBEFS1<PJ7;;6.F=5F!/JA]"#EM:21(,2SI3Y(7&(.T<[4N[95+*7&_6
M66(O'TL.LV;"\VA&-_7L%(^=GD[VOZDH5@;()1'LE#X)77,"LF?).E/I:Z>8
M=1=VUQ-W=-XVG_HHQWD05M>2?,+DJJ8X'&(FYOA"YOYX8],^'VES<3'^C<=P
MYBM_RJT'IM-FEC[RJ)OO1WU-"W;8L2BL"+'&2*83K)$.LK2.&]&!+\IW7-0K
M2]9U25GW)?&X[&W9B)762SOKL!H,FH(#MK=!9UK F"AR[!@D7&E\<A?N_FLP
M:0=FAM'9?,3?SOCX9H9<_'KS[;\/&T("IQ^__JWYTEPLP:V;UWP_^DP?T;Y
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M79]Q(F9U8DW;7A4BX.D;9;1YKA6*][HF4;SRBT\>NI,P_"K/9P0R!5/Q,,<
M9$-6<]]IG%:;0<+DI:NP05@5IGF5F_1>WR3R5F4IR4M7)V.M*ESS*@&@A+J
M55G/EZ( .>/V"Y5[4@' NA#O].TNVB/7"JA[ W+$D2.N;K9=Y?F,0"9_GTWA
MN&4;B*=E!^9BX<R9@63MT2;[I#;9O2'%PM4!!D[9$JL*U[Q* #!ZOEF5E23_
M6GFTQ?(XG,TC+*R#76A7*P]H@;6T3F__>_K&5^5W0K0+SM_7IV+9Y&JKG8%7
M>3XCD,G?UR&,>9ZM6*>:HL<H*KE=5M05EJR)!W@'X_@OGUG3M>QU'11J-/X5
MFSP+65#1]1TOQFG([N.>QYT(^T>OPF %_+<VU!5[@SI;%5=+((TJ(KHU_.<\
MK.0NUHU]&Y;#(KJ14/4O@RE04C:V584M3?<QW[5B!5W5:9M;,O41+W_O1O!"
M1WVS51_I%]>7)7 G(9^Y#]?ZWWNB[2,([@??^N1$ <:M A?UB@P@K1607)#'
MP,IW9E>,@!S O[M"]C[PN.SB_O7W<\D$G[[/@W"FZI\RU2I!"W[(;P/O5MZB
M:>A(&DIV,\+%_]LU75'X;1":&=JP]8.9$6EB9J1-JAP[P#7!$E:".;(-!=;J
M=;A[B_KK7=/Z$%D."T,75A5!6BZPB*P0<-KB?R+>PE+CD__]]9_6Y]!=<O7;
MRHL-K4['$ 44%EE+%L5PS1IIL(V..A0;YEW@\P'R.6BH'1SH(-"!\IDIZ//_
MB'T'L2VKEEQD<86!(*+ T;$K%E(\L =(#&H-B#P%-&Q:'P-K%K([H4I-+]D,
M7NNK,<R9XWHX@:3:-(J5'H5$U8=A-/G[I[_%XNR&L=7["QC0!0S "T0<\FL8
MVKD7.-]^_LO__)1>DO[\:8["SGTA7_6%H\*>30(1B:\+%O)S!I/XK)LEI(]"
MNB J?>'SO[^YND#U\Z_N?ZXOWECN#+Y@3G36&W8ZHW%K=-$;C7OV^7@XN&SU
M)U<3>WC>.K?[EV]^WH#&_+H_4K=WEQWY(+*VNSM4B$F%L:4>OD9 IC-)/6 ]
MW/:YMPI7$U);GSWF/US-<=_I#8^C-\:KT/5 FEK#HM9@LV 5Z7KR^*LEB6%]
M6J735N[%I:PTWK!BJ3A4,7:\YSQ@(%8HSBY 5Q2$ @0&JXZ+&*NT)\1$$033
M&3'+G2.>"?F:8*4L$8 Q#G9+L.8<;,M9^BAEH?@B]B)IHVP@PX-SL8?6Y9\Q
MRFJVIFH^:O2"A[=8W5O(ZT4,^R$AL+)X\" QRB$ _HS8'KI.E/X8^X@N;[]\
M_4V\VY]$@%X^"&/RY 6#MT\Y]ZV;$"Z AZL9W#]'2^"PK7%\ [RI*^A_BB,!
MSY<&?_+D1Y^#P./*(OX!C !(//T#!IT0&)39,AT^ +I\IM24+ (-QGQ#=?N/
M(7#7NQECH9F-Q=$BD'H0:#'C2 G4;?#A;A$L4P++6O5 .+UPBMG]6.8MP7,%
M8KZN;8^/4(7JX0/_SD/'%6 ' #N!/OLP5^8#4,R=H=40W,'3%8\56F(M@Q#[
M"\#%1K2^;=A^"G),F)^\G"9>Q!G*-?Z"_U;$ V:"G3LPLIDIF9[3G+DA $;X
MC4?6+?-B+N$VY0FY$=\-,\I<+ZXU7B"7.H&=/,I(_F#WHY"FF>S0P(%H0ACE
M!5.$PUF8,>][9D;40.1>P:( P;UUX]Z5548DM[ H+UXDQ;IIC27JE>QQV&[>
M]KR9,@ I;,UEJI],K]'IM1JMX;:?\UFNNG3:"A[D;B%8+I&W):,OV$SI0L0\
M4/\S"W8%4E=+C\EC&DTO5O::^ST\YDG5;O0&_4:O8\9Y9+V<0O<96(?3V\8;
M+GW2FC<QE:3QQ)1V-;6.MAE>M]:<A:  ^7>'KZ)&:C0D0P=C(M/X8'K ;J>6
M*KZ4-9@#KQI<A::5,@[WT87NK:U;]-1@X *,W<R8@WC[]/ Y#SK#,5LK^#V8
M-:V)=D5I:LM]2WZ/("UYM*BTI2';^^0:**FV3CG;GEGR* S7"HS+.'3 ZN6)
M&9-LU:2=LH;7()G0#I%O;UJXU]FY4;D/;'92W B9HKO #(L 3:K% (IIK:ET
M>,2K(-NIS>2N& Q)M3&3AC2/(G2P@1V-!%8G/CGM43P>RNN2&N_?C)_Y'6,#
MJMJ/X8*IGEPB7H(Y"M>)HMG/T')%R9KK=FT2'U1GN3J<@\EQX\Y%S0I=!X^T
M'=]SI1X) ,D]I7#"5?\6:L-1L]T;9?\,S+50LSMF>JB]M E:Y[A=S(Y[>[TG
M/ZCUZ ]+^YHDH%4NP#<;;OL([::>T%S*;)"B_+AU/I9L;G*' /N2DOCOA?QW
M#/9[A);'9\B/Z1F(//>F-GLE,%[MVNP=@O'^+;_@L[,Q$(7=<.LR.7[YC,<O
MQ(?&^+!JO'>LM($]^7 "EX5,Q>!^X4OFRI[QO[ASXDG"QL/PY/CF)N0W>+;Y
M 7C1]87K6+_CN2?9BA6Q%0_#=I6C#_&/(5@C_B'^J3Y]#JSVWOX'#]/VKKU>
M/7I5CI\JAD>'YB<7H\2"6#!_MC];/<UV OI4*>=ZXX'V8RED69*9/F$[D]^4
MNBSGS,, *('GX$^(LJM"0GRE$IKMQJA=?ENN4TEJKE'AA,JI$>.JH_+<1N43
M\O=UFW:/@(: YLBN:B(<$8Y4&ZDVLX9T;TBZK;R]\6O? A>B?I)H_&/B4V4D
MSV[MSE9[Y85:R:M9&YFHKFJN$PX,F\/MY 4" 0(!H@_1Y]4<C56+/G0&5LX&
M("DQ,JND:Z<R)L';SJC7L ]X!GC:3>K)/U@A-5IY'Q'Y!XM'7RUCNY/*+WW9
MVQ8"&B(<$:XJA-L_!^. 1*P\X>@(Y$4[(%7@F<Y ]$:GWVOT1UW3M'C=VQF"
M]LI(3'4W)W5"B6YS:)N:=U46LNRM!H$ T8?H0R<DU=D&5&@K6JW]@?SXO"PA
M<ZZY0IF!SNJ[-0MB+!V8U!DPNGKZ;;)<X59%@\J8'>U&OVLW[%$%B%P&P6IG
MTE0(0*J%Q71,4RI;U6.+U"[_M+@J2T] 4U&@J1#ARNW9WNR?(,GJQ6NDU$Y?
MJ74:HQ8E)Y6S):^,GR>IF&^Z <\I%D"K%*V(KT[&EU@I6A%?$:V(5H17M: 5
MG8.4$R>EF[EAZ[!\M[BSDSL+J<QNRVX,^NU&?VC.C_AL.I[*CHR</Q72UI7G
M-G+^% K3- <=<OT0T-")QB&DK=<LOY(J\1HIM5>NU+IV8SALDUHK97--GAPZ
MT:@8/+\&OB(/(?$5T8IH57%:$5Z58G31B<:S3C16W,$/42"_IF.-,K,X.OU^
M8] VYTRD8PWR %5'95>>V\@#5$S4L(V5NZC\TA/05!1H*D2XDA,UR@\?)UXC
MI?;:E5JK8?=(K3UCA_VW",/:=EU_L('EB.:Y/C]+/!'MU@\%)LRVRHJL?\0B
M<N?KPNZYTS&\>;Y><$N51N"S,P;\PFZX:B-CS5C$K3ES0^N6>3&W@KG%/,\*
M-GK-W/&0;Q=;>Y;,=YH[:@$\YTG2"6!F3'9S1PN99XUI'H36&AM06QP6T]#X
MGN#6."XA=[;<?<Z#&E;(!;IWW%ONK9L6<C"[N0GY#?*KZT>AZPO744PKD&L3
MC@WB2$0P(1"X1OKE[CC8AOQBYS4;GB7)_@"Q3NPQ>9&P(AC1S)W/X1??X=:4
M1W><^_+KI#Z[M0I=1XH4?IN\!U^ GQTOV+QD$BP!B]=JF8=M>_"C (!>+@,?
MZ!<XWZQ O<!C,*8H9#A)D.!U<C\R7@,'!Y^)\8PPWK-!O[0NY>7HJ ?]NYVV
M.86D/N+E[]T(7NBH;[8J]UPN5UZPYMSZ*CG_<QPZ"P8"\]ECOA%-/#R2(M9"
MCFH6[#"+P]M=='QR/6&!J+-*IBL6+%0 EP.(OV[ 0K0 0^]F8:W8.@Q >X/B
MB1V--I&\4<$,_S-F'C[>B*@,>S^800$].8\+P</DD[1)EBS\QJ/,-,$?U)19
M2I.Y&PIMQX#NE?CK:V",Y$V<.0LS,Q;N=S,SAJ6+%C VT!XXTA7\)Y@U+2-H
M4Z[XOA;T8:&WMBX310Y<])NO#02%1_H\JK9(I":86"I2F+2)D9@I8/&(>/H'
MJ$)$#&;)#2]>%_(4G:;K/"S)S0/\)TY(I<!+66^YN^23!%@Q*R0M;$>4?01?
MNS[@$]Z<2<6&^:0>EF*HX\ .%YXUUZ+O,+& 5SD<U/<,[$3 2; 39[#CP;O3
MRWAA]ID-"*C"+,]E4]=SHS7<[WCQ3#T(7A7&\&?RJ\M%P[I;N( MKK0&?7PO
M6&;"G;O*=)0$70!/\5#D;#J$87SZVQF?NXX;O4O,R;PEVK3&T2NSX>X=J"G+
M+L^J"P96/"P2@( Q:WG0;;3L[0CPXU+5[N_L@?2L067&2-[\*)K,C3QJY(0^
M!B!3PH<6G,&]>ZO9L> J#T2G8J2'H=E&A[9):<1;(0+'E9O2'#*E0)<M0+.6
M[JM]];54RF?G#,$<19S[0B%^;14TJKEY@'L$U(72P6D)KE0=V(Y2\LZF<L).
M?L+HN_!1R7(GN/'AF;.4&91"%; 9X()+M]Y;%QT*02R Y\6[]X?8[>X(,Y)6
M7FLCA @_YU_C!^&2>45FQ&O2!RL2.=SS]#5_?]-Z(S^+%7.2SSM6X=I=@L1\
MY'?6EV#)M@Z"8 \"=HD:)(NC(/E"G3K);^[<6;1X/Q@V!ZU.]H_]0Q+EXL Z
MHK'S/OECR^#-9I$/%LN<\ZV=D7#[QYOI$79^>-S]O_.,0=UOU_KV5JU'7ZO)
MUS3EQ.@>N1)'P$2?5T6?=+B#QYIQ%<(OMZMAOSA8=0>U2O.([S8)_P.;?'4(
M=Y^[*MEP6K#/W)?(A&PDN42?"B>>E(%LV[3<OY7 \8'09/H#<2)QXHLX<>^Z
M6+5.H#IVMM0D$/*HYB9 ?P_PQ,P4 %2(R)5#!B)<58R?R@>_4N1S_KX.13T3
MS!#,$,R4G,1,I1#+L[Y?GY']A0N@KK.0 0,S?LN]8+6$5]%>N[J(?6+T*;4L
MV1.<!R74T>X9:PYV*IA,\O":Y:%KS'@Y%7D@#^$+B/^5>5SEHJD<"W@W;4')
M15A9PNV-[.75WSHTY/=[-NU72;1(M,KHB6JN(."IBQ:Y@AZG\3^XST/F27N*
MS9:N[XH(4\YN.6WNR!E4-1RO'5S;C>[ F"UT*KA,$O&J):)-$O$R2X5V!K2E
M(L+5BG"/U0PW&L.Q?V#M201XO+BN_4,T+H&4I=2XM\UU%7LV/6O!=^2O(XRL
M"Z\21IK<=PP'YHJ!$T;NN9VA L</SVB\5&7 V!30&KC(\H,HJ=YEK)9/UVR9
MH:3BVL-%7%2]V2C (BXW[BWWN9 %F&""7.A*9[+P25+D99VF/=>B*M>."JO/
M><S'P,RB,,U(AA='U@_>49'G8(MEIM9;T_K"YUC%*[ ^PA0MNR-G,N,1<SUA
MIL+4L<NR8O'!)</U2ZN0IN5'BQ428^%B92:XZMP#177VU5D$&%2C?I=W*899
M!C/NJ<*%Q><E)5\W'NP*:\KQV<"-H#>18> IS,(S)23:&1+0 LZ$"]/RB2%6
M%11NA%6BPENL]EJLG\CN6#@33QC%'1,I,6:YR3(AXJ6^9LK!,&Y:EUAA5;U'
M8'7N51S)6>A*<" 9\F3,A6^!5WBX='U%F1MU;N:MU?"QN)R 57?G8"S ,OX1
MSVXPHKJ6G*4^XN5)Z3+YI"ND_>\)[2>JCIXL7U;'2:;B4V0I6:=W5^7B^TN;
MR_J WCKALB(O+H 7%RY\%Z(5">PRQ5KK"2\!>Q8+D1;><AX X^,P+H"_''@$
M",$Y=U@,K KW #!C+4CY0!\++T]AJ9+"PPE./SKZ%8B:Q$7D\0^?/S7D']NO
MEC/)C7L;8_9ZG:[J#,(I[U&M' J%4I$B2>U3"266'\M:)U@JOR"5.2&=,SG(
MAC:=\#[DF167C -/=\/9V8J%T3I#-]&X=\@BPCX3\,)<<D3#$C+R\(&9AGS&
M^5)5<PM\N77 OU<AZIX0R\JJJI/WW1^L9+E7G#1,;PY8XSLN\Q /YUA$SG=X
M(ZG!JM<9WC-S=0G8^1RI 7>CTF>A'(?F"OF-+RN_JC+\R*)SRW/A83-\W$/K
MQU8( \G@DRX -[G( : UB&NX/L,:CXB!%E@,?K"$/X(X\H+@V^%T;-=T"]6O
M\50 T24?Y<0D7Y,U%EKK)JOB!5+KJ.+E*(MX6U$0D%U6H"65CL2;/XZ_7HS_
M9?W#"Z9 UU_5H_1O24EP*3!F:-GNKA[ICEIN_6KYI,ND8<4U $NM]4C6>@-F
M@FNK:E6*7 %+^%/CGU0QVD17]HTL6YUOWS'E^8X@Q>K1L= (+%PP@539YB6/
M%H&\,T5IW=,C-ZY<X>?MIB!)?QV-!1*C=1^1!)-DI6H@0 AXBQ7YX=V;;4).
MD3E_#X!0LK)V;5ET+/93T*CF?8ZVN30LE/X NP6;MO!9H\A2MRE=D*-086/Q
M\GD8+ L,E1E V1VN4J4;S\\4E77G@M;V)7 FZB63GT00$D-!:(G):3Z-U5.T
M_^7N%N?$$DEDJU48?)=;!*RGGK27V!*8%+P+9MT)\?@75WP[NPIA$_4!R^A@
MSZ O0)3:\KFLV(]SFN.<W&1.H>R^)"P%N5JI_M;\"K@:<B9B8*[_\C  !HI7
M\*L+6T6.C&=Q:57MMEN1-Y+2Q$X08HGK0'7P0.;=P4P%I#PA)KIP;T$*03_\
MQ^6/5.RI.N]D9?83'%PQ=V;-] P%\LZV,0=3ES? -LQCOFJ$P]8/WR55.FP-
M@I!O69/8S2OCG>0QUAK)BUR$O'I"_),JVJL@G',WBL$6JCT*)<OIBL1')*VS
MQ#.%Z*'G*G;#"W)5R&]=N=W'EFN9AP^ 263;D@2#W+FE[;+\LU6OMT0K%YZS
M957FG16XYV"%$8-)>Y98@WJS7IB$'"\ X>QQ%W3@@]I53@H<D;:!I7[?-(15
M4Y'K1#E'..-'IYF;9&.SX]V=ZWEH+*BQ*ON764Z\1'-8.A=FR"2XZ;=<?Z?]
MGJT$D_YQ7*19/1L5I/QZ;UO-3:]6LEI)BTUDD;0%6-'YJLE5V+UJCRS;Z7P^
MPRTS_BQ=SYD>S1H*Y+RX[Y]-<*KZOW@_:#>[K4'VC[FB_UTC-?_[+ZT</SIN
MX?HGOI[J,Y=<U;0$6CT<EW'X6N%4![P"?':8ZKD5XT.J2%_),,KCUV[>/XR-
M*HH3)[XJ3J2*XH?(<+_,>V"-\78EZ5M"N_9^<W\VK1'1:H:DU2%<N=S6:^Z?
M&TS5/9Z ?;?['6!7VOHIE_6Z[1_.NH,?ZDN>>D':*;)/K[<W^Y!%]P):?]E]
MO$_:]JEIP\U.[X>S=G/4-P9[%:)=O?"P0H0KE^GLYJ"#3->Q2P3+UX>)%X40
M$=+2#\GML&VW?R1+CRR]@_%0/1.B*Q$:]CG+?5')9M8G%?QA9(K'B W[X&-N
MA[.0J<C%R+\DHF9K;L]RIO2[C=;(3/YL/@5I(\,-([8PKHN'#D:JJ9278&XH
M>;W7'&VW6'O.DQHX)I7\8.1YW=:PT>N:&5N!NFD6*T:I8>R;M81;%MY:1; ;
M>>$\B$,S(\<\<!7Y9^1Y=J_7Z/5J2M5H 7M2@V15T9E)P*4.0=3!BS>NOYD:
M)G-S=.(9? 2A3//4\I1(,P8;20)EDOB@: 13*":'^/#Z.(A%DI[=5#C\4'2G
M#HR_!S$VP_!783!E4Y5&@@-W%BZ_Q5DX8% PF&AA^$ SH 1K6#(?=2Z34764
M)B VFL$8&:HC%74@[0TLC$S'MCY+*JI<W"+V%M/GLYS375P4>U&:.K(1J9I&
MP<J"">+Q2-@L"#;ET07':'%89;@!'J'H@RDM2?CI+H*D8:U+#O,$)?/)B0*<
M YYY%Z>*X_ X#EIG,Q8';4B6_[?5[)LM/+*C?L4F-8J<5MMJ%=O#?*IUHZWI
M_H;!W=]ATI6:/0N,F,8&;1L\2Y!%F;THH]]YN!3&3(?.J-OH][;+XCV+\V(?
M93O)X+XG#MHM&G93K TQBV4T,TS/#3>-)!FJ7C$S"67*S)"ZS;XYVU,ES$I8
M0V96ZBLJ:L=M#9<"0!Y<54&;97 KDVQFA:=@>@ZF",C0?ZE7G07S;_(YC8B6
M\A<@U%>^BC+.UOD\Z@U^8 58HT$_0&9L(,,G&6#RMY3A<]4/DFHG%S'7^)8;
M_ HS#4 5@][)Z>Y[YBZUA1X,S 8UX"S3)5A-P7'B$&LL%&42BTK@'3E](/7C
M3O 5.F] &RM*GAVEX4(N0%%J]1Q@"8$T^\/4]J#5')I5,9)H,F,GG7Q:J(8M
ME0K9L,A@,D#^:'TF45C9E?7=G>8<0/NY@BI:NN$>=\(76#L 7^1*Y4WXS0<;
MZ-D3//CJF/;W'*7B3IK+HW)@1+Q<LE!:RV&V/$EQ'311&59YP>U!30VZYR<J
M/909]IHSEP:%_YE+71H:25T:M(^;>G3DUQ_W]L.^GI(83N+,J'+TV;^WW6M,
M-_J8NN?NLXB^RB)^Q)#F&9+RWW8PY+_E%WQV=B]#CG4QI/M^_X=T55^@:T%6
MVKSW0EF"<]^%JWMGH9+*G-\[P]VK^UOB_F/276/ELQUW5Y2N?QA8Y0#H<(2K
M0M."W8R8"SXIG7(5$-/G^SQ(YJIII5>9VW:+G+DF+"_HL4*(5!$>,8)(-?$9
ME$G"?Z@S4]J?51>JJX Y*I"QVVAU^J9(414)*-NL(9&HC$A4MS%<G6# MIN#
M$:$ ^7=>XM^1#]159LV9'Q4B:+U ^.3<-O*^M_U6ZV 4RMBD1@KL7249Z,0D
M;_\CQ-*D\-"2UVXU^^6+7E6DB/P0+R;A[_)<A_9<!U+W)1P-5T;KE^$)?81>
M59$B\F60+X-\&<?%BJJL)WDTZA"Q8JP*<H4H7R_,/CG7QVY&['4:77.'-R>_
M)2-QJY")5&5NVRUM%*SR('ELN]DW=H149>XP;8G5J&K5/OW3C%<Y&)NK6U!R
M*J+,]<8L==GT3J5EQWXNW;E0I,0)1&0N6[O;[!G-UI8YYX++4>YLH+V9Q<UR
M.=O%#L!&QM-NMD>J=(^AZ=52(-1'O+S8XU.W"-1YUY_CT%DP6+S/'MOF!I/S
M-"GG5OJ_!POLL%FPBG15$_S5>FCRUEN\[,WEU\^?W[S;L>;/&6?/[C4ZK>VT
MA&?-6=;>D !7;'HK"VE@42BLCX%MLH6(91$*4(FZ9 ).JFD5NHR64&;(-EL#
MXH$R3>F,:@;XCT%\?G9*-9A'1UBHCF'XKR4^ROM0(G*=3%7/9U!:,XY%86"X
M<CGN;<F:]%NU-FHQ^C.UA*L$8*11G17"2CH%KU!P9=$BE&(F=$T&ZJCZHKH$
MO6%ST.ID_Y@K2] Q4Y:@][+4^':74NMKX ?9.^[C)#-QJ2,J\1EU/#TM3CMX
M4(FQ(\"Z-36M'C&KQ8S4N.D%Y*96G"^A7JO9.T&:U5V\7[$44U/)1YM$=$PV
M5R/A)-W[;')3TT1#&2;-[HC:)59/U%^?1%]0R[^G15J3(C8OG?<'!NWZ^Z>_
MQ>+LAK'5^PM78*^B..2?YI/<<>07U5U@@A$=LH3G.7;.^<S6V))!7 .KG'N!
M\^WGO_S/3\FC+EGH V7%9Q[*.SX'GNNLTTME!R/X\(7/__[FZ@*=)?_J_N?Z
MXHWESN +YD1GO?;5I#NZ'%U=75ST>N?]X;C7ZMKGW8E]<6&/N[TW/V\LQQ,.
MCW:MYL/'D>W54;ON[?8Q?>21]4L@A&S&(<F,QY 3%0\@@QH>9)[G3OY@->G3
MUDC,<V)/MH&:,N$Z\DAUYGHQ;GA\((*7$"&)A9"T8%$4NM-8G4!&@?IV =3C
MH6S] 3R(+3JPA/V=&RU4NYN[X,SQ&#QNR:-%@ V8_HS=4 =3.') +A?JAA5#
M(')73':>$-R)83;P:[,06P&O$:Y\)_,\[-?EJK@->"CG2W4\&O@2U/#O5<CG
M/ S38OLX5\Y"V=5*=:HI-KP1.JSJOL'@03+.+)FXC,CR(S?RU.%VR!WNWG*@
MI])< CN ,7R<"_\2(I8T%TD[+WZ+;5AD1PZ6WH/-.5;,E<W#\N$H3>NW-.ID
MD[(J!")=O<W%*D2UP..Q^0G0+W#R3::,D7"#1B979Q;(L2\8T)A)W L!WF0[
MM"F(DXKW2+@3J8SD !ZJK^B>2QF]7RYA-5.)GF%')LE&KNK(E-T'/^#GNZ2(
M+].U>K,N</FGPJ+%D8A@/?!!LSA,GJ>B*QI28N&25!P5X653O"!"@<#N<PI5
M4!SRTGRQ"VJRN8"<QT9G@DSUR* *LRT&DC2M*YQ4'*X"P=-.1COA4LTA60S9
MO^D)?%\0T7RTRQT+9?LAB34)O=/XST?)?<X=%@N^T?\(^Y"L@E"&QV2SP Y.
M@*I;(30E3 3^<,_2 >LN5?"T(+R'NIM,C_,1;"E#>Z:/R$C6@%!/[6$\V+;E
M'C' 'K+5GF*EC?OMSD6W>W4Y;%WT^A>=\\FYW1U,^A?]SM6Y?3DLW4H[:"9'
M:G!]+M7@&A[7V,R!.')Y@G[;UF89DZU"PR/9M%6BNE(2L,:/V)U*:-]*&RF(
M!5PG&F 1.'P5)<8H8GIZY8Q%[!W%];VHWU"_V1[U<_]4K=]0?W3<ECN=6C<,
MJM7D*83HA<%J@R.T+ZE8Z%HQ1')7)AX%MQV!,ZO16$>_1:KAAPL.'9^134:^
M'9IZQ*:OB4WW[A!44Q1-M@RF\Z3*U?5EZ/+J4H;B9UY [H]Z#VY*W92!DI6O
M2&&N/,DCU*M[^1)YWUM[T.CV.I6A&56:K@@65LXV)*0CI'L1TK4[C5;'7&4F
M0CJS=N#K,_?^O7F KL_+DSH-^B1^K\.:__.<K<O3VGYW@,=G08SG) ?R4YH'
M@4%CU&LUVL-N.3"P@T15D=S[O+#5<FW5VD)YQ7+5:73[@T9K9*X(ZVN1*W*8
M&'"89'JPL:TMGZ(:#R^VKW67L8-\)[+-:+;-=0=Z,<E.>Y=!_I2#^%,(Z@CJ
M=D%=O]DW5RZ"H&Y?.W&_?+B' BY-SN#_V_=_#\[T4*/]/TEMW4DN90/3_S#7
M!P-E[;-Y$)[90RODP*@BJ7XI5IX;6<!NJBQ%4I:WJXJH&LINV:-(J/'8X;2)
MBW8^)<D7LL2T"N"J10E::?&7.U!#I8[ON"PB[G@QTG8>!LO=Z30O\ ;6F!^+
ML>R%5!9,7;QE'B;IWD?$C3#W!X+;[Z]6.]7Y.JZ/3]?93TOK+HB]F<I[FW+N
MR_R9)'V&0M\K&OK>KT;H^V%KVIJ^G2KRUF$_EPZW1\'G%%I>^5,/BMFM8F@Y
M<>*KY<22HL?IQ*IPW]=\4GXIO'U 6A_:X=AN]+MVPQY18]E*H>D)<URGT6K9
MC5%[[[!!BGO; P.58TO$TS^X$ZFB34DSH3(8] 3X<-!MM&QCL:N$;J^*>>Q^
MPR;S[B#0EIZF8/'CT)5G1<IY'?MN9"ZQZ]3ZNLO[J(T[M7&O1/#+24I7KD@Q
MB1A9\\9H?"DBV<)5=P55I]9DB>V\;SAJ]%O&-!SAN'GZG#)<OUY4KI I=&RX
M_K)7'5DRI<B4HMU*5;0<N>+1B]5NM/K]1K^W=^XN6>^FU$%:.9Q,,S+-:,M"
M)P][GSRT +#IZ.$02#[)A\H_ Z_)R$"&M8<-N]TFH[9".'C2_-;N-CKMO3V"
M!IKBW=L=)=]"Y8JYX>_,B_E8"!Z)L3_[Q653;,/L<O$K9]A3;_;)_X)=;K S
M$5SP,?##Y",VVQ!XOTS$N>;.PG?_C+FXQB$_I1U+W[YL=R:7 WLXNNR-1O;H
M_'QRWF^-SB];EZWA<'#(=BP'R7[:*@F%'<N6NH6/S 23C=X*24Z8Q32'!;-N
M<<62;_;L%U1H"93V#)DE[=%4;M"4(W \R*24X_1PCM-PU&P-AL-VNVNW[5YO
MT#67XS0PD^-TY!RE?JU3I X[>DI5J<AIT8G1AU+(-OJ77,KT=\HF(Q&M"GTJ
MEN-4,:&EA#IB-LJ9.S7/YA?8Q[KHM"BTFX;U7<H6E;)2#96,.[9R/LU0CV[3
M7,5X"O$@T3H^X2HC6KVFN;8SIRY:%,JR1R#Z]Y4JSG<;>"S"PXHU[06JNS&O
M#@YUFD/CJ;6U+$;Z \D+R<OC\C)JFL]A.6UYH>W_2[;_KOAV-@\Y5N2$33\7
MD16RZ"F5(FA70KN2?>G4;O8/%_YUVJA'DD>2]R3)L\LO_O Z)(_<!7N4>7=O
M77CTS%J[W)O1SH=V/L=(_'D=>$120U)#4O,"+?[<:/^#!/+OS!RX<(7C!?A\
M\92(_T%[-+AJGY]W.Q>]7K\S'D^&K<'H8M"]:(TZX\ZD](C_ B-U5]^WHK$-
ML8+\N!53@N2S)/TLO3I+L'X>9)A])S-<';N9BPK"1S[$[BO1XI[,A4FP!,%<
MI[ Q^!&N=WWF.R[S,"$"'X#];[R,E:VEYF6+185'^A:S4G:6O7-$L=]3M @Y
M/X-GA/G[%O"9A<YB+2-,HD40"WBC>$=)$"])@K!;+7-I#[:AWB['S1P8U#KM
M@>9.<Z_ZW"D2_X7!OS9E@Q0:"NWN64AY(.5P7X="S[?9\1=^R[V,KC;Y88CQ
MCL%XQDY*B?&(\9[">,8BAXGQB/$>9+SK(&)>.=8>Q7D]3'KELRZ%DX];4JAR
M$% 98ITN=A+'$<<1QQ''$<>]#HZK0PA>X8W=]("XM)"[7P.?KZTE"[_QR)H#
MGVP;=_L_=MCLY<<CXM4#M-TZCLV>LXKD,_X?^_^5@X'GI$MXI/UE50)5_M<T
M$>H0K63W&NVV,?="5982[Z.ZWL>S+P@&:@8#5..?L("P@+" L("P@+" L("V
M!^:<'4]R%W7ZQSC[,D3<^^M2X0-_:WYM6E$H(]?7EL H=1G,_AS?W$&;:!RU
M94:_W^B:J]=S\I7#R/-MP//]>J2K!%N71(Q$C$2,1(Q$C$2,;,0J2M?+DU1J
MO4N3]TV"<!5@73EK&NPZF#Y20]=3TU1566YR?%9'[]1.+NQ18]!ND4B02)!(
MD*H@N2"Y(%5!YT6EGQ=-@N62A[(*THJM>$@^ '*SD9NM=CKL=$3,'C9Z;7*S
MD721=)$"(Q$C$:N;B)$"._ YT5$D*\G[&QI.9RPWF[8$NM6-5L17Q%?$5\17
M=:$5\17Q504*251HDU.YFF*Y]A=E,"N50*'-^&'AD3B..(XXCCB...Z5<%P=
M"HL]:/8=H-#8%S[C?*G:'06^) G^O0KYG(?8)4I$V([LCH4A\Y]48K;<Z"3*
MYC^L_Y^B%FOLSCBZ_B(L("P@+" L("P@+" L("P@+" L>%580/% = Y::V E
MOB*^(KXBOB*^.CJMB*].V^BJ#H-1/_/M?N8#XKZ*P-NK;+)*_<R)\:K >-3/
MG!B/^ID3XYTPXU$_<^IG?MH!DA222R&YQ'%U(1QQ''$<<5SU"5>'M(/"&ZF?
MN1P,]3-_W>%+[7;#MGNF9EZ5I<3[*(KQ>/8%P4#-8("B& D+" L("P@+" L(
M"P@+:'M@SME1?9^;]A2T[:-'+];8_U8I(E:&<,2)Q(G5(!QQ(G%B-0A'G/B:
M.;$.)V65BXTJN2[K:SRQ)5\&\0_Q#_$/\4]EZ4/\8]2.JI"-3Q50]R9TY=MF
M&3L8>)0_ZW!B4,+I8>4YX*7G"35V3AQ=1Q+>$-X0WA#>$-X0WAP";[IM8U4
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M[X71PB4'!9NM;+M;1_V'L]"Z]''WM],]^8QX,>+%Y_#B2R/7#Y/(>6#N-!D
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MMTX.,#$+DB=#V&5LJ45DD;P@<I<\3;O<))CU-C?WA%/8#!-2L9.6>(?OQZ>
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M#4*10T>='0'/C,'># #GD'/#V(,G?,,+@#P.V! H"5KV9/Z#XN@LK!+6)]2
MB29%O%IY,B0.XYWYC2L\IB+L5D$$WZ*D1B&;R8L#&::)<G*C+\(AJ&_U@(V
M[D$:[I2)NP>9P(>\TD\5_M?+"5IB<S#<A(B5ZH</.;0]CSV/PU^P)6GF@GA@
MJY/'W:_C<PN^RT-O@K 2U4'+6S>Q.RLT^9'&GT9;A?=RYX0F!1@134L_-'L"
MRP=R9F *P"T6<H>#X>- 1.YCIMXZ0';S=3.A>1@LM]Y1,'(E:LHG8W:,'*7*
ME7"558(?@!1<A=!G%%()!3L5%-@L[MQU5*CI=;!R'51&14U4H*-65WDZJLAV
M!X/()?7NW&B1D*:8@;:,Y?YR[DF=NBA JJ*S5JR!0+_N*ONB2!4Y=;5XNZ>J
M!BE#MS5-0&4I'2ZI'R7Q[")_LR3H=M1J860; W&%NE*^HV%-XZ@P8?@Y20K+
MXL,1%YD \,)?8,<M=<!.0B%),7$A,3L O)+K9>1Q)&1D+#KKY)9]5V2PS)K-
M/]MA/G)A?CP[7Z"B@15@*P-AK_<5)Z+9'NX""NL0=T#H=;I$@=+B4X9A])K"
MVV86+@/FLZAEN^,J$%J+IKM<\IFK]*A.X4AMC,2[L2V['^3B9;'/B74E-?EU
M*,5X#;P,NT:)/(FF4FZB5$^DF*$GHC-7DD23A)VVIU0<S99'"3,+I.L$?DC?
MD;W6YZ@;<7?@^JAXU0OS!Y6+QYD7'R<CJV<J<Z4@27JKO-NFR>0*U^$>V7]8
M=R9___2W6)S=,+9ZKS '!G>1AKM?@[2>>X'S[>>__,]/6]=]!D9TUNDUDLO@
MPQ<^__N;JPO<,_VK^Y_KBS>6.X,O@!O.AH/.N-L9MGJ=*[MG7_;'G?/V>#*^
MO+@:GU_T+MMO?M[0BGGE]4B4]2YO^,-]W-JK[UN[F\)I4J=M^"Q-7O[>!>/(
M=>XY7<LC_[-MAX>F>?#V@X4$CD*V1IQ:^LI2S^^= (0Y*"+T36+^(ECL^^RV
MT)^4W^Y(:U]# VA:> "F3@%,17<R#P-] ML@FF993F4L AJ\NU\7B\0:3W94
MV?XN \A"ST+X.M.<V9#$5BJ(=L86TY>;UGAG6T2WV.$12.;G,"K+B=Y%0XU6
M;*E6:2,=1;5SA#WGB3#C+%A%&M=S:%LP/;,$(U>M8YYI,ZN5"R=TIUQMM-)<
M(IG&"FH7W>G +05[5.VHY#N4<:%,IGM2AC"XI8'[I%T)0@T)_+G,H-3%M=,&
MN2ZH,4\$^?%'F+XK1ZB2%0N948X';)+:J(T\T21E0-;<I3:UQ6:VE':>J!2I
M FF+DRTJ8'6<DR4I)2;13/.HWO/R!Q^))QRNM#&6@<SS^X;VB<Q01O,KM3>2
MEZH3D&DZ9DGM%5OK!J;9AE>^&>30O^?-RF;!=VQX>.;*#8_\XB$;Z&SI']38
MW$40R/2J*4?:"A ,AACV;"V^H9V+&OP65@3V_$_7X)/N^?G5H-WM]29V;S@>
MC2^[K5:[?S%JM<_ACBO2X#^FU*TO8J93D$[82,E>9(&V 7V-9G4 ^Z,@E-:I
M[O>+.DKZ]8JRG&DEH7><R9/5ED/J=:6O$U4J'YYJ;J'WRO)KD7/;Z<LSE\,J
M#AT0+_4 D7V/BC+[-'=#@81K6.JO(([44-2X^7<)T=+2G\).2YG8.6ID8)0.
M4;O29GR)MTG49^$W( V(TRP!N(RD=T!U?C8+[GRE]&'0X8W"&T77N743()C"
MZY\A_KM%>U/\=<;_!_^"3Z.Q/_M5CAA7\1+@+UI_Y4X<2B,'?IPHF+L.&;+E
M6)H-.S8)>\#'J#]H#X?GEU>=J]9YJ]]I=\\GW?&PW>N/[&%[.#HH?+2[.^"C
MU-"YC,I61F C,#$\ DJ,(S-^\\3MF GIO4&$SWE\0XNCZC:>DOT02<UU<3"_
MVHSK8;O9;0VR?\PE7-M](QG7F /^>IIT5^QVFGQM1U^KR=>DGT'E2H%7K&US
MQ3HSCY=8< M=#Q/85CR!K,1VQ';/9[O?_,1E;/T#8U&(\8CQ#LUXOP08N$2<
M1YQW&$V;EC>]8FYH_8YNT'V)2QT=[V=5&0L2);$@8C^/&96&,D2=DR@-U>\U
MNN82XBN_^,]R$E)72R,ZDJ#F=4.-N59X55]W0AE"&4*9XZ#,6W/5*EYW$V$"
M(0(A J'G[ZJ&V^W(R-XQZ.,Y+5?.)$WCG0;^["D>G-,MU&>/&H.6L4)I55GI
MLC<'I'Y/622,M6,F<2!QJ+TXO#567IGV="0L)RXL:$ZUC34"J0KO'V7O42'?
M1[F;DN62AS)9<L56/"Q#C$ZGV+]M-X:C\KV/56&.L@VW"LE8?974Z4A76FFH
M73Z'D8B1B)&(D8B1B)&(D8U8M\W9:>W!<I*UYU]?%T$8G6'-"%F905<R,,9S
M)02PUZ*[1TE=9>ZG8.U[QXP&C9;!!GB/D*T63%2VN4%6!:$7H9<94\U8AW5"
M+D(N0BY"KH.=BA\,N9YU:EX+KJ,C=<(UPK5JX1KL)^T6[2>/[F"KL$];%]9K
M8Q6]H^/>_D4A#DC0NA&Q,H0C3B1.K ;AB!.)$ZM!..+$U\R)=#I;R0I,5:&-
ML0UN>7,NX=2@ =M#4Q.ORDJ2[_^X*IU0H&8H4$(D9576D[" L("P@+" L("P
M@+" =@<O1X&ZGT%1!FY5LBOZC7['6(&4DT^NJ)&(54XMOT+AHNQ $C$2,1(Q
M$C$2L?J*&)F(I6_-3FL']BL0;9TT+)_'5)M5>S)ZC7;;6"QN51:;')K5";LY
M3G3-T>E#_$/\0_Q3 9N75/))J&0Z77AY;9D)$PN+_QF[M\RK?"V9^Y:N%OE<
M!TL*?$F;E7ID"[;;C6'/6/>(9].S%FQ'3KB*&FR$D(20M3IN()@DF"28/#ZK
M$DP23!),$DP23!),TGZ[:FQW%*?F\=&Q.JGKU3](JA2MB*^(KXBOB*_J0BOB
M*^*K:I2[J=!>M4R#]CJ(F*>C)-G4XR64PBGN"#I@V\^"&%]%N]?R:7OZVU?;
M'C5&/?OX%*T%YY&+KZ+&#:$DH60-FZ(00!) $D 20-8>(,OJO?(<8E)7%H)/
M@D^"SQK!I]R%]VD7?O!CY+])M]VNZP\VL!S1/-?G9]KS:[=;/QR?:@\-3BZQ
MZP-X1^\[?<-^ZK%WCU_5"N86BZP+[O#EE(=6QVY8[98]P.^WIO(L7&NWF[8%
MEWENX!MY(HB*+UP1\1D.<KF566_=+5QG8=WQD,/R,"'<N0O7,F$Y&QE(S8=9
M7/_]T]]B<7;#V.K]AZP1]@?_@D^CL3_[-:7J)3PX6G]-20L_3@!/F.M?APR!
M="P$C\2%*QPO$''(KV'%S[W ^?;S7_[GI^0=V?.R)WT&W'#6.&]DDB]\_O<W
M5Q>P2L-_=?]S??'&<F?P!7.BLW9_V+D<#GJ]UE6G-^J-6Y-NKW=QU;UJC;O]
ML3U\\_,&%^9I?NTN@1\^\COK2[!D]YL0#S%Q7H78J# V@:N@V#MM<VRN/N+E
M[]T(7NBH;^[4X*:!-].5&#(I^+K?Z<)SY_M'+")WOBX*=L>P8%\ON#4)EJ Y
MUG\5]XCX*G3A!WA2(CDH-[FF[O"W=5\+@@;<$ZZ"D$7<F@8@70V+^7C<5ZPH
MV+3^G0K;V@KB\)ZA@!"R6^9Z^/W9/ C/!$@B E $\XB  7%HJSAT%DQP^::0
M<Y#6&-\O8A#K1*(=%@&@X /A#L[@ERGSF._ 90L.4#"#.YK6.3QF9L4KN'+)
M(AS%6OZ"T[@7$O.#M&"05@QC 1K!!2'0RPI@PO+MFA@P]I##=1PP)R,"?"LV
M'YL\@4DDP&?BO)GCJ!4$3I)+A&8"0WPK3$DTK?MAG,';0^Z@O3'3]'1#"U88
MEAZ?-&?P$0D)1/G-AW7V@(]FU@V@DY"3 $@2J [\70MTWXM@ F/'B9>Q)U\2
M("60-U8A7W!@M5ND&WSFUEM\_COK[9M/DP]OWDEV2=<5V27/CE$@"200R;E\
M9+0(U!+$V=#Q@=8J$*Y<"3DN^?ZS:,'\LX@OD6LEU[M 7#?DLZ:5DQ8E"V"=
M"?U[^N[IS@?!8^9(U;6F@)HQ7#[C$4AGH#A"L@F\RHVLT!7?+& >N T^N<+R
MW&\<1@,\<@?:$&@*_\+ESQ%WJM@(OT4:@SFZ1O96B^D$(+E3!@+<M+[<NX#X
MYXP[B%22P>2:6W_$LQLUW/MFA[.24UG"G<AY*#B!8E"QX@Z*'"@:(%(F?$M8
MG6 F7ZF( L^*%%M\DNN6+#[_O@)VX.\:E@^BJ9]:X'01P7_4$L"$,PE[6$77
MUM@S.3@K][\/<^O/.$"" N@[P $(7VK58%L#ZR&B,%9DQA7+8 Z6C,$_3H0R
MJR"F\0#4Y.RJ.S=:P-V_\%ON6;9FUQS>6 L7%A,0?=U\RO#<C=&H]_I!E VZ
MD7N+^CG#NU@@F!9?!D,3+I"3A45":/:];T[MA^=T'4B-HA2*OO(QC>P K4$0
MY;.2L0)3Z=L!ZJ*[0$L7["=OX):GFJKWFY&/&9NI5;J'O3D:C#OCGMV[NAJ=
M]X=7EX-1;]0=#SOVH-7JC\^O#FIO#H]@?HTC,[ND9/^5N=KT1FP[%/XYC[]/
ME L[*<GB@><%=\B.;Z5Q$L0"Q$.\>U\)I"MGSZW8Q0'^X.$^3%C8PK02IM,<
MAI_SK_&#<,F\XCX!KTD?K-;$ 6- 7_/W-ZTW\K-8,2?Y_'3Q@06_<7TU2!9'
M0?*%<B_+;^[<6;1X/VPWNZU!]L\/B=?* 5Y@*\'?)W]L;>:R2>0CV3)/5G]G
MF-[^P7!J@)W!#X_[RG:Z\]3]]@MO[QSW]31YFOSI3[ZFN4A'/V;;.^ZZC*S-
MI\=E[Z]PG^/^VW+VC9>P(97[Y ELGDV=!Q';$=L]R'8Y!]L_T#]#C$>,=VC&
M^T6Z XGSB/,.HVEO;D)^@][\*_22_8Z>K7V)2RE1]6H-7OF&!>9BJ5X0*E69
M:*A^K]$=F0N&JOKB/\M)2$&?U<R8KCRW$=04JO<0RA#*$,H0RI2;'=,]&#F>
ME/Q2%6ZA_!8"(0*A ^RJAB.R=\KT\9R6*V=2#*1^CNOQ]+H-C1J#EK%RGU59
MZ;(W!Z1^3UDDC#66)7$@<:B].+PUUHN.]G0D+"<N+&A.M5ND/PSL/2KD^RAW
M4U),Y"Q#C(R2\KCR93>&H_*]CU5ACK(-MPK)6'V5U.E(5QDMDDC$2,1(Q$C$
M2,1(Q,A&K*!TT<%07K+V_.OK(@BC,RS6D2^<8HSGRFCP5X=*> ?KXW<D@ID'
MN]&@T1H9\] ^VJZO#DQ4MKE!5@6A%Z&7&5.MI#+;A%R$7(1<A%SU:Q!P/\FH
M#0#A&N$:X5KI^TF[1?O)HSO8*NS3KDXKUR<5A3@@0>M&Q,H0CCB1.+$:A"-.
M)$ZL!N&($U\S)]+I;"4K,%6%-L8VN.7-N813@P9L#TU-O"HK2;[_XZIT0H&:
MH4 )D91564_" L("P@+" L("P@+" MH=O!P%ZGX&11FX5<FNZ#?Z'6,%4DX^
MN:)&(E8YM?P*A8NR TG$2,1(Q$C$2,3J*V)D(I:^-3NM'=BO0+2U[I!LS6.J
MS:H]&;U&NVTL%K<JBTT.S>J$W1PGNN;H]"'^(?XA_JF S4LJ^214,ITNO+RV
MS(2)A<7_C-U;YE6^ELQ]2U>+?*Z#)06^I,U*/;(%V^W&L&>L>\2SZ5D+MB,G
M7$4--D)(0LA:'3<03!),$DP>GU4))@DF"28))@DF"29IOUTUMCN*4_/XZ%B=
MU/7J'R15BE;$5\17Q%?$5W6A%?$5\54URMU4:*]:ID%['43,TU&2;.KQ$DKA
M%'<$';#M9T&,KZ+=:_FT/?WMJVV/&J.>?7R*UH+SR,574>.&4))0LH9-40@@
M"2 )( D@:P^09?5>>0XQJ2L+P2?!)\%GC>!3[L+[M L_^#'RWZ3;;N?U._[^
MZ6^Q.+MA;/7^U]3E]S7U^%W#E,^]P/GV\U_^YZ?DPH\LBD/^:?YIQ4,6N8$O
M@' ^4N<+G__]S=5%NV4/_]7]S_7%&\N=P1?,B<XNNY.K]J1S,3YOG_>&D\'0
M'@_Z_:OQI#68=#K#\S<_;U [3[EK=\F%]9'?65^");L?6'.W>Z[/S[3'V6ZW
M?B@(EMT',2II.>7'._7B:>#-M%=UP:U)L 3F6EO,GUF*AE8PM\YC 4,5#SM7
M]YW8L#BO/V(1N?.U^LKU02=%[SL=P^[WKQ_.SC]]O&Q8'WRG:;V-8*9)G%V[
M]:.>]/_/WILW-VXD^Z)_G_,I$/V.XW;?@&@")+BT9R:"VN;U"=O=I]6>B8D;
M-UZ4B*((&P0X6*26/_W+K ) 0"0E+@6R0.:$QQ9)+%59OUPK,ZOXQOKI@_'$
M8L,+QF$T#P% W(4/!MX6)_ ):7+-??;$D#Z! ; <3Q?:SQJ8AMUN#P05O=B8
M<N;^.V51PB/YH#L6),RX\EG$3.,*Z# )H\!C+:.\!' C,V;<13ECN/S1&W/
ML/PMF;+$F,(0YP!M+A[+C'D4SB,/V"-Z-F9>X,V8[S_CH=PL]AYAY&GT()[E
MS>8^0QH^QPF?&4EH3-*8R]FQ<11ZOL?&QN^A!]? P$3#>7&J-TX;KYJ%<8)#
MF<'4D^<YP!Y^6+K5]6(AU6(YVC'#EX#EP2,#Y: Q9U[P8L9!$H5N.D8B)4#^
M6[SC4S;:.S%:TX !B1],)"10>9BOS&^!A^MTAPL49[]:;?SO&*0UP_^"Y$V
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MJ?H7:(47P^!2+YYR*7R%,;C"!&P9([$OX(M],G&5Z\7C,!7!$0[L_00#2'@
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M^W?C,;_9^67YZ>+RC/*\'SB+Q:/O6?!'E,Z3\;-IN!P(X(6RM7=QX:HW9PW
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MRB)3^08SE0TZ3+4Y8?/S.=]2L_1C MLI@ZW>)&*- G)U>O7?L'M)LL(E0#]
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M&H7E^<G$:^_1@T>[QK/'?67G&9\:^"3?#FS+_HDL/;+T#H:AG5-L7LQLBS2
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MME'C]EC.QW8A-ZI#]GF$-/LKNL8>66^/G/.X0M$868F/;T64J]R5-Y7AT<C
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M7=*'S9]1[X3AB[,NE.,] [GYTUI_[A,-ER4,5Q?XMYR?@PB5$CKA8N*'FHI
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M#WDAE(3)3*:,<=B+/'W1E@72>OG1TCO\,(TL*E,<8^)8G C@%A?4!>;)+TU
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MEPM!)7LSXUXWJ:U'?(<G3&\Y")FH/F-JTGI(6[2;5OJ.F]O%EV'_>!_(24$
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M^<MUY,#.M^A$X*]<$O[*:;%?/.B%,^E\7(DH:#Z*JBX5M\J;7-> K\#Q3(L
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M&L7PG;%1:?6[P-U!AON<)%A^+1'<RR)\7[,T2>$+L K#E*]_SNXA4YZZ<;Q
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ML!K+FT=OPIJ$<XOK:KMR*_4X61AM#],[+>AA$O6TLT-9 \P7'^X!CV]'\\O
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MH<]'"F*;L;L9/$-B(S_*)(PR?!,YO' E=<08OEDQ=TO92&A;CK/P%J*/'9M
MA]^5\H+BC1QNM'<(.E6DIH!MKC"N7.#[HWE$\XB(;._[@-M"\M:/7OLY<=2&
MKB\07]PAN;.-"<J]F$9/IMR3-W-S3_$(7 :;GK=P!5P7.K--S& $[6>DLG_<
M+RDSA'F43O4B4U(N4,NV+T7\B4#J0#:(W0D#A?[TR8N;]C4BT&::]<75*$QA
M4V_@LC<*AJO UF<980H7D.QN%MMWPO8#NO0(^K?(3R/\VO?K@"\6C 5F%;]F
M8(=R (71@\1";'O9P$%7H'G!4#@,@(2/[N=S9,-DM2_'55FYPP=$A?N#PP\^
M#\ )HSUERKA\+>889^OHY(_=O4P!J7=L$+0*5MG5P1N/I"R4<FN$XB"AR?XE
M$Y_$L@<)%:$Z=%.YAC,65#Y"S H.+H?3ZS[K*^\AC=;SIH L8#1O-(7/]-(5
M)Z.$$J@)NX/ITQC-SM8OTQXIC%$^84&$/R4 N4QETR?H/L([#].EWU_Q]1(5
MXU6 &Q>Q%WIZF<.P>^T_(U_%?^:K&8,._>"@%;_\SQ-N?*LKIMQ>]MYWY6F^
M%OU(,4_)]\/W53)Q<0OKG8G6)=^W&!JABB,3H,:US@S[0^;,B+@^\,KU>([Q
M#81,3WRR!2R@S'-IR1U\+D>R#Y<KT9CU(_Q>W>AFY *>=.5?4(4.G-7O=K,L
MA.:%[#'8\)]#-LQ@P3<=87>3'0%4!ZLO@+@A[L56"XEF$2*VT1JX+#2.&:C
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M4EQ\N$N>.VW9@_,:7D?EVTNX I]^^0]02P,$%     @ *X1N3@.>"\*D)
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M@/!ZI=+:%"W$(Y(J*"1<P:%3PY"0,"^<$,J[Q%OE.4OH"PR]LBD7(%I$"ZU
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MOWULPO?E2^\M]D0Q5!28H\(0C+C% 443"P>2DTAS\ Z['C#0%W.&OKWSRKV
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M+*+H$"FR7Z=#YYG_/KI^2+;N#6"_F_JOT&2):G7/LU7],@0:K<0:><X4 M6
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M?\LSBPBA8(VZ4"#AL/*><TY)ER1K6;;[7F;T^\/!OMF6[<AX2?@9B.?:C'=
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M:<31QB[/!N?9XG* :B!F9I=12[6N@XQ:VT"I&':&F0(1S@H437KB0A<.,4S
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M#PF/\.5Q'7S5(OUAVX9*7:BH'&<(IL @E;RKE@4*:]6; M1D86('W&5Z7_B
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MJ@U'*U;8YAST0[;XE$ZR^><BS4,'MY__RB9ARL^FB[NYNH\YO%5,M,J=)9P
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M:/V-I_7J(ET)0TO0].;;V0XV#M)]6^33VV4^OXL?FME\<<AE?[1M8ET,.W)
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M.FBV6BX&3>;[11Y)MH946ZO[R\J()IW?;:XEJKC&[VT?EC%.@Y;"%&::2\X
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M\;6:"&R>39Q&1#A.@3+:4"HLB'>5;&@"K/YU'IW%DW;.^'K0=!F?<R!:I.N
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M6,S5=&SS(AL%!L\#=G'BQCIBL9#7FM959>3T,2)25KD]N QW],Y$.V^X0!(
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M3\Y$25LPJ0=8 GH@ M,<S-Y*"ZRLYZTQ;?-YC)P+MK/Z$N!(1X<R08ZV36!
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M(X\-*[&CH$&=D\ZLB$N3U29XGU]Y?$EE+2WQ91>)]K%"F2, *,>LILA"OD$
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MZ605Z *M_A:#HS<55%@8*O81]CP@#>;*>2<%D5Q8C4L,8),0XLX\.QTN$MV
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M;%4O*-@ W9NM"T ;P/0K *:6 .QLM2I<#S%F@2JLI4 $6%W2B1D9X*4DK0M
M&\#T*P"VE@#L;)50*KRT"F(*#=5,!0!E26?0E@=XH4CK M &,/T*@*LE #M;
M)<0A3^-];L8K[Q60&H.GE8[7+^[>F:>R=0%H YA^!<#7$H"=K1+$N+4: BL%
M0UQY : MZ60&UL]=[<PGV;H M %,OP+P:RT!V-DJ<4'5M?&J'"L,4XS06,-T
M0Z?$KOX!8F>.RM8%H U@^A* 5T=@Z]";S3V=_SIXX=B1EHF'G(J@Y6B!PB\!
M1;6Y="W2ZQML!=U5FN[X3+DA1&<5B7?S^>'[YPZT2JPT*$@]A@HY[S0,M-&2
M3N[@$,M&]R(*M> YJQA<+1?S13J-F;JGRL*SIHGF2EAH25"&N#/0.<!(2;$&
M#>X ZJXL="\"41^C,TE%69=G'<Z@%HLB_[)<Y;9_GET'B@[?97MJ7PD*B&"*
MF-;0XC U8KV&$A/#&QPP=%<CNF.Y:1VT,PG2^SS\&*^"9=;:4[QK[Q37_8[F
M"51,6:0]<CRH;2)LMQ ]J5RPOB[:F37:M;BT@5/M<,A78_F8W]XMYI]G?\P6
MP6B:%2X=W:V6P7W1D57;)U@1&8QMJ#FQGAM)6+"^A #(04@QKJ]O=&:$ML;W
M+H&JS?B7]M"'9<3BZL;F138*P,_==)$O)MGX\\Q-LIW%%FOTDGA/C'080F>P
M-IKAH%H%5=L:@YAWOGYT=&>&:+M"T"E<;81$KXWESW_-Z@I$G;X2:*V$##C
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MYO,_?9%EY;EOG]-@U[L30I&S 6R$/>'26@Q(N8]3XZD>7D##6YD$+;#C(J=
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M#=[<A'E;;F6K>L=?TTGKJOWNUR3!K@>0&4D@D8(:XB0%)3H6-CCJDV](2@>
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M0[+Q3"$-).A3VLYTSEU9! Y&+IR&XP_W;W4?%@HJ.I5 <\J18!H34=["C;3
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M]%M;)LT8;Z1\8.E9DY2]!'\ Z@4)(&X0^"F.O-3/$D327C-2/_+4Q-P8O"C
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M:^S8U9S&N(BXR!$V,Q61!'])+E0XD-:%5H5(^?!8;G.>-/"+&H(8T2 D%.,
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M(B\[9C_?;AV$(,9^Z ,"TP"F,>SKR/Q/J8OZ3-NVO<IV_@3#N5[SNJ=&-,=
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M&&"Y6?=4*.W/O[LFU'WOV<[1?_FG!'CQ7YQMN<MKI]H[+#L;FVQT1:?A/\+
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M8ETLJ^_752MP/^>[+^7Z77O\/__,)N[7=XT,XN\O?[G_M1L^=5J R$41R,(
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MW795/N3OR[K^D.^N[VZ6WQ8!2F!,_2#+8DA@0@,"^S;5(2!$JB^K:=NV%>H
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M)R/DSD.AS+CRLMV.*7Y>/7)6[1:?=VQ6R$7PKWEY7RT?OQ2KY:8Y+NU[813
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M \IL>;SF(=BVG2Q'?0=DN]=L^%97-OW9'5<%#@<2P@ &-",P22)F%<?\@N<
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M@-&A?#O:/]Y5"]%WQ*]+M>_.P;S;B(T<GT@![-./R(LB 0S26+WM'9.4%?$
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M'N!UR;*=_DU$\&@15#@C!30:D'8/7H2AA:=9-!!$!Z$(4Q5=./:*-#KC;NR
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MW?O4^&R+!KGD\5:'W^_55H</U[S>5E>2[9W8[.O]NEI]:<1:?F51EFF1B00
M421YD>.D%&I"GQ<%Q*4HM0X,^[ [;5ZYB#8M8'7R;#5 CJH>LSIJ7"G4!AKH
M.@P:26?&")BEGB?;K2ZB#FOTX3HZH(T&N$H4Q<SD&Z2A&8-@EXP<!T,O)9FQ
M="HQ>>(Z@/3DR[/&?TLU2%5%<WO;;%KSW3Z]+W\UK^( G&< QR(FB83 \Z3(
M&:%%@E >\S+3'P)YL3[-AE_87OO5;'PE+S^!T4AAL\?$+)%U< ?A[(,C(;O/
M:'XB8I#79H^,77;S%2&]-&=#VJEDYS4  :0\O_XU4S5E^UF_=D3XM5E+DMG=
MW;;YMES_5F_JV_O;Y^NE6(B$)W*0F!4"XS@7ZD(82HM4#B43@)#M/*!+#+Y3
MX0/4:-ECO8AN.[3]3@+C#0;3!LE\(G&N^#C97=4'BQV"U4,?]EX=@0\D0/;3
MCW,%RM6$I+. 64U1&K"G.6GI(QX!),TIO#PSL>F/5>V+GQ\-8GG]K5Y5F]6G
MY;[Z6&UYLUXOM]U.A46:8,0SF&.<E9#3)*&IM)]!3#B,$3.Z0,.=5<])<H 6
M;26V-@.N6G1'2VB&6X8=$JZW;V >KD=.:!YX5S@O(HGTUP[JKQW6B6^;UJ7P
MS%8"]V$(8S^!![^>7EGMB;EQ$KF3QEN1YM651%"M%H20 K$BRP40#+.L2-2V
MK8RCG$J-1D97Q[JR.?'N@M4 -%KU"#UJID4$QBBF7_(=Z>5.26577LHO]D!#
M$,MG[!E+I3W_(0OE"*^T9'(L:[HB>30G=-HTC5%*,<P1@;A,B*",,$*9E&N2
M)WF)S7:'.S'I?T/XT4*#+WUT0[Z>.$[.^I@5A0/"B_EU48>X,Z+HE/<P%-&M
M2XW'=NI^I_T 99$ ]19FPDN,A(AS5@A0$IH#Q!%+"V!T 9Q3PQ/NO+\[H'N0
M0"?"Z#82>@(Y6Q#&SC&_O%__03C#V[D_T#AR![]Q-,*03S^N6>SHM^3/9HWO
MV/YRNZ^OZKOV+\7R[H "$LX%2#"' J=Q#E*,B$2!>);$G)9:BNK+]I2B>HPQ
MNEK>.=)6;V$Q7\V;.B).%?91>"1B#:&=)@[VBW93Q\/58MW8N%BMT6F0I;DV
MYY+V\-;DG'IW9BW./8N:>S@/USL\GL'IOK%K,VU]52U2#C$0#&5)B6.>HB1-
MJ+HY**4%@B6"!OLV'5GTG,P>X,@!@L0S/FNYXUHC5\U"L^EDR</5(L^FE(_H
M;W'.PK/1!LL9^+;=5.F"=]TME'JTG-XVZ9C6 #*,>Y\:GPW1=";^A/GC.YS^
MN).)[0!GP0"(Y2 -<$!13#'E% &))&,EI*A,L<DDE _[TV4:]?)Z8W\AG!?R
M=2?FY^7=8>IY=)=<='^G"O$#Z*EG[8U9/3N)[R]&84Q*>?7PV12_;S;'5?#]
M5KZ/]Y?K^NK#M?Q.O;DIF^T1' A0*D<2J$@)1A( 1;@@E'(A2DQ1KO42NG<0
MGM5WV!1[UT*,FAYC=-UL^\OOSG;[B0,RIO*?.!8.%7F(40<]&K"W]RQH2//$
M,7(Q:I@X5AX&$B-C-G)X\3I_QB,.AR$)>1#BTDVM<8ES7CVDS6$*[C$L7J0\
M$1EF &*"8U#$0.V)%PQF,!=0ZTK8R<#,E$8?5GT>)U2/TVDN(^@\W_H/W@1Y
M][ F,54&MHR>MTSL/XH39F3C:/K(S2\RZB9'CPO6F\O5(]VUS]DN>-:=9A3+
M[4::/.RI^U)]W^>2L'\M2I (^<&,YK$<7Y,B(SA/\R++TY0P1HTF$^VM>,ZV
MOU?[Z'VS.]IOKVX/.=Y]:C9Q.().O>G!:9@T2WT#IB,2_U2XHA;8Q"]VG23H
MS'S>>%+#F+5SX$?CNKEI#B6V^\4GV:8J]KW>+4H6EX06,5)7+5%("Y'$"8$Y
MI (D"=>[UN'1)T*<DI0AC JJKN0N,SG>2=2S]1F&:1S[OI^Z!1+]J:!H/O]G
M2,@KY;4W+LR$0HL&'560#ATI@OS;4S5XY/%+U8\5(S.7,':8FS%MP+#W]B^*
MXCR!N& (YHP@:84D' [-%0-:&O7?_C-3D9-4:DZ&&$ 9RRG/2082()*$9"7P
M_I)+UW1Y<[NL-Z9]6)<6S5[L@1&K?OP:&6Y[\LD7@&UY":0WFZ)^VI^MO-;I
MT?W8I/]\F"=$ME61T[S /($EDZFG:[Q23(I<MT\__E1:< KC#  20U26D!(N
M)4BPA+!4B-3W/8(]&/WN;,C)ZQW:'QUF77J8TW#RY+=6IW[D^8EN;<?._!W;
M$G<SMET8=.[E]Z//)Q !43">)BPN0!(CD@[U)90M66AW[D>?RH00O,Q+FLM"
M@W/Y7_65+*<0BB*/O<^D=V ,.K<9)QJ=VQL=AIV[PS%EYS[V_%3GMF(G@,YM
MA[L9VRY,KSMI[JKM_L='V1+V;+-2N^/OU$3X^\/#VWE!1%G*M$53*J4$\;0L
MAA;.RY*;W73RJCD:TS0#,D5B%"-8Y*R :9911 !A19'X'H,/""^B%F.TW*RB
M \H9GYA_G;DS,U<.:0]C"LNE0\]NUG#,U>BN^,>NNKY?OZ^OJP4N.0594@A*
M2E'(GA\7P]@0%B(%3OKBD3W$,L#SC*8HSA!BD#*JGG*")2ARBKRO<HO=OKY=
M[M6VT!93M):@3&\3<L"JWJ3[U(2:9?>SPG81=1BC]^<(GE;8'EBS438+S@.7
M-AN/=+7-FBU=<6N7!?+EKEH5S>U=M=FU"^ULNU5S$PI!_N/A1SXN?Z@OL;^6
MV]6'._6#QW=C?FK6Z[+9JF^J#;XIR&%*.$C4YB26B910692(1.1Y:71-Y4P0
M?2]='AX[Z/9)FZGG7&'3$]PW$#$SC6[1_GJIX$;'+D5'/D67/Z+CG^O]BEK'
M+J+>M8OCZX:C/Y5[4>_?Q(6KGR"=20DSMXHPLLC<)#1!]=39<E6GO@N<\R1'
M.2$"$T@HCRF& \X,"[206;EN5I_WR^U^\F2EB=%$]9ZZHRV >753;]16@NAR
M*;_1'P.W.IPW0Q0GSUH>0A=$PAK>FWFSF:J#/TV2,FP$/UU^,O7?7VJRBL14
M6>GO\@?WNW>;CZTV_WW;['8+0B%A>5+BLBBX_ > #/1(RY(F1ILWY\#G>>S4
M(XMN%+3^]M99<I%5[*;)1K[#-E\^ZCR+9,P[W]17I'=O*R>]$!Z/66E,8_@Y
M\M(H!AQGIO'1T,Y-:@M\=P*?W_=G$]0 H-7*]IL])/&]VE[5$NXBDTCB@J",
M4\H@QK@L\P$(RHMRL:ENU,R_9O)Q#T!+I+).I(ZQ&F>7:H"DE5_\J(PQ?>=$
MQ%\L M$(CPX^E0#?7$Y5?8KO=W5[V\[F($B+6,1I0A.2)4PB2X#(BV) FF*
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MK:K]T:/"#Q<[%!ARSF5]CU(F54Z.[#%(\R++0<Z H*71I7@N#7M>!NGQ12W
M]B:69J.NO#"\H<XIU7J"-1O+9BIV##-ZS/:C5]QGN]+&A,<SBN<E'&'(H!_7
MGEYBYH\_7<'\5.V7]:9:B>56O?:Q8U=R3'+?7HPCB\GZ2BIU3HL<$T%E84A9
M&9,T(3&A4JY%24O";:8='5B=9J+Q")B:BU#(INVIKS-UIG\ZI#F,7NG2H<9;
MDS3K@7)05BQW7]LAPZI:Y3_^V*D!7+]O>'/#KO;UMWI?5[L%*%E9) 7C28$I
MS,N$ -$#8"EBR*(G.K0^38]4\QI7$G%TKZZ'JS=1<]A@;5:_N.1=KWJ9FFNK
MVD7QJU!& TQU8>TO?W1D_RTZ@(T>T$ZKB/HLGE%&#Z$(0R%].-9X;\:FNSXN
M]^\VN_VVG3U]+U7[W;ZZW2TPP8+Q&*> <I*52 @,"54:C5(N9#?]5FTO&_TM
M;7963+KF,2"#">!+-6K[5FV6FWWTIT(6M= F/[;T(D%G=R.,HS2,+C;:BV>[
M#URPHK40^:F2K>:^^K+<WE3[_^=^N=U7V_6/=YNK;;7<51^KK;HM=WE3+8HR
MH;C,8LYC01.,8Y"UM@MU2)[JO>KKUJ+G.9$#-#5;VV)3M<6V0Q_M6_C1+W<=
M7LTW=!U3KK'H. O;9O5%#S'J,%Y$#\0/,"^B!Z"S$&VPBC@+X7;KAHZ(UULD
MU.7EU+*@<UX#6 AT[U/CLR6:SB/)!%:KB_3;Z]?_V-3[W:?/?_Q6W5Y6VT6)
M6$9Q(9)24,PQ1BE(NRN489R3.#>9:1]GR7,:>0 7M>BB%I[9P'0DE7ICT>E8
M-$T/+Q$8_2*Q[?X6_=GAF[C0/<O5V>DW%QR'4?0Z\N79I)L[AKP_PB7^?5_O
M?SQ4ZKL/^Z_5]LO7Y:9_4^3W9M.]__2I6:_+9JM^:<%3(*MX("@E@!&085X4
MO1. \]3H-KK H'O6TM_O52M0CT6T3IDN3X;%E>]7L^:/L.$2Z?BGLCJ7HR.?
MH];I:"^]?GA(Z^"X_..3%A7]J<B(>C:F7H.=--3G5G'#;'-AY+U0R7'U'-84
M,0PH,W<*L("\%(10D!:D$"6F@F1PP$\+019WU;9NU!GN[3Z8U*R)W42SG[JI
M+=]_'#3ULKJI-VK%-+KL-[K\4F^B7:NOFO-DX7$83K;V$/0WDZA_NGS<N35O
M*C9L4/\Q6=B4E^D3L%7DYL^]?Y<?L=^]VWQL<\U"B"*F*2I!44#!,4$QX@-\
MY4H8XV%#T)Y'PBT:J:L!9E;3Z,Z=6#T&-M2\VKFLEC,[IW^6M/HXE+-D5<O6
M]+,G55M:)LNIH^(V?TJ5P_#KJMZK75>]!ZC,4HF9@)@5(DX8(64Y>)#D&%OL
M# T)_C1;2P^X0DRT%C&?.]=ZBG/@Z?:A%?UT&?=90&=)NO;-ZF?/NR.8F2SU
MCHW>_-GW'^UH_  ?8AISAEA*&8(,E 610_(./LP $T&E7D/LT^3=#E2(2=<T
MU'-G7!_A#3S=]HWGI\NUCT,Y2Z*U;$T_>Y:UI66R%#LJ;O/GUZ<3W@AP4*:(
M04A!EO($0#1L X,%BF&_6"LVJ[FSJRER\Z7:P4F+A=IJLS)=I7UCDAGB.IMN
M$_C91=.:E]G6V<PB%Y!L_K.J;[[*_[)OU79Y4[5SG5R6YN6RWJK+OZKCG3RB
M@ #PF (0XZQ$!)5\&'S!E.(DC.4X/[YY7K4;L/X:]6B[E9A(X8T4X/9R/L/K
MN=\:Q[,/B>9O.J&.G([VVPS<G&^ILSV0&%CKF+>P\-*._V/*#S_L35^D>&P%
M;ZF460"4(\:)@!G.RP3D@N9#E98DA(,@=_*.=RN(3;XKV<26VUTD#71#R6#F
M;5TVH+=3P#AM-3]-U?*?5ZH$7I]H-]/_59284Q9@)6(8[_G+C\>[PU[WCZ8)
MX%E&935%29PE!8OSP;\2"Z,G9M^.5Q/N>0ZWT'#>5.:N-N9L):&6'$\W4/^G
M51Z&;2* G=CNVNW/7H-XXVVFO=RN(S]_-=)OF%.7@;_NG$ \96G"8E0D:0I+
M(3 >G(MI2L,H19RZY+D.>;PI/-Q*Q&TSF;L,F:V%A%J#'!'RGU9^F+2%.3>D
MNVVL/WOAX8>TJ;>Q^XCY_"7'XPV$K_L72R\HY)!)U](L+XL"E0?_1"A5AVNO
M/!<>1[OBPZTZG+>4N0N/.1M)J+7'TRWV_VD%B&&;"&"OOKMV^[.7(=YXFVFW
MO^O(SU^,&"PT)2E%E#&<L"SC@#**<M2[EN8<Y@&>%!COU-R'" R*DS>F^S_/
MBKMN&_K9U=X'92&NN)O%6^OI&/5*S?#H4)=JV/=ZMX IYQ"G A# H> BY7&.
M!69)2=3AB4+[H1C+S_<\"'O\UE*'*_I3(3N]!=H==^<'0U/19C8LF9<Q@Z=;
M)F#.[J$6&P;U7F5YV>47DI<+@@)X<66L!XV[YC)*:7ESNZPW"U@01''! ,TI
MR3*& *"#+5I K:<$QEF816T[;./40Y=!*\7U0)X+S9V2MU&ZZX$_.^4=*(NN
MFVTTI0QW=O6%V)"Q(*78U(?S8FS%B)8<=Y__85/UK]+0+ /2>T%%+" K*2L!
M&DSDH-1ZR\KJ@SV+;]_")1X#Q3 F1T-@??)BIJL/E+S^\I0#;@Q$U"='=MII
MPI6>3#[Q\90ZVE(1@"A:0V\<- 5C"?SR5].;B!GE($GC+$504 @*()+.!(TS
M2O1?AS7]X&DD4.(Q[N8&Y&A+H!]>K"100K&70 -NC"70#T>C)%"+*Q,)//AX
M7@+-J0A& BV@/Y= 6_]-)%!&:]!9D8,,XPS3+$]H"@FE@@]&6)&8UH$F'SV1
M#"I$YIW=A")]*?3$CIT8*C CY-"$(7-!],34.$G48\Q(%!_\?$46+0@)1QAM
MP+\@C=8<&(AC*1O!08!1C'(AQ^&9')"GH,@>;$@CI@6BP2=/(XT*D'&_-^%'
M6Q@]46.EBPJ+O2R:T&.LBIYH&B6*>G29:.*#E^<ET8*-8!31!OMS0;1FP$0/
MZV^',7DIBK*@95QF&"(29W%1#C:@,-=#_4^>2 \E(/,.;\"/OA[ZH<9.#R66
M$7IH0(^Y'OJA:9P>:M%EI(<'+U_10W,VPM%#"^POZ*$M P9Z^+G^WIM(4X@0
M*"$M8L92DB*2'"07(V0Z=-;_X&G44.(Q[NT&Y&AKH1]>K*100K%70@-NC(70
M#T>C=%"+*Q,9//AX7@7-J0A&!"V@/]= 6_]-)+#Z5FUZ(QS&1)0XSE,!4YBD
M.*&B-P(PQ<!4! T^>B(95(C,.[L)1?I2Z(D=.S%48$;(H0E#YH+HB:EQDJC'
MF)$H/OCYBBQ:$!*.,-J ?T$:K3DPWO'X6[VI;^]O?Z_VGY?K:O=ENZSEK]U\
M^:M:RQ*UV>R_[MAM<[_9+T@:(ZS6==*8T22F@' P $D885;;(=V9]RRRC[:G
M740][D@"CUKDEMO^'-*O(<[S,V\FX*^1?A$-L*,.=]0!OX@ZZ/,'Q7*CYCS!
M<;!_WF60S'=W:M-V*@7YC4$ :<JS@Z<VC?KBTCC=#98!;*T6S6;7K.N5>DE1
MY.^^<+9 <<K3@D)&*66I_(_\_P @IQFQ2G/CS4Z;W@X]%L!?6\31,>2HPVRI
MK@Y"8)CJIF5_1(H+G7?+;#8M_RY.@8V+@WGB>I4AG83ECN; $I5#QTXE*-?<
M:=_C</6U6MVOJP_7ORWW]]MZ7U>[#]?O&YD;J^VM0OAE>;FNOE3?][GDYE\+
MC&,0<PS+#*8B)AD@689X7F ,""PX-+K[R;5QSTEJP!LUUQ';;.Z7ZZB\5W>"
M'8K.C]MZ<U7?R6_T1[UWT1\;V4RC]\UR$[&;;=6>"=<<K?D+TOD$%D1\S-+8
M<6@>P*J_*;B_RF#?=B>\_FPA1PISU(*>^FTK0TY?$%[OX0GD6@AO[CV]PL$O
MC\9CA$[PEYN5'*Y\4C-Q]]67Y?:FVN^>X(!0Y&G)<,:R,BUY1E$I$"_2.$,@
M%22V&BHXLS[EB*&OB*(>J66%ZHYXPP'"+)R/&2?T=$O$[3Q+CWF@WT1DIXJ(
MY=!AELBX&$&XBY#Y:$*7-)U!A?, !#:V<._?J2&&)R;-1QJ?]])*_J-8+W>=
MZ04NU/UT,<M 0;,$)GG!\E24 C!<ID6&[ 85YG8F'#^TX-1]G2V\OC]JRJ03
M2DV' '[9M*_V#8GT7-0_8TFK?K?G-K12?80G)ZORL>SH*I2Z<*W9UYN;HKF]
M;3:MV7X1/&&80I[G18YDL9\FB*6]01+G,3!Z-GV$&=_Z5&W5H!E$';*N:YE)
MTA@.]11I(OK,!.D ZA%UQCM8W*C1:8;.B)$#6L/0(A>.-,Z;G)D2=79:P6.]
M(5 F\O-PEL4Q@E+O4 I9;PB4$&AM'QSQ\=,H#]13'B^]YCDI9WK+" ;#Z"5C
M'&B<M2;#7J%,].7 ^WI3O=M7M[M%6@) \YABD"9%GE%.Y*BEM\6 WK[:<18\
M]XVNKCU4NG\J8%&+S'"X8,F?7EKV3YU91K9AS8^NO$3,.6D9160@ZC+.AZ<"
MXX 1L\S;FFJO;=Y]N-_O]LOV&O0%2U)IDPNI8$3 G"0Y+1YD#1J- D89\JTX
M71+>M3VG><#5WO_>WOF^,WR19ARMF@HT%:.&0G14T5QTK[/L+J(C;'.4.2^S
M]&K!,Y+<0,3)B2LO%D%.^-%:+_Q2W=XUV^7V1W>-_)%Y]85ORW6UV7= WET7
MZB+Y[;Y:=5]8 ,A32F.,69SB.(D9+E /!THEU=K"X1V$9XG[5*VJZK9= [GJ
MD-7JSW>RIU7;;;5Z+GX7\@>/9+$Z>+@SET7_(=18@ PE>F9R>D#=OV9U\7C&
MY0%Z+[71N^M?#^@'_0TE2@:+DJ%$RVYM\O=[-2Y4Y?B)3M3WGVA;K=L=COLF
MNFOV\AOU<MWWT)UZ[$Q^PO[0 JKN/;/N5_]KY +F"()/K6-.$;, EC,G<;.9
MN"\$]QQ6UX46$,<I9#@K8 E)QM.\Y&5:PKQ *,Z+'(?Q]J8I:N_97B*MK_:'
MO'Z_J67>-AW:O-7WK+H@G%N)#*XAA#%4")"7Z9^?LHJ<=^'L41X-LWJ<%,09
MS#*:HISAA,<QIWP0>%)FV20":8W.]SI+-ZKIT+UQ_3O%L0^=&QW/-ZYGX_UW
MI5N.(J$UR7*FL&R_^!S+(LL9$!0518;S&,6$HI0.*)*$ZE]UY<'V7-KB?.;$
M1UPT)DQF#HG]M//S69&+_AL]9*WIZ&GB8# E,G,\YI@)J;Y7VZMZUVY\W)WJ
M;V-G0LQY/34!XC%" <Q[^/2NF::=3U2L=XW^PW4'FGU;UFLU]5XVV_8QVX6@
M!8@1*%"9(9KQA!<E&> RS/DD-?M8D).FU^4 KWV[[D8!M%^=G2^N>BN[;R*D
M9NFY1?3KI0(<'3L5'7FE-K4?_USO6=2Z=A$]9))^I8,]:A.MAV]D*/=*G'R,
MZ%PUC3<^L'-&@ZOQG=NXZ WSU/ZBYOJ?2X5.1O&3>FZ]P]%<OYQ\JZO^G'"Q
M7*^KU>6/_I=W_6_O%GD"1)DQS@A)RSBE,&&@QYF4C,6+;]7VLM$;"LZ!ST3Z
MCEW15L !45O@RI_Y*EO"4/L.U:W[D>,LH=896X8>8\/1Y[#[LL<D%3!J01VG
MK9-#U(-G4>>:2H2'YC)\DLDB_CQA-QG*AA[^^9?]_QH:0"T)>O1Y%T^W[5RH
M1O)TF\#H4;&'$)T<-\_9'$(86<_J?Q-*QS2H8;KE/+99/=D;T6^#V.WNJY7\
M[J=J5VV_52M93G4W%ZGO+&5 %DF1($SR$HB82E Y8#P;,.5IK/]DC7<DGL?9
M7YJ]U)ZZQ=E>G[#MD;:CJKI':5E_^ ^31JT15(3,ZHH.:"311<\W @X;_KK0
MJ9\97(BD#\-578,7047-H%0(*GIV9<$44=1+ZF/)/)7 )PM2 ,EZ.E^;.;J!
M@R1\;H/BZT )S#$BM)3PXKRD94[Q<)@RH5S0T9G9+[P@TK7SB8290CTBNX<3
M98<I_[6]_Y.5 I[C[J ^""?^'HH&S^U@7#$QBGG3"F.:, =<=DQ$@$XM,F4L
MM"\Y4E><5A^N/]Q5V[8#[A:B*!#"J$ 9IF6!8U3&&<A@GG"&.*%:+PZ<^?@X
M)4CP!. B PB7(,/RKR O.(,9A*#P72!\K=H5UN7F1W<;8HM0S2CF][MZ4^T,
M+V.V(5!OF=LS=V9I]X&F!SC1G[-=F_R<FS.+PB.(#&,Y=XP#3^\N&LN%KK#T
M!C8W[ZOEKMIU8M;?BSY<AL[O*W:YVV^75_M%+F4-\40*&6=,=A^(9&])6(I
M"G).C%3'M6W/DL1N;K;5S7)?/;T^OH5_N#K>3)><\Z\G6G-2;Z9H!Z0=S;N+
M9Y?W#U?V2[SRF_7N2HXL_]]JN1UNE/\1_3GX,;'\&;)\1AM]Q2L,X?3F73--
MJW<ON9^JJTI6GI?KJKC?;N57%J"(\X*469G*ZC(%-,TA';#P&#@77G,$GN57
M]K',O;9:$.U.8?UR[$MG'U#+$7R'.SQ9?4;M2'&U#]7;D=@1/EH([5A&'5>X
M[S9?_FI4V;!;I"A.TR15)],@( 4N*,M['# %V$>-:V#=N\S"V$L):T*PTR+6
M$[>>Y/5"U;%1O8DDZ+:,/3V@F+-F?2!U?-5J$:"W(ZJ6_ME5KM9,NA=3V2:K
M#DD)1(G3C B8E1"D5,2X')"P4AC=O^C#OG]!!;X$U8!DUY+JAU_OHJI@ARVK
M!V*="*MYF-Z:M%IX:"VNMFPZE]=2=HD."*<HS=(\!Y#BN$2,8I@.0#),C0YA
M>C#O7URA)W$UH-BQMOIAU[>T*M1!*^N!5A?":AZC-Z:K%@[:RJHME^Y5M?[6
MRWM!<M7<\B0OTSR#><[+@[PCCHW>2_9@WK^J)KY459]BUZKJA5WOJBI1AZVJ
M ZU.5-4X1F]-5<T=M%952RX=J^J7K]6V6EY+%5J4:9DGO,!$/<$<0X($9@<<
MI1=1-;#N?T-3C\2+LIK0[%18/3'L55<U8C&GJ#[ &Z^I%N%Y4Y)JXY^=HEHS
MZ5A0%R(M&2L00;!$!'-4<)SUUI,$LVRQ5X<KG,KHJS:-Q/, 3U\\U:]XT<W7
MV72JEDZ)]+B1*DA='*^&VO2_*0W4]\I.^0Q9,WFTJ]ZW1MAF530;A:3:7-75
MCM>[JW6SDV@>WC?'B!59#@6!11*S@@C(4)K++^$,<I"7IL]X.33MN70\0MON
MA7^$U_Q%+Y><ZXGCC'2;:>19IJ,'K#-NJ3?C\HQD>@I*&,KIR[D7W@_SQJ&N
MCGZJ%"GUNFX/"GRX_F.SE5^YV=3_7:V^++_GU::ZKO<[\?UJ?:^N&66WS;T$
M_+':[I=2ZS<W7QKQ?7E;;]H?_U3))+#9?6K6Z[+9JKO=%ADK2UXF61R7(*8I
M0EE:HA0(!$5,.3%ZJW5VL)ZU^@_9/%NH4;VY:FZK:+_\'MTUN[H_BJ.@1CU6
MPX=@9Z=.4^UGQ^DO/SQV31VS.G8NDG"CP;V+Z.!@U'L8/;BHKLP:G&Q_K7=3
MMX%X22V^ W<F&0739L)(7^'0T03:M\U2Y F8"P@RGN 4Q#RC )<YI&D\6,,P
MSQ9R@%0WJ\_[Y7:OE]]L+9EHUE-0CI+31719W=2;5IXNEVO]*Q9&LZR75Z:@
MUBP=G!3_:77[!#%GY'8LE6&HY&@O&K<-S(DFO=M<;=O9F$_5[GZMQA.E=+P_
M(O&Q[?GRIS\.G7:1D215-Q$RF!8(@9) # 9P99D9[:Z=")+G$OP 5ZV?]T+V
MZ*[2QR7Y?OFO:A.M[K=*]ZXZIZ).8IW(G_. CE++.6/I2%POHL&)Z.!$I-1A
M.(T6=7ZTOW3P) A)-F3?7,%]A3=HP??FM%Y^\,OYV!(74 R%R#$#&00TIR2G
MA^25)FG<E[ABLQI7X+YFQ[S '2 Y*V^K[LW$UVK;P&LT7:*#[K+Z7FC6:&:L
M:#^==/6U6MVOJP_7G[KRX:,<<_WXLEUN=LNKME7E/QY]1QUG710093&")<DR
M01+.TS(OTES  G >,U$8O8OD!8'G"FP K2;(>G!1BRXZ!GZA'@AX_.T_6_B&
M\Z*>@J179LT?'[.JREMH_#Q-9,/N&4WU&ZTP%->SCT]?#)J 4?V%,!T$['N]
M6U#,9 &6%1C'C.1"8%3R 4#!&3-;TG)FUK,N/^G1"I+Q&I0[BG57DV9AUW1=
MR(!83VLWNC2=785QSG48FNC#L6<K(YZXLU$_WMS*8=!"%KY)7I0\02@NBBS%
M"<Q[0Z(H ;95.<V/GU;-.E C]$R7-'/=\L#7*'UZC2KO"M4!T%0B0_;"4QQ3
M!\XHBQ47VALRO];5=5EOEINK>KG^<'U=7U7;WRKU:M("):7(LPP@0#) .*!I
M# >+<5D82<D8.[ZW6BIHT0%;U(,SW&0YAD<]=9F*0C.9.<%>]&>';.J=DJ<Y
M.K<MT@&S84B0$T^>;GATQHZ1*(GOU=7]OOY6/;:8\C@O@""4ES%.J!PY)L,P
M4E#&C38FCK$SB2@=L(T0)5L>#41I @IM1.D9>W.*TLL<O29*(YD-2)3&>O*2
M*#EA9^1,4SNZ$S#&(&?2A*!$_H4!GAYJ,TZ,3CF/L3/IZ.L(G,MY)3U"1TTD
M.>=RS,C,@,8I9Y'LIHV,F U#G9QXHC<Q9,'.2'7JQXX"P7;$* A*69;QA(.R
MMUFF#!E=&#;.TGP*-7JNR(+642KE@5%G.C7[;-(SGLRURI#?H-7*U!<]O;)B
M2.O]S5+Z+^LV]:;3XU7$C]+C>K=KMC]^;_957]#E":)E+K 0.2H+AG-&#P $
M*;7DRX-9SUIV!/;YROT#X$@A-G@7T3'UYR5N9M;-].Z8\ ^O$/[Z4-([\P8O
M3<X7 ;L7)-U&0N]-2"..7L@V'HD.X U'3XXUWANIDS+Z?;VIWNVKV]T"Q30K
M@$"40)IQQG",Q&"V!(5P4$GK&YNOF%88HQ:DFX+:@.!1-;4?;IV5U3JT3EE:
M'^@RKZ[-F0ZZP+9P1Z_&MN7)X*:(_LD==4*AGRA5-U?P>EM=2:9W4G>'EVP_
M7!?+NWJ_7+<OX2XH20A*2H8*C.*8Y1F3(X 6D8@)+ RG#?SA\*R#+8BOS5JV
MO-W_\;]1",C_%6UD)E('S :GC*]U\!<478$,(QZFVCF@[DY_#;C;FWL.R*/K
M9GMX*ER-G7KTW:OCDU^P8,OS6='U'[U0]'@"3Y_?># 1NR/KTD_RBPM(2IPG
MN$ LIUAD'*5%<;"8<N2@)-6R,Z$*_Y^M_D;U1GY.M=M'6_5"[R]WE?S-S?YO
M3BI2/6I'%:/.6754AUY$"ED0!:@"8EY[&A$;BLPY\$2OXK1@1U^F[KHK)#]<
MJZ'Z[K&0'N&IJ]T"D"(31+""LB*+$\Y2D0P08@$,SV,X-.Q]6-UC597)SD-M
MZ3(&N@(W$_VFBG?$? LT>EI0'HOBN9LV/8F@/HUG5=%#-$*121^N/=--;_QI
M+8Z-*#^'.=0%QG&20E"DL2A)5N*4@ ,L7$"M><K)P'@6W-^?Z*D:'K; #-9N
M)HF)QEI::.&P'KZ7CX;O[-'PO3P>OG]X,GR_B,I PV>P(!=:&.V6Z28*I][Z
MG0-*3ZWJ31FM -;Z)G6WF:E73).//W93$LL;^?6/VWIS5=\MU^SN;MM\JU;R
MMX[6/!<<9##)<):G25KD90(R0 ;D((FU-A&'A'?JK'YWP*[*^[L!?;3LX;>S
MPM</#DR3/IRV +\%PES!GZ.&>/!5??/@;32XV_Y^^:8;RS3ER%R-9LZ*Q5GC
M\5[9&$3'0_'CHVV\[?K("R..2BA_T=*=/F;K-J[5ZO/7Y;;*E[MJ532W=]5F
MU_9R\5W]L5H0CC+$ 8PQ%8#$/*6\W_HE &6IT;8$1R:G6/OZ]5*ABZZ.X$55
MA\]LAM@5S7ISPS,P;%90' !&+<*>YF.,D7B%9B^SP7K$G9D'=LQ\&#/ KIUJ
MO+96,_U[UZ]G#U9@47*>Y"0K$B9HFN.89X.5G".C2R5-/]NSH@UP7E4P+UWK
M"1EG^I M;6%T%FOTC9O&8];\RV6]_<=R?5^QW:YJ7]=Z7R\OZW6M%EI^JY;J
M8:W5AXTL<>ZWZN9V^0._-^INV.ZOLK/6N^ZNP3A!@ D(4($8+$L 4L+2LDSR
M(N,"\LRDXTR'RG.74XY$K2=1#[M_'OD O=U%=PS>[G+6">.H5X*$&4*S*L5'
M]+QHJS.RSZCR] $-0\]G\+N9NRM9YI#\QU$W*;?5O^^KS55W%Z,@*$]+QA,
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M6J'L]]JV!AF*,<Z*)!$(B4+0$L99;Q"@1!B-N4:8\2PU?_S7Y_^*]CVX:'=
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MU)S;'C&2S$#V28SUXNF&"2>LZ$K-/ZJ=NHNGV[650I$(P?,\8QG,"2AR?+"
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MRR,M3L]F>XN;5KGVOEY>UNMZ_Z-LMH^@?+CN 1;WVVT[\T2HB'.18TH@C'/
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M@=.F^0NAI-60KI%HWR_S\O1R=Z\D<CL)4GTL=CM1E&K?V!60F2R2 >6,B33
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M?B>(LYCZQ3">9=O(%%'6;7[,JW_2,MOF!_6K5<+\6" 2Q(!"B!",,1-=BS
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M[*/JYM1+[2$8,]XB.]KN'D!/V)?+P/>4 5]_D#&UU[;0_XH8Q@& /F0P0GZ
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MFG=]R2#M.NBV6ZO/[ZAN:A9MRWXX;K3,Q*>% G&4,FVM5\1!6=/J.4XI.#7
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M=7J"]?K^E/!V2J<?S9!'#'(E8^41QYV2=I. H2T222;^7X=BIY=87];^MBJ
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M2!2RF%B,D_)_?IAP;(L<[M8;N@W*KXFA^[AA9CU6P5(W)D =8BBI<"02$%:
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M*:7VZ8#B:)WBISB)*+I6'GXT*:OW.G\//OMR-?N3:8_-9![XUJ2PT*YNF=#
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MU#LA:CH!5TEY/@.&6+L8V(:T9'Z?$E?H*%RAFDZ&1>"8$T AA3V&P;Y8T:F
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M806-7-=2>22H)UGVUY@#^-WQO/D=;!=<^;C^>C^]^7 7?Y.ZD\\7)T&6.V5
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M2B7Z-%W^VR^*HKQSZU*%#GUW(!0Y&YF-L"=<6HL!*0UE:CRM5(SJ>A+OQJ)
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M !#&L56JI 4R/+(+X%I2/(R$6OSK.7BV48.H*5&;/LR.%P^O,4M@RD=?V D
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MK!@5B%B-5/0YMOQB@'*=E9'\^UIT:/(;C'E3E=QWLYO%9L#D_OE,J750&W[
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M163?=LD;ZIY;T\NR@?9).^KBR8*,; &&4VF%4(@QYKTNN4*UR7'YZA9/>U-
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M     '-I8FXM,C Q.#$R,S$N>&UL4$L! A0#%     @ *X1N3GSMQ_0*%P
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M,#$X,3(S,5]L86(N>&UL4$L! A0#%     @ +(1N3@1S2+0-H@  !#<( !4
M             ( !^GP# '-I8FXM,C Q.#$R,S%?<')E+GAM;%!+!08
..!@ & (H!   Z'P0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
